{
  "id": [
    1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21,
    22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40,
    41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59,
    60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78,
    79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97,
    98, 99, 100, 101, 102, 103, 104, 105, 106, 107, 108, 109, 110, 111, 112,
    113, 114, 115, 116, 117, 118, 119, 120, 121, 122, 123, 124, 125, 126, 127,
    128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, 141, 142,
    143, 144, 145, 146, 147, 148, 149, 150, 151, 152, 153, 154, 155, 156, 157,
    158, 159, 160, 161, 162, 163, 164, 165, 166, 167, 168, 169, 170, 171, 172,
    173, 174, 175, 176, 177, 178, 179, 180, 181, 182, 183, 184, 185, 186, 187,
    188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 202,
    203, 204, 205, 206, 207, 208, 209, 210, 211, 212, 213, 214, 215, 216, 217,
    218, 219, 220, 221, 222, 223, 224, 225, 226, 227, 228, 229, 230, 231, 232,
    233, 234, 235, 236, 237, 238, 239, 240, 241, 242, 243, 244, 245, 246, 247,
    248, 249, 250, 251, 252, 253, 254, 255, 256, 257, 258, 259, 260, 261, 262,
    263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 274, 275, 276, 277,
    278, 279, 280, 281, 282, 283, 284, 285, 286, 287, 288, 289, 290, 291, 292,
    293, 294, 295, 296, 297, 298, 299, 300, 301, 302, 303, 304, 305, 306, 307,
    308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322,
    323, 324, 325, 326, 327, 328, 329, 330, 331, 332, 333, 334, 335, 336, 337,
    338, 339, 340, 341, 342, 343, 344, 345, 346, 347, 348, 349, 350, 351, 352,
    353, 354, 355, 356, 357, 358, 359, 360, 361, 362, 363, 364, 365, 366, 367,
    368, 369, 370, 371, 372, 373, 374, 375, 376, 377, 378, 379, 380, 381, 382,
    383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396, 397,
    398, 399, 400, 401, 402, 403, 404, 405, 406, 407, 408, 409, 410, 411, 412,
    413, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 427,
    428, 429, 430, 431, 432, 433, 434, 435, 436, 437, 438, 439, 440, 441, 442,
    443, 444, 445, 446, 447, 448, 449, 450, 451, 452, 453, 454, 455, 456, 457,
    458, 459, 460, 461, 462, 463, 464, 465, 466, 467, 468, 469, 470, 471, 472,
    473, 474, 475, 476, 477, 478, 479, 480, 481, 482, 483, 484, 485, 486, 487,
    488, 489, 490, 491, 492, 493, 494, 495, 496, 497, 498, 499, 500, 501, 502,
    503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517,
    518, 519, 520, 521, 522, 523, 524, 525, 526, 527, 528, 529, 530, 531, 532,
    533, 534, 535, 536, 537, 538, 539, 540, 541, 542, 543, 544, 545, 546, 547,
    548, 549, 550, 551, 552, 553, 554, 555, 556, 557, 558, 559, 560, 561, 562,
    563, 564, 565, 566, 567, 568, 569, 570, 571, 572, 573, 574, 575, 576, 577,
    578, 579, 580, 581, 582, 583, 584, 585, 586, 587, 588, 589, 590, 591, 592,
    593, 594, 595, 596, 597, 598, 599, 600, 601, 602, 603, 604, 605, 606, 607,
    608, 609, 610, 611, 612, 613, 614, 615, 616, 617, 618, 619, 620, 621, 622,
    623, 624, 625, 626, 627, 628, 629, 630, 631, 632, 633, 634, 635, 636, 637,
    638, 639, 640, 641, 642, 643, 644, 645, 646, 647, 648, 649, 650, 651, 652,
    653, 654, 655, 656, 657, 658, 659, 660, 661, 662, 663, 664, 665, 666, 667,
    668, 669, 670, 671, 672, 673, 674, 675, 676, 677, 678, 679, 680, 681, 682,
    683, 684, 685, 686, 687, 688, 689, 690, 691, 692, 693, 694, 695, 696, 697,
    698, 699, 700, 701, 702, 703, 704, 705, 706, 707, 708, 709, 710, 711, 712,
    713, 714, 715, 716, 717, 718, 719, 720, 721, 722, 723, 724, 725, 726, 727,
    728, 729, 730, 731, 732, 733, 734, 735, 736, 737, 738, 739, 740, 741, 742,
    743, 744, 745, 746, 747, 748, 749, 750, 751, 752, 753, 754, 755, 756, 757,
    758, 759, 760, 761, 762, 763, 764, 765, 766, 767, 768, 769, 770, 771, 772,
    773, 774, 775, 776, 777, 778, 779, 780, 781, 782, 783, 784, 785, 786, 787,
    788, 789, 790, 791, 792, 793, 794, 795, 796, 797, 798, 799, 800, 801, 802,
    803, 804, 805, 806, 807, 808, 809, 810, 811, 812, 813, 814, 815, 816, 817,
    818, 819, 820, 821, 822, 823, 824, 825, 826, 827, 828, 829, 830, 831, 832,
    833, 834, 835, 836, 837, 838, 839, 840, 841, 842, 843, 844, 845, 846, 847,
    848, 849, 850, 851, 852, 853, 854, 855, 856, 857, 858, 859, 860, 861, 862,
    863, 864, 865, 866, 867, 868, 869, 870, 871, 872, 873, 874, 875, 876, 877,
    878, 879, 880, 881, 882, 883, 884, 885, 886, 887, 888, 889, 890, 891, 892,
    893, 894, 895, 896, 897, 898, 899, 900, 901, 902, 903, 904, 905, 906, 907,
    908, 909, 910, 911, 912, 913, 914, 915, 916, 917, 918, 919, 920, 921, 922,
    923, 924, 925, 926, 927, 928, 929, 930, 931, 932, 933, 934, 935, 936, 937,
    938, 939, 940, 941, 942, 943, 944, 945, 946, 947, 948, 949, 950, 951, 952,
    953, 954, 955, 956, 957, 958, 959, 960, 961, 962, 963, 964, 965, 966, 967,
    968, 969, 970, 971, 972, 973, 974, 975, 976, 977, 978, 979, 980, 981, 982,
    983, 984, 985, 986, 987, 988, 989, 990, 991, 992, 993, 994, 995, 996, 997,
    998, 999, 1000, 1001, 1002, 1003, 1004, 1005, 1006, 1007, 1008, 1009, 1010,
    1011, 1012, 1013, 1014, 1015, 1016, 1017, 1018, 1019, 1020, 1021, 1022,
    1023, 1024, 1025, 1026, 1027, 1028, 1029, 1030, 1031, 1032, 1033, 1034,
    1035, 1036, 1037, 1038, 1039, 1040, 1041, 1042, 1043, 1044, 1045, 1046,
    1047, 1048, 1049, 1050, 1051, 1052, 1053, 1054, 1055, 1056, 1057, 1058,
    1059, 1060, 1061, 1062, 1063, 1064, 1065, 1066, 1067, 1068, 1069, 1070,
    1071, 1072, 1073, 1074, 1075, 1076, 1077, 1078, 1079, 1080, 1081, 1082,
    1083, 1084, 1085, 1086, 1087, 1088, 1089, 1090, 1091, 1092, 1093, 1094,
    1095, 1096, 1097, 1098, 1099, 1100, 1101, 1102, 1103, 1104, 1105, 1106,
    1107, 1108, 1109, 1110, 1111, 1112, 1113, 1114, 1115, 1116, 1117, 1118,
    1119, 1120, 1121, 1122, 1123, 1124, 1125, 1126, 1127, 1128, 1129, 1130,
    1131, 1132, 1133, 1134, 1135, 1136, 1137, 1138, 1139, 1140, 1141, 1142,
    1143, 1144, 1145, 1146, 1147, 1148, 1149, 1150, 1151, 1152, 1153, 1154,
    1155, 1156, 1157, 1158, 1159, 1160, 1161, 1162, 1163, 1164, 1165, 1166,
    1167, 1168, 1169, 1170, 1171, 1172, 1173, 1174, 1175, 1176, 1177, 1178,
    1179, 1180, 1181, 1182, 1183, 1184, 1185, 1186, 1187, 1188, 1189, 1190,
    1191, 1192, 1193, 1194, 1195, 1196, 1197, 1198, 1199, 1200, 1201, 1202,
    1203, 1204, 1205, 1206, 1207, 1208, 1209, 1210, 1211, 1212, 1213, 1214,
    1215, 1216, 1217, 1218, 1219, 1220, 1221, 1222, 1223, 1224, 1225, 1226,
    1227, 1228, 1229, 1230, 1231, 1232, 1233, 1234, 1235, 1236, 1237, 1238,
    1239, 1240, 1241, 1242, 1243, 1244, 1245, 1246, 1247, 1248, 1249, 1250,
    1251, 1252, 1253, 1254, 1255, 1256, 1257, 1258, 1259, 1260, 1261, 1262,
    1263, 1264, 1265, 1266, 1267, 1268, 1269, 1270, 1271, 1272, 1273, 1274,
    1275, 1276, 1277, 1278, 1279, 1280, 1281, 1282, 1283, 1284, 1285, 1286,
    1287, 1288, 1289, 1290, 1291, 1292, 1293, 1294, 1295, 1296, 1297, 1298,
    1299, 1300, 1301, 1302, 1303, 1304, 1305, 1306, 1307, 1308, 1309, 1310,
    1311, 1312, 1313, 1314, 1315, 1316, 1317, 1318, 1319, 1320, 1321, 1322,
    1323, 1324, 1325, 1326, 1327, 1328, 1329, 1330, 1331, 1332, 1333, 1334,
    1335, 1336, 1337, 1338, 1339, 1340, 1341, 1342, 1343, 1344, 1345, 1346,
    1347, 1348, 1349, 1350, 1351, 1352, 1353, 1354, 1355, 1356, 1357, 1358,
    1359, 1360, 1361, 1362, 1363, 1364, 1365, 1366, 1367, 1368, 1369, 1370,
    1371, 1372, 1373, 1374, 1375, 1376, 1377, 1378, 1379, 1380, 1381, 1382,
    1383, 1384, 1385, 1386, 1387, 1388, 1389, 1390, 1391, 1392, 1393, 1394,
    1395, 1396, 1397, 1398, 1399, 1400, 1401, 1402, 1403, 1404, 1405, 1406,
    1407, 1408, 1409, 1410, 1411, 1412, 1413, 1414, 1415, 1416, 1417, 1418,
    1419, 1420, 1421, 1422, 1423, 1424, 1425, 1426, 1427, 1428, 1429, 1430,
    1431, 1432, 1433, 1434, 1435, 1436, 1437, 1438, 1439, 1440, 1441, 1442,
    1443, 1444, 1445, 1446, 1447, 1448, 1449, 1450, 1451, 1452, 1453, 1454,
    1455, 1456, 1457, 1458, 1459, 1460, 1461, 1462, 1463, 1464, 1465, 1466,
    1467, 1468, 1469, 1470, 1471, 1472, 1473, 1474, 1475, 1476, 1477, 1478,
    1479, 1480, 1481, 1482, 1483, 1484, 1485, 1486, 1487, 1488, 1489, 1490,
    1491, 1492, 1493, 1494, 1495, 1496, 1497, 1498, 1499, 1500, 1501, 1502,
    1503, 1504, 1505, 1506, 1507, 1508, 1509, 1510, 1511, 1512, 1513, 1514,
    1515, 1516, 1517, 1518, 1519, 1520, 1521, 1522, 1523, 1524, 1525, 1526,
    1527, 1528, 1529, 1530, 1531, 1532, 1533, 1534, 1535, 1536, 1537, 1538,
    1539, 1540, 1541, 1542, 1543, 1544, 1545, 1546, 1547, 1548, 1549, 1550,
    1551, 1552, 1553, 1554, 1555, 1556, 1557, 1558, 1559, 1560, 1561, 1562,
    1563, 1564, 1565, 1566, 1567, 1568, 1569, 1570, 1571, 1572, 1573, 1574,
    1575, 1576, 1577, 1578, 1579, 1580, 1581, 1582, 1583, 1584, 1585, 1586,
    1587, 1588, 1589, 1590, 1591, 1592, 1593, 1594, 1595, 1596, 1597, 1598,
    1599, 1600, 1601, 1602, 1603, 1604, 1605, 1606, 1607, 1608, 1609, 1610,
    1611, 1612, 1613, 1614, 1615, 1616, 1617, 1618, 1619, 1620, 1621, 1622,
    1623, 1624, 1625, 1626, 1627, 1628, 1629, 1630, 1631, 1632, 1633, 1634,
    1635, 1636, 1637, 1638, 1639, 1640, 1641, 1642, 1643, 1644, 1645, 1646,
    1647, 1648, 1649, 1650, 1651, 1652, 1653, 1654, 1655, 1656, 1657, 1658,
    1659, 1660, 1661, 1662, 1663, 1664, 1665, 1666, 1667, 1668, 1669, 1670,
    1671, 1672, 1673, 1674, 1675, 1676, 1677, 1678, 1679, 1680, 1681, 1682,
    1683, 1684, 1685, 1686, 1687, 1688, 1689, 1690, 1691, 1692, 1693, 1694,
    1695, 1696, 1697, 1698, 1699, 1700, 1701, 1702, 1703, 1704, 1705, 1706,
    1707, 1708, 1709, 1710, 1711, 1712, 1713, 1714, 1715, 1716, 1717, 1718,
    1719, 1720, 1721, 1722, 1723, 1724, 1725, 1726, 1727, 1728, 1729, 1730,
    1731, 1732, 1733, 1734, 1735, 1736, 1737, 1738, 1739, 1740, 1741, 1742,
    1743, 1744, 1745, 1746, 1747, 1748, 1749, 1750, 1751, 1752, 1753, 1754,
    1755, 1756, 1757, 1758, 1759, 1760, 1761, 1762, 1763, 1764, 1765, 1766,
    1767, 1768, 1769, 1770, 1771, 1772, 1773, 1774, 1775, 1776, 1777, 1778,
    1779, 1780, 1781, 1782, 1783, 1784, 1785, 1786, 1787, 1788, 1789, 1790,
    1791, 1792, 1793, 1794, 1795, 1796, 1797, 1798, 1799, 1800, 1801, 1802,
    1803, 1804, 1805, 1806, 1807, 1808, 1809, 1810, 1811, 1812, 1813, 1814,
    1815, 1816, 1817, 1818, 1819, 1820, 1821, 1822, 1823, 1824, 1825, 1826,
    1827, 1828, 1829, 1830, 1831, 1832, 1833, 1834, 1835, 1836, 1837, 1838,
    1839, 1840, 1841, 1842, 1843, 1844, 1845, 1846, 1847, 1848, 1849, 1850,
    1851, 1852, 1853, 1854, 1855, 1856, 1857, 1858, 1859, 1860, 1861, 1862,
    1863, 1864, 1865, 1866, 1867, 1868, 1869, 1870, 1871, 1872, 1873, 1874,
    1875, 1876, 1877, 1878, 1879, 1880, 1881, 1882, 1883, 1884, 1885, 1886,
    1887, 1888, 1889, 1890, 1891, 1892, 1893, 1894, 1895, 1896, 1897, 1898,
    1899, 1900, 1901, 1902, 1903, 1904, 1905, 1906, 1907, 1908, 1909, 1910,
    1911, 1912, 1913, 1914, 1915, 1916, 1917, 1918, 1919, 1920, 1921, 1922,
    1923, 1924, 1925, 1926, 1927, 1928, 1929, 1930, 1931, 1932, 1933, 1934,
    1935, 1936, 1937, 1938, 1939, 1940, 1941, 1942, 1943, 1944, 1945, 1946,
    1947, 1948, 1949, 1950, 1951, 1952, 1953, 1954, 1955, 1956, 1957, 1958,
    1959, 1960, 1961, 1962, 1963, 1964, 1965, 1966, 1967, 1968, 1969, 1970,
    1971, 1972, 1973, 1974, 1975, 1976, 1977, 1978, 1979, 1980, 1981, 1982,
    1983, 1984, 1985, 1986, 1987, 1988, 1989, 1990, 1991, 1992, 1993, 1994,
    1995, 1996, 1997, 1998, 1999, 2000, 2001, 2002, 2003, 2004, 2005, 2006,
    2007, 2008, 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016, 2017, 2018,
    2019, 2020, 2021, 2022, 2023, 2024, 2025, 2026, 2027, 2028, 2029, 2030,
    2031, 2032, 2033, 2034, 2035, 2036, 2037, 2038, 2039, 2040, 2041, 2042,
    2043, 2044, 2045, 2046, 2047, 2048, 2049, 2050, 2051, 2052, 2053, 2054,
    2055, 2056, 2057, 2058, 2059, 2060, 2061, 2062, 2063, 2064, 2065, 2066,
    2067, 2068, 2069, 2070, 2071, 2072, 2073, 2074, 2075, 2076, 2077, 2078,
    2079, 2080, 2081, 2082, 2083, 2084, 2085, 2086, 2087, 2088, 2089, 2090,
    2091, 2092, 2093, 2094, 2095, 2096, 2097, 2098, 2099, 2100, 2101, 2102,
    2103, 2104, 2105, 2106, 2107, 2108, 2109, 2110, 2111, 2112, 2113, 2114,
    2115, 2116, 2117, 2118, 2119, 2120, 2121, 2122, 2123, 2124, 2125, 2126,
    2127, 2128, 2129, 2130, 2131, 2132, 2133, 2134, 2135, 2136, 2137, 2138,
    2139, 2140, 2141, 2142, 2143, 2144, 2145, 2146, 2147, 2148, 2149, 2150,
    2151, 2152, 2153, 2154, 2155, 2156, 2157, 2158, 2159, 2160, 2161, 2162,
    2163, 2164, 2165, 2166, 2167, 2168, 2169, 2170, 2171, 2172, 2173, 2174,
    2175, 2176, 2177, 2178, 2179, 2180, 2181, 2182, 2183, 2184, 2185, 2186,
    2187, 2188, 2189, 2190, 2191, 2192, 2193, 2194, 2195, 2196, 2197, 2198,
    2199, 2200, 2201, 2202, 2203, 2204, 2205, 2206, 2207, 2208, 2209, 2210,
    2211, 2212, 2213, 2214, 2215, 2216, 2217, 2218, 2219, 2220, 2221, 2222,
    2223, 2224, 2225, 2226, 2227, 2228, 2229, 2230, 2231, 2232, 2233, 2234,
    2235, 2236, 2237, 2238, 2239, 2240, 2241, 2242, 2243, 2244, 2245, 2246,
    2247, 2248, 2249, 2250, 2251, 2252, 2253, 2254, 2255, 2256, 2257, 2258,
    2259, 2260, 2261, 2262, 2263, 2264, 2265, 2266, 2267, 2268, 2269, 2270,
    2271, 2272, 2273, 2274, 2275, 2276, 2277, 2278, 2279, 2280, 2281, 2282,
    2283, 2284, 2285, 2286, 2287, 2288, 2289, 2290, 2291, 2292, 2293, 2294,
    2295, 2296, 2297, 2298, 2299, 2300, 2301, 2302, 2303, 2304, 2305, 2306,
    2307, 2308, 2309, 2310, 2311, 2312, 2313, 2314, 2315, 2316, 2317, 2318,
    2319, 2320, 2321, 2322, 2323, 2324, 2325, 2326, 2327, 2328, 2329, 2330,
    2331, 2332, 2333, 2334, 2335, 2336, 2337, 2338, 2339, 2340, 2341, 2342,
    2343, 2344, 2345, 2346, 2347, 2348, 2349, 2350, 2351, 2352, 2353, 2354,
    2355, 2356, 2357, 2358, 2359, 2360, 2361, 2362, 2363, 2364, 2365, 2366,
    2367, 2368, 2369, 2370, 2371, 2372, 2373, 2374, 2375, 2376, 2377, 2378,
    2379, 2380, 2381, 2382, 2383, 2384, 2385, 2386, 2387, 2388, 2389, 2390,
    2391, 2392, 2393, 2394, 2395, 2396, 2397, 2398, 2399, 2400, 2401, 2402,
    2403, 2404, 2405, 2406, 2407, 2408, 2409, 2410, 2411, 2412, 2413, 2414,
    2415, 2416, 2417, 2418, 2419, 2420, 2421, 2422, 2423, 2424, 2425, 2426,
    2427, 2428, 2429, 2430, 2431, 2432, 2433, 2434, 2435, 2436, 2437, 2438,
    2439, 2440, 2441, 2442, 2443, 2444, 2445, 2446, 2447, 2448, 2449, 2450,
    2451, 2452, 2453, 2454, 2455, 2456, 2457, 2458, 2459, 2460, 2461, 2462,
    2463, 2464, 2465, 2466, 2467, 2468, 2469, 2470, 2471, 2472, 2473, 2474,
    2475, 2476, 2477, 2478, 2479, 2480, 2481, 2482, 2483, 2484, 2485, 2486,
    2487, 2488, 2489, 2490, 2491, 2492, 2493, 2494, 2495, 2496, 2497, 2498,
    2499, 2500, 2501, 2502, 2503, 2504, 2505, 2506, 2507, 2508, 2509, 2510,
    2511, 2512, 2513, 2514, 2515, 2516, 2517, 2518, 2519, 2520, 2521, 2522,
    2523, 2524, 2525, 2526, 2527, 2528, 2529, 2530, 2531, 2532, 2533, 2534,
    2535, 2536, 2537, 2538, 2539, 2540, 2541, 2542, 2543, 2544, 2545, 2546,
    2547, 2548, 2549, 2550, 2551, 2552, 2553, 2554, 2555, 2556, 2557, 2558,
    2559, 2560, 2561, 2562, 2563, 2564, 2565, 2566, 2567, 2568, 2569, 2570,
    2571, 2572, 2573, 2574, 2575, 2576, 2577, 2578, 2579, 2580, 2581, 2582,
    2583, 2584, 2585, 2586, 2587, 2588, 2589, 2590, 2591, 2592, 2593, 2594,
    2595, 2596, 2597, 2598, 2599, 2600, 2601, 2602, 2603, 2604, 2605, 2606,
    2607, 2608, 2609, 2610, 2611, 2612, 2613, 2614, 2615, 2616, 2617, 2618,
    2619, 2620, 2621, 2622, 2623, 2624, 2625, 2626, 2627, 2628, 2629, 2630,
    2631, 2632, 2633, 2634, 2635, 2636, 2637, 2638, 2639, 2640, 2641, 2642,
    2643, 2644, 2645, 2646, 2647, 2648, 2649, 2650, 2651, 2652, 2653, 2654,
    2655, 2656, 2657, 2658, 2659, 2660, 2661, 2662, 2663, 2664, 2665, 2666,
    2667, 2668, 2669, 2670, 2671, 2672, 2673, 2674, 2675, 2676, 2677, 2678,
    2679, 2680, 2681, 2682, 2683, 2684, 2685, 2686, 2687, 2688, 2689, 2690,
    2691, 2692, 2693, 2694, 2695, 2696, 2697, 2698, 2699, 2700, 2701, 2702,
    2703, 2704, 2705, 2706, 2707, 2708, 2709, 2710, 2711, 2712, 2713, 2714,
    2715, 2716, 2717, 2718, 2719, 2720, 2721, 2722, 2723, 2724, 2725, 2726,
    2727, 2728, 2729, 2730, 2731, 2732, 2733, 2734, 2735, 2736, 2737, 2738,
    2739, 2740, 2741, 2742, 2743, 2744, 2745, 2746, 2747, 2748, 2749, 2750,
    2751, 2752, 2753, 2754, 2755, 2756, 2757, 2758, 2759, 2760, 2761, 2762,
    2763, 2764, 2765, 2766, 2767, 2768, 2769, 2770, 2771, 2772, 2773, 2774,
    2775, 2776, 2777, 2778, 2779, 2780, 2781, 2782, 2783, 2784, 2785, 2786,
    2787, 2788, 2789, 2790, 2791, 2792, 2793, 2794, 2795, 2796, 2797, 2798,
    2799, 2800, 2801, 2802, 2803, 2804, 2805, 2806, 2807, 2808, 2809, 2810,
    2811, 2812, 2813, 2814, 2815, 2816, 2817, 2818, 2819, 2820, 2821, 2822,
    2823, 2824, 2825, 2826, 2827, 2828, 2829, 2830, 2831, 2832, 2833, 2834,
    2835, 2836, 2837, 2838, 2839, 2840, 2841, 2842, 2843, 2844, 2845, 2846,
    2847, 2848, 2849, 2850, 2851, 2852, 2853, 2854, 2855, 2856, 2857, 2858,
    2859, 2860, 2861, 2862, 2863, 2864, 2865, 2866, 2867, 2868, 2869, 2870,
    2871, 2872, 2873, 2874, 2875, 2876, 2877, 2878, 2879, 2880, 2881, 2882,
    2883, 2884, 2885, 2886, 2887, 2888, 2889, 2890, 2891, 2892, 2893, 2894,
    2895, 2896, 2897, 2898, 2899, 2900, 2901, 2902, 2903, 2904, 2905, 2906,
    2907, 2908, 2909, 2910, 2911, 2912, 2913, 2914, 2915, 2916, 2917, 2918,
    2919, 2920, 2921, 2922, 2923, 2924, 2925, 2926, 2927, 2928, 2929, 2930,
    2931, 2932, 2933, 2934, 2935, 2936, 2937, 2938, 2939, 2940, 2941, 2942,
    2943, 2944, 2945, 2946, 2947, 2948, 2949, 2950, 2951, 2952, 2953, 2954,
    2955, 2956, 2957, 2958, 2959, 2960, 2961, 2962, 2963, 2964, 2965, 2966,
    2967, 2968, 2969, 2970, 2971, 2972, 2973, 2974, 2975, 2976, 2977, 2978,
    2979, 2980, 2981, 2982, 2983, 2984, 2985, 2986, 2987, 2988, 2989, 2990,
    2991, 2992, 2993, 2994, 2995, 2996, 2997, 2998, 2999, 3000, 3001, 3002,
    3003, 3004, 3005, 3006, 3007, 3008, 3009, 3010, 3011, 3012, 3013, 3014,
    3015, 3016, 3017, 3018, 3019, 3020, 3021, 3022, 3023, 3024, 3025, 3026,
    3027, 3028, 3029, 3030, 3031, 3032, 3033, 3034, 3035, 3036, 3037, 3038,
    3039, 3040, 3041, 3042, 3043, 3044, 3045, 3046, 3047, 3048, 3049, 3050,
    3051, 3052, 3053, 3054, 3055, 3056, 3057, 3058, 3059, 3060, 3061, 3062,
    3063, 3064, 3065, 3066, 3067, 3068, 3069, 3070, 3071, 3072, 3073, 3074,
    3075, 3076, 3077, 3078, 3079, 3080, 3081, 3082, 3083, 3084, 3085, 3086,
    3087, 3088, 3089, 3090, 3091, 3092, 3093, 3094, 3095, 3096, 3097, 3098,
    3099, 3100, 3101, 3102, 3103, 3104, 3105, 3106, 3107, 3108, 3109, 3110,
    3111, 3112, 3113, 3114, 3115, 3116, 3117, 3118, 3119, 3120, 3121, 3122,
    3123, 3124, 3125, 3126, 3127, 3128, 3129, 3130, 3131, 3132, 3133, 3134,
    3135, 3136, 3137, 3138, 3139, 3140, 3141, 3142, 3143, 3144, 3145, 3146,
    3147, 3148, 3149, 3150, 3151, 3152, 3153, 3154, 3155, 3156, 3157, 3158,
    3159, 3160, 3161, 3162, 3163, 3164, 3165, 3166, 3167, 3168, 3169, 3170,
    3171, 3172, 3173, 3174, 3175, 3176, 3177, 3178, 3179, 3180, 3181, 3182,
    3183, 3184, 3185, 3186, 3187, 3188, 3189, 3190, 3191, 3192, 3193, 3194,
    3195, 3196, 3197, 3198, 3199, 3200, 3201, 3202, 3203, 3204, 3205, 3206,
    3207, 3208, 3209, 3210, 3211, 3212, 3213, 3214, 3215, 3216, 3217, 3218,
    3219, 3220, 3221, 3222, 3223, 3224, 3225, 3226, 3227, 3228, 3229, 3230,
    3231, 3232, 3233, 3234, 3235, 3236, 3237, 3238, 3239, 3240, 3241, 3242,
    3243, 3244, 3245, 3246, 3247, 3248, 3249, 3250, 3251, 3252, 3253, 3254,
    3255, 3256, 3257, 3258, 3259, 3260, 3261, 3262, 3263, 3264, 3265, 3266,
    3267, 3268, 3269, 3270, 3271, 3272, 3273, 3274, 3275, 3276, 3277, 3278,
    3279, 3280, 3281, 3282, 3283, 3284, 3285, 3286, 3287, 3288, 3289, 3290,
    3291, 3292, 3293, 3294, 3295, 3296, 3297, 3298, 3299, 3300, 3301, 3302,
    3303, 3304, 3305, 3306, 3307, 3308, 3309, 3310, 3311, 3312, 3313, 3314,
    3315, 3316, 3317, 3318, 3319, 3320, 3321, 3322, 3323, 3324, 3325, 3326,
    3327, 3328, 3329, 3330, 3331, 3332, 3333, 3334, 3335, 3336, 3337, 3338,
    3339, 3340, 3341, 3342, 3343, 3344, 3345, 3346, 3347, 3348, 3349, 3350,
    3351, 3352, 3353, 3354, 3355, 3356, 3357, 3358, 3359, 3360, 3361, 3362,
    3363, 3364, 3365, 3366, 3367, 3368, 3369, 3370, 3371, 3372, 3373, 3374,
    3375, 3376, 3377, 3378, 3379, 3380, 3381, 3382, 3383, 3384, 3385, 3386,
    3387, 3388, 3389, 3390, 3391, 3392, 3393, 3394, 3395, 3396, 3397, 3398,
    3399, 3400, 3401, 3402, 3403, 3404, 3405, 3406, 3407, 3408, 3409, 3410,
    3411, 3412, 3413, 3414, 3415, 3416, 3417, 3418, 3419, 3420, 3421, 3422,
    3423, 3424, 3425, 3426, 3427, 3428, 3429, 3430, 3431, 3432, 3433, 3434,
    3435, 3436, 3437, 3438, 3439, 3440, 3441, 3442, 3443, 3444, 3445, 3446,
    3447, 3448, 3449, 3450, 3451, 3452, 3453, 3454, 3455, 3456, 3457, 3458,
    3459, 3460, 3461, 3462, 3463, 3464, 3465, 3466, 3467, 3468, 3469, 3470,
    3471, 3472, 3473, 3474, 3475, 3476, 3477, 3478, 3479, 3480, 3481, 3482,
    3483, 3484, 3485, 3486, 3487, 3488, 3489, 3490, 3491, 3492, 3493, 3494,
    3495, 3496, 3497, 3498, 3499, 3500, 3501, 3502, 3503, 3504, 3505, 3506,
    3507, 3508, 3509, 3510, 3511, 3512, 3513, 3514, 3515, 3516, 3517, 3518,
    3519, 3520, 3521, 3522, 3523, 3524, 3525, 3526, 3527, 3528, 3529, 3530,
    3531, 3532, 3533, 3534, 3535, 3536, 3537, 3538, 3539, 3540, 3541, 3542,
    3543, 3544, 3545, 3546, 3547, 3548, 3549, 3550, 3551, 3552, 3553, 3554,
    3555, 3556, 3557, 3558, 3559, 3560, 3561, 3562, 3563, 3564, 3565, 3566,
    3567, 3568, 3569, 3570, 3571, 3572, 3573, 3574, 3575, 3576, 3577, 3578,
    3579, 3580, 3581, 3582, 3583, 3584, 3585, 3586, 3587, 3588, 3589, 3590,
    3591, 3592, 3593, 3594, 3595, 3596, 3597, 3598, 3599, 3600, 3601, 3602,
    3603, 3604, 3605, 3606, 3607, 3608, 3609, 3610, 3611, 3612, 3613, 3614,
    3615, 3616, 3617, 3618, 3619, 3620, 3621, 3622, 3623, 3624, 3625, 3626,
    3627, 3628, 3629, 3630, 3631, 3632, 3633, 3634, 3635, 3636, 3637, 3638,
    3639, 3640, 3641, 3642, 3643, 3644, 3645, 3646, 3647, 3648, 3649, 3650,
    3651, 3652, 3653, 3654, 3655, 3656, 3657, 3658, 3659, 3660, 3661, 3662,
    3663, 3664, 3665, 3666, 3667, 3668, 3669, 3670, 3671, 3672, 3673, 3674,
    3675, 3676, 3677, 3678, 3679, 3680, 3681, 3682, 3683, 3684, 3685, 3686,
    3687, 3688, 3689, 3690, 3691, 3692, 3693, 3694, 3695, 3696, 3697, 3698,
    3699, 3700, 3701, 3702, 3703, 3704, 3705, 3706, 3707, 3708, 3709, 3710,
    3711, 3712, 3713, 3714, 3715, 3716, 3717, 3718, 3719, 3720, 3721, 3722,
    3723, 3724, 3725, 3726, 3727, 3728, 3729, 3730, 3731, 3732, 3733, 3734,
    3735, 3736, 3737, 3738, 3739, 3740, 3741, 3742, 3743, 3744, 3745, 3746,
    3747, 3748, 3749, 3750, 3751, 3752, 3753, 3754, 3755, 3756, 3757, 3758,
    3759, 3760, 3761, 3762, 3763, 3764, 3765, 3766, 3767, 3768, 3769, 3770,
    3771, 3772, 3773, 3774, 3775, 3776, 3777, 3778, 3779, 3780, 3781, 3782,
    3783, 3784, 3785, 3786, 3787, 3788, 3789, 3790, 3791, 3792, 3793, 3794,
    3795, 3796, 3797, 3798, 3799, 3800, 3801, 3802, 3803, 3804, 3805, 3806,
    3807, 3808, 3809, 3810, 3811, 3812, 3813, 3814, 3815, 3816, 3817, 3818,
    3819, 3820, 3821, 3822, 3823, 3824, 3825, 3826, 3827, 3828, 3829, 3830,
    3831, 3832, 3833, 3834, 3835, 3836, 3837, 3838, 3839, 3840, 3841, 3842,
    3843, 3844, 3845, 3846, 3847, 3848, 3849, 3850, 3851, 3852, 3853, 3854,
    3855, 3856, 3857, 3858, 3859, 3860, 3861, 3862, 3863, 3864, 3865, 3866,
    3867, 3868, 3869, 3870, 3871, 3872, 3873, 3874, 3875, 3876, 3877, 3878,
    3879, 3880, 3881, 3882, 3883, 3884, 3885, 3886, 3887, 3888, 3889, 3890,
    3891, 3892, 3893, 3894, 3895, 3896, 3897, 3898, 3899, 3900, 3901, 3902,
    3903, 3904, 3905, 3906, 3907, 3908, 3909, 3910, 3911, 3912, 3913, 3914,
    3915, 3916, 3917, 3918, 3919, 3920, 3921, 3922, 3923, 3924, 3925, 3926,
    3927, 3928, 3929, 3930, 3931, 3932, 3933, 3934, 3935, 3936, 3937, 3938,
    3939, 3940, 3941, 3942, 3943, 3944, 3945, 3946, 3947, 3948, 3949, 3950,
    3951, 3952, 3953, 3954, 3955, 3956, 3957, 3958, 3959, 3960, 3961, 3962,
    3963, 3964, 3965, 3966, 3967, 3968, 3969, 3970, 3971, 3972, 3973, 3974,
    3975, 3976, 3977, 3978, 3979, 3980, 3981, 3982, 3983, 3984, 3985, 3986,
    3987, 3988, 3989, 3990, 3991, 3992, 3993, 3994, 3995, 3996, 3997, 3998,
    3999, 4000, 4001, 4002, 4003, 4004, 4005, 4006, 4007, 4008, 4009, 4010,
    4011, 4012, 4013, 4014, 4015, 4016, 4017, 4018, 4019, 4020, 4021, 4022,
    4023, 4024, 4025, 4026, 4027, 4028, 4029, 4030, 4031, 4032, 4033, 4034,
    4035, 4036, 4037, 4038, 4039, 4040, 4041, 4042, 4043, 4044, 4045, 4046,
    4047, 4048, 4049, 4050, 4051, 4052, 4053, 4054, 4055, 4056, 4057, 4058,
    4059, 4060, 4061, 4062, 4063, 4064, 4065, 4066, 4067, 4068, 4069, 4070,
    4071, 4072, 4073, 4074, 4075, 4076, 4077, 4078, 4079, 4080, 4081, 4082,
    4083, 4084, 4085, 4086, 4087, 4088, 4089, 4090, 4091, 4092, 4093, 4094,
    4095, 4096, 4097, 4098, 4099, 4100, 4101, 4102, 4103, 4104, 4105, 4106,
    4107, 4108, 4109, 4110, 4111, 4112, 4113, 4114, 4115, 4116, 4117, 4118,
    4119, 4120, 4121, 4122, 4123, 4124, 4125, 4126, 4127, 4128, 4129, 4130,
    4131, 4132, 4133, 4134, 4135, 4136, 4137, 4138, 4139, 4140, 4141, 4142,
    4143, 4144, 4145, 4146, 4147, 4148, 4149, 4150, 4151, 4152, 4153, 4154,
    4155, 4156, 4157, 4158, 4159, 4160, 4161, 4162, 4163, 4164, 4165, 4166,
    4167, 4168, 4169, 4170, 4171, 4172, 4173, 4174, 4175, 4176, 4177, 4178,
    4179, 4180, 4181, 4182, 4183, 4184, 4185, 4186, 4187, 4188, 4189, 4190,
    4191, 4192, 4193, 4194, 4195, 4196, 4197, 4198, 4199, 4200, 4201, 4202,
    4203, 4204, 4205, 4206, 4207, 4208, 4209, 4210, 4211, 4212, 4213, 4214,
    4215, 4216, 4217, 4218, 4219, 4220, 4221, 4222, 4223, 4224, 4225, 4226,
    4227, 4228, 4229, 4230, 4231, 4232, 4233, 4234, 4235, 4236, 4237, 4238,
    4239, 4240, 4241, 4242, 4243, 4244, 4245, 4246, 4247, 4248, 4249, 4250,
    4251, 4252, 4253, 4254, 4255, 4256, 4257, 4258, 4259, 4260, 4261, 4262,
    4263, 4264, 4265, 4266, 4267, 4268, 4269, 4270, 4271, 4272, 4273, 4274,
    4275, 4276, 4277, 4278, 4279, 4280, 4281
  ],
  "nct_id": [
    "NCT02070549",
    "NCT02359565",
    "NCT03137771",
    "NCT03300544",
    "NCT03907475",
    "NCT04047628",
    "NCT04197713",
    "NCT04494113",
    "NCT04539366",
    "NCT04665739",
    "NCT04743661",
    "NCT04550494",
    "NCT04576091",
    "NCT04577755",
    "NCT04750954",
    "NCT04847453",
    "NCT05001880",
    "NCT02862275",
    "NCT02993146",
    "NCT03971734",
    "NCT04108858",
    "NCT04317105",
    "NCT02437851",
    "NCT03321643",
    "NCT03798678",
    "NCT04139304",
    "NCT04294628",
    "NCT04535401",
    "NCT04585958",
    "NCT04803201",
    "NCT02502266",
    "NCT02797470",
    "NCT02879695",
    "NCT03031730",
    "NCT03803761",
    "NCT03973918",
    "NCT04068194",
    "NCT04221438",
    "NCT04250545",
    "NCT04557956",
    "NCT04751383",
    "NCT04851119",
    "NCT01861093",
    "NCT02890329",
    "NCT03041688",
    "NCT03218826",
    "NCT03250299",
    "NCT03603808",
    "NCT03772925",
    "NCT04491942",
    "NCT05040360",
    "NCT02595866",
    "NCT03375307",
    "NCT03842228",
    "NCT03939897",
    "NCT03953898",
    "NCT04301076",
    "NCT04460937",
    "NCT04500548",
    "NCT04652960",
    "NCT04840602",
    "NCT02298959",
    "NCT02799485",
    "NCT03030378",
    "NCT03107780",
    "NCT03513952",
    "NCT03528642",
    "NCT03598244",
    "NCT03816332",
    "NCT03965494",
    "NCT02568553",
    "NCT02717455",
    "NCT03389802",
    "NCT03904862",
    "NCT04514497",
    "NCT04595747",
    "NCT02595879",
    "NCT03878095",
    "NCT04052555",
    "NCT04201457",
    "NCT04234568",
    "NCT04295759",
    "NCT04345913",
    "NCT04533750",
    "NCT04704661",
    "NCT02498613",
    "NCT03033992",
    "NCT03600701",
    "NCT03831932",
    "NCT03604978",
    "NCT04391049",
    "NCT04541017",
    "NCT02595931",
    "NCT03606967",
    "NCT02567422",
    "NCT02923778",
    "NCT03077451",
    "NCT03914742",
    "NCT04458922",
    "NCT02059499",
    "NCT02305654",
    "NCT03220022",
    "NCT03237780",
    "NCT03284385",
    "NCT02978625",
    "NCT03317392",
    "NCT04438382",
    "NCT04071236",
    "NCT04167514",
    "NCT04203316",
    "NCT04609046",
    "NCT04158141",
    "NCT03587311",
    "NCT04729959",
    "NCT02323880",
    "NCT02408861",
    "NCT03186898",
    "NCT03854474",
    "NCT03803774",
    "NCT01989585",
    "NCT04090398",
    "NCT04467021",
    "NCT03180502",
    "NCT04172532",
    "NCT04216316",
    "NCT03126630",
    "NCT04071223",
    "NCT04616560",
    "NCT03592641",
    "NCT04684368",
    "NCT03896503",
    "NCT03872427",
    "NCT03904134",
    "NCT04423211",
    "NCT04588246",
    "NCT03816358",
    "NCT03141684",
    "NCT03212274",
    "NCT04340843",
    "NCT02466971",
    "NCT02849496",
    "NCT03217266",
    "NCT03816345",
    "NCT02179086",
    "NCT04871529",
    "NCT02314169",
    "NCT03550391",
    "NCT04576117",
    "NCT01993810",
    "NCT04394858",
    "NCT03190915",
    "NCT04333537",
    "NCT04216290",
    "NCT03801876",
    "NCT04530565",
    "NCT04628767",
    "NCT04751370",
    "NCT04671667",
    "NCT04385277",
    "NCT04484818",
    "NCT03941860",
    "NCT04799275",
    "NCT03834961",
    "NCT04708418",
    "NCT04759586",
    "NCT03224767",
    "NCT03504644",
    "NCT04339738",
    "NCT04195399",
    "NCT03233204",
    "NCT04166409",
    "NCT04310020",
    "NCT03871257",
    "NCT03220035",
    "NCT02375204",
    "NCT04315324",
    "NCT03213652",
    "NCT03213704",
    "NCT03210714",
    "NCT03213678",
    "NCT03526250",
    "NCT00980954",
    "NCT03493425",
    "NCT03794349",
    "NCT04994132",
    "NCT04546399",
    "NCT03233191",
    "NCT02443077",
    "NCT04647916",
    "NCT04114981",
    "NCT04858334",
    "NCT04579224",
    "NCT03701308",
    "NCT04145115",
    "NCT03944941",
    "NCT03180268",
    "NCT02981628",
    "NCT03817398",
    "NCT04164082",
    "NCT02582697",
    "NCT04739800",
    "NCT03997370",
    "NCT03126916",
    "NCT02135042",
    "NCT03155620",
    "NCT04322318",
    "NCT04195555",
    "NCT04284774",
    "NCT04320888",
    "NCT03598257",
    "NCT03994796",
    "NCT04455750",
    "NCT02724579",
    "NCT04293562",
    "NCT02521493",
    "NCT03533582",
    "NCT01810913",
    "NCT04527549",
    "NCT03007147",
    "NCT04340141",
    "NCT02176967",
    "NCT04402788",
    "NCT03959085",
    "NCT04396860",
    "NCT03516279",
    "NCT04548752",
    "NCT03914625",
    "NCT04510597",
    "NCT04269902",
    "NCT04214262",
    "NCT04852887",
    "NCT03866382",
    "NCT03367702",
    "NCT03694002",
    "NCT04239573",
    "NCT03739814",
    "NCT04444921",
    "NCT03914612",
    "NCT04181060",
    "NCT03775265",
    "NCT04214067",
    "NCT04155034",
    "NCT03375320",
    "NCT03609216",
    "NCT04559139",
    "NCT03267433",
    "NCT02567435",
    "NCT03678025",
    "NCT03488693",
    "NCT01896999",
    "NCT04511013",
    "NCT04462406",
    "NCT03952585",
    "NCT02997228",
    "NCT04637594",
    "NCT03269669",
    "NCT04625647",
    "NCT04533451",
    "NCT01101451",
    "NCT03604991",
    "NCT03150693",
    "NCT03937635",
    "NCT03907488",
    "NCT03737981",
    "NCT04205968",
    "NCT03811015",
    "NCT02734537",
    "NCT04115631",
    "NCT03793166",
    "NCT04166318",
    "NCT04566328",
    "NCT03654768",
    "NCT03811002",
    "NCT02523014",
    "NCT03067181",
    "NCT03712605",
    "NCT04334941",
    "NCT04457596",
    "NCT02339571",
    "NCT04094688",
    "NCT03660826",
    "NCT04310007",
    "NCT04071457",
    "NCT03199885",
    "NCT04095364",
    "NCT02912559",
    "NCT04233866",
    "NCT03365882",
    "NCT04092283",
    "NCT03698019",
    "NCT04068103",
    "NCT04266249",
    "NCT03851445",
    "NCT02834013",
    "NCT01901094",
    "NCT03793179",
    "NCT02488967",
    "NCT02465060",
    "NCT02201992",
    "NCT02194738",
    "NCT00001379",
    "NCT00107289",
    "NCT00357565",
    "NCT00412594",
    "NCT00501826",
    "NCT00630565",
    "NCT00707473",
    "NCT00719888",
    "NCT00801489",
    "NCT00959140",
    "NCT01050855",
    "NCT01059786",
    "NCT01087294",
    "NCT01088789",
    "NCT01089374",
    "NCT01176006",
    "NCT01245712",
    "NCT01349101",
    "NCT01371630",
    "NCT01411345",
    "NCT01415882",
    "NCT01424982",
    "NCT01473628",
    "NCT01473784",
    "NCT01515527",
    "NCT01552434",
    "NCT01582191",
    "NCT01624805",
    "NCT01644591",
    "NCT01701986",
    "NCT01703949",
    "NCT01712308",
    "NCT01712659",
    "NCT01737502",
    "NCT01738139",
    "NCT01746836",
    "NCT01760655",
    "NCT01783535",
    "NCT01787487",
    "NCT01812252",
    "NCT01850888",
    "NCT01861106",
    "NCT01879085",
    "NCT01890590",
    "NCT01891318",
    "NCT01946854",
    "NCT02038478",
    "NCT02047474",
    "NCT02054689",
    "NCT02061800",
    "NCT02064673",
    "NCT02068586",
    "NCT02072356",
    "NCT02106988",
    "NCT02112617",
    "NCT02115295",
    "NCT02122081",
    "NCT02126553",
    "NCT02135874",
    "NCT02146924",
    "NCT02159495",
    "NCT02160925",
    "NCT02161705",
    "NCT02199184",
    "NCT02202772",
    "NCT02207465",
    "NCT02210078",
    "NCT02211755",
    "NCT02231775",
    "NCT02245997",
    "NCT02251821",
    "NCT02286687",
    "NCT02302833",
    "NCT02311621",
    "NCT02311998",
    "NCT02314364",
    "NCT02321501",
    "NCT02333162",
    "NCT02343224",
    "NCT02356159",
    "NCT02369458",
    "NCT02370329",
    "NCT02372409",
    "NCT02378428",
    "NCT02379416",
    "NCT02389309",
    "NCT02390518",
    "NCT02390752",
    "NCT02397720",
    "NCT02401347",
    "NCT02411656",
    "NCT02451553",
    "NCT02452697",
    "NCT02453191",
    "NCT02456857",
    "NCT02458014",
    "NCT02462460",
    "NCT02473536",
    "NCT02476786",
    "NCT02479698",
    "NCT02482376",
    "NCT02484404",
    "NCT02494700",
    "NCT02508038",
    "NCT02512497",
    "NCT02530463",
    "NCT02535533",
    "NCT02542202",
    "NCT02566304",
    "NCT02579967",
    "NCT02600949",
    "NCT02605421",
    "NCT02611037",
    "NCT02613650",
    "NCT02624258",
    "NCT02629809",
    "NCT02633397",
    "NCT02638090",
    "NCT02643667",
    "NCT02649972",
    "NCT02650414",
    "NCT02658565",
    "NCT02659930",
    "NCT02661035",
    "NCT02666105",
    "NCT02666378",
    "NCT02669251",
    "NCT02684162",
    "NCT02689427",
    "NCT02689440",
    "NCT02690545",
    "NCT02698254",
    "NCT02698293",
    "NCT02700230",
    "NCT02701153",
    "NCT02706353",
    "NCT02707666",
    "NCT02709226",
    "NCT02713269",
    "NCT02715609",
    "NCT02722668",
    "NCT02728050",
    "NCT02738606",
    "NCT02752685",
    "NCT02759731",
    "NCT02769962",
    "NCT02774421",
    "NCT02777385",
    "NCT02780128",
    "NCT02790515",
    "NCT02792582",
    "NCT02793466",
    "NCT02816021",
    "NCT02824575",
    "NCT02827838",
    "NCT02834975",
    "NCT02846623",
    "NCT02858310",
    "NCT02859415",
    "NCT02861417",
    "NCT02864147",
    "NCT02867618",
    "NCT02875561",
    "NCT02877303",
    "NCT02880293",
    "NCT02885324",
    "NCT02892305",
    "NCT02897375",
    "NCT02897427",
    "NCT02902484",
    "NCT02910700",
    "NCT02911142",
    "NCT02913430",
    "NCT02916979",
    "NCT02921893",
    "NCT02922777",
    "NCT02928991",
    "NCT02933255",
    "NCT02947386",
    "NCT02949284",
    "NCT02959463",
    "NCT02962661",
    "NCT02970448",
    "NCT02971748",
    "NCT02977468",
    "NCT02979977",
    "NCT02980029",
    "NCT02981914",
    "NCT02988466",
    "NCT02990819",
    "NCT02994069",
    "NCT03003546",
    "NCT03006302",
    "NCT03007030",
    "NCT03011814",
    "NCT03012230",
    "NCT03013933",
    "NCT03017833",
    "NCT03019666",
    "NCT03021460",
    "NCT03025256",
    "NCT03028337",
    "NCT03032406",
    "NCT03032783",
    "NCT03033225",
    "NCT03037437",
    "NCT03043664",
    "NCT03047746",
    "NCT03054298",
    "NCT03057990",
    "NCT03063944",
    "NCT03064490",
    "NCT03065387",
    "NCT03066206",
    "NCT03067571",
    "NCT03068819",
    "NCT03073785",
    "NCT03076554",
    "NCT03078010",
    "NCT03085056",
    "NCT03086642",
    "NCT03087071",
    "NCT03087760",
    "NCT03089554",
    "NCT03092518",
    "NCT03093844",
    "NCT03093909",
    "NCT03094637",
    "NCT03094884",
    "NCT03096418",
    "NCT03096782",
    "NCT03100045",
    "NCT03101748",
    "NCT03103971",
    "NCT03104439",
    "NCT03114865",
    "NCT03118492",
    "NCT03120624",
    "NCT03121677",
    "NCT03122301",
    "NCT03122444",
    "NCT03123978",
    "NCT03125642",
    "NCT03126331",
    "NCT03127774",
    "NCT03128866",
    "NCT03128879",
    "NCT03132454",
    "NCT03133221",
    "NCT03133650",
    "NCT03136146",
    "NCT03143985",
    "NCT03147612",
    "NCT03147885",
    "NCT03153202",
    "NCT03158129",
    "NCT03158896",
    "NCT03161522",
    "NCT03164460",
    "NCT03173976",
    "NCT03175432",
    "NCT03181100",
    "NCT03187353",
    "NCT03188432",
    "NCT03190967",
    "NCT03197506",
    "NCT03198026",
    "NCT03200587",
    "NCT03202316",
    "NCT03203525",
    "NCT03206060",
    "NCT03206177",
    "NCT03207529",
    "NCT03207555",
    "NCT03210662",
    "NCT03211988",
    "NCT03214562",
    "NCT03215719",
    "NCT03216421",
    "NCT03222076",
    "NCT03223610",
    "NCT03223779",
    "NCT03223922",
    "NCT03226418",
    "NCT03228186",
    "NCT03233724",
    "NCT03233854",
    "NCT03237572",
    "NCT03237611",
    "NCT03240016",
    "NCT03245489",
    "NCT03245892",
    "NCT03246074",
    "NCT03247088",
    "NCT03251027",
    "NCT03253289",
    "NCT03253744",
    "NCT03258567",
    "NCT03258593",
    "NCT03259503",
    "NCT03259581",
    "NCT03259763",
    "NCT03260504",
    "NCT03262103",
    "NCT03262779",
    "NCT03263572",
    "NCT03264404",
    "NCT03267836",
    "NCT03267888",
    "NCT03269526",
    "NCT03272334",
    "NCT03272633",
    "NCT03277638",
    "NCT03277729",
    "NCT03282396",
    "NCT03283917",
    "NCT03286335",
    "NCT03287271",
    "NCT03290079",
    "NCT03292536",
    "NCT03295227",
    "NCT03304418",
    "NCT03311308",
    "NCT03313804",
    "NCT03314974",
    "NCT03315871",
    "NCT03321188",
    "NCT03321630",
    "NCT03324373",
    "NCT03326310",
    "NCT03331250",
    "NCT03331341",
    "NCT03333486",
    "NCT03338959",
    "NCT03341143",
    "NCT03342196",
    "NCT03345420",
    "NCT03348748",
    "NCT03352245",
    "NCT03352765",
    "NCT03359239",
    "NCT03360890",
    "NCT03361436",
    "NCT03361735",
    "NCT03366155",
    "NCT03367871",
    "NCT03370718",
    "NCT03376477",
    "NCT03376659",
    "NCT03377517",
    "NCT03378102",
    "NCT03386500",
    "NCT03388619",
    "NCT03389230",
    "NCT03389477",
    "NCT03390296",
    "NCT03395847",
    "NCT03398161",
    "NCT03401853",
    "NCT03404193",
    "NCT03404960",
    "NCT03407976",
    "NCT03409432",
    "NCT03412812",
    "NCT03413995",
    "NCT03417284",
    "NCT03420963",
    "NCT03421782",
    "NCT03422302",
    "NCT03424850",
    "NCT03425526",
    "NCT03430882",
    "NCT03431090",
    "NCT03434262",
    "NCT03435952",
    "NCT03436290",
    "NCT03436563",
    "NCT03439085",
    "NCT03439891",
    "NCT03441061",
    "NCT03442556",
    "NCT03447808",
    "NCT03448393",
    "NCT03449108",
    "NCT03450850",
    "NCT03452930",
    "NCT03458234",
    "NCT03459859",
    "NCT03460067",
    "NCT03463460",
    "NCT03467516",
    "NCT03468075",
    "NCT03469362",
    "NCT03471286",
    "NCT03471650",
    "NCT03472573",
    "NCT03480360",
    "NCT03481114",
    "NCT03482557",
    "NCT03482791",
    "NCT03483883",
    "NCT03486197",
    "NCT03488472",
    "NCT03488667",
    "NCT03490292",
    "NCT03494569",
    "NCT03495713",
    "NCT03498612",
    "NCT03500991",
    "NCT03501368",
    "NCT03502330",
    "NCT03505762",
    "NCT03507608",
    "NCT03508570",
    "NCT03508726",
    "NCT03508752",
    "NCT03512405",
    "NCT03513484",
    "NCT03513562",
    "NCT03514017",
    "NCT03514069",
    "NCT03516708",
    "NCT03519997",
    "NCT03520842",
    "NCT03521830",
    "NCT03527108",
    "NCT03531645",
    "NCT03533816",
    "NCT03533946",
    "NCT03535350",
    "NCT03535506",
    "NCT03535727",
    "NCT03539822",
    "NCT03542409",
    "NCT03543189",
    "NCT03543969",
    "NCT03546829",
    "NCT03548285",
    "NCT03553004",
    "NCT03554356",
    "NCT03560882",
    "NCT03564873",
    "NCT03565783",
    "NCT03572283",
    "NCT03572387",
    "NCT03573024",
    "NCT03573700",
    "NCT03573947",
    "NCT03576547",
    "NCT03579875",
    "NCT03581487",
    "NCT03582475",
    "NCT03585764",
    "NCT03586609",
    "NCT03586661",
    "NCT03587038",
    "NCT03587662",
    "NCT03591861",
    "NCT03592888",
    "NCT03598595",
    "NCT03600155",
    "NCT03600350",
    "NCT03601507",
    "NCT03602157",
    "NCT03602235",
    "NCT03603223",
    "NCT03607890",
    "NCT03608631",
    "NCT03612466",
    "NCT03613727",
    "NCT03618381",
    "NCT03620019",
    "NCT03620201",
    "NCT03621748",
    "NCT03622775",
    "NCT03622788",
    "NCT03623854",
    "NCT03627403",
    "NCT03629171",
    "NCT03630991",
    "NCT03631043",
    "NCT03632941",
    "NCT03634228",
    "NCT03634267",
    "NCT03638141",
    "NCT03642067",
    "NCT03642626",
    "NCT03643861",
    "NCT03649321",
    "NCT03656133",
    "NCT03657108",
    "NCT03660930",
    "NCT03661307",
    "NCT03661424",
    "NCT03663933",
    "NCT03670056",
    "NCT03670069",
    "NCT03671811",
    "NCT03672318",
    "NCT03672539",
    "NCT03678350",
    "NCT03680586",
    "NCT03683433",
    "NCT03685331",
    "NCT03689894",
    "NCT03690921",
    "NCT03694249",
    "NCT03694834",
    "NCT03695471",
    "NCT03696030",
    "NCT03696784",
    "NCT03697408",
    "NCT03698552",
    "NCT03699319",
    "NCT03699995",
    "NCT03707925",
    "NCT03710421",
    "NCT03712098",
    "NCT03712878",
    "NCT03714828",
    "NCT03718767",
    "NCT03719430",
    "NCT03719768",
    "NCT03725436",
    "NCT03726359",
    "NCT03727789",
    "NCT03728673",
    "NCT03729115",
    "NCT03729518",
    "NCT03730948",
    "NCT03735875",
    "NCT03737955",
    "NCT03741673",
    "NCT03744793",
    "NCT03746080",
    "NCT03749018",
    "NCT03749460",
    "NCT03751436",
    "NCT03755414",
    "NCT03756818",
    "NCT03756896",
    "NCT03757689",
    "NCT03760523",
    "NCT03762161",
    "NCT03763162",
    "NCT03765229",
    "NCT03767582",
    "NCT03768492",
    "NCT03769155",
    "NCT03769415",
    "NCT03769766",
    "NCT03770416",
    "NCT03771651",
    "NCT03776487",
    "NCT03776864",
    "NCT03784326",
    "NCT03784677",
    "NCT03785210",
    "NCT03786354",
    "NCT03786796",
    "NCT03789097",
    "NCT03789240",
    "NCT03792516",
    "NCT03792633",
    "NCT03796273",
    "NCT03796767",
    "NCT03798301",
    "NCT03799445",
    "NCT03801369",
    "NCT03801915",
    "NCT03805932",
    "NCT03808558",
    "NCT03808610",
    "NCT03810196",
    "NCT03810651",
    "NCT03812289",
    "NCT03818776",
    "NCT03819985",
    "NCT03824327",
    "NCT03825289",
    "NCT03829111",
    "NCT03830164",
    "NCT03831295",
    "NCT03832361",
    "NCT03838692",
    "NCT03839498",
    "NCT03842696",
    "NCT03844750",
    "NCT03844815",
    "NCT03844997",
    "NCT03849651",
    "NCT03851081",
    "NCT03853707",
    "NCT03854903",
    "NCT03856216",
    "NCT03862157",
    "NCT03864419",
    "NCT03867175",
    "NCT03870529",
    "NCT03872388",
    "NCT03873818",
    "NCT03878524",
    "NCT03878979",
    "NCT03879694",
    "NCT03885284",
    "NCT03891784",
    "NCT03892044",
    "NCT03892642",
    "NCT03892720",
    "NCT03894553",
    "NCT03896269",
    "NCT03896568",
    "NCT03896646",
    "NCT03899987",
    "NCT03902951",
    "NCT03903640",
    "NCT03909282",
    "NCT03909412",
    "NCT03911388",
    "NCT03911557",
    "NCT03912818",
    "NCT03913559",
    "NCT03914794",
    "NCT03916419",
    "NCT03919292",
    "NCT03921008",
    "NCT03922724",
    "NCT03922893",
    "NCT03923270",
    "NCT03927261",
    "NCT03927274",
    "NCT03927989",
    "NCT03932409",
    "NCT03932643",
    "NCT03936478",
    "NCT03942224",
    "NCT03942328",
    "NCT03943173",
    "NCT03943901",
    "NCT03944915",
    "NCT03946527",
    "NCT03946878",
    "NCT03950609",
    "NCT03951831",
    "NCT03954236",
    "NCT03955978",
    "NCT03957551",
    "NCT03957876",
    "NCT03958045",
    "NCT03958383",
    "NCT03958721",
    "NCT03959891",
    "NCT03961971",
    "NCT03962647",
    "NCT03963414",
    "NCT03964090",
    "NCT03964337",
    "NCT03968406",
    "NCT03969446",
    "NCT03969706",
    "NCT03970252",
    "NCT03972930",
    "NCT03972943",
    "NCT03977233",
    "NCT03978624",
    "NCT03979066",
    "NCT03980509",
    "NCT03980769",
    "NCT03982212",
    "NCT03983668",
    "NCT03983850",
    "NCT03987217",
    "NCT03989466",
    "NCT03990571",
    "NCT03990610",
    "NCT03990961",
    "NCT03991884",
    "NCT03991962",
    "NCT03995706",
    "NCT03999515",
    "NCT04002947",
    "NCT04002986",
    "NCT04003246",
    "NCT04004442",
    "NCT04005690",
    "NCT04006652",
    "NCT04007029",
    "NCT04009044",
    "NCT04009148",
    "NCT04010357",
    "NCT04011410",
    "NCT04013854",
    "NCT04015700",
    "NCT04017650",
    "NCT04019262",
    "NCT04019964",
    "NCT04020094",
    "NCT04020276",
    "NCT04021043",
    "NCT04022213",
    "NCT04022239",
    "NCT04022343",
    "NCT04022785",
    "NCT04023669",
    "NCT04027348",
    "NCT04027946",
    "NCT04028063",
    "NCT04028245",
    "NCT04029038",
    "NCT04030455",
    "NCT04030559",
    "NCT04033432",
    "NCT04034251",
    "NCT04037527",
    "NCT04038489",
    "NCT04038619",
    "NCT04040569",
    "NCT04043195",
    "NCT04046094",
    "NCT04046575",
    "NCT04047641",
    "NCT04049539",
    "NCT04050280",
    "NCT04051606",
    "NCT04052334",
    "NCT04054167",
    "NCT04054752",
    "NCT04056910",
    "NCT04062266",
    "NCT04069923",
    "NCT04070781",
    "NCT04071756",
    "NCT04073745",
    "NCT04074746",
    "NCT04074785",
    "NCT04074967",
    "NCT04080804",
    "NCT04081220",
    "NCT04081389",
    "NCT04081688",
    "NCT04082520",
    "NCT04082572",
    "NCT04083495",
    "NCT04083898",
    "NCT04088890",
    "NCT04089904",
    "NCT04095221",
    "NCT04098081",
    "NCT04098393",
    "NCT04099836",
    "NCT04104139",
    "NCT04106362",
    "NCT04106856",
    "NCT04107077",
    "NCT04108481",
    "NCT04108624",
    "NCT04109729",
    "NCT04111107",
    "NCT04111172",
    "NCT04111510",
    "NCT04112641",
    "NCT04114136",
    "NCT04116073",
    "NCT04116320",
    "NCT04117087",
    "NCT04120246",
    "NCT04120454",
    "NCT04123262",
    "NCT04123379",
    "NCT04128501",
    "NCT04128748",
    "NCT04129515",
    "NCT04131413",
    "NCT04131738",
    "NCT04134325",
    "NCT04136275",
    "NCT04139902",
    "NCT04139993",
    "NCT04140487",
    "NCT04141644",
    "NCT04145297",
    "NCT04146038",
    "NCT04147806",
    "NCT04148430",
    "NCT04150640",
    "NCT04150692",
    "NCT04150900",
    "NCT04150939",
    "NCT04151667",
    "NCT04156828",
    "NCT04157127",
    "NCT04157985",
    "NCT04158349",
    "NCT04160052",
    "NCT04160494",
    "NCT04160832",
    "NCT04162665",
    "NCT04162873",
    "NCT04163432",
    "NCT04163718",
    "NCT04164979",
    "NCT04165941",
    "NCT04166383",
    "NCT04166435",
    "NCT04167917",
    "NCT04169074",
    "NCT04169737",
    "NCT04171219",
    "NCT04171440",
    "NCT04171791",
    "NCT04174352",
    "NCT04175431",
    "NCT04176497",
    "NCT04177498",
    "NCT04185038",
    "NCT04187703",
    "NCT04187833",
    "NCT04188405",
    "NCT04189757",
    "NCT04190446",
    "NCT04191187",
    "NCT04195347",
    "NCT04195633",
    "NCT04195945",
    "NCT04196010",
    "NCT04196413",
    "NCT04199754",
    "NCT04204122",
    "NCT04205240",
    "NCT04205409",
    "NCT04206319",
    "NCT04207190",
    "NCT04209686",
    "NCT04210492",
    "NCT04212416",
    "NCT04213794",
    "NCT04214392",
    "NCT04216329",
    "NCT04216472",
    "NCT04216524",
    "NCT04216563",
    "NCT04217317",
    "NCT04218617",
    "NCT04220229",
    "NCT04220684",
    "NCT04220775",
    "NCT04220827",
    "NCT04221503",
    "NCT04221893",
    "NCT04222062",
    "NCT04222413",
    "NCT04225039",
    "NCT04227028",
    "NCT04228042",
    "NCT04230304",
    "NCT04231877",
    "NCT04233567",
    "NCT04235660",
    "NCT04239157",
    "NCT04239989",
    "NCT04240808",
    "NCT04242238",
    "NCT04248192",
    "NCT04248569",
    "NCT04249622",
    "NCT04250051",
    "NCT04251416",
    "NCT04251715",
    "NCT04252612",
    "NCT04253964",
    "NCT04256018",
    "NCT04256941",
    "NCT04257578",
    "NCT04262141",
    "NCT04262843",
    "NCT04263090",
    "NCT04264143",
    "NCT04266912",
    "NCT04267120",
    "NCT04267887",
    "NCT04276870",
    "NCT04278781",
    "NCT04281199",
    "NCT04282187",
    "NCT04285671",
    "NCT04288687",
    "NCT04292119",
    "NCT04292743",
    "NCT04295720",
    "NCT04296305",
    "NCT04298242",
    "NCT04298983",
    "NCT04299113",
    "NCT04301089",
    "NCT04301414",
    "NCT04301778",
    "NCT04303117",
    "NCT04305236",
    "NCT04305379",
    "NCT04305834",
    "NCT04306367",
    "NCT04308837",
    "NCT04312841",
    "NCT04315467",
    "NCT04317781",
    "NCT04318678",
    "NCT04318717",
    "NCT04321954",
    "NCT04322383",
    "NCT04322643",
    "NCT04323202",
    "NCT04324112",
    "NCT04326257",
    "NCT04326439",
    "NCT04327700",
    "NCT04331067",
    "NCT04331119",
    "NCT04332367",
    "NCT04334174",
    "NCT04334863",
    "NCT04336943",
    "NCT04337580",
    "NCT04337827",
    "NCT04339036",
    "NCT04339101",
    "NCT04339777",
    "NCT04340882",
    "NCT04342572",
    "NCT04347226",
    "NCT04352205",
    "NCT04352777",
    "NCT04354675",
    "NCT04357587",
    "NCT04360330",
    "NCT04361708",
    "NCT04369937",
    "NCT04370301",
    "NCT04370509",
    "NCT04372927",
    "NCT04373044",
    "NCT04373369",
    "NCT04373642",
    "NCT04374019",
    "NCT04375228",
    "NCT04375384",
    "NCT04375527",
    "NCT04375631",
    "NCT04377087",
    "NCT04379518",
    "NCT04380545",
    "NCT04380831",
    "NCT04381806",
    "NCT04383743",
    "NCT04384692",
    "NCT04386746",
    "NCT04386993",
    "NCT04388852",
    "NCT04393350",
    "NCT04393454",
    "NCT04394416",
    "NCT04395079",
    "NCT04397679",
    "NCT04398199",
    "NCT04401995",
    "NCT04403620",
    "NCT04404088",
    "NCT04407247",
    "NCT04409639",
    "NCT04412629",
    "NCT04415944",
    "NCT04426669",
    "NCT04427228",
    "NCT04427306",
    "NCT04428203",
    "NCT04430036",
    "NCT04430699",
    "NCT04432506",
    "NCT04432597",
    "NCT04435691",
    "NCT04438824",
    "NCT04439006",
    "NCT04442581",
    "NCT04446182",
    "NCT04447716",
    "NCT04449549",
    "NCT04450173",
    "NCT04452357",
    "NCT04454489",
    "NCT04454528",
    "NCT04458532",
    "NCT04458610",
    "NCT04459650",
    "NCT04462328",
    "NCT04463615",
    "NCT04464200",
    "NCT04464759",
    "NCT04465500",
    "NCT04467801",
    "NCT04469530",
    "NCT04469764",
    "NCT04472767",
    "NCT04473781",
    "NCT04473833",
    "NCT04473911",
    "NCT04473937",
    "NCT04474353",
    "NCT04476537",
    "NCT04477200",
    "NCT04477512",
    "NCT04478227",
    "NCT04479267",
    "NCT04479306",
    "NCT04481113",
    "NCT04482855",
    "NCT04483206",
    "NCT04483778",
    "NCT04484012",
    "NCT04484909",
    "NCT04485026",
    "NCT04486755",
    "NCT04487106",
    "NCT04491084",
    "NCT04493138",
    "NCT04493164",
    "NCT04493203",
    "NCT04495257",
    "NCT04495894",
    "NCT04497038",
    "NCT04497779",
    "NCT04501939",
    "NCT04502602",
    "NCT04504331",
    "NCT04505254",
    "NCT04505267",
    "NCT04506008",
    "NCT04506554",
    "NCT04508647",
    "NCT04508790",
    "NCT04509765",
    "NCT04510051",
    "NCT04510285",
    "NCT04511039",
    "NCT04512105",
    "NCT04512716",
    "NCT04514692",
    "NCT04515836",
    "NCT04516070",
    "NCT04516135",
    "NCT04517435",
    "NCT04517851",
    "NCT04518345",
    "NCT04518748",
    "NCT04521335",
    "NCT04521764",
    "NCT04521946",
    "NCT04522336",
    "NCT04522804",
    "NCT04523818",
    "NCT04525859",
    "NCT04526288",
    "NCT04526730",
    "NCT04526795",
    "NCT04528199",
    "NCT04528680",
    "NCT04530487",
    "NCT04532372",
    "NCT04533373",
    "NCT04534283",
    "NCT04535102",
    "NCT04535323",
    "NCT04536077",
    "NCT04538378",
    "NCT04539808",
    "NCT04541173",
    "NCT04541407",
    "NCT04543071",
    "NCT04543279",
    "NCT04543955",
    "NCT04544098",
    "NCT04544501",
    "NCT04544592",
    "NCT04545710",
    "NCT04545762",
    "NCT04550442",
    "NCT04552223",
    "NCT04552769",
    "NCT04552990",
    "NCT04553471",
    "NCT04555551",
    "NCT04555577",
    "NCT04555811",
    "NCT04555837",
    "NCT04556266",
    "NCT04560322",
    "NCT04560439",
    "NCT04560972",
    "NCT04562129",
    "NCT04562480",
    "NCT04565665",
    "NCT04572100",
    "NCT04574856",
    "NCT04577014",
    "NCT04577326",
    "NCT04578600",
    "NCT04580446",
    "NCT04581382",
    "NCT04583488",
    "NCT04585477",
    "NCT04585490",
    "NCT04587128",
    "NCT04587687",
    "NCT04588545",
    "NCT04590664",
    "NCT04590872",
    "NCT04594187",
    "NCT04598009",
    "NCT04599140",
    "NCT04601831",
    "NCT04603365",
    "NCT04604509",
    "NCT04605614",
    "NCT04605731",
    "NCT04607954",
    "NCT04608409",
    "NCT04609592",
    "NCT04610658",
    "NCT04610671",
    "NCT04614155",
    "NCT04614194",
    "NCT04614558",
    "NCT04615013",
    "NCT04616183",
    "NCT04620603",
    "NCT04620681",
    "NCT04623801",
    "NCT04623931",
    "NCT04624113",
    "NCT04624256",
    "NCT04625699",
    "NCT04626791",
    "NCT04628338",
    "NCT04633252",
    "NCT04634071",
    "NCT04635683",
    "NCT04639245",
    "NCT04643366",
    "NCT04643379",
    "NCT04644016",
    "NCT04655157",
    "NCT04655755",
    "NCT04657094",
    "NCT04658147",
    "NCT04659616",
    "NCT04659811",
    "NCT04661384",
    "NCT04665947",
    "NCT04668300",
    "NCT04668768",
    "NCT04668885",
    "NCT04670068",
    "NCT04673448",
    "NCT04675710",
    "NCT04676087",
    "NCT04677413",
    "NCT04677816",
    "NCT04680468",
    "NCT04681105",
    "NCT04682158",
    "NCT04684563",
    "NCT04684862",
    "NCT04690855",
    "NCT04691960",
    "NCT04693468",
    "NCT04696575",
    "NCT04697576",
    "NCT04701307",
    "NCT04703101",
    "NCT04703920",
    "NCT04708067",
    "NCT04710498",
    "NCT04712539",
    "NCT04712851",
    "NCT04717804",
    "NCT04720417",
    "NCT04724980",
    "NCT04727242",
    "NCT04728230",
    "NCT04728633",
    "NCT04729725",
    "NCT04732065",
    "NCT04732845",
    "NCT04734990",
    "NCT04735068",
    "NCT04738292",
    "NCT04739813",
    "NCT04740164",
    "NCT04741542",
    "NCT04741997",
    "NCT04742595",
    "NCT04742751",
    "NCT04744935",
    "NCT04745559",
    "NCT04745949",
    "NCT04746235",
    "NCT04747912",
    "NCT04750941",
    "NCT04752163",
    "NCT04753216",
    "NCT04754945",
    "NCT04756505",
    "NCT04757662",
    "NCT04759911",
    "NCT04761614",
    "NCT04762199",
    "NCT04762953",
    "NCT04762979",
    "NCT04764942",
    "NCT04765111",
    "NCT04768426",
    "NCT04771520",
    "NCT04774068",
    "NCT04774393",
    "NCT04777708",
    "NCT04779554",
    "NCT04781088",
    "NCT04783415",
    "NCT04785287",
    "NCT04789668",
    "NCT04791839",
    "NCT04795869",
    "NCT04798339",
    "NCT04800627",
    "NCT04802031",
    "NCT04804007",
    "NCT04804709",
    "NCT04805333",
    "NCT04807777",
    "NCT04808999",
    "NCT04809766",
    "NCT04810091",
    "NCT04827732",
    "NCT04827745",
    "NCT04828486",
    "NCT04829383",
    "NCT04831320",
    "NCT04834349",
    "NCT04836429",
    "NCT04836832",
    "NCT04837209",
    "NCT04837716",
    "NCT04840615",
    "NCT04841148",
    "NCT04848064",
    "NCT04848116",
    "NCT04848337",
    "NCT04848519",
    "NCT04848974",
    "NCT04849364",
    "NCT04849871",
    "NCT04850495",
    "NCT04854304",
    "NCT04855253",
    "NCT04856189",
    "NCT04857684",
    "NCT04858269",
    "NCT04862455",
    "NCT04862650",
    "NCT04863885",
    "NCT04863950",
    "NCT04869137",
    "NCT04870788",
    "NCT04870840",
    "NCT04871607",
    "NCT04872413",
    "NCT04872595",
    "NCT04875728",
    "NCT04876456",
    "NCT04877613",
    "NCT04878029",
    "NCT04879121",
    "NCT04881240",
    "NCT04883242",
    "NCT04887805",
    "NCT04892264",
    "NCT04892303",
    "NCT04892953",
    "NCT04895592",
    "NCT04897022",
    "NCT04897217",
    "NCT04901299",
    "NCT04901702",
    "NCT04902040",
    "NCT04903119",
    "NCT04906382",
    "NCT04910152",
    "NCT04914845",
    "NCT04915508",
    "NCT04915612",
    "NCT04919369",
    "NCT04920344",
    "NCT04922307",
    "NCT04923126",
    "NCT04923542",
    "NCT04928677",
    "NCT04936529",
    "NCT04936841",
    "NCT04940286",
    "NCT04940299",
    "NCT04947501",
    "NCT04956302",
    "NCT04963283",
    "NCT04964505",
    "NCT04967196",
    "NCT04968990",
    "NCT04971187",
    "NCT04975152",
    "NCT04976257",
    "NCT04977024",
    "NCT04980404",
    "NCT04981912",
    "NCT04983901",
    "NCT04996160",
    "NCT04996823",
    "NCT04997018",
    "NCT04997993",
    "NCT04998682",
    "NCT05004116",
    "NCT05009992",
    "NCT05010122",
    "NCT05013450",
    "NCT05015426",
    "NCT05017103",
    "NCT05018325",
    "NCT05019976",
    "NCT05020444",
    "NCT05021172",
    "NCT05024552",
    "NCT05024968",
    "NCT05025800",
    "NCT05026736",
    "NCT05030454",
    "NCT05030675",
    "NCT05035706",
    "NCT05036109",
    "NCT05039801",
    "NCT05055843",
    "NCT05056207",
    "NCT05064085",
    "NCT05064410",
    "NCT05065866",
    "NCT05070403",
    "NCT05071014",
    "NCT05079698",
    "NCT05081492",
    "NCT05101356",
    "NCT05114421",
    "NCT00092222",
    "NCT00291096",
    "NCT00923013",
    "NCT00924027",
    "NCT01419561",
    "NCT01543763",
    "NCT01661400",
    "NCT01804634",
    "NCT01947140",
    "NCT02041936",
    "NCT02072148",
    "NCT02287428",
    "NCT02291848",
    "NCT02307058",
    "NCT02315612",
    "NCT02323867",
    "NCT02334865",
    "NCT02355340",
    "NCT02359929",
    "NCT02362451",
    "NCT02366819",
    "NCT02422641",
    "NCT02470897",
    "NCT02474368",
    "NCT02513563",
    "NCT02553447",
    "NCT02588651",
    "NCT02644291",
    "NCT02657551",
    "NCT02665143",
    "NCT02681549",
    "NCT02696993",
    "NCT02737046",
    "NCT02747303",
    "NCT02765854",
    "NCT02872025",
    "NCT02876107",
    "NCT02879617",
    "NCT02885974",
    "NCT02932956",
    "NCT02944578",
    "NCT02945631",
    "NCT02946996",
    "NCT02950766",
    "NCT02989636",
    "NCT02992990",
    "NCT02993068",
    "NCT02996825",
    "NCT02997761",
    "NCT02999477",
    "NCT03014648",
    "NCT03015896",
    "NCT03026062",
    "NCT03054038",
    "NCT03064867",
    "NCT03071406",
    "NCT03073694",
    "NCT03085719",
    "NCT03087903",
    "NCT03094052",
    "NCT03104491",
    "NCT03106415",
    "NCT03114527",
    "NCT03132532",
    "NCT03152318",
    "NCT03170206",
    "NCT03171025",
    "NCT03174275",
    "NCT03189381",
    "NCT03194932",
    "NCT03195699",
    "NCT03201250",
    "NCT03211416",
    "NCT03223155",
    "NCT03237377",
    "NCT03241940",
    "NCT03277482",
    "NCT03294954",
    "NCT03310879",
    "NCT03311958",
    "NCT03324425",
    "NCT03384836",
    "NCT03393845",
    "NCT03396926",
    "NCT03398694",
    "NCT03418038",
    "NCT03428802",
    "NCT03433781",
    "NCT03457948",
    "NCT03462342",
    "NCT03465592",
    "NCT03467789",
    "NCT03467867",
    "NCT03479268",
    "NCT03485547",
    "NCT03496805",
    "NCT03500445",
    "NCT03503344",
    "NCT03507491",
    "NCT03531736",
    "NCT03534180",
    "NCT03534804",
    "NCT03536182",
    "NCT03548961",
    "NCT03554044",
    "NCT03556904",
    "NCT03579316",
    "NCT03579472",
    "NCT03581136",
    "NCT03590054",
    "NCT03605719",
    "NCT03609593",
    "NCT03611738",
    "NCT03613532",
    "NCT03614949",
    "NCT03617328",
    "NCT03638167",
    "NCT03644342",
    "NCT03665675",
    "NCT03667820",
    "NCT03668340",
    "NCT03672773",
    "NCT03681028",
    "NCT03682289",
    "NCT03690986",
    "NCT03707938",
    "NCT03708224",
    "NCT03709758",
    "NCT03711058",
    "NCT03727880",
    "NCT03739619",
    "NCT03765983",
    "NCT03777982",
    "NCT03778294",
    "NCT03787680",
    "NCT03821246",
    "NCT03829020",
    "NCT03830918",
    "NCT03835819",
    "NCT03854032",
    "NCT03861091",
    "NCT03865212",
    "NCT03874052",
    "NCT03875287",
    "NCT03875716",
    "NCT03884998",
    "NCT03900793",
    "NCT03904043",
    "NCT03919175",
    "NCT03924245",
    "NCT03970096",
    "NCT03971461",
    "NCT03990896",
    "NCT04005144",
    "NCT04005339",
    "NCT04013542",
    "NCT04030507",
    "NCT04032418",
    "NCT04047706",
    "NCT04050462",
    "NCT04052880",
    "NCT04055649",
    "NCT04065776",
    "NCT04076579",
    "NCT04081259",
    "NCT04085315",
    "NCT04088864",
    "NCT04099797",
    "NCT04115059",
    "NCT04115254",
    "NCT04123535",
    "NCT04123704",
    "NCT04140162",
    "NCT04163952",
    "NCT04197310",
    "NCT04198922",
    "NCT04214418",
    "NCT04239040",
    "NCT04242173",
    "NCT04249830",
    "NCT04269213",
    "NCT04276194",
    "NCT04278118",
    "NCT04288323",
    "NCT04290546",
    "NCT04294264",
    "NCT04294641",
    "NCT04295863",
    "NCT04329494",
    "NCT04339062",
    "NCT04345601",
    "NCT04368702",
    "NCT04387071",
    "NCT04401267",
    "NCT04408092",
    "NCT04445844",
    "NCT04489212",
    "NCT04507828",
    "NCT04526886",
    "NCT04545957",
    "NCT04548648",
    "NCT04553770",
    "NCT04571138",
    "NCT04572763",
    "NCT04575935",
    "NCT04580771",
    "NCT04584255",
    "NCT04608487",
    "NCT04610684",
    "NCT04620187",
    "NCT04624633",
    "NCT04626024",
    "NCT04640987",
    "NCT04655404",
    "NCT04656041",
    "NCT04659044",
    "NCT04661852",
    "NCT04672005",
    "NCT04676360",
    "NCT04678401",
    "NCT04685915",
    "NCT04701918",
    "NCT04719273",
    "NCT04724018",
    "NCT04751929",
    "NCT04775550",
    "NCT04789486",
    "NCT04801797",
    "NCT04805788",
    "NCT04843904",
    "NCT04846478",
    "NCT04849377",
    "NCT04870762",
    "NCT04883671",
    "NCT04899908",
    "NCT04899921",
    "NCT04900623",
    "NCT04906096",
    "NCT04906902",
    "NCT04947254",
    "NCT05010629",
    "NCT05016947",
    "NCT05057247",
    "NCT00716066",
    "NCT00881920",
    "NCT01046825",
    "NCT01189786",
    "NCT01345539",
    "NCT01356290",
    "NCT01665794",
    "NCT01743950",
    "NCT01853631",
    "NCT02035787",
    "NCT02050347",
    "NCT02095184",
    "NCT02177578",
    "NCT02199665",
    "NCT02287311",
    "NCT02364713",
    "NCT02400658",
    "NCT02442297",
    "NCT02494167",
    "NCT02502786",
    "NCT02644460",
    "NCT02648997",
    "NCT02760030",
    "NCT02896335",
    "NCT02917083",
    "NCT02920996",
    "NCT02956382",
    "NCT02960555",
    "NCT03016871",
    "NCT03026517",
    "NCT03065062",
    "NCT03081910",
    "NCT03087448",
    "NCT03095781",
    "NCT03110978",
    "NCT03116529",
    "NCT03125928",
    "NCT03153982",
    "NCT03209401",
    "NCT03220477",
    "NCT03267680",
    "NCT03283137",
    "NCT03319901",
    "NCT03337087",
    "NCT03344211",
    "NCT03346135",
    "NCT03368963",
    "NCT03417544",
    "NCT03434418",
    "NCT03454529",
    "NCT03457142",
    "NCT03468218",
    "NCT03471260",
    "NCT03482102",
    "NCT03516617",
    "NCT03523702",
    "NCT03526432",
    "NCT03537690",
    "NCT03571321",
    "NCT03586453",
    "NCT03598998",
    "NCT03599752",
    "NCT03652428",
    "NCT03663712",
    "NCT03668431",
    "NCT03681535",
    "NCT03681561",
    "NCT03689699",
    "NCT03709446",
    "NCT03725761",
    "NCT03732950",
    "NCT03736720",
    "NCT03740256",
    "NCT03750227",
    "NCT03774654",
    "NCT03785288",
    "NCT03800693",
    "NCT03821792",
    "NCT03833921",
    "NCT03891615",
    "NCT03918252",
    "NCT03922555",
    "NCT03942653",
    "NCT03961672",
    "NCT03964532",
    "NCT03979508",
    "NCT03983993",
    "NCT03987386",
    "NCT03995147",
    "NCT04007744",
    "NCT04013802",
    "NCT04039230",
    "NCT04055844",
    "NCT04068649",
    "NCT04085510",
    "NCT04091750",
    "NCT04097028",
    "NCT04111497",
    "NCT04130854",
    "NCT04150913",
    "NCT04191421",
    "NCT04197934",
    "NCT04219163",
    "NCT04231851",
    "NCT04253483",
    "NCT04273139",
    "NCT04288726",
    "NCT04305145",
    "NCT04315701",
    "NCT04322955",
    "NCT04323956",
    "NCT04342429",
    "NCT04361162",
    "NCT04417062",
    "NCT04421560",
    "NCT04433949",
    "NCT04443348",
    "NCT04443413",
    "NCT04493060",
    "NCT04524702",
    "NCT04551131",
    "NCT04551430",
    "NCT04567771",
    "NCT04606316",
    "NCT04627064",
    "NCT04634110",
    "NCT04665765",
    "NCT04683653",
    "NCT04703426",
    "NCT04725903",
    "NCT04729348",
    "NCT04781374",
    "NCT04855695",
    "NCT04895735",
    "NCT04938232",
    "NCT04992013",
    "NCT05062720",
    "NCT01659606",
    "NCT01858168",
    "NCT02122172",
    "NCT02173093",
    "NCT02332850",
    "NCT02515110",
    "NCT02524275",
    "NCT02531932",
    "NCT02555189",
    "NCT02574728",
    "NCT02616965",
    "NCT02824029",
    "NCT02918162",
    "NCT02927912",
    "NCT02957968",
    "NCT03008408",
    "NCT03054896",
    "NCT03095612",
    "NCT03113643",
    "NCT03172754",
    "NCT03257163",
    "NCT03264131",
    "NCT03267498",
    "NCT03285412",
    "NCT03330691",
    "NCT03373188",
    "NCT03392246",
    "NCT03433469",
    "NCT03446157",
    "NCT03521570",
    "NCT03532295",
    "NCT03557359",
    "NCT03573648",
    "NCT03583710",
    "NCT03601923",
    "NCT03617679",
    "NCT03704714",
    "NCT03728426",
    "NCT03729804",
    "NCT03779854",
    "NCT03801434",
    "NCT03843775",
    "NCT03844620",
    "NCT03872180",
    "NCT03955783",
    "NCT03962465",
    "NCT03999749",
    "NCT04028167",
    "NCT04042831",
    "NCT04054557",
    "NCT04068753",
    "NCT04088188",
    "NCT04134559",
    "NCT04169763",
    "NCT04176718",
    "NCT04203160",
    "NCT04234386",
    "NCT04284540",
    "NCT04356729",
    "NCT04367311",
    "NCT04386057",
    "NCT04413123",
    "NCT05054374",
    "NCT01409161",
    "NCT01684397",
    "NCT02140021",
    "NCT02152254",
    "NCT02259621",
    "NCT02419495",
    "NCT02710253",
    "NCT02909777",
    "NCT02912312",
    "NCT02912572",
    "NCT02981940",
    "NCT03047135",
    "NCT03075072",
    "NCT03286530",
    "NCT03311126",
    "NCT03316573",
    "NCT03328104",
    "NCT03330821",
    "NCT03391362",
    "NCT03391869",
    "NCT03410043",
    "NCT03528408",
    "NCT03595917",
    "NCT03610711",
    "NCT03637543",
    "NCT03657641",
    "NCT03674047",
    "NCT03722407",
    "NCT03770429",
    "NCT03841565",
    "NCT03879577",
    "NCT03904251",
    "NCT03911973",
    "NCT03934840",
    "NCT03960177",
    "NCT03971409",
    "NCT04096417",
    "NCT04109924",
    "NCT04181684",
    "NCT04200443",
    "NCT04374305",
    "NCT04390243",
    "NCT04416568",
    "NCT04430894",
    "NCT04485559",
    "NCT04527900",
    "NCT04552288",
    "NCT04609280",
    "NCT04660760",
    "NCT04699773",
    "NCT04722523",
    "NCT01928589",
    "NCT02199236",
    "NCT02452008",
    "NCT02755272",
    "NCT03117751",
    "NCT03217669",
    "NCT03238495",
    "NCT03283761",
    "NCT03304080",
    "NCT03368729",
    "NCT03525262",
    "NCT03541902",
    "NCT03580928",
    "NCT03590652",
    "NCT03616184",
    "NCT03654716",
    "NCT04166487",
    "NCT04238455",
    "NCT04351230",
    "NCT04406272",
    "NCT04447768",
    "NCT04569747",
    "NCT04648904",
    "NCT04690348",
    "NCT04844736",
    "NCT01815359",
    "NCT01864109",
    "NCT02315326",
    "NCT02675829",
    "NCT02738866",
    "NCT02778685",
    "NCT02833610",
    "NCT02886065",
    "NCT02962063",
    "NCT02974647",
    "NCT03069378",
    "NCT03158064",
    "NCT03173950",
    "NCT03241745",
    "NCT03245541",
    "NCT03323463",
    "NCT03333616",
    "NCT03422198",
    "NCT03490344",
    "NCT03504163",
    "NCT03520491",
    "NCT03523312",
    "NCT03557918",
    "NCT03567642",
    "NCT03581942",
    "NCT03583086",
    "NCT03610971",
    "NCT03635892",
    "NCT03639948",
    "NCT03643510",
    "NCT03703167",
    "NCT03716531",
    "NCT03755102",
    "NCT03767257",
    "NCT03803553",
    "NCT03808662",
    "NCT03810105",
    "NCT03813615",
    "NCT03832569",
    "NCT03879798",
    "NCT03909152",
    "NCT03936465",
    "NCT04040231",
    "NCT04042753",
    "NCT04068831",
    "NCT04094961",
    "NCT04106414",
    "NCT04126070",
    "NCT04161755",
    "NCT04162015",
    "NCT04165772",
    "NCT04174196",
    "NCT04192981",
    "NCT04238624",
    "NCT04241341",
    "NCT04288375",
    "NCT04329325",
    "NCT04332874",
    "NCT04337970",
    "NCT04343573",
    "NCT04384146",
    "NCT04401774",
    "NCT04416451",
    "NCT04457284",
    "NCT04462471",
    "NCT04468061",
    "NCT04478123",
    "NCT04497961",
    "NCT04513665",
    "NCT04544111",
    "NCT04624178",
    "NCT04635735",
    "NCT04666740",
    "NCT04671901",
    "NCT04683679",
    "NCT04694560",
    "NCT04716946",
    "NCT04716959",
    "NCT04722172",
    "NCT04757363",
    "NCT04761770",
    "NCT04774419",
    "NCT04784247",
    "NCT04792073",
    "NCT04824443",
    "NCT04872543",
    "NCT04872608",
    "NCT04883762",
    "NCT04891289",
    "NCT04905316",
    "NCT04916249",
    "NCT04917796",
    "NCT04960618",
    "NCT04965090",
    "NCT04983862",
    "NCT05010031",
    "NCT05024994",
    "NCT05038124",
    "NCT01639508",
    "NCT01928576",
    "NCT02659241",
    "NCT02670707",
    "NCT02783625",
    "NCT02928978",
    "NCT02932280",
    "NCT02958774",
    "NCT03011671",
    "NCT03095352",
    "NCT03179917",
    "NCT03217188",
    "NCT03233347",
    "NCT03285152",
    "NCT03532880",
    "NCT03534323",
    "NCT03542175",
    "NCT03563248",
    "NCT03570619",
    "NCT03587844",
    "NCT03618537",
    "NCT03618550",
    "NCT03684980",
    "NCT03728972",
    "NCT03749187",
    "NCT03755804",
    "NCT03824483",
    "NCT03939182",
    "NCT03988595",
    "NCT04179162",
    "NCT04209660",
    "NCT04212013",
    "NCT04262154",
    "NCT04268498",
    "NCT04317534",
    "NCT04419519",
    "NCT04448886",
    "NCT02101736",
    "NCT02114229",
    "NCT02658279",
    "NCT02923570",
    "NCT02945579",
    "NCT03020030",
    "NCT03093922",
    "NCT03122522",
    "NCT03143270",
    "NCT03179930",
    "NCT03220646",
    "NCT03377387",
    "NCT03436654",
    "NCT03667482",
    "NCT03693014",
    "NCT03858205",
    "NCT03999710",
    "NCT04019327",
    "NCT04084730",
    "NCT02628405",
    "NCT02717156",
    "NCT02841748",
    "NCT03033914",
    "NCT03271372",
    "NCT03740334",
    "NCT03743662",
    "NCT03793140",
    "NCT04025372",
    "NCT04388839",
    "NCT04893109",
    "NCT00715611",
    "NCT01570998",
    "NCT02962167",
    "NCT03556332",
    "NCT03691493",
    "NCT03712202",
    "NCT03808337",
    "NCT04425018",
    "NCT02205762",
    "NCT03117309",
    "NCT03164057",
    "NCT02724540",
    "NCT02960230",
    "NCT03144765",
    "NCT03456843",
    "NCT03739372",
    "NCT03992456",
    "NCT03995017",
    "NCT04117945",
    "NCT04323046",
    "NCT04410796",
    "NCT01494662",
    "NCT01617161",
    "NCT02570542",
    "NCT03509961",
    "NCT02632045",
    "NCT02945800",
    "NCT03012321",
    "NCT03077841",
    "NCT03535675",
    "NCT03765736",
    "NCT01878617",
    "NCT03530696",
    "NCT03893487",
    "NCT02553460",
    "NCT03628209",
    "NCT03786692",
    "NCT03344965",
    "NCT03414658",
    "NCT03147287",
    "NCT02468024",
    "NCT03574571",
    "NCT02875314",
    "NCT00920972",
    "NCT01028716",
    "NCT01071941",
    "NCT01130077",
    "NCT01174108",
    "NCT01203722",
    "NCT01376505",
    "NCT01430390",
    "NCT01492972",
    "NCT01586767",
    "NCT01629498",
    "NCT01660607",
    "NCT01740557",
    "NCT01810588",
    "NCT01892371",
    "NCT01898793",
    "NCT01912612",
    "NCT01955460",
    "NCT02062827",
    "NCT02068794",
    "NCT02094794",
    "NCT02143830",
    "NCT02153229",
    "NCT02157051",
    "NCT02159989",
    "NCT02188459",
    "NCT02207439",
    "NCT02261415",
    "NCT02303392",
    "NCT02303678",
    "NCT02342613",
    "NCT02358187",
    "NCT02382549",
    "NCT02427581",
    "NCT02446457",
    "NCT02451982",
    "NCT02465268",
    "NCT02530034",
    "NCT02626312",
    "NCT02706392",
    "NCT02727803",
    "NCT02732171",
    "NCT02755896",
    "NCT02782546",
    "NCT02882620",
    "NCT02905578",
    "NCT02905591",
    "NCT02914405",
    "NCT02927964",
    "NCT02935205",
    "NCT02993900",
    "NCT02996773",
    "NCT03016377",
    "NCT03030417",
    "NCT03035331",
    "NCT03047993",
    "NCT03068624",
    "NCT03092453",
    "NCT03114462",
    "NCT03128034",
    "NCT03150914",
    "NCT03162627",
    "NCT03199274",
    "NCT03206645",
    "NCT03207958",
    "NCT03219047",
    "NCT03224000",
    "NCT03240861",
    "NCT03246906",
    "NCT03262662",
    "NCT03263429",
    "NCT03276559",
    "NCT03298087",
    "NCT03306992",
    "NCT03326921",
    "NCT03334305",
    "NCT03354390",
    "NCT03387553",
    "NCT03388632",
    "NCT03407417",
    "NCT03410901",
    "NCT03432741",
    "NCT03477513",
    "NCT03483038",
    "NCT03496662",
    "NCT03511690",
    "NCT03546361",
    "NCT03567330",
    "NCT03575611",
    "NCT03604315",
    "NCT03617133",
    "NCT03646617",
    "NCT03649841",
    "NCT03650894",
    "NCT03657576",
    "NCT03661047",
    "NCT03670966",
    "NCT03674814",
    "NCT03688178",
    "NCT03719131",
    "NCT03721068",
    "NCT03726320",
    "NCT03727061",
    "NCT03735095",
    "NCT03737370",
    "NCT03747484",
    "NCT03750513",
    "NCT03759431",
    "NCT03760744",
    "NCT03769311",
    "NCT03774472",
    "NCT03804944",
    "NCT03810365",
    "NCT03820817",
    "NCT03843294",
    "NCT03859765",
    "NCT03873805",
    "NCT03921021",
    "NCT03927222",
    "NCT03929029",
    "NCT03956056",
    "NCT03960008",
    "NCT03970226",
    "NCT03975231",
    "NCT03975491",
    "NCT04003649",
    "NCT04016389",
    "NCT04023110",
    "NCT04025229",
    "NCT04049474",
    "NCT04049669",
    "NCT04076696",
    "NCT04083170",
    "NCT04083183",
    "NCT04083378",
    "NCT04086771",
    "NCT04090060",
    "NCT04090567",
    "NCT04105543",
    "NCT04119024",
    "NCT04132505",
    "NCT04136353",
    "NCT04139577",
    "NCT04141995",
    "NCT04152343",
    "NCT04177810",
    "NCT04188418",
    "NCT04192071",
    "NCT04201873",
    "NCT04205903",
    "NCT04223765",
    "NCT04272801",
    "NCT04276090",
    "NCT04300855",
    "NCT04301843",
    "NCT04315233",
    "NCT04329065",
    "NCT04331041",
    "NCT04336397",
    "NCT04339140",
    "NCT04348292",
    "NCT04363164",
    "NCT04364230",
    "NCT04374760",
    "NCT04387227",
    "NCT04390724",
    "NCT04402151",
    "NCT04405167",
    "NCT04407442",
    "NCT04420975",
    "NCT04449458",
    "NCT04452292",
    "NCT04469556",
    "NCT04471974",
    "NCT04472338",
    "NCT04490057",
    "NCT04498052",
    "NCT04517643",
    "NCT04547985",
    "NCT04582864",
    "NCT04590404",
    "NCT04630769",
    "NCT04640779",
    "NCT04668833",
    "NCT04674306",
    "NCT04729322",
    "NCT04734730",
    "NCT04744116",
    "NCT04747236",
    "NCT04785534",
    "NCT04797884",
    "NCT04883645",
    "NCT04890054",
    "NCT04902443",
    "NCT04936334",
    "NCT04941274",
    "NCT04965181",
    "NCT04973683",
    "NCT04985565",
    "NCT04995536",
    "NCT05055323",
    "NCT05080946",
    "NCT00592592",
    "NCT01434316",
    "NCT01587352",
    "NCT01851369",
    "NCT02018367",
    "NCT02079740",
    "NCT02090114",
    "NCT02101944",
    "NCT02172651",
    "NCT02203903",
    "NCT02204098",
    "NCT02405221",
    "NCT02407405",
    "NCT02501954",
    "NCT02693990",
    "NCT02843568",
    "NCT02905188",
    "NCT02998268",
    "NCT03007732",
    "NCT03017820",
    "NCT03034096",
    "NCT03051516",
    "NCT03085004",
    "NCT03141346",
    "NCT03219450",
    "NCT03312972",
    "NCT03323489",
    "NCT03366116",
    "NCT03642990",
    "NCT03805594",
    "NCT03898167",
    "NCT03912064",
    "NCT04024878",
    "NCT04040205",
    "NCT04090528",
    "NCT04092257",
    "NCT04144023",
    "NCT04207255",
    "NCT04289779",
    "NCT04375813",
    "NCT04399876",
    "NCT04406714",
    "NCT04459416",
    "NCT04494945",
    "NCT04497142",
    "NCT04514484",
    "NCT04557423",
    "NCT04585893",
    "NCT04592237",
    "NCT04601428",
    "NCT04927650",
    "NCT00859781",
    "NCT01333046",
    "NCT01555892",
    "NCT01787409",
    "NCT01794403",
    "NCT01906385",
    "NCT02188745",
    "NCT02203526",
    "NCT02312245",
    "NCT02756962",
    "NCT02763384",
    "NCT02884648",
    "NCT02886585",
    "NCT03017326",
    "NCT03060642",
    "NCT03179904",
    "NCT03202940",
    "NCT03248570",
    "NCT03554083",
    "NCT03635632",
    "NCT03679650",
    "NCT03719105",
    "NCT03796884",
    "NCT03974217",
    "NCT04024761",
    "NCT04037358",
    "NCT04197687",
    "NCT04207944",
    "NCT04294225",
    "NCT04563754",
    "NCT02512926",
    "NCT02565498",
    "NCT03266627",
    "NCT03266640",
    "NCT03266653",
    "NCT03295981",
    "NCT03303846",
    "NCT03455608",
    "NCT03520790",
    "NCT03762759",
    "NCT03879629",
    "NCT03941730",
    "NCT04021108",
    "NCT04022980",
    "NCT04281498",
    "NCT04411849",
    "NCT02029937",
    "NCT02276443",
    "NCT02584647",
    "NCT02718131",
    "NCT03059485",
    "NCT03433183",
    "NCT01085864",
    "NCT03471364",
    "NCT04104893",
    "NCT04283669",
    "NCT02048371",
    "NCT03091257",
    "NCT03976843",
    "NCT04298086",
    "NCT05010005",
    "NCT02000089",
    "NCT02847559",
    "NCT03384914",
    "NCT02620852",
    "NCT02694809",
    "NCT01659203",
    "NCT02498951",
    "NCT03231306",
    "NCT00539162",
    "NCT02693535",
    "NCT03012100",
    "NCT02178163",
    "NCT03092323",
    "NCT03599765",
    "NCT02206984",
    "NCT02397083",
    "NCT03732703",
    "NCT03013998",
    "NCT01893307",
    "NCT01656603",
    "NCT01042379",
    "NCT03561220",
    "NCT02603341",
    "NCT00781612",
    "NCT00986661",
    "NCT01954992",
    "NCT01972867",
    "NCT02136797",
    "NCT02215265",
    "NCT02365597",
    "NCT02519270",
    "NCT02576431",
    "NCT02601950",
    "NCT02672917",
    "NCT02705196",
    "NCT02720068",
    "NCT02730312",
    "NCT02735707",
    "NCT02773524",
    "NCT02795520",
    "NCT02797795",
    "NCT02825836",
    "NCT02840409",
    "NCT02843945",
    "NCT02901717",
    "NCT02908906",
    "NCT02934568",
    "NCT02960022",
    "NCT02988960",
    "NCT03008187",
    "NCT03040973",
    "NCT03077685",
    "NCT03164616",
    "NCT03168061",
    "NCT03207867",
    "NCT03259867",
    "NCT03290534",
    "NCT03306264",
    "NCT03316222",
    "NCT03329001",
    "NCT03337698",
    "NCT03363373",
    "NCT03364114",
    "NCT03371017",
    "NCT03385486",
    "NCT03395210",
    "NCT03439462",
    "NCT03444714",
    "NCT03444753",
    "NCT03446417",
    "NCT03456076",
    "NCT03457896",
    "NCT03467373",
    "NCT03473743",
    "NCT03476681",
    "NCT03484702",
    "NCT03498716",
    "NCT03518203",
    "NCT03518554",
    "NCT03526835",
    "NCT03530397",
    "NCT03536728",
    "NCT03544723",
    "NCT03549000",
    "NCT03569280",
    "NCT03576131",
    "NCT03583164",
    "NCT03594981",
    "NCT03595657",
    "NCT03647163",
    "NCT03653247",
    "NCT03656718",
    "NCT03682796",
    "NCT03695380",
    "NCT03697109",
    "NCT03724747",
    "NCT03733990",
    "NCT03739710",
    "NCT03742349",
    "NCT03743246",
    "NCT03754933",
    "NCT03767335",
    "NCT03773107",
    "NCT03779113",
    "NCT03781362",
    "NCT03781986",
    "NCT03829501",
    "NCT03856099",
    "NCT03860207",
    "NCT03864042",
    "NCT03894618",
    "NCT03897543",
    "NCT03905148",
    "NCT03907527",
    "NCT03915405",
    "NCT03916627",
    "NCT03918278",
    "NCT03921879",
    "NCT03940352",
    "NCT03945162",
    "NCT03949283",
    "NCT03988855",
    "NCT03993106",
    "NCT04000529",
    "NCT04000737",
    "NCT04008706",
    "NCT04013217",
    "NCT04013334",
    "NCT04014205",
    "NCT04032847",
    "NCT04033081",
    "NCT04045795",
    "NCT04056195",
    "NCT04058756",
    "NCT04060394",
    "NCT04069273",
    "NCT04072458",
    "NCT04084366",
    "NCT04093167",
    "NCT04098744",
    "NCT04103879",
    "NCT04105010",
    "NCT04119050",
    "NCT04123470",
    "NCT04130542",
    "NCT04150042",
    "NCT04154488",
    "NCT04165525",
    "NCT04167696",
    "NCT04170153",
    "NCT04176757",
    "NCT04182204",
    "NCT04182516",
    "NCT04187404",
    "NCT04190628",
    "NCT04193904",
    "NCT04197999",
    "NCT04198818",
    "NCT04203901",
    "NCT04205227",
    "NCT04205630",
    "NCT04210219",
    "NCT04219254",
    "NCT04225026",
    "NCT04240886",
    "NCT04243499",
    "NCT04245397",
    "NCT04249362",
    "NCT04272034",
    "NCT04278924",
    "NCT04283097",
    "NCT04285567",
    "NCT04288089",
    "NCT04293458",
    "NCT04303169",
    "NCT04305444",
    "NCT04316442",
    "NCT04319224",
    "NCT04323657",
    "NCT04335981",
    "NCT04354727",
    "NCT04358393",
    "NCT04362072",
    "NCT04364620",
    "NCT04365179",
    "NCT04394624",
    "NCT04396340",
    "NCT04408924",
    "NCT04409080",
    "NCT04412616",
    "NCT04417699",
    "NCT04419532",
    "NCT04431635",
    "NCT04431726",
    "NCT04441099",
    "NCT04442022",
    "NCT04443088",
    "NCT04443907",
    "NCT04444427",
    "NCT04450732",
    "NCT04453046",
    "NCT04457778",
    "NCT04468607",
    "NCT04478279",
    "NCT04484623",
    "NCT04501614",
    "NCT04502394",
    "NCT04509596",
    "NCT04511845",
    "NCT04516447",
    "NCT04518046",
    "NCT04521621",
    "NCT04522180",
    "NCT04522323",
    "NCT04524689",
    "NCT04525131",
    "NCT04530981",
    "NCT04537715",
    "NCT04538742",
    "NCT04541082",
    "NCT04544865",
    "NCT04551053",
    "NCT04561258",
    "NCT04561362",
    "NCT04562870",
    "NCT04573881",
    "NCT04576156",
    "NCT04577963",
    "NCT04586270",
    "NCT04589650",
    "NCT04592484",
    "NCT04592653",
    "NCT04593758",
    "NCT04594811",
    "NCT04602117",
    "NCT04606030",
    "NCT04608045",
    "NCT04608812",
    "NCT04617522",
    "NCT04623996",
    "NCT04628494",
    "NCT04629508",
    "NCT04634435",
    "NCT04635995",
    "NCT04641247",
    "NCT04642469",
    "NCT04646057",
    "NCT04650984",
    "NCT04657068",
    "NCT04659096",
    "NCT04671251",
    "NCT04672434",
    "NCT04685135",
    "NCT04695847",
    "NCT04697069",
    "NCT04699838",
    "NCT04701476",
    "NCT04702880",
    "NCT04711161",
    "NCT04712097",
    "NCT04714983",
    "NCT04717414",
    "NCT04718675",
    "NCT04727554",
    "NCT04728893",
    "NCT04731675",
    "NCT04740918",
    "NCT04745689",
    "NCT04747470",
    "NCT04752358",
    "NCT04752696",
    "NCT04755244",
    "NCT04761601",
    "NCT04762069",
    "NCT04764474",
    "NCT04765059",
    "NCT04768881",
    "NCT04771572",
    "NCT04787042",
    "NCT04789655",
    "NCT04790903",
    "NCT04795713",
    "NCT04796194",
    "NCT04797390",
    "NCT04802733",
    "NCT04803305",
    "NCT04803877",
    "NCT04806035",
    "NCT04810078",
    "NCT04810611",
    "NCT04815720",
    "NCT04824092",
    "NCT04830124",
    "NCT04834778",
    "NCT04837196",
    "NCT04862195",
    "NCT04862663",
    "NCT04865419",
    "NCT04868877",
    "NCT04878003",
    "NCT04882917",
    "NCT04884035",
    "NCT04886622",
    "NCT04887298",
    "NCT04887831",
    "NCT04902872",
    "NCT04905407",
    "NCT04910568",
    "NCT04910685",
    "NCT04913285",
    "NCT04913337",
    "NCT04914897",
    "NCT04920383",
    "NCT04925284",
    "NCT04926831",
    "NCT04929223",
    "NCT04936178",
    "NCT04939701",
    "NCT04946864",
    "NCT04956042",
    "NCT04956640",
    "NCT04958226",
    "NCT04960709",
    "NCT04965493",
    "NCT04975256",
    "NCT04975399",
    "NCT04975958",
    "NCT04976634",
    "NCT04979442",
    "NCT04995653",
    "NCT04996030",
    "NCT05001451",
    "NCT05002140",
    "NCT05005728",
    "NCT05011058",
    "NCT05013554",
    "NCT05024045",
    "NCT05036291",
    "NCT05053880",
    "NCT05059262",
    "NCT05061420",
    "NCT05068024",
    "NCT01766297",
    "NCT02559778",
    "NCT02576496",
    "NCT02611024",
    "NCT02628067",
    "NCT02635672",
    "NCT02649790",
    "NCT02667873",
    "NCT02706626",
    "NCT02730338",
    "NCT02783300",
    "NCT02900651",
    "NCT02926690",
    "NCT02963064",
    "NCT03073967",
    "NCT03220347",
    "NCT03221400",
    "NCT03241186",
    "NCT03329950",
    "NCT03335540",
    "NCT03362177",
    "NCT03371004",
    "NCT03379051",
    "NCT03398200",
    "NCT03424005",
    "NCT03440437",
    "NCT03448042",
    "NCT03449381",
    "NCT03452137",
    "NCT03485729",
    "NCT03502746",
    "NCT03510104",
    "NCT03556228",
    "NCT03592264",
    "NCT03598608",
    "NCT03602079",
    "NCT03608020",
    "NCT03625323",
    "NCT03665285",
    "NCT03672695",
    "NCT03729596",
    "NCT03737643",
    "NCT03743051",
    "NCT03743064",
    "NCT03744715",
    "NCT03748134",
    "NCT03755791",
    "NCT03761914",
    "NCT03764293",
    "NCT03782415",
    "NCT03805841",
    "NCT03816163",
    "NCT03827655",
    "NCT03836352",
    "NCT03838367",
    "NCT03853109",
    "NCT03860844",
    "NCT03867682",
    "NCT03871348",
    "NCT03871829",
    "NCT03873883",
    "NCT03875235",
    "NCT03878719",
    "NCT03878849",
    "NCT03897036",
    "NCT03907969",
    "NCT03937154",
    "NCT03940703",
    "NCT03943004",
    "NCT03964233",
    "NCT03971799",
    "NCT03975387",
    "NCT04009681",
    "NCT04047251",
    "NCT04049331",
    "NCT04060342",
    "NCT04064060",
    "NCT04069026",
    "NCT04070768",
    "NCT04078152",
    "NCT04083599",
    "NCT04099888",
    "NCT04116437",
    "NCT04116658",
    "NCT04132817",
    "NCT04135352",
    "NCT04147234",
    "NCT04157088",
    "NCT04167137",
    "NCT04167618",
    "NCT04176198",
    "NCT04186637",
    "NCT04192344",
    "NCT04208178",
    "NCT04224272",
    "NCT04234113",
    "NCT04240704",
    "NCT04244656",
    "NCT04250155",
    "NCT04251117",
    "NCT04257110",
    "NCT04260217",
    "NCT04270409",
    "NCT04272931",
    "NCT04282044",
    "NCT04294576",
    "NCT04305496",
    "NCT04306224",
    "NCT04319757",
    "NCT04338399",
    "NCT04354246",
    "NCT04365374",
    "NCT04380805",
    "NCT04382898",
    "NCT04388475",
    "NCT04393753",
    "NCT04398433",
    "NCT04401020",
    "NCT04406623",
    "NCT04408638",
    "NCT04417465",
    "NCT04418661",
    "NCT04426201",
    "NCT04429087",
    "NCT04432207",
    "NCT04434196",
    "NCT04436029",
    "NCT04440943",
    "NCT04442126",
    "NCT04447755",
    "NCT04452214",
    "NCT04455620",
    "NCT04456699",
    "NCT04472429",
    "NCT04486378",
    "NCT04487236",
    "NCT04496349",
    "NCT04521413",
    "NCT04526704",
    "NCT04526834",
    "NCT04526899",
    "NCT04543305",
    "NCT04543591",
    "NCT04570631",
    "NCT04571645",
    "NCT04584112",
    "NCT04588922",
    "NCT04594642",
    "NCT04604132",
    "NCT04606771",
    "NCT04613557",
    "NCT04619797",
    "NCT04622319",
    "NCT04624659",
    "NCT04631211",
    "NCT04634344",
    "NCT04634825",
    "NCT04640532",
    "NCT04644068",
    "NCT04644770",
    "NCT04649112",
    "NCT04649385",
    "NCT04657991",
    "NCT04658862",
    "NCT04659603",
    "NCT04660929",
    "NCT04662580",
    "NCT04662710",
    "NCT04669002",
    "NCT04670679",
    "NCT04676477",
    "NCT04678648",
    "NCT04678921",
    "NCT04681131",
    "NCT04686383",
    "NCT04699188",
    "NCT04699630",
    "NCT04706962",
    "NCT04707248",
    "NCT04710043",
    "NCT04731467",
    "NCT04735471",
    "NCT04742959",
    "NCT04754100",
    "NCT04756726",
    "NCT04770246",
    "NCT04771897",
    "NCT04775745",
    "NCT04778397",
    "NCT04789408",
    "NCT04800822",
    "NCT04807972",
    "NCT04811560",
    "NCT04814108",
    "NCT04821622",
    "NCT04833582",
    "NCT04854499",
    "NCT04861987",
    "NCT04873362",
    "NCT04887870",
    "NCT04892017",
    "NCT04895709",
    "NCT04900818",
    "NCT04901806",
    "NCT04916002",
    "NCT04935229",
    "NCT04951778",
    "NCT04959981",
    "NCT04961996",
    "NCT04965818",
    "NCT04973137",
    "NCT04983810",
    "NCT04993677",
    "NCT04996875",
    "NCT05027139",
    "NCT05050006",
    "NCT05061537",
    "NCT05075603",
    "NCT01351103",
    "NCT02267863",
    "NCT02584478",
    "NCT02704858",
    "NCT02760498",
    "NCT02766543",
    "NCT02794571",
    "NCT02930109",
    "NCT03150810",
    "NCT03171493",
    "NCT03178552",
    "NCT03251378",
    "NCT03275402",
    "NCT03287817",
    "NCT03297424",
    "NCT03311334",
    "NCT03317158",
    "NCT03414034",
    "NCT03417882",
    "NCT03422679",
    "NCT03440450",
    "NCT03441100",
    "NCT03471663",
    "NCT03520686",
    "NCT03551249",
    "NCT03588039",
    "NCT03604445",
    "NCT03610724",
    "NCT03616587",
    "NCT03637803",
    "NCT03651271",
    "NCT03653507",
    "NCT03658772",
    "NCT03686124",
    "NCT03697304",
    "NCT03721978",
    "NCT03724890",
    "NCT03742102",
    "NCT03753789",
    "NCT03761095",
    "NCT03762447",
    "NCT03764618",
    "NCT03768063",
    "NCT03797391",
    "NCT03835533",
    "NCT03839524",
    "NCT03840967",
    "NCT03850574",
    "NCT03854227",
    "NCT03854721",
    "NCT03861702",
    "NCT03869190",
    "NCT03872947",
    "NCT03891953",
    "NCT03899636",
    "NCT03906526",
    "NCT03910660",
    "NCT03930953",
    "NCT03933735",
    "NCT03956680",
    "NCT04016805",
    "NCT04021368",
    "NCT04023331",
    "NCT04026412",
    "NCT04030195",
    "NCT04042701",
    "NCT04043104",
    "NCT04045496",
    "NCT04056611",
    "NCT04059484",
    "NCT04064359",
    "NCT04067115",
    "NCT04073615",
    "NCT04077021",
    "NCT04091126",
    "NCT04096638",
    "NCT04106492",
    "NCT04111458",
    "NCT04117958",
    "NCT04137289",
    "NCT04139434",
    "NCT04140526",
    "NCT04145349",
    "NCT04145700",
    "NCT04147819",
    "NCT04152499",
    "NCT04155710",
    "NCT04155749",
    "NCT04161885",
    "NCT04169711",
    "NCT04200963",
    "NCT04243785",
    "NCT04249843",
    "NCT04260191",
    "NCT04261439",
    "NCT04284228",
    "NCT04291664",
    "NCT04294160",
    "NCT04305041",
    "NCT04305054",
    "NCT04318080",
    "NCT04329728",
    "NCT04336098",
    "NCT04344795",
    "NCT04350463",
    "NCT04358458",
    "NCT04362748",
    "NCT04363242",
    "NCT04370704",
    "NCT04379596",
    "NCT04384484",
    "NCT04385368",
    "NCT04390737",
    "NCT04404595",
    "NCT04408599",
    "NCT04421222",
    "NCT04432857",
    "NCT04446351",
    "NCT04452591",
    "NCT04475939",
    "NCT04485013",
    "NCT04487080",
    "NCT04492488",
    "NCT04504669",
    "NCT04505826",
    "NCT04506086",
    "NCT04509700",
    "NCT04513925",
    "NCT04523350",
    "NCT04534205",
    "NCT04540705",
    "NCT04572633",
    "NCT04582539",
    "NCT04585035",
    "NCT04586335",
    "NCT04596033",
    "NCT04601857",
    "NCT04612751",
    "NCT04622007",
    "NCT04622774",
    "NCT04623944",
    "NCT04624204",
    "NCT04626635",
    "NCT04629729",
    "NCT04630756",
    "NCT04631445",
    "NCT04634552",
    "NCT04637763",
    "NCT04639219",
    "NCT04640623",
    "NCT04648202",
    "NCT04655976",
    "NCT04659629",
    "NCT04665843",
    "NCT04666259",
    "NCT04673617",
    "NCT04675333",
    "NCT04679194",
    "NCT04683250",
    "NCT04689828",
    "NCT04700072",
    "NCT04730258",
    "NCT04737187",
    "NCT04740307",
    "NCT04744831",
    "NCT04774952",
    "NCT04778410",
    "NCT04799054",
    "NCT04799249",
    "NCT04832854",
    "NCT04835805",
    "NCT04846920",
    "NCT04849273",
    "NCT04855136",
    "NCT04859777",
    "NCT04879849",
    "NCT04904588",
    "NCT04924075",
    "NCT04939610",
    "NCT04972110",
    "NCT04983407",
    "NCT05002270",
    "NCT01676259",
    "NCT01716806",
    "NCT02290951",
    "NCT02428712",
    "NCT02521844",
    "NCT02525692",
    "NCT02549937",
    "NCT02557321",
    "NCT02974725",
    "NCT03114319",
    "NCT03149003",
    "NCT03161431",
    "NCT03247309",
    "NCT03250676",
    "NCT03289299",
    "NCT03294083",
    "NCT03330561",
    "NCT03355066",
    "NCT03409458",
    "NCT03416335",
    "NCT03416530",
    "NCT03422627",
    "NCT03428958",
    "NCT03437941",
    "NCT03447769",
    "NCT03459222",
    "NCT03478462",
    "NCT03492125",
    "NCT03521154",
    "NCT03567889",
    "NCT03589339",
    "NCT03605550",
    "NCT03621982",
    "NCT03677596",
    "NCT03682068",
    "NCT03682536",
    "NCT03690154",
    "NCT03702725",
    "NCT03726333",
    "NCT03744468",
    "NCT03748186",
    "NCT03755518",
    "NCT03761017",
    "NCT03761069",
    "NCT03786926",
    "NCT03809624",
    "NCT03821935",
    "NCT03829410",
    "NCT03841110",
    "NCT03852511",
    "NCT03881488",
    "NCT03888105",
    "NCT03893955",
    "NCT03900598",
    "NCT03922204",
    "NCT03924856",
    "NCT03947255",
    "NCT03947385",
    "NCT03952078",
    "NCT03968419",
    "NCT03972488",
    "NCT03986606",
    "NCT03994601",
    "NCT04008030",
    "NCT04009109",
    "NCT04020185",
    "NCT04032704",
    "NCT04045028",
    "NCT04045613",
    "NCT04047862",
    "NCT04089449",
    "NCT04093362",
    "NCT04102020",
    "NCT04105335",
    "NCT04109482",
    "NCT04121676",
    "NCT04123366",
    "NCT04142619",
    "NCT04152018",
    "NCT04158336",
    "NCT04165083",
    "NCT04165096",
    "NCT04179864",
    "NCT04180371",
    "NCT04191499",
    "NCT04196283",
    "NCT04198766",
    "NCT04239092",
    "NCT04240639",
    "NCT04242147",
    "NCT04250597",
    "NCT04252339",
    "NCT04254978",
    "NCT04257617",
    "NCT04260022",
    "NCT04260698",
    "NCT04262856",
    "NCT04267822",
    "NCT04274738",
    "NCT04291079",
    "NCT04305795",
    "NCT04332653",
    "NCT04351555",
    "NCT04370587",
    "NCT04390763",
    "NCT04398485",
    "NCT04398524",
    "NCT04428788",
    "NCT04438083",
    "NCT04440735",
    "NCT04450069",
    "NCT04454658",
    "NCT04460456",
    "NCT04474470",
    "NCT04475523",
    "NCT04476797",
    "NCT04479436",
    "NCT04488354",
    "NCT04489888",
    "NCT04502082",
    "NCT04502706",
    "NCT04503265",
    "NCT04504916",
    "NCT04515394",
    "NCT04524455",
    "NCT04526509",
    "NCT04526691",
    "NCT04529772",
    "NCT04551066",
    "NCT04553133",
    "NCT04553692",
    "NCT04556617",
    "NCT04557449",
    "NCT04557735",
    "NCT04562389",
    "NCT04590781",
    "NCT04601402",
    "NCT04609566",
    "NCT04613492",
    "NCT04613596",
    "NCT04614636",
    "NCT04626479",
    "NCT04628780",
    "NCT04631601",
    "NCT04644237",
    "NCT04647526",
    "NCT04648254",
    "NCT04650451",
    "NCT04655118",
    "NCT04665921",
    "NCT04669067",
    "NCT04674813",
    "NCT04675294",
    "NCT04676633",
    "NCT04682431",
    "NCT04691375",
    "NCT04700124",
    "NCT04703192",
    "NCT04726332",
    "NCT04727151",
    "NCT04759664",
    "NCT04762602",
    "NCT04787991",
    "NCT04797780",
    "NCT04802759",
    "NCT04817761",
    "NCT04891757",
    "NCT04894994",
    "NCT04965753",
    "NCT01796171",
    "NCT02520427",
    "NCT02566772",
    "NCT02744287",
    "NCT02756845",
    "NCT02781883",
    "NCT02892123",
    "NCT02913313",
    "NCT02924402",
    "NCT02952508",
    "NCT02964013",
    "NCT02996110",
    "NCT03006172",
    "NCT03011372",
    "NCT03049189",
    "NCT03075696",
    "NCT03129139",
    "NCT03249792",
    "NCT03250338",
    "NCT03255070",
    "NCT03263559",
    "NCT03289962",
    "NCT03313778",
    "NCT03369223",
    "NCT03377179",
    "NCT03377361",
    "NCT03390504",
    "NCT03400176",
    "NCT03401385",
    "NCT03412643",
    "NCT03435250",
    "NCT03446040",
    "NCT03468426",
    "NCT03474640",
    "NCT03530683",
    "NCT03537482",
    "NCT03544281",
    "NCT03564691",
    "NCT03567720",
    "NCT03575819",
    "NCT03597581",
    "NCT03604783",
    "NCT03614728",
    "NCT03647800",
    "NCT03648372",
    "NCT03667716",
    "NCT03672292",
    "NCT03677154",
    "NCT03715933",
    "NCT03742895",
    "NCT03746431",
    "NCT03834493",
    "NCT03834688",
    "NCT03836261",
    "NCT03837899",
    "NCT03845166",
    "NCT03847519",
    "NCT03854110",
    "NCT03860883",
    "NCT03861793",
    "NCT03865082",
    "NCT03872778",
    "NCT03907852",
    "NCT03915379",
    "NCT03928314",
    "NCT03935555",
    "NCT03940196",
    "NCT03950570",
    "NCT03972657",
    "NCT03975829",
    "NCT04002297",
    "NCT04023071",
    "NCT04036461",
    "NCT04046445",
    "NCT04053283",
    "NCT04053673",
    "NCT04083534",
    "NCT04092673",
    "NCT04108195",
    "NCT04126200",
    "NCT04145622",
    "NCT04150497",
    "NCT04169347",
    "NCT04171141",
    "NCT04171843",
    "NCT04189445",
    "NCT04215809",
    "NCT04221542",
    "NCT04222972",
    "NCT04227847",
    "NCT04229979",
    "NCT04230499",
    "NCT04237649",
    "NCT04241185",
    "NCT04242199",
    "NCT04245722",
    "NCT04246671",
    "NCT04256317",
    "NCT04258943",
    "NCT04259450",
    "NCT04278768",
    "NCT04279847",
    "NCT04301011",
    "NCT04310592",
    "NCT04318327",
    "NCT04373265",
    "NCT04374630",
    "NCT04382664",
    "NCT04389632",
    "NCT04396821",
    "NCT04397185",
    "NCT04398680",
    "NCT04417088",
    "NCT04417530",
    "NCT04420884",
    "NCT04429191",
    "NCT04445701",
    "NCT04446117",
    "NCT04447118",
    "NCT04455841",
    "NCT04468984",
    "NCT04477291",
    "NCT04489771",
    "NCT04493619",
    "NCT04505839",
    "NCT04538664",
    "NCT04541225",
    "NCT04557098",
    "NCT04570839",
    "NCT04575766",
    "NCT04579757",
    "NCT04580485",
    "NCT04586231",
    "NCT04607668",
    "NCT04623541",
    "NCT04626518",
    "NCT04637009",
    "NCT04638309",
    "NCT04665206",
    "NCT04669899",
    "NCT04672460",
    "NCT04680052",
    "NCT04698915",
    "NCT04704154",
    "NCT04704219",
    "NCT04762641",
    "NCT04762875",
    "NCT04794699",
    "NCT04829604",
    "NCT04830137",
    "NCT04862780",
    "NCT04881045",
    "NCT02264678",
    "NCT02629692",
    "NCT02675452",
    "NCT02709512",
    "NCT03058289",
    "NCT03110107",
    "NCT03138889",
    "NCT03145181",
    "NCT03215030",
    "NCT03281369",
    "NCT03287908",
    "NCT03295396",
    "NCT03309111",
    "NCT03310619",
    "NCT03393884",
    "NCT03399799",
    "NCT03400332",
    "NCT03420014",
    "NCT03423628",
    "NCT03460977",
    "NCT03480971",
    "NCT03484923",
    "NCT03485209",
    "NCT03486067",
    "NCT03519178",
    "NCT03522142",
    "NCT03543813",
    "NCT03555149",
    "NCT03582033",
    "NCT03611868",
    "NCT03684694",
    "NCT03685591",
    "NCT03706365",
    "NCT03768505",
    "NCT03769506",
    "NCT03783403",
    "NCT03800134",
    "NCT03802695",
    "NCT03821233",
    "NCT03829436",
    "NCT03924895",
    "NCT03929666",
    "NCT03948763",
    "NCT03960840",
    "NCT03973333",
    "NCT03974022",
    "NCT03976375",
    "NCT03978611",
    "NCT04000282",
    "NCT04025879",
    "NCT04029688",
    "NCT04033328",
    "NCT04036682",
    "NCT04084951",
    "NCT04095273",
    "NCT04099251",
    "NCT04109066",
    "NCT04109456",
    "NCT04113616",
    "NCT04115306",
    "NCT04150029",
    "NCT04165070",
    "NCT04165317",
    "NCT04184050",
    "NCT04204941",
    "NCT04209114",
    "NCT04210115",
    "NCT04218071",
    "NCT04231747",
    "NCT04247126",
    "NCT04262466",
    "NCT04268706",
    "NCT04282668",
    "NCT04330664",
    "NCT04381650",
    "NCT04387461",
    "NCT04402541",
    "NCT04417517",
    "NCT04418167",
    "NCT04463771",
    "NCT04471415",
    "NCT04471727",
    "NCT04493853",
    "NCT04497116",
    "NCT04497844",
    "NCT04502888",
    "NCT04505813",
    "NCT04524871",
    "NCT04527991",
    "NCT04543617",
    "NCT04564027",
    "NCT04577807",
    "NCT04590326",
    "NCT04616196",
    "NCT04656652",
    "NCT04657081",
    "NCT04672980",
    "NCT04697628",
    "NCT04722146",
    "NCT04772989",
    "NCT04775485",
    "NCT04792489",
    "NCT02099058",
    "NCT02138734",
    "NCT02598661",
    "NCT02675946",
    "NCT02719574",
    "NCT02841540",
    "NCT02899052",
    "NCT03132675",
    "NCT03190278",
    "NCT03263091",
    "NCT03280563",
    "NCT03284957",
    "NCT03310957",
    "NCT03314181",
    "NCT03326102",
    "NCT03336333",
    "NCT03386513",
    "NCT03478514",
    "NCT03546582",
    "NCT03562637",
    "NCT03564340",
    "NCT03621644",
    "NCT03634540",
    "NCT03635983",
    "NCT03650491",
    "NCT03666273",
    "NCT03669718",
    "NCT03711032",
    "NCT03778957",
    "NCT03792841",
    "NCT03798626",
    "NCT03801525",
    "NCT03808922",
    "NCT03878550",
    "NCT03961698",
    "NCT03993873",
    "NCT03997123",
    "NCT04025216",
    "NCT04042480",
    "NCT04044859",
    "NCT04062708",
    "NCT04075747",
    "NCT04082936",
    "NCT04130516",
    "NCT04144140",
    "NCT04150965",
    "NCT04160065",
    "NCT04163900",
    "NCT04189614",
    "NCT04249947",
    "NCT04254107",
    "NCT04277637",
    "NCT04293094",
    "NCT04300140",
    "NCT04349436",
    "NCT04372706",
    "NCT04429542",
    "NCT04449874",
    "NCT04458259",
    "NCT04485260",
    "NCT04502446",
    "NCT04569032",
    "NCT04607421",
    "NCT04634877",
    "NCT04662255",
    "NCT04663347",
    "NCT04666688",
    "NCT04695977",
    "NCT04736706",
    "NCT04793958",
    "NCT04871282",
    "NCT04879017",
    "NCT01969643",
    "NCT02266745",
    "NCT02343042",
    "NCT02657005",
    "NCT02817633",
    "NCT02973789",
    "NCT03107988",
    "NCT03162536",
    "NCT03192345",
    "NCT03194542",
    "NCT03298451",
    "NCT03327857",
    "NCT03328078",
    "NCT03374085",
    "NCT03424603",
    "NCT03504488",
    "NCT03516981",
    "NCT03555422",
    "NCT03634982",
    "NCT03678883",
    "NCT03793478",
    "NCT03809000",
    "NCT03815682",
    "NCT03833180",
    "NCT03860272",
    "NCT03901573",
    "NCT03902184",
    "NCT03915184",
    "NCT03924869",
    "NCT03946800",
    "NCT03954067",
    "NCT03964727",
    "NCT03970382",
    "NCT03970616",
    "NCT04029922",
    "NCT04038437",
    "NCT04083976",
    "NCT04102098",
    "NCT04119453",
    "NCT04172675",
    "NCT04251533",
    "NCT04266301",
    "NCT04285086",
    "NCT04328740",
    "NCT04348916",
    "NCT04372433",
    "NCT04380636",
    "NCT04383938",
    "NCT04393285",
    "NCT04404283",
    "NCT04423029",
    "NCT04430738",
    "NCT04482309",
    "NCT04488003",
    "NCT04495153",
    "NCT04585815",
    "NCT04590248",
    "NCT04592913",
    "NCT04603001",
    "NCT04614103",
    "NCT04698187",
    "NCT02303821",
    "NCT02663518",
    "NCT02716116",
    "NCT02732275",
    "NCT02861573",
    "NCT02922764",
    "NCT02975934",
    "NCT03069469",
    "NCT03138512",
    "NCT03165994",
    "NCT03236857",
    "NCT03332667",
    "NCT03395197",
    "NCT03454451",
    "NCT03539744",
    "NCT03547115",
    "NCT03560531",
    "NCT03589326",
    "NCT03661320",
    "NCT03666000",
    "NCT03725059",
    "NCT03739931",
    "NCT03761108",
    "NCT03767348",
    "NCT03787602",
    "NCT03817320",
    "NCT03834948",
    "NCT03867084",
    "NCT03899155",
    "NCT03909334",
    "NCT04024436",
    "NCT04035486",
    "NCT04072952",
    "NCT04094610",
    "NCT04101331",
    "NCT04104776",
    "NCT04106219",
    "NCT04154189",
    "NCT04260126",
    "NCT04381832",
    "NCT04394650",
    "NCT04398745",
    "NCT04461600",
    "NCT04484142",
    "NCT04543188",
    "NCT04590963",
    "NCT04603495",
    "NCT04625270",
    "NCT04633278",
    "NCT04853017",
    "NCT04855656",
    "NCT02074839",
    "NCT02500407",
    "NCT02503423",
    "NCT02573896",
    "NCT02665065",
    "NCT02879643",
    "NCT02927067",
    "NCT03022825",
    "NCT03176277",
    "NCT03257033",
    "NCT03275103",
    "NCT03288493",
    "NCT03319940",
    "NCT03334617",
    "NCT03372057",
    "NCT03397706",
    "NCT03425643",
    "NCT03547973",
    "NCT03600649",
    "NCT03656536",
    "NCT03662126",
    "NCT03849469",
    "NCT03897881",
    "NCT03906071",
    "NCT03917381",
    "NCT03926624",
    "NCT03939689",
    "NCT03941093",
    "NCT03989414",
    "NCT04082364",
    "NCT04136756",
    "NCT04143711",
    "NCT04155580",
    "NCT04181827",
    "NCT04209465",
    "NCT04224493",
    "NCT04278144",
    "NCT04322539",
    "NCT04401748",
    "NCT04472598",
    "NCT04478266",
    "NCT04499924",
    "NCT04585750",
    "NCT04660812",
    "NCT04729608",
    "NCT02158858",
    "NCT02568267",
    "NCT02811783",
    "NCT02831959",
    "NCT02972840",
    "NCT03036098",
    "NCT03230318",
    "NCT03539536",
    "NCT03595059",
    "NCT03646123",
    "NCT03671018",
    "NCT03673124",
    "NCT03731260",
    "NCT03752398",
    "NCT03825367",
    "NCT03847428",
    "NCT03884556",
    "NCT03893682",
    "NCT03894215",
    "NCT03899792",
    "NCT03934814",
    "NCT04013685",
    "NCT04042116",
    "NCT04067336",
    "NCT04100018",
    "NCT04104672",
    "NCT04129502",
    "NCT04137900",
    "NCT04180215",
    "NCT04221945",
    "NCT04229004",
    "NCT04246177",
    "NCT04269200",
    "NCT04383210",
    "NCT04466891",
    "NCT04494425",
    "NCT04511130",
    "NCT04554914",
    "NCT04567420",
    "NCT04596150",
    "NCT04620330",
    "NCT04649359",
    "NCT04696055",
    "NCT04720976",
    "NCT02152956",
    "NCT02268253",
    "NCT02625480",
    "NCT03132792",
    "NCT03377491",
    "NCT03517488",
    "NCT03561259",
    "NCT03565445",
    "NCT03601078",
    "NCT03640481",
    "NCT03645928",
    "NCT03778229",
    "NCT03799003",
    "NCT03888612",
    "NCT03953235",
    "NCT04065399",
    "NCT04199104",
    "NCT04215146",
    "NCT04244552",
    "NCT04245839",
    "NCT04334759",
    "NCT04417621",
    "NCT04546009",
    "NCT02631044",
    "NCT02914938",
    "NCT03016819",
    "NCT03175224",
    "NCT03425279",
    "NCT03520075",
    "NCT03577028",
    "NCT03584516",
    "NCT03674567",
    "NCT03763318",
    "NCT03773302",
    "NCT03886831",
    "NCT03944772",
    "NCT04077099",
    "NCT04086264",
    "NCT04133636",
    "NCT04161391",
    "NCT04188548",
    "NCT04211337",
    "NCT04306900",
    "NCT04404660",
    "NCT04421378",
    "NCT04428151",
    "NCT04579380",
    "NCT04589845",
    "NCT04619004",
    "NCT02715284",
    "NCT02953509",
    "NCT03005782",
    "NCT03037385",
    "NCT03108495",
    "NCT03502668",
    "NCT03625037",
    "NCT03765918",
    "NCT03969004",
    "NCT03981796",
    "NCT04035434",
    "NCT04068896",
    "NCT04171700",
    "NCT04196491",
    "NCT04291105",
    "NCT04498117",
    "NCT04521686",
    "NCT04539938",
    "NCT02912949",
    "NCT03319628",
    "NCT03458728",
    "NCT03504397",
    "NCT03606174",
    "NCT03690869",
    "NCT03709706",
    "NCT03815058",
    "NCT03833167",
    "NCT03872206",
    "NCT03978689",
    "NCT03997968",
    "NCT04223856",
    "NCT04374877",
    "NCT04459715",
    "NCT04526106",
    "NCT02609776",
    "NCT02650401",
    "NCT02927769",
    "NCT03616470",
    "NCT03684785",
    "NCT03767244",
    "NCT03915951",
    "NCT04044768",
    "NCT04077463",
    "NCT04195750",
    "NCT04471844",
    "NCT02773030",
    "NCT03248479",
    "NCT03407144",
    "NCT03639194",
    "NCT03836209",
    "NCT04302025",
    "NCT04338269",
    "NCT04390113",
    "NCT01953926",
    "NCT02332668",
    "NCT03776071",
    "NCT04050436",
    "NCT04363801",
    "NCT03651128",
    "NCT03962543",
    "NCT03967223",
    "NCT04209855",
    "NCT04512235",
    "NCT04710576",
    "NCT03740529",
    "NCT03833154",
    "NCT03600883",
    "NCT04225117",
    "NCT03093116",
    "NCT03258931",
    "NCT04504825",
    "NCT03165734",
    "NCT03170960",
    "NCT03394365",
    "NCT03486873",
    "NCT03709680",
    "NCT04185883",
    "NCT03318939",
    "NCT03876769",
    "NCT04197986",
    "NCT04410445",
    "NCT03719690",
    "NCT03901963",
    "NCT04480502",
    "NCT02796261",
    "NCT03157128",
    "NCT03331198",
    "NCT03398655",
    "NCT03435796",
    "NCT03288545",
    "NCT03785249",
    "NCT03970447",
    "NCT03975647",
    "NCT04313881",
    "NCT02926911",
    "NCT04164901",
    "NCT02723994"
  ],
  "disease_names": [
    "Unresectable Solid Tumor, Metastatic Malignant Neoplasm to the Liver, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Refractory Ependymoma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Medulloblastoma, Recurrent Brain Neoplasm, Lynch Syndrome, Recurrent Ependymoma, Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Medulloblastoma, Malignant Glioma, Refractory Brain Neoplasm, Biallelic Mismatch Repair Deficiency",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Locally Advanced Rectal Adenocarcinoma, Stage IVA Rectal Cancer, Metastatic Rectal Adenocarcinoma, Stage IV Rectal Cancer, Stage IIIB Rectal Cancer, Rectal Adenocarcinoma, Stage IVB Rectal Cancer, Stage IIIC Rectal Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Relapsing-Remitting Multiple Sclerosis",
    "Metastatic Malignant Neoplasm in the Brain, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Endometrial Serous Adenocarcinoma",
    "Recurrent Osteosarcoma, Recurrent Neuroblastoma, Refractory Osteosarcoma, Refractory Neuroblastoma",
    "Lung Atypical Carcinoid Tumor, Metastatic Lung Carcinoid Tumor, Lung Typical Carcinoid Tumor, Unresectable Lung Neuroendocrine Neoplasm, Lung Neuroendocrine Neoplasm, Advanced Lung Carcinoid Tumor, Locally Advanced Lung Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Neoplasm, Functioning Lung Carcinoid Tumor, Recurrent Lung Neuroendocrine Neoplasm, Unresectable Lung Carcinoid Tumor, Non-Functioning Lung Carcinoid Tumor",
    "Recurrent Ependymoma, Refractory Ependymoma, Refractory Medulloblastoma, Recurrent Medulloblastoma",
    "HER2-Positive Breast Carcinoma, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Carcinoma, Advanced Prostate Carcinoma, Platinum Sensitive Ovarian Cancer, Advanced Gastric Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Metastatic Prostate Cancer, Advanced Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Metastatic Ovarian Carcinoma, Stage IIIA Prostate Cancer, Stage IIIA1 Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IV Gastric (Stomach) Cancer, Castration-Resistant Prostate Cancer",
    "Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Oropharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Unresectable Laryngeal Squamous Cell Carcinoma, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer",
    "Cutaneous (Skin) Kaposi Sarcoma",
    "Neuroendocrine Tumor",
    "Refractory AL Amyloidosis, Recurrent AL Amyloidosis",
    "Peritoneal Malignant Mesothelioma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Anaplastic Astrocytoma, Recurrent Malignant Glioma, Recurrent Anaplastic Oligodendroglioma, Recurrent Oligodendroglioma, Recurrent Diffuse Astrocytoma, Glioblastoma, Oligodendroglioma, Gliosarcoma, Anaplastic Oligodendroglioma, Malignant Glioma, Diffuse Astrocytoma, Anaplastic Astrocytoma",
    "Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "HIV Infection, Anal Squamous Cell Cancer",
    "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Plasmablastic Lymphoma, Stage I Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor, HER2-Positive Breast Carcinoma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Gastric Carcinoma, Advanced Digestive System Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Digestive System Cancer, Stage IVB Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Endometrial Serous Adenocarcinoma",
    "Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Enteropathy-Associated T-Cell Lymphoma, Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Angioimmunoblastic T-Cell Lymphoma, Follicular T-Cell Lymphoma",
    "Ovarian Clear Cell Adenocarcinoma, Ovarian Seromucinous Carcinoma, Fallopian Tube Serous Adenocarcinoma, Undifferentiated Ovarian Cancer, Ovarian Transitional Cell Cancer, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Cancer, Ovarian Serous Adenocarcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Serous Adenocarcinoma, Fallopian Tube Transitional Cell Cancer, Ovarian Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer",
    "HIV Infection, Recurrent Hodgkin Lymphoma, Stage IV Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage III Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Advanced Follicular Lymphoma, Recurrent Plasmablastic Lymphoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Plasmacytoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Malignant Glioma, Recurrent Anaplastic Pleomorphic Xanthoastrocytoma, Recurrent Anaplastic Ependymoma, Gliosarcoma, Malignant Glioma, Anaplastic Astrocytoma, Recurrent Anaplastic Ganglioglioma, Glioblastoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Malignant Solid Tumor, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Refractory Gallbladder Carcinoma, Metastatic Gallbladder Carcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Melanoma of Unknown Primary, Metastatic Malignant Neoplasm in the Lymph Nodes, Recurrent Cutaneous (Skin) Melanoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Leptomeningeal Neoplasm, Recurrent Non-Small Cell Lung Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm to the Central Nervous System",
    "Recurrent Osteosarcoma, Recurrent Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Resectable Osteosarcoma",
    "Recurrent Malignant Solid Tumor, Endometrial Cancer, Refractory Ewing Sarcoma, Recurrent Desmoid-Type Fibromatosis, Solid Pseudopapillary Neoplasm of the Pancreas, Recurrent Hepatocellular Cancer, Recurrent Osteosarcoma, Melanoma, Refractory Hepatocellular Carcinoma, Wilms Tumor, Pancreatic Ductal Adenocarcinoma, Recurrent Ewing Sarcoma, Refractory Non-Hodgkin Lymphoma, Recurrent Hepatoblastoma, Ovarian Cancer, Recurrent Non-Hodgkin Lymphoma, Refractory Hepatoblastoma, Refractory Desmoid-Type Fibromatosis, Refractory Osteosarcoma, Refractory Malignant Solid Tumor, Colorectal (Colon or Rectal) Cancer, Neuroblastoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Aplastic Anemia, Leukemia, Lymphoma, Myelodysplastic Syndrome",
    "Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Previously Treated Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Breast Carcinoma, Advanced Prostate Carcinoma, Advanced Breast Carcinoma, Triple-Negative Breast Cancer, Metastatic Prostate Cancer",
    "MGMT-Unmethylated Glioblastoma, Glioblastoma",
    "Anal Intraepithelial Neoplasia 3, High Grade Anal Canal Intraepithelial Neoplasia, Perianal Intraepithelial Neoplasia, HIV Infection, High Grade Squamous Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia 2",
    "Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Advanced Bile Duct Carcinoma, Advanced Urothelial Cancer, Unresectable Urothelial Carcinoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Esophageal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Advanced Penile Carcinoma, Triple-Negative Breast Cancer, Advanced Pleural Malignant Mesothelioma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IIIB Extrahepatic (Distal) Bile Duct Cancer, Stage III Pleural Malignant Mesothelioma, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Stage IIIA Extrahepatic (Distal) Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Extrahepatic (Distal) Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage III Intrahepatic Bile Duct Cancer",
    "Stage III Pancreatic Neuroendocrine Tumor, Stage II Pancreatic Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Stage I Pancreatic Neuroendocrine Tumor, Metastatic Malignant Neoplasm to the Liver",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Kaposi Sarcoma, Hepatocellular Cancer, HIV Infection, Metastatic Neoplasm, AIDS-Related Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Refractory Neoplasm, Recurrent Kaposi Sarcoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Malignant Neoplasm, Metastatic Melanoma, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer",
    "Metastatic Urothelial Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Advanced Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Advanced Bladder Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Recurrent Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, High-Grade Treatment-Related Myeloid Neoplasm",
    "Adult T-Cell Leukemia/Lymphoma, Acute Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection, Chronic Adult T-Cell Leukemia/Lymphoma",
    "Unresectable Esophageal Cancer, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Distal Esophagus Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Adenocarcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm to the Leptomeninges, Gastric Cardia Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Biallelic Mismatch Repair Deficiency, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Refractory Lymphoma, Recurrent Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Xeroderma Pigmentosum, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Recurrent Neuroblastoma, Lynch Syndrome",
    "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia",
    "Metastatic Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IV Renal Cell Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Ovarian Carcinoma, Metastatic Colorectal Carcinoma, Refractory Renal Cell Carcinoma, Recurrent Melanoma, Recurrent Renal Cell Cancer, Metastatic Melanoma, Refractory Melanoma, Metastatic Renal Cell Cancer, Sarcoma",
    "HIV Infection, Cutaneous (Skin) Kaposi Sarcoma",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor",
    "MGMT-Unmethylated Glioblastoma, Glioblastoma, Gliosarcoma, Recurrent Glioblastoma",
    "Metastatic Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Recurrent Urethral Urothelial Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Recurrent Ureter Urothelial Cancer, Recurrent Renal Pelvis Urothelial Cancer, Unresectable Bladder Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Bladder Urothelial Carcinoma",
    "Diffuse Astrocytoma, IDH-Mutant, Anaplastic Astrocytoma, IDH-Mutant",
    "Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Malignant Glioma, Refractory Malignant Glioma, Refractory Medulloblastoma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Skin Squamous Cell Carcinoma, Unresectable Melanoma, Metastatic Basal Cell Carcinoma, Unresectable Basal Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Metastatic Melanoma",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma, Supratentorial Gliosarcoma, Supratentorial Glioblastoma",
    "Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mediastinal Lymphoma, Refractory Mediastinal Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma",
    "Refractory Central Nervous System Neoplasm, Recurrent Central Nervous System Neoplasm, Diffuse Intrinsic Pontine Glioma",
    "Recurrent Medulloblastoma, SHH-Activated",
    "Stage IIIA Lung Cancer, Metastatic Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Unresectable Malignant Solid Tumor, Stage IVA Lung Cancer, Stage IIIC Lung Cancer, Metastatic Malignant Solid Tumor, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Metastatic Neuroendocrine Carcinoma, Unresectable Lung Small Cell Carcinoma, Unresectable Neuroendocrine Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Gastrointestinal Stromal Tumor (GIST), Recurrent Sarcoma",
    "Advanced Cervical Squamous Cell Carcinoma, Advanced Cervical Adenocarcinoma, Advanced Cervical Adenosquamous Carcinoma, Advanced Vaginal Adenocarcinoma, Stage IB2 Cervical Cancer, Stage IIB Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage II Vaginal Cancer, Stage III Vaginal Cancer, Stage IVA Vaginal Cancer, Stage IIA1 Cervical Cancer, Stage IIA2 Cervical Cancer, Stage II Cervical Cancer",
    "Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Cholangiocarcinoma",
    "Non-Metastatic Breast Carcinoma, HER2 Negative Breast Carcinoma, Triple-Negative Breast Cancer, Recurrent Breast Cancer, Bilateral Breast Cancer",
    "Recurrent Malignant Glioma, Recurrent Grade II Glioma, Neurofibromatosis Type 1",
    "Metastatic Well Differentiated Neuroendocrine Neoplasm, Digestive System Neuroendocrine Tumor",
    "Recurrent Glioblastoma, Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Anaplastic Astrocytoma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Malignant Glioma, Recurrent Anaplastic Oligoastrocytoma, Recurrent Anaplastic Oligodendroglioma, Glioblastoma, Recurrent Spinal Cord Neoplasm, Metastatic Malignant Neoplasm to the Leptomeninges",
    "Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Carcinoma, Triple-Negative Breast Cancer, Unresectable Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer",
    "Advanced Oral Cavity Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer",
    "Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IV Breast Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Advanced Salivary Gland Carcinoma, Unresectable Malignant Solid Tumor, Stage IV Uterine (including Endometrial) Cancer, Stage IV Breast Cancer, Stage IVC Major Salivary Gland Cancer, Stage IIIC Colon Cancer, Advanced Colon Carcinoma, Advanced Gastric Carcinoma, Unresectable Colorectal Carcinoma, Stage IVA Uterine (including Endometrial) Cancer, Metastatic Malignant Solid Tumor, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIB Colon Cancer, Stage III Major Salivary Gland Cancer, Advanced Malignant Solid Tumor, Stage IVB Major Salivary Gland Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Stage IIIC Breast Cancer, Stage IVA Major Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIA Colon Cancer, Stage IV Major Salivary Gland Cancer, Advanced Endometrial Carcinoma, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IIIB Breast Cancer, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Metastatic Breast Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Stage IVC Colon Cancer, Stage IIIA Breast Cancer, Stage IVB Colon Cancer, Stage IVA Colon Cancer, Stage III Breast Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IIIB Breast Cancer, Stage IV Colon Cancer",
    "Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIA Small Cell Lung Cancer, Metastatic Lung Small Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Stage IIIB Small Cell Lung Cancer, Stage IIIA Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage III Pancreatic Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage IV Small Cell Lung Cancer, Triple-Negative Breast Cancer",
    "Malignant Glioma, Supratentorial Ependymoma",
    "Refractory Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma",
    "Stage IIIB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIB Esophageal Adenocarcinoma, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage II Esophageal Adenocarcinoma, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Refractory Mycosis Fungoides and Sezary Syndrome, Recurrent Sezary Syndrome, Refractory Sezary Syndrome, Sezary Syndrome, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides",
    "Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Invasive Breast Cancer",
    "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IV Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Head and Neck Carcinoma of Unknown Primary, Head and Neck Squamous Cell Carcinoma, Stage IV Oral Cavity Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage IVC Oral Cavity Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer",
    "Resectable Liposarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Leiomyosarcoma, Stage I Soft Tissue Sarcoma, Stage II Soft Tissue Sarcoma, Stage IB Soft Tissue Sarcoma, Stage IIA Soft Tissue Sarcoma, Stage IIB Soft Tissue Sarcoma, Stage IA Soft Tissue Sarcoma, FNCLCC Sarcoma Grade 2, FNCLCC Sarcoma Grade 3",
    "Refractory Kaposi Sarcoma, Cutaneous (Skin) Kaposi Sarcoma",
    "Recurrent Glioblastoma, Refractory Glioma, Recurrent Grade II Glioma, Recurrent Grade III Glioma, Refractory WHO Grade III Glioma, Refractory WHO Grade II Glioma",
    "Clear Cell Sarcoma of Soft Tissue, Dedifferentiated Chondrosarcoma, Primary Central Chondrosarcoma, Chondrosarcoma NCI Grade 3, Chondrosarcoma NCI Grade 2",
    "High Grade Squamous Intraepithelial Neoplasia, HIV Infection, Anal Intraepithelial Neoplasia",
    "Stage IIIA Penile Cancer, Penile Squamous Cell Cancer, Stage IV Penile Cancer, Stage IIIB Penile Cancer, Stage III Penile Cancer",
    "AIDS-Related Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma",
    "Recurrent Bladder Urothelial Cancer, Recurrent Urethral Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Recurrent Ureter Urothelial Cancer, Recurrent Renal Pelvis Urothelial Cancer, Unresectable Urethral Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Stage III Renal Pelvis Cancer, Stage IV Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Ureter Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Stage III Bladder Urothelial Cancer, Stage IV Bladder Urothelial Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Locally Advanced Clear Cell Renal Cell Carcinoma, Clear Cell Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Refractory Skin Squamous Cell Carcinoma, NK-Cell Lymphoma, Unclassifiable, Refractory Merkel Cell Carcinoma, Endocrine Mucin-Producing Sweat Gland Carcinoma, Primary Cutaneous Mucinous Carcinoma, Digital Papillary Adenocarcinoma, Papillary Adenocarcinoma, Skin Basal Cell Cancer, Skin Basosquamous Cell Carcinoma, Keratoacanthoma, Extramammary Paget Disease, Sezary Syndrome, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-Negative, Signet Ring Cell Carcinoma, Adnexal Carcinoma, Vulvar Squamous Cell Cancer, Apocrine Carcinoma, Trichilemmal Carcinoma, Extraocular Cutaneous Sebaceous Carcinoma, Cylindrocarcinoma, Squamoid Eccrine Ductal Carcinoma, Adenoid Cystic Skin Carcinoma, Malignant Sweat Gland Neoplasm, Skin Squamous Cell Cancer, Spiradenocarcinoma, Hidradenocarcinoma, Porocarcinoma, Sweat Gland Carcinoma, Microcystic Adnexal Carcinoma, Squamous Cell Cancer of Unknown Primary Origin, Refractory Anaplastic Large Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Merkel Cell Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Malignant Solid Tumor, Steroid-Refractory Pneumonitis, Hematopoietic and Lymphoid Cell Neoplasm",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Prostate Cancer",
    "Acute Graft Versus Host Disease",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Diffuse Large B-Cell Lymphoma, Central Nervous System Lymphoma",
    "Stage I Pleural Malignant Mesothelioma, Stage IB Pleural Malignant Mesothelioma, Stage II Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IA Pleural Malignant Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Biphasic Mesothelioma",
    "High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Fallopian Tube Endometrioid Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma",
    "Recurrent Glioblastoma, Diffuse Astrocytoma, IDH-Wildtype",
    "Recurrent Glioblastoma, Recurrent Malignant Solid Tumor, WHO Grade III Glioma, Refractory Malignant Solid Tumor, Recurrent Lymphoma, Malignant Glioma, Recurrent Brain Neoplasm, Refractory Central Nervous System Neoplasm, Recurrent Central Nervous System Neoplasm, Refractory Lymphoma",
    "Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Lung Cancer, Kaposi Sarcoma, Anal Cancer, HIV Infection, Metastatic Malignant Solid Tumor",
    "Unresectable Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage III Hepatocellular Cancer, Recurrent Hepatocellular Cancer",
    "Metastatic Urothelial Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Locally Advanced Urothelial Cancer, Stage IV Bladder Cancer",
    "Nasopharyngeal Squamous Cell Carcinoma, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Squamous Cell Cancer",
    "Malignant Solid Tumor, Unresectable Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm to the Bone",
    "Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Cardiovascular Disorder, Thyroid Gland Cancer, Chronic Kidney Disease",
    "Glioma, WHO Grade III Glioma, Oligodendroglioma, Oligoastrocytoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Diffuse Astrocytoma, Anaplastic Astrocytoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma",
    "Non-Small Cell Squamous Lung Cancer, Stage IV Lung Cancer",
    "Pleural Malignant Mesothelioma",
    "Stage IV Renal Cell Cancer, Advanced Renal Cell Carcinoma, Unclassified Renal Cell Cancer, Metastatic Malignant Neoplasm to the Bone, Clear Cell Renal Cell Cancer, Chromophobe Renal Cell Cancer, Collecting Duct Carcinoma, Papillary Renal Cell Cancer, Kidney Medullary Carcinoma",
    "Recurrent Osteosarcoma, Osteosarcoma",
    "Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Colorectal (Colon or Rectal) Cancer",
    "Immature Teratoma, Embryonal Carcinoma, Pineal Region Immature Teratoma, Suprasellar Germ Cell Tumor, Malignant Teratoma, Pineal Region Germ Cell Tumor, Mixed Germ Cell Tumor, Central Nervous System Nongerminomatous Germ Cell Tumor, Pineal Region Yolk Sac Tumor, Choriocarcinoma",
    "Extrapulmonary Small Cell Carcinoma, Platinum-Resistant Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Prostate Small Cell Neuroendocrine Carcinoma, Limited Stage Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Bladder Small Cell Neuroendocrine Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, NF1 Mutation Positive Malignant Peripheral Nerve Sheath Tumor",
    "Hematologic and Lymphocytic Disorder, Aplastic Anemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Sickle Cell Disease, Hodgkin Lymphoma",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma, Metastatic Prostate Cancer",
    "Metastatic Malignant Digestive System Neoplasm, Metastatic Renal Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer, Metastatic Malignant Breast Neoplasm, Recurrent Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Stage IV Breast Cancer",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Recurrent Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Unresectable Alveolar Soft Part Sarcoma, Metastatic Alveolar Soft Part Sarcoma",
    "Recurrent Malignant Solid Tumor, WHO Grade III Glioma, Advanced Malignant Solid Tumor, Grade II Glioma, Recurrent Glioma, Recurrent Cholangiocarcinoma, Glioblastoma",
    "Unresectable Primary Central Chondrosarcoma, Metastatic Primary Central Chondrosarcoma, Locally Advanced Unresectable Primary Central Chondrosarcoma",
    "Unresectable Vaginal Carcinoma, Advanced Vaginal Adenocarcinoma, Advanced Vaginal Adenosquamous Carcinoma, Advanced Vaginal Squamous Cell Carcinoma, Vaginal Cancer, Vaginal Adenosquamous Cancer, Cervical Squamous Cell Cancer, Endocervical Cancer, Cervical Adenosquamous Cancer, Stage IB2 Cervical Cancer, Stage IIB Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IV Vaginal Cancer, Vaginal Squamous Cell Cancer, NOS, Stage II Vaginal Cancer, Stage III Vaginal Cancer, Stage IVA Vaginal Cancer, Vaginal Adenocarcinoma, Stage II Cervical Cancer, Stage IIA Cervical Cancer",
    "Metastatic Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Soft Tissue Sarcoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Dermatomyositis, Sjogren Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Rheumatoid Arthritis, Autoimmune Disease, Ulcerative Colitis, Crohn Disease, Inflammatory Bowel Disease, Multiple Sclerosis, Systemic Lupus Erythematosus, Systemic Scleroderma",
    "Glioblastoma",
    "High Grade Ureter Urothelial Carcinoma, High Grade Urothelial Carcinoma, Stage IIIA Bladder Cancer, Infiltrating Renal Pelvis and Ureter Urothelial Carcinoma, High Grade Renal Pelvis Urothelial Carcinoma, Stage II Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Metastatic Anal Canal Carcinoma, Stage IV Anal Canal Cancer, Anal Canal Squamous Cell Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Grade II Glioma, Recurrent Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory Low Grade Astrocytoma, Refractory WHO Grade I Glioma",
    "Stage IIB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Metastatic Paraganglioma, Unresectable Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Advanced Adrenal Gland Pheochromocytoma, Metastatic Pheochromocytoma",
    "Neurofibromatosis Type 1, Juvenile Myelomonocytic Leukemia",
    "Stage I Lip and Oral Cavity Cancer, Gingival Squamous Cell Carcinoma, Stage II Lip and Oral Cavity Cancer, Upper Alveolar Ridge Squamous Cell Carcinoma, Lower Alveolar Ridge Squamous Cell Carcinoma, Buccal Mucosa Squamous Cell Carcinoma, Floor of Mouth Squamous Cell Carcinoma, Lip Squamous Cell Carcinoma, Tongue Squamous Cell Carcinoma, Oral Cavity Squamous Cell Cancer, Hard Palate Squamous Cell Carcinoma, Retromolar Trigone Squamous Cell Carcinoma",
    "Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Bladder Urothelial Cancer",
    "Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage I Esophageal Adenocarcinoma, Stage IA Esophageal Adenocarcinoma, Stage IB Esophageal Adenocarcinoma, Stage IC Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage I Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage I Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage I Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage I Esophageal Squamous Cell Cancer, Stage IA Esophageal Squamous Cell Cancer, Stage IB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Thoracic Esophagus Squamous Cell Carcinoma",
    "B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",
    "Renal Pelvis and Ureter Urothelial Cancer",
    "Stage IIIC Rectal Cancer, Stage IIB Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIC Rectal Cancer, Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer, Stage III Rectal Cancer",
    "Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "High-Risk Neuroblastoma, Ganglioneuroblastoma, Nodular",
    "Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Diffuse Large B-Cell Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Grade 3b Follicular Lymphoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Double-Hit Lymphoma, Triple-Hit Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Stage III Diffuse Large B-Cell Lymphoma, Lymphoplasmacytic Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation",
    "Recurrent Acute Leukemia, Refractory Acute Leukemia, Infantile Fibrosarcoma, Solid Tumor, Brain/Spinal Cord Tumor",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Melanoma of Unknown Primary, Recurrent Cutaneous (Skin) Melanoma",
    "Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Papillary Craniopharyngioma",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, Recurrent Lymphoblastic Lymphoma, Recurrent B Lymphoblastic Lymphoma, Refractory B Lymphoblastic Lymphoma",
    "Visceral Angiosarcoma, Skin Radiation-Related Angiosarcoma, Cutaneous Angiosarcoma",
    "Recurrent Desmoid-Type Fibromatosis, Unresectable Desmoid Fibromatosis, Deep Fibromatosis/Desmoid Tumor",
    "Recurrent Non-Hodgkin Lymphoma, Refractory Malignant Germ Cell Tumor, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Low Grade Glioma, Recurrent Glioma, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Soft Tissue Sarcoma, Refractory Rhabdomyosarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Osteosarcoma, Refractory Ependymoma, Refractory Glioma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Rhabdoid Tumor, Malignant Glioma, Recurrent Medulloblastoma, Refractory Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Ependymoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Central Nervous System Neoplasm, Recurrent Malignant Germ Cell Tumor, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma",
    "Low Grade Astrocytoma, Low Grade Glioma, Metastatic Low Grade Glioma, Metastatic Low Grade Astrocytoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Low Grade Glioma, Neurofibromatosis Type 1, Visual Pathway Glioma",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Ependymoma, Langerhans Cell Histiocytosis, Wilms Tumor, Rhabdomyosarcoma, Hepatoblastoma, Rhabdoid Tumor, Ewing Sarcoma, Malignant Glioma, Malignant Germ Cell Tumor, Refractory Central Nervous System Neoplasm, Recurrent Neuroblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Central Nervous System Neoplasm, Osteosarcoma, Soft Tissue Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma",
    "Malignant Peritoneal Germ Cell Tumor, Non-Seminomatous Lesion, Germ Cell Tumor, Mediastinal Germ Cell Tumor, Malignant Mediastinal Nongerminomatous Germ Cell Tumor, Retroperitoneal Germ Cell Tumor, Mediastinal Seminoma, Testicular Seminoma, Testicular Germ Cell Tumor, Seminoma, Testicular Non-Seminomatous Germ Cell Tumor",
    "Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, T Lymphoblastic Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Malignant Solid Tumor, Recurrent Germ Cell Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Malignant Glioma, Refractory Rhabdomyosarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Osteosarcoma, Refractory Medulloblastoma, Recurrent Grade II Glioma, Refractory Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ependymoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Medulloblastoma, Wilms Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Refractory Non-Hodgkin Lymphoma, Recurrent Hepatoblastoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Glioma, Refractory Malignant Solid Tumor, Recurrent Germ Cell Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Soft Tissue Sarcoma, Refractory Langerhans Cell Histiocytosis, Recurrent Malignant Glioma, Recurrent Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Glioma, Refractory Ependymoma, Refractory Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Ependymoma, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Recurrent Medulloblastoma, Refractory Central Nervous System Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Low Grade Glioma, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Rhabdoid Tumor, Malignant Glioma, Recurrent Medulloblastoma, Refractory Central Nervous System Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Recurrent Rhabdomyosarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Ependymoma, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Malignant Germ Cell Tumor, Stage III Non-Hodgkin Lymphoma, Stage IV Non-Hodgkin Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Glioma, Recurrent Germ Cell Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Recurrent Soft Tissue Sarcoma, Recurrent Ependymoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Rhabdoid Tumor, Malignant Glioma, Recurrent Medulloblastoma, Stage III Osteosarcoma, Stage IV Osteosarcoma, Stage IVA Osteosarcoma, Stage IVB Osteosarcoma, Refractory Central Nervous System Neoplasm, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Osteosarcoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Advanced Malignant Solid Tumor, Recurrent Glioma, Recurrent Germ Cell Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Malignant Glioma, Recurrent Rhabdoid Tumor, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Osteosarcoma, Refractory Medulloblastoma, Refractory Rhabdoid Tumor, Refractory Glioma, Refractory Ependymoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Recurrent Ewing Sarcoma, Recurrent Kidney Wilms Tumor, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Ependymoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Cervical Squamous Cell Cancer, Endocervical Cancer, Cervical Adenosquamous Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage IIA Cervical Cancer",
    "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Cancer",
    "High-Risk Neuroblastoma, Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Botryoid-Type Embryonal Rhabdomyosarcoma, Metastatic Embryonal Rhabdomyosarcoma, Metastatic Rhabdomyosarcoma, Spindle Cell/Sclerosing Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma, Solid Alveolar Rhabdomyosarcoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Down Syndrome",
    "Atypical Hyperplasia, Atypical Breast Papilloma, Lobular Carcinoma In Situ (LCIS), Hereditary Breast Cancer, Atypical Lobular Breast Hyperplasia, Atypical Ductal Breast Hyperplasia",
    "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic HER2-Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Invasive Breast Cancer",
    "Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm of Unknown Primary Origin",
    "Stage 0 Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Acinar Cell Carcinoma, Pancreatic Squamous Cell Carcinoma, Resectable Pancreatic Cancer, Pancreatic Adenosquamous Cancer, Stage II Pancreatic Cancer, Pancreatic Acinar Cell Cancer, Pancreatic Cancer, Resectable Pancreatic Adenosquamous Carcinoma",
    "Stage IV Renal Pelvis Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer, Stage IV Urethral Cancer, Refractory Urothelial Carcinoma, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Refractory Bladder Urothelial Carcinoma, Refractory Ureter Urothelial Carcinoma, Refractory Urethral Urothelial Carcinoma, Refractory Renal Pelvis Urothelial Carcinoma, Metastatic Urothelial Cancer, Stage IVA Bladder Cancer, Stage IV Renal Pelvis and Ureter Cancer, Stage IV Ureter Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Glioblastoma, Secondary Glioblastoma",
    "Metastatic Skin Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma",
    "Grade II Meningioma, Intracranial Meningioma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Lymphoblastic Lymphoma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage 0a Bladder Cancer, Stage 0is Bladder Cancer, Stage I Bladder Cancer, Infiltrating Bladder Mixed Carcinoma, Bladder Urothelial Carcinoma In Situ, Bladder Urothelial Cancer",
    "Metastatic Germ Cell Tumor, Metastatic Malignant Testicular Germ Cell Tumor, Malignant Germ Cell Tumor, Mediastinal Germ Cell Tumor, Retroperitoneal Germ Cell Tumor, Stage IV Ovarian Germ Cell Tumor, Ovarian Yolk Sac Tumor, Ovarian Mixed Germ Cell Tumor, Stage IV Ovarian Choriocarcinoma, Malignant Testicular Germ Cell Tumor",
    "Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Low Grade Ovarian Serous Adenocarcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Endometrioid Primary Peritoneal Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Fallopian Tube Mucinous Adenocarcinoma, Refractory Ovarian Seromucinous Carcinoma, Refractory Fallopian Tube Clear Cell Adenocarcinoma, Refractory Fallopian Tube Endometrioid Adenocarcinoma, Refractory Fallopian Tube Transitional Cell Carcinoma, Refractory Fallopian Tube Undifferentiated Carcinoma, Refractory High Grade Fallopian Tube Serous Adenocarcinoma, Refractory High Grade Ovarian Serous Adenocarcinoma, Refractory Low Grade Fallopian Tube Serous Adenocarcinoma, Refractory Low Grade Ovarian Serous Adenocarcinoma, Refractory Ovarian Clear Cell Adenocarcinoma, Refractory Ovarian Mucinous Adenocarcinoma, Refractory Ovarian Transitional Cell Carcinoma, Refractory Ovarian Undifferentiated Carcinoma, Refractory Primary Peritoneal Clear Cell Adenocarcinoma, Refractory Primary Peritoneal Endometrioid Adenocarcinoma, Refractory Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Low Grade Serous Adenocarcinoma, Refractory Primary Peritoneal Transitional Cell Carcinoma, Refractory Primary Peritoneal Undifferentiated Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Mucinous Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Recurrent Fallopian Tube Mucinous Adenocarcinoma, Recurrent Ovarian Seromucinous Carcinoma, Refractory Ovarian Endometrioid Adenocarcinoma",
    "Malignant Solid Tumor",
    "INRG Stage L2, INRG Stage M, INRG Stage MS, Neuroblastoma, Ganglioneuroblastoma",
    "Stage IVB Nasopharyngeal Throat Cancer, Epstein-Barr Virus Infection, Stage IVA Nasopharyngeal Throat Cancer, Stage II Nasopharyngeal Throat Cancer, Stage III Nasopharyngeal Throat Cancer",
    "Stage IVB Osteosarcoma, Recurrent Ewing Sarcoma, Refractory Non-Hodgkin Lymphoma, Recurrent Hepatoblastoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Stage IV Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Medulloblastoma, Recurrent Osteosarcoma, Langerhans Cell Histiocytosis, Recurrent Malignant Solid Tumor, Recurrent Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Recurrent Ependymoma, Histiocytic Sarcoma, Recurrent Germ Cell Tumor, Refractory Malignant Germ Cell Tumor, Malignant Glioma, Refractory Neuroblastoma, Recurrent Neuroblastoma, Recurrent Soft Tissue Sarcoma, Refractory Malignant Solid Tumor, Refractory Langerhans Cell Histiocytosis, Recurrent Langerhans Cell Histiocytosis, Rhabdoid Tumor, Recurrent Rhabdomyosarcoma, Advanced Malignant Solid Tumor, Stage IV Soft Tissue Sarcoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Refractory Central Nervous System Neoplasm, Wilms Tumor, Refractory Glioma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Juvenile Xanthogranuloma, Recurrent Glioma, Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Stage III Soft Tissue Sarcoma, Stage III Osteosarcoma, Refractory Osteosarcoma, Refractory Peripheral Primitive Neuroectodermal Tumor, Stage IVA Osteosarcoma",
    "Recurrent Kidney Wilms Tumor, Anaplastic Kidney Wilms Tumor, Stage II Wilms Tumor, Stage III Wilms Tumor, Stage IV Wilms Tumor",
    "Recurrent Rhabdoid Tumor, Recurrent Malignant Glioma, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Refractory Malignant Germ Cell Tumor, Recurrent Malignant Solid Tumor, Recurrent Germ Cell Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Ependymoma, Recurrent Grade II Glioma, Recurrent Ependymoma, Refractory WHO Grade II Glioma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Recurrent Medulloblastoma, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Recurrent Germ Cell Tumor, Refractory Neuroblastoma, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Malignant Glioma, Recurrent Rhabdoid Tumor, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Thyroid Gland Cancer, Refractory Ependymoma, Refractory Melanoma, Recurrent Grade II Glioma, Recurrent Ependymoma, Refractory WHO Grade II Glioma, Refractory Adrenal Gland Pheochromocytoma, Recurrent Rhabdoid Tumor of the Kidney, Refractory Rhabdoid Tumor of the Kidney, Recurrent Ectomesenchymoma, Recurrent Peripheral Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Recurrent Melanoma, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Kidney Wilms Tumor, Recurrent Osteosarcoma, Recurrent Thyroid Gland Cancer, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Malignant Germ Cell Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Malignant Solid Tumor, Recurrent Germ Cell Tumor, Recurrent Lymphoma, Refractory Histiocytic and Dendritic Cell Neoplasm, Recurrent Histiocytic and Dendritic Cell Neoplasm, Recurrent Langerhans Cell Histiocytosis, Refractory Langerhans Cell Histiocytosis, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Malignant Glioma, Recurrent Rhabdoid Tumor, Refractory Peripheral Primitive Neuroectodermal Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Malignant Glioma, Refractory Medulloblastoma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Ependymoma, Recurrent Grade II Glioma, Recurrent Ependymoma, Refractory WHO Grade II Glioma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Peripheral Primitive Neuroectodermal Tumor, Wilms Tumor, Recurrent Medulloblastoma, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Hepatoblastoma, Refractory Non-Hodgkin Lymphoma, Recurrent Rhabdomyosarcoma, Recurrent Non-Hodgkin Lymphoma, Refractory Lymphoma",
    "Inflammatory Breast Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Metastatic Prostatic Adenocarcinoma, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer",
    "Medulloblastoma",
    "Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML), Down Syndrome, Myelodysplastic Syndrome, Myeloid Leukemia Associated with Down Syndrome, Chronic Myeloproliferative Disease",
    "Hepatocellular Malignant Neoplasm, Not Otherwise Specified, Fibrolamellar Cancer, Hepatoblastoma, Malignant Liver Neoplasm, Hepatocellular Cancer",
    "p16INK4a Negative Oropharyngeal Squamous Cell Cancer, Stage III Oral Cavity Squamous Cell Cancer, Stage IV Oral Cavity Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Squamous Cell Cancer",
    "Stage IIIC Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "T Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Mixed Phenotype Acute Leukemia, B Acute Lymphoblastic Leukemia",
    "Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Cancer",
    "Neuroblastoma, Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma",
    "Extensive Stage Small Cell Lung Cancer",
    "Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Testicular Leukemia",
    "MGMT-Unmethylated Glioblastoma, Gliosarcoma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Down Syndrome, B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma",
    "Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage IA Breast Cancer, Stage IA Breast Cancer, Lobular Carcinoma In Situ (LCIS)",
    "Stage IV Penile Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Renal Cell Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage IV Urethral Cancer, Metastatic Bladder Carcinoma, Metastatic Bladder Squamous Cell Carcinoma, Metastatic Plasmacytoid Urothelial Carcinoma, Metastatic Lipid Rich Urothelial Carcinoma, Metastatic Kidney Medullary Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Bladder Neuroendocrine Carcinoma, Metastatic Bladder Large Cell Neuroendocrine Carcinoma, Metastatic Bladder Small Cell Neuroendocrine Carcinoma, Metastatic Small Cell Neuroendocrine Prostate Cancer, Metastatic Sarcomatoid Urothelial Carcinoma, Metastatic Micropapillary Urothelial Carcinoma, Metastatic Clear Cell Urothelial Carcinoma, Metastatic Genitourinary Tumor, Metastatic Penile Carcinoma, Metastatic Urethral Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Sarcomatoid Renal Cell Cancer, Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Lymphoepithelioma-Like Carcinoma, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma with Giant Cells, Bladder Mixed Adenocarcinoma, Bladder Urachal Adenocarcinoma, Bladder Squamous Cell Cancer, Bladder Adenocarcinoma, Chromophobe Renal Cell Cancer, Testicular Sertoli Cell Tumor, Urethral Clear Cell Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Collecting Duct Carcinoma, Testicular Leydig Cell Tumor, Large Cell Neuroendocrine Carcinoma, Papillary Renal Cell Cancer, Kidney Medullary Carcinoma, Bladder Small Cell Neuroendocrine Cancer",
    "Stage II Prostate Adenocarcinoma",
    "Stage III Thymus Epithelial Neoplasm, Stage IIIA Thymic Epithelial Neoplasm AJCC v8, Stage IIIB Thymic Epithelial Neoplasm AJCC v8, Stage IV Thymus Epithelial Neoplasm, Stage IVA Thymus Epithelial Neoplasm, Stage IVB Thymus Epithelial Neoplasm, Unresectable Thymic Carcinoma, Locally Advanced Thymic Carcinoma, Recurrent Thymic Carcinoma, Metastatic Thymic Carcinoma",
    "Pancreatic Neoplasm",
    "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia",
    "Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Recurrent Anal Squamous Cell Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Unresectable Anal Squamous Cell Carcinoma, Anal Canal Cloacogenic Cancer, Anal Basaloid Carcinoma",
    "Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified, Recurrent Endometrial Dedifferentiated Carcinoma, Endometrial Serous Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma",
    "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Cancer",
    "Stage I Uterine (including Endometrial) Cancer, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Endometrial Endometrioid Adenocarcinoma",
    "Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer",
    "Metastatic Gastrointestinal Neuroendocrine Tumor G1, Metastatic Pancreatic Neuroendocrine Tumor, Metastatic Digestive System Neuroendocrine Neoplasm, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Metastatic Thymic Neuroendocrine Neoplasm, Locally Advanced Pancreatic Neuroendocrine Tumor, Carcinoid Tumor, Neuroendocrine Tumor, Lung Carcinoid Tumor, Pancreatic Serotonin-Producing Neuroendocrine Tumor, Lung Atypical Carcinoid Tumor, Low Grade Lung Neuroendocrine Neoplasm, Intermediate Grade Lung Neuroendocrine Neoplasm, Non-Functioning Pancreatic Neuroendocrine Tumor, Functioning Pancreatic Neuroendocrine Tumor, Atypical Carcinoid Tumor, Stage IIIA Digestive System Neuroendocrine Tumor, Stage IIIB Digestive System Neuroendocrine Tumor, Stage IV Digestive System Neuroendocrine Tumor",
    "Infiltrating Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Cancer, Stage III Bladder Urothelial Cancer",
    "Stage II Gallbladder Cancer, Stage IIA Gallbladder Cancer, Stage IIB Gallbladder Cancer, Stage III Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IIIA Gallbladder Cancer",
    "Mantle Cell Lymphoma",
    "Sclerosing Rhabdomyosarcoma, Alveolar Rhabdomyosarcoma, Rhabdomyosarcoma, Spindle Cell Rhabdomyosarcoma, Embryonal Rhabdomyosarcoma, Botryoid-Type Embryonal Rhabdomyosarcoma",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Metastatic Mucosal Melanoma, Acral Lentiginous Melanoma, Metastatic Malignant Neoplasm in the Brain",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Unresectable Melanoma, Advanced Melanoma, Melanoma of Unknown Primary, Unresectable Acral Lentiginous Melanoma, Unresectable Mucosal Melanoma, Advanced Cutaneous Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Basaloid Squamous Cell Carcinoma, Oropharyngeal Throat Squamous Cell Cancer",
    "Metastatic Colorectal Adenocarcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IVB Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Primary Prostate Urothelial Cancer, Locally Advanced Urethral Urothelial Carcinoma",
    "Grade 1 Follicular Lymphoma, Recurrent Follicular Lymphoma, Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma, Grade 2 Follicular Lymphoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma",
    "Stage IB Cervical Cancer, Stage IA Cervical Cancer, Stage IIA Cervical Cancer, Stage I Cervical Cancer, Cervical Squamous Cell Cancer, Endocervical Cancer, Cervical Adenosquamous Cancer",
    "Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IC Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "B Acute Lymphoblastic Leukemia",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Nodular Sclerosis Classical Hodgkin Lymphoma, Stage III Nodular Sclerosis Classical Hodgkin Lymphoma, Stage III Mixed Cellularity Classical Hodgkin Lymphoma, Stage III Lymphocyte-Depleted Classical Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Stage IIIA Hodgkin Lymphoma, Stage IIIB Hodgkin Lymphoma, Stage IVA Hodgkin Lymphoma, Stage IVB Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Stage IV Lymphocyte-Depleted Classical Hodgkin Lymphoma, Stage IV Mixed Cellularity Classical Hodgkin Lymphoma",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage III Small Intestinal Adenocarcinoma, Stage IIIA Small Intestinal Adenocarcinoma, Stage IIIB Small Intestinal Adenocarcinoma, Stage IV Small Intestinal Adenocarcinoma, Locally Advanced Small Intestinal Adenocarcinoma, Unresectable Small Intestinal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma",
    "Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Lip and Oral Cavity Squamous Cell Cancer, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Stage IVA Oral Cavity Verrucous Cancer, Stage III Oral Cavity Verrucous Cancer",
    "Mantle Cell Lymphoma, Liver Lymphoma",
    "Metastatic Malignant Neoplasm to Soft Tissues, Stage IV Renal Cell Cancer, Metastatic Malignant Neoplasm in the Viscera, Sarcomatoid Renal Cell Cancer, Metastatic Malignant Neoplasm to the Bone, Clear Cell Renal Cell Cancer, Metastatic Malignant Neoplasm in the Lymph Nodes",
    "Stage I Anal Cancer, Stage IIA Anal Cancer, Anal Margin Squamous Cell Carcinoma, Anal Canal Squamous Cell Carcinoma, Anal Canal Cloacogenic Cancer, Anal Basaloid Carcinoma",
    "RISS Stage I Plasma Cell Myeloma, Multiple Myeloma/Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Limited Stage Small Cell Lung Cancer",
    "Intracranial Meningioma, Recurrent Meningioma",
    "Germ Cell Tumor, Malignant Ovarian Teratoma, Malignant Germ Cell Tumor, Testicular Mixed Choriocarcinoma and Embryonal Carcinoma, Testicular Mixed Choriocarcinoma and Teratoma, Testicular Mixed Choriocarcinoma and Yolk Sac Tumor, Extracranial Germ Cell Tumor, Stage II Testicular Choriocarcinoma, Stage II Ovarian Embryonal Carcinoma, Stage III Ovarian Embryonal Carcinoma, Stage IV Ovarian Embryonal Carcinoma, Stage I Ovarian Choriocarcinoma, Stage II Ovarian Choriocarcinoma, Stage III Ovarian Choriocarcinoma, Stage IV Ovarian Choriocarcinoma, Stage I Ovarian Embryonal Carcinoma, Stage I Ovarian Yolk Sac Tumor, Stage II Ovarian Yolk Sac Tumor, Stage III Ovarian Yolk Sac Tumor, Stage IV Ovarian Yolk Sac Tumor, Stage I Ovarian Teratoma, Extragonadal Embryonal Carcinoma, Stage III Testicular Choriocarcinoma, Stage I Testicular Choriocarcinoma, Stage I Testicular Embryonal Carcinoma, Stage II Testicular Embryonal Carcinoma, Stage III Testicular Embryonal Carcinoma, Stage I Testicular Seminoma, Stage I Testicular Yolk Sac Tumor, Stage II Testicular Yolk Sac Tumor, Stage III Testicular Yolk Sac Tumor",
    "Pathologic Stage I Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage I Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Synchronous Bilateral Breast Carcinoma, HER2-Positive Breast Carcinoma, Invasive Breast Cancer, Multifocal Breast Cancer",
    "Unresectable Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma",
    "Recurrent Endometrial Serous Adenocarcinoma, Endometrioid Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Recurrent Uterine (Including Endometrial) Cancer",
    "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Breast Carcinoma, Metastatic Breast Adenocarcinoma, Stage IV Breast Cancer, Breast Adenocarcinoma, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Invasive Ovarian Micropapillary Serous Carcinoma, Invasive Micropapillary Serous Carcinoma of the Peritoneum, Low Grade Fallopian Tube Serous Adenocarcinoma, Stage II Ovarian Cancer, Stage IIA Ovarian Cancer, Stage IIB Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage II Fallopian Tube Cancer, Stage IIA Fallopian Tube Cancer, Stage IIB Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage II Primary Peritoneal Cancer, Stage IIA Primary Peritoneal Cancer, Stage IIB Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer",
    "Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Colon Adenocarcinoma, DNA Repair Disorder, Lynch Syndrome, Stage III Colon Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Stage IVB Rectal Cancer, Metastatic Colorectal Carcinoma, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVA Rectal Cancer, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Locally Advanced Unresectable Colon Adenocarcinoma, Locally Advanced Unresectable Rectal Adenocarcinoma, Advanced Colorectal Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Mucosal Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Acral Lentiginous Melanoma",
    "Stage IIA Colon Cancer, Colon Adenocarcinoma",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, HER2-Positive Breast Carcinoma, Invasive Breast Cancer",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Pheochromocytoma, Pseudomyxoma Peritonei, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Mixed Mesodermal (Mullerian) Tumor, Acinar Cell Carcinoma, Endometrioid Adenocarcinoma, Pancreatic Neuroendocrine Cancer, Mucinous Cystadenocarcinoma, Serous Cystadenocarcinoma, Giant Cell Carcinoma, Malignant Peripheral Nerve Sheath Tumor, PEComa, Gallbladder Cancer, Extrahepatic Bile Duct Cancer, Gastrointestinal Stromal Tumor (GIST), Nasopharyngeal Throat Cancer, Ovarian Germ Cell Tumor, Seminal Vesicle Adenocarcinoma, Malignant Testicular Sex Cord-Stromal Tumor, Ovarian Squamous Cell Cancer, Fallopian Tube Transitional Cell Cancer, Endometrial Transitional Cell Carcinoma, Endocervical Cancer, Bartholin Gland Transitional Cell Carcinoma, Bladder Adenocarcinoma, Lung Carcinoid Tumor, Teratoma with Somatic-Type Malignancy, Small Intestinal Squamous Cell Cancer, Appendix Mucinous Adenocarcinoma, Colorectal (Colon or Rectal) Squamous Cell Cancer, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Pituitary Gland Cancer, Lung Sarcomatoid Carcinoma, Scrotal Squamous Cell Carcinoma, Gestational Trophoblastic Tumor, Malignant Odontogenic Tumor, Thyroid Gland Cancer, Vulvar Cancer, Rare Disorder, Parathyroid Gland Cancer, Breast Metaplastic Carcinoma, Ovarian Transitional Cell Cancer, Ovarian Mucinous Adenocarcinoma, Nasopharyngeal Throat Papillary Adenocarcinoma, Gastric (Stomach) Squamous Cell Cancer, Undifferentiated Gastric (Stomach) Cancer, Major Salivary Gland Cancer, Paranasal Sinus Cancer, Nasal Cavity Adenocarcinoma, Paranasal Sinus Adenocarcinoma, Ureter Squamous Cell Carcinoma, Ureter Adenocarcinoma, Urethral Squamous Cell Cancer, Urethral Adenocarcinoma, Fallopian Tube Adenocarcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Fibromyxoid Tumor, Apocrine Neoplasm, Undifferentiated Oropharyngeal Throat Cancer, Peritoneal Mesothelioma, Ovarian Adenocarcinoma, Penile Squamous Cell Cancer, Vaginal Squamous Cell Cancer, NOS, Small Intestinal Adenocarcinoma, Pancreatic Acinar Cell Cancer, Vaginal Adenocarcinoma, Undifferentiated Nasopharyngeal Throat Cancer, Metastatic Malignant Neoplasm of Unknown Primary Origin, Placental Choriocarcinoma, Oral Cavity Cancer, Deep Fibromatosis/Desmoid Tumor, Seminoma, Testicular Non-Seminomatous Germ Cell Tumor, Adrenal Cortex Cancer, Nasal Cavity Cancer, Tracheal Carcinoma, Esophageal Neuroendocrine Cancer, Gastric (Stomach) Neuroendocrine Cancer, Intestinal Neuroendocrine Carcinoma, Anal Canal Undifferentiated Carcinoma, Anal Canal Neuroendocrine Carcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Malignant Solid Tumor, Basal Cell Carcinoma, Mucinous Adenocarcinoma, Spindle Cell Neoplasm, Undifferentiated Esophageal Cancer, Bronchioloalveolar Carcinoma, Transitional Cell Carcinoma, Chordoma, Adenoid Cystic Carcinoma, Angiosarcoma, Extramammary Paget Disease, Paraganglioma",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Lymphedema, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer",
    "Non-Squamous Non-Small Cell Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Unilateral Breast Cancer, Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer",
    "Endometrial Cancer, Glioma, Recurrent Colon Cancer, Recurrent Head and Neck Carcinoma, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Pancreatic Cancer, Recurrent Esophageal Cancer, Recurrent Breast Cancer, Lymphoma, Recurrent Cervical Cancer, Thyroid Gland Cancer, Recurrent Ovarian Cancer, Recurrent Bladder Cancer, Prostate Cancer, Recurrent Prostate Cancer, Melanoma, Recurrent Skin Cancer, Refractory Lymphoma, Breast Cancer, Recurrent Thyroid Gland Cancer, Liver Cancer, Lung Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Multiple Myeloma/Plasma Cell Myeloma, Recurrent Lung Cancer, Ovarian Cancer, Cervical Cancer, Recurrent Uterine (Including Endometrial) Cancer, Colon Cancer, Recurrent Gastric (Stomach) Cancer, Esophageal Cancer, Recurrent Rectal Cancer, Gastric (Stomach) Cancer, Recurrent Malignant Solid Tumor, Rectal Cancer, Recurrent Lymphoma, Kidney (including Renal Cell) Cancer, Bladder Cancer, Malignant Uterine Neoplasm, Non-Melanoma Skin Cancer, Uterine (Including Endometrial) Cancer, Head and Neck Carcinoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Glioma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Melanoma, Recurrent Liver Cancer, Colorectal (Colon or Rectal) Cancer, Pancreatic Cancer",
    "Stage II Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer",
    "Stage IIB Squamous Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IB Squamous Cell Lung Cancer, Lung Adenocarcinoma, Large Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Resectable Lung Non-Small Cell Carcinoma, Stage IIA Squamous Cell Lung Cancer, Stage IIIA Squamous Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage II Squamous Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer",
    "Lymphomatoid Granulomatosis, Grade I Lymphomatoid Granulomatosis, Grade II Lymphomatoid Granulomatosis, Grade III Lymphomatoid Granulomatosis",
    "Malignant Adrenal Gland Pheochromocytoma, Recurrent Neuroblastoma, Malignant Paraganglioma",
    "Acute Myeloid Leukemia (AML), Leukemia, Myelodysplastic Syndrome with Excess Blasts, High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Refractory Anemia, Recurrent Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia (AML), High Risk Acute Lymphoblastic Leukemia",
    "Recurrent Hairy Cell Leukemia, Hairy Cell Leukemia",
    "T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "Stage II Nasal Cavity and Paranasal Sinus Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Nasal Cavity and Paranasal Sinus Poorly Differentiated Carcinoma, Undifferentiated Sinonasal Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Prolymphocytic Leukemia, Follicular Lymphoma, Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Myelodysplastic Syndrome, Myelofibrosis, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Acute Biphenotypic Leukemia, Small Lymphocytic Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, Refractory Anemia",
    "Acute Myeloid Leukemia with inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia with t(16;16)(p13.1;q22); CBFB-MYH11, de novo Myelodysplastic Syndrome, Acute Myeloid Leukemia with t(8;21); (q22; q22.1); RUNX1-RUNX1T1, Myelodysplastic Syndrome with Excess Blasts",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Langerhans Cell Histiocytosis, Macrophage Activation Syndrome, Common Variable Immunodeficiency, Wiskott-Aldrich Syndrome, Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome, Congenital Neutropenia, Congenital Pure Red Cell Aplasia, Thalassemia Major, Hemophagocytic Lymphohistiocytosis, Congenital Amegakaryocytic Thrombocytopenia, Adenosine Deaminase Deficiency, Acute Chest Syndrome, Bone Marrow Failure, Severe Combined Immunodeficiency, Sickle Cell Disease, Cerebrovascular Accident",
    "Refractory Hairy Cell Leukemia, Recurrent Hairy Cell Leukemia",
    "Recurrent B Acute Lymphoblastic Leukemia, Recurrent High-Grade B-Cell Lymphoma, B-Cell Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage I Pancreatic Cancer, Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Phyllodes Tumor",
    "Viral Infection, Molluscum Contagiosum Virus Infection, Hematopoietic and Lymphoid Cell Neoplasm, Herpes Simplex Virus Infection, Herpes Zoster, Infectious Disorder, Human Papillomavirus Infection, Fungal Infection, Skin Infection, Bacterial Infection, Infectious Lung Disorder",
    "Stage 0 Breast Cancer, Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Ductal Carcinoma In Situ (DCIS), Stage I Breast Cancer, Invasive Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer",
    "Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia, Refractory Anemia, Myelodysplastic Syndrome with Multilineage Dysplasia, Myelodysplastic Syndrome with Isolated del(5q), Chronic Myelomonocytic Leukemia (CMML), Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome with Ring Sideroblasts, Myelodysplastic Syndrome with Excess Blasts-2",
    "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Pre-B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",
    "Prostate Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Lymphoblastic Leukemia (ALL), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage II Grade 2 Follicular Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage II Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma",
    "Benign Tonsillar Neoplasm, Benign Hypopharyngeal Neoplasm, Laryngeal Neoplasm, Benign Laryngeal Neoplasm, Benign Palate Neoplasm, Subglottic Throat Cancer, Supraglottic Throat Cancer, Malignant Hypopharyngeal Neoplasm, Malignant Tonsillar Neoplasm, Oral Cavity Neoplasm, Pharyngeal Neoplasm, Benign Oral Cavity Neoplasm, Retromolar Trigone Squamous Cell Carcinoma, Malignant Tongue Neoplasm, Malignant Palate Neoplasm, Benign Pharyngeal Neoplasm, Epiglottic Throat Cancer, Benign Tongue Neoplasm",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Thyroid Gland Neoplasm, Soft Tissue Tumor, Castleman Disease, Neurofibromatosis Type 2, Malignant Endocrine Neoplasm, Malignant Thoracic Neoplasm, Metastatic Malignant Neoplasm, Lymphangioleiomyomatosis, Stage IV Breast Cancer, Mesothelial Neoplasm, Malignant Respiratory System Neoplasm, Recurrent Malignant Neoplasm, Malignant Female Reproductive System Neoplasm, Recurrent Pharyngeal Throat Cancer, Erdheim-Chester Disease, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Stage IIIA Breast Cancer, Recurrent Male Reproductive System Carcinoma, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Recurrent Digestive System Carcinoma, Recurrent Soft Tissue Sarcoma, Recurrent Thyroid Gland Cancer, Malignant Male Reproductive System Neoplasm, Stage III Pharyngeal Throat Cancer, Stage IV Pharyngeal Throat Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Advanced Malignant Neoplasm, Recurrent Soft Tissue Sarcoma, Malignant Urinary System Neoplasm, Metastatic Urothelial Cancer, Recurrent Female Reproductive System Carcinoma, Digestive System Carcinoma, Malignant Neoplasm, Lip and Oral Cavity Cancer, Refractory Malignant Neoplasm",
    "Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Refractory Malignant Neoplasm, Advanced Malignant Neoplasm",
    "Aplastic Anemia, de novo Myelodysplastic Syndrome, Myelodysplastic Syndrome",
    "Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain",
    "Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma",
    "Anemia, Myelodysplastic/Myeloproliferative Disease, Myelofibrosis",
    "Smoldering Adult T-Cell Leukemia/Lymphoma, Lymphomatous Adult T-Cell Leukemia/Lymphoma",
    "Stage IIIB Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Lung Adenocarcinoma, Advanced Lung Small Cell Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Squamous Cell Lung Cancer",
    "Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Solid Tumor, Unresectable Melanoma, Metastatic Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Advanced Malignant Solid Tumor, Metastatic Gastrointestinal Stromal Tumor (GIST)",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia (CML), Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia with Gene Mutations, Refractory Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm, Secondary Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML) with FLT3/ITD, Multiple Myeloma/Plasma Cell Myeloma, Acute Myeloid Leukemia with t(6;9), Recurrent Acute Myeloid Leukemia (AML), Myelofibrosis, Polycythemia Vera, Follicular Lymphoma, Non-Hodgkin Lymphoma, Myeloid Leukemia, Hodgkin Lymphoma, Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM, Chronic Myelogenous Leukemia (CML), Aplastic Anemia, Recurrent Acute Myeloid Leukemia (AML)",
    "Intraocular Retinoblastoma",
    "Primary Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Chronic Myelomonocytic Leukemia (CMML), Secondary Myelodysplastic Syndrome, Myelodysplastic Syndrome, de novo Myelodysplastic Syndrome",
    "Refractory Neuroblastoma, Metastatic Pheochromocytoma, Recurrent Neuroblastoma",
    "Myelodysplastic Syndrome, GATA2 Deficiency, Infectious Disorder",
    "Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma",
    "Stage I Renal Cell Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm in the Brain",
    "Stage IVB Appendix Cancer, Appendix Mucinous Adenocarcinoma, Peritoneal Carcinomatosis, Stage IVC Appendix Cancer, Stage IVA Appendix Cancer",
    "Anemia, Thalassemia Major, Sickle Cell Disease",
    "Stage I Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Resectable Pancreatic Cancer",
    "Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Lymphoblastic Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Graft Versus Host Disease, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Juvenile Myelomonocytic Leukemia, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Non-Hodgkin Lymphoma",
    "Stage IIB Prostate Cancer, Stage IIA Prostate Cancer, Prostate Adenocarcinoma, Stage III Prostate Cancer, Stage I Prostate Cancer",
    "Stage IIA Uveal Melanoma, Stage IIIB Uveal Melanoma, Stage IIIA Uveal Melanoma, Stage IIIC Uveal Melanoma, Stage II Uveal Melanoma, Stage IIB Uveal Melanoma, Stage III Uveal Melanoma, Stage I Uveal Melanoma",
    "Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIC Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Ocular Melanoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Hepatocellular Cancer, Malignant Adrenal Gland Neoplasm, Metastatic Neuroendocrine Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Hepatocellular Carcinoma, Stage IVA Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Colorectal Carcinoma, Unresectable Neuroendocrine Neoplasm, Stage IIIA Hepatocellular Cancer",
    "Stage II Nasal Type NK/T-Cell Lymphoma, Stage I Nasal Type NK/T-Cell Lymphoma",
    "Neuroblastoma, Ganglioneuroblastoma",
    "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia (AML), Refractory Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), de novo Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Chronic Myelogenous Leukemia (CML), Acute Biphenotypic Leukemia",
    "Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Alkylating Agent-Related Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia (AML)",
    "Acute Leukemia of Ambiguous Lineage, Recurrent Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia, Acute Biphenotypic Leukemia, Mixed Phenotype Acute Leukemia, T/Myeloid, Not Otherwise Specified, Mixed Phenotype Acute Leukemia, B/Myeloid, Not Otherwise Specified, Acute Bilineal Leukemia",
    "Refractory Acute Lymphoblastic Leukemia (ALL), B Acute Lymphoblastic Leukemia, Recurrent Acute Lymphoblastic Leukemia",
    "Refractory Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Biphenotypic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Kidney Oncocytoma, Chromophobe Renal Cell Cancer, Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Breast Cancer",
    "Triple-Hit Lymphoma, AIDS-Related Burkitt Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Double-Hit Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, Recurrent Burkitt Lymphoma, Refractory Burkitt Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Stage I Bladder Urothelial Cancer, Stage 0a Bladder Urothelial Cancer, Refractory Bladder Urothelial Carcinoma, Bladder Non-Invasive Papillary Urothelial Carcinoma, Recurrent Bladder Urothelial Cancer, Stage 0is Bladder Urothelial Cancer, Stage 0 Bladder Urothelial Cancer",
    "Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer",
    "Malignant Neoplasm, Cytomegaloviral Infection",
    "Refractory Myelodysplastic Syndrome, Refractory Lymphoma, Refractory Malignant Solid Tumor",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Stage 2B Neuroblastoma, Stage 4S Neuroblastoma, Stage 3 Neuroblastoma, Stage 2A Neuroblastoma, Stage 4 Neuroblastoma",
    "Secondary Myelofibrosis, Primary Myelofibrosis",
    "Recurrent Malignant Neoplasm, Metastatic Malignant Neoplasm, Advanced Malignant Neoplasm, Refractory Malignant Neoplasm",
    "Locally Advanced Paraganglioma, Metastatic Paraganglioma, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Locally Advanced Adrenal Gland Pheochromocytoma, Unresectable Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Metastatic Pheochromocytoma",
    "Ganglioneuroblastoma, Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Refractory Chronic Myelogenous Leukemia (CML), B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia (CML)",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage IV Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Stage IIIB Non-Small Cell Lung Cancer, Locally Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes",
    "Recurrent Pilocytic Astrocytoma, Juvenile Pilocytic Astrocytoma, Neurofibromatosis Type 1, Recurrent Visual Pathway Glioma",
    "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myeloproliferative Disease, Myelofibrosis, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Multiple Myeloma/Plasma Cell Myeloma, Secondary Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Lymphoma",
    "Unresectable Head and Neck Squamous Cell Carcinoma, Squamous Cell Cancer of Unknown Primary Origin, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Laryngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, Unresectable Oropharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IVC Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oral Cavity Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Oropharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Squamous Cell Cancer, Stage IVC Oral Cavity Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage III Oral Cavity Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Secondary Myelofibrosis, Primary Myelofibrosis",
    "Recurrent Brain Neoplasm, Glioma",
    "Recurrent Neuroblastoma, Recurrent Adrenal Gland Pheochromocytoma",
    "Refractory Malignant Solid Tumor",
    "Refractory Brain Neoplasm, Recurrent Malignant Solid Tumor, Recurrent Brain Neoplasm, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Visual Pathway Glioma, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Neurofibromatosis Type 1, Recurrent Grade III Glioma, Recurrent Malignant Peripheral Nerve Sheath Tumor, Refractory Ewing Sarcoma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Rhabdomyosarcoma, Refractory Visual Pathway Glioma, Plexiform Neurofibroma, Recurrent Malignant Solid Tumor, Recurrent Acute Lymphoblastic Leukemia, Refractory WHO Grade III Glioma, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Neurofibromatosis Type 1, Refractory Rhabdomyosarcoma, Recurrent Glioblastoma, Recurrent Ewing Sarcoma, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Malignant Solid Tumor, Precursor Lymphoid Neoplasm, Refractory Soft Tissue Sarcoma, Refractory Malignant Central Nervous System Neoplasm, Recurrent Soft Tissue Sarcoma, Recurrent Malignant Central Nervous System Neoplasm",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia (AML), Acute Bilineal Leukemia, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML)",
    "Recurrent Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Metastatic Malignant Neoplasm",
    "Triple-Negative Breast Cancer, Stage IV Inflammatory Breast Cancer, Recurrent Breast Inflammatory Carcinoma",
    "Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Bile Duct Cancer (including Cholangiocarcinoma), Recurrent Pancreatic Cancer, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Hematologic and Lymphocytic Disorder",
    "Stage IV Soft Tissue Sarcoma, Stage IIB Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma",
    "Invasive Breast Cancer, Triple-Negative Breast Cancer",
    "B Acute Lymphoblastic Leukemia",
    "Ovarian Cancer, Pancreatic Cancer",
    "Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Invasive Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Early-Stage Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer",
    "Acquired Immunodeficiency Syndrome, Merkel Cell Cancer, Viral Encephalitis, JC Virus Infection, HIV Infection, Hematopoietic and Lymphoid Cell Neoplasm, BK Virus Infection, Merkel Cell Polyomavirus Infection, Malignant Solid Tumor",
    "Ductal Carcinoma In Situ (DCIS), Invasive Breast Cancer, Early-Stage Breast Cancer, Stage IA Breast Cancer",
    "Stage IVB Ovarian Cancer, Stage III Breast Cancer, Stage IIIB Ovarian Cancer, Recurrent Prostate Cancer, Stage IVB Fallopian Tube Cancer, Stage IIIC Prostate Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Recurrent Primary Peritoneal Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage IIIB Primary Peritoneal Cancer, Recurrent Ovarian Cancer, Stage IIIC Lung Cancer, Castration-Resistant Prostate Cancer, Refractory Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Triple-Negative Breast Cancer, Stage IVA Prostate Cancer, Platinum-Resistant Primary Peritoneal Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIB Breast Cancer, Platinum-Resistant Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IIIB Breast Cancer, Stage IV Prostate Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Prostate Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Advanced Ovarian Carcinoma, Stage IIIA2 Ovarian Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IVA Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Stage III Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, Advanced Malignant Solid Tumor, Stage IIIB Prostate Cancer, Stage IIIA Fallopian Tube Cancer, Stage III Prostate Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Breast Cancer, Stage IVB Prostate Cancer, Stage IVB Primary Peritoneal Cancer, Metastatic Prostate Cancer, Stage IIIB Lung Cancer, Stage IV Breast Cancer, Small Cell Lung Cancer, Stage IV Ovarian Cancer, Refractory Ovarian Carcinoma, Stage IV Primary Peritoneal Cancer, Stage IIIC Breast Cancer, Refractory Fallopian Tube Cancer, Stage IIIA1 Ovarian Cancer, Stage III Ovarian Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVB Lung Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIC Ovarian Cancer",
    "Stage II Grade 2 Follicular Lymphoma, Stage I Indolent Non-Hodgkin Lymphoma, Stage II B-Cell Non-Hodgkin Lymphoma, Stage III Indolent Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage II Indolent Non-Hodgkin Lymphoma, Stage I Mantle Cell Lymphoma, Stage III B-Cell Non-Hodgkin Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage IV B-Cell Non-Hodgkin Lymphoma, Ocular Adnexal Mucosa-Associated Lymphoid Tissue Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Orbit Lymphoma, Stage IV Mantle Cell Lymphoma, Stage II Grade 1 Follicular Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage II Mantle Cell Lymphoma, Ocular Adnexal Non-Hodgkin Lymphoma, Stage I B-Cell Non-Hodgkin Lymphoma, Stage IV Indolent Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Ewing Sarcoma, Refractory Acute Lymphoblastic Leukemia (ALL), Metastatic Malignant Neoplasm to the Bone, Refractory Peripheral Primitive Neuroectodermal Tumor, Recurrent Primitive Neuroectodermal Tumor, Recurrent Non-Hodgkin Lymphoma, Refractory Ewing Sarcoma, Refractory Neuroblastoma, Metastatic Soft Tissue Sarcoma, Refractory Non-Hodgkin Lymphoma, Recurrent Soft Tissue Sarcoma, Myelodysplastic Syndrome, Refractory Rhabdomyosarcoma, Myelodysplastic/Myeloproliferative Disease, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Metastatic Malignant Neoplasm to the Lung, Metastatic Ewing Sarcoma, Recurrent Rhabdomyosarcoma, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Hodgkin Lymphoma",
    "Cutaneous T-Cell Non-Hodgkin Lymphoma, T-Cell Prolymphocytic Leukemia, T Lymphoblastic Leukemia/Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, T-Cell Large Granular Lymphocyte Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Recurrent Myelodysplastic Syndrome, de novo Myelodysplastic Syndrome",
    "Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Metastatic Kidney Carcinoma, Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Aplastic Anemia, Multiple Myeloma/Plasma Cell Myeloma, Indolent Non-Hodgkin Lymphoma, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Multilineage Dysplasia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Ring Sideroblasts and Multilineage Dysplasia, Myelodysplastic Syndrome with Ring Sideroblasts, Hodgkin Lymphoma, Refractory Anemia, Acute Myeloid Leukemia in Remission, Chronic Myeloproliferative Disease, Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts-2, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Neoplasm",
    "Hypogammaglobulinemia, T-Cell Immunodeficiency, Solid Tumor, Primary Immunodeficiency Syndrome, Common Variable Immunodeficiency, Hemophagocytic Lymphohistiocytosis, Macrophage Activation Syndrome, Lymphoproliferative Disorder, Autoimmune Lymphoproliferative Syndrome, Autoimmune Disease, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Neuroblastoma",
    "Stage IV Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma",
    "Metastatic Colorectal Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Sickle Cell-Thalassemia, Sickle Cell-SS Disease, Sickle Cell-Hemoglobin C Disease, Sickle Cell-Hemoglobin D Disease",
    "Recurrent Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Prostate Adenocarcinoma",
    "Hematopoietic and Lymphoid System Neoplasm, Erdheim-Chester Disease, Langerhans Cell Histiocytosis, Hemophagocytic Lymphohistiocytosis",
    "B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Stem Cell Transplant Recipient, Allogeneic Hematopoietic Stem Cell Transplantation Recipient",
    "Endometrial Cancer",
    "KSHV Inflammatory Cytokine Syndrome, Cutaneous (Skin) Kaposi Sarcoma, Advanced Kaposi Sarcoma, Multicentric Angiofollicular Lymphoid Hyperplasia, HHV8-Positive Multicentric Castleman Disease, Immune Reconstitution Inflammatory Syndrome Associated with Kaposi Sarcoma, Refractory Kaposi Sarcoma",
    "Myelodysplastic Syndrome, Burkitt Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Plasma Cell Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Acute Myeloid Leukemia (AML), Prolymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Marginal Zone Lymphoma, Acute Lymphoblastic Leukemia (ALL), Myelodysplastic/Myeloproliferative Disease, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Stage IV Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage III Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Stage IA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Stage IV Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage IIIA Breast Cancer, Breast Cancer",
    "Chronic Graft Versus Host Disease, Bronchiolitis Obliterans",
    "High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Invasive Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma",
    "Recurrent Brain Neoplasm",
    "Microinvasive Malignant Neoplasm, Microinvasive Anal Carcinoma, Anal Intraepithelial Neoplasia, Anal Intraepithelial Neoplasia 3, Carcinoma In Situ",
    "Metastatic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Recurrent Malignant Peripheral Nerve Sheath Tumor",
    "Recurrent Soft Tissue Sarcoma",
    "Unresectable Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Mucosal Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Melanoma",
    "Pleural Biphasic Mesothelioma, Pleural Epithelioid Mesothelioma",
    "Recurrent Giant Cell Glioblastoma, Giant Cell Glioblastoma, Recurrent Glioblastoma, Gliosarcoma, Recurrent Gliosarcoma",
    "Malignant Thyroid Gland Neoplasm, Metastatic Malignant Neoplasm of Unknown Primary Origin, Metastatic Malignant Neoplasm to the Spine, Malignant Prostate Neoplasm, Malignant Head and Neck Neoplasm, Melanoma, Malignant Gastrointestinal Neoplasm, Renal Cell Cancer, Malignant Solid Tumor, Malignant Breast Neoplasm, Sarcoma, Non-Small Cell Lung Cancer",
    "Glioblastoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Follicular Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma/Plasma Cell Myeloma, Recurrent Marginal Zone Lymphoma, Hodgkin Lymphoma, Myelofibrosis, Anaplastic Large Cell Lymphoma, Plasma Cell Leukemia, Myelodysplastic Syndrome with Excess Blasts-2, Bone Marrow Failure Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Follicular Lymphoma, Acute Leukemia, Acute Myeloid Leukemia (AML), Refractory Follicular Lymphoma, Acute Biphenotypic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Acute Undifferentiated Leukemia, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome, Recurrent Small Lymphocytic Lymphoma, Chronic Myeloproliferative Disease, Bone Marrow Aplasia, Burkitt Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Myeloproliferative Disease, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Acute Biphenotypic Leukemia, de novo Myelodysplastic Syndrome",
    "Metastatic Malignant Neoplasm to the Liver, Resectable Colorectal Carcinoma, Metastatic Malignant Neoplasm to the Lung, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Breast Adenocarcinoma, Stage IV Breast Cancer, Triple-Negative Breast Cancer, Hormone Receptor Positive Breast Carcinoma",
    "Chronic Graft Versus Host Disease",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain, Refractory Malignant Solid Tumor, Recurrent Renal Pelvis Urothelial Cancer, Recurrent Urethral Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Recurrent Ureter Urothelial Cancer, Refractory Lung Small Cell Carcinoma, Metastatic Prostate Cancer, Advanced Malignant Solid Tumor, Stage IVB Prostate Cancer, Recurrent Small Cell Lung Cancer, Castration-Resistant Prostate Cancer",
    "Recurrent Ependymoma",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer, Stage III Oral Cavity Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Squamous Cell Cancer of Unknown Primary Origin, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer",
    "Refractory Neuroblastoma, Neuroblastoma, Recurrent Neuroblastoma",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Myeloid Sarcoma, Refractory Non-Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Chronic Myelogenous Leukemia (CML), Refractory Chronic Myelogenous Leukemia (CML), Refractory Acute Myeloid Leukemia (AML), Recurrent Non-Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome",
    "Craniopharyngioma",
    "Refractory Lymphoma, Recurrent Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Recurrent Lymphoma, Stage III Cutaneous (Skin) Melanoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Stage IIIC Cutaneous (Skin) Melanoma, Recurrent Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Refractory Melanoma, Refractory Malignant Solid Tumor, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Recurrent Osteosarcoma, Unresectable Melanoma",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Unresectable Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Breast Adenocarcinoma, Stage IV Breast Cancer",
    "Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oral Cavity Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage I Oral Cavity Squamous Cell Cancer, Stage IVC Oropharyngeal Throat Squamous Cell Cancer, Stage III Oral Cavity Squamous Cell Cancer, Stage I Oropharyngeal Throat Squamous Cell Cancer, Stage II Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Human Papillomavirus Infection, Stage IVA Oral Cavity Squamous Cell Cancer, Stage IVC Oral Cavity Squamous Cell Cancer, Stage II Oral Cavity Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer",
    "Stage IIIB Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Advanced Fallopian Tube Carcinoma, Stage IIIA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Ovarian Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Advanced Ovarian Carcinoma, Stage IIIA2 Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IVB Primary Peritoneal Cancer, Advanced Primary Peritoneal Carcinoma, Stage III Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IVB Fallopian Tube Cancer",
    "Richter Syndrome, Refractory Transformed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Human Papillomavirus-Related Malignant Neoplasm, Recurrent Human Papillomavirus-Related Malignant Neoplasm, Refractory Human Papillomavirus-Related Malignant Neoplasm",
    "Unresectable Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVA Thymus Epithelial Neoplasm, Metastatic Germ Cell Tumor, Stage III Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Metastatic Malignant Neoplasm in the Thoracic Cavity, Stage III Renal Cell Cancer, Stage IIIB Thymic Epithelial Neoplasm AJCC v8, Stage III Pleural Malignant Mesothelioma, Unresectable Pancreatic Cancer, Unresectable Renal Cell Carcinoma, Stage IVB Lung Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Pancreatic Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Unresectable Esophageal Cancer, Stage IIIC Lung Cancer, Stage III Thymus Epithelial Neoplasm, Unresectable Pleural Malignant Mesothelioma, Stage IV Thymus Epithelial Neoplasm, Stage IIIC Gastric (Stomach) Cancer, Germ Cell Tumor, Unresectable Lung Small Cell Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Pancreatic Cancer, Stage IIIA Pleural Malignant Mesothelioma, Chest Wall Sarcoma, Stage IIIA Thymic Epithelial Neoplasm AJCC v8, Stage IIIA Lung Cancer, Stage IVB Gastric (Stomach) Cancer, Metastatic Colorectal Carcinoma, Stage IV Pleural Malignant Mesothelioma, Kidney (including Renal Cell) Cancer, Stage IIIA Gastric (Stomach) Cancer, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Metastatic Unresectable Sarcoma, Stage IIIB Pleural Malignant Mesothelioma, Metastatic Gastric Carcinoma, Stage IVB Thymus Epithelial Neoplasm, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Lymphoproliferative Disorder, Recurrent Hodgkin Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, High Risk Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Recurrent High Risk Myelodysplastic Syndrome, Recurrent Chronic Myelogenous Leukemia (CML), Myelodysplastic/Myeloproliferative Disease, Myelodysplastic Syndrome",
    "Cervical Intraepithelial Neoplasia Grade 2/3",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "High Grade Vulvar Squamous Intraepithelial Lesion",
    "B Lymphoblastic Lymphoma, B Acute Lymphoblastic Leukemia",
    "Acute Bilineal Leukemia, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Acute Lymphoblastic Leukemia (ALL), Chronic Myelomonocytic Leukemia (CMML), B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Myelofibrosis, Myelodysplastic/Myeloproliferative Disease, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloproliferative Disease, Chronic Myelogenous Leukemia (CML)",
    "Metastatic Malignant Neoplasm to the Spine, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Metastatic Pancreatic Carcinoma, Metastatic Malignant Neoplasm to the Liver, Stage IV Pancreatic Cancer",
    "Stage IIIA Breast Cancer, Advanced Pancreatobiliary Carcinoma, Stage III Pancreatic Cancer, Stage IIIB Breast Cancer, Advanced Malignant Solid Tumor, Stage IIIA Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Stage IV Breast Cancer",
    "Human Papillomavirus-Related Malignant Neoplasm, Human Papillomavirus Infection",
    "Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Melanoma",
    "Diffuse Large B-Cell Lymphoma Arising in HHV8-Positive Multicentric Castleman Disease, Primary Effusion Lymphoma, Extracavitary Primary Effusion Lymphoma, Lymphoma",
    "Invasive Breast Cancer, Metastatic Breast Cancer in the Brain, Stage IV Breast Cancer",
    "Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Chronic Myelogenous Leukemia (CML), Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia, Multiple Myeloma/Plasma Cell Myeloma, Myelofibrosis, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL)",
    "Plasmacytoma, POEMS Syndrome",
    "Recurrent Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Congenital Neutropenia, Shwachman-Diamond Syndrome, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Congenital Dyserythropoietic Anemia, Fanconi Anemia, Congenital Pure Red Cell Aplasia, Severe Aplastic Anemia, Dyskeratosis Congenita, Inherited Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia",
    "Castration-Resistant Prostate Cancer, Prostate Adenocarcinoma",
    "Advanced Head and Neck Squamous Cell Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIB Non-Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Stage II Prostate Adenocarcinoma, Stage III Prostate Adenocarcinoma",
    "Pleural Malignant Mesothelioma",
    "Heart Failure, Cardiomyopathy",
    "Malignant Brain Glioma",
    "Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Inflammatory Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer",
    "Invasive Breast Cancer, Triple-Negative Breast Cancer",
    "Metastatic Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Colon Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Classical Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Mature B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Myelodysplastic Syndrome",
    "Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma, Acute Leukemia, Myelofibrosis, Recurrent Chronic Myelogenous Leukemia (CML), Recurrent Mantle Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Anaplastic Large Cell Lymphoma, Acute Biphenotypic Leukemia, Burkitt Lymphoma, Prolymphocytic Leukemia, Lymphoplasmacytic Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Marginal Zone Lymphoma, Acute Undifferentiated Leukemia, Chronic Myeloproliferative Disease, Bone Marrow Failure Syndrome, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Follicular Lymphoma",
    "Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome, Hemophagocytic Lymphohistiocytosis, Recurrent Hemophagocytic Lymphohistiocytosis, Refractory Hemophagocytic Lymphohistiocytosis, Severe Combined Immunodeficiency, Chronic Granulomatous Disease, Macrophage Activation Syndrome, Wiskott-Aldrich Syndrome, Hyperimmunoglobulin M Syndrome, Immunodeficiency with Hyper-IgM, Primary Immunodeficiency Syndrome, Refractory Langerhans Cell Histiocytosis, X-Linked Lymphoproliferative Syndrome",
    "Stage III Oral Cavity Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Paranasal Sinus Squamous Cell Carcinoma, Stage III Laryngeal Throat Squamous Cell Cancer",
    "Recurrent Small Lymphocytic Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Pancreatic Ductal Adenocarcinoma",
    "Malignant Mesothelioma",
    "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Recurrent Mycosis Fungoides, Folliculotropic Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Stage IV Breast Cancer, Triple-Negative Breast Cancer, Metastatic Malignant Neoplasm to the Bone",
    "Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma",
    "Refractory Neoplasm, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Refractory Grade 3a Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Nodal Marginal Zone Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Grade 3b Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Waldenstrom Macroglobulinemia, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 3b Follicular Lymphoma, Refractory Splenic Marginal Zone Lymphoma",
    "Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Melanoma",
    "Metastatic Uveal Melanoma, Central Nervous System Melanoma, Acral Lentiginous Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Mucosal Melanoma, Stage IV Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Leptomeningeal Neoplasm, Metastatic Melanoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Melanocytoma",
    "Metastatic Malignant Neoplasm to the Spine, Metastatic Malignant Solid Tumor",
    "Triple-Negative Breast Cancer, Disseminated Malignant Neoplasm, Invasive Breast Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage III Pancreatic Cancer, Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Stage II Pancreatic Cancer, Unresectable Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Pancreatic Neoplasm, Stage IV Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer",
    "Metastatic Hepatocellular Carcinoma, Stage IIIA Hepatocellular Cancer, Stage III Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Stage IVA Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer",
    "Intestinal Neuroendocrine Tumor, Pancreatic Neuroendocrine Tumor, Advanced Digestive System Neuroendocrine Neoplasm, Gastric Neuroendocrine Tumor",
    "Recurrent Severe Aplastic Anemia, Hereditary Sideroblastic Anemia, Severe Congenital Neutropenia, Severe Aplastic Anemia, Congenital Pure Red Cell Aplasia, Refractory Severe Aplastic Anemia, Dyskeratosis Congenita, Paroxysmal Nocturnal Hemoglobinuria, Inherited Bone Marrow Failure Syndrome, Fanconi Anemia, Shwachman-Diamond Syndrome, Congenital Dyserythropoietic Anemia, Congenital Amegakaryocytic Thrombocytopenia",
    "Epithelioid Mesothelioma, Pleural Malignant Mesothelioma, Recurrent Lung Adenocarcinoma, Peritoneal Malignant Mesothelioma, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Ovarian Serous Adenocarcinoma, Metastatic Lung Adenocarcinoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent High Risk Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "Stage IIIC Gastric (Stomach) Cancer, Stage IIIC Esophageal Cancer, Gastric (Stomach) Adenocarcinoma, Stage IIIB Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Esophageal Cancer, Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer",
    "Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Recurrent Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Leukemia/Lymphoma, Recurrent Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome, Refractory T Lymphoblastic Leukemia/Lymphoma, Refractory T Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IIB Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Recurrent Thymic Carcinoma, Stage IVB Thymoma, Recurrent Malignant Thymoma, Refractory Thymic Carcinoma, Advanced Malignant Thymoma, Refractory Malignant Thymoma, Stage IV Thymoma, Stage IIIA Thymoma, Stage IVA Thymoma, Unresectable Thymic Carcinoma, Stage III Thymoma, Stage IIIB Thymoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",
    "Stage II Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Recurrent Non-Small Cell Lung Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Refractory Malignant Solid Tumor",
    "Peritoneal Carcinomatosis, Gastroesophageal Junction Adenocarcinoma, Gastric (Stomach) Adenocarcinoma",
    "Aplastic Anemia, Hematologic and Lymphocytic Disorder",
    "Metastatic Malignant Neoplasm to the Lung, Metastatic Malignant Solid Tumor",
    "High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome",
    "Stage III Esophageal Cancer, Stage IIIC Esophageal Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIB Esophageal Cancer, Stage II Esophageal Cancer, Acute Esophagitis, Stage IIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IB Esophageal Cancer, Stage IIIA Esophageal Cancer",
    "Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer",
    "Secondary Acute Myeloid Leukemia (AML), Hodgkin Lymphoma, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Chronic Myelogenous Leukemia (CML), Refractory Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts, Recurrent Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Acute Leukemia, Chronic Lymphocytic Leukemia (CLL), Acute Biphenotypic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Recurrent Hodgkin Lymphoma, Langerhans Cell Histiocytosis, Chemotherapy-Related Leukemia, Acute Myeloid Leukemia (AML), Recurrent Double-Hit Lymphoma, Therapy-Related Myelodysplastic Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Anal Intraepithelial Neoplasia 2, Anal Intraepithelial Neoplasia 3, High Grade Anal Canal Intraepithelial Neoplasia",
    "Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Inflammatory Breast Cancer, Locally Advanced Breast Carcinoma, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Double-Hit Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Double-Hit Lymphoma, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Pancreatic Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma",
    "B-Cell Non-Hodgkin Lymphoma, Ph-Like Acute Lymphoblastic Leukemia, Pre-B Acute Lymphoblastic Leukemia",
    "Secondary Myelofibrosis",
    "Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Mixed Epithelial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Stage IV Uterine (including Endometrial) Cancer, Recurrent Endometrial Clear Cell Adenocarcinoma, Stage IVA Uterine (including Endometrial) Cancer, Recurrent Endometrial Endometrioid Adenocarcinoma",
    "Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Grade 1 Follicular Lymphoma",
    "Breast Cancer",
    "Invasive Breast Cancer, Triple-Negative Breast Cancer",
    "Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Lymphoblastic Lymphoma, Sezary Syndrome, Secondary Central Nervous System Lymphoma, Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Advanced Non-Hodgkin Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Refractory Central Nervous System Lymphoma, Burkitt Lymphoma, Mature B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Mantle Cell Lymphoma, Mycosis Fungoides, Refractory Non-Hodgkin Lymphoma, Cutaneous T-Cell Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Refractory Hodgkin Lymphoma, Follicular Lymphoma, Central Nervous System Lymphoma",
    "Stage III Renal Cell Cancer, Advanced Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Adrenal Cortex Cancer",
    "Pelvis Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Lymphoplasmacytic Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Recurrent Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Refractory Indolent Adult Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Marginal Zone Lymphoma",
    "Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Metastatic Esophageal Adenocarcinoma, Stage IV Esophageal Cancer, Stage III Esophageal Adenocarcinoma, Stage IIIC Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Poorly Differentiated Esophageal Squamous Cell Cancer, Stage IIIC Esophageal Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer",
    "Recurrent Burkitt Leukemia, Recurrent Acute Lymphoblastic Leukemia, Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory Burkitt Leukemia, Refractory Lymphoblastic Lymphoma, Double-Hit Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Lymphoblastic Lymphoma, Recurrent Burkitt Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Lymphoblastic Lymphoma, Recurrent Double-Hit Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia with BCR-ABL1",
    "Stage III Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Richter Syndrome, Refractory Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage IV Diffuse Large B-Cell Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage III B-Cell Non-Hodgkin Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Double-Hit Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Low Grade B-Cell Non-Hodgkin's Lymphoma, Refractory Waldenstrom Macroglobulinemia, Recurrent Mantle Cell Lymphoma, Stage IV B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer",
    "Hematologic and Lymphocytic Disorder, Steroid Refractory Graft Versus Host Disease, Acute Graft Versus Host Disease",
    "Stage IV Esophageal Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Gastric (Stomach) Adenocarcinoma",
    "Recurrent Head and Neck Carcinoma",
    "Chondrosarcoma, Grade 2, Chondrosarcoma, Grade 3, Atypical Cartilaginous Tumor/Chondrosarcoma, Grade 1, Localized Chondrosarcoma, Dedifferentiated Chondrosarcoma",
    "Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Refractory Melanoma, Stage IV Cutaneous (Skin) Melanoma, Intracranial Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Unresectable Thyroid Gland Cancer, Poorly Differentiated Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Metastatic Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Breast Cancer, Executive Function Disorder, Malignant Female Reproductive System Neoplasm",
    "Stage IV Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer",
    "HER2-Positive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain",
    "Supratentorial Glioblastoma, Gliosarcoma, Glioblastoma",
    "Stage II Nodal Marginal Zone Lymphoma, Stage IV Nodal Marginal Zone Lymphoma, Stage II Follicular Lymphoma, Stage III B-Cell Non-Hodgkin Lymphoma, Stage II Splenic Marginal Zone Lymphoma, Stage III Nodal Marginal Zone Lymphoma, Grade 3a Follicular Lymphoma, Stage IV Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Stage IV Splenic Marginal Zone Lymphoma, Stage IV B-Cell Non-Hodgkin Lymphoma, Stage III Follicular Lymphoma, Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage III Splenic Marginal Zone Lymphoma, Grade 2 Follicular Lymphoma, Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
    "Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",
    "Stage IV Inflammatory Breast Cancer, Recurrent Breast Inflammatory Carcinoma",
    "Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm to the Liver, Refractory Malignant Neoplasm, Colorectal Carcinoma Metastatic in the Liver",
    "Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma, Metastatic Pheochromocytoma, Unresectable Paraganglioma, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8",
    "Recurrent Malignant Female Reproductive System Neoplasm, Fallopian Tube Carcinosarcoma, Stage IIIC Primary Peritoneal Cancer, Recurrent Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIB Primary Peritoneal Cancer, Recurrent Ovarian Carcinosarcoma, Stage IIIA Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Recurrent Uterine (Including Endometrial) Cancer, Stage IV Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Stage IIA Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage II Primary Peritoneal Cancer",
    "Stage III Breast Cancer, Advanced Breast Carcinoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Refractory Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer",
    "Stage II Small Lymphocytic Lymphoma, Stage II Chronic Lymphocytic Leukemia (CLL), Stage I Small Lymphocytic Lymphoma, Stage I Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma",
    "Recurrent Abdominal Neuroendocrine Tumor, Unresectable Abdominal Neuroendocrine Neoplasm, Refractory Abdominal Neuroendocrine Tumor",
    "High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Ductal Carcinoma In Situ (DCIS)",
    "Hepatocellular Cancer, Resectable Hepatocellular Cancer",
    "Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Burkitt Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Burkitt Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Double-Hit Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma",
    "Stage IV Pancreatic Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Therapy-Related Myeloid Neoplasm, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Myeloid Sarcoma, Secondary Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm, High-Grade Myeloid Neoplasm",
    "Stage IV Squamous Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IV Large Cell Lung Cancer, Stage IV Lung Adenocarcinoma, Stage IV Non-Small Cell Lung Cancer",
    "Stage III Esophageal Squamous Cell Cancer, Stage IIIB Pleural Malignant Mesothelioma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IVB Lung Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Pleural Malignant Mesothelioma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Lung Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Lung Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Tumor, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Locally Advanced Esophageal Carcinoma, Stage IV Esophageal Squamous Cell Cancer, Metastatic Pleural Malignant Mesothelioma, Stage IIIA Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage III Pleural Malignant Mesothelioma, Stage IVB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IIIA Pleural Malignant Mesothelioma, Stage III Lung Cancer, Stage IV Lung Cancer, Stage IV Esophageal Squamous Cell Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Esophageal Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Metastatic Esophageal Carcinoma, Unresectable Esophageal Cancer, Unresectable Pleural Malignant Mesothelioma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Esophageal Squamous Cell Cancer, Metastatic Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Tumor, Stage IIIB Esophageal Squamous Cell Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Pleural Malignant Mesothelioma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Lung Cancer, Stage III Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Lung Cancer, Stage III Esophageal Squamous Cell Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IVB Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia",
    "Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Unresectable Breast Carcinoma, Stage IV Breast Cancer",
    "Malignant Neoplasm",
    "Metastatic Urothelial Cancer, Unresectable Urothelial Carcinoma, Advanced Urothelial Cancer",
    "Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer",
    "Primary Peritoneal High Grade Serous Adenocarcinoma, Stage III Primary Peritoneal Cancer, Stage IIIB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIB Primary Peritoneal Cancer, High Grade Ovarian Serous Adenocarcinoma, Stage IIIA Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IV Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, High Grade Fallopian Tube Serous Adenocarcinoma",
    "Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "WHO Grade III Glioma, Glioblastoma, Grade II Glioma",
    "Hepatocellular Cancer",
    "Recurrent Prostate Cancer, Prostate Adenocarcinoma, Biochemically Recurrent Prostate Carcinoma",
    "EBV-Related Non-Hodgkin Lymphoma, Recurrent EBV-Related Lymphoma, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, EBV-Related Lymphoproliferative Disorder, Recurrent Grade II Lymphomatoid Granulomatosis, EBV-Related Post-Transplant Lymphoproliferative Disorder, Recurrent Grade I Lymphomatoid Granulomatosis, Recurrent Grade III Lymphomatoid Granulomatosis, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form",
    "Superficial Bladder Cancer, Bladder Urothelial Carcinoma In Situ, Infiltrating Bladder Urothelial Carcinoma",
    "Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma",
    "Hepatocellular Cancer",
    "Stage IV Gastric (Stomach) Cancer, Unresectable Gastric Carcinoma, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Malignant Gastric Neoplasm, Stage IVA Gastric (Stomach) Cancer, Pyloric Stenosis, Stage IIIA Gastric (Stomach) Cancer, Malignant Gastric Neoplasm, Stage IVB Gastric (Stomach) Cancer",
    "Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer, Clear Cell Renal Cell Cancer",
    "Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Stage IIC Prostate Cancer, Stage IIB Prostate Cancer, Prostate Adenocarcinoma, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IIIB Lung Cancer",
    "Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia (ALL), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IIB Pancreatic Cancer",
    "Grade II Meningioma, Recurrent Meningioma, Grade III Meningioma, Grade I Meningioma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, ISS Stage I Multiple Myeloma/Plasma Cell Myeloma, ISS Stage III Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, ISS Stage II Multiple Myeloma/Plasma Cell Myeloma",
    "Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage IIA Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma",
    "Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma",
    "Acute Myeloid Leukemia in Remission, High-Grade Treatment-Related Myeloid Neoplasm, Therapy-Related Myelodysplastic Syndrome, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma/Plasma Cell Myeloma, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Refractory Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid System Neoplasm, Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma",
    "Refractory Mantle Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Transformed Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma",
    "Mantle Cell Lymphoma",
    "Refractory Primary Amyloidosis, Recurrent Primary Amyloidosis",
    "Pituitary Gland Adenoma, Low Grade Glioma, Meningioma, Malignant Glioma, Malignant Brain Tumor, Acoustic Schwannoma",
    "Ovarian Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Undifferentiated Fallopian Tube Cancer, Fallopian Tube Mucinous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Undifferentiated Ovarian Cancer, Ovarian Seromucinous Carcinoma, Fallopian Tube Transitional Cell Cancer, Ovarian Transitional Cell Cancer, Recurrent Fallopian Tube Cancer, Ovarian Mucinous Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Cancer, Malignant Ovarian Brenner Tumor, Recurrent Primary Peritoneal Cancer",
    "Metastatic Small Intestinal Neuroendocrine Carcinoma, Stage IV Jejunal Neuroendocrine Tumor, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm of Unknown Primary Origin, Stage IV Lung Cancer, Stage IV Duodenal Neuroendocrine Tumor, Metastatic Thymic Neuroendocrine Neoplasm, Stage IV Colorectal Neuroendocrine Tumor, Metastatic Neuroendocrine Carcinoma, Advanced Well Differentiated Neuroendocrine Neoplasm, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Well Differentiated Neuroendocrine Neoplasm, Stage IV Ileal Neuroendocrine Tumor",
    "Metastatic Breast Cancer in the Bone",
    "Stage IVB Thymoma, Unresectable Thymic Carcinoma, Stage IIIB Thymoma, Stage IVA Thymoma, Stage IV Thymoma, Stage III Thymoma, Stage IIIA Thymoma",
    "Metastatic Malignant Neoplasm to the Bone, Oligometastatic Prostate Carcinoma, Stage IV Prostate Adenocarcinoma",
    "Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts, Recurrent Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Mantle Cell Lymphoma, Acute Biphenotypic Leukemia, Chronic Myeloproliferative Disease, Acute Myeloid Leukemia (AML), Diffuse Large B-Cell Lymphoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Plasma Cell Leukemia, Lymphoblastic Lymphoma, Acute Undifferentiated Leukemia, Juvenile Myelomonocytic Leukemia, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Burkitt Lymphoma, Acute Lymphoblastic Leukemia (ALL), Refractory Anemia, Dyskeratosis Congenita, Hematologic and Lymphocytic Disorder, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Lymphoplasmacytic Lymphoma, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia",
    "Biochemically Recurrent Prostate Carcinoma",
    "Ovarian Endometrioid Adenocarcinoma, Stage IIIB Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Stage IIIB Fallopian Tube Cancer, Fallopian Tube Mucinous Adenocarcinoma, Stage IIIB Primary Peritoneal Cancer, Undifferentiated Ovarian Cancer, Undifferentiated Fallopian Tube Cancer, Ovarian Mucinous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Stage IIIC Ovarian Cancer, Ovarian Serous Adenocarcinoma, Stage IIIC Fallopian Tube Cancer, Ovarian Seromucinous Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma",
    "Stage IV Gastric (Stomach) Cancer, Recurrent Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma",
    "Stage III Renal Cell Cancer, Metastatic Renal Cell Cancer, Clear Cell Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myelomonocytic Leukemia (CMML)",
    "Locally Advanced Angiosarcoma, Metastatic Epithelioid Hemangioendothelioma, Metastatic Angiosarcoma, Locally Advanced Epithelioid Hemangioendothelioma",
    "Classical Hodgkin Lymphoma",
    "Shwachman-Diamond Syndrome, Severe Aplastic Anemia, Thalassemia, T-Cell Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Multiple Myeloma/Plasma Cell Myeloma, B-Cell Non-Hodgkin Lymphoma, Wiskott-Aldrich Syndrome, Polycythemia Vera, Acute Myeloid Leukemia (AML) with FLT3/ITD, Secondary Acute Myeloid Leukemia (AML), Severe Congenital Neutropenia Type 3, Autosomal Recessive, Acute Myeloid Leukemia with Gene Mutations, Chronic Myelogenous Leukemia (CML), Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia (CMML), Acute Lymphoblastic Leukemia (ALL), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Sickle Cell Disease, Congenital Amegakaryocytic Thrombocytopenia, Glanzmann Thrombasthenia, Radial Aplasia-Thrombocytopenia Syndrome, Chronic Granulomatous Disease, Congenital Neutropenia, CD40 Ligand Deficiency, Waldenstrom Macroglobulinemia, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Chronic Myeloproliferative Disease, Secondary Myelodysplastic Syndrome, Congenital Pure Red Cell Aplasia, Aplastic Anemia, Acute Myeloid Leukemia (AML), Immunodeficiency Syndrome, Paroxysmal Nocturnal Hemoglobinuria, Myelofibrosis",
    "Recurrent Soft Tissue Sarcoma, Soft Tissue Sarcoma",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Myelodysplastic Syndrome, High-Grade Treatment-Related Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Myelofibrosis, Acute Myeloid Leukemia (AML), Refractory Hodgkin Lymphoma, Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Refractory Non-Hodgkin Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage 0 Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Ductal Carcinoma In Situ (DCIS)",
    "Stage IB Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer",
    "Stage III Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Bladder Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Stage III Urethral Cancer, Stage IVB Bladder Cancer, Stage III Renal Pelvis Cancer, Infiltrating Bladder Urothelial Carcinoma, Metastatic Ureter Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Stage III Ureter Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IV Renal Pelvis Cancer, Stage IIIA Bladder Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IV Urethral Cancer",
    "Salivary Gland Cancer, Undifferentiated (Anaplastic) Thyroid Gland Cancer, Salivary Gland Adenoid Cystic Cancer, Salivary Gland Acinic Cell Cancer, Salivary Gland Adenocarcinoma, Unresectable Thyroid Gland Cancer, Refractory Thyroid Gland Cancer, Salivary Gland Mucoepidermoid Carcinoma, Salivary Gland Neoplasm",
    "Malignant Spermatic Cord Neoplasm, Malignant Scrotal Neoplasm, Liposarcoma, Recurrent Malignant Abdominal Neoplasm, Recurrent Malignant Spermatic Cord Neoplasm, Malignant Retroperitoneal Neoplasm, Malignant Abdominal Neoplasm, Recurrent Malignant Retroperitoneal Neoplasm, Malignant Solid Tumor, Recurrent Malignant Scrotal Neoplasm",
    "Stage IV Prostate Adenocarcinoma, Prostate Adenocarcinoma",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Colorectal Adenocarcinoma",
    "Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Stage IVB Cervical Cancer, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenosquamous Carcinoma, Metastatic Cervical Adenocarcinoma, Recurrent Cervical Squamous Cell Cancer",
    "Unresectable Adrenal Cortex Carcinoma, Metastatic Carcinoma in the Adrenal Cortex, Stage IV Adrenal Cortex Cancer, Stage III Adrenal Cortex Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Neoplasm to the Bone",
    "Refractory Adenovirus Infection",
    "Anal Squamous Cell Cancer",
    "Prostate Adenocarcinoma",
    "Malignant Glioma, WHO Grade III Glioma, Refractory Glioma, Recurrent Glioma, Glioblastoma",
    "Stage III Oral Cavity Squamous Cell Cancer, Stage IVA Lip and Oral Cavity Squamous Cell Cancer, Stage III Lip and Oral Cavity Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Lip and Oral Cavity Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IIIC Gastric (Stomach) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVB Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma",
    "Mycosis Fungoides",
    "Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Mixed Phenotype Acute Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Mixed Phenotype Acute Leukemia, Recurrent Acute Biphenotypic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Locally Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric (Stomach) Cancer, Metastatic Gastric Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVC Colorectal (Colon or Rectal) Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Tumor, Metastatic Urothelial Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage III Cutaneous (Skin) T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Lymphomatoid Papulosis, Stage II Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Cutaneous (Skin) T-Cell Non-Hodgkin Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Stage I Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Malignant Neoplasm, Metastatic Malignant Neoplasm in the Brain",
    "Biochemically Recurrent Prostate Carcinoma, Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVA Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Thyroid Gland Neoplasm, Recurrent Malignant Male Reproductive System Neoplasm, Recurrent Cutaneous (Skin) Melanoma, Refractory Malignant Skin Neoplasm, Refractory Cutaneous (Skin) Melanoma, Recurrent Malignant Neoplasm of Multiple Primary Sites, Recurrent Malignant Urinary System Neoplasm, Recurrent Malignant Endocrine Neoplasm, Recurrent Malignant Oral Neoplasm, Refractory Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Recurrent Malignant Pharyngeal Neoplasm, Refractory Malignant Female Reproductive System Neoplasm, Recurrent Malignant Soft Tissue Neoplasm, Refractory Malignant Oral Neoplasm, Recurrent Lip and Oral Cavity Cancer, Refractory Malignant Urinary System Neoplasm, Refractory Malignant Pharyngeal Throat Neoplasm, Recurrent Malignant Solid Tumor, Refractory Malignant Male Reproductive System Neoplasm, Refractory Malignant Solid Tumor, Refractory Malignant Endocrine Neoplasm, Recurrent Malignant Skin Neoplasm, Refractory Malignant Neoplasm of Multiple Primary Sites, Refractory Malignant Soft Tissue Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Refractory Malignant Bone Neoplasm",
    "Stage IV Prostate Cancer, Advanced Prostate Carcinoma, Stage III Prostate Cancer",
    "Metastatic Malignant Neoplasm to the Lung, Malignant Respiratory System Neoplasm, Lung Cancer",
    "Stage II Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage I Prostate Cancer, Stage IIA Prostate Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Adenovirus Infection, Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Burkitt Leukemia, Burkitt Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts, Secondary Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Refractory Chronic Myelogenous Leukemia (CML), Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Acute Myeloid Leukemia (AML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Anemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Ring Sideroblasts",
    "Medulloblastoma, Not Otherwise Specified, Central Nervous System Embryonal Tumor with Rhabdoid Features, Recurrent Ependymoma, Refractory Glioblastoma, Refractory Medulloblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Medulloblastoma, Non-WNT/Non-SHH, Group 3, Medulloblastoma, SHH-Activated, TP53-Wildtype, Medulloblastoma, Non-WNT/Non-SHH, Medulloepithelioma, Refractory Anaplastic Astrocytoma, Refractory WHO Grade III Glioma, Recurrent Grade III Glioma, Recurrent Anaplastic Oligodendroglioma, Refractory Anaplastic Oligodendroglioma, Recurrent Anaplastic Pleomorphic Xanthoastrocytoma, Refractory Atypical Teratoid/Rhabdoid Tumor, Refractory Anaplastic Pleomorphic Xanthoastrocytoma, Recurrent Glioblastoma, Refractory Central Nervous System Neoplasm, Central Nervous System Neuroblastoma, Malignant Glioma, Recurrent Primary Central Nervous System Neoplasm, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Recurrent Medulloblastoma, Central Nervous System Embryonal Neoplasm, Diffuse Midline Glioma, H3 K27M-Mutant, Pineoblastoma, Central Nervous System Ganglioneuroblastoma, Anaplastic Ependymoma, Medulloblastoma, WNT-Activated, Medulloblastoma, Non-WNT/Non-SHH, Group 4, Medulloblastoma, SHH-Activated, Medulloblastoma, SHH-Activated, TP53-Mutant",
    "Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Endometrial Cancer, Metastatic Malignant Neoplasm, Ovarian Cancer, Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IV Rectal Cancer, Metastatic Colon Adenocarcinoma, Stage IVB Rectal Cancer, Metastatic Rectal Adenocarcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Carcinoma, Refractory Colorectal Cancer, Unresectable Rectal Adenocarcinoma, Stage IVA Colon Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Unresectable Colon Adenocarcinoma, Stage IVB Colon Cancer, Stage IVA Rectal Cancer",
    "Metastatic Malignant Neoplasm, Stage IVB Cervical Cancer, Recurrent Penile Cancer, Stage IVA Vulvar Cancer, Stage IV Anal Cancer, Stage IV Vaginal Cancer, Refractory Malignant Neoplasm, Stage IV Cervical Cancer, Stage IVA Vaginal Cancer, Recurrent Anal Canal Cancer, Recurrent Cervical Cancer, Stage IVB Vaginal Cancer, Recurrent Vulvar Cancer, Stage IV Penile Cancer, Recurrent Vaginal Cancer, Stage IVA Cervical Cancer, Recurrent Malignant Neoplasm, Stage IV Vulvar Cancer, Stage IVB Vulvar Cancer",
    "Stage IIIA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Hepatocellular Cancer, Locally Advanced Hepatocellular Carcinoma, Unresectable Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma",
    "B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Recurrent B Acute Lymphoblastic Leukemia",
    "Castration-Resistant Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Adenocarcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Advanced Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Refractory Non-Hodgkin Lymphoma",
    "Poorly Differentiated Thyroid Gland Cancer, Soft Tissue Sarcoma, Dedifferentiated Chondrosarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Refractory Osteosarcoma, Platinum-Resistant Ovarian Cancer, Undifferentiated (Anaplastic) Thyroid Gland Cancer, Bone Sarcoma, Malignant Solid Tumor, Giant Cell Tumor of Bone, Recurrent Osteosarcoma, Thyroid Gland Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Recurrent Ovarian Cancer, Malignancy in Giant Cell Tumor of Bone",
    "Recurrent Grade III Glioma, Astrocytoma, Recurrent Anaplastic Astrocytoma",
    "Glioblastoma, MGMT-Unmethylated Glioblastoma, Gliosarcoma",
    "Stage IIIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer, Stage II Prostate Cancer, Prostate Adenocarcinoma, Stage I Prostate Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Stage IIA Breast Cancer, Stage II Breast Cancer, Invasive Ductal Carcinoma, NOS, Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, HER2-Positive Breast Carcinoma, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer",
    "Unresectable Thymic Carcinoma, Metastatic Thymic Carcinoma",
    "Metastatic Uveal Melanoma",
    "Locally Advanced Soft Tissue Sarcoma, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Metastatic Bone Sarcoma, Unresectable Soft Tissue Sarcoma, Unresectable Bone Sarcoma, Metastatic Soft Tissue Sarcoma, Locally Advanced Bone Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities",
    "Refractory Urothelial Carcinoma, Stage 0is Bladder Cancer, Stage II Bladder Cancer, Stage I Bladder Cancer, Stage IIIA Bladder Cancer, Stage IVA Bladder Cancer, Bladder Urothelial Carcinoma In Situ, Bladder Urothelial Cancer",
    "Malignant Solid Tumor",
    "Prostate Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Myelofibrosis, Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Hematopoietic and Lymphoid Cell Neoplasm, Chronic Lymphocytic Leukemia (CLL), Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma/Plasma Cell Myeloma, Chronic Myeloproliferative Disease",
    "Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Metastatic Malignant Neoplasm in the Brain, Stage III Non-Small Cell Lung Cancer, Thoracic Disorder",
    "Breast Cancer",
    "Stage IIIC Esophageal Adenocarcinoma, Stage IIIA Esophageal Cancer, Stage II Esophageal Squamous Cell Cancer, Malignant Neoplasm of the Thoracic Esophagus, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IIIB Esophageal Cancer, Stage IIB Esophageal Cancer, Stage IIIC Esophageal Cancer, Stage II Esophageal Adenocarcinoma, Stage II Esophageal Cancer, Stage IIA Esophageal Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Stage III Esophageal Cancer, Malignant Neoplasm of the Cervical Esophagus, Stage IIIC Esophageal Squamous Cell Cancer, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Gastric Cardia Adenocarcinoma",
    "Sarcomatoid Renal Cell Cancer, Metastatic Kidney Carcinoma, Stage IV Renal Cell Cancer",
    "Advanced Urothelial Cancer",
    "Small Cell Lung Cancer, Lung Carcinoma Metastatic in the Brain",
    "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage II Gastric (Stomach) Cancer, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIA Gastric (Stomach) Cancer, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IA Gastric (Stomach) Cancer, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage I Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IB Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage I Gastric (Stomach) Cancer, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric (Stomach) Adenocarcinoma, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Undifferentiated Esophageal Cancer, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer",
    "Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma",
    "Follicular Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Marginal Zone Lymphoma",
    "Brain/Spinal Cord Tumor, Refractory Brain Neoplasm, Recurrent Brain Neoplasm",
    "Stage IIIC Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Unresectable Melanoma",
    "Stage IIIB Cutaneous (Skin) Melanoma, Recurrent Non-Small Cell Lung Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Lung Cancer, Locally Advanced Unresectable Renal Cell Carcinoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Advanced Malignant Solid Tumor, Metastatic Melanoma, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Lung Cancer, Unresectable Melanoma, Stage III Renal Cell Cancer, Stage IV Cutaneous (Skin) Melanoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Localized Prostate Carcinoma, Stage IIIC Prostate Cancer, Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIB Prostate Cancer, Stage I Prostate Cancer, Stage IVA Prostate Cancer",
    "Stage IVB Ovarian Cancer, Recurrent Ovarian Cancer, Recurrent Cervical Cancer, Malignant Peritoneal Neoplasm, Platinum-Resistant Fallopian Tube Cancer, Recurrent Endometrial Carcinoma, Malignant Retroperitoneal Neoplasm, Stage IV Fallopian Tube Cancer, Peritoneal Carcinomatosis, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Primary Peritoneal Cancer, Stage IVB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Recurrent Fallopian Tube Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Stage IVB Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer",
    "Recurrent Soft Tissue Sarcoma, Stage IV Retroperitoneal Sarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Locally Advanced Soft Tissue Sarcoma, Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Metastatic Soft Tissue Sarcoma, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Soft Tissue Sarcoma of the Trunk and Extremities",
    "Small Cell Lung Cancer, Metastatic Malignant Neoplasm in the Brain",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Refractory Acute Myeloid Leukemia (AML)",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Anaplastic Astrocytoma, Supratentorial Glioblastoma, Anaplastic Oligoastrocytoma, WHO Grade III Glioma, MGMT-Unmethylated Glioblastoma, Anaplastic Oligodendroglioma, Malignant Glioma",
    "Stage IIIC Rectal Cancer, Stage III Rectal Cancer, Locally Advanced Rectal Carcinoma, Stage IIIB Rectal Cancer, Stage IIIA Rectal Cancer",
    "Stage IVB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer",
    "Recurrent Lung Adenosquamous Carcinoma, Stage IV Adenosquamous Lung Cancer, Stage IV Lung Adenocarcinoma, Recurrent Lung Adenocarcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Adenosquamous Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",
    "Unresectable Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma",
    "Recurrent Non-Small Cell Lung Cancer, Refractory Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Stage III Fallopian Tube Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IVB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage III Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Invasive Micropapillary Serous Carcinoma of the Peritoneum, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Invasive Ovarian Micropapillary Serous Carcinoma, Stage IIIB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Low Grade Fallopian Tube Serous Adenocarcinoma",
    "Recurrent Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Hematologic and Lymphocytic Disorder, Acute Lymphoblastic Leukemia (ALL), Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome",
    "Stage II Prostate Cancer, Stage IIC Prostate Cancer, Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIIB Prostate Cancer, Stage III Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIIA Prostate Cancer, Castration-Sensitive Prostate Carcinoma",
    "MGMT-Unmethylated Glioblastoma, Supratentorial Glioblastoma, MGMT-Methylated Glioblastoma",
    "Stage 0 Breast Cancer, Stage I Breast Cancer, Stage 0 Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Multicentric Breast Cancer, Multifocal Breast Cancer, Stage IB Breast Cancer, Ductal Carcinoma In Situ (DCIS)",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Stage III Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Hepatocellular Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Hepatocellular Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Unresectable Esophageal Cancer, Stage IV Esophageal Adenocarcinoma, Unresectable Colorectal Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Malignant Gastrointestinal Neoplasm, Unresectable Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma",
    "Grade II Glioma, WHO Grade III Glioma, Glioblastoma",
    "Stage IVA Prostate Cancer, Stage IV Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVB Prostate Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Stage IA3 Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Non-Small Cell Lung Cancer, Stage I Lung Cancer, Stage IB Lung Cancer",
    "Stage 0 Laryngeal Throat Squamous Cell Cancer, Laryngeal Basaloid Carcinoma, Laryngeal Papillary Squamous Cell Carcinoma, Glottic Throat Cancer, Stage II Laryngeal Throat Verrucous Cancer, Laryngeal Squamous Cell Carcinoma, Spindle Cell Variant, Stage II Laryngeal Throat Cancer, Stage II Laryngeal Throat Squamous Cell Cancer, Stage I Laryngeal Throat Cancer, Glottic Squamous Cell Carcinoma, Laryngeal Throat Verrucous Cancer, Stage I Laryngeal Throat Squamous Cell Cancer, Stage I Laryngeal Throat Verrucous Cancer, Glottis Verrucous Carcinoma",
    "Pancreatic Adenocarcinoma",
    "Refractory Barrett Esophagus, Esophageal Intraepithelial Neoplasia",
    "Recurrent Myelodysplastic Syndrome, Malignant Solid Tumor, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts, Chronic Myelomonocytic Leukemia (CMML)",
    "Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Head and Neck Squamous Cell Cancer, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Stage IIA Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage I Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer, Stage IB Pancreatic Cancer",
    "Prostate Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Stage IV Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Non-Small Cell Squamous Lung Cancer",
    "Refractory Chronic Myelogenous Leukemia (CML), Recurrent Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Lymphoblastic Leukemia (ALL), Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Acute Lymphoblastic Leukemia",
    "Myelodysplastic Syndrome, Severe Aplastic Anemia, Fanconi Anemia, Acute Leukemia",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Malignant Neoplasm to the Bone, Metastatic Bladder Urothelial Cancer, Ureter Small Cell Neuroendocrine Carcinoma, Stage IV Bladder Cancer, Prostate Neuroendocrine Neoplasm, Stage IV Urethral Cancer, Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Urethral Urothelial Cancer, Bladder Small Cell Neuroendocrine Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage III Bladder Cancer, Castration-Resistant Prostate Cancer, Urothelial Carcinoma, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IVA Bladder Cancer",
    "Stage IIIA2 Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IIIA1 Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IIB Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Recurrent Primary Peritoneal Serous Adenocarcinoma, Recurrent Fallopian Tube Serous Adenocarcinoma, Stage IVA Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Stage IVB Primary Peritoneal Cancer, Stage II Primary Peritoneal Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Sensitive Fallopian Tube Cancer, Platinum-Sensitive Primary Peritoneal Cancer, Platinum-Resistant Primary Peritoneal Cancer, Stage IIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Recurrent Ovarian Cancer, High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage IIB Fallopian Tube Cancer, Stage IIIA2 Ovarian Cancer, Stage III Ovarian Cancer, Stage IIB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage II Fallopian Tube Cancer, Stage II Ovarian Cancer, Stage IIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Primary Peritoneal Cancer, Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Platinum-Resistant Ovarian Cancer, Recurrent Fallopian Tube Cancer, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Recurrent Ovarian Cancer",
    "Glioblastoma",
    "Metastatic Kidney Medullary Carcinoma, Metastatic Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Localized Brain Neoplasm, Recurrent Brain Neoplasm",
    "Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage III Pancreatic Cancer, KRAS NP_004976.2:p.G12R, Resectable Pancreatic Ductal Adenocarcinoma, Stage I Pancreatic Cancer, Stage IIB Pancreatic Cancer, HLA-C*08 Positive Cells Present, Stage IB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Recurrent Osteosarcoma, Refractory Osteosarcoma",
    "Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer, Stage I Prostate Cancer, Stage IIIA Prostate Cancer, Prostate Adenocarcinoma, Stage IIIB Prostate Cancer, Biochemically Recurrent Prostate Carcinoma, Stage IIIC Prostate Cancer",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage I Oropharyngeal Throat Squamous Cell Cancer, Stage II Oropharyngeal Throat Squamous Cell Cancer",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Mycosis Fungoides, Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma",
    "Non-Secretory Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Proliferative Verrucous Leukoplakia, Erythroleukoplakia, Leukoplakia",
    "Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Unresectable Osteosarcoma, Metastatic Malignant Neoplasm to the Bone, Metastatic Osteosarcoma",
    "Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome",
    "Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Other Carcinoma, Wilms Tumor, Clear Cell Sarcoma of Soft Tissue, Malignant Peripheral Nerve Sheath Tumor, Desmoplastic Small Round Cell Tumor, Retinoblastoma, Ewing Sarcoma, Rhabdoid Tumor, Soft Tissue Sarcoma, Osteosarcoma, Solid Tumor, Hepatoblastoma, Germ Cell Tumor",
    "Metastatic Cutaneous Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Vaginal Melanoma, Stage III Cutaneous (Skin) Melanoma, Mucosal Melanoma, Melanoma of Unknown Primary, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Anal Melanoma",
    "Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer",
    "WHO Grade III Glioma, Glioblastoma, Grade II Glioma, Glioma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Multiple Myeloma/Plasma Cell Myeloma, Hodgkin Lymphoma, Chronic Myeloproliferative Disease, Mantle Cell Lymphoma, Chronic Myelogenous Leukemia (CML), Aplastic Anemia, Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Myelodysplastic Syndrome, Bone Marrow Failure",
    "Unresectable Chordoma, Chordoma, Metastatic Chordoma, Locally Advanced Chordoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Chronic Myeloproliferative Disease, Recurrent Chronic Myelogenous Leukemia (CML), Refractory Chronic Myelogenous Leukemia (CML), Chronic Myelogenous Leukemia (CML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Very High Risk Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Disease, Recurrent Acute Myeloid Leukemia (AML), Secondary Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Stage IIIB Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IVA Vaginal Cancer, Stage II Cervical Cancer, Human Papillomavirus-Related Carcinoma, Stage IIA1 Cervical Cancer, Stage IIA2 Cervical Cancer, Stage IB2 Cervical Cancer, Stage IVA Cervical Cancer, Stage IIA Vaginal Cancer, Stage III Vaginal Cancer, Stage IIIA Cervical Cancer, Stage II Vaginal Cancer, Stage IIB Vaginal Cancer, Human Papillomavirus (HPV)-Related Cervical Cancer, Stage IIIB Cervical Cancer, Stage III Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer",
    "BCLC Stage B Hepatocellular Cancer, Recurrent Hepatocellular Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Locally Advanced Microsatellite Stable Colorectal Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Colorectal (Colon or Rectal) Adenocarcinoma",
    "Recurrent High-Grade B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High-Grade B-Cell Lymphoma, Down Syndrome, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Central Nervous System Leukemia",
    "Stage IB Breast Cancer, Ductal Carcinoma In Situ (DCIS), Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIA Breast Cancer, Mucinous Breast Cancer, Papillary Breast Cancer, Medullary Breast Cancer, Invasive Ductal Carcinoma, NOS, Tubular Breast Cancer, Stage 0 Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Recurrent Pancreatic Adenocarcinoma",
    "Head and Neck Basaloid Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Papillary Squamous Cell Carcinoma, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IVA Prostate Cancer, Prostate Adenocarcinoma",
    "Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma",
    "Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Stage IV Breast Cancer, Metastatic Malignant Neoplasm to the Leptomeninges, Stage IV Breast Cancer, Metastatic Breast Carcinoma",
    "Herpesvirus Infection, Hemophagocytic Lymphohistiocytosis, Lymphoproliferative Disorder",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Metastatic Round Cell Liposarcoma, Refractory Leiomyosarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Advanced Myxoid Liposarcoma, Refractory Round Cell Liposarcoma, Refractory Myxoid Liposarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Chondrosarcoma, Advanced Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Refractory Soft Tissue Sarcoma, Advanced Leiomyosarcoma, Metastatic Synovial Sarcoma, Refractory Undifferentiated Pleomorphic Sarcoma, Refractory Synovial Sarcoma, Metastatic Leiomyosarcoma, Advanced Synovial Sarcoma",
    "Atypical Endometrial Hyperplasia, Endometrial Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Myelomonocytic Leukemia (CMML), Recurrent Acute Myeloid Leukemia (AML), High Risk Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Pleural Disorder, Non-Small Cell Lung Cancer, Malignant Mesothelioma",
    "Gastric Mucosa-Associated Lymphoid Tissue Lymphoma",
    "Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Acute Biphenotypic Leukemia, Acute Bilineal Leukemia, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Breast Carcinoma, Stage IIIC Breast Cancer, Locally Advanced Unresectable Breast Carcinoma, Somatic BRCA2 Gene Mutation, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Somatic BRCA1 Gene Mutation, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Germline BRCA2 Gene Mutation, Germline BRCA1 Gene Mutation",
    "Chronic Graft Versus Host Disease, Steroid Refractory Graft Versus Host Disease",
    "Anal Canal Squamous Cell Carcinoma, Stage I Anal Cancer, Stage IIA Anal Cancer, Stage III Anal Cancer, Stage IIIB Anal Cancer, Stage IIB Anal Cancer, Stage IIIA Anal Cancer, Stage II Anal Cancer, Stage IIIC Anal Cancer",
    "Malignant Solid Tumor",
    "Stage IIIC1 Uterine (including Endometrial) Cancer, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IVB Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Grade 3 Endometrial Endometrioid Adenocarcinoma, Stage IV Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer",
    "Mycosis Fungoides, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Sezary Syndrome, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Metastatic Malignant Neoplasm to the Leptomeninges, Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Burkitt Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Nodal Marginal Zone Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Recurrent Indolent Non-Hodgkin Lymphoma, Follicular Lymphoma, Central Nervous System Disorder, High Grade B-Cell Lymphoma, Not Otherwise Specified, Lymphoplasmacytic Lymphoma, Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation, Splenic Marginal Zone Lymphoma, Mantle Cell Lymphoma, Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Intravascular Large B-Cell Lymphoma, Refractory Intravascular Large B-Cell Lymphoma, Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Lymphomatoid Granulomatosis",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia",
    "Locally Advanced Unresectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Non-Melanoma Skin Cancer, Melanocytic Nevus, Cutaneous (Skin) Melanoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Carcinoma, Lung Carcinoid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Cigarette Smoking-Related Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Keratoacanthoma, Skin Squamous Cell Cancer",
    "Malignant Glioma, Low Grade Glioma, Glioma, Recurrent Glioma, Glioblastoma",
    "Metastatic Soft Tissue Sarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Advanced Leiomyosarcoma, Unresectable Myxofibrosarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Advanced Soft Tissue Sarcoma, Advanced Dedifferentiated Liposarcoma, Advanced Myxofibrosarcoma, Unresectable Leiomyosarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Retroperitoneal Sarcoma, Metastatic Leiomyosarcoma, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Metastatic Myxofibrosarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Unresectable Undifferentiated Pleomorphic Sarcoma",
    "Malignant Leptomeningeal Neoplasm, Leptomeningeal Neoplasm, Malignant Solid Tumor",
    "Stage III Breast Cancer, Unresectable Malignant Solid Tumor, Stage III Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Locally Advanced Breast Carcinoma, Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain, Malignant Neoplasm",
    "Recurrent Cutaneous Melanoma of the Extremity, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Advanced Sarcoma of the Extremity, Advanced Cutaneous Melanoma of the Extremity, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Recurrent Sarcoma of the Extremity",
    "Glioblastoma",
    "Breast Cancer",
    "Stage II Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage I Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Polymerase Proofreading Associated Polyposis, Stage I Colorectal (Colon or Rectal) Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IIB Colorectal (Colon or Rectal) Cancer, Lynch Syndrome, Hypermutated Colorectal Carcinoma, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD, Refractory Acute Leukemia, Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Chronic Myeloproliferative Disease",
    "Metastatic Malignant Neoplasm in the Brain, Malignant Neoplasm",
    "Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Metastatic Urothelial Cancer",
    "Malignant Glioma, Glioblastoma with Primitive Neuronal Component, Glioblastoma, Gliosarcoma",
    "Stage III B-Cell Non-Hodgkin Lymphoma, Stage IV Mediastinal (Thymic) Large B-Cell Lymphoma, Stage III Mediastinal (Thymic) Large B-Cell Lymphoma, Stage II Mediastinal (Thymic) Large B-Cell Lymphoma, Stage I Mediastinal (Thymic) Large B-Cell Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma, Aggressive Non-Hodgkin Lymphoma, Transformed Non-Hodgkin Lymphoma, Mediastinal B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Stage IV B-Cell Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Stage II B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Neoplasm to the Lung, Metastatic Malignant Neoplasm to the Bone, Salivary Gland Cancer, Stage IVC Major Salivary Gland Cancer, Stage IV Major Salivary Gland Cancer, Stage IVA Major Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer",
    "Myelodysplastic Syndrome, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)",
    "Refractory Malignant Solid Tumor, Refractory Ovarian Carcinoma, Advanced Malignant Solid Tumor, Ovarian Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIC Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Bladder Urothelial Cancer, Unresectable Bladder Urothelial Carcinoma, Stage IVA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer, Locally Advanced Bladder Urothelial Carcinoma, Stage III Bladder Cancer, Stage IIIA Bladder Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Mucosal Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Ocular Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Locally Advanced Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Stage IV Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage 0 Breast Cancer, Stage IB Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage II Breast Cancer, Stage I Breast Cancer, Stage 0 Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer",
    "Recurrent Central Nervous System Lymphoma, Central Nervous System B-Cell Non-Hodgkin Lymphoma, Refractory Central Nervous System Lymphoma",
    "Ovarian Cancer, Fallopian Tube Neoplasm",
    "Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage I Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IB Gastric (Stomach) Cancer, Stage 0 Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage 0 Gastric (Stomach) Cancer, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage I Gastric (Stomach) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IA Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastric (Stomach) Adenocarcinoma, Localized Gastric Carcinoma, Localized Gastroesophageal Junction Adenocarcinoma, Stage IIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Stage IB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Esophageal Adenocarcinoma, Stage IC Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma",
    "Stage IIIC Prostate Cancer, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IIIB Prostate Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Prostate Cancer, Stage IVA Ovarian Cancer, Stage IV Prostate Cancer, Stage III Prostate Cancer, Stage IVB Ovarian Cancer, Stage IVA Prostate Cancer, Stage IIA Pancreatic Cancer, Stage IVB Prostate Cancer, Stage II Pancreatic Cancer, Refractory Ovarian Carcinoma, Refractory Pancreatic Carcinoma, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage IIB Pancreatic Cancer, Advanced Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Pancreatic Cancer, Refractory Hepatocellular Carcinoma, Stage III Colorectal (Colon or Rectal) Cancer, Unresectable Hepatocellular Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Stage III Pancreatic Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer",
    "Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer",
    "Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IIIB Breast Cancer, Refractory Indolent Adult Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Head and Neck Squamous Cell Cancer, Refractory Breast Cancer, Stage IV Breast Cancer, Inflammatory Breast Cancer, Metastatic Breast Carcinoma, Unresectable Inflammatory Breast Carcinoma, Refractory Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Refractory Mantle Cell Lymphoma, Stage IIIC Breast Cancer",
    "Stage I Follicular Lymphoma, Grade 2 Follicular Lymphoma, Stage III Follicular Lymphoma, Stage II Follicular Lymphoma, Grade 1 Follicular Lymphoma, Stage IV Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma",
    "High Grade Vulvar Squamous Intraepithelial Lesion, High Grade Squamous Intraepithelial Neoplasia",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Invasive Breast Cancer, Recurrent Glioma, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Malignant Neoplasm in the Brain, Oligodendroglioma, Recurrent Oligodendroglioma, Astrocytoma, Glioma, Breast Cancer",
    "Biochemically Recurrent Prostate Carcinoma, Metastatic Malignant Neoplasm in the Lymph Nodes, Prostate Adenocarcinoma, Metastatic Malignant Neoplasm to the Bone, Recurrent Prostate Cancer",
    "Cytomegaloviral Infection, Refractory Cytomegalovirus Infection",
    "Soft Palate Squamous Cell Carcinoma, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Posterior Tongue Squamous Cell Carcinoma, Oropharyngeal Basaloid Carcinoma, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Tonsillar Squamous Cell Carcinoma, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colon Cancer, Colorectal Adenocarcinoma Metastatic in the Liver, Metastatic Colon Carcinoma, Stage IVC Colon Cancer, Stage IVB Colon Cancer, Metastatic Malignant Neoplasm to the Liver, Colon Carcinoma Metastatic in the Liver, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Pancreatic Cancer, Bile Duct Adenocarcinoma, Pancreatic Adenocarcinoma, Ampulla of Vater Adenocarcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer",
    "Hairy Cell Leukemia, Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Refractory Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia",
    "Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Acute Leukemia, Matched Related Donor, Minimal Residual Disease, Allogeneic Hematopoietic Stem Cell Transplantation Recipient, Hematopoietic and Lymphoid Cell Neoplasm, Acute Lymphoblastic Leukemia (ALL), Acute Biphenotypic Leukemia, Burkitt Lymphoma, Blasts Under 10 Percent of Bone Marrow Nucleated Cells, Juvenile Myelomonocytic Leukemia, Matched Unrelated Donor, Acute Myeloid Leukemia (AML)",
    "Anaplastic Kidney Wilms Tumor, Stage III Wilms Tumor, Clear Cell Sarcoma of the Kidney",
    "Hepatocellular Cancer",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIA Lung Cancer, Stage II Lung Cancer",
    "Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities",
    "Stage IVA Pancreatic Cancer, Stage IV Skin Cancer, Metastatic Malignant Neoplasm to the Lung, Metastatic Bladder Carcinoma, Metastatic Breast Carcinoma, Metastatic Soft Tissue Sarcoma, Metastatic Kidney Carcinoma, Metastatic Colorectal Carcinoma, Non-Small Cell Lung Cancer, Stage IVB Pancreatic Cancer, Metastatic Melanoma, Stage IVB Bladder Cancer, Stage IVA Bladder Cancer, Stage IV Bladder Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IA1 Lung Cancer, Stage I Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Metastatic Sarcoma, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Metastatic Pancreatic Carcinoma, Stage III Lung Cancer, Metastatic Anal Canal Carcinoma, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Pancreatic Cancer, Stage IIIA Lung Cancer, Stage IIB Lung Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IA3 Lung Cancer, Stage IV Anal Cancer, Stage IA2 Lung Cancer, Stage II Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer",
    "Stage III Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Unresectable Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Stage IV Pancreatic Cancer",
    "Unresectable Renal Cell Carcinoma, Stage III Renal Cell Cancer, Advanced Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Clear Cell Renal Cell Cancer",
    "Prostate Adenocarcinoma, Male Erectile Disorder",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Extracranial Solid Tumor",
    "Endometrial Adenocarcinoma, Endometrial Cancer, Endometrial Serous Adenocarcinoma, Recurrent Endometrial Carcinoma",
    "Unresectable Thyroid Gland Medullary Carcinoma, Stage IVB Thyroid Gland Medullary Cancer, Stage IVA Thyroid Gland Medullary Cancer, Metastatic Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Cancer, Stage IV Thyroid Gland Medullary Cancer, Stage IVC Thyroid Gland Medullary Cancer",
    "Unresectable Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma, Metastatic Pheochromocytoma, Recurrent Adrenal Gland Pheochromocytoma, Recurrent Paraganglioma, Metastatic Paraganglioma",
    "Acute Myeloid Leukemia (AML), Follicular Lymphoma, Myelodysplastic Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Mantle Cell Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia (ALL), Hematopoietic and Lymphoid Cell Neoplasm, Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Metastatic Microsatellite Stable Colorectal Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, High-Grade Treatment-Related Myeloid Neoplasm, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)",
    "Secondary Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Biphenotypic Leukemia, Myeloid Sarcoma, Myelodysplastic Syndrome, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, High-Grade Treatment-Related Myeloid Neoplasm, Aggressive NK-Cell Leukemia, Juvenile Myelomonocytic Leukemia, Hodgkin Lymphoma, Acute Undifferentiated Leukemia, Non-Hodgkin Lymphoma, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma",
    "Estrogen Receptor Positive, Metastatic Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Advanced Breast Carcinoma, Recurrent Breast Cancer, HER2/Neu Negative, Refractory Breast Cancer, Progesterone Receptor Positive, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer",
    "Lymphocytic Neoplasm, Acute Lymphoblastic Leukemia (ALL), Lymphoma, B Acute Lymphoblastic Leukemia",
    "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic Syndrome, Essential Thrombocythemia, Polycythemia Vera, Chronic Neutrophilic Leukemia, Myeloproliferative Neoplasm, Unclassifiable, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Prefibrotic/Early Primary Myelofibrosis, Chronic Myeloproliferative Disease, Chronic Eosinophilic Leukemia, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myeloid Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Overt Primary Myelofibrosis",
    "Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, HHV8-Positive Multicentric Castleman Disease",
    "Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer",
    "Stage I Lung Cancer, Stage IIIB Lung Cancer, Stage IA1 Lung Cancer, Stage IIIC Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Resectable Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IB Lung Cancer, Stage IIIA Lung Cancer",
    "Stage IIIA Breast Cancer, Triple-Negative Breast Cancer, Inflammatory Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Metastatic Malignant Neoplasm in the Brain",
    "Stage IVB Hodgkin Lymphoma, Stage IVA Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm, Stage IIB Pancreatic Cancer, Refractory Acute Lymphoblastic Leukemia (ALL), Stage IV Pancreatic Cancer, Stage IIIB Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Stage IIIA Hodgkin Lymphoma, Metastatic Malignant Solid Tumor, Stage IVB Prostate Cancer, Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Primary Myelofibrosis, Stage IIA Pancreatic Cancer, Stage IV Prostate Cancer, Ann Arbor Stage IV Hodgkin Lymphoma, Castration-Resistant Prostate Cancer, Refractory Malignant Solid Tumor, Stage II Pancreatic Cancer, Refractory Acute Myeloid Leukemia (AML), Stage IV Breast Cancer, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anemia, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Hodgkin Lymphoma, Refractory Chronic Myelogenous Leukemia (CML), Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia (CML), Refractory Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Primary Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Refractory Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Ann Arbor Stage IV Non-Hodgkin Lymphoma, Metastatic Pancreatic Adenocarcinoma, Refractory Small Lymphocytic Lymphoma, Stage IVA Prostate Cancer, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Unresectable Pancreatic Adenocarcinoma, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Stage IV Breast Cancer, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Refractory Hematologic Malignancy",
    "Hypopharyngeal Throat Squamous Cell Cancer, Oral Cavity Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Squamous Cell Cancer Metastatic to the Neck with Occult Primary, Oropharyngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Paranasal Sinus Squamous Cell Carcinoma, Laryngeal Throat Squamous Cell Cancer, Nasal Cavity Squamous Cell Carcinoma, Resectable Oropharyngeal Squamous Cell Carcinoma, Recurrent Metastatic Squamous Cell Cancer to the Neck with Occult Primary, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Cancer, Recurrent Paranasal Sinus Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Lung Neuroendocrine Neoplasm, Malignant Solid Tumor, Pancreatic Neuroendocrine Tumor, Digestive System Neuroendocrine Neoplasm",
    "Resectable Pancreatic Adenocarcinoma",
    "Refractory Gastroenteropancreatic Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Neoplasm, Midgut Neuroendocrine Tumor G1, Foregut Carcinoid Tumor, Advanced Digestive System Neuroendocrine Neoplasm, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm, Pancreatic Neuroendocrine Tumor, Hindgut Carcinoid Tumor, Digestive System Neuroendocrine Tumor",
    "Small Lymphocytic Lymphoma, Richter Syndrome, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Recurrent Bladder Cancer, Superficial Bladder Cancer",
    "Unresectable Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma, Stage III Head and Neck Squamous Cell Cancer",
    "Maxillary Sinus Carcinoma, Salivary Gland Cancer, Nasal Cavity and Paranasal Sinus Cancer, Non-Melanoma Skin Cancer, Laryngeal Throat Cancer, Lip Cancer, Oral Cavity Cancer, Thyroid Gland Cancer, Malignant Solid Tumor, Nasal Cavity Cancer, Paranasal Sinus Cancer, Throat Carcinoma, Eye Cancer, Head and Neck Carcinoma, Nasopharyngeal Throat Cancer, Laryngeal Throat Squamous Cell Cancer",
    "Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma, Recurrent Malignant Glioma, Recurrent Anaplastic Astrocytoma",
    "Stage IIIB Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage III Hepatocellular Cancer",
    "Prostate Adenocarcinoma",
    "Stage IVB Prostate Cancer, Recurrent Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Prostate Adenocarcinoma with Neuroendocrine Differentiation",
    "Metastatic Melanoma, Metastatic Malignant Neoplasm in the Brain",
    "Ductal Carcinoma In Situ (DCIS)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Malignant Brain Neoplasm, Refractory Anaplastic Astrocytoma, Refractory Atypical Teratoid/Rhabdoid Tumor, Recurrent Ependymoma, Recurrent Giant Cell Glioblastoma, Refractory Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Primitive Neuroectodermal Tumor, Refractory Giant Cell Glioblastoma, Refractory Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Ependymoma, Metastatic Malignant Neoplasm in the Brain, Refractory Malignant Germ Cell Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Glioblastoma, Refractory Medulloblastoma, Recurrent Germ Cell Tumor, Recurrent Malignant Brain Neoplasm",
    "Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Infiltrating Bladder Urothelial Carcinoma, Nested Variant, Infiltrating Bladder Urothelial Carcinoma with Trophoblastic Differentiation, Infiltrating Bladder Urothelial Carcinoma, Plasmacytoid Variant, Infiltrating Bladder Urothelial Carcinoma with Giant Cells, Bladder Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Squamous Cell Cancer, Bladder Urothelial Cancer, Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Infiltrating Bladder Urothelial Carcinoma, Clear Cell Variant, Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Bladder Urothelial Cancer, Bladder Non-Invasive Urothelial Neoplasm, Stage 0a Bladder Cancer",
    "Stage IIIC Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIB Lung Cancer, Stage IIB Lung Cancer, Non-Small Cell Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer",
    "Stage IVC Colon Cancer, Stage IIB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IVB Colon Cancer, Stage IVA Colon Cancer, Advanced Uveal Melanoma, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Advanced Glioblastoma, Advanced Pancreatic Carcinoma, Stage II Pancreatic Cancer, Conjunctival Melanoma, Iris Melanoma, Retinal Melanoma, Advanced Malignant Solid Tumor, Stage III Colon Cancer, Advanced Colon Carcinoma, Stage IIIA Colon Cancer, Stage IV Colon Cancer, Stage IIIC Colon Cancer, Stage IIIB Colon Cancer",
    "Cutaneous Angiosarcoma",
    "Refractory Anaplastic Large Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Hereditary Malignant Neoplasm",
    "Extensive Stage Small Cell Lung Cancer",
    "Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Excess Blasts",
    "Recurrent Malignant Glioma, Supratentorial Glioblastoma, Recurrent Grade III Glioma, Recurrent Glioblastoma",
    "Lung Cancer",
    "Stage IB Uterine (including Endometrial) Cancer, Stage I Uterine (including Endometrial) Cancer, Stage IA Uterine (including Endometrial) Cancer, Uterine Corpus Endometrial Stromal and Related Neoplasms, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Stage II Uterine (including Endometrial) Cancer",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Stage 0 Breast Cancer, Ductal Carcinoma In Situ (DCIS), Stage I Breast Cancer, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage 0 Breast Cancer, Invasive Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Hepatocellular Cancer, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Hepatocellular Cancer",
    "High Grade Fallopian Tube Serous Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IVB Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, BRCA-Associated Ovarian Carcinoma, Stage IVB Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage III Ovarian Cancer, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma",
    "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma",
    "Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IVB Laryngeal Throat Cancer, Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage III Nasopharyngeal Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Locally Advanced Laryngeal Squamous Cell Carcinoma, Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Stage IVB Hypopharyngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVA Hypopharyngeal Throat Cancer",
    "Malignant Carotid Body Paraganglioma, Malignant Adrenal Gland Pheochromocytoma, Malignant Paraganglioma, Metastatic Pheochromocytoma, Metastatic Paraganglioma, Unresectable Paraganglioma, Unresectable Adrenal Gland Pheochromocytoma",
    "Blastoid Variant Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Pleomorphic Variant Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Multiple Endocrine Neoplasia Type 1, Neuroendocrine Tumor, Advanced Carcinoid Tumor, Unresectable Carcinoid Tumor, Digestive System Neuroendocrine Neoplasm",
    "Stage IV Prostate Cancer, Metastatic Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer",
    "Chronic Cutaneous Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm",
    "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, Stage IA Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage I Uterine (including Endometrial) Cancer, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Advanced Melanoma, Unresectable Melanoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm",
    "Stage IVA Lung Cancer, Stage IV Lung Cancer, Platinum-Sensitive Lung Small Cell Carcinoma, Stage IVB Lung Cancer, Extensive Stage Small Cell Lung Cancer, Small Cell Lung Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Triple-Negative Breast Cancer, Invasive Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer",
    "Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma",
    "Stage II Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Secondary Central Nervous System Lymphoma",
    "Stage IIC Prostate Cancer, Prostate Adenocarcinoma, Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer",
    "Recurrent Fallopian Tube Cancer, Recurrent Vaginal Cancer, Stage IVA Cervical Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IV Cervical Cancer, Stage IVA Fallopian Tube Cancer, Recurrent Cervical Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Vaginal Cancer, Stage IV Fallopian Tube Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IVA Ovarian Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Vaginal Cancer, Malignant Female Reproductive System Neoplasm, Recurrent Endometrial Carcinoma, Stage IVB Primary Peritoneal Cancer, Recurrent Primary Peritoneal Cancer, Stage IVB Ovarian Cancer, Stage IV Vaginal Cancer, Recurrent Ovarian Cancer, Stage IVB Cervical Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Fallopian Tube Cancer, Stage IV Ovarian Cancer",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome",
    "Oligodendroglioma",
    "Borderline Resectable Pancreatic Adenocarcinoma, Resectable Pancreatic Ductal Adenocarcinoma",
    "Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma",
    "Polycythemia Vera, Obstructive Sleep Apnea Syndrome, Essential Thrombocythemia",
    "Borderline Resectable Pancreatic Adenocarcinoma, Stage IB Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer, Stage I Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Infiltrating Bladder Cancer, Bladder Urothelial Cancer",
    "Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IIA Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IB Pancreatic Cancer",
    "Stage IB Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Invasive Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer",
    "Non-Neoplastic Hematologic and Lymphocytic Disorder",
    "Malignant Neoplasm, Skin Squamous Cell Cancer, Squamous Cell Carcinoma, Basal Cell Carcinoma",
    "Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma",
    "Myelodysplastic Syndrome, DS Stage III Multiple Myeloma/Plasma Cell Myeloma, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Hematopoietic and Lymphoid System Neoplasm, B-Cell Non-Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Mature T-Cell and NK-Cell Neoplasm, Acute Myeloid Leukemia (AML), Lymphoma, Leukemia, Primary Myelofibrosis, T Acute Lymphoblastic Leukemia, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Histiocytic Sarcoma, Chronic Myelomonocytic Leukemia (CMML), Follicular Dendritic Cell Sarcoma, Recurrent B-Cell Non-Hodgkin Lymphoma, ISS Stage III Multiple Myeloma/Plasma Cell Myeloma, Interdigitating Dendritic Cell Sarcoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Multiple Myeloma/Plasma Cell Myeloma, B Acute Lymphoblastic Leukemia, Fibroblastic Reticular Cell Tumor",
    "Stage IVA Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia",
    "Recurrent Adenoid Cystic Cancer, Metastatic Adenoid Cystic Cancer",
    "Breast Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Double-Hit Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma",
    "Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Recurrent B Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia",
    "Borderline Resectable Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma",
    "Recurrent Glioblastoma, Hormone Receptor Positive Breast Carcinoma, HER2-Positive Breast Carcinoma, Breast Cancer, Metastatic Malignant Neoplasm in the Brain, Triple-Negative Breast Cancer",
    "Stage IVB Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer, Double Negative Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer",
    "Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, High Grade B-Cell Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, ALK-Positive Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Stage IV B-Cell Non-Hodgkin Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, B-Cell Non-Hodgkin Lymphoma, Stage III B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Stage II B-Cell Non-Hodgkin Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation",
    "Breast Cancer",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer",
    "Metastatic Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Locally Advanced Renal Pelvis Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Bladder Urothelial Cancer, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Locally Advanced Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Stage IV Renal Pelvis Cancer, Unresectable Urothelial Carcinoma, Stage IV Ureter Cancer, Stage IVA Bladder Cancer, Metastatic Urethral Urothelial Cancer, Stage IV Urethral Cancer, Metastatic Renal Pelvis Urothelial Cancer",
    "Resectable Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage III Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)",
    "Recurrent Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Mantle Cell Lymphoma",
    "Ductal Carcinoma In Situ (DCIS), Invasive Breast Cancer",
    "Hereditary Breast and Ovarian Cancer Syndrome",
    "Refractory Extensive Stage Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Recurrent Prostate Cancer, Oligometastatic Malignant Solid Neoplasm, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Stage IVA Prostate Cancer",
    "Stage III Cutaneous (Skin) Melanoma",
    "Secondary Glioblastoma, Glioblastoma, IDH-Mutant, MGMT-Unmethylated Glioblastoma",
    "Metastatic Microsatellite Stable Colorectal Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Unresectable Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer",
    "Glioblastoma",
    "Recurrent Prostate Adenocarcinoma, Biochemically Recurrent Prostate Carcinoma",
    "Stage IIC Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIIB Prostate Cancer, Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIIA Prostate Cancer, Stage II Prostate Cancer, Stage III Prostate Cancer",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm to the Liver, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity, Metastatic Carcinoma in the Liver, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Peritoneal Desmoplastic Small Round Cell Tumor, Peritoneal Neoplasm",
    "Hematopoietic and Lymphoid System Neoplasm",
    "Locally Advanced Unresectable Renal Cell Carcinoma, Clear Cell Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Disease, Chronic Myeloproliferative Disease, Acute Myeloid Leukemia (AML)",
    "Recurrent Medulloblastoma, Medulloblastoma, SHH-Activated, Medulloblastoma, Non-WNT/Non-SHH, Refractory Medulloblastoma",
    "Carcinomatosis, Malignant Gastrointestinal Neoplasm, Metastatic Malignant Digestive System Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm",
    "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Metastatic Dedifferentiated Liposarcoma, Metastatic Myxoid Liposarcoma, Stage IIIB Uterine Corpus Leiomyosarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma, Stage IIIA Uterine Corpus Leiomyosarcoma, Unresectable Dedifferentiated Liposarcoma, Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Advanced Synovial Sarcoma, Unresectable Synovial Sarcoma, Metastatic Round Cell Liposarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Advanced Myxoid Liposarcoma, Malignant Myoepithelioma, Unresectable Fibrosarcoma, Advanced Dedifferentiated Liposarcoma, Advanced Fibrosarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Epithelioid Hemangioendothelioma, Advanced Malignant Peripheral Nerve Sheath Tumor, Unresectable Myxoid Liposarcoma, Unresectable Round Cell Liposarcoma, Unresectable Angiosarcoma, Advanced Epithelioid Hemangioendothelioma, Unresectable Epithelioid Hemangioendothelioma, Advanced Round Cell Liposarcoma, Advanced Angiosarcoma, Stage IVA Uterine Corpus Leiomyosarcoma, Metastatic Soft Tissue Leiomyosarcoma, Advanced Soft Tissue Leiomyosarcoma, Unresectable Soft Tissue Leiomyosarcoma, Spindle Cell Sarcoma, Malignant Solitary Fibrous Tumor, Myxofibrosarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Pleomorphic Liposarcoma, Malignant Phyllodes Tumor, Metastatic Fibrosarcoma, Metastatic Angiosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Stage IVB Uterine Corpus Leiomyosarcoma, Metastatic Synovial Sarcoma, Stage IV Uterine Corpus Leiomyosarcoma, Stage IIIC Uterine Corpus Leiomyosarcoma, Hemangiopericytoma, Undifferentiated Sarcoma, Not Otherwise Specified, Stage III Uterine Corpus Leiomyosarcoma",
    "Stage I Renal Cell Cancer, Stage II Renal Cell Cancer, Clear Cell Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma",
    "Stage III Laryngeal Throat Cancer, Stage II Laryngeal Throat Cancer, Laryngeal Throat Squamous Cell Cancer",
    "Prostate Cancer",
    "Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Metastatic Prostate Cancer in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Castration-Resistant Prostate Cancer",
    "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Peritoneal Carcinomatosis, Stage IV Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Gastroesophageal Junction Adenocarcinoma, Gastric (Stomach) Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer",
    "Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma",
    "Stage III Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, HER2 Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage I Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer",
    "Malignant Genitourinary System Neoplasm, Colitis",
    "Stage IA Breast Cancer, Stage I Breast Cancer, Invasive Ductal Carcinoma, NOS, Invasive Breast Papillary Carcinoma, Medullary Breast Cancer, Mucinous Breast Cancer, Tubular Breast Cancer, Invasive Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Early-Stage Breast Cancer, Invasive Lobular Breast Carcinoma, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer",
    "Stage III Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Unresectable Esophageal Cancer, Stage IVA Esophageal Squamous Cell Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Biphenotypic Leukemia, Recurrent Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Gliosarcoma, Recurrent Glioblastoma, Small Cell Glioblastoma, Recurrent Small Cell Glioblastoma, Refractory Small Cell Glioblastoma, Refractory Glioblastoma, Recurrent Gliosarcoma",
    "Metastatic High Grade Sarcoma, Stage IV Retroperitoneal Sarcoma, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)",
    "Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma",
    "Stage IIIA Bladder Cancer, Stage III Bladder Cancer, Stage IIIB Bladder Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage II Bladder Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Malignant Gastrointestinal Neoplasm, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Malignant Solid Tumor, HER2-Positive Breast Carcinoma, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IVA Prostate Cancer, Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage I Breast Cancer",
    "Advanced Malignant Solid Tumor, Glioma",
    "Acute Myeloid Leukemia (AML)",
    "Metabolic Bone Disorder",
    "Steroid Refractory Graft Versus Host Disease",
    "Malignant Solid Tumor",
    "Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage III Lung Cancer",
    "Refractory Mycosis Fungoides, Recurrent Classical Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Anaplastic Large Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Classical Hodgkin Lymphoma",
    "Recurrent Glioblastoma",
    "Unresectable Malignant Solid Tumor, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Renal Cell Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Renal Cell Carcinoma, Unresectable Melanoma, Metastatic Melanoma, Metastatic Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Stage III Hypopharyngeal Throat Cancer, Oral Cavity Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Oropharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Resectable Head and Neck Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Essential Thrombocythemia",
    "Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage 0 Breast Cancer, Early-Stage Breast Cancer, Stage IB Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage IIA Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage 0 Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer",
    "Grade I Meningioma, Unresectable Meningioma, Grade II Meningioma, Recurrent Meningioma, Grade III Meningioma",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Plasmacytoma",
    "B-Cell Non-Hodgkin Lymphoma, Minimal Residual Disease Persistence, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Epstein-Barr Virus Positive, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Ph-Like Acute Lymphoblastic Leukemia, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma, Detection of Minimal Residual Disease, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage IB Esophageal Adenocarcinoma, Stage IC Esophageal Adenocarcinoma, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIA Esophageal Adenocarcinoma, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage I Esophageal Adenocarcinoma, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIB Esophageal Adenocarcinoma",
    "Refractory Rhabdomyosarcoma, Recurrent Rhabdomyosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Metastatic Rhabdomyosarcoma, Metastatic Desmoplastic Small Round Cell Tumor, Locally Advanced Rhabdomyosarcoma, Refractory Desmoplastic Small Round Cell Tumor",
    "Refractory Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myeloproliferative Disease, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma/Plasma Cell Myeloma, Myelodysplastic Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia (CMML), Acute Lymphoblastic Leukemia (ALL), Therapy-Related Myelodysplastic Syndrome, Acute Leukemia of Ambiguous Lineage, Therapy-Related Myelodysplastic/Myeloproliferative Neoplasm, Refractory Chronic Myelogenous Leukemia (CML), Recurrent Multiple Myeloma/Plasma Cell Myeloma, Severe Aplastic Anemia, Recurrent Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Disease, Recurrent Acute Myeloid Leukemia (AML), Recurrent Non-Hodgkin Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IVB Lung Cancer",
    "Stage IIIA Rectal Cancer, Stage IIIC Rectal Cancer, Stage IIA Rectal Cancer, Stage III Rectal Cancer, Stage IIB Rectal Cancer, Rectal Adenocarcinoma, Stage IIIB Rectal Cancer",
    "Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Stage III Pancreatic Cancer, Stage IIA Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Malignant Neoplasm to the Peritoneum, Metastatic Gastric Carcinoma, Stage IV Gastric (Stomach) Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Metastatic Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Gastric (Stomach) Cancer, Small Intestinal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage IIB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Small Intestinal Adenocarcinoma, Stage IIIB Small Intestinal Adenocarcinoma, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage III Small Intestinal Adenocarcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIB Esophageal Adenocarcinoma, Stage II Gastric (Stomach) Cancer, Stage III Pancreatic Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIA Pancreatic Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IB Pancreatic Cancer, Stage I Pancreatic Cancer, Malignant Gastrointestinal Neoplasm, Stage III Esophageal Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma, Gastric (Stomach) Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Stage IA Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer",
    "Malignant Solid Tumor, Small Cell Lung Cancer, Sarcoma, Breast Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Ovarian Cancer, Head and Neck Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colorectal (Colon or Rectal) Cancer",
    "Stage IV Head and Neck Squamous Cell Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Advanced Hepatocellular Carcinoma, Stage IIIB Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastric Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IVA Hepatocellular Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Renal Cell Cancer, Stage IV Hepatocellular Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage III Renal Cell Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Stage III Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IVB Lung Cancer, Advanced Urothelial Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Advanced Melanoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Lung Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Hepatocellular Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Hepatocellular Cancer",
    "Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Pancreatic Adenosquamous Cancer, Unresectable Pancreatic Cancer",
    "Stage IIIA Lung Cancer, Metastatic Malignant Solid Tumor, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IIIC Lung Cancer, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIC Anal Cancer, Stage IIIB Anal Cancer, Stage IV Head and Neck Squamous Cell Cancer, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Stage IV Ovarian Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Breast Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Breast Cancer, Stage IV Anal Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Cervical Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIC Ovarian Cancer, Stage III Cervical Cancer, Stage IV Breast Cancer, Stage IVB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IVA Cervical Cancer, Stage IV Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage III Lung Cancer, Advanced Melanoma, Advanced Soft Tissue Sarcoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Soft Tissue Sarcoma, Advanced Uveal Melanoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IVA Ovarian Cancer, Metastatic Ovarian Carcinoma, Metastatic Cervical Carcinoma, Metastatic Breast Carcinoma, Stage IIIB Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Cervical Carcinoma, Metastatic Uveal Melanoma, Stage IIIA Breast Cancer, Advanced Breast Carcinoma, Metastatic Merkel Cell Carcinoma, Stage IV Breast Cancer, Metastatic Anal Squamous Cell Carcinoma, Advanced Merkel Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma, Advanced Ovarian Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Metastatic Melanoma, Stage IIIA Anal Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IVB Ovarian Cancer",
    "Stage III Colon Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIA Rectal Cancer, Stage IV Colon Cancer, Stage IVC Colon Cancer, Stage III Pancreatic Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVA Rectal Cancer, Stage IV Rectal Cancer, Stage IIIC Colon Cancer, Stage IIIB Colon Cancer, Stage IIIA Colon Cancer, Stage IVA Colon Cancer, Stage III Rectal Cancer, Stage IVB Colon Cancer, Stage IIIB Rectal Cancer, Pancreatic Adenocarcinoma, Microsatellite Stable Colon Carcinoma, Microsatellite Stable Colorectal Carcinoma, Stage IV Pancreatic Cancer, Stage IVC Rectal Cancer, Microsatellite Stable Rectal Carcinoma",
    "Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer",
    "Recurrent Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Unresectable Well Differentiated Neuroendocrine Neoplasm, Metastatic Well Differentiated Neuroendocrine Neoplasm, Advanced Well Differentiated Neuroendocrine Neoplasm",
    "Resectable Hepatocellular Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "T Acute Lymphoblastic Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia, High-Grade Treatment-Related Myeloid Neoplasm, Acute Bilineal Leukemia",
    "Acute Myeloid Leukemia (AML), Blasts More than 10 Percent of Bone Marrow Nucleated Cells, Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome",
    "Metastatic Malignant Neoplasm in the Brain, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "High Grade Cervical Intraepithelial Neoplasia",
    "Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)",
    "Refractory Classical Hodgkin Lymphoma, Recurrent Classical Hodgkin Lymphoma",
    "Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Grade 2 Follicular Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Grade 2 Follicular Lymphoma, Recurrent Classical Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Grade 1 Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Mature B-Cell Non-Hodgkin Lymphoma, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Refractory Hematologic Malignancy, Recurrent Grade 3a Follicular Lymphoma, Grade 3b Follicular Lymphoma, Grade 3a Follicular Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Hodgkin Lymphoma, Recurrent B-Cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia, Recurrent T-Cell Prolymphocytic Leukemia, Refractory Classical Hodgkin Lymphoma",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Recurrent Melanoma, Acral Lentiginous Melanoma, Melanoma of Unknown Primary, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Invasive Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Triple-Negative Breast Cancer, Stage III Breast Cancer, Breast Adenocarcinoma, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer",
    "Recurrent Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IVB Gallbladder Cancer, Stage IV Pancreatic Cancer, Stage IIA Esophageal Adenocarcinoma, Advanced Cholangiocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIA Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage II Esophageal Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Hilar Cholangiocarcinoma, Advanced Colorectal Adenocarcinoma, Duodenal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IVB Esophageal Adenocarcinoma, Esophageal Squamous Cell Cancer, Appendix Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage III Esophageal Squamous Cell Cancer, Advanced Esophageal Adenocarcinoma, Stage IIIB Gallbladder Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIB Esophageal Adenocarcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIA Hilar Cholangiocarcinoma, Stage III Gallbladder Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hilar Cholangiocarcinoma, Stage IVA Gallbladder Cancer, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Gastric (Stomach) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Gallbladder Adenocarcinoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIIB Gastric (Stomach) Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Myeloblasts 10 Percent or More of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Chronic Myeloproliferative Disease, Chronic Myelomonocytic Leukemia (CMML)",
    "Prostate Adenocarcinoma, Stage IIC Prostate Cancer, Stage IIB Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Esophageal Adenocarcinoma, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Esophageal Adenocarcinoma, Stage IIIC Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Unresectable Gastric Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Recurrent Esophageal Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Neoplasm",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Grade 3b Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Resectable Pancreatic Adenocarcinoma, Stage IB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage 0 Pancreatic Cancer, Stage I Pancreatic Cancer",
    "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Renal Cell Carcinoma, Advanced Melanoma, Stage IVA Bladder Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Bladder Cancer, Stage IIIB Bladder Cancer, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Bladder Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIA Bladder Cancer, Stage IVB Colon Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IIIA Breast Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIA2 Ovarian Cancer, Stage IV Renal Cell Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Breast Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IIIC Ovarian Cancer, Stage III Renal Cell Cancer, Stage IIIB Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Advanced Malignant Solid Tumor, Advanced Cholangiocarcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Gastric (Stomach) Cancer, Stage IIIC Colon Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Anal Cancer, Stage IVA Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Breast Cancer, Stage III Gastric (Stomach) Cancer, Triple-Negative Breast Cancer, Stage III Hepatocellular Cancer, Malignant Uterine Neoplasm, Advanced Anal Carcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Breast Carcinoma, Advanced Bladder Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Esophageal Carcinoma, Stage IVA Colon Cancer, Stage IVB Bladder Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Colon Carcinoma, Advanced Gastric Carcinoma, Stage IIIB Lung Cancer, Stage IIIB Colon Cancer, Stage IIIA Colon Cancer, Stage III Colon Cancer, Stage IIIC Anal Cancer, Stage IIIA Anal Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Anal Cancer, Stage IIIA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIB Anal Cancer, Stage IIIC Breast Cancer, Stage IV Ovarian Cancer, Kidney (including Renal Cell) Cancer, Stage IV Colon Cancer, Stage IIIA1 Ovarian Cancer, Stage III Breast Cancer, Stage IVB Lung Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIC Lung Cancer, Stage IV Hepatocellular Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IV Rectal Cancer, Stage IVB Rectal Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Hepatocellular Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage IVC Rectal Cancer, Stage IVA Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage III Breast Cancer, Stage IIIB Rectal Cancer, Stage IIIA Rectal Cancer, Stage III Rectal Cancer, Stage IVC Colon Cancer",
    "Malignant Gastrointestinal Neoplasm, Stage IVB Appendix Cancer, Stage IVC Appendix Cancer, Stage IV Appendix Cancer, Appendix Adenocarcinoma, Stage IVA Appendix Cancer, Peritoneal Carcinomatosis, Unresectable Colorectal Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Stage IVC Colon Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVC Rectal Cancer, Unresectable Colon Adenocarcinoma",
    "Refractory Myelodysplastic Syndrome, Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Recurrent Myelodysplastic Syndrome",
    "Recurrent Glioblastoma, Supratentorial Glioblastoma",
    "Colorectal Traditional Serrated Adenoma, Colorectal Adenomatous Polyp, Colorectal Serrated Lesions and Polyps, Colorectal Polyp, Colorectal Villous Adenoma",
    "Stage IIIA Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IA Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IB Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer",
    "Stage IVA Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Recurrent Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Recurrent Hypopharyngeal Throat Cancer, Nasal Cavity and Paranasal Sinus Cancer, Recurrent Oropharyngeal Throat Cancer, Recurrent Laryngeal Throat Cancer, Recurrent Oral Cavity Carcinoma, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Stage IV Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Gastric (Stomach) Cancer, Unresectable Gastric Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastric Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma",
    "Glioblastoma",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver",
    "Metastatic Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Adenocarcinoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Refractory Myeloid Neoplasm, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Myeloid Neoplasm, Refractory Myelodysplastic Syndrome",
    "Oral Cavity Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage II Head and Neck Squamous Cell Cancer, Stage II Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage III Lip and Oral Cavity Cancer, Stage II Lip and Oral Cavity Cancer, Stage I Lip and Oral Cavity Cancer, Stage III Laryngeal Throat Cancer, Stage I Laryngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage II Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage II Hypopharyngeal Throat Cancer, Stage I Oropharyngeal (p16-Negative) Throat Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer, Stage I Hypopharyngeal Throat Cancer, Human Papillomavirus Negative, Head and Neck Squamous Cell Carcinoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Benign Pancreatic Neoplasm, Pancreatic Precancerous Condition, Resectable Pancreatic Cancer, Resectable Periampullary Adenocarcinoma",
    "Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Sezary Syndrome, Recurrent Mycosis Fungoides, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer",
    "PSA Level Less than Ten, PSA Level Greater than or Equal to 0.5, Prostate Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Unresectable Skin Squamous Cell Carcinoma, Epidermolysis Bullosa Dystrophica, Autosomal Recessive, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma",
    "Recurrent Primary Central Nervous System Neoplasm, Diffuse Intrinsic Pontine Glioma, Refractory Central Nervous System Neoplasm, Diffuse Midline Glioma, H3 K27M-Mutant",
    "Myelodysplastic Syndrome with Isolated del(5q), Chronic Myeloproliferative Disease, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic Syndrome with Ring Sideroblasts, Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome with Excess Blasts, Myelodysplastic Syndrome with Single Lineage Dysplasia, Myelodysplastic/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myelodysplastic Syndrome with Multilineage Dysplasia, Myelodysplastic/Myeloproliferative Disease, Myelodysplastic Syndrome, Unclassifiable, Myelodysplastic Syndrome",
    "Stage III Cutaneous (Skin) Melanoma, Recurrent Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Metastatic Mucosal Melanoma, Recurrent Uveal Melanoma, Stage IV Cutaneous (Skin) Melanoma, Recurrent Melanoma, Metastatic Melanoma, Recurrent Mucosal Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Uveal Melanoma",
    "Acute Myeloid Leukemia (AML), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelogenous Leukemia (CML)",
    "Mantle Cell Lymphoma",
    "Recurrent Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Oligometastatic Prostate Carcinoma, Stage IVA Prostate Cancer",
    "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Myelofibrosis, Prolymphocytic Leukemia, Chronic Myeloproliferative Disease, Burkitt Lymphoma, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), Refractory Marginal Zone Lymphoma, Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Aggressive NK-Cell Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Marginal Zone Lymphoma, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia (AML), Acute Biphenotypic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Mantle Cell Lymphoma, Lymphoplasmacytic Lymphoma, Chronic Lymphoproliferative Disorder of NK-Cells, Myelodysplastic Syndrome, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Acute Undifferentiated Leukemia, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Small Lymphocytic Lymphoma, NK-Cell Lymphoma, Unclassifiable, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Acute Lymphoblastic Leukemia (ALL), Acute Pancreatitis, Lymphoblastic Lymphoma",
    "Refractory Marginal Zone Lymphoma, Mantle Cell Lymphoma, Mixed Phenotype Acute Leukemia, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), Refractory Follicular Lymphoma, Refractory Small Lymphocytic Lymphoma, Acute Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Anaplastic Large Cell Lymphoma, Diffuse Large Cell Lymphoma, Myelodysplastic Syndrome, Lymphoplasmacytic Lymphoma, Acute Myeloid Leukemia (AML), Prolymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Burkitt Lymphoma, Chronic Myelomonocytic Leukemia (CMML), Hodgkin Lymphoma",
    "Myeloid Neoplasm, Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Myeloid Neoplasm",
    "Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma",
    "Pelvis Cancer, Malignant Abdominal Neoplasm",
    "Ocular Graft Versus Host Disease",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Grade 2 Follicular Lymphoma, Refractory Marginal Zone Lymphoma",
    "Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Advanced Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage IIA Lung Cancer, Non-Small Cell Lung Cancer, Metastatic Malignant Neoplasm to the Lung, Stage IA2 Lung Cancer, Stage IB Lung Cancer, Stage IA3 Lung Cancer, Stage I Lung Cancer, Stage IA1 Lung Cancer",
    "Steroid Refractory Graft Versus Host Disease, Chronic Graft Versus Host Disease",
    "Recurrent Ovarian Cancer, Recurrent Malignant Mesothelioma, Recurrent Liposarcoma, Recurrent Rhabdomyosarcoma, Recurrent Gastric (Stomach) Cancer, Recurrent Colon Cancer, Recurrent Rectal Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Refractory Rhabdomyosarcoma, Refractory Fallopian Tube Cancer, Refractory Colon Carcinoma, Resectable Malignant Mesothelioma, Refractory Sarcoma, Recurrent Sarcoma, Refractory Ovarian Carcinoma, Refractory Malignant Mesothelioma, Resectable Liposarcoma, Malignant Abdominal Neoplasm, Recurrent Desmoplastic Small Round Cell Tumor, Resectable Sarcoma, Refractory Liposarcoma, Refractory Desmoplastic Small Round Cell Tumor, Pelvis Cancer, Refractory Gastric (Stomach) Cancer, Refractory Primary Peritoneal Cancer, Refractory Rectal Carcinoma",
    "Recurrent Glioblastoma, Recurrent Malignant Brain Neoplasm",
    "Gliosarcoma, Glioblastoma",
    "Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Cancer, Stage I Breast Cancer, Refractory Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IIIC Breast Cancer",
    "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Refractory Mycosis Fungoides and Sezary Syndrome, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent Mycosis Fungoides and Sezary Syndrome, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Melanoma, Metastatic Sarcoma, Metastatic Malignant Neoplasm to the Spine",
    "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Sarcoma of the Extremity, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma of the Trunk and Extremities",
    "Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Second Primary Squamous Cell Carcinoma of the Head and Neck, Recurrent Head and Neck Squamous Cell Cancer",
    "Stage IV Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Peritoneal Carcinomatosis, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer",
    "Recurrent Glioblastoma",
    "Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IVA Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Stage IV Esophageal Squamous Cell Cancer, Metastatic Esophageal Carcinoma, Metastatic Small Intestinal Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Gastric Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Stage IV Anal Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Pancreatobiliary Carcinoma, Metastatic Malignant Digestive System Neoplasm, Metastatic Anal Canal Carcinoma, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Squamous Cell Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Adenocarcinoma",
    "Metastatic Malignant Neoplasm in the Brain, Malignant Solid Tumor",
    "Stage IIIC Breast Cancer, Metastatic Malignant Solid Tumor, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Malignant Peripheral Nerve Sheath Tumor, Stage IIIA Breast Cancer, Metastatic Pancreatic Carcinoma, Stage IV Pancreatic Cancer, Advanced Malignant Solid Tumor, Stage IIIC Breast Cancer, Stage III Breast Cancer",
    "Recurrent Glioblastoma, Gliosarcoma, Secondary Glioblastoma, Low Grade Glioma",
    "Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Stage III Lung Cancer",
    "Renal Pelvis and Ureter Urothelial Cancer",
    "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Mediastinal (Thymic) Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Aggressive Non-Hodgkin Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, ALK-Positive Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Advanced Malignant Solid Tumor",
    "Stage I Hepatocellular Cancer, Stage II Hepatocellular Cancer",
    "Recurrent Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia",
    "Bronchiolitis Obliterans",
    "High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Refractory Burkitt Lymphoma, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Transformed Recurrent Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma",
    "Locally Advanced Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Myxofibrosarcoma, Metastatic Myxofibrosarcoma, Locally Advanced High Grade Sarcoma, Metastatic High Grade Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Leiomyosarcoma, Locally Advanced Leiomyosarcoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection",
    "Fibrolamellar Cancer",
    "Stage IIIB Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, HER2-Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome",
    "Endometrial Cancer, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma",
    "Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Liver Cancer, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Skin Basaloid Carcinoma, Malignant Skin Neoplasm, Skin Spindle Cell Squamous Cell Carcinoma, Skin Squamous Cell Cancer, Skin Squamous Cell Carcinoma with Sarcomatoid Differentiation",
    "Stage IIIA Lung Cancer, Refractory Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage III Lung Cancer",
    "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Grade 2 Follicular Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Grade 1 Follicular Lymphoma, Grade 3a Follicular Lymphoma, B-Cell Non-Hodgkin Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Polycythemia Vera, Essential Thrombocythemia",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL)",
    "Metastatic Lung Adenocarcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Bilateral Thalamic Glioma, Diffuse Intrinsic Pontine Glioma",
    "Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Metastatic Chromophobe Renal Cell Carcinoma, Unclassified Renal Cell Cancer, Advanced Chromophobe Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Metastatic Sarcomatoid Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Unclassified Renal Cell Carcinoma, Metastatic Unclassified Renal Cell Carcinoma, Chromophobe Renal Cell Cancer, Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Stage IVA Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Stage IVB Prostate Cancer, Castration-Sensitive Prostate Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Hypodiploid B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Central Nervous System Involvement in Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Chondrosarcoma, Metastatic Chondrosarcoma, Chondrosarcoma, Grade 3, Chondrosarcoma, Grade 2, Locally Advanced Chondrosarcoma",
    "Myelodysplastic Syndrome, Acute Leukemia",
    "Secondary Myelofibrosis, Acute Myeloid Leukemia (AML), Primary Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia, Chronic Myeloproliferative Disease, Myelodysplastic/Myeloproliferative Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Unclassifiable",
    "Refractory Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer",
    "Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IV Prostate Cancer",
    "Stage IV Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer",
    "Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Cancer-related Cognitive Difficulties, Malignant Solid Tumor",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer",
    "Stage IIC Prostate Cancer, Prostate Adenocarcinoma, Stage IIIC Prostate Cancer, Locally Advanced Prostate Adenocarcinoma, Stage IIIB Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer",
    "Refractory Rhabdomyosarcoma, Unresectable Rhabdomyosarcoma, Locally Advanced Rhabdomyosarcoma, Recurrent Rhabdomyosarcoma",
    "Primary Brain Neoplasm",
    "Stage IIIC Prostate Cancer, Prostate Adenocarcinoma, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer, Stage I Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage II Prostate Cancer",
    "Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Locally Advanced Intrahepatic Cholangiocarcinoma",
    "Kaposi Sarcoma",
    "Stage IB Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Recurrent Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIC Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer",
    "Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Stage IV Breast Cancer",
    "Metastatic Gallbladder Carcinoma, Stage IV Intrahepatic Bile Duct Cancer, Metastatic Intrahepatic Cholangiocarcinoma, Stage IV Gallbladder Cancer, Metastatic Cholangiocarcinoma, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Resectable Cholangiocarcinoma, Resectable Intrahepatic Cholangiocarcinoma",
    "Stage II Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer",
    "T-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia (CLL), Cutaneous T-Cell Non-Hodgkin Lymphoma, Sezary Syndrome, B-Cell Prolymphocytic Leukemia, Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Mucosal Melanoma",
    "Recurrent Thyroid Gland Cancer, Poorly Differentiated Thyroid Gland Cancer, Thyroid Gland Papillary Cancer, Stage III Thyroid Gland Papillary Cancer, Locally Advanced Thyroid Gland Hurthle Cell Carcinoma, Recurrent Thyroid Gland Hurthle Cell Carcinoma, Locally Advanced Thyroid Gland Carcinoma, Stage III Thyroid Gland Follicular Cancer, Thyroid Gland Follicular Cancer, Follicular Variant Thyroid Gland Papillary Carcinoma",
    "Recurrent Hairy Cell Leukemia Variant, Refractory Hairy Cell Leukemia Variant, Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia",
    "Metastatic Urothelial Cancer, Advanced Urothelial Cancer",
    "Skin Nodular Basal Cell Carcinoma, Basal Cell Carcinoma",
    "Recurrent Hairy Cell Leukemia, Refractory Hairy Cell Leukemia",
    "Metastatic Head and Neck Squamous Cell Cancer, Head and Neck Carcinoma of Unknown Primary, Recurrent Head and Neck Squamous Cell Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Hepatocellular Carcinoma, Stage IIIA Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Stage IIIB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Stage IV Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer",
    "Stage III Breast Cancer, Stage IIA Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma, Lymphoplasmacytic Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Marginal Zone Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Transformed Non-Hodgkin Lymphoma, Systemic Anaplastic Large Cell Lymphoma",
    "Stage IVB Lung Cancer, Stage IV Lung Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer, Stage IVA Lung Cancer",
    "Adult T-Cell Leukemia/Lymphoma, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Hepatosplenic T-Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Recurrent Medulloblastoma, Intraspinal Neoplasm, Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Malignant Glioma, Refractory Malignant Brain Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Medulloblastoma, Refractory Malignant Glioma",
    "Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma",
    "Refractory Prostate Carcinoma, Castration-Resistant Prostate Cancer",
    "Polymorphic Post-Transplant Lymphoproliferative Disorder, Plasmacytic Hyperplasia Post-Transplant Lymphoproliferative Disorder, Classic Hodgkin Lymphoma Type Post-Transplant Lymphoproliferative Disorder, Infectious Mononucleosis-Like Post-Transplant Lymphoproliferative Disorder, Florid Follicular Hyperplasia Post-Transplant Lymphoproliferative Disorder, Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder",
    "Metastatic Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm to the Liver",
    "Hematologic and Lymphocytic Disorder, Acute Leukemia, Myelodysplastic Syndrome, Secondary Myelofibrosis, Primary Myelofibrosis",
    "Lymphoproliferative Disorder, Hemophagocytic Lymphohistiocytosis, Autoimmune Lymphoproliferative Syndrome, Common Variable Immunodeficiency, Primary Immunodeficiency Syndrome, Hypogammaglobulinemia",
    "Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Stage IV Lung Cancer",
    "Retinoblastoma, Unilateral Retinoblastoma, Bilateral Retinoblastoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Renal Failure, Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Unresectable Breast Carcinoma, Stage IIIB Breast Cancer, Breast Adenocarcinoma, Stage IIIC Breast Cancer",
    "Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer, Stage IIB Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer",
    "Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVA Rectal Cancer, Stage IVC Rectal Cancer, Locally Advanced Rectal Carcinoma, Stage IV Rectal Cancer, Locally Advanced Rectal Adenocarcinoma, Rectal Adenocarcinoma, Stage IIC Rectal Cancer, Stage II Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIIB Rectal Cancer, Stage IVB Rectal Cancer",
    "Stage IA Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage I Breast Cancer, HER2 Negative Breast Carcinoma, Stage IB Breast Cancer, Stage IA Breast Cancer",
    "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Gallbladder Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gallbladder Cancer, Stage IIIB Ampulla of Vater Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage III Ampulla of Vater Cancer, Metastatic Digestive System Cancer, Stage IIIA Ampulla of Vater Cancer, Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Digestive System Carcinoma, Locally Advanced Gallbladder Carcinoma, Stage III Gallbladder Cancer, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Gallbladder Carcinoma, Metastatic Cholangiocarcinoma, Stage IIIB Gallbladder Cancer, Locally Advanced Cholangiocarcinoma, Locally Advanced Ampulla of Vater Carcinoma, Adenocarcinoma of Unknown Primary, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Ampulla of Vater Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Ampulla of Vater Carcinoma, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IIB Pancreatic Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage II Pancreatic Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIA Pancreatic Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage IV Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Squamous Cell Cancer of Unknown Primary Origin, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma",
    "Secondary Myelofibrosis, Primary Myelofibrosis",
    "Stage III Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Locally Advanced Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma",
    "Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage III Lung Cancer",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Extensive Stage Small Cell Lung Cancer",
    "Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVA Hypopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Cancer, Stage III Lip and Oral Cavity Cancer, Head and Neck Carcinoma of Unknown Primary, Stage IVA Nasopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Nasopharyngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Metastatic Nasopharyngeal Throat Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage IVB Nasopharyngeal Throat Cancer, Metastatic Oral Cavity Squamous Cell Cancer",
    "Diabetes Mellitus, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed, Sickle Cell Disease, Cystic Fibrosis, Thalassemia, Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Emphysema, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Locally Advanced Cutaneous Melanoma, Unresectable Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Undifferentiated Leukemia, Refractory Myelodysplastic Syndrome, Refractory Mixed Phenotype Acute Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Platinum-Sensitive Primary Peritoneal Cancer, Platinum Sensitive Ovarian Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Sensitive Fallopian Tube Cancer, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed, Malignant Solid Tumor",
    "Stage IIIB Hepatocellular Cancer, Unresectable Fibrolamellar Carcinoma, Stage IVB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer",
    "Systemic Scleroderma",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IIIA Bladder Cancer, Stage II Bladder Cancer",
    "Secondary Myelofibrosis, Primary Myelofibrosis",
    "Bladder Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Stage 0a Bladder Cancer, Stage I Bladder Cancer, Bladder Non-Invasive Papillary Urothelial Carcinoma, High Grade, Stage 0is Bladder Cancer",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Uterine Corpus Carcinosarcoma, Endometrial Serous Adenocarcinoma, Uterine Carcinosarcoma",
    "Metastatic Urothelial Cancer, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVB Prostate Cancer, Aggressive Variant Prostate Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Metastatic Malignant Solid Tumor, Stage IVA Prostate Cancer",
    "Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer, Unresectable Clear Cell Renal Cell Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Recurrent Cervical Cancer, Metastatic Malignant Female Reproductive System Neoplasm, Stage IVA Uterine (including Endometrial) Cancer, Stage IVA Cervical Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Cervical Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Refractory Malignant Female Reproductive System Neoplasm, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Refractory Cervical Carcinoma, Metastatic Ovarian Carcinoma, Recurrent Ovarian Cancer, Stage IV Ovarian Cancer, Stage IV Cervical Cancer, Platinum-Resistant Ovarian Cancer, Refractory Endometrial Carcinoma, Refractory Ovarian Carcinoma, Metastatic Cervical Carcinoma",
    "Glioblastoma, Gliosarcoma",
    "Stage IIIB Lung Cancer, Stage IIA Lung Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIC Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Melanoma of Unknown Primary, Stage III Cutaneous (Skin) Melanoma, Recurrent Cutaneous (Skin) Melanoma",
    "Stage II Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage I Oropharyngeal (p16-Negative) Throat Cancer, Stage III Lip and Oral Cavity Cancer, Stage II Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II Head and Neck Squamous Cell Cancer, Stage I Hypopharyngeal Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage I Head and Neck Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage II Laryngeal Throat Cancer, Stage I Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Oral Cavity Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Stage I Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage II Hypopharyngeal Throat Cancer",
    "Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 1 Follicular Lymphoma",
    "Malignant Genitourinary System Neoplasm, Malignant Solid Tumor, Melanoma, Colitis, Non-Small Cell Lung Cancer",
    "Chronic Myelomonocytic Leukemia-1, Refractory Chronic Myelomonocytic Leukemia (CMML), Chronic Myelomonocytic Leukemia-2, Chronic Myelomonocytic Leukemia-0",
    "Mixed Neuroendocrine Non-Neuroendocrine Neoplasm, Neuroendocrine Tumor, Prostate Neuroendocrine Neoplasm",
    "Stage II Ovarian Cancer, Stage IB Ovarian Cancer, Stage IA Ovarian Cancer, Stage IC Ovarian Cancer, Stage I Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIA Ovarian Cancer, Stage IIB Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIB Fallopian Tube Cancer, Stage IC Fallopian Tube Cancer, Stage IA Fallopian Tube Cancer, Stage IIA Fallopian Tube Cancer, Stage II Fallopian Tube Cancer, Stage I Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIB Fallopian Tube Cancer, Stage IB Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIA Primary Peritoneal Cancer, Stage II Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage IIB Primary Peritoneal Cancer, Stage III Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer",
    "Metastatic Digestive System Cancer",
    "Malignant Brain Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Cutaneous (Skin) Melanoma",
    "Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma",
    "Stage IIIB Bladder Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage II Bladder Cancer, Stage IVA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Cancer",
    "Recurrent Vulvar Squamous Cell Carcinoma, Metastatic Vulvar Squamous Cell Carcinoma, Unresectable Vulvar Squamous Cell Carcinoma, Stage II Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IV Vulvar Cancer, Stage IIIC Vulvar Cancer",
    "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Metastatic Vulvar Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Oropharyngeal Carcinoma, Locally Advanced Cervical Carcinoma, Human Papillomavirus (HPV)-Related Cervical Cancer, Human Papillomavirus-Related Malignant Neoplasm, Locally Advanced Penile Carcinoma, Sinonasal Human Papillomavirus-Related Carcinoma with Adenoid Cystic-Like Features, Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IVA Vaginal Cancer, Stage III Vaginal Cancer, Stage IVB Cervical Cancer, Metastatic Vaginal Carcinoma, Stage III Lung Cancer, Metastatic Penile Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Carcinoma, Locally Advanced Lung Carcinoma, Stage IIIC Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IV Vaginal Cancer, Stage IVB Vulvar Cancer, Metastatic Cervical Carcinoma, Stage IVB Vaginal Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIA Lung Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Locally Advanced Vaginal Carcinoma, Stage IIIB Anal Cancer, Stage IIIA Rectal Cancer, Stage IVA Rectal Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Rectal Cancer, Locally Advanced Rectal Squamous Cell Carcinoma, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Cervical Cancer, Metastatic Malignant Solid Tumor, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVB Rectal Cancer, Stage IV Rectal Cancer, Locally Advanced Malignant Solid Tumor, Stage IV Anal Cancer, Stage III Rectal Cancer, Stage III Anal Cancer, Stage IIIC Anal Cancer, Stage IIIA Anal Cancer, Metastatic Sinonasal Squamous Cell Carcinoma, Metastatic Anal Carcinoma, Locally Advanced Vulvar Carcinoma, Metastatic Rectal Squamous Cell Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Anal Carcinoma",
    "Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Liposarcoma, Unresectable Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Well Differentiated Liposarcoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, Hematopoietic and Lymphoid Cell Neoplasm, Monoclonal Gammopathy of Undetermined Significance, Myelodysplastic Syndrome, Malignant Solid Tumor, Monoclonal B-Cell Lymphocytosis, Aplastic Anemia",
    "Advanced Hepatocellular Carcinoma, BCLC Stage C Hepatocellular Cancer, BCLC Stage B Hepatocellular Cancer",
    "Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Marginal Zone Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Lepidic Adenocarcinoma, Malignant Solid Tumor, Stage IV Anal Cancer, Malignant Adrenal Gland Pheochromocytoma, Stage IV Gallbladder Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Stage IVA Gallbladder Cancer, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Extramammary Paget Disease, Appendix Mucinous Adenocarcinoma, Pituitary Gland Cancer, Lymphoma, Parathyroid Gland Cancer, Papillary Renal Cell Cancer, Bronchioloalveolar Carcinoma, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Stage IV Vulvar Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IVA Vulvar Cancer, Malignant Giant Cell Neoplasm, Basal Cell Carcinoma, Lung Adenocarcinoma In Situ, Breast Metaplastic Carcinoma, Thyroid Gland Cancer, Thymic Carcinoma, Uterine Corpus Carcinosarcoma, Peritoneal Mesothelioma, Malignant Extragonadal Germ Cell Tumor, Endometrial Clear Cell Adenocarcinoma, Deep Fibromatosis/Desmoid Tumor, Minimally Invasive Lung Mucinous Adenocarcinoma, Soft Tissue Sarcoma, Prostate Small Cell Neuroendocrine Carcinoma, Bone Sarcoma, Gestational Trophoblastic Tumor, Adenoid Cystic Carcinoma, Angiosarcoma, Ovarian Small Cell Carcinoma, Hypercalcemic Type, Ovarian Mucinous Adenocarcinoma, Transitional Cell Carcinoma, Chordoma, Lung Sarcomatoid Carcinoma, Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type, Adrenal Cortex Cancer, Pleural Mesothelioma, Penile Squamous Cell Cancer, Small Intestinal Adenocarcinoma, Malignant Odontogenic Tumor, Genitourinary System Carcinoma, Trophoblastic Tumor, Apocrine Neoplasm, Pancreatic Neuroendocrine Neoplasm, Stage IVB Vulvar Cancer, Stage IVB Gallbladder Cancer, Paraganglioma, Acinar Cell Carcinoma, Neuroendocrine Cancer, Mucinous Cystadenocarcinoma, PEComa, Gastrointestinal Stromal Tumor (GIST), Malignant Ovarian Clear Cell Tumor, Serous Cystadenocarcinoma, Malignant Peripheral Nerve Sheath Tumor, Olfactory Neuroblastoma, Uterine Corpus Leiomyosarcoma",
    "Grade 3a Follicular Lymphoma, Stage II Follicular Lymphoma, Stage III Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 1 Follicular Lymphoma, Stage IV Follicular Lymphoma",
    "Stage III Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Locally Recurrent Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage III Head and Neck Squamous Cell Cancer",
    "Triple-Negative Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Recurrent Breast Cancer, Stage II Breast Cancer",
    "Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Early-Stage Breast Cancer",
    "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Breast Cancer, Endocrine Therapy-Induced Alopecia, Chemotherapy-Induced Alopecia",
    "Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Secondary Central Nervous System Lymphoma, Central Nervous System Lymphoma",
    "Refractory Lymphoproliferative Disorder, Recurrent Lymphoproliferative Disorder",
    "Recurrent High-Grade B-Cell Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Burkitt Lymphoma, Refractory Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Recurrent Marginal Zone Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Prostate Cancer",
    "Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IIIA Lung Cancer",
    "Metastatic Desmoplastic Small Round Cell Tumor, Metastatic Ewing Sarcoma, Unresectable Osteosarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Desmoplastic Small Round Cell Tumor, Metastatic Osteosarcoma, Metastatic Rhabdoid Tumor, Recurrent Extracranial Malignant Solid Neoplasm, Unresectable Rhabdoid Tumor, Malignant Solid Tumor",
    "Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Ovarian Cancer, Recurrent Primary Peritoneal Cancer",
    "Unresectable Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer",
    "Stage I Renal Cell Cancer, Stage II Renal Cell Cancer",
    "Ovarian Tumor",
    "Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Chronic Myeloproliferative Disease, Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Graft Versus Host Disease, Acute Lymphoblastic Leukemia (ALL), Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High-Grade B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Mantle Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Astrocytoma, Glioblastoma",
    "Unresectable Pancreatic Ductal Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "Inherited Bone Marrow Failure Syndrome, Refractory Cytopenia of Childhood, Hematopoietic and Lymphoid Cell Neoplasm, Severe Aplastic Anemia",
    "Double-Hit Lymphoma, Triple-Hit Lymphoma",
    "Stage IIIB Lung Cancer, Stage IV Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer",
    "Unilateral Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage IB Breast Cancer, Multifocal Breast Cancer, Invasive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage I Breast Cancer, HER2 Negative Breast Carcinoma, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer",
    "Lymphedema of the Head and Neck, Head and Neck Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Neuroblastoma",
    "Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Resectable Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer",
    "Metastatic Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Prostate Adenocarcinoma",
    "Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Chronic Myeloproliferative Disease, Recurrent Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Recurrent Myeloproliferative Neoplasm",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia with Gene Mutations, Refractory Acute Myeloid Leukemia (AML), Chronic Myeloproliferative Disease, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Advanced Mucosal Melanoma, Advanced Melanoma, Unresectable Melanoma, Unresectable Mucosal Melanoma, Refractory Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Mucosal Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Unresectable Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Metastatic Renal Cell Cancer, Locally Advanced Unresectable Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Advanced Melanoma, Stage IV Renal Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Stage II Lung Cancer, Stage IB Lung Cancer, Stage IA2 Lung Cancer, Stage IIB Lung Cancer, Non-Small Cell Lung Cancer, Stage IA3 Lung Cancer, Stage I Lung Cancer, Stage IIA Lung Cancer, Stage IA1 Lung Cancer, Stage III Renal Cell Cancer",
    "Unresectable Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Stage IV Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage III Hepatocellular Cancer",
    "Asymptomatic COVID-19 Infection Laboratory-Confirmed, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Recurrent Platinum-Resistant Ovarian Carcinoma, Stage IV Ovarian Cancer, Advanced Ovarian Carcinoma, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage III Ovarian Cancer, Advanced Malignant Solid Tumor",
    "Unresectable Breast Carcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Stage IA1 Lung Cancer, Stage IIIC Lung Cancer, Stage II Lung Cancer, Stage IIB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Stage III Lung Cancer, Stage IA2 Lung Cancer, Stage IIIA Lung Cancer, Stage IIA Lung Cancer, Stage I Lung Cancer, Stage IB Lung Cancer, Stage IIIB Lung Cancer, Stage IA3 Lung Cancer",
    "Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Pelvic Sarcoma",
    "Stage IIIA Bladder Cancer, Bladder Urothelial Cancer, Prostatic Urethra Urothelial Carcinoma, Stage II Bladder Cancer",
    "Splenic Marginal Zone Lymphoma, Marginal Zone Lymphoma, B-Cell Non-Hodgkin Lymphoma, Stage II Grade 3 Follicular Lymphoma, Stage II Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage II Grade 1 Follicular Lymphoma, Stage III Nodal Marginal Zone Lymphoma, Stage IV Nodal Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage IV Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Stage IV Marginal Zone Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Grade 3 Follicular Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Malignant Brain Neoplasm, Malignant Brain Tumor, Recurrent Malignant Brain Neoplasm",
    "Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Gastric (Stomach) Adenocarcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Locally Advanced Colorectal Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Colorectal (Colon or Rectal) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Refractory High-Grade B-Cell Lymphoma, Splenic B Lymphoblastic Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Chronic Myelogenous Leukemia (CML), Recurrent Diffuse Large B-Cell Lymphoma, Refractory Chronic Myelogenous Leukemia (CML), Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Stage IIIA Uterine (including Endometrial) Cancer, Stage IA2 Cervical Cancer FIGO 2018, Stage IIB Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IA1 Cervical Cancer FIGO 2018, Stage IB1 Cervical Cancer FIGO 2018, Stage I Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IB Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage IB2 Cervical Cancer FIGO 2018, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IA Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018",
    "Peritoneal Epithelioid Mesothelioma, Pleural Biphasic Mesothelioma, Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Pleural Epithelioid Mesothelioma, Paratesticular Sarcomatoid Mesothelioma, Paratesticular Epithelioid Mesothelioma, Peritoneal Biphasic Mesothelioma, Paratesticular Malignant Mesothelioma, Peritoneal Malignant Mesothelioma, Pleural Malignant Mesothelioma, Peritoneal Sarcomatoid Mesothelioma, Paratesticular Biphasic Mesothelioma",
    "Metastatic Malignant Neoplasm in the Brain, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Small Cell Carcinoma",
    "Metastatic Malignant Female Reproductive System Neoplasm",
    "Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma",
    "Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Refractory Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IVB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage IV Hepatocellular Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Invasive Breast Cancer, Metastatic Breast Adenocarcinoma, Recurrent Breast Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Recurrent Malignant Glioma, Refractory Atypical Teratoid/Rhabdoid Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor, Refractory Anaplastic Ependymoma, Recurrent Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Primitive Neuroectodermal Tumor, Choroid Plexus Cancer, Central Nervous System Germ Cell Tumor, Recurrent Anaplastic Ependymoma, Refractory Malignant Glioma, Recurrent Malignant Brain Neoplasm, Intracranial Myeloid Sarcoma, Refractory Malignant Brain Neoplasm, Refractory Medulloblastoma",
    "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Localized Gastroesophageal Junction Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Depression",
    "Stage IIIC Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Gastric (Stomach) Adenocarcinoma, Stage II Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IB Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer",
    "Resectable Malignant Pleural Mesothelioma",
    "Acute Myeloid Leukemia (AML), Myeloid Neoplasm, Myelodysplastic Syndrome with Excess Blasts-2",
    "Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Recurrent Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Biphenotypic Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory T-Cell Prolymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia (CML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Recurrent T-Cell Prolymphocytic Leukemia, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Recurrent Prostate Adenocarcinoma, Prostate Adenocarcinoma",
    "Recurrent Glioblastoma",
    "Refractory Neuroblastoma, Refractory Malignant Peripheral Nerve Sheath Tumor, Refractory Rhabdomyosarcoma, Refractory Malignant Solid Tumor, Desmoplastic Small Round Cell Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Recurrent Rhabdomyosarcoma, Recurrent Neuroblastoma, Refractory Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Breast Cancer",
    "Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IIIA Lung Cancer, Metastatic Malignant Solid Tumor, Stage III Lung Cancer, Advanced Malignant Solid Tumor, Stage IIIB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Advanced Lung Non-Small Cell Carcinoma",
    "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Double-Hit Lymphoma, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Double-Hit Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma, Not Otherwise Specified, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage I Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage 0 Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Genitourinary Syndrome of Menopause, Breast Adenocarcinoma, Stage IIIB Breast Cancer",
    "Stage IA Pancreatic Cancer, Stage I Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Stage IIB Pancreatic Cancer",
    "Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Neuroendocrine Tumor",
    "Stage IA Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Borderline Resectable Pancreatic Carcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Stage 0 Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IB Pancreatic Cancer",
    "BCLC Stage B Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, BCLC Stage D Hepatocellular Cancer",
    "Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Non-Small Cell Lung Cancer",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma",
    "Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Metastatic Well Differentiated Neuroendocrine Neoplasm, Unresectable Well Differentiated Neuroendocrine Neoplasm",
    "Unresectable Lung Carcinoid Tumor, Metastatic Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Malignant Neoplasm to the Liver, Digestive System Neuroendocrine Tumor, Neuroendocrine Carcinoma of Unknown Primary, Unresectable Digestive System Neuroendocrine Neoplasm, Unresectable Lung Neuroendocrine Neoplasm",
    "Hereditary Breast Cancer, Hereditary Ovarian Cancer",
    "Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Adenocarcinoma",
    "Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Follicular Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma",
    "Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML), Therapy-Related Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia",
    "Metastatic Uveal Melanoma",
    "Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Unresectable Thyroid Gland Anaplastic Carcinoma, Metastatic Thyroid Gland Anaplastic Carcinoma, Malignant Neck Neoplasm, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",
    "Superficial Basal Cell Carcinoma, Skin Nodular Basal Cell Carcinoma, Skin Basal Cell Cancer",
    "Malignant Solid Tumor, Pelvis Cancer, Sarcoma, Malignant Thoracic Neoplasm, Malignant Esophageal Neoplasm, Malignant Abdominal Neoplasm",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Glioblastoma, Gliosarcoma",
    "Diffuse Large B-Cell Lymphoma, Double-Hit Lymphoma, Triple-Hit Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma",
    "Malignant Solid Tumor, Head and Neck Squamous Cell Carcinoma",
    "Recurrent Transformed Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma",
    "Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Early-Stage Breast Cancer, Stage I Breast Cancer, Stage IIIB Breast Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Advanced Melanoma, Locally Advanced Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Recurrent Melanoma, Metastatic Melanoma, Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities, Resectable Soft Tissue Sarcoma, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Stage I Soft Tissue Sarcoma of the Trunk and Extremities",
    "COVID-19-Associated Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed, COVID-19, Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Supratentorial Glioblastoma, Supratentorial Gliosarcoma",
    "Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma",
    "Pleural Biphasic Mesothelioma, Pleural Malignant Mesothelioma, Pleural Epithelioid Mesothelioma, Peritoneal Malignant Mesothelioma",
    "Refractory Lymphoplasmacytic Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Hairy Cell Leukemia, Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Refractory Hairy Cell Leukemia, Recurrent Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma",
    "Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Melanoma",
    "Gastric (Stomach) Cancer, Peritoneal Carcinomatosis",
    "Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIC Lung Cancer, Non-Small Cell Lung Cancer, Stage II Lung Cancer, Stage IIIA Lung Cancer, Stage IA3 Lung Cancer, Stage IIIB Lung Cancer, Stage IA2 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer",
    "Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma",
    "Metastatic Malignant Neoplasm to the Leptomeninges, Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Recurrent Glioblastoma, Glioblastoma",
    "Type 1 Diabetes Mellitus",
    "Melanoma",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage III Rectal Cancer, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Stage IIIC Rectal Cancer, Metastatic Colorectal Carcinoma, Stage IVA Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colon Adenocarcinoma, Stage IIIA Rectal Cancer, Stage IIIA Colon Cancer, Stage IVC Colon Cancer, Stage IVA Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage III Colon Cancer, Stage IIIB Colon Cancer, Stage IIIB Rectal Cancer, Stage IV Rectal Cancer, Stage IVB Rectal Cancer, Stage IVB Colon Cancer",
    "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Renal Cell Cancer, Metastatic Unclassified Renal Cell Carcinoma, Stage III Renal Cell Cancer, Papillary Renal Cell Cancer, Stage IV Renal Cell Cancer, Hereditary Leiomyomatosis and Renal Cell Cancer, Collecting Duct Carcinoma, Clear Cell Papillary Renal Neoplasm, Tubulocystic Renal Cell Cancer, Unresectable Renal Cell Carcinoma, Hereditary Papillary Renal Cell Cancer",
    "Cigarette Smoking-Related Carcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "BCLC Stage C Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, BCLC Stage B Hepatocellular Cancer",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma, Platinum-Sensitive Lung Small Cell Carcinoma, Refractory Extensive Stage Lung Small Cell Carcinoma",
    "Recurrent Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Resistant Fallopian Tube Cancer, Recurrent Fallopian Tube Cancer",
    "Digestive System Neuroendocrine Tumor G2, Digestive System Neuroendocrine Tumor, Metastatic Gastrointestinal Neuroendocrine Tumor G1",
    "Lung Large Cell Neuroendocrine Carcinoma, Refractory Lung Small Cell Carcinoma, Recurrent Small Cell Lung Cancer, Lung Neuroendocrine Carcinoma",
    "Stage II Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage IIIA Bladder Cancer",
    "Human Papillomavirus (HPV)-Related Cervical Cancer",
    "Invasive Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIIB Breast Cancer",
    "Monoclonal Gammopathy of Renal Significance",
    "Stage III Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Cervical Esophagus Adenocarcinoma, Thoracic Esophagus Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma",
    "Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Metastatic Colorectal Carcinoma, Stage IVB Colon Cancer, Metastatic Rectal Adenocarcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Rectal Cancer, Stage III Rectal Cancer, Stage IIIB Rectal Cancer, Stage III Colon Cancer, Stage IIIB Colon Cancer, Unresectable Rectal Adenocarcinoma, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IVC Rectal Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Unresectable Colon Adenocarcinoma, Unresectable Colorectal Carcinoma, Stage IVA Colon Cancer, Stage IVC Colon Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIC Colon Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Colon Cancer, Stage IIIA Rectal Cancer, Stage IVA Rectal Cancer, Metastatic Colon Adenocarcinoma",
    "Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Refractory Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia (AML), Macrocytic Anemia, Myelodysplastic/Myeloproliferative Disease",
    "Thyroid Gland Papillary Microcarcinoma",
    "Anaplastic Astrocytoma, IDH-Wildtype, Glioblastoma, Anaplastic Oligoastrocytoma, Grade II Glioma, Oligoastrocytoma, WHO Grade III Glioma, Diffuse Astrocytoma, IDH-Wildtype, Oligodendroglioma, Anaplastic Oligodendroglioma",
    "Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Recurrent Malignant Head and Neck Neoplasm, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Metastatic Head and Neck Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IVA Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVC Laryngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer",
    "Stage II Prostate Cancer, Stage IIA Prostate Cancer, Prostate Adenocarcinoma, Stage I Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer",
    "Stage IIB Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIA Lung Cancer, Non-Small Cell Lung Cancer, Stage II Lung Cancer",
    "Mantle Cell Lymphoma",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Castration-Resistant Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Stage IVA Prostate Cancer",
    "Vulvar Cancer, Lung Cancer, Recurrent Bladder Cancer, Recurrent Pancreatic Cancer, Recurrent Lung Cancer, Recurrent Rectal Cancer, Recurrent Kidney Carcinoma, Carcinoma In Situ, Head and Neck Carcinoma, Esophageal Cancer, Gastric (Stomach) Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Vulvar Cancer, Kidney (including Renal Cell) Cancer, Rectal Cancer, Cervical Cancer, Vaginal Cancer, Recurrent Esophageal Cancer, Bronchogenic Lung Cancer, Colon Cancer, Bladder Cancer, Recurrent Colon Cancer, Recurrent Cervical Cancer, Recurrent Head and Neck Carcinoma, Pancreatic Cancer, Recurrent Vaginal Cancer, Malignant Solid Tumor",
    "Refractory Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Splenic Marginal Zone Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 3a Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Refractory Grade 2 Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage IVB Lung Cancer, Stage IV Breast Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage IVA Lung Cancer, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage IV Lung Cancer, Stage IV Breast Cancer",
    "Stage II Rectal Cancer, Stage IIC Rectal Cancer, Stage IIA Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIC Rectal Cancer, Rectal Adenocarcinoma, Stage IIB Rectal Cancer, Stage III Rectal Cancer, Stage IIIB Rectal Cancer",
    "Recurrent Metastatic Squamous Cell Cancer to the Neck with Occult Primary, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Squamous Cell Cancer Metastatic to the Neck with Occult Primary, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IV Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Adrenoleukodystrophy, Sly Syndrome, Acute Leukemia, Hodgkin Lymphoma, High-Grade Treatment-Related Myeloid Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hunter Syndrome, Hurler Syndrome, Hemophagocytic Lymphohistiocytosis, Immunodeficiency Syndrome, T-Cell Non-Hodgkin Lymphoma, Bone Marrow Failure Syndrome, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), Follicular Lymphoma, Metabolic Disorder, Refractory Acute Leukemia, Hemoglobinopathy, Mantle Cell Lymphoma, Chronic Myeloproliferative Disease, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Acute Leukemia of Ambiguous Lineage, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Leukemia, Recurrent Acute Leukemia of Ambiguous Lineage, Osteopetrosis, Myelodysplastic/Myeloproliferative Disease, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Marginal Zone Lymphoma, Metachromatic Leukodystrophy, Krabbe Disease, Acute Leukemia of Ambiguous Lineage, Alpha-Mannosidosis, Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Neoplasm in the Brain, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Viscera, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Unresectable Melanoma",
    "Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome",
    "Autoimmune Hemolytic Anemia, Warm Antibody Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Resectable Hepatocellular Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Grade II Meningioma, Grade III Meningioma, Recurrent Meningioma, Grade I Meningioma",
    "Ependymoma, Medulloblastoma, Recurrent Metastatic Malignant Neoplasm in the Leptomeninges, Glioblastoma",
    "Stage III Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma",
    "Metastatic Osteosarcoma, Metastatic Dedifferentiated Liposarcoma, Recurrent Osteosarcoma, Recurrent Angiosarcoma, Refractory Dedifferentiated Liposarcoma, Refractory Osteosarcoma, Metastatic Angiosarcoma, Recurrent Dedifferentiated Liposarcoma",
    "Non-Hodgkin Lymphoma, Blastoid Variant Mantle Cell Lymphoma, Central Nervous System B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, Central Nervous System Lymphoma, Plasmablastic Lymphoma, Richter Syndrome, Diffuse Large B-Cell Lymphoma, Aggressive Non-Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Platinum-Resistant Primary Peritoneal Cancer, Recurrent High Grade Ovarian Serous Adenocarcinoma",
    "Stage IV Primary Peritoneal Cancer, Stage IIIB Breast Cancer, Unresectable Pancreatic Cancer, BRCA-Mutated Metastatic Breast Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Metastatic Fallopian Tube Carcinoma, Stage IIIB Primary Peritoneal Cancer, Metastatic Pancreatic Carcinoma, Stage IIIA1 Ovarian Cancer, BRCA-Mutated Malignant Neoplasm, Unresectable Primary Peritoneal Carcinoma, Stage IVB Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Metastatic Ovarian Carcinoma, BRCA-Associated Ovarian Carcinoma, Stage IIIB Fallopian Tube Cancer, Stage III Pancreatic Cancer, Unresectable Malignant Solid Tumor, Unresectable Fallopian Tube Carcinoma, Stage IIIB Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIB Breast Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Primary Peritoneal Cancer, Metastatic Malignant Solid Tumor, Stage IV Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IVA Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Stage IV Breast Cancer, Stage IVB Ovarian Cancer",
    "Thyroid Gland Squamous Cell Carcinoma, Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Cutaneous T-Cell Non-Hodgkin Lymphoma, Mycosis Fungoides, Sezary Syndrome",
    "Stage IIC Rectal Cancer, Stage II Rectal Cancer, Stage IIA Rectal Cancer, Stage III Rectal Cancer, Locally Advanced Rectal Adenocarcinoma, Stage IIIB Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIB Rectal Cancer",
    "Invasive Breast Cancer, Triple-Negative Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent T Acute Lymphoblastic Leukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Refractory Hairy Cell Leukemia, Recurrent Chronic Myelogenous Leukemia (CML), Refractory B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Hodgkin Lymphoma, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hairy Cell Leukemia, Refractory Acute Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Acute Leukemia, Refractory T Acute Lymphoblastic Leukemia, Systemic Mastocytosis, Refractory Chronic Myelogenous Leukemia (CML)",
    "Esophageal Adenocarcinoma",
    "Recurrent Mantle Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, ALK-Positive Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma",
    "Anaplastic Astrocytoma, WHO Grade III Glioma, Gliosarcoma, Anaplastic Oligodendroglioma, Anaplastic Oligoastrocytoma, Glioblastoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage IA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage I Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma, Stage IB Cutaneous (Skin) Melanoma",
    "Stage IIIB Lung Cancer, Small Cell Lung Cancer, Neuroendocrine Cancer, Stage III Lung Cancer, Stage IIIC Lung Cancer, Stage IIIA Lung Cancer",
    "Rectal Adenocarcinoma, Stage IIIC Rectal Cancer, Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer",
    "Stage IIIB Breast Cancer, Castration-Resistant Prostate Cancer, Malignant Ovarian Serous Tumor, HER2 Negative Breast Carcinoma, Metastatic Breast Carcinoma, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIA Breast Cancer, Metastatic Prostate Cancer, Stage IVB Ovarian Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Breast Carcinoma, Metastatic Ovarian Carcinoma, Stage III Breast Cancer, Stage IVA Prostate Cancer",
    "Metastatic Intrahepatic Cholangiocarcinoma, Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Locally Advanced Intrahepatic Cholangiocarcinoma, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Resectable Skin Squamous Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Influenza",
    "Cervical Squamous Intraepithelial Neoplasia 2, Cervical Intraepithelial Neoplasia, Cervical Squamous Cell Carcinoma In Situ",
    "Lung Cancer",
    "Metastatic Uveal Melanoma",
    "Human Papillomavirus Infection, Recurrent Respiratory Papillomatosis",
    "Locally Recurrent Uterine Corpus Leiomyosarcoma",
    "Extensive Stage Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer",
    "Metastatic Malignant Neoplasm to the Liver, Metastatic Uveal Melanoma, Stage IV Choroidal and Ciliary Body Melanoma",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Recurrent Ependymoma, Spinal Cord Glioma, Glioblastoma, Diffuse Midline Glioma, H3 K27M-Mutant, WHO Grade III Glioma, Recurrent Malignant Brain Neoplasm",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Chronic Myelomonocytic Leukemia-1, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-2, Myelodysplastic Syndrome",
    "Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Recurrent Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, HER2 Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer",
    "High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma",
    "Pancreatic Ductal Adenocarcinoma, Bile Duct Cancer (including Cholangiocarcinoma), Gallbladder Cancer",
    "Sickle Cell Disease, Myelodysplastic Syndrome, Myelofibrosis",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Prediabetes",
    "Basal Cell Carcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage III Mediastinal (Thymic) Large B-Cell Lymphoma, Stage IV Mediastinal (Thymic) Large B-Cell Lymphoma, Stage II Mediastinal (Thymic) Large B-Cell Lymphoma, Stage I Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Ph-Like Acute Lymphoblastic Leukemia",
    "Recurrent Follicular Lymphoma, Refractory Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Carcinoma, Advanced Endometrial Endometrioid Adenocarcinoma, Stage IIIA Uterine (including Endometrial) Cancer, Advanced Endometrial Adenocarcinoma, Not Otherwise Specified, Stage III Uterine (including Endometrial) Cancer, Refractory Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Dedifferentiated Carcinoma, Advanced Endometrial Carcinoma, Refractory Endometrial Mucinous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Refractory Endometrial Serous Adenocarcinoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Advanced Endometrial Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Stage IV Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Refractory Follicular Lymphoma, Stage IIIB Uterine (including Endometrial) Cancer, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Mucinous Adenocarcinoma, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified, Recurrent Endometrial Transitional Cell Carcinoma, Refractory Endometrial Squamous Cell Carcinoma, Refractory Endometrial Adenocarcinoma, Not Otherwise Specified, Refractory Endometrial Transitional Cell Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Refractory Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Refractory Primary Peritoneal Cancer, Recurrent Ovarian Cancer, Refractory Ovarian Carcinoma, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer",
    "AL Amyloidosis",
    "Hormone Receptor Positive Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma",
    "Anaplastic Astrocytoma, Glioblastoma, Diffuse Astrocytoma, IDH-Wildtype, Gliosarcoma, Supratentorial Glioblastoma, High Grade Astrocytic Tumor",
    "Undifferentiated (Anaplastic) Thyroid Gland Cancer, Thyroid Gland Papillary Cancer, Thyroid Gland Medullary Cancer, Thyroid Gland Squamous Cell Carcinoma, Recurrent Thyroid Gland Cancer, Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer",
    "Stage IVA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IV Lung Cancer",
    "Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis, Gastric (Stomach) Adenocarcinoma",
    "Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Unresectable Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Mantle Cell Lymphoma",
    "Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Early-Stage Breast Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-Negative Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer",
    "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Lung Cancer, Locally Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Breast Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Colorectal (Colon or Rectal) Cancer, Locally Advanced Melanoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Melanoma, Metastatic Primary Malignant Central Nervous System Neoplasm, Locally Advanced Primary Malignant Central Nervous System Neoplasm, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIC Lung Cancer, Metastatic Sarcoma, Locally Advanced Sarcoma",
    "Refractory Transformed Mycosis Fungoides, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Mycosis Fungoides, T-Cell Non-Hodgkin Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Refractory Hepatocellular Carcinoma",
    "Peritoneal Carcinomatosis, Colorectal (Colon or Rectal) Cancer, Pseudomyxoma Peritonei, Low Grade Appendix Mucinous Neoplasm, Advanced Malignant Digestive System Neoplasm, Appendix Cancer",
    "Recurrent Endometrial Carcinoma, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer",
    "Mantle Cell Lymphoma",
    "Stage III Lung Cancer, Stage IVB Lung Cancer, Stage III Liver Cancer, Stage IIIC Lung Cancer, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Malignant Adrenal Gland Neoplasm, Metastatic Liver Carcinoma, Stage IVA Lung Cancer, Metastatic Lung Carcinoma, Stage IIIA Lung Cancer, Advanced Malignant Solid Tumor, Advanced Lung Carcinoma, Metastatic Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage IV Lung Cancer",
    "Stage IVB Lung Cancer, Stage IV Breast Cancer, Hematopoietic and Lymphoid Cell Neoplasm, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Solid Tumor, Metastatic Melanoma, Hormone Receptor Positive Breast Carcinoma, Stage IVA Lung Cancer, Metastatic Malignant Neoplasm in the Brain, Metastatic Triple-Negative Breast Carcinoma, Stage IV Lung Cancer, Stage IV Breast Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma, Stage IV Lung Cancer",
    "Recurrent Angioimmunoblastic T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma",
    "Myelodysplastic Syndrome",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Nongerminomatous Germ Cell Tumor, Metastatic Malignant Nongerminomatous Germ Cell Tumor, Recurrent Malignant Nongerminomatous Germ Cell Tumor",
    "Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant",
    "Stage IVB Ovarian Cancer, Stage III Ovarian Cancer, Stage IIB Ovarian Cancer, Stage II Ovarian Cancer, Stage IIA Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer",
    "Unresectable Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma",
    "Stage II Skin Cancer, Skin Squamous Cell Cancer, Stage III Skin Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Metastatic Well Differentiated Neuroendocrine Neoplasm, Locally Advanced Well Differentiated Neuroendocrine Neoplasm",
    "Stage III Rectal Cancer, Stage IIIC Anal Cancer, Stage IIC Rectal Cancer, Stage II Rectal Cancer, Stage IVC Rectal Cancer, Stage IVB Rectal Cancer, Malignant Rectosigmoid Neoplasm, Stage IIIA Anal Cancer, Stage IIB Rectal Cancer, Recurrent Anal Adenocarcinoma, Stage IIA Anal Cancer, Stage IIB Anal Cancer, Stage IIIB Anal Cancer, Stage IV Rectal Cancer, Stage IIIC Rectal Cancer, Stage 0 Anal Cancer, Stage I Anal Cancer, Stage II Anal Cancer, Stage III Anal Cancer, Stage IV Anal Cancer, Stage 0 Rectal Cancer, Stage IIIA Rectal Cancer, Stage IVA Rectal Cancer, Recurrent Rectal Adenocarcinoma, Stage I Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIA Rectal Cancer",
    "Mixed Phenotype Acute Leukemia, Refractory Mixed Phenotype Acute Leukemia, Recurrent Mixed Phenotype Acute Leukemia",
    "Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Cancer, BCLC Stage A Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer",
    "Stage IVB Hepatocellular Cancer, Locally Advanced Hepatocellular Carcinoma, Stage IVA Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Hepatocellular Cancer, Liver and Intrahepatic Bile Duct Disorder, Stage IIIA Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Cirrhosis, Metastatic Hepatocellular Carcinoma, Stage IIIB Hepatocellular Cancer",
    "Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVB Laryngeal Throat Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer",
    "Unresectable Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer",
    "Non-Small Cell Lung Cancer, Pleural Disorder",
    "Refractory Follicular Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma",
    "Recurrent Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Refractory Triple-Negative Breast Carcinoma",
    "Stage IV Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage IVA Lung Cancer",
    "Peritoneal Malignant Mesothelioma, Malignant Mesothelioma, Pleural Malignant Mesothelioma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer",
    "Refractory Adult T-Cell Leukemia/Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Cancer, Head and Neck Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Laryngeal Throat Cancer, Nasal Cavity Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Laryngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Squamous Cell Cancer of Unknown Primary Origin, Stage IV Lip and Oral Cavity Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Paranasal Sinus Squamous Cell Carcinoma, Stage IV Laryngeal Throat Cancer, Malignant Solid Tumor, Oral Cavity Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Cancer, Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Lip and Oral Cavity Cancer, Metastatic Nasal Cavity Squamous Cell Carcinoma",
    "Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVA Prostate Cancer, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Metastatic Small Cell Neuroendocrine Prostate Cancer",
    "Stage IV Ureter Cancer, Stage IV Urethral Cancer, Recurrent Urothelial Cancer, Metastatic Urothelial Cancer, Recurrent Urethral Urothelial Cancer, Locally Advanced Urothelial Cancer, Stage IIIB Bladder Cancer, Locally Advanced Urethral Urothelial Carcinoma, Recurrent Bladder Urothelial Cancer, Stage III Ureter Cancer, Metastatic Ureter Urothelial Cancer, Stage IV Renal Pelvis Cancer, Recurrent Renal Pelvis Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Recurrent Ureter Urothelial Cancer, Stage III Renal Pelvis Cancer, Locally Advanced Renal Pelvis Urothelial Carcinoma, Stage III Bladder Cancer, Metastatic Urethral Urothelial Cancer, Stage IV Bladder Cancer, Stage IIIA Bladder Cancer, Stage III Urethral Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Renal Pelvis Urothelial Cancer",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Triple-Negative Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Lobular Carcinoma In Situ (LCIS), Stage IIIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Ductal Carcinoma In Situ (DCIS), Invasive Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer",
    "Lobular Breast Carcinoma, Medullary Breast Cancer, Stage 0 Breast Cancer, Stage IA Breast Cancer, Papillary Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Ductal Carcinoma In Situ (DCIS)",
    "Triple-Hit Lymphoma, Indolent Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Double-Hit Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS",
    "Breast Cancer",
    "Refractory High-Grade B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Locally Advanced Urothelial Cancer, Refractory Urothelial Carcinoma",
    "Resectable Hepatocellular Cancer",
    "Stage IVA Hypopharyngeal Throat Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Stage IVB Laryngeal Throat Cancer, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Laryngeal Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IVC Hypopharyngeal Throat Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Recurrent Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IV Hypopharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Squamous Cell Cancer of Unknown Primary Origin, Stage IVB Hypopharyngeal Throat Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Metastatic Urothelial Cancer, Locally Advanced Urothelial Cancer",
    "Recurrent Glioblastoma",
    "Clinical Stage IIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage II Merkel Cell Carcinoma AJCC v8, Clinical Stage II Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IIB Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIA Merkel Cell Carcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8",
    "Advanced Malignant Solid Tumor",
    "Stage II Nasopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage III Nasopharyngeal Throat Cancer, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage II Hypopharyngeal Throat Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Stage III Head and Neck Squamous Cell Cancer, Stage II Laryngeal Throat Cancer, Malignant Posterior Tongue Neoplasm, Stage III Laryngeal Throat Cancer, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Stage II Head and Neck Squamous Cell Cancer, Locally Advanced Nasopharyngeal Squamous Cell Carcinoma, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage II Oropharyngeal (p16-Negative) Throat Cancer, Unresectable Oropharyngeal Squamous Cell Carcinoma",
    "Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma",
    "Therapy-Related Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Acute Leukemia of Ambiguous Lineage",
    "Stage IB Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage IA Cutaneous (Skin) Melanoma, Stage I Cutaneous (Skin) Melanoma, Stage IA Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage I Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IB Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma",
    "Advanced Malignant Germ Cell Tumor, Malignant Mediastinal Nongerminomatous Germ Cell Tumor, Seminoma, Nongerminomatous Germ Cell Tumor, Refractory Malignant Germ Cell Tumor, Recurrent Germ Cell Tumor, Ovarian Germ Cell Tumor",
    "Stage IVA Thyroid Gland Medullary Cancer, Stage IVC Thyroid Gland Medullary Cancer, Recurrent Thyroid Gland Medullary Carcinoma, Stage IVB Thyroid Gland Medullary Cancer, Stage IV Thyroid Gland Medullary Cancer, Metastatic Thyroid Gland Medullary Carcinoma",
    "Locally Advanced Urothelial Cancer, Unresectable Urothelial Carcinoma, Metastatic Urothelial Cancer, Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation",
    "Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Advanced Leukemia, Recurrent Leukemia",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer, Stage II Pancreatic Cancer, Unresectable Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Thyroid Gland Papillary Cancer, Stage IVB Differentiated Thyroid Gland Cancer, Stage III Differentiated Thyroid Gland Cancer, Stage III Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Follicular Cancer, Thyroid Gland Follicular Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVA Differentiated Thyroid Gland Cancer, Stage III Thyroid Gland Follicular Cancer, Stage IV Differentiated Thyroid Gland Cancer, Stage IVB Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Follicular Cancer, Stage IVB Thyroid Gland Follicular Cancer, Stage IV Thyroid Gland Papillary Cancer, Unresectable Differentiated Thyroid Gland Carcinoma",
    "Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm in the Brain",
    "Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Unresectable Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma",
    "Atypical Endometrial Hyperplasia",
    "Metastatic Breast Carcinoma, Stage IV Breast Cancer, Invasive Breast Cancer, Stage IV Breast Cancer",
    "Refractory Ewing Sarcoma, Recurrent Ewing Sarcoma, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Stage IV Bladder Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IVA Bladder Cancer, Stage IIIB Lung Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IIIB Bladder Cancer, Stage III Bladder Cancer, Advanced Merkel Cell Carcinoma, Stage IVB Bladder Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Renal Cell Cancer, Stage IVA Lung Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Advanced Bladder Carcinoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Stage IIIB Cutaneous (Skin) Melanoma, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Stage IIIC Lung Cancer, Stage III Lung Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IVB Lung Cancer, Advanced Melanoma, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIID Cutaneous (Skin) Melanoma, Advanced Renal Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Bladder Cancer",
    "Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Lynch Syndrome",
    "Steroid Refractory Graft Versus Host Disease, Acute Graft Versus Host Disease",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Prostate Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Stage III Renal Cell Cancer, Locally Advanced Kidney Carcinoma",
    "Neuroepithelial Neoplasm, Desmoplastic Infantile Ganglioglioma, Pleomorphic Xanthoastrocytoma, Diffuse Astrocytoma, Oligoastrocytoma, Dysembryoplastic Neuroepithelial Tumor, Oligodendroglioma, Angiocentric Glioma, Ganglioglioma, Pilomyxoid Astrocytoma, Tectal Glioma, Dysembryoplastic Neuroepithelial-Like Tumor of the Septum Pellucidum, Central Neurocytoma, Pilocytic Astrocytoma, Diffuse Glioma, Polymorphous Low Grade Neuroepithelial Tumor of the Young, Neuronal and Mixed Neuronal-Glial Tumors, Multinodular and Vacuolated Tumor of the Cerebrum, Extraventricular Neurocytoma, Low Grade Glioma, Myxoid Glioneuronal Tumor, PDGFRA p.K385-Mutant, Desmoplastic Infantile Astrocytoma, Gangliocytoma, Papillary Glioneuronal Tumor, Rosette-Forming Glioneuronal Tumor, Diffuse Leptomeningeal Glioneuronal Tumor, Astrocytic Tumor",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2 Negative Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Hormone Receptor Positive Breast Carcinoma",
    "Refractory Extracranial Malignant Solid Neoplasm, Recurrent Extracranial Malignant Solid Neoplasm",
    "High-Risk Neuroblastoma, Neuroblastoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Stage IB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer",
    "Stage III Renal Pelvis Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Stage III Urethral Cancer, Stage IV Urethral Cancer, Stage III Cutaneous (Skin) Melanoma, Locally Advanced Bladder Carcinoma, Stage IV Lung Cancer, Metastatic Bladder Urothelial Cancer, Stage IIIB Bladder Cancer, Stage III Bladder Cancer, Metastatic Melanoma, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Lung Cancer, Metastatic Urethral Urothelial Cancer, Stage IIIA Bladder Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Metastatic Renal Pelvis Urothelial Cancer, Unresectable Melanoma, Metastatic Ureter Urothelial Cancer, Locally Advanced Renal Pelvis Carcinoma, Metastatic Bladder Carcinoma, Stage IV Bladder Cancer, Locally Advanced Bladder Urothelial Carcinoma, Metastatic Urethral Carcinoma, Stage IIIA Lung Cancer, Malignant Solid Tumor, Stage IV Ureter Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer",
    "Neuroblastoma, High-Risk Neuroblastoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Stage IV Wilms Tumor, Wilms Tumor, Stage III Wilms Tumor, Stage V Wilms Tumor",
    "Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Lung Cancer",
    "Clinical Stage II Merkel Cell Carcinoma AJCC v8, Clinical Stage IIA Merkel Cell Carcinoma AJCC v8, Clinical Stage IIB Merkel Cell Carcinoma AJCC v8, Clinical Stage I Merkel Cell Carcinoma AJCC v8",
    "Stage IV Prostate Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IVB Prostate Cancer, Stage IIIA Prostate Cancer, Prostate Adenocarcinoma, Prostate Cancer, Stage IIC Prostate Cancer, Stage IVA Prostate Cancer, Stage IIIC Prostate Cancer",
    "Leukemia, Hematopoietic and Lymphoid System Neoplasm, COVID-19, Lymphoma, Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia",
    "Refractory Melanoma, Advanced Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Unresectable Melanoma, Recurrent Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage IIA Prostate Cancer, Stage II Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IIIA Breast Cancer, Breast Adenocarcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer, Stage IIIB Breast Cancer",
    "Desmoplastic Small Round Cell Tumor, Recurrent Malignant Solid Tumor, Refractory Neuroblastoma, Primary Central Nervous System Neoplasm, Recurrent Neuroblastoma, Metastatic Malignant Neoplasm to the Central Nervous System, Refractory Malignant Solid Tumor",
    "Recurrent Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Midline Glioma, H3 K27M-Mutant, WHO Grade III Glioma, Recurrent Grade III Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG)",
    "Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "Recurrent Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer, Refractory Non-Small Cell Lung Cancer, Stage IVA Lung Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Undifferentiated Pleomorphic Sarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Breast Cancer, Colorectal (Colon or Rectal) Cancer",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Stage IV Marginal Zone Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Stage III Grade 3 Follicular Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Composite Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Aggressive B-Cell Non-Hodgkin Lymphoma",
    "Locally Advanced Angiosarcoma, Metastatic Angiosarcoma, Recurrent Angiosarcoma",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Thoracic Cavity, Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Abdominal Cavity",
    "Recurrent Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Myelodysplastic Syndrome",
    "Myeloid Leukemia, Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer, Colorectal (Colon or Rectal) Adenocarcinoma, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Refractory Melanoma, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IVA Ovarian Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA1 Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Advanced Melanoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Advanced Endometrial Carcinoma, Stage IVB Ovarian Cancer, Refractory Head and Neck Squamous Cell Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IVA Uterine (including Endometrial) Cancer, Refractory High Grade Ovarian Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Stage IIIB Ovarian Cancer, Chondrosarcoma, Stage IV Ovarian Cancer, Stage IV Uterine (including Endometrial) Cancer, Advanced Malignant Solid Tumor, Advanced Ovarian Clear Cell Adenocarcinoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIC Ovarian Cancer, Refractory Ovarian Clear Cell Adenocarcinoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Prostate Adenocarcinoma, Prostate Cancer",
    "Breast Cancer",
    "Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Locally Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Unresectable Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic HER2-Positive Breast Carcinoma, Invasive Breast Cancer",
    "Colorectal (Colon or Rectal) Cancer",
    "Mediastinal (Thymic) Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Subcutaneous Panniculitis-Like T-Cell Lymphoma, T-Cell Prolymphocytic Leukemia, Angioimmunoblastic T-Cell Lymphoma, Mantle Cell Lymphoma, Nasal Type Extranodal NK/T-Cell Lymphoma, High Grade B-Cell Lymphoma, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Aggressive NK-Cell Leukemia, Lymphocytic Neoplasm, Peripheral T-Cell Lymphoma, Not Otherwise Specified, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Enteropathy-Associated T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Adult T-Cell Leukemia/Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive",
    "Metastatic Skin Squamous Cell Carcinoma, Stage III Skin Cancer, Locally Advanced Skin Squamous Cell Carcinoma, Stage IV Skin Cancer, Unresectable Skin Squamous Cell Carcinoma",
    "Unresectable Pleural Malignant Mesothelioma, Unresectable Peritoneal Malignant Mesothelioma",
    "Prostate Adenocarcinoma, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Stage IV Prostate Cancer, Oligometastatic Prostate Carcinoma",
    "Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Adenocarcinoma, Advanced Adenocarcinoma, Recurrent Malignant Solid Tumor, Metastatic Adenocarcinoma",
    "Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma",
    "HHV8-Positive Multicentric Castleman Disease",
    "Breast Cancer",
    "Hairy Cell Leukemia",
    "Malignant Solid Tumor, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage III Cervical Cancer, Stage IIIB Prostate Cancer, Recurrent Endometrial Carcinoma, Unresectable Lung Carcinoma, Locally Advanced Cervical Carcinoma, Ductal Carcinoma In Situ (DCIS), Metastatic Malignant Neoplasm to the Lung, Invasive Ductal Carcinoma, NOS",
    "Anorexia, Coagulation Disorder, Kaposi Sarcoma, Neuropathy, Primary Effusion Lymphoma, KSHV Inflammatory Cytokine Syndrome",
    "Locally Advanced Soft Tissue Sarcoma, Locally Advanced Ovarian Carcinoma, Stage IIIC Ovarian Cancer, Stage III Ovarian Cancer, Stage III Renal Cell Cancer, Locally Advanced Renal Cell Carcinoma, Stage IIIB Ovarian Cancer, Locally Advanced Thyroid Gland Carcinoma, Stage IIIA Ovarian Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor, Ependymoma, Medulloblastoma, Wilms Tumor, Malignant Glioma, Retinoblastoma, Brain Stem Glioma, Rhabdomyosarcoma, Ewing Sarcoma, Primitive Neuroectodermal Tumor (PNET)",
    "Metastatic Malignant Neoplasm to the Lung, Alveolar Rhabdomyosarcoma, Ganglioneuroblastoma, Metastatic Ewing Sarcoma, Recurrent Neuroblastoma, Metastatic Osteosarcoma, Solid Tumor, Desmoplastic Small Round Cell Tumor, Soft Tissue Sarcoma, Refractory Neuroblastoma, Metastatic Fibrolamellar Carcinoma, Recurrent Fibrolamellar Carcinoma",
    "Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Pancreatic Cancer, Stage III Pancreatic Cancer",
    "Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage I Oropharyngeal Throat Squamous Cell Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Glioblastoma, Gliosarcoma, Giant Cell Glioblastoma, Brain Oligodendroglioma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage III Prostate Cancer, Prostate Adenocarcinoma, Stage IIIC Prostate Cancer, Prostate Ductal Adenocarcinoma, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Hematopoietic and Lymphoid System Neoplasm, Recurrent Follicular Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Lymphoma, Refractory Anaplastic Large Cell Lymphoma",
    "Acute Myeloid Leukemia (AML), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Burkitt Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Mixed Phenotype Acute Leukemia, Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL), Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome, Burkitt Lymphoma, Secondary Acute Myeloid Leukemia (AML)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Lymphoblastic Leukemia (ALL), Malignant Neoplasm",
    "Hematologic and Lymphocytic Disorder, Transplant-Related Disorder, Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid System Neoplasm, Acute Graft Versus Host Disease",
    "Prostate Adenocarcinoma",
    "Stage IIB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma",
    "Triple-Negative Breast Cancer, Invasive Breast Cancer, Hormone-Resistant Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm to the Leptomeninges",
    "Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma",
    "Stage IVB Major Salivary Gland Cancer, Stage IVC Major Salivary Gland Cancer, Metastatic Adenocarcinoma, Stage IV Major Salivary Gland Cancer, Stage IVC Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Poorly Differentiated Thyroid Gland Cancer, Recurrent Melanoma, Recurrent Head and Neck Carcinoma, Recurrent Thyroid Gland Cancer, Recurrent Salivary Gland Cancer, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV Mature T- and NK-Cell Lymphoma, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Stage IV Nasopharyngeal Throat Cancer, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Sarcoma, Recurrent Nasopharyngeal Throat Cancer, Solid Tumor, Stage IVA Major Salivary Gland Cancer, Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Cancer",
    "Recurrent Lung Squamous Cell Carcinoma, Stage IIIA Squamous Cell Lung Cancer, Stage IIIB Squamous Cell Lung Cancer, Stage III Squamous Cell Lung Cancer, Stage IV Squamous Cell Lung Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, Vitamin D Deficiency",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma",
    "Diffuse Midline Glioma, H3 K27M-Mutant, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm",
    "Stage IV Thyroid Gland Medullary Cancer, Stage IVA Thyroid Gland Medullary Cancer, Metastatic Thyroid Gland Medullary Carcinoma, Stage IVB Thyroid Gland Medullary Cancer, Differentiated Thyroid Gland Cancer, Stage IVC Thyroid Gland Medullary Cancer, Refractory Thyroid Gland Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Melanoma",
    "Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer",
    "Adult T-Cell Leukemia/Lymphoma",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "High Grade Ductal Breast Carcinoma In Situ",
    "Inflammatory Breast Cancer, Breast Cancer, Triple-Negative Breast Cancer, Invasive Breast Cancer",
    "Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Infiltrating Bladder Urothelial Carcinoma, Bladder Urothelial Cancer",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Hepatocellular Cancer, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, BCLC Stage A Hepatocellular Cancer",
    "High Grade Cervical Squamous Intraepithelial Neoplasia",
    "Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Nasopharyngeal Throat Keratinizing Squamous Cell Cancer, Stage IVB Nasopharyngeal Throat Keratinizing Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Squamous Cell Cancer of Unknown Primary Origin, Nasal Cavity Squamous Cell Carcinoma, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage III Nasopharyngeal Throat Keratinizing Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, p16-Positive Neoplastic Cells Present, Stage IV Laryngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer",
    "Prostate Adenocarcinoma",
    "Stage IV Renal Cell Cancer, Clear Cell Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Metastatic Chordoma, Recurrent Chordoma",
    "Recurrent Bladder Urothelial Cancer, Stage 0a Bladder Cancer, Stage 0is Bladder Cancer, Stage I Bladder Cancer, Bladder Urothelial Cancer",
    "Triple-Negative Breast Cancer",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Malignant Solid Tumor, Recurrent Triple-Negative Breast Carcinoma, Recurrent Ovarian Cancer, Endometrial Cancer, Recurrent Uterine (Including Endometrial) Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Inflammatory Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer",
    "Stage IV Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Stage IIIB Lung Cancer",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Burkitt Lymphoma, Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, B-Cell Non-Hodgkin Lymphoma, B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Classical Hodgkin Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular Lymphocyte Predominant Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Recurrent Ovarian Clear Cell Adenocarcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer",
    "Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Recurrent Merkel Cell Cancer, Stage IV Merkel Cell Cancer, Unresectable Merkel Cell Carcinoma, Stage IIIB Merkel Cell Carcinoma AJCC v7, Stage III Merkel Cell Cancer, Stage IIIA Merkel Cell Carcinoma AJCC v7",
    "Peritoneal Carcinomatosis, Colorectal (Colon or Rectal) Cancer, Appendix Adenocarcinoma",
    "Metastatic Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma",
    "Prostate Adenocarcinoma",
    "Breast Adenocarcinoma, HER2-Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Ph-Like Acute Lymphoblastic Leukemia, Refractory Ph-Like Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Chronic Myelogenous Leukemia (CML), Refractory Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia (CML), Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Breast Adenocarcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Dedifferentiated Liposarcoma, Metastatic Leiomyosarcoma, Recurrent Leiomyosarcoma, Refractory Liposarcoma, Metastatic Liposarcoma, Recurrent Liposarcoma, Refractory Leiomyosarcoma",
    "Stage III Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIB Non-Small Cell Lung Cancer",
    "Malignant Brain Glioma, Oligodendroglioma, Oligoastrocytoma, Anaplastic Oligodendroglioma, Astrocytoma, Malignant Glioma, Anaplastic Astrocytoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer",
    "Stage II Bladder Squamous Cell Cancer, Stage II Ureter Cancer, Stage III Ureter Cancer, Ureter Adenocarcinoma, Urethral Squamous Cell Cancer, Urethral Urothelial Cancer, Urethral Adenocarcinoma, Stage II Urethral Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Stage II Bladder Adenocarcinoma, Stage III Bladder Adenocarcinoma, Stage IV Bladder Adenocarcinoma, Stage III Bladder Squamous Cell Cancer, Stage IV Bladder Squamous Cell Cancer, Stage II Bladder Urothelial Cancer, Stage III Bladder Urothelial Cancer, Ureter Squamous Cell Carcinoma, Stage IV Bladder Urothelial Cancer, Stage IV Ureter Cancer, Ureter Urothelial Cancer",
    "Oral Cavity Squamous Cell Cancer, Resectable Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Lymphoma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage III Vaginal Cancer, Stage IV Vaginal Cancer, Stage IVA Vaginal Cancer, Stage IVB Vaginal Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Refractory Ovarian Carcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Metastatic Cervical Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Metastatic Endometrial Carcinoma, Unresectable Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Unresectable Fallopian Tube Carcinoma, Unresectable Primary Peritoneal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Cervical Carcinoma, Unresectable Vulvar Carcinoma, Refractory Vulvar Carcinoma, Refractory Vaginal Carcinoma, Malignant Female Reproductive System Neoplasm, Recurrent Cervical Cancer, Recurrent Ovarian Cancer, Refractory Cervical Carcinoma, Recurrent Vulvar Cancer, Unresectable Vaginal Carcinoma, Recurrent Vaginal Cancer",
    "Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Advanced Malignant Solid Tumor",
    "Double-Hit Lymphoma, Triple-Hit Lymphoma, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Composite Lymphoma, Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Adenocarcinoma, HER2-Positive Breast Carcinoma",
    "Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer",
    "Metastatic Colorectal Adenocarcinoma, Locally Advanced Unresectable Colorectal Adenocarcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Double-Hit Lymphoma, Refractory Lymphoma, Recurrent Lymphoma, Clonal Cytopenia of Undetermined Significance, Recurrent Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Recurrent Ovarian Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome",
    "Neuroendocrine Tumor, Metastatic Malignant Neoplasm to the Liver",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Recurrent BRCA-Mutated Ovarian Cancer, Recurrent Ovarian Cancer",
    "Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Palmar-Plantar Erythrodysthesia, Nevoid Basal Cell Cancer Syndrome, Skin Basal Cell Cancer, Medulloblastoma, Macrocephaly",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Marginal Zone Lymphoma, Richter Syndrome, B-Cell Prolymphocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Prostate Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Prostate Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic/Myeloproliferative Disease, Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome, Chronic Myeloproliferative Disease, Severe Aplastic Anemia, Recurrent Multiple Myeloma/Plasma Cell Myeloma, High-Grade Treatment-Related Myeloid Neoplasm, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma",
    "Metastatic Urothelial Cancer, Unresectable Transitional Cell Cancer, Metastatic Transitional Cell Cancer, Advanced Urothelial Cancer, Unresectable Urothelial Carcinoma, Locally Advanced Urothelial Cancer",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Unresectable Pancreatic Cancer, Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma",
    "Rectal Adenocarcinoma, Stage I Rectal Cancer, Stage IIA Rectal Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2 Negative Breast Carcinoma, Recurrent Breast Cancer, Invasive Breast Cancer",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Resistant Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, Prostate Adenocarcinoma, Metastatic Prostate Cancer",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Ovarian Cancer",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Ductal Carcinoma In Situ (DCIS), Stage 0 Breast Cancer, Invasive Ductal Carcinoma, NOS, Stage IIA Breast Cancer, Invasive Lobular Breast Carcinoma, Invasive Breast Papillary Carcinoma, Stage IB Breast Cancer, Stage I Breast Cancer, Medullary Breast Cancer, Stage IA Breast Cancer, Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Breast Cancer",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Ureter Cancer, Locally Advanced Thymic Carcinoma, Metastatic Thymic Carcinoma, Locally Advanced Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Locally Advanced Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Non-Small Cell Lung Cancer, Mesothelioma, Metastatic Squamous Cell Carcinoma, Metastatic Melanoma, Stage III Ureter Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage I Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IB Lung Cancer, Stage IV Lung Cancer",
    "Therapy-Related Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Acute Myeloid Leukemia with Myelodysplasia-Related Changes, High-Grade Treatment-Related Myeloid Neoplasm, Secondary Acute Myeloid Leukemia (AML)",
    "Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage IV Vaginal Cancer, Stage IVA Vaginal Cancer, Stage IVB Vaginal Cancer, Stage IVB Cervical Cancer, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Adenosquamous Carcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Vaginal Squamous Cell Cancer, NOS, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer, Vulvar Squamous Cell Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer",
    "Mucosal Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Melanoma of Unknown Primary, Recurrent Melanoma, Intraocular Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma",
    "Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Infiltrating Cervical Cancer, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IV Cervical Cancer FIGO 2018",
    "Cytomegaloviral Infection",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Lung Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Non-Small Cell Lung Cancer",
    "Recurrent Endometrial Serous Adenocarcinoma, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Uterine Carcinosarcoma",
    "Lung Neuroendocrine Carcinoma, Limited Stage Small Cell Lung Cancer, Refractory Extensive Stage Lung Small Cell Carcinoma, Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Endometrial Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Urothelial Cancer, Metastatic Prostate Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Endometrial Carcinoma",
    "Stage II Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage I Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Advanced Lung Carcinoma, Recurrent Non-Small Cell Lung Cancer, Stage IV Lung Cancer",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Unresectable Malignant Solid Tumor",
    "Stage 0 Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain",
    "Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVA Prostate Cancer",
    "Glioblastoma, Malignant Glioma",
    "Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer in the Soft Tissue, Stage IV Prostate Cancer, Prostate Carcinoma Metastatic in Lymph Node, Stage IVA Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Prostate Carcinoma Metastatic in the Bone",
    "Prostate Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Extensive Stage Small Cell Lung Cancer",
    "Recurrent Endometrial Serous Adenocarcinoma, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Advanced Endometrial Serous Adenocarcinoma",
    "Stage I Lip and Oral Cavity Cancer, Stage II Lip and Oral Cavity Cancer, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I Oropharyngeal (p16-Negative) Throat Cancer, Stage II Hypopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage II Nasal Cavity and Paranasal Sinus Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage II Laryngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Oral Cavity Squamous Cell Cancer, Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer",
    "Lung Neoplasm",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Uveal Melanoma, Metastatic Choroid Melanoma, Metastatic Mucosal Melanoma, Metastatic Melanoma, Unresectable Melanoma",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Tongue Squamous Cell Carcinoma, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Tonsillar Squamous Cell Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Richter Syndrome, Marginal Zone Lymphoma, Diffuse Large B-Cell Lymphoma, Indolent Non-Hodgkin Lymphoma",
    "Refractory Osteosarcoma, Recurrent Osteosarcoma",
    "Stage I Rectal Cancer, Stage II Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Rectal Adenocarcinoma",
    "Grade 1 Follicular Lymphoma, Follicular Lymphoma, Grade 3a Follicular Lymphoma, Marginal Zone Lymphoma, Grade 2 Follicular Lymphoma",
    "RAD51 wt Allele, High Grade Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, High Grade Fallopian Tube Serous Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Refractory Ovarian Carcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Recurrent Ovarian Carcinosarcoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Primary Peritoneal Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Carcinosarcoma, ATM wt Allele, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, BRIP1 wt Allele, Recurrent Ovarian Cancer, Ovarian Endometrioid Adenocarcinoma, PALB2 wt Allele, Ovarian Carcinosarcoma, FANCL wt Allele",
    "Hematopoietic and Lymphoid Cell Neoplasm, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Acute Biphenotypic Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Leukemia of Ambiguous Lineage, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Acute Leukemia, Lymphoblastic Lymphoma",
    "Grade I Meningioma, Grade II Meningioma, Grade III Meningioma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer",
    "Advanced Bile Duct Carcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Refractory Biliary Tract Carcinoma, Metastatic Biliary Tract Carcinoma, Advanced Cholangiocarcinoma, Refractory Gallbladder Carcinoma, Metastatic Gallbladder Carcinoma, Advanced Gallbladder Carcinoma, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer, Gallbladder Adenocarcinoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer",
    "Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Unresectable Inflammatory Breast Carcinoma, Stage IIIC Breast Cancer, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Recurrent Breast Cancer, Stage IV Inflammatory Breast Cancer, Unresectable Breast Carcinoma, Recurrent Breast Inflammatory Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer",
    "Non-Small Cell Lung Cancer",
    "Glioblastoma",
    "Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Unresectable Hepatocellular Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Ovarian Cancer",
    "Diffuse Astrocytoma, Low Grade Glioma, Neuroepithelial Neoplasm, Ganglioglioma, Pilomyxoid Astrocytoma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Visual Pathway Glioma",
    "Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Sarcoma, Metastatic Sarcoma, Advanced Sarcoma, Metastatic Leiomyosarcoma, Metastatic Liposarcoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
    "Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Refractory Marginal Zone Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Marginal Zone Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Malignant Glioma, Diffuse Intrinsic Pontine Glioma",
    "Waldenstrom Macroglobulinemia",
    "Malignant Solid Tumor",
    "Resectable Undifferentiated Pleomorphic Sarcoma",
    "Stage III Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Metastatic Triple-Negative Breast Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma",
    "Metastatic Well Differentiated Neuroendocrine Neoplasm, Unresectable Carcinoid Tumor, Advanced Carcinoid Tumor, Unresectable Well Differentiated Neuroendocrine Neoplasm, Metastatic Carcinoid Tumor",
    "Recurrent Moderate-Severe Chronic Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Colorectal Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Malignant Solid Tumor, Recurrent Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Unresectable Colorectal Adenocarcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer",
    "Recurrent Neuroblastoma, Refractory Neuroblastoma",
    "Unresectable Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Locally Recurrent Skin Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "High-Grade Treatment-Related Myeloid Neoplasm, Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia with Myelodysplasia-Related Changes",
    "Malignant Central Nervous System Neoplasm",
    "Grade II Meningioma, Pituitary Gland Adenoma, Intracranial Neoplasm, Schwannoma, Grade I Meningioma, Grade III Meningioma, Nerve Sheath Neoplasm",
    "Hepatocellular Cancer, Cirrhosis",
    "Metastatic Oral Cavity Squamous Cell Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Stage III Laryngeal Throat Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVA Hypopharyngeal Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Recurrent Paranasal Sinus Squamous Cell Cancer, Stage IVC Hypopharyngeal Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage III Hypopharyngeal Throat Cancer, Salivary Gland Cancer, Stage IVC Laryngeal Throat Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer",
    "Metastatic Colorectal Carcinoma, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Refractory Colorectal Cancer, Recurrent Colon Cancer, Stage IV Colon Cancer",
    "Acute Graft Versus Host Disease, Chronic Graft Versus Host Disease",
    "Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm to the Peritoneum, Metastatic Colorectal Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Appendix Cancer, Stage IVB Appendix Cancer, Stage IVC Appendix Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Gastric Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Appendix Carcinoma, Peritoneal Carcinomatosis, Malignant Uterine Neoplasm, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Ovarian Cancer, Stage IV Appendix Cancer",
    "Metastatic Skin Squamous Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, COVID-19-Associated Acute Respiratory Distress Syndrome",
    "Stage II Gastric (Stomach) Cancer, Malignant Solid Tumor, Stage I Laryngeal Throat Cancer, Stage II Laryngeal Throat Cancer, Stage II Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Infiltrating Bladder Urothelial Carcinoma, Bladder Urothelial Cancer, Laryngeal Throat Squamous Cell Cancer, Mantle Cell Lymphoma, Invasive Breast Cancer, Stage 0 Laryngeal Throat Squamous Cell Cancer, Ductal Carcinoma In Situ (DCIS), Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer",
    "Locally Advanced Malignant Solid Tumor, Stage IV Pancreatic Cancer, Unresectable Malignant Solid Tumor, Metastatic Pancreatic Adenocarcinoma",
    "Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL)",
    "Ependymoma, Recurrent Ependymoma",
    "Stage IV Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Head and Neck Carcinoma of Unknown Primary",
    "Metastatic Malignant Neoplasm to the Lung, Lung Cancer",
    "Colorectal (Colon or Rectal) Adenocarcinoma, Gastric (Stomach) Adenocarcinoma, Esophageal Squamous Cell Cancer, Esophageal Adenocarcinoma, Colon Adenocarcinoma, Malignant Gastrointestinal Neoplasm, Appendix Adenocarcinoma, Small Intestinal Adenocarcinoma, Rectal Adenocarcinoma",
    "Malignant Solid Tumor",
    "Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Early-Stage Breast Cancer, Invasive Breast Cancer, Stage II Breast Cancer",
    "Advanced Leukemia, Recurrent Leukemia, Refractory Lymphoma, Recurrent Lymphoma",
    "Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Primary Peritoneal Endometrioid Adenocarcinoma, Fallopian Tube Transitional Cell Cancer, Stage IVB Ovarian Cancer, Stage IVB Fallopian Tube Cancer, Ovarian Clear Cell Adenocarcinoma, Stage IVA Primary Peritoneal Cancer, Fallopian Tube Serous Neoplasm, Ovarian Transitional Cell Cancer, Stage IV Primary Peritoneal Cancer, Fallopian Tube Clear Cell Adenocarcinoma, Stage IVB Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Carcinoma, Primary Peritoneal Serous Adenocarcinoma, Fallopian Tube Endometrioid Tumor",
    "Stage IIB Cervical Cancer FIGO 2018, Stage IIA2 Cervical Cancer FIGO 2018, Stage IIIC Cervical Cancer FIGO 2018, Stage IIA1 Cervical Cancer FIGO 2018, Locally Advanced Cervical Squamous Cell Carcinoma, Stage IVA Cervical Cancer FIGO 2018, Stage IIIC2 Cervical Cancer FIGO 2018, Stage IIIB Cervical Cancer FIGO 2018, Stage IB3 Cervical Cancer FIGO 2018, Stage II Cervical Cancer FIGO 2018, Stage IIA Cervical Cancer FIGO 2018, Stage III Cervical Cancer FIGO 2018, Stage IIIA Cervical Cancer FIGO 2018, Stage IIIC1 Cervical Cancer FIGO 2018",
    "Multicentric Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Multifocal Breast Cancer, Stage IIIB Breast Cancer, Invasive Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Bilateral Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Triple-Negative Breast Cancer",
    "Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Follicular Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Secondary Central Nervous System Lymphoma, Refractory Follicular Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Extensive Stage Small Cell Lung Cancer, Metastatic Malignant Neoplasm in the Brain",
    "Stage II Major Salivary Gland Cancer, Stage III Major Salivary Gland Cancer, Stage IVA Major Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer",
    "Recurrent Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Chronic Myelogenous Leukemia (CML)",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Myelodysplastic Syndrome, B-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma",
    "Malignant Brain Glioma, Diffuse Intrinsic Pontine Glioma",
    "Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Recurrent Grade 1 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Osteosarcoma, Primitive Neuroectodermal Tumor (PNET), Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Refractory Ewing Sarcoma",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Refractory Plasmablastic Lymphoma, Recurrent Plasmablastic Lymphoma, ALK-Positive Large B-Cell Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Excess Blasts-2",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Stage IV Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Urethral Cancer, Metastatic Ureter Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Urothelial Cancer, Stage IVB Bladder Cancer, Stage IV Bladder Cancer, Metastatic Urethral Urothelial Cancer, Stage IVA Bladder Cancer, Stage IV Renal Pelvis and Ureter Cancer, Metastatic Bladder Urothelial Cancer",
    "Refractory Endometrial Undifferentiated Carcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Adenocarcinoma, Not Otherwise Specified, Refractory Endometrial Carcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Clear Cell Adenocarcinoma",
    "Metastatic Bladder Urothelial Cancer, Locally Advanced Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Urethral Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Locally Advanced Bladder Urothelial Carcinoma",
    "Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Lung Non-Small Cell Carcinoma, Stage II Pancreatic Cancer, Stage IIIA Lung Cancer, Unresectable Pancreatic Ductal Adenocarcinoma, Stage IIA Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Malignant Lung Neoplasm, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IIB Pancreatic Cancer",
    "Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Stage IB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Recurrent Hepatocellular Cancer, Stage I Hepatocellular Cancer, Stage IA Hepatocellular Cancer, Stage II Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer",
    "Refractory Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Stage IVA Prostate Cancer, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Stage I Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVC Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Nasopharyngeal Squamous Cell Carcinoma, Human Papillomavirus-Related Mucosal Head and Neck Squamous Cell Carcinoma, Stage IVA Laryngeal Throat Squamous Cell Cancer, Stage IVC Laryngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer",
    "Tonsillar Cancer, Head and Neck Carcinoma, Malignant Parotid Gland Neoplasm, Tongue Cancer, Maxillary Sinus Carcinoma, Nasal Cavity Cancer, Oral Cavity Cancer",
    "Metastatic Adenoid Cystic Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Digestive System Cancer, Metastatic Malignant Solid Tumor",
    "Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain",
    "Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Malignant Posterior Tongue Neoplasm, Tonsillar Squamous Cell Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Stage IIIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Stage IIC Prostate Cancer, Stage IVA Prostate Cancer, Prostate Cancer",
    "Advanced Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer, Stage IVA Major Salivary Gland Cancer, Recurrent Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer, Metastatic Salivary Gland Carcinoma, Stage IVC Major Salivary Gland Cancer, Stage IV Major Salivary Gland Cancer, Unresectable Salivary Gland Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent B Lymphoblastic Lymphoma",
    "Stage IVB Lip and Oral Cavity Cancer, Advanced Oral Cavity Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Sinonasal Squamous Cell Carcinoma, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Laryngeal Throat Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IVA Lip and Oral Cavity Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III Hypopharyngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVB Hypopharyngeal Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer",
    "Rasmussen Subacute Encephalitis, Autoimmune Disease, Lambert Eaton Myasthenic Syndrome, Multiple Sclerosis, Opsoclonus Myoclonus Syndrome, Myasthenia Gravis, Central Nervous System Vasculitis, Cerebellar Degeneration, Chronic Inflammatory Demyelinating Polyneuropathy, Neuromyelitis Optica, Stiff Person Syndrome, Autoimmune Nervous System Disorder",
    "B-Cell Neoplasm, Multiple Myeloma/Plasma Cell Myeloma, Bone Marrow Failure, Recurrent B-Cell Non-Hodgkin Lymphoma, Anemia, Lymphoproliferative Disorder, Chronic Lymphocytic Leukemia (CLL), Refractory B-Cell Non-Hodgkin Lymphoma",
    "Burkitt Lymphoma, B-Cell Non-Hodgkin Lymphoma, Atypical Burkitt/Burkitt-Like Lymphoma, Burkitt Leukemia, Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IVB Vulvar Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Skin Squamous Cell Cancer, Stage IV Pancreatic Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage IV Anal Canal Cancer, Stage IV Vaginal Cancer, Metastatic Osteosarcoma, Stage IV Ovarian Cancer, Stage IVA Vaginal Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Prostate Cancer, Stage IVA Vulvar Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IV Esophageal Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Rectal Cancer, Stage IVB Vaginal Cancer, Extensive Stage Small Cell Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor",
    "Recurrent Medulloblastoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Ependymoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Grade III Glioma, Recurrent Glioblastoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B Lymphoblastic Lymphoma, Refractory B Lymphoblastic Lymphoma, Stage III B Lymphoblastic Lymphoma, Stage IV B Lymphoblastic Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma",
    "Complex Endometrial Hyperplasia with Atypia, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 1 Endometrial Mucinous Adenocarcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma, B Acute Lymphoblastic Leukemia",
    "Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer",
    "Glioblastoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent EBV-Related Lymphoma, EBV-Related Hodgkin Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Lymphoproliferative Disorder, Recurrent Lymphoproliferative Disorder, EBV-Related Non-Hodgkin Lymphoma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Undifferentiated Carcinoma, Primary Peritoneal Transitional Cell Carcinoma, Primary Peritoneal Clear Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma, Ovarian Clear Cell Adenocarcinoma, Ovarian Seromucinous Carcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Transitional Cell Cancer, Fallopian Tube Carcinosarcoma, Undifferentiated Ovarian Cancer, Ovarian Mucinous Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Cancer, Ovarian Serous Adenocarcinoma, Recurrent Ovarian Cancer, Ovarian Endometrioid Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Ovarian Transitional Cell Cancer, Ovarian Carcinosarcoma",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Early-Stage Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer",
    "Malignant Solid Tumor, Metastatic Malignant Neoplasm to the Central Nervous System, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Osteosarcoma",
    "Recurrent Glioblastoma, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Osteosarcoma, Refractory Rhabdoid Tumor, Refractory Glioblastoma, Recurrent Grade III Glioma, Recurrent Malignant Central Nervous System Neoplasm, Recurrent Malignant Brain Neoplasm, Refractory Malignant Central Nervous System Neoplasm, Refractory Malignant Brain Neoplasm, Refractory WHO Grade III Glioma, Malignant Glioma, Refractory Central Nervous System Neoplasm, Refractory Brain Neoplasm, Recurrent Ewing Sarcoma, Recurrent Brain Neoplasm, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Recurrent Central Nervous System Neoplasm, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma",
    "Metastatic Meningioma, Recurrent Meningioma, Grade III Meningioma, Grade II Meningioma",
    "Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Invasive Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer",
    "Solid Tumor, Metastatic Malignant Neoplasm to the Central Nervous System, Recurrent Brain Neoplasm",
    "Recurrent Hodgkin Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma",
    "Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Stage III Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor, Stage IV Non-Small Cell Lung Cancer",
    "Grade 1 Follicular Lymphoma, Recurrent Follicular Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Advanced Malignant Solid Tumor, Advanced Head and Neck Squamous Cell Cancer, Unresectable Malignant Neoplasm, Metastatic Malignant Neoplasm, Stage IV Pancreatic Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage IIIA Squamous Cell Lung Cancer, Stage IIIB Squamous Cell Lung Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage III Squamous Cell Lung Cancer, Stage IIB Pancreatic Cancer, Stage IV Squamous Cell Lung Cancer, Stage IIA Pancreatic Cancer",
    "Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Non-Hodgkin Lymphoma, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent Mycosis Fungoides and Sezary Syndrome",
    "Stage IV Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Unresectable Digestive System Adenocarcinoma, Unresectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Unresectable Hepatocellular Cancer, Unresectable Pancreatic Cancer, Colorectal (Colon or Rectal) Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IV Pancreatic Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Recurrent Pancreatic Cancer, Stage III Pancreatic Cancer, Small Intestinal Adenocarcinoma, Recurrent Small Intestinal Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Unresectable Small Intestinal Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Small Intestinal Cancer, Stage IIIB Small Intestinal Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer, Stage IV Small Intestinal Cancer, Stage III Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma, Stage III Small Intestinal Cancer",
    "Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer, Bronchioloalveolar Carcinoma, Neuroendocrine Cancer, Lung Atypical Carcinoid Tumor, Lung Neuroendocrine Neoplasm, Recurrent Lung Large Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer, Stage I Lung Cancer",
    "Angiosarcoma, Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Undifferentiated Pleomorphic Sarcoma, Soft Tissue Sarcoma, Epithelioid Sarcoma, Fibrosarcoma",
    "Unresectable Breast Carcinoma, Stage IV Breast Cancer, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer",
    "Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Resectable Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "High Grade Vulvar Squamous Intraepithelial Lesion, Cervical Squamous Cell Carcinoma In Situ",
    "Recurrent Small Lymphocytic Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory B-Cell Non-Hodgkin Lymphoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Untreated Acute Lymphoblastic Leukemia (ALL)",
    "Metastatic Biliary Tract Carcinoma, Stage IV Pancreatic Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Digestive System Neoplasm, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Carcinoma",
    "Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer",
    "Secondary Amyloidosis, Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Locally Advanced Unresectable Colorectal Adenocarcinoma, Locally Advanced Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Advanced Malignant Digestive System Neoplasm, Unresectable Cholangiocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm to the Central Nervous System, HER2-Positive Breast Carcinoma",
    "Stage IV Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage 0 Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Paranasal Sinus Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Nasopharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Unresectable Oropharyngeal Squamous Cell Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Squamous Cell Cancer of Unknown Primary Origin, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Nasopharyngeal Throat Cancer",
    "Myelodysplastic Syndrome, Hematopoietic and Lymphoid System Neoplasm, Chronic Myeloproliferative Disease, Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Intrahepatic Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Extrahepatic (Distal) Bile Duct Cancer, Stage IIIA Extrahepatic (Distal) Bile Duct Cancer, Stage IIIB Extrahepatic (Distal) Bile Duct Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Locally Advanced Bile Duct Cancer, Metastatic Bile Duct Carcinoma, Unresectable Hepatocellular Cancer",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Locally Advanced Lung Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer",
    "Recurrent Endometrial Serous Adenocarcinoma, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Carcinosarcoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Carcinosarcoma, Refractory Endometrial Clear Cell Adenocarcinoma",
    "Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Ph-Like Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia",
    "Recurrent Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer",
    "Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Anaplastic Large Cell Lymphoma, Recurrent Follicular Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Refractory Mycosis Fungoides, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Enteropathy-Associated T-Cell Lymphoma, Recurrent Mycosis Fungoides",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Lung, Colorectal (Colon or Rectal) Adenocarcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Locally Advanced Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer",
    "Metastatic Digestive System Cancer, Metastatic Ovarian Carcinoma",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Double-Hit Lymphoma, Triple-Hit Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Stage I Diffuse Large B-Cell Lymphoma, Stage II Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Castration-Sensitive Prostate Carcinoma, Prostate Adenocarcinoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Triple-Negative Breast Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostate Cancer",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Ovarian Cancer",
    "Refractory Pancreatic Neuroendocrine Cancer, Metastatic Pancreatic Neuroendocrine Cancer, Unresectable Pancreatic Neuroendocrine Cancer, Locally Advanced Pancreatic Neuroendocrine Carcinoma, Locally Advanced Digestive System Neuroendocrine Carcinoma, Unresectable Digestive System Neuroendocrine Carcinoma, Metastatic Digestive System Neuroendocrine Carcinoma, Refractory Digestive System Neuroendocrine Carcinoma",
    "Unresectable Esophageal Cancer, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Lung Carcinoma, Refractory Breast Cancer, Refractory Colorectal Cancer, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Refractory Head and Neck Squamous Cell Cancer, Refractory Bladder Cancer, Advanced Lung Carcinoma, Unresectable Lung Carcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Advanced Esophageal Carcinoma, Refractory Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, Unresectable Bladder Carcinoma, Advanced Bladder Carcinoma, Refractory Esophageal Carcinoma, Unresectable Salivary Gland Carcinoma, Refractory Salivary Gland Carcinoma, Advanced Salivary Gland Carcinoma, Malignant Salivary Gland Tumor",
    "Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Indolent Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma",
    "Malignant Gastrointestinal Neoplasm",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Metastatic Prostate Cancer",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage I Pleural Malignant Mesothelioma, Stage IB Pleural Malignant Mesothelioma, Stage II Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IA Pleural Malignant Mesothelioma, Resectable Malignant Pleural Mesothelioma",
    "Low Grade Glioma, Recurrent Glioma",
    "Metastatic Salivary Gland Carcinoma, Locally Advanced Salivary Gland Carcinoma, Recurrent Salivary Gland Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unresectable Breast Carcinoma, Advanced Breast Carcinoma, Hormone Receptor Negative Breast Carcinoma, HER2 Negative Breast Carcinoma, Triple-Negative Breast Cancer",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Ductal Carcinoma In Situ (DCIS), Breast Fibrocystic Change, Lobular Carcinoma In Situ (LCIS), Triple-Negative Breast Cancer, Invasive Breast Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer",
    "Diffuse Large B-Cell Lymphoma Activated B-Cell Type, High Grade B-Cell Lymphoma, Not Otherwise Specified",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Unresectable Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Urothelial Cancer, Metastatic Melanoma",
    "Adenovirus Infection, BK Virus Infection, JC Virus Infection, Recurrent Adenovirus Infection, Recurrent Epstein-Barr Virus Infection, Hematopoietic and Lymphoid Cell Neoplasm, EBV-Related Lymphoma, Viral Infection, Epstein-Barr Virus Infection, Cytomegaloviral Infection",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Invasive Breast Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic/Myeloproliferative Disease, Myeloid Sarcoma, Hematopoietic and Lymphoid System Neoplasm",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Breast Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Advanced Cutaneous Melanoma",
    "Stage IIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Chronic Graft Versus Host Disease, Fasciitis",
    "Stage II Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Rectal Adenocarcinoma",
    "Recurrent High-Grade B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Non-Hodgkin Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Anaplastic Astrocytoma, IDH-Wildtype, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm to the Leptomeninges, Glioblastoma, IDH-Wildtype, Metastatic Malignant Neoplasm to the Central Nervous System",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, High-Grade Treatment-Related Myeloid Neoplasm",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer",
    "Waldenstrom Macroglobulinemia",
    "Refractory Anaplastic Large Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Positive, Anaplastic Large Cell Lymphoma, ALK-Negative, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Colitis, Metastatic Malignant Neoplasm in the Brain, Stage IIID Cutaneous (Skin) Melanoma",
    "Stage III Skin Cancer, Recurrent Skin Squamous Cell Carcinoma, Resectable Skin Squamous Cell Carcinoma, Stage I Skin Cancer, Stage II Skin Cancer",
    "Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Cancer",
    "Stage II Diffuse Large B-Cell Lymphoma, Double-Hit Lymphoma, Triple-Hit Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Stage IV Follicular Lymphoma, Stage II Marginal Zone Lymphoma, Stage IV Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage II Follicular Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Follicular Lymphoma",
    "Limited Stage Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Unresectable Osteosarcoma, Refractory Osteosarcoma, Metastatic Malignant Neoplasm to the Lung, Recurrent Osteosarcoma",
    "Recurrent Central Nervous System Lymphoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, Pneumonia, Severe Acute Respiratory Syndrome",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer",
    "Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer",
    "Recurrent Hemophagocytic Lymphohistiocytosis, Refractory Hemophagocytic Lymphohistiocytosis, Hemophagocytic Lymphohistiocytosis, Primary Hemophagocytic Lymphohistiocytosis",
    "Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage III Retroperitoneal Sarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage IV Retroperitoneal Sarcoma, Refractory Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Unresectable Soft Tissue Sarcoma",
    "Endometriosis, Pelvic Inflammatory Disease, Endometrial Cancer, Cervical Cancer",
    "Glioblastoma, IDH-Wildtype, Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Glioma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma, Sarcomatoid Renal Cell Cancer, Refractory Clear Cell Renal Cell Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain, Lung Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Endometrial Clear Cell Adenocarcinoma, Endometrial Cancer, Endometrial Serous Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Uterine Corpus Carcinosarcoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIC Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm to the Leptomeninges",
    "Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Recurrent Salivary Gland Cancer, Stage IV Major Salivary Gland Cancer, Stage IVA Major Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer, Stage IVC Major Salivary Gland Cancer, Metastatic Salivary Gland Carcinoma",
    "Refractory Classical Hodgkin Lymphoma, Recurrent Classical Hodgkin Lymphoma",
    "Stage IVB Ovarian Cancer, Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Malignant Central Nervous System Neoplasm, Stage IV Breast Cancer, Metastatic Malignant Neoplasm to the Central Nervous System, Metastatic Ovarian Carcinoma, Metastatic Triple-Negative Breast Carcinoma",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer",
    "Dyskeratosis Congenita, X-Linked Dyskeratosis Congenita, Revesz Syndrome, Telomere Syndrome, Severe Aplastic Anemia",
    "Metastatic Rhabdomyosarcoma, Recurrent Ewing Sarcoma, Recurrent Rhabdomyosarcoma, Metastatic Ewing Sarcoma",
    "Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage IV Urethral Cancer, Refractory Urothelial Carcinoma, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Unresectable Urothelial Carcinoma, Locally Advanced Urothelial Cancer, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Metastatic Urothelial Cancer, Stage III Urethral Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer",
    "Spindle Cell Sarcoma, Metastatic Osteosarcoma, Recurrent Neuroblastoma, Stage 4 Neuroblastoma, Desmoplastic Small Round Cell Tumor, Recurrent Osteosarcoma, Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Lobular Carcinoma In Situ (LCIS), Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer",
    "Metastatic Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Stage IV Breast Cancer, Metastatic Breast Cancer in the Bone, Triple-Negative Breast Cancer",
    "Castration-Resistant Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer, Metastatic Prostate Cancer",
    "Recurrent Visual Pathway Glioma, Refractory Visual Pathway Glioma, Pineal Region Neoplasm, Recurrent Brain Neoplasm, Refractory Brain Neoplasm, Extracranial Solid Tumor, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Primary Cutaneous CD30-Positive T-Cell Lymphoproliferative Disorder, Stage IB Mycosis Fungoides and Sezary Syndrome, Stage II Mycosis Fungoides and Sezary Syndrome, Stage IIA Mycosis Fungoides and Sezary Syndrome, Stage IIB Mycosis Fungoides and Sezary Syndrome, Stage III Mycosis Fungoides and Sezary Syndrome, Stage IIIA Mycosis Fungoides and Sezary Syndrome, Stage IIIB Mycosis Fungoides and Sezary Syndrome, Stage IVA Mycosis Fungoides and Sezary Syndrome, Stage IVB Mycosis Fungoides and Sezary Syndrome, Stage IV Mycosis Fungoides and Sezary Syndrome, Lymphomatoid Papulosis, Primary Cutaneous Anaplastic Large Cell Lymphoma",
    "Refractory Classical Hodgkin Lymphoma, Recurrent Classical Hodgkin Lymphoma",
    "Stage IB Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma, Gastric (Stomach) Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer",
    "Stage IA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer",
    "Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Breast Adenocarcinoma, Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage IV Inflammatory Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer, Stage III Breast Cancer",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Stage IVB Uterine (including Endometrial) Cancer, Refractory Endometrial Carcinoma",
    "Richter Syndrome, Small Lymphocytic Lymphoma, Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Stage IV Non-Small Cell Lung Cancer",
    "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Advanced Sarcomatoid Renal Cell Carcinoma, Clear Cell Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Gastric (Stomach) Adenocarcinoma, Stage IB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer",
    "Lymphomatous Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, Acute Adult T-Cell Leukemia/Lymphoma, HTLV-1 Infection",
    "Nasopharyngeal-Type Undifferentiated Carcinoma, Stage IVC Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Nasopharyngeal Throat Nonkeratinizing Cancer, Stage II Undifferentiated Nasopharyngeal Throat Cancer, Stage III Undifferentiated Nasopharyngeal Throat Cancer, Stage IV Undifferentiated Nasopharyngeal Throat Cancer, Stage III Nasopharyngeal Throat Cancer, Stage II Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer",
    "Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer",
    "Recurrent Leukemia, Advanced Leukemia",
    "Metastatic Malignant Neoplasm to the Liver, Resectable Pancreatic Cancer, Colorectal (Colon or Rectal) Adenocarcinoma, Stage I Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Pancreatic Adenocarcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIA Pancreatic Cancer, Stage IB Pancreatic Cancer",
    "EGFR Exon 19 Deletion Mutation, Stage IV Non-Small Cell Lung Cancer, EGFR NP_005219.2:p.L858R",
    "Stage IA Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma, Glioblastoma, IDH-Mutant, Secondary Glioblastoma",
    "Recurrent Grade III Glioma, Recurrent Glioblastoma, Recurrent Grade II Glioma",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer",
    "ENSAT Stage I Adrenal Cortex Cancer, ENSAT Stage II Adrenal Cortex Cancer, ENSAT Stage III Adrenal Cortex Cancer",
    "Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Cancer, Stage II Pancreatic Cancer",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma",
    "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Intravascular Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Unclassifiable",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid System Disorder, Cytomegaloviral Infection",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML), Acute Biphenotypic Leukemia, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Excess Blasts-2, Mixed Phenotype Acute Leukemia, Acute Undifferentiated Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Leukemia of Ambiguous Lineage",
    "BCR-JAK2 Fusion in Hematologic Malignancies, Hypereosinophilic Syndrome, Chronic Eosinophilic Leukemia, Myeloid/Lymphoid Neoplasms with PCM1-JAK2",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Cancer",
    "Mantle Cell Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Lymphoblastic Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma",
    "Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "Metastatic Bile Duct Carcinoma, Fanconi Anemia Complementation Group Gene Mutation, Bile Duct Adenocarcinoma, PTEN Gene Deletion",
    "Stage 0 Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Recurrent Cervical Cancer",
    "Metastatic Cholangiocarcinoma, Advanced Cholangiocarcinoma, Unresectable Cholangiocarcinoma",
    "Hepatocellular Malignant Neoplasm, Not Otherwise Specified, Refractory Hepatocellular Carcinoma, Recurrent Hepatocellular Cancer",
    "Stage II Vulvar Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IVA Vulvar Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Intrahepatic Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage III Extrahepatic (Distal) Bile Duct Cancer, Stage IIIA Extrahepatic (Distal) Bile Duct Cancer, Stage IIIB Extrahepatic (Distal) Bile Duct Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Biliary Tract Carcinoma, Metastatic Gallbladder Carcinoma, Unresectable Liver and Intrahepatic Bile Duct Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Unresectable Gallbladder Cancer, Unresectable Extrahepatic (Distal) Bile Duct Cancer",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Invasive Ductal Carcinoma, NOS",
    "Stage I Lip and Oral Cavity Cancer, Stage II Lip and Oral Cavity Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage I Nasopharyngeal Throat Cancer, Stage II Nasopharyngeal Throat Cancer, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage I Hypopharyngeal Throat Cancer, Stage II Hypopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage I Laryngeal Throat Cancer, Stage II Laryngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Head and Neck Squamous Cell Carcinoma, Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Oral Cavity Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma",
    "Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Adenosquamous Lung Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Pancreatic Adenocarcinoma",
    "Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Unclassified Renal Cell Carcinoma, Collecting Duct Carcinoma",
    "Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Advanced Malignant Solid Tumor, Stage IV Breast Cancer",
    "Acute Promyelocytic Leukemia with PML-RARA",
    "Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",
    "Malignant Female Reproductive System Neoplasm, Stage IB Vaginal Cancer, Vulvar Adenocarcinoma, Stage III Vaginal Cancer, Stage IB Cervical Cancer, Stage IIIB Vulvar Cancer, Low Grade Vaginal Intraepithelial Neoplasia, Stage IV Cervical Cancer, Vaginal Adenocarcinoma, Stage IVA Vaginal Cancer, Stage IA Vulvar Cancer, Stage IA1 Cervical Cancer, High Grade Cervical Squamous Intraepithelial Neoplasia, Stage IIA1 Cervical Cancer, Stage IA Cervical Cancer, Stage IIA Vaginal Cancer, Cervical Squamous Cell Cancer, Stage IVA Cervical Cancer, Stage IVA Vulvar Cancer, Early Invasive Cervical Squamous Cell Carcinoma, Stage IIIC Vulvar Cancer, Vulvar Squamous Cell Cancer, Stage IIA Cervical Cancer, Stage I Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IA2 Cervical Cancer, Cervical Intraepithelial Neoplasia, Stage IB2 Cervical Cancer, Stage II Vulvar Cancer, Stage IV Vaginal Cancer, Stage IIB Vaginal Cancer, Cervical Adenocarcinoma In Situ, Stage II Cervical Cancer, Stage IIA2 Cervical Cancer, Stage I Vaginal Cancer, Early Invasive Cervical Adenocarcinoma, Vulvar Intraepithelial Neoplasia, Endocervical Cancer, Stage IIIB Cervical Cancer, Stage II Vaginal Cancer, Stage III Cervical Cancer, High Grade Vulvar Squamous Intraepithelial Lesion, Stage IA Vaginal Cancer, Stage IIB Cervical Cancer, Stage III Vulvar Cancer, Cervical Squamous Intraepithelial Neoplasia, Vulvar Squamous Intraepithelial Lesion, HPV-Associated, Stage IVB Vulvar Cancer, High Grade Vaginal Intraepithelial Neoplasia, Stage IB1 Cervical Cancer, Stage IV Vulvar Cancer, Stage IVB Vaginal Cancer, Stage I Cervical Cancer, Stage IVB Cervical Cancer, Stage IIIA Cervical Cancer, Stage IB Vulvar Cancer",
    "Recurrent Malignant Neoplasm, Metastatic Malignant Neoplasm",
    "Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unresectable Melanoma, Metastatic Renal Cell Cancer, Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Primary Peritoneal Cancer, Ovarian Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Visual Pathway Glioma, Refractory Visual Pathway Glioma, Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Recurrent Neuroblastoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Diffuse Intrinsic Pontine Glioma",
    "Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer, Stage IIA Breast Cancer",
    "Recurrent Endometrial Carcinoma, Recurrent Uterine (Including Endometrial) Cancer",
    "Recurrent Glioblastoma, Astrocytoma",
    "Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Recurrent Prostate Adenocarcinoma, Prostate Adenocarcinoma, Stage IIA Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain, Intracranial Neoplasm",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Mantle Cell Lymphoma",
    "Histiocytic Sarcoma, Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Plasmablastic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Aggressive Non-Hodgkin Lymphoma, Follicular Dendritic Cell Sarcoma, Interdigitating Dendritic Cell Sarcoma, Histiocytic and Dendritic Cell Neoplasm",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, High-Grade Treatment-Related Myeloid Neoplasm, Acute Myeloid Leukemia with Myelodysplasia-Related Changes",
    "Small Cell Carcinoma, Small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Metastatic Malignant Neoplasm in the Brain",
    "Stage IV Lung Cancer, Non-Small Cell Lung Cancer, Lung Adenocarcinoma",
    "Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Ocular Melanoma",
    "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Gastric (Stomach) Squamous Cell Cancer, Recurrent Esophageal Adenocarcinoma, Recurrent Esophageal Squamous Cell Cancer",
    "Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer",
    "Hematopoietic and Lymphoid System Disorder, Bronchiolitis Obliterans, Hematopoietic and Lymphoid System Neoplasm",
    "Chronic Myelomonocytic Leukemia (CMML)",
    "Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Triple-Negative Breast Cancer",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm in the Viscera, Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostate Cancer",
    "Osteosarcoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unresectable Breast Carcinoma, Recurrent Breast Cancer, Invasive Breast Cancer, Triple-Negative Breast Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Unresectable Colorectal Carcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Recurrent Colon Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Advanced Colorectal Carcinoma, Unresectable Colorectal Carcinoma",
    "WHO Grade III Glioma, Recurrent Grade II Glioma, Grade II Glioma, Recurrent Grade III Glioma, Glioblastoma, Recurrent Glioblastoma",
    "Unresectable Leiomyosarcoma, Stage III Uterine Corpus Leiomyosarcoma, Stage IIIA Uterine Corpus Leiomyosarcoma, Stage IIIB Uterine Corpus Leiomyosarcoma, Stage IIIC Uterine Corpus Leiomyosarcoma, Stage IV Uterine Corpus Leiomyosarcoma, Stage IVA Uterine Corpus Leiomyosarcoma, Stage IVB Uterine Corpus Leiomyosarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Leiomyosarcoma",
    "Ependymoma, Glioma, Meningioma, Schwannoma, Neurofibroma, Neurofibromatosis Type 2, Acoustic Schwannoma",
    "Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Recurrent Pancreatic Cancer",
    "Refractory Malignant Solid Tumor, Recurrent Rhabdoid Tumor, Refractory Rhabdoid Tumor, Recurrent Malignant Solid Tumor, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Chordoma, Refractory Chordoma, Refractory Epithelioid Sarcoma, Refractory Atypical Teratoid/Rhabdoid Tumor, Recurrent Dedifferentiated Chordoma, Refractory Dedifferentiated Chordoma, Recurrent Rhabdoid Tumor of the Kidney, Refractory Rhabdoid Tumor of the Kidney, Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Epithelioid Sarcoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Multiple Myeloma/Plasma Cell Myeloma, Plasmacytoma",
    "Recurrent Grade II Glioma",
    "Endometrial Serous Adenocarcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage I Uterine (including Endometrial) Cancer, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Grade 3 Endometrial Endometrioid Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Uterine Corpus Carcinosarcoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Papillary Squamous Cell Carcinoma, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Floor of Mouth Basaloid Squamous Cell Carcinoma, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Basaloid Squamous Cell Carcinoma",
    "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Malignant Glioma",
    "Stage IVB Hypopharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage III Hypopharyngeal Throat Cancer, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Resectable Head and Neck Squamous Cell Cancer, Stage III Lip and Oral Cavity Cancer, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Stage IVB Lip and Oral Cavity Cancer, Stage III Nasal Cavity and Paranasal Sinus Cancer, Locally Advanced Laryngeal Squamous Cell Carcinoma, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Stage IVA Laryngeal Throat Cancer, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage IVA Lip and Oral Cavity Cancer, Stage III Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IVB Laryngeal Throat Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Nasal Cavity Squamous Cell Carcinoma, Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Resectable Oropharyngeal Squamous Cell Carcinoma, Recurrent Hypopharyngeal Throat Squamous Cell Cancer",
    "Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer, Early-Stage Breast Cancer, Stage IA Breast Cancer",
    "Recurrent Anal Canal Cancer, Recurrent Rectal Cancer",
    "Hormone-Resistant Prostate Cancer, Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer",
    "Triple-Negative Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer",
    "B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Mixed Phenotype Acute Leukemia, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma",
    "Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Unilateral Breast Cancer, HER2-Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Bilateral Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Multifocal Breast Cancer, Stage IIIC Breast Cancer, Multicentric Breast Cancer",
    "Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Breast Adenocarcinoma",
    "Stage IV Breast Cancer, Metastatic Breast Carcinoma, Stage IV Breast Cancer, HER2-Positive Breast Carcinoma",
    "Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma",
    "Metastatic Renal Cell Cancer, Renal Cell Cancer Associated with Xp11.2 Translocations/TFE3 Gene Fusions, Unclassified Renal Cell Cancer, Sarcomatoid Renal Cell Cancer, Chromophobe Renal Cell Cancer, Papillary Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "B-Cell Prolymphocytic Leukemia, Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL), Anemia",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Graft Versus Host Disease, Fasciitis",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Undifferentiated Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Mixed Phenotype Acute Leukemia, Lymphoma, Hematopoietic and Lymphoid System Neoplasm, Hepatoblastoma, Rhabdoid Tumor, Extrarenal Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Retinoblastoma, Rhabdoid Tumor of the Kidney",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer",
    "Malignant Lung Neoplasm",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma, Resectable Glioblastoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIA Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2-Positive Breast Carcinoma, Bilateral Breast Cancer, Invasive Breast Cancer",
    "Invasive Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer",
    "Metastatic Malignant Neoplasm in the Brain",
    "Limited Stage Small Cell Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Colorectal Carcinoma, Metastatic Appendix Carcinoma, Metastatic Malignant Neoplasm to the Peritoneum, Stage IVA Appendix Cancer, Stage IVB Appendix Cancer, Stage IVC Appendix Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Ewing Sarcoma",
    "Refractory Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma, Central Nervous System Lymphoma, Recurrent Central Nervous System Lymphoma",
    "Advanced Malignant Solid Tumor, Lung Cancer, Bladder Cancer, Malignant Urinary System Neoplasm",
    "Locally Advanced Breast Adenocarcinoma, Breast Adenocarcinoma, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Adenocarcinoma",
    "Metastatic Breast Carcinoma, Stage IV Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Plasmacytoma, Renal Failure, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage I Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma, Stage IA Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Stage IB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma",
    "Recurrent T-Cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia, Recurrent T-Cell Large Granular Lymphocyte Leukemia, Refractory T-Cell Large Granular Lymphocyte Leukemia, Leukemia, Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage IB Mycosis Fungoides and Sezary Syndrome, Stage II Mycosis Fungoides and Sezary Syndrome, Stage III Mycosis Fungoides and Sezary Syndrome, Stage IV Mycosis Fungoides and Sezary Syndrome, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Recurrent Sarcoma, Metastatic Sarcoma, Locally Advanced Sarcoma, Epithelioid Sarcoma, Undifferentiated Pleomorphic Sarcoma, Cutaneous Angiosarcoma, Myxofibrosarcoma, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma",
    "Nongerminomatous Germ Cell Tumor, Refractory Malignant Germ Cell Tumor, Recurrent Germ Cell Tumor, Dysgerminoma, Germinoma, Malignant Intracranial Germ Cell Tumor, Pineal Region Germ Cell Tumor, Seminoma",
    "Anaplastic Pleomorphic Xanthoastrocytoma, Embryonal Tumor with Multilayered Rosettes, Not Otherwise Specified, Chordoma, Ependymoma, Medulloblastoma, Neuroblastoma, Choroid Plexus Papilloma, Ganglioneuroblastoma, Gliosarcoma, Anaplastic (Malignant) Meningioma, Gliomatosis Cerebri, Pleomorphic Xanthoastrocytoma, Medulloepithelioma, Choroid Plexus Cancer, Atypical Meningioma, Brain Sarcoma, Atypical Choroid Plexus Papilloma, Atypical Teratoid/Rhabdoid Tumor, Pineocytoma, Pineal Parenchymal Tumor of Intermediate Differentiation, Central Nervous System Embryonal Neoplasm, Brain Stem Glioma, Papillary Tumor of the Pineal Region, Pineoblastoma",
    "Uterine Corpus High Grade Endometrial Stromal Sarcoma, Fallopian Tube Carcinosarcoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Uterine Corpus Leiomyosarcoma, Endometrial Clear Cell Adenocarcinoma, Recurrent Uterine Corpus Sarcoma, Stage IVA Uterine Sarcoma, Stage IVB Uterine Sarcoma, Stage IV Uterine (including Endometrial) Cancer, Uterine Corpus Undifferentiated Sarcoma, Recurrent Uterine (Including Endometrial) Cancer, Stage IV Uterine Sarcoma, Uterine Corpus Carcinosarcoma, Ovarian Carcinosarcoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma",
    "Head and Neck Squamous Cell Carcinoma, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Refractory Malignant Germ Cell Tumor, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage III Adrenal Cortex Cancer, Stage IV Adrenal Cortex Cancer, Unresectable Adrenal Cortex Carcinoma, Metastatic Bladder Carcinoma, Metastatic Adrenal Cortex Carcinoma, Advanced Prostate Carcinoma, Metastatic Penile Carcinoma, Neuroendocrine Cancer, Small Cell Carcinoma, Metastatic Prostate Cancer",
    "Endometrial Serous Adenocarcinoma, FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Grade 3 Endometrial Endometrioid Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Uterine Sarcoma, Endometrial Clear Cell Adenocarcinoma, Stage I Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Uterine Corpus Carcinosarcoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Bladder Urothelial Cancer, Stage I Bladder Cancer, Stage I Bladder Cancer with Carcinoma In Situ",
    "Stage II Renal Pelvis Cancer, Stage II Ureter Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Bladder Urothelial Cancer, Ureter Urothelial Cancer, Renal Pelvis Urothelial Cancer",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma",
    "Metastatic Urothelial Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Central Nervous System Lymphoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer, Thoracic Neoplasm, Thymic Carcinoma, Refractory Lung Small Cell Carcinoma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Myelogenous Leukemia (CML)",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Advanced Renal Cell Carcinoma",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Cancer, Invasive Breast Cancer",
    "Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified, Recurrent Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Transitional Cell Carcinoma, Recurrent Endometrial Mucinous Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Squamous Cell Carcinoma",
    "Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Secondary Central Nervous System Lymphoma, Diffuse Large B-Cell Lymphoma, Central Nervous System Lymphoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Colon Adenocarcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Biochemically Recurrent Prostate Carcinoma, Non-Metastatic Prostate Carcinoma",
    "Malignant Solid Tumor, Prostate Cancer, Breast Cancer, Lung Cancer, Endometrial Cancer, Early-Stage Breast Cancer",
    "Malignant Solid Tumor",
    "Recurrent Small Cell Lung Cancer",
    "Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Low Grade Ovarian Serous Adenocarcinoma, Recurrent Malignant Ovarian Granulosa Cell Tumor",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm",
    "Refractory Pleural Malignant Mesothelioma, Pleural Malignant Mesothelioma",
    "Unresectable Pituitary Gland Carcinoma, Pituitary Gland Adenoma, Pituitary Gland Cancer",
    "Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Succinate Dehydrogenase-Deficient Renal Cell Carcinoma, Metastatic Kidney Medullary Carcinoma, Fumarate Hydratase-Deficient Renal Cell Carcinoma, Hereditary Clear Cell Renal Cell Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Refractory Endometrial Serous Adenocarcinoma, Refractory Endometrial Mixed Cell Adenocarcinoma, Refractory Endometrial Clear Cell Adenocarcinoma, Refractory Endometrial Carcinosarcoma, Recurrent Endometrial Dedifferentiated Carcinoma, Recurrent Endometrial Squamous Cell Carcinoma, Recurrent Endometrial Transitional Cell Carcinoma, Refractory Endometrial Dedifferentiated Carcinoma, Refractory Endometrial Squamous Cell Carcinoma, Refractory Endometrial Transitional Cell Carcinoma, Refractory Endometrial Mucinous Adenocarcinoma, Recurrent Endometrial Mucinous Adenocarcinoma, Refractory Endometrial Undifferentiated Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Squamous Cell Carcinoma",
    "Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Metastatic Prostatic Adenocarcinoma",
    "Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Pancreatic Adenocarcinoma",
    "Resectable Malignant Pleural Mesothelioma",
    "Locally Advanced Malignant Solid Tumor",
    "Solitary Plasmacytoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Plasmacytoma",
    "Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain, Metastatic Malignant Neoplasm to the Leptomeninges, Metastatic Malignant Neoplasm to the Spine",
    "Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Metastatic Thyroid Gland Anaplastic Carcinoma, Refractory Thyroid Gland Anaplastic Carcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma",
    "Breast Cancer",
    "Resectable Soft Tissue Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Metastatic Sarcoma, Locally Advanced Sarcoma, Sarcoma of the Extremity",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma",
    "Malignant Solid Tumor, Metastatic Malignant Neoplasm to the Leptomeninges",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Central Nervous System Lymphoma",
    "Marginal Zone Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Small Intestinal Mucosa-Associated Lymphoid Tissue Lymphoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Locally Advanced Unresectable Colorectal Adenocarcinoma",
    "Stage IV Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Follicular Cancer, Stage IVA Thyroid Gland Follicular Cancer, Stage IVB Thyroid Gland Follicular Cancer, Recurrent Thyroid Gland Papillary Carcinoma, Recurrent Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Poorly Differentiated Thyroid Gland Carcinoma, Thyroid Gland Papillary Cancer, Thyroid Gland Follicular Cancer, Poorly Differentiated Thyroid Gland Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer",
    "Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Hodgkin Lymphoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Refractory Endometrial Carcinosarcoma, Advanced Endometrial Carcinosarcoma, Advanced Endometrial Carcinoma",
    "Stage III Differentiated Thyroid Gland Cancer, Stage IV Differentiated Thyroid Gland Cancer, Stage IVA Differentiated Thyroid Gland Cancer, Stage IVB Differentiated Thyroid Gland Cancer, Stage III Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Stage III Thyroid Gland Follicular Cancer, Stage IV Thyroid Gland Follicular Cancer, Stage IVA Thyroid Gland Follicular Cancer, Stage IVB Thyroid Gland Follicular Cancer, Recurrent Malignant Thyroid Gland Neoplasm, Refractory Malignant Thyroid Gland Neoplasm, Recurrent Thyroid Gland Papillary Carcinoma, Recurrent Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Follicular Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Unresectable Differentiated Thyroid Gland Carcinoma, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Poorly Differentiated Thyroid Gland Carcinoma, Recurrent Poorly Differentiated Thyroid Gland Carcinoma, Unresectable Poorly Differentiated Thyroid Gland Carcinoma, Unresectable Thyroid Gland Papillary Carcinoma, Unresectable Thyroid Gland Follicular Carcinoma, Unresectable Thyroid Gland Hurthle Cell Carcinoma, Recurrent Thyroid Gland Hurthle Cell Carcinoma, Metastatic Thyroid Gland Hurthle Cell Carcinoma",
    "Unresectable Leiomyosarcoma, Metastatic Leiomyosarcoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Malignant Solid Tumor",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Non-Small Cell Lung Cancer, Stage IB Lung Cancer",
    "Breast Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Stage IVA Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Adenocarcinoma",
    "Myelodysplastic/Myeloproliferative Disease, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Chronic Myeloproliferative Disease, Chronic Myelomonocytic Leukemia (CMML)",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Endometrial Cancer",
    "Unresectable Epithelioid Hemangioendothelioma, Unresectable Leiomyosarcoma, Metastatic Epithelioid Hemangioendothelioma, Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Bone Sarcoma, Unresectable Synovial Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Osteosarcoma, Metastatic Angiosarcoma, Metastatic Malignant Peripheral Nerve Sheath Tumor, Unresectable Angiosarcoma, Metastatic Synovial Sarcoma, Unresectable Primary Central Chondrosarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Unresectable Undifferentiated Pleomorphic Sarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Metastatic Bone Sarcoma, Metastatic Leiomyosarcoma, Metastatic Chondrosarcoma, Unresectable Osteosarcoma",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Metastatic Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Unresectable Malignant Peripheral Nerve Sheath Tumor, Metastatic Malignant Peripheral Nerve Sheath Tumor, Advanced Malignant Peripheral Nerve Sheath Tumor",
    "Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma, Unresectable Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Small Duct Intrahepatic Cholangiocarcinoma, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Malignant Neoplasm to the Liver, Metastatic Intrahepatic Cholangiocarcinoma",
    "Stage III Lung Cancer, Unresectable Lung Non-Small Cell Squamous Carcinoma, Stage IIIC Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid System Neoplasm",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Chemotherapy-Induced Peripheral Neuropathy",
    "Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Metastatic Malignant Neoplasm to the Central Nervous System, Metastatic Malignant Neoplasm to the Leptomeninges, Stage III Lung Cancer, Stage IV Lung Cancer",
    "Prostate Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor, Metastatic Malignant Neoplasm to the Bone",
    "Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Stage IV Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "High Grade Ovarian Serous Adenocarcinoma, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Carcinomatosis, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer",
    "Langerhans Cell Histiocytosis",
    "Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage I T-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage II T-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III T-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage IV T-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Lobular Carcinoma In Situ (LCIS), Microinvasive Breast Carcinoma, Atypical Lobular Breast Hyperplasia, Atypical Ductal Breast Hyperplasia, Ductal Carcinoma In Situ (DCIS)",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Refractory Central Nervous System Neoplasm, Recurrent Primary Central Nervous System Neoplasm",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Glioblastoma, Malignant Glioma, Anaplastic Astrocytoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Hormone Receptor Positive Breast Carcinoma, Unresectable Breast Carcinoma, Advanced Breast Carcinoma, Advanced Triple-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Malignant Chest Wall Neoplasm",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Stage I Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Classical Hodgkin Lymphoma",
    "Recurrent Head and Neck Carcinoma, Unresectable Head and Neck Carcinoma",
    "Stage IA Hodgkin Lymphoma, Stage IIA Hodgkin Lymphoma, Stage IIB Hodgkin Lymphoma, Stage IB Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Stage I Hodgkin Lymphoma",
    "Endometrial Serous Adenocarcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Endometrial Endometrioid Adenocarcinoma, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Endometrial Adenocarcinoma, Endometrial Cancer, Endometrial Clear Cell Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Stage II Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage I Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Uterine Corpus Carcinosarcoma, Stage IIIC2 Uterine (including Endometrial) Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Richter Syndrome, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma",
    "Triple-Negative Breast Cancer, Breast Cancer",
    "Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Carcinoma, Metastatic Prostatic Adenocarcinoma",
    "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Mycosis Fungoides, Lymphomatoid Papulosis",
    "Primary Amyloidosis",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Central Nervous System B-Cell Non-Hodgkin Lymphoma",
    "Nasal Type Extranodal NK/T-Cell Lymphoma",
    "Recurrent Glioblastoma, WHO Grade III Glioma, Grade II Glioma, Recurrent Glioma, Recurrent Grade II Glioma, Recurrent Grade III Glioma, Glioblastoma, Glioma, Spinal Cord Tumor, Secondary Glioblastoma, Multifocal Glioblastomas",
    "Ann Arbor Stage III Hodgkin Lymphoma, Stage IA Hodgkin Lymphoma, Stage IIA Hodgkin Lymphoma, Stage IIB Hodgkin Lymphoma, Stage IIIA Hodgkin Lymphoma, Stage IIIB Hodgkin Lymphoma, Stage IVA Hodgkin Lymphoma, Stage IB Hodgkin Lymphoma, Stage IVB Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Stage I Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Chronic Lymphocytic Leukemia (CLL), Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma, Stage II Mantle Cell Lymphoma",
    "Recurrent Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma",
    "Stage 0a Bladder Cancer, Stage 0is Bladder Cancer, Stage I Bladder Cancer",
    "Metastatic Adenoid Cystic Cancer, Recurrent Salivary Gland Cancer, Metastatic Salivary Gland Carcinoma, Recurrent Adenoid Cystic Cancer",
    "Nodal Marginal Zone Lymphoma, Marginal Zone Lymphoma, Splenic Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Non-Small Cell Lung Cancer, Lung Adenocarcinoma, Adenosquamous Lung Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Invasive Breast Cancer",
    "Neurofibromatosis Type 1, Plexiform Neurofibroma",
    "Extrarenal Rhabdoid Tumor, Atypical Teratoid/Rhabdoid Tumor, Rhabdoid Tumor of the Kidney",
    "Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma, Recurrent Malignant Glioma, Recurrent Grade II Glioma, Oligodendroglial Tumor",
    "Melanoma, Non-Melanoma Skin Cancer, Salivary Gland Cancer",
    "HER2-Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer",
    "Pre-B Acute Lymphoblastic Leukemia, T Acute Lymphoblastic Leukemia",
    "Metastatic Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Locally Advanced Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Stage IV Ureter Cancer, Stage IV Renal Pelvis and Ureter Cancer, Stage IV Bladder Urothelial Cancer, Locally Advanced Bladder Urothelial Carcinoma, Metastatic Urothelial Cancer of the Renal Pelvis and Ureter",
    "Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Recurrent Glioblastoma, Recurrent Glioma, Recurrent Central Nervous System Lymphoma, Recurrent Grade II Glioma, Recurrent Grade III Glioma, Recurrent Malignant Brain Neoplasm, Recurrent Ependymoma, Recurrent Schwannoma, Schwannoma, Recurrent Meningioma",
    "HER2-Positive Breast Carcinoma, Stage IV Breast Cancer",
    "Stage IV Prostate Cancer, Prostate Adenocarcinoma, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostate Cancer",
    "Stage III Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Stage IV Head and Neck Squamous Cell Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Metastatic Lung Carcinoma, Metastatic Bladder Carcinoma, Metastatic Kidney Carcinoma, Metastatic Melanoma, Stage IVB Bladder Cancer, Metastatic Malignant Neoplasm, Kidney (including Renal Cell) Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Metastatic Malignant Neoplasm to the Bone",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Lung Adenocarcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Stage IA Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Invasive Ductal Carcinoma, NOS, Invasive Lobular Breast Carcinoma, Breast Ductal Carcinoma In Situ, Intermediate Grade, Breast Ductal Carcinoma In Situ, Low Grade",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma",
    "Stage IV Bladder Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Metastatic Bladder Urothelial Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer, Nasopharyngeal Squamous Cell Carcinoma, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Stage IA Hodgkin Lymphoma, Stage IIB Hodgkin Lymphoma, Ann Arbor Stage III Hodgkin Lymphoma, Stage IIA Hodgkin Lymphoma, Stage IIIB Hodgkin Lymphoma, Stage IIIA Hodgkin Lymphoma, Stage IB Hodgkin Lymphoma, Stage IVB Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Stage IVA Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Stage I Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Chronic Myelogenous Leukemia (CML), Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelogenous Leukemia (CML)",
    "Recurrent Glioblastoma, MGMT-Methylated Glioblastoma",
    "High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Burkitt Leukemia, Refractory Burkitt Leukemia, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Burkitt Lymphoma, Recurrent Burkitt Lymphoma",
    "Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma",
    "Metastatic Rhabdomyosarcoma, Rhabdomyosarcoma",
    "Stage IA Breast Cancer, Invasive Breast Cancer, HER2-Positive Breast Carcinoma, Stage I Breast Cancer, Stage IB Breast Cancer",
    "Stage II Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma, Stage IA Pleural Malignant Mesothelioma, Stage IB Pleural Malignant Mesothelioma, Pleural Epithelioid Mesothelioma, Pleural Biphasic Mesothelioma, Stage I Pleural Malignant Mesothelioma",
    "Stage IIA Breast Cancer, Stage IA Breast Cancer, Invasive Breast Cancer",
    "Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Medulloblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm to the Bone",
    "Stage IA Hodgkin Lymphoma, Stage IIA Hodgkin Lymphoma, Stage IIB Hodgkin Lymphoma, Stage II Lymphocyte-Depleted Classical Hodgkin Lymphoma, Stage I Lymphocyte-Depleted Classical Hodgkin Lymphoma, Stage II Mixed Cellularity Classical Hodgkin Lymphoma, Stage II Nodular Sclerosis Classical Hodgkin Lymphoma, Stage IB Hodgkin Lymphoma, Lymphocyte-Rich Classical Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Stage I Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Stage I Mixed Cellularity Classical Hodgkin Lymphoma, Stage I Nodular Sclerosis Classical Hodgkin Lymphoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage II Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, HER2-Positive Breast Carcinoma, Bilateral Breast Cancer, Invasive Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer",
    "Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement, Childhood Langerhans Cell Histiocytosis without Risk Organ Involvement, Central Nervous System Langerhans Cell Histiocytosis",
    "Stage IV Renal Cell Cancer, Clear Cell Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Myeloid Sarcoma, Granulocytic Sarcoma, High-Grade Treatment-Related Myeloid Neoplasm, Therapy-Related Myelodysplastic Syndrome",
    "Neuroendocrine Tumor, Metastatic Malignant Neoplasm to the Liver",
    "Spinal Cord Glioma, Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Glioma",
    "Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage I Rectal Cancer, Stage III Rectal Cancer, Rectal Adenocarcinoma, Stage IIIC Rectal Cancer, Stage IIA Rectal Cancer",
    "Stage IV Prostate Adenocarcinoma",
    "Diffuse Midline Glioma, H3 K27M-Mutant, Malignant Glioma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IIIB Colon Cancer, Stage IIIA Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVB Colon Cancer, Stage IVA Colon Cancer, Stage IVC Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colorectal Carcinoma, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Unresectable Colon Adenocarcinoma, Unresectable Rectal Adenocarcinoma, Unresectable Colorectal Carcinoma",
    "Unresectable Esophageal Cancer, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Esophageal Adenocarcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Adenocarcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Locally Advanced Unresectable Colorectal Adenocarcinoma",
    "Recurrent Glioblastoma, Glioblastoma, Recurrent Grade III Glioma, Malignant Glioma, WHO Grade III Glioma, Recurrent Malignant Glioma",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Metastatic Breast Carcinoma, Metastatic Breast Cancer in the Brain, Stage IV Breast Cancer, HER2-Positive Breast Carcinoma, Recurrent Breast Cancer, Invasive Breast Cancer",
    "Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma",
    "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "T Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia, B Acute Lymphoblastic Leukemia",
    "Unresectable Breast Carcinoma, Stage IV Breast Cancer, Breast Adenocarcinoma, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Carcinoma",
    "Refractory Soft Tissue Sarcoma, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Osteosarcoma, Recurrent Soft Tissue Sarcoma, Recurrent Rhabdomyosarcoma",
    "Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Ductal Carcinoma In Situ (DCIS), Stage 0 Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Invasive Breast Cancer, Early-Stage Breast Cancer",
    "Prostate Adenocarcinoma",
    "Stage IIIC Rectal Cancer, Unresectable Colon Adenocarcinoma, Stage IV Colon Cancer, Stage IIIA Colon Cancer, Stage IVA Colon Cancer, Stage IVA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIB Colon Cancer, Stage IVB Colon Cancer, Stage III Colon Cancer, Stage IIIA Rectal Cancer, Stage III Rectal Cancer, Stage IVB Rectal Cancer, Unresectable Rectal Adenocarcinoma, Stage IV Rectal Cancer, Stage IVC Colon Cancer, Metastatic Colon Adenocarcinoma, Stage IIIC Colon Cancer, Metastatic Rectal Adenocarcinoma, Stage IVC Rectal Cancer",
    "Medulloblastoma, Central Nervous System Embryonal Tumor, Not Otherwise Specified",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma, Recurrent Breast Cancer",
    "Recurrent Glioblastoma, WHO Grade III Glioma, Grade II Glioma, Recurrent Anaplastic Astrocytoma, Recurrent Malignant Glioma, Recurrent Medulloblastoma, Diffuse Intrinsic Pontine Glioma",
    "T Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia (ALL), Acute Biphenotypic Leukemia, Acute Undifferentiated Leukemia",
    "Resectable Osteosarcoma, Metastatic Malignant Neoplasm to the Lung, Metastatic Osteosarcoma, Recurrent Osteosarcoma",
    "Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer",
    "Stage IA Non-Small Cell Lung Cancer, Stage I Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "Large Cell/Anaplastic Medulloblastoma, Medulloepithelioma, Central Nervous System Neuroblastoma, Embryonal Tumor with Multilayered Rosettes, C19MC-Altered, Desmoplastic/Nodular Medulloblastoma, Central Nervous System Embryonal Tumor, Not Otherwise Specified, Brain/Spinal Cord Tumor, Central Nervous System Ganglioneuroblastoma, Pineoblastoma",
    "Hemoglobinopathy, Thalassemia, Non-Neoplastic Hematologic and Lymphocytic Disorder",
    "Secondary Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm, Acute Lymphoblastic Leukemia (ALL), DS Stage III Multiple Myeloma/Plasma Cell Myeloma, Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia with t(6;9), Acute Myeloid Leukemia (AML) with FLT3/ITD, Acute Megakaryoblastic Leukemia, Recurrent Hodgkin Lymphoma, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, DS Stage II Multiple Myeloma/Plasma Cell Myeloma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Acute Myeloid Leukemia with Multilineage Dysplasia, Recurrent Anaplastic Large Cell Lymphoma, Acute Undifferentiated Leukemia, Acute Myeloid Leukemia with inv(3) (q21.3;q26.2) or t(3;3) (q21.3;q26.2); GATA2, MECOM, Recurrent Marginal Zone Lymphoma, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Follicular Lymphoma, Burkitt Lymphoma, Myelodysplastic Syndrome, T Lymphoblastic Lymphoma",
    "Hepatocellular Cancer, Metastatic Malignant Neoplasm to the Liver, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Gallbladder Cancer",
    "Recurrent Brain Stem Glioma, Brain Stem Glioma, Diffuse Intrinsic Pontine Glioma, Malignant Glioma, Brain Stem Glioma",
    "Refractory Anemia, Bone Marrow Failure, Paroxysmal Nocturnal Hemoglobinuria, Severe Aplastic Anemia, Pure Red Cell Aplasia",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Secondary Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm, Secondary Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Therapy-Related Myelodysplastic Syndrome, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia-Negative Myelogenous Leukemia, Chronic Myelomonocytic Leukemia (CMML), Prolymphocytic Leukemia, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, T-Cell Large Granular Lymphocyte Leukemia, Plasma Cell Tumor, Acute Biphenotypic Leukemia, Recurrent Burkitt Lymphoma, Acute Myeloid Leukemia (AML) with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Angioimmunoblastic T-Cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Small Lymphocytic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Hepatosplenic T-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Juvenile Myelomonocytic Leukemia, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Chronic Myelogenous Leukemia (CML)",
    "Unresectable Pancreatic Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Ovarian Cancer, Advanced Breast Carcinoma, Advanced Malignant Solid Tumor, Recurrent Digestive System Carcinoma, Stage IIIA Esophageal Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Digestive System Neoplasm, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Recurrent Breast Cancer, Unresectable Endometrial Carcinoma, Stage III Pancreatic Cancer, Stage IIIB Esophageal Cancer, Locally Advanced Esophageal Carcinoma, Stage IV Esophageal Cancer, Stage IIIA Breast Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm in the Brain, Recurrent Pancreatic Cancer, Stage III Esophageal Cancer, Unresectable Ovarian Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IV Ovarian Cancer, Metastatic Pancreatic Carcinoma, Recurrent Ovarian Cancer, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Stage IIIC Breast Cancer, Advanced Ovarian Carcinoma, Stage III Breast Cancer, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable Esophageal Cancer, Stage IIIC Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Pancreatic Cancer, Stage IIIC Esophageal Cancer, Metastatic Esophageal Carcinoma, Locally Advanced Pancreatic Carcinoma, Unresectable Malignant Digestive System Neoplasm, Recurrent Esophageal Cancer",
    "Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent B Acute Lymphoblastic Leukemia",
    "Stage I Prostate Adenocarcinoma, Stage II Prostate Adenocarcinoma",
    "Paranasal Sinus Mucoepidermoid Carcinoma, Paranasal Sinus Adenocarcinoma, Stage IVA Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Nasal Cavity and Paranasal Sinus Cancer, Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Malignant Myoepithelioma, Malignant Hard Palate Neoplasm, Nasal Cavity Olfactory Neuroblastoma, Malignant Salivary Gland Tumor, Paranasal Sinus Olfactory Neuroblastoma, Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Undifferentiated Sinonasal Cancer, Sinonasal Non-Keratinizing Squamous Cell Carcinoma, Skull Base Neoplasm, Melanoma, Paranasal Sinus Adenoid Cystic Carcinoma, Stage IVB Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Malignant Lacrimal Gland Neoplasm, Malignant Soft Palate Neoplasm, Intracranial Neoplasm",
    "Stage IIIB Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer",
    "Myelodysplastic Syndrome, Mixed Phenotype Acute Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Refractory Acute Myeloid Leukemia (AML), Chronic Myeloproliferative Disease, Acute Myeloid Leukemia with t(3;3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 5q, Acute Myeloid Leukemia (AML) with Abnormalities of Chromosome 7, Acute Myeloid Leukemia with inv(3) (q21.3;q26.2); GATA2, MECOM, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Acute Myeloid Leukemia with t(6;9), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML) with FLT3/ITD",
    "Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Hemoglobinopathy, Recurrent Acute Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia, Lymphoid Leukemia, Aplastic Anemia, Refractory Lymphoma, Refractory Hodgkin Lymphoma, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hodgkin Lymphoma, Chronic Myeloproliferative Disease, Chronic Lymphocytic Leukemia (CLL), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Lymphoma, Refractory Acute Leukemia, Multiple Myeloma/Plasma Cell Myeloma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome",
    "Myelodysplastic Syndrome with Excess Blasts, Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Isolated del(5q), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Stage 0 Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Gliosarcoma",
    "Recurrent Fallopian Tube Cancer, Fallopian Tube Transitional Cell Cancer, Fallopian Tube Serous Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Serous Adenocarcinoma, Malignant Ovarian Brenner Tumor, Undifferentiated Ovarian Cancer, Undifferentiated Fallopian Tube Cancer, Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Transitional Cell Cancer, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Recurrent Primary Peritoneal Cancer, Ovarian Mucinous Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Recurrent Ovarian Cancer, Primary Peritoneal Serous Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia",
    "Fanconi Anemia, Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Severe Aplastic Anemia",
    "Stage II Pleural Malignant Mesothelioma, Stage IA Pleural Malignant Mesothelioma, Recurrent Malignant Mesothelioma, Stage IB Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma, Epithelioid Mesothelioma",
    "HER2 Negative Breast Carcinoma, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer",
    "Recurrent Malignant Solid Tumor, Unresectable Solid Tumor, Ovarian Cancer, Fibrolamellar Cancer, Refractory Malignant Solid Tumor, Pancreatic Neuroendocrine Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Cigarette Smoking-Related Carcinoma",
    "Stage III Laryngeal Throat Verrucous Cancer, Stage IVA Laryngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Verrucous Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, Stage IVB Laryngeal Throat Verrucous Cancer",
    "Liver Cancer",
    "Aggressive Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, B-Cell Prolymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Mantle Cell Lymphoma",
    "Malignant Supratentorial Neoplasm, Recurrent Glioma, Glioblastoma, WHO Grade III Glioma",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Glioma",
    "BRAF V600K Mutation Present, Stage IV Cutaneous (Skin) Melanoma, Mucosal Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, BRAF V600E Mutation Present, Advanced Uveal Melanoma, Melanoma of Unknown Primary, Recurrent Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Triple-Negative Breast Cancer, Invasive Breast Cancer",
    "Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma",
    "Pancreatic Adenocarcinoma, Stage IB Pancreatic Cancer, Resectable Pancreatic Cancer, Stage I Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer",
    "Astrocytoma, Malignant Glioma, Supratentorial Glioblastoma",
    "Myelofibrosis, Secondary Acute Myeloid Leukemia (AML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Myelodysplastic Syndrome with Excess Blasts-2, High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome with Excess Blasts-1, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Cirrhosis, Metastatic Malignant Neoplasm to the Liver, Hepatocellular Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Stage IIIB Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Refractory Chronic Lymphocytic Leukemia (CLL), Metastatic Triple-Negative Breast Carcinoma, Recurrent Acute Lymphoblastic Leukemia, Stage IV Breast Cancer, Recurrent Mantle Cell Lymphoma",
    "Myelodysplastic Syndrome with Somatic Mutations, ISS Stage II Multiple Myeloma/Plasma Cell Myeloma, Double-Hit Lymphoma, Recurrent Acute Myeloid Leukemia (AML), B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Acute Lymphoblastic Leukemia (ALL), Refractory Acute Lymphoblastic Leukemia (ALL), Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia with Variant MLL Translocations, ISS Stage III Multiple Myeloma/Plasma Cell Myeloma, Recurrent Non-Hodgkin Lymphoma, Chronic Myelomonocytic Leukemia (CMML), Acute Biphenotypic Leukemia, Therapy-Related Myelodysplastic Syndrome, Chemotherapy-Related Leukemia, Myelodysplastic Syndrome, Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Refractory Acute Lymphoblastic Leukemia (ALL), Myelodysplastic/Myeloproliferative Disease, Recurrent Hodgkin Lymphoma, Myelodysplastic Syndrome with Excess Blasts",
    "Stage IIIC Breast Cancer, Invasive Breast Cancer, Stage IIA Breast Cancer, Stage IV Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Triple-Negative Breast Cancer",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Colorectal (Colon or Rectal) Cancer",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Non-Small Cell Lung Cancer",
    "Recurrent Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma",
    "Recurrent Mantle Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma",
    "Stage IV Prostate Cancer, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer, Recurrent Prostate Cancer",
    "Stage III Cervical Cancer, Stage IVA Cervical Cancer, Stage II Vulvar Cancer, Stage IIA1 Cervical Cancer, Stage IB1 Cervical Cancer, Stage IIIA Vulvar Cancer, Stage I Cervical Cancer, Stage IIB Cervical Cancer, Malignant Female Reproductive System Neoplasm, Stage IB2 Cervical Cancer, Stage IIIB Cervical Cancer, Stage IIA Cervical Cancer, Recurrent Vulvar Cancer, Stage IB Vulvar Cancer, Stage IA1 Cervical Cancer, Stage IB Cervical Cancer, Stage I Vaginal Cancer, Urethral Cancer, Stage IA Vulvar Cancer, Stage IA Cervical Cancer, Stage II Vaginal Cancer, Recurrent Vaginal Cancer, Stage II Cervical Cancer, Stage IVA Vaginal Cancer, Stage IIA2 Cervical Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIA Cervical Cancer, Stage III Vaginal Cancer, Stage III Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IA2 Cervical Cancer, Stage I Vulvar Cancer",
    "Acute Undifferentiated Leukemia, Leukemia, B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Hematopoietic and Lymphoid System Disorder, Mantle Cell Lymphoma, Myelodysplastic Syndrome, Refractory Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Non-Hodgkin Lymphoma, Hodgkin Lymphoma, Follicular Lymphoma, Acute Myeloid Leukemia (AML), Lymphoma, Burkitt Lymphoma, Marginal Zone Lymphoma",
    "Acute Lymphoblastic Leukemia (ALL), Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Lymphoma",
    "Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Indolent Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Aggressive Non-Hodgkin Lymphoma, Small Lymphocytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma",
    "High Risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia with Multilineage Dysplasia, Myelodysplastic Syndrome",
    "Metastatic Malignant Neoplasm to the Liver, Metastatic Uveal Melanoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Stage III Laryngeal Throat Cancer, Laryngeal Throat Squamous Cell Cancer, Stage II Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Mixed Phenotype Acute Leukemia, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Recurrent Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome with Excess Blasts, Recurrent Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia, Recurrent Acute Lymphoblastic Leukemia, Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML)",
    "Lymphangioleiomyomatosis, Tuberous Sclerosis, Angiomyolipoma",
    "Refractory Malignant Solid Tumor, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIA1 Ovarian Cancer, Recurrent Endometrial Carcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Ovarian Cancer, Refractory Endometrial Carcinoma, Stage IV Uterine (including Endometrial) Cancer, Recurrent Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Ovarian Cancer, Recurrent Malignant Solid Tumor, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIB Ovarian Cancer, Refractory Ovarian Carcinoma, Advanced Malignant Solid Tumor, Stage IIIC Ovarian Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Ovarian Cancer, Stage IIIA2 Ovarian Cancer",
    "Hepatocellular Cancer",
    "Unresectable Fallopian Tube Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Stage IVA Ovarian Cancer, Undifferentiated Fallopian Tube Cancer, Ovarian Seromucinous Carcinoma, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Ovarian Cancer, Unresectable Primary Peritoneal Serous Adenocarcinoma, Unresectable Ovarian Undifferentiated Carcinoma, Stage IVB Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, High Grade Fallopian Tube Serous Adenocarcinoma, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Undifferentiated Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, High Grade Ovarian Serous Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IVB Primary Peritoneal Cancer, Stage IIIB Ovarian Cancer, Ovarian Clear Cell Adenocarcinoma, Stage IVA Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Unresectable Ovarian Serous Adenocarcinoma, Stage III Ovarian Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Non-Hodgkin Lymphoma, Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL), Hodgkin Lymphoma, Chronic Myelogenous Leukemia (CML)",
    "Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Tonsillar Squamous Cell Carcinoma, Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Tongue Squamous Cell Carcinoma, Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Soft Palate Squamous Cell Carcinoma",
    "Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Prolymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Myelodysplastic Syndrome, Aggressive Non-Hodgkin Lymphoma, Myelodysplastic/Myeloproliferative Disease, Hematologic and Lymphocytic Disorder, Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Waldenstrom Macroglobulinemia, Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia (CLL), Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Acute Myeloid Leukemia (AML), Recurrent Hodgkin Lymphoma, Recurrent Chronic Myelogenous Leukemia (CML), Acute Lymphoblastic Leukemia (ALL), Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Cigarette Smoking-Related Carcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Colorectal (Colon or Rectal) Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Post-Traumatic Stress Disorder, Behavioral Disorder, Depression, Anxiety Disorder",
    "Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage I Non-Small Cell Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIA Non-Small Cell Lung Cancer, Stage IIB Non-Small Cell Lung Cancer, Stage IB Non-Small Cell Lung Cancer, Stage IA Non-Small Cell Lung Cancer",
    "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Biphenotypic Leukemia, Mixed Phenotype Acute Leukemia, Acute Lymphoblastic Leukemia (ALL), Leukemia, Myelodysplastic Syndrome, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia (CMML), Juvenile Myelomonocytic Leukemia, Acute Biphenotypic Leukemia, Refractory Acute Myeloid Leukemia (AML), Chronic Myelogenous Leukemia (CML), Recurrent Acute Lymphoblastic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia (CML), Recurrent Acute Undifferentiated Leukemia, Acute Myeloid Leukemia (AML), Recurrent Chronic Myelogenous Leukemia (CML), Acute Undifferentiated Leukemia",
    "Malignant Glioma, Glioblastoma, WHO Grade III Glioma",
    "Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma",
    "HER2-Positive Breast Carcinoma, Invasive Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Colorectal (Colon or Rectal) Cancer",
    "Lymphoplasmacytic Lymphoma, B-Cell Non-Hodgkin Lymphoma, Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Grade 1 Follicular Lymphoma, Mantle Cell Lymphoma",
    "Refractory Breast Cancer, Recurrent Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Stage IV Breast Cancer, Refractory Mycosis Fungoides, Recurrent Mycosis Fungoides, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Metastatic Breast Carcinoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Breast Cancer, Refractory Non-Hodgkin Lymphoma, Breast Adenocarcinoma, Recurrent Hodgkin Lymphoma",
    "Glioblastoma",
    "Localized Pancreatic Adenocarcinoma, Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma",
    "Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer",
    "Hereditary Female Breast Carcinoma",
    "Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIB Breast Cancer, Stage IIIB Prostate Cancer, Malignant Solid Tumor, Stage IIB Colorectal (Colon or Rectal) Cancer, Stage I Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Prostate Cancer, Stage IIA Prostate Cancer, Stage I Prostate Cancer, Stage III Lung Cancer, Stage II Lung Cancer, Stage III Prostate Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage I Colorectal (Colon or Rectal) Cancer, Stage IIIA Breast Cancer, Stage IB Breast Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage II Breast Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer, Stage II Breast Cancer, Stage IIIA Lung Cancer, Stage IA Breast Cancer, Stage IA Breast Cancer, Stage IIIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage II Prostate Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIC Prostate Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage I Lung Cancer, Stage I Breast Cancer, Stage IIIB Lung Cancer, Stage IIB Lung Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer",
    "Metastatic Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Recurrent Primary Peritoneal Cancer, Solid Tumor, Breast Cancer, Ovarian Cancer, Recurrent Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer",
    "Endocervical Cancer, Cervical Cancer, Cervical Squamous Neoplasm, Cervical Adenosquamous Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma",
    "Stage IVB Prostate Cancer, Metastatic Prostate Cancer, Stage IVA Prostate Cancer, Prostate Small Cell Neuroendocrine Carcinoma, Metastatic Malignant Neoplasm to the Bone, Castration-Sensitive Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Locally Advanced Breast Carcinoma, HER2 Negative Breast Carcinoma, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Unresectable Breast Carcinoma, Stage IIIB Breast Cancer",
    "Recurrent Gliosarcoma, Recurrent Anaplastic Astrocytoma, Recurrent Glioblastoma, Recurrent Malignant Glioma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer, Stage IIB Colorectal (Colon or Rectal) Cancer, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage I Colorectal (Colon or Rectal) Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Hematopoietic and Lymphoid Cell Neoplasm, Refractory Acute Myeloid Leukemia (AML), Refractory Mixed Phenotype Acute Leukemia, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome with Excess Blasts, Recurrent Mixed Phenotype Acute Leukemia",
    "Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Glioblastoma",
    "Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Recurrent Osteosarcoma, Recurrent Neuroblastoma, Ganglioneuroblastoma, High-Risk Neuroblastoma, Refractory Neuroblastoma, Refractory Osteosarcoma",
    "Prostate Cancer",
    "Locally Advanced Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma",
    "Metastatic Malignant Neoplasm to the Lung, Stage IIIA Lung Cancer, Small Cell Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Non-Small Cell Lung Cancer, Locally Advanced Lung Carcinoma",
    "Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Metastatic Merkel Cell Carcinoma, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Unresectable Merkel Cell Carcinoma, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8",
    "Anaplastic Ependymoma, Ependymoma",
    "Glottis Verrucous Carcinoma, Glottic Squamous Cell Carcinoma",
    "Breast Cancer, Secondary Lymphedema",
    "Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer",
    "Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Stage IIIA Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage I Breast Cancer, Stage IV Breast Cancer, Stage IA Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer",
    "Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer",
    "Stage IA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Lung Cancer, Stage II Breast Cancer, Stage IIIA Lung Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IIB Lung Cancer, Stage IIB Colorectal (Colon or Rectal) Cancer, Stage IIB Breast Cancer, Stage IA2 Lung Cancer, Stage IIA Breast Cancer, Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage IIA Breast Cancer, Stage IA3 Lung Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IA1 Lung Cancer, Stage I Lung Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage II Breast Cancer, Stage III Lung Cancer, Stage IIA Lung Cancer, Stage II Lung Cancer, Stage IIIB Lung Cancer, Stage IB Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IA Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage IIIB Breast Cancer, Stage I Colorectal (Colon or Rectal) Cancer, Stage IIIC Prostate Cancer, Insomnia, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIC Prostate Cancer, Stage IIB Prostate Cancer, Stage IIA Prostate Cancer, Stage II Prostate Cancer, Stage I Prostate Cancer, Stage IB Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Monoclonal Gammopathy of Undetermined Significance, Light Chain Deposition Disease, Waldenstrom Macroglobulinemia, IgM Monoclonal Gammopathy of Undetermined Significance, Non-IgM Monoclonal Gammopathy of Undetermined Significance, Smoldering Waldenstrom Macroglobulinemia",
    "Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer",
    "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "MGMT-Unmethylated Glioblastoma, Cytomegaloviral Infection",
    "Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Pancreatic Adenocarcinoma",
    "Hepatocellular Cancer",
    "Adamantinomatous Craniopharyngioma, Recurrent Adamantinomatous Craniopharyngioma",
    "Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Stage IIC Colon Cancer, Stage IIB Colon Cancer, Stage III Colon Cancer, Stage II Colon Cancer, Stage IIIA Colon Cancer, Stage IIIC Colon Cancer, Stage I Colon Cancer, Stage IIIB Colon Cancer, Stage IIA Colon Cancer",
    "Refractory Glioblastoma, Recurrent Glioblastoma",
    "Cervical Squamous Cell Cancer, Stage IB2 Cervical Cancer FIGO 2018, Cervical Adenosquamous Cancer, Endocervical Cancer",
    "Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage I Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IA Breast Cancer",
    "Stage I Uterine (including Endometrial) Cancer, Stage IA Uterine (including Endometrial) Cancer, Complex Endometrial Hyperplasia, Stage II Uterine (including Endometrial) Cancer, Endometrial Endometrioid Adenocarcinoma, Stage IB Uterine (including Endometrial) Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer",
    "Refractory Ependymoma, Recurrent Ependymoma, Recurrent Brain Neoplasm, Recurrent Medulloblastoma, Recurrent Glioblastoma, Refractory Medulloblastoma, Refractory Glioblastoma, Diffuse Intrinsic Pontine Glioma",
    "Lung Cancer, Lung Neoplasm",
    "Chronic Myelogenous Leukemia (CML), Hematopoietic and Lymphoid Cell Neoplasm, Acute Megakaryoblastic Leukemia, Myelodysplastic Syndrome with Excess Blasts, Acute Erythroid Leukemia, Refractory Anemia, HIV Infection, Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Non-Malignant Neoplasm",
    "Primary Malignant Liver Neoplasm",
    "Cervical Cancer, Breast Cancer",
    "Anal Cancer",
    "Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Advanced HER2 Negative Breast Carcinoma, BRCA-Mutated Metastatic Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Stage IV Breast Cancer, Advanced Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma",
    "Recurrent Olfactory Neuroblastoma, Recurrent Malignant Solid Tumor, Recurrent Head and Neck Carcinoma, Recurrent Malignant Salivary Gland Neoplasm, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Malignant Head and Neck Neoplasm, Recurrent Head and Neck Squamous Cell Cancer",
    "Metastatic Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Metastatic Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Refractory Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Recurrent Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Prostate Adenocarcinoma",
    "Acute Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage II Pancreatic Cancer, Resectable Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage 0 Pancreatic Cancer, Stage I Pancreatic Cancer",
    "Hepatocellular Cancer",
    "Stage IVA Pancreatic Cancer, Stage IVB Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Colorectal (Colon or Rectal) Cancer",
    "Recurrent Glioblastoma",
    "Stage I Breast Cancer, Stage IIIB Breast Cancer, Stage IB Breast Cancer, Stage IB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer",
    "Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 3a Follicular Lymphoma, Recurrent Burkitt Lymphoma, ALK-Positive Large B-Cell Lymphoma, Recurrent Lymphomatoid Granulomatosis, Diffuse Large B-Cell Lymphoma Associated with Chronic Inflammation, Refractory Burkitt Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Splenic Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 1 Follicular Lymphoma, Recurrent EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Recurrent Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Grade 3b Follicular Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Grade 3 Follicular Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, High Grade B-Cell Lymphoma, Not Otherwise Specified, Large B-Cell Lymphoma with IRF4 Rearrangement, Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Intravascular Large B-Cell Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Primary Cutaneous (Skin) Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Grade 2 Follicular Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Stage IA Breast Cancer, Invasive Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Malignant Neoplasm to the Liver, Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Stage IIIB Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IVB Ovarian Cancer",
    "Stage IB Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IB Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer",
    "Stage II Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IIA Pancreatic Cancer",
    "Colorectal (Colon or Rectal) Cancer",
    "Recurrent Ovarian Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer",
    "Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer",
    "Stage IIB Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IB Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma, Mucosal Melanoma, Intraocular Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Cervical Cancer",
    "Recurrent Ovarian Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer",
    "Unresectable Hepatocellular Cancer",
    "Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage IV Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIIB Prostate Cancer, Stage III Prostate Cancer, Stage IVA Prostate Cancer, Prostate Adenocarcinoma, Stage IVB Prostate Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIIB Retroperitoneal Sarcoma, Resectable Dedifferentiated Liposarcoma, Resectable Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Inflammatory Variant, Soft Tissue Fibrosarcoma, Storiform-Pleomorphic Malignant Fibrous Histiocytoma, Spindle Cell Sarcoma, Synovial Sarcoma, Malignant Peripheral Nerve Sheath Tumor, Leiomyosarcoma, Resectable Undifferentiated Pleomorphic Sarcoma, Stage IB Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage I Soft Tissue Sarcoma of the Trunk and Extremities, Stage IA Soft Tissue Sarcoma of the Trunk and Extremities, Undifferentiated Spindle Cell Sarcoma, Pleomorphic Rhabdomyosarcoma, Undifferentiated Pleomorphic Sarcoma with Osteoclast-Like Giant Cells, Myxofibrosarcoma, Undifferentiated Pleomorphic Sarcoma, Stage I Retroperitoneal Sarcoma, Stage IB Retroperitoneal Sarcoma, Stage II Retroperitoneal Sarcoma, Stage IA Retroperitoneal Sarcoma, Undifferentiated High Grade Pleomorphic Sarcoma of Bone, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage II Soft Tissue Sarcoma of the Trunk and Extremities",
    "HIV Infection, Cigarette Smoking-Related Carcinoma",
    "Unresectable Large Cell Neuroendocrine Carcinoma, Unresectable Digestive System Mixed Adenoneuroendocrine Carcinoma, Large Cell Neuroendocrine Carcinoma, Metastatic Digestive System Mixed Adenoneuroendocrine Carcinoma, Unresectable Neuroendocrine Carcinoma, Metastatic Large Cell Neuroendocrine Carcinoma, Metastatic Neuroendocrine Carcinoma",
    "Stage II Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage III Pancreatic Cancer, Pancreatic Adenosquamous Cancer, Stage IIB Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Carcinoma, Advanced Pancreatic Carcinoma",
    "Stage IVA Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Metastatic Small Cell Neuroendocrine Prostate Cancer",
    "Prostate Cancer",
    "Cigarette Smoking-Related Carcinoma, HIV Infection",
    "Lung Cancer",
    "Metastatic Malignant Neoplasm to the Liver",
    "Prolonged Grief Disorder",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Cigarette Smoking-Related Carcinoma",
    "Recurrent Ovarian Cancer, Platinum-Sensitive Fallopian Tube Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum Sensitive Ovarian Cancer, Recurrent Primary Peritoneal Cancer, Platinum-Resistant Primary Peritoneal Cancer, Platinum-Sensitive Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer",
    "Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Stage IIIA Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage II Lung Cancer, Non-Small Cell Lung Cancer, Stage IIB Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIB Lung Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Esophageal Cancer, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Lung Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Lung Cancer, Stage III Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage IIA Lung Cancer",
    "Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, High Risk Breast Carcinoma, Triple-Negative Breast Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Adenocarcinoma, Metastatic Small Intestinal Adenocarcinoma, Stage IV Small Intestinal Adenocarcinoma",
    "Stage IVA Prostate Cancer, Stage IV Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Steroid Refractory Graft Versus Host Disease, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Angioimmunoblastic T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Transformed Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous CD4-Positive Small/Medium T-Cell Lymphoproliferative Disorder, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Refractory Adult T-Cell Leukemia/Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Positive, Primary Cutaneous Anaplastic Large Cell Lymphoma, Recurrent Transformed Mycosis Fungoides, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Primary Cutaneous Acral CD8-Positive T-Cell Lymphoma, Primary Systemic Anaplastic Large Cell Lymphoma, ALK-Negative, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma",
    "Liver Cancer",
    "Stage III Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Locally Advanced Hepatocellular Carcinoma, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma",
    "Stage II Lip and Oral Cavity Cancer, Oral Cavity Squamous Cell Cancer, Stage I Lip and Oral Cavity Cancer",
    "Colorectal (Colon or Rectal) Cancer",
    "Stage III Nasopharyngeal Throat Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IV Penile Cancer, Recurrent Primary Effusion Lymphoma, Refractory Anal Cancer, Stage IVB Vulvar Cancer, Stage IIIB Penile Cancer, Refractory Gastric (Stomach) Cancer, Stage IVB Vaginal Cancer, Stage IV Vaginal Cancer, Stage IIIB Vulvar Cancer, Refractory Primary Effusion Lymphoma, Stage IVA Gastric (Stomach) Cancer, Nasopharyngeal Throat Nonkeratinizing Cancer, Recurrent Vaginal Cancer, Merkel Cell Polyomavirus Infection, Stage IVB Cervical Cancer, Refractory Hepatocellular Carcinoma, Stage IV Gastric (Stomach) Cancer, Locally Advanced Malignant Solid Tumor, Stage IIIB Hepatocellular Cancer, EBV-Related Leiomyosarcoma, Refractory Kaposi Sarcoma, Stage IV Cervical Cancer, Metastatic Head and Neck Cancer, Recurrent Head and Neck Carcinoma, Refractory Nasopharyngeal Throat Cancer, Hepatitis B Virus-Related Hepatocellular Carcinoma, EBV-Related Gastric Carcinoma, Stage IIIB Gastric (Stomach) Cancer, Recurrent Hodgkin Lymphoma, Stage III Gastric (Stomach) Cancer, Metastatic Malignant Solid Tumor, Stage IVB Gastric (Stomach) Cancer, Stage IVB Hepatocellular Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Vaginal Carcinoma, Refractory Head and Neck Carcinoma, Recurrent Nasopharyngeal Throat Cancer, Recurrent Kaposi Sarcoma, Recurrent Leiomyosarcoma, Recurrent Vulvar Cancer, EBV-Related Hodgkin Lymphoma, Refractory Leiomyosarcoma, Recurrent Anal Canal Cancer, Refractory Vulvar Carcinoma, EBV-Related Malignant Neoplasm, Stage IVA Nasopharyngeal Throat Cancer, Hepatitis C Virus-Related Hepatocellular Carcinoma, Stage IV Anal Cancer, Stage IVA Hepatocellular Cancer, Stage III Penile Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage IVA Cervical Cancer, Refractory Non-Hodgkin Lymphoma, Human Papillomavirus (HPV)-Related Cervical Cancer, Refractory Cervical Carcinoma, Stage IIIA Anal Cancer, Stage IVA Vulvar Cancer, Recurrent Cervical Cancer, Stage IIIA Cervical Cancer, Stage IV Hepatocellular Cancer, Stage IVA Vaginal Cancer, Stage III Cervical Cancer, Refractory Hodgkin Lymphoma, Recurrent Gastric (Stomach) Cancer, Stage III Hepatocellular Cancer, Recurrent Non-Hodgkin Lymphoma, Recurrent Hepatocellular Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IIIB Anal Cancer, Locally Advanced Head and Neck Carcinoma, Stage IIIA Penile Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIC Anal Cancer, EBV-Related Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IIIA Hepatocellular Cancer, Stage III Anal Cancer, Refractory Malignant Solid Tumor, Stage IIIB Cervical Cancer, Stage III Vaginal Cancer, Stage IV Vulvar Cancer",
    "Prostate Cancer",
    "Kaposi Sarcoma",
    "Cigarette Smoking-Related Carcinoma",
    "Adenoid Cystic Carcinoma, Metastatic Adenoid Cystic Cancer",
    "Stage IIA Prostate Cancer, Stage I Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIB Prostate Cancer, Prostate Adenocarcinoma, Stage II Prostate Cancer, Stage IIC Prostate Cancer",
    "Refractory Grade 2 Follicular Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma",
    "Stage IIA Pancreatic Cancer, Stage IB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage I Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma, Stage 0 Pancreatic Cancer",
    "Primary Peritoneal Serous Adenocarcinoma, Ovarian Cancer, Primary Peritoneal Carcinosarcoma, Malignant Ovarian Serous Tumor, Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Ovarian Carcinosarcoma, Fallopian Tube Carcinosarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer, Ovarian Mixed Epithelial Carcinoma",
    "Rhabdomyosarcoma",
    "Advanced Malignant Solid Tumor",
    "Stage IV Uveal Melanoma, Metastatic Uveal Melanoma",
    "Recurrent Non-Small Cell Lung Cancer, Recurrent Malignant Solid Tumor, Recurrent Colorectal Adenocarcinoma, Recurrent Lymphoma, Recurrent Malignant Ovarian Granulosa Cell Tumor",
    "Intraepithelial Neoplasia in Barrett Esophagus, Barrett Esophagus",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Recurrent Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Anemia, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIIC Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Colon Adenocarcinoma, Stage IIA Colon Cancer, Metastatic Malignant Neoplasm to the Liver, Stage I Colon Cancer, Stage IIB Colon Cancer, Stage IIIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Refractory Acute Leukemia of Ambiguous Lineage, Recurrent Hodgkin Lymphoma, Refractory Chronic Myelogenous Leukemia (CML), Recurrent Mantle Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Refractory Lymphoma, Recurrent Chronic Myelogenous Leukemia (CML), Recurrent Anaplastic Large Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Leukemia of Ambiguous Lineage",
    "Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Invasive Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer",
    "Stage IB Cervical Cancer, Stage IB1 Cervical Cancer, Stage IB2 Cervical Cancer, Stage II Cervical Cancer, Stage IIA Cervical Cancer, Stage IIA1 Cervical Cancer, Stage IIA2 Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Human Papillomavirus (HPV)-Related Cervical Cancer",
    "Neurofibromatosis Type 1, Plexiform Neurofibroma",
    "Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Endometrial Clear Cell Adenocarcinoma, Stage I Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer",
    "Neurofibromatosis Type 2, Grade II Meningioma, Grade III Meningioma, Anaplastic (Malignant) Meningioma, Atypical Meningioma, Recurrent Meningioma, Neurofibromatosis Type 1",
    "Metastatic Malignant Neoplasm to the Lung, Non-Small Cell Lung Cancer",
    "Metastatic Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Unresectable Hepatocellular Cancer, BCLC Stage A Hepatocellular Cancer",
    "Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IC Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Locally Advanced Esophageal Adenocarcinoma",
    "Metastatic Malignant Neoplasm to the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes, Oligometastatic Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Adenocarcinoma, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Previously Treated Myelodysplastic Syndrome, Myelodysplastic Syndrome, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Acute Myeloid Leukemia (AML), Refractory Anaplastic Large Cell Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Anaplastic Large Cell Lymphoma",
    "Malignant Neoplasm",
    "High Grade Anal Canal Intraepithelial Neoplasia, High Grade Vulvar Squamous Intraepithelial Lesion",
    "Pancreatic Mucinous-Cystic Neoplasm",
    "Obesity-Related Malignant Neoplasm",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage I Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIC Prostate Cancer, Recurrent Prostate Adenocarcinoma",
    "Retroperitoneal Pain Syndrome, Metastatic Unresectable Malignant Neoplasm, Pancreatic Cancer",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Recurrent Primary Peritoneal Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Platinum-Resistant Ovarian Cancer, Recurrent Endometrial Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Platinum-Resistant Head and Neck Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck Carcinoma, Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma",
    "Cervical Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Disease, Myelofibrosis, Chronic Myeloproliferative Disease",
    "High Grade Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Carcinosarcoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Primary Peritoneal Carcinosarcoma, Platinum Sensitive Ovarian Cancer, Platinum-Sensitive Primary Peritoneal Cancer, Platinum-Sensitive Fallopian Tube Cancer, Primary Peritoneal Clear Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Endometrioid Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Carcinosarcoma, Ovarian Cancer, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Ovarian Cancer, Ovarian Endometrioid Adenocarcinoma, Ovarian Carcinosarcoma",
    "Unresectable Osteosarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage IV Retroperitoneal Sarcoma, Locally Advanced Soft Tissue Sarcoma, Unresectable Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma, Dedifferentiated Chondrosarcoma, Metastatic Osteosarcoma, Metastatic Chondrosarcoma",
    "Metastatic Prostatic Adenocarcinoma, Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone",
    "Human Papillomavirus Infection, Cervical Cancer",
    "Ductal Carcinoma In Situ (DCIS)",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Prostate Cancer, Stage IVB Prostate Cancer",
    "Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Urothelial Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Stage 0a Bladder Cancer, Stage 0is Bladder Cancer, Stage I Bladder Cancer",
    "Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Locally Advanced Prostate Carcinoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Non-Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Hodgkin Lymphoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid System Neoplasm, Hereditary Neoplastic Syndrome, Ductal Carcinoma In Situ (DCIS), Hereditary Breast and Ovarian Cancer Syndrome, Lynch Syndrome",
    "Anaplastic Astrocytoma, Glioblastoma, Malignant Glioma",
    "Stage IIIA Hepatocellular Cancer, Advanced Malignant Solid Tumor, Stage IVB Hepatocellular Cancer, Advanced Renal Cell Carcinoma, Metastatic Ovarian Carcinoma, Triple-Negative Breast Cancer, Recurrent Hepatocellular Cancer, Metastatic Prostate Cancer, Recurrent Ovarian Cancer, Metastatic Differentiated Thyroid Gland Carcinoma, Metastatic Kaposi Sarcoma, Refractory Differentiated Thyroid Gland Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IVA Prostate Cancer, Stage III Breast Cancer, Stage IIIA Prostate Cancer, Stage IV Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Urothelial Cancer, Metastatic Head and Neck Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Head and Neck Cancer, Castration-Resistant Prostate Cancer, Stage III Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage IV Differentiated Thyroid Gland Cancer, Stage IVA Differentiated Thyroid Gland Cancer, Stage IVB Differentiated Thyroid Gland Cancer, Stage III Thyroid Gland Medullary Cancer, Stage IV Thyroid Gland Medullary Cancer, Stage IVA Thyroid Gland Medullary Cancer, Stage IVB Thyroid Gland Medullary Cancer, Advanced Urothelial Cancer, Metastatic Renal Cell Cancer, Advanced Melanoma, Metastatic Triple-Negative Breast Carcinoma, Recurrent Thyroid Gland Medullary Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Prostate Carcinoma, Advanced Kaposi Sarcoma, Recurrent Urothelial Cancer, Advanced Lung Small Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Advanced Ovarian Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Advanced Differentiated Thyroid Gland Carcinoma, HIV Infection, Recurrent Melanoma, Recurrent Head and Neck Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Recurrent Prostate Cancer, Recurrent Kaposi Sarcoma, Metastatic Melanoma, Recurrent Small Cell Lung Cancer, Stage IIIC Lung Cancer, Stage IVC Thyroid Gland Medullary Cancer, Stage III Differentiated Thyroid Gland Cancer",
    "Cervical Cancer",
    "Multicentric Angiofollicular Lymphoid Hyperplasia",
    "Aggressive Variant Prostate Carcinoma, Metastatic Small Cell Neuroendocrine Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer",
    "Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, BCLC Stage B Hepatocellular Cancer",
    "Cervical Cancer",
    "Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Refractory Hodgkin Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma",
    "EBV-Positive T-Cell Lymphoproliferative Disorder of Childhood, Hodgkin Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Non-Hodgkin Lymphoma, EBV-Positive Neoplastic Cells Present",
    "Chronic Lymphocytic Leukemia (CLL), Anaplastic Large Cell Lymphoma, B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Nasal Type Extranodal NK/T-Cell Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, Nodular Lymphocyte Predominant Hodgkin Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Composite Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Hepatosplenic T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Small Lymphocytic Lymphoma, Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Triple-Hit Lymphoma, Double-Hit Lymphoma",
    "Stage III Prostate Cancer, Prostate Adenocarcinoma, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer",
    "Recurrent Glioblastoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma, HER2 Negative Breast Carcinoma, Recurrent Breast Cancer, Metastatic Breast Carcinoma",
    "Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Recurrent Primary Peritoneal Cancer, Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer",
    "Acute Myeloid Leukemia with Mutated NPM1, Acute Myeloid Leukemia with Gene Mutations",
    "Refractory T Acute Lymphoblastic Leukemia, Recurrent T Acute Lymphoblastic Leukemia, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory T Lymphoblastic Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma",
    "Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIB Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Recurrent Ovarian Cancer, Stage III Fallopian Tube Cancer",
    "Metastatic Malignant Neoplasm in the Brain, Recurrent Brain Neoplasm, Metastatic Malignant Neoplasm in the Brain Stem, Solid Tumor, Metastatic Malignant Neoplasm to the Leptomeninges, Brain/Spinal Cord Tumor, Metastatic Malignant Neoplasm to the Central Nervous System, Metastatic Malignant Neoplasm to the Spinal Cord",
    "Hepatocellular Cancer, Hepatoblastoma",
    "High Grade Dysplasia in Barrett Esophagus, Barrett Esophagus-Negative for Dysplasia, Barrett Esophagus, Barrett Adenocarcinoma, Low Grade Dysplasia in Barrett Esophagus, Dysplasia in Barrett Esophagus, Intestinal Metaplasia, Healthy Control",
    "Advanced Breast Carcinoma, Stage IV Breast Cancer, HER2-Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer, Metastatic Malignant Neoplasm to Soft Tissues",
    "Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Refractory Osteosarcoma, Metastatic Uveal Melanoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Recurrent Neuroblastoma, Recurrent Breast Cancer, Recurrent Osteosarcoma",
    "Acute Myeloid Leukemia (AML)",
    "Hematopoietic and Lymphoid Cell Neoplasm, T-Cell and NK-Cell Neoplasm, Mature T-Cell and NK-Cell Neoplasm, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Nasal Type Extranodal NK/T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Aggressive NK-Cell Leukemia, Stage III Nasal Type NK/T-Cell Lymphoma, Stage IV Nasal Type NK/T-Cell Lymphoma, Stage III Angioimmunoblastic T-Cell Lymphoma, Stage IV Angioimmunoblastic T-Cell Lymphoma, Stage III Enteropathy-Associated T-Cell Lymphoma, Stage IV Enteropathy-Associated T-Cell Lymphoma",
    "Stage 0 Colorectal (Colon or Rectal) Cancer, Stage I Colorectal (Colon or Rectal) Cancer, Stage II Colorectal (Colon or Rectal) Cancer, Stage IIA Colorectal (Colon or Rectal) Cancer, Stage IIB Colorectal (Colon or Rectal) Cancer, Stage IIC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Colorectal Adenoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelofibrosis, Recurrent Myeloproliferative Neoplasm, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Juvenile Myelomonocytic Leukemia",
    "Metastatic Malignant Neoplasm to Soft Tissues, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Prostate Cancer, Metastatic Prostate Cancer",
    "Breast Adenocarcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Pancreatic Intraductal Papillary-Mucinous Tumor",
    "Stage II Breast Cancer, Stage IA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Early-Stage Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Invasive Breast Cancer, Stage IIB Breast Cancer",
    "HIV Infection, High Grade Anal Canal Intraepithelial Neoplasia",
    "Recurrent Malignant Solid Tumor, Advanced Leukemia, Refractory Malignant Solid Tumor, Recurrent Leukemia",
    "Soft Tissue Sarcoma of the Trunk and Extremities, Recurrent Soft Tissue Sarcoma of the Trunk and Extremities",
    "Pneumonitis, Hemorrhagic Cystitis, Primary Immunodeficiency Syndrome, Refractory Adenovirus Infection, Colitis, Hepatitis",
    "Refractory Cytomegalovirus Infection",
    "Primary Immunodeficiency Syndrome, Epstein-Barr Virus Infection, Colitis",
    "Giant Cell Tumor of Bone",
    "Breast Cancer",
    "Head and Neck Carcinoma, Malignant Head and Neck Neoplasm",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage 0 Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, HER2-Positive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Recurrent Breast Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Recurrent Breast Cancer",
    "Unresectable Esophageal Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Esophageal Adenocarcinoma",
    "Central Nervous System Lymphoma",
    "Myelofibrosis, Chronic Myeloproliferative Disease",
    "Cervical Cancer, Human Papillomavirus Infection",
    "Esophageal Squamous Intraepithelial Neoplasia",
    "Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer, Stage IIA Breast Cancer, Stage IIIC Breast Cancer",
    "Recurrent Sarcoma, Unresectable Sarcoma, Advanced Sarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Advanced Malignant Peripheral Nerve Sheath Tumor, Recurrent Malignant Peripheral Nerve Sheath Tumor, Metastatic Sarcoma",
    "Congenital Pseudarthrosis of Tibia, Neurofibroma, Neurofibromatosis Type 1, Plexiform Neurofibroma, Visual Pathway Glioma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Unresectable Malignant Peripheral Nerve Sheath Tumor, Sporadic Malignant Peripheral Nerve Sheath Tumor, Neurofibromatosis Type 1, Metastatic Malignant Peripheral Nerve Sheath Tumor",
    "Lung Neoplasm",
    "Malignant Neoplasm",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Small Cell Neuroendocrine Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Glioma, Meningioma, Schwannoma, Neurofibroma, Neurofibromatosis Type 2, Acoustic Schwannoma",
    "Fusion-Positive Alveolar Rhabdomyosarcoma, Fusion-Negative Alveolar Rhabdomyosarcoma, Advanced Liposarcoma, Mesenchymal Chondrosarcoma, Metastatic Osteosarcoma, Metastatic Ewing Sarcoma, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Metastatic Liposarcoma, Embryonal Rhabdomyosarcoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Prostate Adenocarcinoma",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Hormone Receptor Positive Breast Carcinoma",
    "Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Aggressive NK-Cell Leukemia, Refractory T-Cell Prolymphocytic Leukemia, Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Primary Cutaneous Gamma-Delta T-Cell Lymphoma, Primary Cutaneous Anaplastic Large Cell Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Refractory T-Cell Large Granular Lymphocyte Leukemia, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Aggressive NK-Cell Leukemia, Recurrent T-Cell Large Granular Lymphocyte Leukemia, Recurrent T-Cell Prolymphocytic Leukemia, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Peutz-Jeghers Syndrome, Pancreatic Intraductal Papillary-Mucinous Tumor, Lynch Syndrome, Hereditary Pancreatic Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma",
    "Anaplastic (Malignant) Meningioma, Atypical Meningioma, Unresectable Meningioma, Recurrent Meningioma, Grade II Meningioma, Grade III Meningioma",
    "HER2-Positive Breast Carcinoma, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer",
    "Breast Cancer",
    "Ductal Carcinoma In Situ (DCIS)",
    "Recurrent Soft Tissue Sarcoma, Extraskeletal Myxoid Chondrosarcoma, Stage I Soft Tissue Sarcoma, Stage II Soft Tissue Sarcoma, Stage IB Soft Tissue Sarcoma, Stage IIA Soft Tissue Sarcoma, Stage IIB Soft Tissue Sarcoma, Stage IA Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma",
    "Central Nervous System B-Cell Non-Hodgkin Lymphoma",
    "Neurofibromatosis Type 1, Plexiform Neurofibroma",
    "Ovarian Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Multiple Myeloma/Plasma Cell Myeloma, B-Cell Non-Hodgkin Lymphoma",
    "Inflammatory Breast Cancer, Unilateral Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Triple-Negative Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Bilateral Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Stage IV Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer",
    "Dedifferentiated Liposarcoma, Pleomorphic Liposarcoma, Prostate Cancer, Non-Melanoma Skin Cancer, Soft Tissue Sarcoma, Undifferentiated Pleomorphic Sarcoma, Carcinoma In Situ",
    "Oligometastatic Malignant Solid Neoplasm",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Invasive Lobular Breast Carcinoma, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer",
    "FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma, FIGO Grade 2 Endometrial Endometrioid Adenocarcinoma, Atypical Endometrial Hyperplasia",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Aplastic Anemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Chronic Myeloproliferative Disease",
    "Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Hematopoietic and Lymphoid System Disorder",
    "Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Invasive Breast Cancer, Stage IIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Inflammatory Breast Cancer, Breast Angiosarcoma",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Prostate Adenocarcinoma",
    "Stage 0 Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Invasive Breast Ductal Carcinoma and Invasive Lobular Carcinoma, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Bilateral Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage IIIC Breast Cancer",
    "Recurrent Breast Cancer, HER2-Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Adenocarcinoma, Locally Advanced Breast Adenocarcinoma, Metastatic Breast Carcinoma",
    "Unresectable Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Metastatic Carcinoma in the Liver",
    "Recurrent Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Stage IIA Prostate Cancer, Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer",
    "Retinitis, Interstitial Pneumonia, Viral Infection, Hepatitis, Colitis, Viremia",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage I Oropharyngeal Throat Squamous Cell Cancer, Stage II Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer",
    "Unresectable Urothelial Carcinoma, Stage IV Bladder Urothelial Cancer, Infiltrating Bladder Urothelial Carcinoma, Micropapillary Variant, Infiltrating Bladder Urothelial Carcinoma with Glandular Differentiation, Infiltrating Bladder Urothelial Carcinoma Sarcomatoid Variant, Metastatic Urothelial Cancer, Stage III Bladder Urothelial Cancer, Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation, Refractory Urothelial Carcinoma",
    "Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Breast Cancer, Locally Advanced Breast Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Locally Advanced Colorectal Carcinoma, Stage IIIC Breast Cancer, Stage IVB Lung Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Metastatic Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Breast Cancer, Metastatic Breast Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Breast Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIC Lung Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Locally Advanced Melanoma, Locally Advanced Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage III Lung Cancer, Stage IV Lung Cancer, Locally Advanced Lung Carcinoma, Metastatic Colorectal Carcinoma, Stage IIIB Breast Cancer, Metastatic Melanoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Lung Carcinoma, Stage IIIC Breast Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer",
    "Malignant Solid Tumor, Metastatic Epithelioid Sarcoma, Metastatic Synovial Sarcoma, Unresectable Rhabdoid Tumor, Refractory Kidney Medullary Carcinoma, Unresectable Epithelioid Sarcoma, Refractory Extrarenal Rhabdoid Tumor of the Ovary, Recurrent Kidney Medullary Carcinoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Rhabdoid Tumor of the Kidney, Refractory Rhabdoid Tumor of the Kidney, Refractory Dedifferentiated Chordoma, Metastatic Rhabdoid Tumor, Recurrent Epithelioid Sarcoma, Refractory Epithelioid Sarcoma, Refractory Rhabdoid Tumor, Recurrent Extrarenal Rhabdoid Tumor of the Ovary, Recurrent Dedifferentiated Chordoma, Refractory Synovial Sarcoma, Recurrent Rhabdoid Tumor, Unresectable Synovial Sarcoma, Refractory Atypical Teratoid/Rhabdoid Tumor, Recurrent Synovial Sarcoma",
    "Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Malignant Neoplasm, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage II Pancreatic Cancer",
    "Pancreatic Ductal Adenocarcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML), Erythroleukemia, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Secondary Acute Myeloid Leukemia (AML), Recurrent B Acute Lymphoblastic Leukemia, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Chronic Myelogenous Leukemia (CML), Refractory Acute Myeloid Leukemia (AML), Refractory B Acute Lymphoblastic Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Eosinophilic Leukemia, Recurrent Chronic Myelogenous Leukemia (CML)",
    "Community-Acquired Pneumonia, Influenza, COVID-19",
    "Recurrent Gastric Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Leukemia, Acute Biphenotypic Leukemia, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Disease, Recurrent Acute Myeloid Leukemia (AML), Chronic Myeloproliferative Disease, Chronic Myelogenous Leukemia (CML), Refractory Acute Leukemia, Acute Lymphoblastic Leukemia (ALL)",
    "Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Mantle Cell Lymphoma, B-Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Hematologic Malignancy, Recurrent Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Unresectable Low Grade Glioma, Low Grade Glioma, Neurofibromatosis Type 1",
    "Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer, Resectable Pancreatic Cancer",
    "Catheter-Related Infection, Central Line Infection",
    "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Bladder Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Esophageal Squamous Cell Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Bladder Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Malignant Neoplasm, Stage III Lung Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Esophageal Squamous Cell Cancer, Stage III Renal Cell Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage III Esophageal Squamous Cell Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Bladder Cancer, Stage IIIB Bladder Cancer, Stage IIIA Lung Cancer, Advanced Colorectal Carcinoma, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Advanced Esophageal Carcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Gastric (Stomach) Cancer, Stage IIIB Lung Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Lung Non-Small Cell Carcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Esophageal Squamous Cell Cancer, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Squamous Cell Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Renal Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Advanced Kidney Carcinoma, Advanced Lung Small Cell Carcinoma, Stage IVB Bladder Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIC Lung Cancer, Advanced Melanoma, Advanced Gastric Carcinoma, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Gastric (Stomach) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Gastric (Stomach) Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IVA Lung Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Lung Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IVB Lung Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVA Esophageal Squamous Cell Cancer, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer",
    "Malignant Neoplasm, Solid Tumor, Solid Tumor, Malignant Neoplasm, Advanced Malignant Neoplasm, Advanced Malignant Solid Tumor",
    "Prostate Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Stage III Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Refractory Soft Tissue Sarcoma, Stage III Soft Tissue Sarcoma, Advanced Malignant Solid Tumor, Stage IV Soft Tissue Sarcoma, Sarcoma, Recurrent Soft Tissue Sarcoma",
    "Stage IIIB Non-Small Cell Lung Cancer, Advanced Head and Neck Cancer, Stage IV Prostate Cancer, Stage IVB Colon Cancer, Stage IV Breast Cancer, Advanced Melanoma, Stage III Non-Small Cell Lung Cancer, Stage IIIC Breast Cancer, Stage IV Colon Cancer, Stage III Colon Cancer, Stage IV Renal Cell Cancer, Advanced Lymphoma, Stage IV Pancreatic Cancer, Stage IIIB Colon Cancer, Stage III Breast Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Advanced Urothelial Cancer, Stage III Prostate Cancer, Castration-Resistant Prostate Cancer, Triple-Negative Breast Cancer, Advanced Diffuse Large B-Cell Lymphoma, Stage II Pancreatic Cancer, Stage IVA Colon Cancer, Stage IIIA Breast Cancer, Metastatic Malignant Solid Tumor, Metastatic Urothelial Cancer, Stage IIIB Breast Cancer, Metastatic Melanoma, Stage III Pancreatic Cancer, Stage III Renal Cell Cancer, Metastatic Head and Neck Cancer, Advanced Malignant Solid Tumor, Stage IIIC Colon Cancer, Stage IIIA Colon Cancer",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVA Hepatocellular Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIC Hepatocellular Cancer, Metastatic Malignant Neoplasm to the Liver, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Hepatocellular Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Lung Cancer, Advanced Hepatocellular Carcinoma, Stage IIIA Hepatocellular Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIB Gastric (Stomach) Cancer, Metastatic Gastric Carcinoma, Metastatic Colorectal Carcinoma, Stage IIIB Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage III Hepatocellular Cancer, Stage III Gastric (Stomach) Cancer, BCLC Stage C Hepatocellular Cancer",
    "Stage I Lung Cancer, Stage IIB Lung Cancer, Stage IIA Lung Cancer, Non-Small Cell Lung Cancer, Stage IA1 Lung Cancer, Stage II Lung Cancer, Stage IB Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer",
    "Secondary Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), Refractory Anemia, Secondary Acute Myeloid Leukemia (AML), Hematologic and Lymphocytic Disorder, Myelodysplastic Syndrome with Excess Blasts, Myelodysplastic Syndrome with Ring Sideroblasts, Acute Myeloid Leukemia (AML)",
    "Locally Advanced Intrahepatic Cholangiocarcinoma, Hepatitis B Infection, Stage IIIA Hepatocellular Cancer, Metastatic Intrahepatic Cholangiocarcinoma, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Locally Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Hepatocellular Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma",
    "High-Risk Neuroblastoma",
    "Refractory Barrett Esophagus",
    "Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Triple-Negative Breast Cancer, Locally Advanced Breast Carcinoma, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Recurrent Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Stage IIID Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage III Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Idiopathic Thrombocytopenic Purpura",
    "Metastatic Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Neoplasm, Advanced Malignant Neoplasm",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage III Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Stage IB Lung Cancer, Stage II Lung Cancer, Stage II Non-Small Cell Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIA Lung Cancer, Stage IIIA Lung Cancer, Non-Small Cell Lung Cancer",
    "Metastatic Colorectal Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma",
    "Locally Advanced Urothelial Cancer, Advanced Urothelial Cancer, Metastatic Transitional Cell Cancer, Metastatic Urothelial Cancer",
    "Metastatic Colorectal Carcinoma, Metastatic Lung Squamous Cell Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Recurrent Lung Adenocarcinoma, Recurrent Ovarian Cancer, Metastatic Breast Carcinoma, Stage IVB Ovarian Cancer, Recurrent Lung Squamous Cell Carcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Colorectal Carcinoma, Unresectable Breast Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Pancreatic Carcinoma, Unresectable Ovarian Carcinoma, Locally Advanced Ovarian Carcinoma, Metastatic Lung Adenocarcinoma, Locally Advanced Lung Adenocarcinoma, Unresectable Lung Adenocarcinoma, Unresectable Pancreatic Cancer, Recurrent Pancreatic Cancer, Recurrent Breast Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IVA Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Breast Cancer, Stage IVB Lung Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer, Stage IV Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Stage IIIC Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Recurrent Ovarian Mucinous Adenocarcinoma, Unresectable Malignant Solid Tumor, Stage IIIB Colorectal (Colon or Rectal) Cancer, Ovarian Signet Ring Stromal Tumor, Stage IIIA Colorectal (Colon or Rectal) Cancer, Metastatic Ovarian Carcinoma, Stage IIIB Lung Cancer, Recurrent Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Central Nervous System Lymphoma, Refractory Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Stage IIIB Breast Cancer, Triple-Negative Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIIC Breast Cancer",
    "Multiple Organ Dysfunction Syndrome, Transplant-Associated Thrombotic Microangiopathy, Atypical Hemolytic Uremic Syndrome",
    "Advanced Esophageal Carcinoma, Stage IIIA Lung Cancer, Stage III Lung Cancer, Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Stage IIIC Lung Cancer, Advanced Head and Neck Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer, Advanced Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage IVA Lung Cancer",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Recurrent Lymphoma, Recurrent Malignant Solid Tumor, Recurrent Head and Neck Squamous Cell Cancer",
    "Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Malignant Neoplasm, Stage IV Colorectal (Colon or Rectal) Cancer, Pancreatic Ductal Adenocarcinoma, Stage III Ovarian Cancer, Stage IVB Prostate Cancer, Stage IV Breast Cancer, Stage IIIC Ovarian Cancer, Stage IVA Prostate Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Prostate Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Metastatic Prostate Cancer, Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer, Triple-Negative Breast Cancer, Non-Small Cell Lung Cancer, Advanced Microsatellite Stable Colorectal Carcinoma, Advanced Renal Cell Carcinoma, Stage IV Ovarian Cancer, Castration-Resistant Prostate Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IVB Lung Cancer, Stage III Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IIA Pancreatic Cancer",
    "Castration-Resistant Prostate Cancer",
    "Advanced Renal Cell Carcinoma, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage II Pancreatic Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIB Pancreatic Cancer, Stage IV Lung Cancer, Stage IIA Pancreatic Cancer, Stage IIIC Lung Cancer, Stage III Pancreatic Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Malignant Solid Tumor, Advanced Colorectal Carcinoma, Metastatic Colorectal Carcinoma, Advanced Malignant Solid Tumor, Metastatic Gastric Carcinoma, Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer, Metastatic Renal Cell Cancer, Stage IIIB Lung Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Pancreatic Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Urothelial Cancer, Advanced Urothelial Cancer, Stage IIIB Breast Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Breast Cancer",
    "Fungal Infection",
    "Adenoviridae, BK Virus Reactivation, Epstein-Barr Virus Positive, Cytomegaloviral Infection, Viral Infection, BK Virus Infection",
    "Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma",
    "Metastatic Head and Neck Squamous Cell Cancer, Metastatic Malignant Solid Tumor, Advanced Head and Neck Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage III Lung Cancer, Refractory Head and Neck Squamous Cell Cancer, Stage IV Lung Cancer, Advanced Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer",
    "Sickle Beta 0 Thalassemia, Sickle Cell-SS Disease, Sickle Cell Disease, Acute Chest Syndrome",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage IIIA Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Lung Cancer, Stage IV Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Lung Cancer, Stage IVA Hepatocellular Cancer, Stage IV Lung Cancer, Stage IVB Hepatocellular Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Unresectable Melanoma, Advanced Renal Cell Carcinoma, Advanced Melanoma, Metastatic Renal Cell Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Renal Cell Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Colorectal Carcinoma, Advanced Colorectal Carcinoma, Advanced Hepatocellular Carcinoma, Metastatic Melanoma, Unresectable Hepatocellular Cancer, Stage IIID Cutaneous (Skin) Melanoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Metastatic Urothelial Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer",
    "Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Marginal Zone Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage III Ovarian Cancer",
    "Type 2 Diabetes Mellitus, Endogenous Cushing Syndrome",
    "Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Refractory Cutaneous (Skin) Melanoma, Metastatic Uveal Melanoma, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gallbladder Cancer, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Ovarian Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Metastatic Distal Esophagus Adenocarcinoma, Unresectable Distal Esophagus Adenocarcinoma, Unresectable Uveal Melanoma, Stage IV Pancreatic Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Distal Bile Duct Adenocarcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma, Metastatic Gallbladder Carcinoma, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Thyroid Gland Anaplastic Carcinoma, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Unresectable Colorectal Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Unresectable Distal Bile Duct Adenocarcinoma, Metastatic Ovarian Undifferentiated Carcinoma, Unresectable Ovarian Undifferentiated Carcinoma, Stage IV Breast Cancer, Unresectable Pancreatic Ductal Adenocarcinoma, Stage III Hepatocellular Cancer, Unresectable Hepatocellular Cancer, High Grade Ovarian Serous Adenocarcinoma, Advanced Thyroid Gland Anaplastic Carcinoma, Stage IV Gallbladder Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Gallbladder Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Hepatocellular Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gallbladder Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Gallbladder Cancer, Stage IVB Hepatocellular Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVA Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIB Hepatocellular Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIA Hepatocellular Cancer, Metastatic Cutaneous Melanoma, Metastatic Colorectal Adenocarcinoma, Stage IVA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Pancreatic Cancer, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IIIA2 Ovarian Cancer, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Breast Carcinoma, Stage IIIB Ovarian Cancer, Metastatic Gastric Adenocarcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Breast Cancer, Advanced Malignant Solid Tumor, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Metastatic Lung Non-Small Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer",
    "Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL), Refractory B Acute Lymphoblastic Leukemia, Secondary Central Nervous System Lymphoma, Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Nasopharyngeal Throat Cancer, Advanced Head and Neck Squamous Cell Cancer, Recurrent Metastatic Squamous Cell Cancer to the Neck with Occult Primary, Recurrent Head and Neck Carcinoma, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer",
    "Metastatic Breast Adenocarcinoma, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Invasive Breast Cancer, HER2-Positive Breast Carcinoma, Advanced Breast Adenocarcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Hodgkin Lymphoma, Waldenstrom Macroglobulinemia, Recurrent Small Lymphocytic Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Grade 3a Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Grade 1 Follicular Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Grade 2 Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Lymphoma, Refractory Marginal Zone Lymphoma, Grade 3 Follicular Lymphoma, Refractory Lymphoma",
    "Refractory Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Malignant Salivary Gland Tumor",
    "Stage IV Hepatocellular Cancer, Stage III Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage III Cervical Cancer, Stage III Pancreatic Cancer, Stage IV Cervical Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IIB Pancreatic Cancer, Stage III Esophageal Adenocarcinoma, Stage IIIA Breast Cancer, Stage IVA Hepatocellular Cancer, Stage IV Head and Neck Squamous Cell Cancer, Advanced Triple-Negative Breast Carcinoma, Advanced Pancreatic Carcinoma, Advanced Gastric Carcinoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IVB Esophageal Adenocarcinoma, Metastatic Cervical Carcinoma, Advanced Esophageal Carcinoma, Advanced Cervical Carcinoma, Metastatic Pancreatic Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIA Pancreatic Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Cervical Cancer, Stage II Pancreatic Cancer, Stage IIIA Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Advanced Melanoma, Stage IVB Cervical Cancer, Triple-Negative Breast Cancer, Stage IV Pancreatic Cancer, Metastatic Gastric Carcinoma, Stage IV Breast Cancer, Advanced Renal Cell Carcinoma, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Advanced Malignant Neoplasm, Metastatic Esophageal Carcinoma, Stage IVA Cervical Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Triple-Negative Breast Carcinoma, Stage IIIB Breast Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IIIC Breast Cancer, Stage IV Renal Cell Cancer, Metastatic Malignant Neoplasm, Advanced Hepatocellular Cancer, Stage III Breast Cancer, Metastatic Renal Cell Cancer, Metastatic Hepatocellular Carcinoma, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage III Lung Cancer, Stage III Breast Cancer, Stage IVB Hepatocellular Cancer, Stage III Renal Cell Cancer, Stage IIIB Cervical Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Recurrent Gliosarcoma, Recurrent Glioblastoma",
    "Retinoblastoma, Undifferentiated Pleomorphic Sarcoma, Metastatic Malignant Neoplasm in the Bone Marrow, Refractory Neuroblastoma, Spindle Cell Sarcoma, Fibrosarcoma, Soft Tissue Sarcoma, Recurrent Osteosarcoma, Desmoplastic Small Round Cell Tumor, Refractory Osteosarcoma, Liposarcoma, Melanoma, Recurrent Neuroblastoma, Metastatic Medulloblastoma, Refractory Malignant Solid Tumor, Leiomyosarcoma, Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Locally Advanced Cutaneous Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage IVA Lung Cancer, Stage IV Lung Cancer, Skin Squamous Cell Cancer, Hodgkin Lymphoma, Anal Canal Squamous Cell Carcinoma, Gastroesophageal Junction Adenocarcinoma, Metastatic Melanoma, Unresectable Skin Carcinoma, Cervical Squamous Neoplasm, Stage IVB Lung Cancer, Locally Advanced Skin Squamous Cell Carcinoma, Stage III Cutaneous (Skin) Melanoma, Non-Small Cell Lung Cancer, Unresectable Lymphoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Urothelial Cancer, Unresectable Renal Cell Carcinoma, Metastatic Renal Cell Cancer, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Unresectable Gastric Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Advanced Malignant Solid Tumor, Metastatic Urothelial Cancer, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Metastatic Skin Squamous Cell Carcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Renal Cell Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Head and Neck Squamous Cell Cancer, Advanced Lymphoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Diffuse Large B-Cell Lymphoma, Unresectable Melanoma, Stage IV Head and Neck Squamous Cell Cancer, Unresectable Urothelial Carcinoma, Metastatic Anal Canal Carcinoma, Stage IIIC Lung Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage IIIA Lung Cancer, Stage IIIB Anal Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIC Anal Cancer, Stage III Lung Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Anal Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Anal Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Lung Cancer",
    "Hepatocellular Cancer",
    "Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage III Pancreatic Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Lung Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA2 Ovarian Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Refractory Pancreatic Carcinoma, Refractory Colorectal Cancer, Stage IVB Ovarian Cancer, Stage II Pancreatic Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVA Uterine (including Endometrial) Cancer, Refractory Thyroid Gland Cancer, Unresectable Melanoma, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Lung Cancer, Metastatic Melanoma, Advanced Melanoma, Refractory Non-Small Cell Lung Cancer, Unresectable Malignant Solid Tumor, Stage IIB Pancreatic Cancer, Refractory Melanoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Thyroid Gland Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Unresectable Thyroid Gland Cancer, Metastatic Malignant Solid Tumor, Stage IIA Pancreatic Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Ovarian Carcinoma, Advanced Thyroid Gland Carcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Refractory Endometrial Carcinoma, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Pancreatic Cancer",
    "Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IVB Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Recurrent Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Refractory Fallopian Tube Cancer, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Stage IVA Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Refractory Ovarian Carcinoma, Stage IVB Primary Peritoneal Cancer, Advanced Fallopian Tube Carcinoma, Refractory Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Recurrent Primary Peritoneal Cancer, Stage IVA Ovarian Cancer, Stage IIIB Ovarian Cancer",
    "Advanced Urothelial Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Metastatic Urothelial Cancer, Locally Advanced Urothelial Cancer, Stage IIIB Bladder Cancer, Metastatic Urethral Urothelial Cancer, Stage IVB Bladder Cancer, Stage IV Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Metastatic Ureter Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Stage III Renal Pelvis Cancer, Stage IIIA Bladder Cancer, Stage IVA Bladder Cancer, Stage III Urethral Cancer",
    "Resectable Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, Resectable Hepatocellular Cancer",
    "Stage IIIA Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Soft Tissue Sarcoma, Locally Advanced Soft Tissue Sarcoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Advanced Glioblastoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IIIB Breast Cancer, Advanced Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Breast Cancer, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Unresectable Triple-Negative Breast Carcinoma, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IV Pancreatic Cancer, Metastatic Malignant Solid Tumor, Metastatic Glioblastoma",
    "Refractory Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Marginal Zone Lymphoma, Lymphoplasmacytic Lymphoma, Follicular Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma, Recurrent Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia with Multilineage Dysplasia, Secondary Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Stage I Bladder Cancer, Refractory Bladder Cancer, Superficial Bladder Cancer, Stage 0a Bladder Cancer",
    "Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Endometrioid Primary Peritoneal Carcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Primary Peritoneal Undifferentiated Carcinoma, Recurrent Primary Peritoneal Transitional Cell Carcinoma, Recurrent Fallopian Tube Undifferentiated Carcinoma, Recurrent Ovarian Undifferentiated Carcinoma, Recurrent Fallopian Tube Transitional Cell Carcinoma, Recurrent Primary Peritoneal Clear Cell Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Recurrent Ovarian Transitional Cell Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma",
    "Clostridium difficile Colitis",
    "Kaposi Sarcoma",
    "Stage IV Esophageal Squamous Cell Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IIIC Lung Cancer, Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IVA Lung Cancer, Advanced Esophageal Squamous Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Gastrointestinal Stromal Tumor, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IVA Esophageal Squamous Cell Cancer",
    "Stage IIIB Hepatocellular Cancer, Stage III Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Stage IVB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Unresectable Breast Carcinoma, Metastatic Liposarcoma, Metastatic Breast Carcinoma, Unresectable Solid Tumor, Unresectable Liposarcoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Metastatic Malignant Solid Tumor",
    "Recurrent Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Pleural Mesothelioma, Pleural Malignant Mesothelioma, Metastatic Pleural Malignant Mesothelioma",
    "Refractory Mantle Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Stage IIIC Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Retroperitoneal Sarcoma, Soft Tissue Sarcoma of the Trunk and Extremities, Pelvic Sarcoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Idiopathic Thrombocytopenic Purpura",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm to the Bone, Castration-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Stage IV Prostate Cancer",
    "Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Gastric (Stomach) Cancer, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Mantle Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Refractory Classical Hodgkin Lymphoma, Recurrent Lymphoma, Recurrent Classical Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage III Gastric (Stomach) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIA Pancreatic Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIB Pancreatic Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Advanced Esophageal Carcinoma, Stage III Esophageal Adenocarcinoma, Stage II Pancreatic Cancer, Stage IVB Esophageal Adenocarcinoma, Advanced Malignant Solid Tumor, Stage IVB Esophageal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IIIA Gastric (Stomach) Cancer, Advanced Colorectal Carcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Esophageal Adenocarcinoma, Advanced Gastric Carcinoma, Stage IV Esophageal Adenocarcinoma, Advanced Pancreatic Carcinoma",
    "Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Cervical Squamous Intraepithelial Neoplasia 2, Cervical Squamous Cell Carcinoma In Situ, Cervical Intraepithelial Neoplasia Grade 2/3, Human Papillomavirus Infection",
    "Chronic Myelogenous Leukemia (CML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Warm Antibody Autoimmune Hemolytic Anemia",
    "Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Locally Advanced Melanoma",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Severe Congenital Neutropenia, Congenital Neutropenia, GATA2 Deficiency",
    "Lymphedema",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome",
    "Unresectable Malignant Solid Tumor, Metastatic Malignant Neoplasm in the Brain, Refractory Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Breast Adenocarcinoma",
    "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Stage IIA Pancreatic Cancer, Metastatic Malignant Solid Tumor, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Locally Advanced Prostate Carcinoma, Locally Advanced Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Prostate Cancer, Stage IIIB Breast Cancer, Stage IIIA1 Ovarian Cancer, Stage IVA Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Ovarian Carcinoma, Locally Advanced Breast Carcinoma, Stage IVB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IV Pancreatic Cancer, Stage III Breast Cancer, Stage IIIA Prostate Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage III Pancreatic Cancer, Stage IV Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Castration-Resistant Prostate Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Breast Cancer, Locally Advanced Malignant Solid Tumor, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer",
    "Metastatic Adrenal Cortex Carcinoma, Metastatic Paraganglioma, Stage III Adrenal Cortex Cancer, Stage IV Adrenal Cortex Cancer, Unresectable Adrenal Gland Pheochromocytoma, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Unresectable Paraganglioma, Unresectable Adrenal Cortex Carcinoma, Metastatic Pheochromocytoma, Locally Advanced Adrenal Cortex Carcinoma, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Stage I Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IA Pancreatic Cancer, Stage IB Pancreatic Cancer, Resectable Pancreatic Adenocarcinoma",
    "Hormone Receptor Positive Breast Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Melanoma, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Refractory Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Metastatic Melanoma, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Refractory Erdheim-Chester Disease, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Refractory Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Stage III Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",
    "Fallopian Tube Endometrioid Adenocarcinoma, Unresectable Synovial Sarcoma, Undifferentiated Pleomorphic Sarcoma, Locally Advanced Ewing Sarcoma, Ovarian Clear Cell Adenocarcinoma, Mesenchymal Chondrosarcoma, Dedifferentiated Liposarcoma, Primary Peritoneal Endometrioid Adenocarcinoma, Primary Peritoneal Clear Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Locally Advanced Leiomyosarcoma, Locally Advanced Synovial Sarcoma, Locally Advanced Osteosarcoma, Stage IV Cutaneous (Skin) Melanoma, Fallopian Tube Clear Cell Adenocarcinoma, Stage III Cutaneous (Skin) Melanoma, Advanced Melanoma, Unresectable Melanoma, High Grade Ovarian Serous Adenocarcinoma, Metastatic Bone Ewing Sarcoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Unresectable Osteosarcoma, Stage IIIA Cutaneous (Skin) Melanoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Unresectable Ewing Sarcoma, Unresectable Leiomyosarcoma, High Grade Fallopian Tube Serous Adenocarcinoma, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Ovarian Endometrioid Adenocarcinoma, Metastatic Melanoma, Advanced Synovial Sarcoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Advanced Leiomyosarcoma, Metastatic Synovial Sarcoma, Metastatic Leiomyosarcoma, Dedifferentiated Chondrosarcoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Metastatic Osteosarcoma",
    "Stage IVB Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage IV Uterine (including Endometrial) Cancer",
    "Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Melanoma, Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage IIB Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Limited Stage Small Cell Lung Cancer",
    "Fungal Infection",
    "Refractory Prostate Carcinoma, Refractory Lymphoma, Advanced Ovarian Carcinoma, Advanced Follicular Lymphoma, Advanced Cervical Carcinoma, Stage IV Gastric (Stomach) Cancer, Refractory Pancreatic Ductal Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Breast Carcinoma, Advanced Prostate Carcinoma, Stage IVB Bladder Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IIIC Breast Cancer, Recurrent Acute Lymphoblastic Leukemia, Refractory Head and Neck Squamous Cell Cancer, Refractory Breast Cancer, Recurrent Acute Myeloid Leukemia (AML), Refractory Gastric (Stomach) Cancer, Refractory Melanoma, Recurrent Pancreatic Ductal Adenocarcinoma, Refractory Bladder Cancer, Refractory Ovarian Carcinoma, Stage IV Colon Cancer, Advanced Melanoma, Refractory Colon Carcinoma, Advanced Lymphoma, Recurrent Lymphoma, Stage III Cutaneous (Skin) Melanoma, Advanced Malignant Solid Tumor, Stage IVB Cervical Cancer, Stage IV Cervical Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Advanced Colon Carcinoma, Refractory Malignant Solid Tumor, Recurrent Ovarian Cancer, Advanced Bladder Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Ovarian Cancer, Recurrent Malignant Solid Tumor, Stage IV Cutaneous (Skin) Melanoma, Recurrent Breast Cancer, Stage IV Ovarian Cancer, Recurrent Gastric (Stomach) Cancer, Hematopoietic and Lymphoid Cell Neoplasm, Advanced Diffuse Large B-Cell Lymphoma, Stage IIIA2 Ovarian Cancer, Refractory Cervical Carcinoma, Stage IVA Bladder Cancer, Recurrent Melanoma, Recurrent Colon Cancer, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Bladder Cancer, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Prostate Cancer, Recurrent Cervical Cancer, Refractory Follicular Lymphoma, Stage IVB Gastric (Stomach) Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IVB Prostate Cancer, Stage III Cervical Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage III Gastric (Stomach) Cancer, Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Acute Myeloid Leukemia (AML), Stage IIIC Colon Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Colon Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Colon Cancer, Stage III Colon Cancer, Stage IVC Colon Cancer, Stage IVB Colon Cancer, Stage IVA Colon Cancer, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IVA Cervical Cancer, Stage IIIB Cervical Cancer, Stage III Bladder Cancer, Stage IVA Prostate Cancer, Stage III Prostate Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IV Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIC Prostate Cancer, Stage IIIB Prostate Cancer, Stage IV Breast Cancer, Stage IIIA Bladder Cancer, Stage IIIC Breast Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Recurrent Follicular Lymphoma, Stage IIIC Ovarian Cancer",
    "Myelodysplastic Syndrome",
    "Stage III Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Unresectable Skin Squamous Cell Carcinoma, Stage IIIA Anal Cancer, Advanced Penile Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Unresectable Basal Cell Carcinoma, Unresectable Lung Small Cell Carcinoma, Stage IVA Esophageal Squamous Cell Cancer, Metastatic Basal Cell Carcinoma, Stage IVB Esophageal Squamous Cell Cancer, Stage III Anal Cancer, Stage III Esophageal Squamous Cell Cancer, Advanced Lung Small Cell Carcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Nasopharyngeal Throat Cancer, Advanced Malignant Solid Tumor, Unresectable Merkel Cell Carcinoma, Unresectable Nasopharyngeal Carcinoma, Stage IIIB Anal Cancer, Advanced Merkel Cell Carcinoma, Advanced Ovarian Carcinoma, Advanced Skin Squamous Cell Carcinoma, Unresectable Endometrial Carcinoma, Stage IVB Esophageal Squamous Cell Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IVB Cervical Cancer, Unresectable Malignant Mesothelioma, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Anal Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Advanced Basal Cell Carcinoma, Advanced Urothelial Cancer, Advanced Cervical Carcinoma, Unresectable Urothelial Carcinoma, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Stage IV Cervical Cancer, Stage III Penile Cancer, Stage IVA Cervical Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Advanced Nasopharyngeal Carcinoma, Malignant Ovarian Clear Cell Tumor, Penile Squamous Cell Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIC Anal Cancer, Stage IVB Lung Cancer, Stage IIIB Cervical Cancer, Unresectable Malignant Solid Tumor, Advanced Endometrial Carcinoma, Advanced Anal Carcinoma, Sarcomatoid Renal Cell Cancer",
    "Idiopathic Thrombocytopenic Purpura",
    "Mantle Cell Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Indolent Non-Hodgkin Lymphoma, Adult T-Cell Leukemia/Lymphoma, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Hematopoietic and Lymphoid Cell Neoplasm",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, HER2 Negative Breast Carcinoma, Stage IV Breast Cancer, Recurrent Breast Cancer, Locally Advanced Breast Carcinoma, Stage IIIB Breast Cancer, Metastatic Breast Carcinoma",
    "Barrett Esophagus, Barrett Esophagus-Indefinite for Dysplasia, Barrett Esophagus-Negative for Dysplasia, Esophageal Adenocarcinoma, Gastroesophageal Reflux Disease",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Richter Syndrome, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Recurrent AL Amyloidosis, Refractory AL Amyloidosis",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Mantle Cell Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Acute Lymphoblastic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma",
    "Oropharyngeal Throat Cancer, Lymphedema, Lymphedema of the Head and Neck",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Refractory Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis",
    "Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Refractory Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer",
    "Stage IIIC Lung Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Stage III Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer",
    "Stage IIIB Lung Cancer, Stage III Lung Cancer, High Grade Ovarian Serous Adenocarcinoma, Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Stage IIIA1 Ovarian Cancer, Locally Advanced Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Lung Cancer, Lung Adenocarcinoma, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Locally Advanced Primary Peritoneal Carcinoma, Stage IVB Fallopian Tube Cancer, Stage IVB Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Metastatic Fallopian Tube Carcinoma, Stage IIIB Fallopian Tube Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Primary Peritoneal Carcinoma, Metastatic Ovarian Carcinoma, Locally Advanced Ovarian Carcinoma, Locally Advanced Fallopian Tube Carcinoma, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IV Ovarian Cancer",
    "Metastatic Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Recurrent Severe Aplastic Anemia, Refractory Severe Aplastic Anemia",
    "Advanced Malignant Solid Tumor",
    "Stage IIA Rectal Cancer, Stage IIIA Rectal Cancer, Rectal Adenocarcinoma",
    "Locally Advanced Malignant Solid Tumor, Refractory Esophageal Carcinoma, Recurrent Esophageal Cancer, Recurrent Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Metastatic Gastric Carcinoma, Stage IV Gastric (Stomach) Cancer, Metastatic Esophageal Carcinoma, Locally Advanced Gastric Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Locally Advanced Esophageal Carcinoma, Recurrent Malignant Head and Neck Neoplasm, Refractory Malignant Solid Tumor, Refractory Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Head and Neck Neoplasm, Locally Advanced Head and Neck Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Head and Neck Cancer",
    "Refractory Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Indolent Non-Hodgkin Lymphoma",
    "Hemophilia A",
    "Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Advanced Sarcoma, Advanced Malignant Solid Tumor, Stage IV Breast Cancer, Triple-Negative Breast Cancer, Advanced Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Sickle Cell-Hemoglobin C Disease, Sickle Cell Disease, Sickle Beta 0 Thalassemia, Sickle Cell-SS Disease",
    "Recurrent Glioblastoma, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Refractory Malignant Solid Tumor, Advanced Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor, Metastatic Breast Carcinoma, Stage IVA Lung Cancer, Stage IV Breast Cancer, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IIIB Lung Cancer",
    "Advanced Malignant Solid Tumor, Unresectable Breast Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Breast Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma, Unresectable Gastric Carcinoma, Metastatic Gastric Carcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Breast Carcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Breast Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Breast Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Unresectable Gastroesophageal Junction Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Breast Cancer, Refractory Breast Cancer, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Breast Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage IV Gastric (Stomach) Cancer, Stage IIIB Breast Cancer",
    "Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Laryngeal Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Stage IVC Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Locally Advanced Colorectal Carcinoma, Refractory Colorectal Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Carcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Metastatic Breast Carcinoma, Stage IIIB Prostate Cancer, Metastatic Prostate Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Metastatic Carcinoma, Locally Advanced Glioblastoma, Metastatic Glioblastoma, Stage IV Breast Cancer, Metastatic Melanoma, Stage IIIA Prostate Cancer, Stage IV Prostate Cancer, Metastatic Sarcoma, Unresectable Melanoma, Stage III Prostate Cancer, Stage IIIC Breast Cancer, Locally Advanced Breast Carcinoma, Locally Advanced Unresectable Sarcoma, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Melanoma, Locally Advanced Unresectable Carcinoma, Locally Advanced Unresectable Prostate Carcinoma, Stage IVA Prostate Cancer, Stage III Cutaneous (Skin) Melanoma, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Recurrent Glioblastoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Unresectable Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2-Positive Breast Carcinoma, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Advanced Breast Carcinoma",
    "Stage III Lung Cancer, Malignant Solid Tumor, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Locally Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Stage IIIA1 Ovarian Cancer, Stage III Ovarian Cancer, Recurrent Malignant Solid Tumor, Stage IVA Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIA2 Ovarian Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Ovarian Cancer, Stage IIIA Ovarian Cancer, Metastatic Ovarian Carcinoma, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Stage IIIC Ovarian Cancer, Locally Advanced Ovarian Carcinoma, Stage IVB Ovarian Cancer, Stage IVB Lung Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Lung Cancer",
    "Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Primary Peritoneal Cancer, Platinum-Resistant Fallopian Tube Cancer, High Grade Fallopian Tube Serous Adenocarcinoma",
    "Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Metastatic Oral Cavity Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Breast Cancer, Triple-Negative Breast Cancer, Stage III Gastric (Stomach) Cancer, Metastatic Breast Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastric Adenocarcinoma, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma, Advanced Laryngeal Throat Squamous Cell Cancer, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Hepatocellular Cancer, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Malignant Solid Tumor, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Locally Advanced Breast Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Breast Cancer, Locally Advanced Skin Squamous Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Stage IVA Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Hepatocellular Cancer, Stage IIIB Breast Cancer, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IIIC Breast Cancer, Stage IV Hepatocellular Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Advanced Oral Cavity Squamous Cell Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Hepatocellular Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IIIA Breast Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Breast Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Breast Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Metastatic Gastric Adenocarcinoma, Stage III Breast Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Unresectable Breast Carcinoma, Recurrent Metastatic Skin Squamous Cell Carcinoma, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Adenocarcinoma, Advanced Malignant Solid Tumor, Locally Recurrent Skin Squamous Cell Carcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Acromegaly",
    "Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage III Lung Cancer",
    "Bladder Neoplasm, Recurrent Malignant Bladder Neoplasm",
    "Advanced Gastrointestinal Stromal Tumor",
    "Recurrent Non-Hodgkin Lymphoma, Advanced Epithelioid Sarcoma, Metastatic Malignant Solid Tumor, Refractory Non-Hodgkin Lymphoma, Metastatic Epithelioid Sarcoma, Hematopoietic and Lymphoid Cell Neoplasm, Advanced Rhabdoid Tumor, Advanced Kidney Medullary Carcinoma, Unresectable Kidney Medullary Carcinoma, Advanced Malignant Mesothelioma, Recurrent Follicular Lymphoma, Unresectable Rhabdoid Tumor, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Metastatic Synovial Sarcoma, Unresectable Epithelioid Sarcoma, Advanced Synovial Sarcoma, Unresectable Malignant Mesothelioma, Metastatic Rhabdoid Tumor, Metastatic Malignant Mesothelioma, Metastatic Kidney Medullary Carcinoma, Advanced Malignant Solid Tumor, Unresectable Synovial Sarcoma, Unresectable Malignant Solid Tumor",
    "Stage III Breast Cancer, Stage IIIB Breast Cancer, Unresectable Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Stage IIIC Breast Cancer, Advanced Breast Carcinoma, Stage IIIB Breast Cancer, Metastatic Breast Carcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, HER2-Positive Breast Carcinoma",
    "Recurrent Anaplastic Oligodendroglioma, Recurrent Anaplastic Astrocytoma, Recurrent Ependymoma, Recurrent Atypical Teratoid/Rhabdoid Tumor, Recurrent Gliosarcoma, Diffuse Midline Glioma, H3 K27M-Mutant, Pilocytic Astrocytoma, Central Nervous System Sarcoma, Neuronal and Mixed Neuronal-Glial Tumors, Gliomatosis Cerebri, Advanced Glioblastoma, Atypical Meningioma, Recurrent Anaplastic Ependymoma, Recurrent Oligodendroglioma, Recurrent Anaplastic Pleomorphic Xanthoastrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic (Malignant) Meningioma, Choroid Plexus Neoplasm, Pineal Region Neoplasm, Recurrent Diffuse Astrocytoma, Recurrent Primitive Neuroectodermal Tumor, Recurrent Primary Central Nervous System Neoplasm, Recurrent Medulloblastoma, Recurrent Meningioma, Malignant Glioma, Recurrent Glioblastoma",
    "Lung Neoplasm, Gastric Neoplasm",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis",
    "HIV Infection",
    "Stage IIIB Breast Cancer, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage III Breast Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IIIB Lung Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IVA Esophageal Adenocarcinoma, Advanced Head and Neck Cancer, Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IIIA2 Ovarian Cancer, Stage IV Ovarian Cancer, Advanced Pancreatic Carcinoma, Stage IIIA Breast Cancer, Refractory Esophageal Carcinoma, Stage IIIB Ovarian Cancer, Stage IIIC Lung Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Malignant Solid Tumor, Advanced Ovarian Carcinoma, Stage III Breast Cancer, Advanced Breast Carcinoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIA Breast Cancer, Stage IVA Ovarian Cancer, Refractory Pancreatic Carcinoma, Stage IIIC Breast Cancer, Stage IVB Esophageal Squamous Cell Cancer, Advanced Gastric Carcinoma, Refractory Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Esophageal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIA Lung Cancer, Stage IV Breast Cancer, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IVA Lung Cancer, Stage IV Gastric (Stomach) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Ovarian Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Refractory Ovarian Carcinoma, Advanced Urothelial Cancer, Refractory Urothelial Carcinoma, Refractory Breast Cancer, Refractory Head and Neck Carcinoma, Stage III Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer",
    "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis Transformation in Essential Thrombocythemia, Refractory Primary Myelofibrosis, Recurrent Primary Myelofibrosis",
    "Hepatocellular Cancer, Metastatic Malignant Neoplasm to the Liver",
    "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia",
    "Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Advanced Triple-Negative Breast Carcinoma, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Refractory Triple-Negative Breast Carcinoma, Stage IIIC Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, HER2 Negative Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma",
    "PIK3CA-Related Overgrowth Spectrum",
    "Metastatic Triple-Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Metastatic Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Malignant Solid Tumor, Stage IV Breast Cancer, Metastatic Skin Squamous Cell Carcinoma, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Advanced Malignant Solid Tumor, Advanced Thyroid Gland Anaplastic Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Recurrent Skin Squamous Cell Carcinoma, Stage IIIC Breast Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Stage IIIB Breast Cancer, Recurrent Thyroid Gland Anaplastic Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Thyroid Gland Anaplastic Carcinoma, Advanced Skin Squamous Cell Carcinoma, Unresectable Thyroid Gland Anaplastic Carcinoma",
    "Stage IV Breast Cancer, Stage IVA Ovarian Cancer, Advanced Microsatellite Stable Colorectal Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIA Breast Cancer, Stage IIIA1 Ovarian Cancer, Stage III Ovarian Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVB Ovarian Cancer, Stage IV Renal Cell Cancer, Stage IIIC Breast Cancer, Advanced Malignant Solid Tumor, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage III Renal Cell Cancer",
    "Recurrent Clear Cell Sarcoma of Soft Tissue, Refractory Clear Cell Sarcoma of Soft Tissue, Refractory Ewing Sarcoma, Recurrent Ewing Sarcoma",
    "Locally Advanced Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Adenocarcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Locally Advanced Gastric Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage IV Breast Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Breast Cancer, Stage IVB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVA Colon Cancer, Stage IV Colon Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVB Colon Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Advanced Endometrial Carcinoma, Stage IVB Bladder Cancer, Advanced Malignant Solid Tumor, Stage IIIC Ovarian Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Colon Cancer, Stage IVA Ovarian Cancer, Stage IIIA Bladder Cancer, Advanced Urothelial Cancer, Advanced Colorectal Carcinoma, Advanced Ovarian Carcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIA Breast Cancer, Stage IIIA Colon Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IIIB Breast Cancer, Stage III Bladder Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Breast Cancer, Stage IIIB Colon Cancer, Stage IVA Bladder Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Stage IIIC Colon Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Ovarian Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IV Ovarian Cancer, Stage IV Bladder Cancer, Stage IIIC Breast Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, HER2-Positive Breast Carcinoma, Stage IIIB Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IVC Colon Cancer, Stage III Breast Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Bladder Cancer",
    "Secondary Lymphedema, Lymphedema, Breast Cancer",
    "Infiltrating Bladder Urothelial Carcinoma, Stage IIIB Bladder Cancer, Stage IIIA Bladder Cancer, Infiltrating Bladder Mixed Carcinoma, Stage IVA Bladder Cancer, Advanced Malignant Solid Tumor, Stage III Bladder Cancer",
    "Recurrent Grade III Glioma, Recurrent Malignant Glioma, Recurrent Glioblastoma, Recurrent Anaplastic Astrocytoma",
    "Advanced Malignant Solid Tumor, Liver Failure, Metastatic Malignant Solid Tumor",
    "Refractory Myelodysplastic Syndrome, Secondary Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, de novo Myelodysplastic Syndrome",
    "Transformed Small Lymphocytic Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Transformed Chronic Lymphocytic Leukemia to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Grade 3b Follicular Lymphoma",
    "Polycythemia Vera, Essential Thrombocythemia, Primary Myelofibrosis, Secondary Myelofibrosis",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Breast Neoplasm, Ovarian Tumor",
    "Stage IIIC Lung Cancer, Non-Small Cell Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer",
    "Breast Cancer",
    "Metastatic Fibrosarcoma, Metastatic Myxofibrosarcoma, Advanced Myxofibrosarcoma, Alveolar Rhabdomyosarcoma, Pleomorphic Rhabdomyosarcoma, Advanced Dedifferentiated Liposarcoma, Unresectable Myxoid Liposarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Leiomyosarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Advanced Angiosarcoma, Metastatic Soft Tissue Sarcoma, Advanced Leiomyosarcoma, Advanced Myxoid Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma, Metastatic Round Cell Liposarcoma, Unresectable Leiomyosarcoma, Unresectable Round Cell Liposarcoma, Undifferentiated Sarcoma, Not Otherwise Specified, Unresectable Dedifferentiated Liposarcoma, Advanced Soft Tissue Sarcoma, Metastatic Dedifferentiated Liposarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Unresectable Fibrosarcoma, Unresectable Angiosarcoma, Advanced Round Cell Liposarcoma, Pleomorphic Liposarcoma, Metastatic Angiosarcoma, Advanced Fibrosarcoma, Unresectable Myxofibrosarcoma",
    "Stage IVA Fallopian Tube Cancer, Refractory Malignant Solid Tumor, Stage III Ovarian Cancer, High Grade Fallopian Tube Serous Adenocarcinoma, Stage IV Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Advanced Malignant Solid Tumor, Stage IVB Fallopian Tube Cancer, Metastatic Ovarian Carcinoma, Advanced Ovarian Carcinoma, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Primary Peritoneal Cancer, Metastatic Prostate Cancer, Stage IVA Prostate Cancer, Advanced Prostate Carcinoma, Platinum-Resistant Ovarian Cancer, Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IV Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage III Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIIB Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Platinum-Resistant Fallopian Tube Cancer",
    "Recurrent Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Metastatic Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Advanced Malignant Solid Tumor, Metastatic Malignant Neoplasm to the Bone, Refractory Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIA Pancreatic Cancer, Stage IIA Esophageal Adenocarcinoma, Unresectable Gastric Carcinoma, Stage IIB Pancreatic Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Lung Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Carcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Esophageal Squamous Cell Cancer, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage II Pancreatic Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIB Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Locally Advanced Colorectal Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage II Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Refractory Cholangiocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage III Esophageal Squamous Cell Cancer, Stage III Pancreatic Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage II Esophageal Adenocarcinoma, Pleural Mesothelioma, Unresectable Head and Neck Squamous Cell Carcinoma, Refractory Esophageal Squamous Cell Carcinoma, Stage IIIB Lung Cancer, Locally Advanced Gastric Carcinoma, Stage III Lung Cancer, Stage IIB Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Refractory Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Stage IIIB Esophageal Squamous Cell Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Esophageal Adenocarcinoma, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Locally Advanced Microsatellite Stable Colorectal Carcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Unresectable Colorectal Carcinoma, Stage II Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Tumor, Metastatic Esophageal Carcinoma, Stage III Esophageal Adenocarcinoma, Stage III Head and Neck Squamous Cell Cancer, Stage IIA Esophageal Adenocarcinoma, Locally Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Malignant Solid Tumor, Metastatic Esophageal Squamous Cell Carcinoma, Stage III Esophageal Adenocarcinoma, Unresectable Esophageal Cancer, Stage IIIC Gastric (Stomach) Cancer, Locally Advanced Esophageal Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Ductal Adenocarcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Esophageal Adenocarcinoma, Refractory Esophageal Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Adenocarcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Peritoneal Mesothelioma, Refractory Esophageal Adenocarcinoma, Refractory Colorectal Cancer, Stage IVB Lung Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage IVA Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Refractory Head and Neck Squamous Cell Cancer, Stage IV Lung Cancer, Metastatic Head and Neck Squamous Cell Cancer, Unresectable Cholangiocarcinoma, Locally Advanced Cholangiocarcinoma",
    "Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer",
    "Stage IVB Ovarian Cancer, Locally Advanced Ovarian Carcinoma, Stage III Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Metastatic Breast Carcinoma, Refractory Esophageal Squamous Cell Carcinoma, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer, Metastatic Ovarian Carcinoma, Locally Advanced Lung Carcinoma, Refractory Malignant Solid Tumor, Locally Advanced Esophageal Squamous Cell Carcinoma, Stage IIIB Lung Cancer, Stage III Ovarian Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IVA Lung Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Refractory Breast Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIC Breast Cancer, Locally Advanced Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Refractory Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Refractory Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIA2 Ovarian Cancer, Stage IVA Ovarian Cancer, Refractory Head and Neck Squamous Cell Cancer, Metastatic Lung Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage IVB Lung Cancer, Metastatic Malignant Neoplasm to the Liver, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Lung Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Extensive Stage Small Cell Lung Cancer, Stage IV Lung Cancer",
    "Recurrent Fallopian Tube Cancer, Stage IVB Primary Peritoneal Cancer, Stage IVB Fallopian Tube Cancer, Metastatic Malignant Solid Tumor, Stage IV Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Recurrent Primary Peritoneal Cancer, Stage IVB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Fallopian Tube Cancer, Stage IVA Primary Peritoneal Cancer, Recurrent Ovarian Cancer, Stage IVA Ovarian Cancer",
    "Grade 2 Follicular Lymphoma, Grade 3a Follicular Lymphoma, Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma, Grade 1 Follicular Lymphoma",
    "Stage IV Gastric (Stomach) Cancer, Metastatic Gastrointestinal Stromal Tumor (GIST), Stage IV Renal Cell Cancer, Metastatic Malignant Solid Tumor, Metastatic Renal Cell Cancer, Metastatic Sarcoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Melanoma, Metastatic Colorectal Carcinoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Squamous Cell Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Breast Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Periampullary Adenocarcinoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Gastric (Stomach) Cancer, Metastatic Gastric Carcinoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis",
    "Recurrent Non-Hodgkin Lymphoma, Refractory Malignant Solid Tumor, Recurrent Soft Tissue Sarcoma, Refractory Non-Hodgkin Lymphoma, Refractory Soft Tissue Sarcoma, Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Recurrent High Grade Ovarian Serous Adenocarcinoma, Stage IVB Ovarian Cancer, Recurrent Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Malignant Solid Tumor, Recurrent Malignant Mesothelioma, Recurrent Lung Non-Small Cell Squamous Carcinoma, Stage IIIC Lung Cancer, Advanced Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Locally Advanced Lung Adenocarcinoma, Metastatic Lung Adenocarcinoma, Stage IIIB Pleural Malignant Mesothelioma, Stage III Pleural Malignant Mesothelioma, High Grade Ovarian Serous Adenocarcinoma, Stage IVA Lung Cancer, Refractory High Grade Ovarian Serous Adenocarcinoma, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage IIIA2 Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage IV Ovarian Cancer, Recurrent Lung Adenocarcinoma, Refractory Lung Non-Small Cell Squamous Carcinoma, Metastatic Pancreatic Adenocarcinoma, Refractory Lung Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Refractory Malignant Mesothelioma, Recurrent Malignant Solid Tumor, Stage IV Pancreatic Cancer, Refractory Malignant Solid Tumor, Stage III Pancreatic Cancer, Stage IIIC Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IV Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Malignant Mesothelioma, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIB Pancreatic Cancer",
    "Refractory Marginal Zone Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Mantle Cell Lymphoma, Refractory Waldenstrom Macroglobulinemia, Recurrent Marginal Zone Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma",
    "Tenosynovial Giant Cell Tumor, Diffuse Type, Tenosynovial Giant Cell Tumor",
    "Stage III Breast Cancer, HER2-Positive Breast Carcinoma, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Stage IIIB Breast Cancer, Locally Advanced Breast Carcinoma, Stage IIIC Breast Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage IVA Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IVB Pancreatic Cancer, Stage IV Pancreatic Cancer",
    "Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Glioblastoma",
    "Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IIIB Lung Cancer, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer",
    "Recurrent Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Unresectable Melanoma, Stage IIIA Cutaneous (Skin) Melanoma",
    "Recurrent T-Cell Prolymphocytic Leukemia, Recurrent Mycosis Fungoides, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Mantle Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Therapy-Related Myeloid Neoplasm, Myelodysplastic Syndrome with Excess Blasts-1, Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Recurrent T Acute Lymphoblastic Leukemia, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Myelodysplastic Syndrome with Excess Blasts-2, Refractory Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory T Acute Lymphoblastic Leukemia, Richter Syndrome, Secondary Acute Myeloid Leukemia (AML), Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Refractory Marginal Zone Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Refractory Mycosis Fungoides, Refractory Hematologic Malignancy, Refractory T-Cell Prolymphocytic Leukemia, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma",
    "Metastatic Melanoma, Recurrent Gastric (Stomach) Cancer, Refractory Head and Neck Squamous Cell Cancer, Recurrent Small Cell Lung Cancer, Recurrent Merkel Cell Cancer, Recurrent Renal Cell Cancer, Refractory Bladder Urothelial Carcinoma, Advanced Hepatocellular Carcinoma, Refractory Esophageal Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Merkel Cell Carcinoma, Recurrent Endometrial Carcinoma, Refractory Gastric (Stomach) Cancer, Stage IVA Hepatocellular Cancer, Recurrent Hepatocellular Cancer, Metastatic Esophageal Carcinoma, Stage IIIA Breast Cancer, Metastatic Platinum-Resistant Ovarian Carcinoma, Stage IV Gastric (Stomach) Cancer, Advanced Cervical Carcinoma, Recurrent Melanoma, Metastatic Lung Small Cell Carcinoma, Recurrent Head and Neck Squamous Cell Cancer, Advanced Ovarian Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Hepatocellular Cancer, Recurrent Cervical Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Recurrent Triple-Negative Breast Carcinoma, Recurrent Bladder Urothelial Cancer, Metastatic Endometrial Carcinoma, Stage IV Hepatocellular Cancer, Advanced Bladder Urothelial Carcinoma, Stage IV Gastric (Stomach) Cancer, Refractory Melanoma, Metastatic Merkel Cell Carcinoma, Stage IIIA Hepatocellular Cancer, Refractory Triple-Negative Breast Carcinoma, Stage IVB Hepatocellular Cancer, Unresectable Platinum-Resistant Ovarian Carcinoma, Refractory Merkel Cell Carcinoma, Refractory Malignant Solid Tumor, Refractory Hepatocellular Carcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IIIA Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Stage III Lung Cancer, Stage IVA Ovarian Cancer, Refractory Renal Cell Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Refractory Cervical Carcinoma, Metastatic Hepatocellular Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Esophageal Cancer, Stage IIIC Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Lung Cancer, Recurrent Hepatocellular Cancer, Stage IIIB Ovarian Cancer, Recurrent Malignant Solid Tumor, Advanced Esophageal Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Hepatocellular Cancer, Refractory Endometrial Carcinoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIC Lung Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIA Gastric (Stomach) Cancer, Stage III Cutaneous (Skin) Melanoma, Metastatic Renal Cell Cancer, Advanced Melanoma, Metastatic Bladder Urothelial Cancer, Stage IIIA Ovarian Cancer, Refractory Lung Small Cell Carcinoma, Stage IV Breast Cancer, Stage IVB Ovarian Cancer, Stage III Breast Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Hepatocellular Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Ovarian Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IV Cervical Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IVA Cervical Cancer, Metastatic Gastric Carcinoma, Stage IIIB Cervical Cancer, Metastatic Cervical Carcinoma, Stage IVB Cervical Cancer, Recurrent Platinum-Resistant Ovarian Carcinoma, Advanced Renal Cell Carcinoma, Recurrent Cervical Cancer, Stage IIIA1 Ovarian Cancer, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Stage IVB Lung Cancer, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Stage IIIB Lung Cancer, Stage IVA Lung Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Diffuse Large B-Cell Lymphoma",
    "Metastatic Lung Non-Small Cell Carcinoma, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Locally Advanced Malignant Solid Tumor, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Malignant Solid Tumor, Recurrent Hypopharyngeal Throat Squamous Cell Cancer",
    "Stage IIIC Breast Cancer, Stage IVB Hepatocellular Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Cervical Carcinoma, Refractory Melanoma, Refractory Renal Cell Carcinoma, Refractory Lung Small Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Stage IIID Cutaneous (Skin) Melanoma, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Refractory Head and Neck Squamous Cell Cancer, Stage IIIC Lung Cancer, Stage IIIA Lung Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Breast Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Triple-Negative Breast Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IVA Esophageal Squamous Cell Cancer, Refractory Non-Small Cell Lung Cancer, Stage IV Breast Cancer, Stage IIIC Gastric (Stomach) Cancer, Locally Advanced Esophageal Squamous Cell Carcinoma, Stage III Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IVB Lung Cancer, Refractory Hepatocellular Carcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IVA Gastric (Stomach) Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Advanced Lung Non-Small Cell Carcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Refractory Cervical Carcinoma, Locally Advanced Urothelial Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Renal Cell Cancer, Recurrent Melanoma, Recurrent Esophageal Squamous Cell Cancer, Refractory Gastric Adenocarcinoma, Metastatic Renal Cell Cancer, Stage IVB Cervical Cancer, Refractory Merkel Cell Carcinoma, Stage IVB Esophageal Squamous Cell Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IVA Esophageal Squamous Cell Cancer, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Stage IIIB Breast Cancer, Stage IIIB Breast Cancer, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Hepatocellular Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Breast Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Melanoma, Stage IVA Hepatocellular Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Triple-Negative Breast Carcinoma, Recurrent Cervical Cancer, Stage III Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Esophageal Squamous Cell Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Gastric Carcinoma, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IV Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Breast Cancer, Stage IVA Cervical Cancer, Unresectable Malignant Solid Tumor, Refractory Urothelial Carcinoma, Metastatic Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IVA Lung Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IV Cervical Cancer, Unresectable Melanoma",
    "Head and Neck Carcinoma, Oral Cavity Cancer, Major Salivary Gland Cancer, Head and Neck Carcinoma of Unknown Primary, Lymphedema of the Head and Neck, Paranasal Sinus Cancer, Pharyngeal Throat Cancer, Laryngeal Throat Cancer",
    "Parkinson's Disease",
    "Stage IV Breast Cancer, Stage IIIC Ovarian Cancer, Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Breast Cancer, Stage III Ovarian Cancer, Stage III Breast Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Prostate Cancer, Stage III Pancreatic Cancer, Stage IVB Lung Cancer, Stage IVA Ovarian Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVA Pancreatic Cancer, Stage IIIA2 Ovarian Cancer, Stage IV Ovarian Cancer, Cancer-Associated Anorexia, Stage IIB Pancreatic Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Breast Cancer, Stage IVA Lung Cancer, Stage IIIA Lung Cancer, Stage IVB Prostate Cancer, Stage IIIB Breast Cancer, Stage IIIA1 Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Ovarian Cancer, Stage IVB Pancreatic Cancer, Stage IV Lung Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IIIC Breast Cancer, Stage IIIA2 Ovarian Cancer, Stage IV Prostate Cancer, Stage II Pancreatic Cancer",
    "Refractory Osteosarcoma, Localized Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma",
    "Aggressive Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Indolent Non-Hodgkin Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer",
    "Myelodysplastic Syndrome",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Stage IVC Laryngeal Throat Cancer, Oral Cavity Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Laryngeal Throat Small Cell Cancer, Stage IVC Hypopharyngeal Throat Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVB Lip and Oral Cavity Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Advanced Head and Neck Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Grade 3b Follicular Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS, Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, ALK-Positive Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, HHV8-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Follicular Lymphoma, T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Double-Hit Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Acral Lentiginous Melanoma, Advanced Cutaneous Melanoma, Metastatic Mucosal Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Mucosal Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Gastric (Stomach) Cancer, Metastatic Breast Carcinoma, Stage III Renal Cell Cancer, Metastatic Gastric Adenocarcinoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Advanced Gastric Adenocarcinoma, Stage IVB Lung Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IV Lung Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIC Gastric (Stomach) Cancer, Metastatic Lung Small Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Carcinoma Of Unknown Primary, Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Stage III Gastric (Stomach) Cancer, HER2-Positive Breast Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Lung Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer, Stage III Lung Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Advanced Breast Carcinoma, Metastatic Colorectal Carcinoma, Advanced Colorectal Carcinoma, Advanced Papillary Renal Cell Carcinoma, Stage IIIB Lung Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Breast Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage IIIA Gastric (Stomach) Cancer",
    "Unresectable Ovarian Carcinoma, Locally Advanced Melanoma, Locally Advanced Colorectal Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Ovarian Carcinoma, Stage IVB Ovarian Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Locally Advanced Malignant Solid Tumor, Stage IIIC Ovarian Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Unresectable Malignant Solid Tumor, Metastatic Melanoma, Stage III Ovarian Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA2 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIID Cutaneous (Skin) Melanoma, Unresectable Colorectal Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Locally Advanced Ovarian Carcinoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer, Metastatic Colorectal Carcinoma, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Metastatic Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Colorectal (Colon or Rectal) Cancer",
    "Stage IA1 Lung Cancer, Stage II Lung Cancer, Stage IIIA Breast Cancer, Stage I Lung Cancer, Stage III Breast Cancer, Stage II Breast Cancer, Stage IIA Lung Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage I Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Lung Cancer, Stage IB Lung Cancer, Stage IA2 Lung Cancer, Stage III Lung Cancer, Stage IIIB Breast Cancer, Stage IIB Lung Cancer, Stage IA3 Lung Cancer, Stage IIA Breast Cancer, Stage I Breast Cancer, Stage III Breast Cancer",
    "Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Locally Advanced Breast Carcinoma, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Metastatic Breast Carcinoma, Advanced Breast Carcinoma, Stage IIIA Breast Cancer, Unresectable Breast Carcinoma",
    "Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm, Acute Lymphoblastic Leukemia (ALL)",
    "Metastatic Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IVB Lung Cancer, Gastric (Stomach) Cancer, Stage IIIC Lung Cancer, Stage IVA Gastric (Stomach) Cancer, Head and Neck Carcinoma, Locally Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Lung Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IVA Lung Cancer, Advanced Gastric Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IVB Gastric (Stomach) Cancer, Stage IIIB Lung Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Lung Cancer, Stage IV Gastric (Stomach) Cancer",
    "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia",
    "Advanced Malignant Solid Tumor",
    "B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm to the Lung, Metastatic Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Soft Tissue Sarcoma",
    "Myelosuppression, Stage IVA Bladder Cancer, Metastatic Urothelial Cancer, Locally Advanced Urothelial Cancer, Neutropenia, Stage III Bladder Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer, Stage IIIB Bladder Cancer",
    "Stage III Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Advanced Ovarian Carcinoma, Metastatic Lung Small Cell Carcinoma, Stage IIIB Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Ovarian Carcinoma, Metastatic Malignant Solid Tumor, Stage IVB Lung Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Ovarian Cancer, Refractory Malignant Solid Tumor, Refractory Ovarian Carcinoma, Advanced Malignant Solid Tumor, Stage IV Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIC Lung Cancer, Advanced Lung Small Cell Carcinoma, Stage III Lung Cancer, Stage IVA Lung Cancer, Stage IVA Ovarian Cancer, Refractory Lung Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Indolent Systemic Mastocytosis, Monoclonal Mast Cell Activation Syndrome",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IIIA Cervical Cancer, Stage IVA Lung Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IVB Esophageal Adenocarcinoma, Stage IIIB Esophageal Squamous Cell Cancer, Stage III Lung Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIC Lung Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Cervical Cancer, Stage IIIA Lung Cancer, Stage IIIA Breast Cancer, Advanced Melanoma, Stage IIIB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Pancreatic Ductal Adenocarcinoma, Stage IIIA Gastric (Stomach) Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage IIIB Cervical Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage III Esophageal Adenocarcinoma, Metastatic Cervical Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Renal Cell Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Locally Advanced Glioblastoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Lung Cancer, Advanced Ovarian Carcinoma, Stage IVB Ovarian Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIB Lung Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Esophageal Adenocarcinoma, Locally Advanced Malignant Mesothelioma, Stage IIA Pancreatic Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIC Ovarian Cancer, Stage IV Breast Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Renal Cell Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Lung Cancer, Locally Advanced Renal Cell Carcinoma, Stage IV Esophageal Adenocarcinoma, Locally Advanced Melanoma, Stage IIIA2 Ovarian Cancer, Advanced Cholangiocarcinoma, Stage IV Pancreatic Cancer, Stage IIIB Pleural Malignant Mesothelioma, Stage IIB Pancreatic Cancer, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage II Esophageal Adenocarcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Ovarian Cancer, Locally Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Stage IV Cervical Cancer, Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Breast Cancer, Metastatic Gastric Carcinoma, Metastatic Breast Carcinoma, Stage IV Breast Cancer, Advanced Esophageal Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Metastatic Ovarian Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Esophageal Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Cutaneous (Skin) Melanoma, Advanced Breast Carcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Locally Advanced Malignant Solid Tumor, Metastatic Glioblastoma, Advanced Colorectal Carcinoma, Stage III Breast Cancer, Stage IIIA Pleural Malignant Mesothelioma, Endocervical Cancer, Advanced Gastric Carcinoma, Stage II Esophageal Squamous Cell Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Stage IVA Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Advanced Malignant Mesothelioma, Stage IIB Esophageal Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Advanced Renal Cell Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIA Esophageal Adenocarcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Esophageal Carcinoma, Stage III Pancreatic Cancer, Stage IIB Esophageal Adenocarcinoma, Metastatic Cholangiocarcinoma, Advanced Malignant Solid Tumor, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage II Pancreatic Cancer, Stage III Pleural Malignant Mesothelioma, Locally Advanced Cervical Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IVA Cervical Cancer, Advanced Glioblastoma, Stage III Renal Cell Cancer, Stage IVA Ovarian Cancer, Metastatic Melanoma, Locally Advanced Pancreatic Ductal Adenocarcinoma, Stage IV Pleural Malignant Mesothelioma, Stage IVB Cervical Cancer, Metastatic Malignant Solid Tumor, Advanced Cervical Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIA Esophageal Adenocarcinoma, Metastatic Malignant Mesothelioma, Stage IIIA1 Ovarian Cancer",
    "Stage IIIA Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Advanced Lung Non-Small Cell Carcinoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Pleural Malignant Mesothelioma, Unresectable Pleural Malignant Mesothelioma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage III Pleural Malignant Mesothelioma, Stage IVB Lung Cancer",
    "Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Unresectable Malignant Solid Tumor, Transformed Non-Hodgkin Lymphoma, Metastatic Malignant Solid Tumor, Hodgkin Lymphoma, Refractory Hodgkin Lymphoma",
    "Renal Pelvis Urothelial Cancer, Bladder Urothelial Cancer, Primary Peritoneal Cancer, Pancreatic Adenocarcinoma, Cervical Cancer, Ureter Urothelial Cancer, Recurrent Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Oropharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Urethral Urothelial Cancer, Unresectable Malignant Solid Tumor, Platinum-Resistant Primary Peritoneal Cancer, Metastatic Malignant Solid Tumor, Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Platinum-Resistant Ovarian Cancer, Hypopharyngeal Throat Squamous Cell Cancer, Head and Neck Squamous Cell Carcinoma, Stage IVB Lung Cancer, Platinum-Sensitive Fallopian Tube Cancer, Stage IV Lung Cancer",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIA Lung Cancer, Non-Small Cell Lung Cancer, Stage II Lung Cancer, Stage IIB Lung Cancer, Stage IB Lung Cancer",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Metastatic Rectal Adenocarcinoma, Metastatic Colon Adenocarcinoma",
    "Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Advanced Malignant Solid Tumor, Recurrent Gastrointestinal Stromal Tumor (GIST), Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Metastatic Gastrointestinal Stromal Tumor (GIST), Unresectable Gastrointestinal Stromal Tumor (GIST), Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST)",
    "Lung Adenocarcinoma, Refractory Round Cell Liposarcoma, Refractory Ovarian Carcinoma, Recurrent Myxoid Liposarcoma, Esophageal Squamous Cell Cancer, Refractory Malignant Solid Tumor, Refractory Melanoma, Refractory Myxoid Liposarcoma, Refractory Lung Carcinoma, Recurrent Melanoma, Recurrent Lung Cancer, Recurrent Malignant Solid Tumor, Recurrent Ovarian Cancer, Recurrent Synovial Sarcoma, Non-Small Cell Lung Cancer",
    "Stage IV Breast Cancer, Locally Advanced Malignant Solid Tumor, Metastatic Breast Carcinoma, Metastatic Malignant Solid Tumor, Stage IV Breast Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIB Pancreatic Cancer, Unresectable Ovarian Carcinoma, Stage III Uterine (including Endometrial) Cancer, Unresectable Pancreatic Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Locally Advanced Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Endometrial Carcinoma, Unresectable Endometrial Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Advanced Colorectal Carcinoma, Stage IV Ovarian Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IVB Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIA Ovarian Cancer, Stage IVB Lung Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Advanced Ovarian Carcinoma, Stage IIIA Lung Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IV Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Ovarian Cancer, Advanced Malignant Solid Tumor, Stage IVA Ovarian Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Metastatic Malignant Solid Tumor, Stage III Pancreatic Cancer, Stage IIA Pancreatic Cancer, Advanced Pancreatic Carcinoma, Locally Advanced Ovarian Carcinoma, Stage IIIB Lung Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Unresectable Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Unresectable Malignant Solid Tumor, Stage IIIB Ovarian Cancer, Stage IV Uterine (including Endometrial) Cancer, Metastatic Ovarian Carcinoma, Advanced Endometrial Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Endometrial Carcinoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Bladder Urothelial Cancer, Stage IIIA Bladder Cancer, Stage II Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Stage IIIB Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Carcinoma, Stage IV Lung Cancer, Stage III Lung Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Stage IVA Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Advanced Hepatocellular Carcinoma, Advanced Colorectal Carcinoma, Unresectable Gallbladder Cancer, Stage IIIB Hepatocellular Cancer, Metastatic Bile Duct Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Metastatic Hepatocellular Carcinoma, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Hepatocellular Cancer, Stage IIB Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Malignant Solid Tumor, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Pancreatic Cancer, Metastatic Gallbladder Carcinoma, Stage IVA Pancreatic Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Gallbladder Carcinoma, Stage III Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Unresectable Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Metastatic Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Pancreatic Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIA Hepatocellular Cancer, Advanced Bile Duct Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Unresectable Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Pancreatic Cancer, Metastatic Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer",
    "Advanced Dedifferentiated Liposarcoma, Atypical Lipomatous Tumor/Well Differentiated Liposarcoma, Unresectable Dedifferentiated Liposarcoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Acute Promyelocytic Leukemia with PML-RARA",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Neoplasm to Soft Tissues, Metastatic Malignant Neoplasm to the Skin, Locally Advanced Malignant Solid Tumor",
    "Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Castration-Resistant Prostate Cancer, Metastatic Prostate Cancer, Stage IVA Prostate Cancer",
    "EBV-Related Hodgkin Lymphoma, Refractory EBV-Related Lymphoma, Primary EBV-Positive Nodal T-Cell or NK-Cell Lymphoma, Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Refractory Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency, Recurrent EBV-Related Lymphoma, Recurrent Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency, EBV-Related Non-Hodgkin Lymphoma, EBV-Positive Diffuse Large B-Cell Lymphoma, NOS",
    "Stage IV Breast Cancer, Refractory Breast Cancer, Stage IVB Lung Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Stage IVA Lung Cancer, Recurrent Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Gastric (Stomach) Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Breast Carcinoma, Stage IV Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Lung Cancer, Stage IVA Gastric (Stomach) Cancer, Advanced Gastric Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Gastric Carcinoma, Refractory Gastric (Stomach) Cancer, Metastatic HER2-Positive Breast Carcinoma, HER2-Positive Breast Carcinoma, Stage IV Gastric (Stomach) Cancer, Recurrent Breast Cancer",
    "Lymphoid Leukemia, Chronic Leukemia, Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Waldenstrom Macroglobulinemia, B-Cell Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Recurrent Glioblastoma",
    "Tenosynovial Giant Cell Tumor, Diffuse Type, Tenosynovial Giant Cell Tumor, Tenosynovial Giant Cell Tumor, Localized Type",
    "Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVA Laryngeal Throat Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Lip and Oral Cavity Cancer",
    "Stage IV Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Stage IA Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Early-Stage Breast Cancer, Stage 0 Breast Cancer",
    "Ganglioneuroblastoma, Nodular, Neuroblastoma, Ganglioneuroblastoma, Intermixed",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Refractory Hodgkin Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Mycosis Fungoides and Sezary Syndrome, Refractory Mycosis Fungoides and Sezary Syndrome, Recurrent T-Cell Prolymphocytic Leukemia",
    "Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Advanced Malignant Solid Tumor, Advanced Digestive System Neuroendocrine Neoplasm, Advanced Lung Small Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Soft Tissue Sarcoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Peritoneal Disorder, Stage III Mesothelioma, Stage IV Mesothelioma, Glioblastoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IV Pancreatic Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Small Cell Lung Cancer, Stage IIIA Small Cell Lung Cancer, Stage IIIB Small Cell Lung Cancer, Stage IV Small Cell Lung Cancer, Endometrial Adenocarcinoma, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Ovarian Cancer, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Fallopian Tube Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Pancreatic Adenocarcinoma, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Primary Peritoneal Cancer",
    "Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Advanced Malignant Solid Tumor, Advanced Well Differentiated Neuroendocrine Neoplasm, Metastatic Colorectal Carcinoma, Advanced Neuroendocrine Neoplasm, Advanced Carcinoid Tumor, Advanced Small Intestinal Neuroendocrine Carcinoma, Advanced Endometrial Carcinoma, Advanced Lung Small Cell Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Advanced Lung Neuroendocrine Neoplasm, Advanced Pancreatic Neuroendocrine Neoplasm, Advanced Thyroid Gland Carcinoma, Advanced Biliary Tract Carcinoma, Advanced Anal Canal Squamous Cell Carcinoma, Stage IVA Major Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer, Stage IVC Major Salivary Gland Cancer, Cervical Squamous Neoplasm, Vulvar Squamous Cell Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Colon Neuroendocrine Neoplasm, Stage III Small Intestinal Cancer, Stage IV Small Intestinal Cancer, Stage III Major Salivary Gland Cancer, Stage IV Major Salivary Gland Cancer, Stage IIIA Anal Canal Cancer, Stage IIIB Anal Canal Cancer, Stage IIIA Appendix Cancer, Stage IIIB Appendix Cancer, Stage IIIC Appendix Cancer, Stage IVA Appendix Cancer, Stage IVB Appendix Cancer, Stage IVC Appendix Cancer, Stage III Appendix Neuroendocrine Tumor, Stage IV Appendix Neuroendocrine Tumor, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Extrahepatic (Distal) Bile Duct Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IVA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Advanced Malignant Mesothelioma, Stage IV Anal Canal Cancer, Stage III Anal Canal Cancer",
    "Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor",
    "Refractory Colorectal Cancer, Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Metastatic Colorectal Carcinoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Prostate Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Recurrent Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Castration-Resistant Prostate Cancer, Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IIIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer",
    "Metastatic Prostate Cancer, Stage IV Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer, Metastatic Malignant Neoplasm to the Bone",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Unresectable Transitional Cell Cancer, Metastatic Transitional Cell Cancer, Recurrent Anaplastic Astrocytoma, Metastatic Bladder Urothelial Cancer, Metastatic Triple-Negative Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Adenoid Cystic Cancer, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Adenoid Cystic Carcinoma, Human Papillomavirus-Related Malignant Neoplasm, Stage IV Non-Small Cell Lung Cancer, Ureter Urothelial Cancer, Triple-Negative Breast Cancer, Renal Pelvis Urothelial Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Bladder Urothelial Cancer, Stage IV Bladder Urothelial Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Non-Hodgkin Lymphoma, Stage IV Breast Cancer, Recurrent Glioblastoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Recurrent Follicular Lymphoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Recurrent Prostate Cancer, Solid Tumor, Ovarian Sarcoma, Stage IIIC Gastric (Stomach) Cancer, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Gastric (Stomach) Cancer, Recurrent Nasopharyngeal Throat Cancer, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor",
    "Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Triple-Negative Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer",
    "Severe Combined Immunodeficiency, Athabascan Type, Severe Combined Immunodeficiency due to CD45 Deficiency, Severe Combined Immunodeficiency due to RAG1 Deficiency, Severe Combined Immunodeficiency due to RAG2 Deficiency, Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B Cell-Positive, NK Cell-Positive, Severe Combined Immunodeficiency, Autosomal Recessive, T-Cell Negative, B-Cell Positive, NK-Cell Negative, Severe Combined Immunodeficiency, Severe Combined Immunodeficiency with Absence of T and B Cells",
    "Viral Infection, HIV Infection, Herpes Simplex Virus Infection",
    "Refractory Marginal Zone Lymphoma, Unresectable Malignant Solid Tumor, Advanced Follicular Lymphoma, Advanced Marginal Zone Lymphoma, Advanced Transformed Non-Hodgkin Lymphoma, Advanced Basal Cell Carcinoma, Advanced Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Advanced Diffuse Large B-Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor, Refractory Transformed Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Recurrent Cervical Squamous Cell Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Penile Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Cervical Squamous Cell Carcinoma, Recurrent Pancreatic Ductal Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Metastatic Vulvar Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Cervical Carcinoma, Recurrent Endometrial Adenocarcinoma, Not Otherwise Specified, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Stage III Penile Cancer, Advanced Lung Small Cell Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Recurrent Anal Squamous Cell Carcinoma, Metastatic Anal Squamous Cell Carcinoma, Metastatic Penile Carcinoma, Vulvar Squamous Cell Cancer, Stage IIIA Penile Cancer, Recurrent Penile Cancer, Metastatic Endometrial Adenocarcinoma, Recurrent Small Cell Lung Cancer, Stage IIIB Penile Cancer, Recurrent Vulvar Cancer, Advanced Endometrial Carcinoma, Penile Squamous Cell Cancer",
    "Mucosal Melanoma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Metastatic Urothelial Cancer, Metastatic Head and Neck Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Locally Advanced Melanoma, Metastatic Renal Cell Cancer, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Liver Carcinoma, Recurrent Pancreatic Adenocarcinoma, Metastatic Bladder Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Cholangiocarcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Bladder Carcinoma, Locally Advanced Ovarian Carcinoma, Locally Advanced Fallopian Tube Carcinoma, Metastatic Primary Peritoneal Carcinoma, Locally Advanced Primary Peritoneal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Renal Cell Carcinoma, Metastatic Mucosal Melanoma, Recurrent Mucosal Melanoma, Advanced Diffuse Large B-Cell Lymphoma, Recurrent Ocular Melanoma, Metastatic Ocular Melanoma, Locally Advanced Ocular Melanoma, Locally Advanced Liver Carcinoma, Indolent B-Cell Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Cholangiocarcinoma, Recurrent Esophageal Cancer, Mantle Cell Lymphoma, Recurrent Melanoma, Recurrent Liver Cancer, Recurrent Head and Neck Carcinoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Recurrent Ovarian Cancer, Recurrent Bladder Cancer, Metastatic Melanoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Gastric (Stomach) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Gastric (Stomach) Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma, Pancreatic Adenocarcinoma, Rectal Adenocarcinoma, Digestive System Carcinoma, Colon Adenocarcinoma",
    "Metastatic Malignant Neoplasm to the Central Nervous System, Malignant Central Nervous System Neoplasm",
    "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Stage IIIB Breast Cancer, Unresectable Triple-Negative Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Head and Neck Squamous Cell Carcinoma, Metastatic Malignant Neoplasm, Advanced Malignant Neoplasm",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Gastric (Stomach) Adenocarcinoma, Recurrent Breast Cancer, Recurrent Gastric (Stomach) Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Head and Neck Squamous Cell Carcinoma",
    "Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Endometrial Adenosquamous Cancer, Recurrent Endometrial Clear Cell Adenocarcinoma, Recurrent Endometrial Mixed Epithelial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Serous Adenocarcinoma, Uterine Corpus Carcinosarcoma, Recurrent Endometrial Carcinoma, Endometrial Clear Cell Adenocarcinoma",
    "Unresectable Malignant Mesothelioma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Refractory Lymphoma, Advanced Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Adenoid Cystic Carcinoma, Hepatocellular Cancer, Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Melanoma, Mesothelioma, Thymoma, Head and Neck Squamous Cell Carcinoma, Squamous Cell Lung Cancer, Esophageal Cancer, Pancreatic Cancer, Prostate Cancer, Ovarian Serous Adenocarcinoma, Thymic Carcinoma, Refractory Malignant Solid Tumor, Cervical Cancer, Ovarian Cancer, Gastric (Stomach) Cancer",
    "Metastatic Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Malignant Solid Tumor, Hepatocellular Cancer, Metastatic Prostatic Adenocarcinoma, Advanced Hepatocellular Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Hodgkin Lymphoma, Indolent Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Stage IIIC Breast Cancer, Metastatic Gastric Carcinoma, HER2-Positive Breast Carcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IV Renal Cell Cancer, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Kidney Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma",
    "Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Refractory Non-Small Cell Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Lung Carcinoma, Advanced Lung Carcinoma, Locally Advanced Lung Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma, Metastatic Ovarian Carcinoma, Non-Small Cell Lung Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Stage III Breast Cancer",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Triple-Negative Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer",
    "Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Ovarian Endometrioid Adenocarcinoma, Ovarian Carcinosarcoma, Ovarian Serous Adenocarcinoma, Stage III Fallopian Tube Cancer, Ovarian Clear Cell Adenocarcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer",
    "Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Anorexia, Unresectable Lung Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer, Stage III Lung Cancer",
    "Non-Small Cell Lung Cancer, Breast Cancer",
    "Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Metastatic Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Recurrent Esophageal Squamous Cell Cancer, Locally Advanced Esophageal Squamous Cell Carcinoma",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Advanced Hepatocellular Cancer",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Refractory Acute Myeloid Leukemia (AML), Refractory Breast Cancer, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Metastatic Colorectal Carcinoma, Secondary Acute Myeloid Leukemia (AML), Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Cancer, Recurrent Ovarian Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Cancer, Recurrent Small Cell Lung Cancer, Recurrent Acute Myeloid Leukemia (AML), Triple-Negative Breast Cancer",
    "Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma, Unresectable Hepatocellular Cancer, Stage III Hepatocellular Cancer",
    "Recurrent Glioblastoma, Gliosarcoma, Glioblastoma, Astrocytoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Pancreatic Carcinoma",
    "Digestive System Disorder",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Metastatic Urothelial Cancer, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Advanced Urothelial Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Urothelial Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Hepatocellular Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer, Recurrent Hepatocellular Cancer",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, CCR5 Gene",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory T Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Recurrent Myelodysplastic Syndrome",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Refractory Chronic Myelomonocytic Leukemia (CMML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Advanced Melanoma, Stage III Head and Neck Squamous Cell Cancer, Advanced Skin Squamous Cell Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Bile Duct Carcinoma, Advanced Bile Duct Carcinoma, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Cholangiocarcinoma, Advanced Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Advanced Gallbladder Carcinoma, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Melanoma of Unknown Primary, Locally Advanced Cutaneous Melanoma, Metastatic Cutaneous Melanoma",
    "Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer",
    "Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Locally Advanced Unresectable Basal Cell Carcinoma, Nevoid Basal Cell Cancer Syndrome, Metastatic Malignant Neoplasm to the Lung, Metastatic Malignant Neoplasm to the Bone, Metastatic Malignant Neoplasm to the Liver, Metastatic Malignant Neoplasm in the Lymph Nodes",
    "Advanced Malignant Neoplasm",
    "Recurrent Malignant Solid Tumor, Malignant Solid Tumor, Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage I Ovarian Cancer, Stage IA Ovarian Cancer, Stage IB Ovarian Cancer, Stage IC Ovarian Cancer, Stage II Ovarian Cancer, Stage IIA Ovarian Cancer, Stage IIB Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor, Refractory Pancreatic Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Refractory Cholangiocarcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Pancreatic Cancer",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Liposarcoma, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Unresectable Dedifferentiated Liposarcoma, Advanced Melanoma, Metastatic Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Dedifferentiated Liposarcoma, Advanced Hepatocellular Carcinoma, Advanced Dedifferentiated Liposarcoma, Unresectable Hepatocellular Cancer, Well Differentiated Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Liposarcoma, Metastatic Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Unresectable Malignant Solid Tumor, Refractory Sarcoma, Recurrent Sarcoma, Unresectable Sarcoma, Metastatic Sarcoma, Advanced Sarcoma, Unresectable Pleural Malignant Mesothelioma, Refractory Pleural Malignant Mesothelioma, Metastatic Pleural Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Unresectable Malignant Solid Tumor, Metastatic Sarcoma, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Cervical Carcinoma, Metastatic Neuroendocrine Neoplasm, Advanced Neuroendocrine Neoplasm, Advanced Lung Small Cell Carcinoma, Advanced Ovarian Carcinoma, Advanced Sarcoma, Stage IVA Ovarian Cancer, Stage IIIA2 Ovarian Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Leukemia, Lymphoma",
    "Malignant Solid Tumor, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Prostate Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Prostate Cancer",
    "X-Linked Thrombocytopenia with Beta-Thalassemia, Myelodysplastic Syndrome, Myelofibrosis, Chronic Myeloproliferative Disease",
    "Advanced Head and Neck Squamous Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Colorectal Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Colorectal Cancer, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Microsatellite Stable Colorectal Carcinoma, Stage IIIC Lung Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Malignant Solid Tumor",
    "Metastatic Melanoma, Advanced Colorectal Carcinoma, Advanced Melanoma, Refractory Colorectal Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Lung Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Unresectable Malignant Solid Tumor, Refractory Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Unresectable Cholangiocarcinoma, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Waldenstrom Macroglobulinemia, Marginal Zone Lymphoma, Leukemia, Chronic Lymphocytic Leukemia (CLL), Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma",
    "Recurrent Glioblastoma",
    "Stage IIIB Breast Cancer, Advanced Breast Adenocarcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Metastatic HER2-Negative Breast Carcinoma, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Adenocarcinoma, Advanced HER2 Negative Breast Carcinoma",
    "Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Recurrent Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Cutaneous Melanoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostatic Adenocarcinoma, Metastatic Prostate Cancer",
    "Unresectable Malignant Solid Tumor, Advanced Lymphoma, Advanced Malignant Solid Tumor, Unresectable Lymphoma, Metastatic Malignant Solid Tumor, Spread of Lymphoma, Stage IV Lymphoma, Stage III Lymphoma",
    "Medulloblastoma, WNT-Activated, Refractory Medulloblastoma, Recurrent Medulloblastoma, SHH-Activated, Refractory Medulloblastoma, SHH-Activated, Recurrent Medulloblastoma",
    "Primary Myelofibrosis, Myelofibrosis Transformation in Essential Thrombocythemia, Secondary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8, Advanced Lymphoma, Unresectable Lymphoma, Unresectable Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Stage IV Breast Cancer, Stage III Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Refractory Breast Cancer, Stage IIIC Breast Cancer",
    "Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage IIIC Breast Cancer, Stage IVB Lung Cancer, Stage III Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIA Anal Cancer, Stage IVB Gastric (Stomach) Cancer, Advanced Bile Duct Carcinoma, Refractory Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Bladder Carcinoma, Metastatic Renal Cell Cancer, Metastatic Breast Carcinoma, Metastatic Thymic Carcinoma, Recurrent Cervical Cancer, Recurrent Malignant Mesothelioma, Refractory Biliary Tract Carcinoma, Recurrent Melanoma, Stage IIIB Breast Cancer, Stage III Renal Cell Cancer, Refractory Cervical Carcinoma, Recurrent Merkel Cell Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Thyroid Gland Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Anal Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Thyroid Gland Cancer, Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Refractory Melanoma, Refractory Gastric (Stomach) Cancer, Recurrent Thymic Carcinoma, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Thymic Carcinoma, Refractory Ovarian Carcinoma, Refractory Bladder Cancer, Refractory Malignant Mesothelioma, Refractory Lung Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Carcinoma, Metastatic Cervical Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Cervical Carcinoma, Recurrent Biliary Tract Carcinoma, Advanced Thymic Carcinoma, Advanced Lung Small Cell Carcinoma, Refractory Hepatocellular Carcinoma, Metastatic Merkel Cell Carcinoma, Advanced Breast Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Malignant Mesothelioma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Refractory Skin Squamous Cell Carcinoma, Refractory Merkel Cell Carcinoma, Refractory Renal Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Bladder Carcinoma, Advanced Skin Squamous Cell Carcinoma, Advanced Anal Carcinoma, Advanced Thyroid Gland Carcinoma, Metastatic Anal Canal Carcinoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Anal Canal Cancer, Recurrent Renal Cell Cancer, Recurrent Ovarian Cancer, Advanced Malignant Mesothelioma, Recurrent Bladder Cancer, Recurrent Thyroid Gland Cancer, Metastatic Melanoma, Recurrent Hepatocellular Cancer, Recurrent Gastric (Stomach) Cancer, Stage IIIC Ovarian Cancer, Recurrent Small Cell Lung Cancer, Stage IVB Cervical Cancer, Advanced Merkel Cell Carcinoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Refractory Waldenstrom Macroglobulinemia, Recurrent Waldenstrom Macroglobulinemia, Waldenstrom Macroglobulinemia",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Neoplasm to the Lung, Unresectable Colorectal Carcinoma",
    "Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Colon Cancer, Refractory Triple-Negative Breast Carcinoma, Stage IVB Rectal Cancer, Stage IIIB Rectal Cancer, Stage IVB Colon Cancer, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVC Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVC Rectal Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Refractory Osteosarcoma, Refractory Gastric (Stomach) Cancer, Refractory Ovarian Carcinoma, Refractory Colon Adenocarcinoma, Refractory Rectal Adenocarcinoma, Recurrent Colon Adenocarcinoma, Refractory Hepatocellular Carcinoma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Advanced Triple-Negative Breast Carcinoma, Recurrent Ovarian Cancer, Recurrent Osteosarcoma, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer, Advanced Rectal Adenocarcinoma, Recurrent Rectal Adenocarcinoma, Stage IIIB Hepatocellular Cancer, Stage III Ovarian Cancer, Stage IIIA Breast Cancer, Advanced Colon Adenocarcinoma, Stage IIIB Ovarian Cancer",
    "Locally Advanced Cholangiocarcinoma, Stage IV Pancreatic Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage II Pancreatic Cancer, Stage IIIA Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Gastric (Stomach) Cancer, Refractory Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Refractory Pancreatic Carcinoma, Refractory Melanoma, Refractory Gastric (Stomach) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Metastatic Gastric Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Unresectable Gastric Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Pancreatic Carcinoma, Unresectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Unresectable Pancreatic Cancer, Recurrent Pancreatic Cancer, Recurrent Non-Small Cell Lung Cancer, Metastatic Melanoma, Refractory Head and Neck Squamous Cell Cancer, Stage IIIB Lung Cancer, Stage IIIC Hilar Cholangiocarcinoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Melanoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Breast Cancer, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Recurrent Lymphoma, Refractory Lymphoma",
    "Advanced Breast Carcinoma, Stage III Breast Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Advanced Gastric Carcinoma, HER2-Positive Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIA Gastric (Stomach) Cancer",
    "Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVA Colon Cancer, Head and Neck Squamous Cell Carcinoma, Plasma Cell Tumor, Advanced Colon Carcinoma, Stage IIIA1 Ovarian Cancer, Advanced Breast Carcinoma, Stage IIIA Lung Cancer, Advanced Malignant Solid Tumor, Stage III Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Advanced Lung Carcinoma, Advanced Ovarian Carcinoma, Stage IVA Lung Cancer, Stage IIIA Colon Cancer",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenosquamous Carcinoma, Stage IVB Cervical Cancer",
    "Stage III Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IIIB Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Localized Prostate Carcinoma",
    "Recurrent Glioblastoma",
    "Advanced Merkel Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Unresectable Merkel Cell Carcinoma",
    "Recurrent Respiratory Papillomatosis, Human Papillomavirus Infection",
    "Refractory Follicular Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Sezary Syndrome, Recurrent Follicular Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma",
    "Stage IV Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IVA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IVA Primary Peritoneal Cancer, Stage III Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Refractory Ovarian Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Cancer, Locally Advanced Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Locally Advanced Primary Peritoneal Carcinoma, Unresectable Fallopian Tube Carcinoma, Locally Advanced Fallopian Tube Carcinoma, Unresectable Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Lymphopenia, COVID-19",
    "Metastatic Small Cell Neuroendocrine Carcinoma, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Metastatic Neuroendocrine Carcinoma, Metastatic Lung Small Cell Carcinoma, Locally Advanced Neuroendocrine Carcinoma, Locally Advanced Small Cell Neuroendocrine Carcinoma, Locally Advanced Lung Small Cell Carcinoma, Metastatic Lung Large Cell Neuroendocrine Carcinoma, Locally Advanced Lung Large Cell Neuroendocrine Carcinoma",
    "Lung Adenocarcinoma, Stage IVB Lung Cancer, Non-Small Cell Squamous Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Non-Small Cell Lung Cancer, Large Cell Lung Cancer",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Lung Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIIA Ovarian Cancer, Stage IVB Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage III Fallopian Tube Cancer, Stage IVA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IVB Lung Cancer, Recurrent Malignant Solid Tumor, Stage III Renal Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Metastatic Bladder Urothelial Cancer, Recurrent Ovarian Cancer, Recurrent Head and Neck Carcinoma, Locally Advanced Liver Carcinoma, Locally Advanced Primary Peritoneal Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Gastric Carcinoma, Stage IVB Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Bladder Urothelial Cancer, Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Renal Cell Cancer, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Liver Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Cholangiocarcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Ovarian Carcinoma, Locally Advanced Fallopian Tube Carcinoma, Metastatic Primary Peritoneal Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Renal Cell Carcinoma, Recurrent Cholangiocarcinoma, Recurrent Esophageal Cancer, Recurrent Liver Cancer, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IIIC Breast Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Esophageal Adenocarcinoma, Recurrent Gastric (Stomach) Cancer, Stage IIIB Breast Cancer",
    "Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Metastatic Melanoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Lung Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Adenosquamous Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Urothelial Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Lung Adenosquamous Carcinoma, Locally Advanced Lung Adenocarcinoma",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Metastatic Colorectal Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Adenocarcinoma",
    "Unresectable Anal Canal Squamous Cell Carcinoma, Stage IV Anal Cancer, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Recurrent Anal Canal Squamous Cell Carcinoma, Locally Recurrent Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Squamous Cell Carcinoma",
    "Stage III Colon Cancer, Stage III Rectal Cancer, Stage II Rectal Cancer, Stage II Colon Cancer, Stage IIA Colon Cancer, Stage IIB Colon Cancer, Stage IIC Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer, Stage IIC Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer",
    "Metastatic Malignant Neoplasm in the Brain, Refractory Breast Cancer, Stage IIIA Breast Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Gastric (Stomach) Cancer, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, HER2-Positive Breast Carcinoma, Recurrent Breast Cancer, Recurrent Gastric (Stomach) Cancer",
    "Recurrent T-Cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia",
    "Recurrent Head and Neck Squamous Cell Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage III Renal Cell Cancer, Stage IV Breast Cancer, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIA Hepatocellular Cancer, Refractory Head and Neck Squamous Cell Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Cervical Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Stage IVB Hepatocellular Cancer, Stage IIIC Lung Cancer, Recurrent Merkel Cell Cancer, Metastatic Urothelial Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Malignant Solid Tumor, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage III Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Renal Cell Cancer, Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Refractory Endometrial Carcinoma, Refractory Urothelial Carcinoma, Refractory Cutaneous (Skin) Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Advanced Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Recurrent Urothelial Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Hepatocellular Carcinoma, Metastatic Merkel Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Refractory Skin Squamous Cell Carcinoma, Refractory Merkel Cell Carcinoma, Refractory Renal Cell Carcinoma, Refractory Triple-Negative Breast Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Skin Squamous Cell Carcinoma, Refractory Cervical Carcinoma, Advanced Cutaneous Melanoma, Refractory Anal Canal Squamous Cell Carcinoma, Advanced Anal Canal Squamous Cell Carcinoma, Recurrent Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Squamous Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer, Recurrent Hepatocellular Cancer, Recurrent Endometrial Carcinoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage III Cutaneous (Skin) Melanoma, Refractory Lung Small Cell Carcinoma, Recurrent Cutaneous (Skin) Melanoma, Advanced Merkel Cell Carcinoma, Recurrent Cervical Cancer, Advanced Triple-Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Endometrial Carcinoma, Advanced Cervical Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma",
    "Tenosynovial Giant Cell Tumor",
    "Recurrent Anaplastic Large Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Unresectable Melanoma, Metastatic Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Recurrent Melanoma",
    "T-Cell Non-Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Chronic Myelomonocytic Leukemia, Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, B-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Acute Myeloid Leukemia (AML)",
    "Transplant-Associated Thrombotic Microangiopathy",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML)",
    "Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Lymphoma, Recurrent Lymphoma, Refractory Acute Myeloid Leukemia (AML), Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoma, Recurrent Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Richter Syndrome, Recurrent Marginal Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Follicular Lymphoma",
    "Recurrent Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Gastric (Stomach) Cancer",
    "Stage IV Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVA Lung Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer",
    "Stage IIA Breast Cancer, Stage I Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, HER2-Positive Breast Carcinoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer",
    "Sickle Cell Disease, Vaso-Occlusive Crisis",
    "Bone Marrow Aplasia, Platelet Disorder, Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Chronic Myeloproliferative Disease",
    "Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IV Prostate Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Refractory Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis Transformation in Essential Thrombocythemia, Recurrent Myelofibrosis",
    "Stage IIIA1 Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Prostate Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Prostate Cancer, Stage IV Breast Cancer, Stage IIB Pancreatic Cancer, Stage IIIC Breast Cancer, Stage IV Pancreatic Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Advanced Malignant Solid Tumor, Stage III Breast Cancer, Stage III Pancreatic Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVB Prostate Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IVA Prostate Cancer, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Prostate Cancer, Stage IIIC Breast Cancer, Stage IIIA Prostate Cancer, Stage IIIB Breast Cancer",
    "Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Small Cell Neuroendocrine Prostate Cancer",
    "Recurrent Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Malignant Solid Tumor",
    "Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage IIIC Cutaneous (Skin) Melanoma, Metastatic Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Cutaneous Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Muscle Invasive Bladder Urothelial Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Breast Cancer, Stage IV Pancreatic Cancer",
    "Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Breast Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IIIA Breast Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Inflammatory Breast Carcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Unresectable Gastric Carcinoma, Unresectable Colorectal Carcinoma, Metastatic Biliary Tract Carcinoma, Stage IVB Ovarian Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Lung Cancer, Recurrent Ovarian Cancer, Metastatic Hepatocellular Carcinoma, Metastatic Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Bile Duct Carcinoma, Stage III Hepatocellular Cancer, Recurrent Biliary Tract Carcinoma, Stage IVA Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Recurrent Malignant Solid Tumor, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Hepatocellular Cancer, Stage III Pancreatic Cancer, Stage IIIB Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Metastatic Bile Duct Carcinoma, Unresectable Malignant Solid Tumor, Metastatic Gastric Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Recurrent Pancreatic Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Recurrent Non-Small Cell Lung Cancer, Unresectable Ovarian Carcinoma, Stage IIIB Ovarian Cancer, Unresectable Biliary Tract Carcinoma, Unresectable Hepatocellular Cancer, Unresectable Pancreatic Cancer, Unresectable Bile Duct Carcinoma, Recurrent Gastric (Stomach) Cancer, Recurrent Breast Inflammatory Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, HER2-Positive Breast Carcinoma, Stage III Breast Cancer",
    "Stage IV Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage III Prostate Cancer, Advanced Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer, Advanced Malignant Solid Tumor, Stage IIIA Prostate Cancer, Stage IVA Prostate Cancer",
    "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Stage IIIB Primary Peritoneal Cancer, Stage IIIA2 Ovarian Cancer, Stage IVB Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVB Fallopian Tube Cancer, Stage IVA Primary Peritoneal Cancer, Advanced Primary Peritoneal Carcinoma, Stage IIIB Ovarian Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Stage IIIC Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Advanced Endometrioid Adenocarcinoma, Stage III Fallopian Tube Cancer, Advanced Fallopian Tube Carcinoma, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Fallopian Tube Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage III Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Refractory Malignant Solid Tumor",
    "Stage IVC Colorectal (Colon or Rectal) Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage III Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Unresectable Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Malignant Solid Tumor, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Metastatic Malignant Solid Tumor, Advanced Colorectal Carcinoma, Stage IIIA Lung Cancer",
    "Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer",
    "Recurrent Ovarian Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IV Breast Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Refractory Triple-Negative Breast Carcinoma, Stage IVB Ovarian Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Triple-Negative Breast Carcinoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Advanced Endometrial Carcinoma, Stage IIIC Breast Cancer, Stage IV Pancreatic Cancer, Stage IIIB Breast Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Metastatic Malignant Solid Tumor, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Refractory Ovarian Carcinoma, Recurrent Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Refractory Malignant Solid Tumor, Stage IIIB Ovarian Cancer, Refractory Endometrial Carcinoma, Refractory Colorectal Cancer, Refractory Pancreatic Carcinoma, Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Recurrent Pancreatic Cancer, Stage IV Breast Cancer",
    "Stage IV Renal Cell Cancer, Advanced Ovarian Carcinoma, Stage III Renal Cell Cancer, Stage III Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Advanced Renal Cell Carcinoma, Stage IVB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Lung Cancer, Stage III Ovarian Cancer, Advanced Pancreatic Carcinoma, Metastatic Colorectal Adenocarcinoma, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Stage IIIA Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Metastatic Pancreatic Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage II Pancreatic Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Recurrent Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Stage IIB Pancreatic Cancer, Recurrent Pancreatic Cancer, Advanced Melanoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IV Thyroid Gland Papillary Cancer, Stage IVB Ovarian Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIA Pancreatic Cancer, Advanced Malignant Solid Tumor, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IVA Ovarian Cancer, Stage III Thyroid Gland Papillary Cancer, Refractory Non-Small Cell Lung Cancer, Recurrent Thyroid Gland Papillary Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Recurrent Colorectal Adenocarcinoma, Advanced Ovarian Carcinoma, Recurrent Melanoma, Metastatic Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIA1 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Refractory Mediastinal Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Refractory Burkitt Lymphoma, Recurrent Mediastinal Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Follicular Lymphoma",
    "Stage IIIA Breast Cancer, Locally Advanced Malignant Solid Tumor, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma, Stage III Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Advanced HER2 Negative Breast Carcinoma, Advanced Triple-Negative Breast Carcinoma, Advanced Cholangiocarcinoma, Advanced Malignant Solid Tumor, Stage IIIC Breast Cancer, Metastatic Malignant Solid Tumor, Stage IIIC Breast Cancer, Stage III Breast Cancer, Metastatic Cholangiocarcinoma, Metastatic HER2-Negative Breast Carcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Locally Advanced HER2 Negative Breast Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Stage IV Breast Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Non-Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma",
    "Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Grade 1 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Waldenstrom Macroglobulinemia, Recurrent Hairy Cell Leukemia, Recurrent Follicular Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Hairy Cell Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, B-Cell Neoplasm, Refractory Grade 2 Follicular Lymphoma, Recurrent Waldenstrom Macroglobulinemia",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia with Multilineage Dysplasia, Secondary Acute Myeloid Leukemia (AML)",
    "Stage IVA Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Advanced Colorectal Carcinoma, Stage IV Lung Cancer, Stage IIIC Lung Cancer",
    "Stage IVB Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IVA Pancreatic Cancer",
    "Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Recurrent Endometrial Serous Adenocarcinoma, Endometrial Serous Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Refractory Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma",
    "Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Advanced Malignant Digestive System Neoplasm, Metastatic Malignant Digestive System Neoplasm, Unresectable Malignant Digestive System Neoplasm",
    "Stage II Breast Cancer, Stage IA Breast Cancer, Stage III Breast Cancer, Stage IB Breast Cancer, Stage IIIB Breast Cancer, Stage I Breast Cancer, Stage IIB Breast Cancer, Stage IB Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIA Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, HER2-Positive Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIC Lung Cancer, Metastatic Colorectal Carcinoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Lung Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Advanced Pancreatic Ductal Adenocarcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Melanoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage IVA Lung Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IIIC Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IVB Lung Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Lung Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Cervical Carcinoma, Stage IIIB Cervical Cancer, Stage IV Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IV Cervical Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Cervical Carcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVA Gastric (Stomach) Cancer, Refractory Gastric Adenocarcinoma, Refractory Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage IIIB Colorectal (Colon or Rectal) Cancer, Advanced Lung Non-Small Cell Carcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Microsatellite Stable Colorectal Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Adenocarcinoma, Stage IIIA Cervical Cancer, Stage IVA Cervical Cancer, Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Stage IIIC Lung Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Lung Cancer, Stage III Lung Cancer, Stage IVB Cervical Cancer, Refractory Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVB Lung Cancer, Advanced Microsatellite Stable Colorectal Carcinoma, Stage III Cervical Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage IVB Gastric (Stomach) Cancer, Metastatic Gastric Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Refractory Cervical Carcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer",
    "Stage IIIB Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Advanced Gastric Carcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Advanced Malignant Solid Tumor, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Metastatic Malignant Solid Tumor, Stage III Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Metastatic Gastric Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Stage IIIA Gastric (Stomach) Cancer, Stage IVB Esophageal Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma",
    "Unresectable Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Malignant Glioma, Locally Advanced Glioma, Metastatic Malignant Solid Tumor, Metastatic Primary Malignant Brain Neoplasm, Metastatic Desmoplastic Small Round Cell Tumor, Unresectable Desmoplastic Small Round Cell Tumor, Advanced Primary Malignant Brain Neoplasm, Locally Advanced Desmoplastic Small Round Cell Tumor, Locally Advanced Primary Malignant Brain Neoplasm, Unresectable Glioma",
    "Stage IV Breast Cancer, Advanced Triple-Negative Breast Carcinoma, Metastatic Merkel Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Stage IIIC Breast Cancer, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Stage III Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIC Breast Cancer, Metastatic Skin Squamous Cell Carcinoma, Advanced Merkel Cell Carcinoma, Unresectable Malignant Solid Tumor, Stage IIIB Breast Cancer, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Stage IIIA Breast Cancer, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Breast Cancer, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Metastatic Uveal Melanoma, Metastatic Malignant Neoplasm to the Liver",
    "Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage III Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer",
    "Stage IB Breast Cancer, HER2 Negative Breast Carcinoma, Stage II Breast Cancer, Stage IB Breast Cancer, Stage IIA Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IIB Breast Cancer, Stage IIA Breast Cancer, Early-Stage Breast Cancer, Stage IA Breast Cancer, Stage II Breast Cancer, Stage IIB Breast Cancer, Stage I Breast Cancer",
    "Metastatic Malignant Solid Tumor, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Advanced Malignant Solid Tumor",
    "AL Amyloidosis",
    "Advanced Malignant Solid Tumor, Lymphoma",
    "Stage IV Choroidal and Ciliary Body Melanoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Metastatic Melanoma, Refractory Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Uveal Melanoma, Advanced Uveal Melanoma, Recurrent Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Melanoma",
    "Systemic Mastocytosis with an Associated Hematological Neoplasm, Mast Cell Leukemia, Aggressive Systemic Mastocytosis",
    "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Breast Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Breast Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Locally Advanced HER2-Positive Breast Carcinoma, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Breast Cancer, Advanced HER2 Positive Breast Carcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic HER2-Positive Breast Carcinoma, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIC Breast Cancer, Stage IIIC Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IIIA Breast Cancer, Stage III Breast Cancer, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Breast Carcinoma, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Breast Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Advanced Cutaneous Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Stage III Cutaneous (Skin) Melanoma, Metastatic Squamous Cell Carcinoma, Metastatic Ovarian Carcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Metastatic Head and Neck Cancer, Stage III Bladder Cancer, Metastatic Renal Cell Cancer, Stage III Ovarian Cancer, Locally Advanced Melanoma, Stage IVB Bladder Cancer, Stage IIIC Lung Cancer, Stage IVB Hepatocellular Cancer, Stage IVA Bladder Cancer, Stage IIIA1 Ovarian Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIB Bladder Cancer, Stage IV Renal Cell Cancer, Locally Advanced Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Ovarian Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Bladder Carcinoma, Metastatic Melanoma, Stage IIIA Lung Cancer, Stage IIIC Ovarian Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Locally Advanced Renal Cell Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Metastatic Hepatocellular Carcinoma, Stage IVA Hepatocellular Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Metastatic Colorectal Carcinoma, Stage III Hepatocellular Cancer, Stage IV Ovarian Cancer, Locally Advanced Ovarian Carcinoma, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Bladder Cancer, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Ovarian Cancer, Locally Advanced Sarcoma, Metastatic Sarcoma, Stage III Renal Cell Cancer, Metastatic Bladder Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Head and Neck Carcinoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA2 Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Bladder Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVB Lung Cancer, Locally Advanced Malignant Solid Tumor, Stage IIIA Ovarian Cancer, Stage III Lung Cancer, Locally Advanced Colorectal Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IVA Lung Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Hepatocellular Cancer",
    "Recurrent High-Grade B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma",
    "Refractory Melanoma, Refractory Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Metastatic Colorectal Carcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Malignant Neoplasm, Stage IV Breast Cancer, Cervical Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IV Pancreatic Cancer, Stage IIIB Cervical Cancer, Stage IIIA Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage IIIA Squamous Cell Lung Cancer, Stage IIIB Squamous Cell Lung Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Malignant Neoplasm, Stage III Squamous Cell Lung Cancer, Stage IV Squamous Cell Lung Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Metastatic Pancreatic Adenocarcinoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Esophageal Squamous Cell Cancer, Stage IV Cervical Cancer, Metastatic Melanoma, Stage III Cervical Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent High Risk Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome",
    "Stage IV Primary Peritoneal Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Endometrial Serous Adenocarcinoma, Malignant Uterine Corpus Neoplasm, Primary Peritoneal Serous Adenocarcinoma, Ovarian Seromucinous Carcinoma, Endometrial Mucinous Adenocarcinoma, Endometrial Transitional Cell Carcinoma, Endometrial Undifferentiated Carcinoma, Cervical Squamous Cell Cancer, Endocervical Cancer, Undifferentiated Ovarian Cancer, Cervical Adenosquamous Cancer, Malignant Female Reproductive System Neoplasm, Endometrial Endometrioid Adenocarcinoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Malignant Uterine Corpus Mixed Epithelial and Mesenchymal Neoplasm, Ovarian Serous Adenocarcinoma, Recurrent Cervical Cancer, Recurrent Ovarian Cancer, Ovarian Endometrioid Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Squamous Cell Carcinoma, Stage IV Fallopian Tube Cancer, Stage IV Uterine (including Endometrial) Cancer, Recurrent Uterine (Including Endometrial) Cancer, Ovarian Clear Cell Adenocarcinoma, Stage IV Ovarian Cancer, Stage IV Cervical Cancer",
    "Recurrent Glioblastoma",
    "Advanced Skin Squamous Cell Carcinoma, Stage III Skin Cancer, Stage IV Skin Cancer",
    "Stage I Prostate Cancer, Stage IIA Prostate Cancer, Prostate Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Chronic Myelogenous Leukemia (CML), Recurrent Acute Lymphoblastic Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelogenous Leukemia (CML), Refractory Acute Myeloid Leukemia (AML)",
    "Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Soft Tissue Sarcoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Small Cell Carcinoma, Locally Advanced Prostate Carcinoma, Advanced Lung Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Breast Carcinoma, Locally Advanced Gastric Carcinoma, Advanced Gastric Carcinoma, Locally Advanced Ovarian Carcinoma, Triple-Negative Breast Cancer, Metastatic Prostate Cancer, Stage IV Ovarian Cancer, Advanced Ovarian Carcinoma, Stage IVA Ovarian Cancer, Advanced Prostate Carcinoma",
    "Bladder Urothelial Cancer",
    "Unresectable Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Malignant Solid Tumor, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma, Colorectal (Colon or Rectal) Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Triple-Negative Breast Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Metastatic Malignant Neoplasm to the Leptomeninges, Metastatic Malignant Neoplasm to the Central Nervous System, Recurrent Neuroblastoma",
    "Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Advanced Uveal Melanoma, Advanced Lung Small Cell Carcinoma, Advanced Ovarian Clear Cell Adenocarcinoma, Advanced Diffuse Large B-Cell Lymphoma, Advanced Follicular Lymphoma, Grade 1 Follicular Lymphoma, Ovarian Clear Cell Tumor, Small Cell Lung Cancer, Grade 3a Follicular Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Grade 2 Follicular Lymphoma",
    "High Grade Ovarian Serous Adenocarcinoma, Metastatic Urothelial Cancer, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Platinum-Resistant Ovarian Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Unresectable Melanoma, Unresectable Urothelial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Hepatocellular Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Cervical Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Locally Advanced Urothelial Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Advanced Gastric Carcinoma, Advanced Hepatocellular Carcinoma, Recurrent Cervical Cancer, Metastatic Melanoma, Recurrent Gastric (Stomach) Cancer, Unresectable Hepatocellular Cancer, Unresectable Gastric Carcinoma",
    "Recurrent Bladder Urothelial Cancer, Bladder Urothelial Cancer",
    "Metastatic Prostatic Adenocarcinoma, Castration-Sensitive Prostate Carcinoma, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer",
    "Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer",
    "Metastatic Malignant Solid Tumor, Malignant Solid Tumor, Unresectable Liposarcoma, Unresectable Osteosarcoma, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Metastatic Digestive System Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Rhabdomyosarcoma, Refractory Osteosarcoma, Refractory Marginal Zone Lymphoma, Refractory Colorectal Cancer, Unresectable Malignant Solid Tumor, Refractory Sarcoma, Unresectable Sarcoma, Refractory Liposarcoma, Refractory Digestive System Carcinoma, Unresectable Rhabdomyosarcoma, Metastatic Sarcoma, Locally Advanced Sarcoma, Metastatic Triple-Negative Breast Carcinoma, Locally Advanced Digestive System Carcinoma, Unresectable Desmoid Fibromatosis, Unresectable Digestive System Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Cholangiocarcinoma, Metastatic Adenoid Cystic Cancer, Refractory Cholangiocarcinoma, Refractory Fibrosarcoma, Locally Advanced Liposarcoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Unresectable Adenoid Cystic Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Locally Advanced Rhabdomyosarcoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Fibrosarcoma, Locally Advanced Cholangiocarcinoma, Refractory Malignant Mastocytosis, Recurrent Malignant Mastocytosis, Locally Advanced Fibrosarcoma, Locally Advanced Triple-Negative Breast Carcinoma, Unresectable Malignant Glomus Tumor, Metastatic Malignant Glomus Tumor, Locally Advanced Malignant Glomus Tumor, Refractory Malignant Glomus Tumor, Locally Advanced Osteosarcoma, Locally Invasive Desmoid-Type Fibromatosis, Refractory Adenoid Cystic Carcinoma, Locally Advanced Adenoid Cystic Carcinoma, Refractory Desmoid-Type Fibromatosis, Hematopoietic and Lymphoid Cell Neoplasm, Unresectable Cholangiocarcinoma, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Splenic Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Metastatic Osteosarcoma, Recurrent Mantle Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Metastatic Fibrosarcoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Metastatic Liposarcoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Refractory Hepatocellular Carcinoma, Recurrent Hepatocellular Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, HER2 Negative Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Glioblastoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Unresectable Malignant Solid Tumor, Advanced Urothelial Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Metastatic Gastric Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Recurrent B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, with Features Intermediate between Diffuse Large B-Cell Lymphoma and Classical Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Refractory Mature B-Cell Non-Hodgkin Lymphoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Metastatic Breast Carcinoma, Advanced Breast Carcinoma, Refractory Breast Adenocarcinoma, HER2 Negative Breast Carcinoma, Metastatic Breast Adenocarcinoma, Recurrent Breast Cancer, Advanced Breast Adenocarcinoma, Recurrent Breast Adenocarcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Melanoma, Refractory Bladder Cancer, Metastatic Renal Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Lung Carcinoma, Metastatic Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Bladder Cancer, Recurrent Renal Cell Cancer, Metastatic Melanoma",
    "Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, CLDN18.2 Positive, Metastatic Gastric Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, HER2/Neu Negative",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Hepatocellular Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Advanced Gastric (Stomach) Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Endometrial Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Adenocarcinoma",
    "Human Papillomavirus Infection, High Grade Cervical Squamous Intraepithelial Neoplasia",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Advanced Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma",
    "Primary Malignant Liver Neoplasm, Liver Cancer",
    "Unresectable Leiomyosarcoma, Refractory Leiomyosarcoma, Locally Advanced Leiomyosarcoma, Metastatic Leiomyosarcoma, Recurrent Leiomyosarcoma",
    "Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Advanced Primary Malignant Brain Neoplasm, Human Papillomavirus-Related Malignant Neoplasm",
    "Warm Antibody Autoimmune Hemolytic Anemia",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Gastric Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Colorectal Carcinoma, Advanced Gastric Carcinoma, Stage III Liver Cancer, Stage IV Liver Cancer, Stage IVA Liver Cancer, Stage IVB Liver Cancer, Liver Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "High Grade Ovarian Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Ovarian Serous Adenocarcinoma, Primary Peritoneal Serous Adenocarcinoma",
    "Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Proximal Gastric Adenocarcinoma, Metastatic Proximal Gastric Adenocarcinoma, Progressive Disease, Recurrent Esophageal Adenocarcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML)",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Cervical Carcinoma, Metastatic Bladder Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Cervical Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Urothelial Cancer, Advanced Endometrial Carcinoma, Advanced Esophageal Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Bladder Carcinoma, Advanced Bladder Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Endometrial Carcinoma",
    "Bladder Non-Invasive Urothelial Neoplasm, Bladder Non-Invasive Papillary Urothelial Carcinoma, Low Grade, Bladder Urothelial Cancer",
    "Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Unresectable Pancreatic Cancer",
    "Metastatic Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Unresectable Transitional Cell Cancer, Metastatic Transitional Cell Cancer, Recurrent Urethral Urothelial Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Recurrent Ureter Urothelial Cancer, Recurrent Renal Pelvis Urothelial Cancer, Unresectable Urothelial Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Transitional Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Locally Advanced Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Carcinoma, Metastatic Bladder Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Cholangiocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Malignant Lesion, Advanced Colorectal Carcinoma, Advanced Cholangiocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Advanced Gastric Carcinoma, Locally Advanced Bladder Carcinoma, Locally Advanced Ovarian Carcinoma, Advanced Bladder Carcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Renal Cell Carcinoma, Recurrent Ovarian Cancer, Metastatic Melanoma",
    "Advanced Malignant Solid Tumor, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Refractory Melanoma, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Nasopharyngeal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm, Metastatic Melanoma, Advanced Malignant Neoplasm",
    "Stage III Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma",
    "Pharyngeal Throat Squamous Cell Cancer, Resectable Oropharyngeal Squamous Cell Carcinoma, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck, Laryngeal Throat Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Small Cell Neuroendocrine Prostate Cancer, Locally Advanced Prostate Adenocarcinoma, Metastatic Prostatic Adenocarcinoma",
    "Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Refractory Melanoma, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Unresectable Melanoma, Refractory Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Metastatic Renal Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Refractory Renal Cell Carcinoma, Refractory Triple-Negative Breast Carcinoma, Advanced Triple-Negative Breast Carcinoma, Metastatic Melanoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent High Risk Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Neuroblastoma, High-Risk Neuroblastoma",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Head and Neck Carcinoma",
    "Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma",
    "Pharyngitis, RSV Infection",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Adenocarcinoma, Locally Advanced Breast Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Recurrent Breast Cancer",
    "Refractory Ewing Sarcoma, Recurrent Ewing Sarcoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Castration-Resistant Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Merkel Cell Cancer, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Locally Advanced Malignant Solid Tumor, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Refractory Colorectal Cancer, Refractory Melanoma, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Hypopharyngeal Throat Squamous Cell Cancer, Refractory Laryngeal Throat Squamous Cell Cancer, Refractory Oral Cavity Squamous Cell Cancer, Refractory Oropharyngeal Throat Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Refractory Ovarian Carcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Refractory Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Metastatic Renal Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Metastatic Gastric Carcinoma, Recurrent Ovarian Carcinosarcoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer, Unresectable Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Merkel Cell Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Unresectable Merkel Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Locally Advanced Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Refractory Renal Cell Carcinoma, Locally Advanced Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Refractory Triple-Negative Breast Carcinoma, Unresectable Hepatocellular Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Melanoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Recurrent Renal Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Colorectal (Colon or Rectal) Cancer, Metastatic Melanoma, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma",
    "Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Intrahepatic Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Advanced Gastric (Stomach) Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Cholangiocarcinoma, Metastatic Colorectal Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Metastatic Malignant Digestive System Neoplasm, Advanced Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Advanced Gallbladder Carcinoma, Unresectable Malignant Digestive System Neoplasm, Advanced Gastric Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Unresectable Colorectal Adenocarcinoma, Unresectable Esophageal Adenocarcinoma, Advanced Malignant Digestive System Neoplasm, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome with Excess Blasts-1, Myelodysplastic Syndrome with Excess Blasts-2",
    "Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Metastatic Sarcoma, Refractory Non-Small Cell Lung Cancer, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Metastatic Merkel Cell Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Locally Advanced Merkel Cell Carcinoma, Advanced Hepatocellular Carcinoma, Locally Advanced Pancreatic Carcinoma, Advanced Cutaneous Melanoma, Recurrent Non-Small Cell Lung Cancer",
    "Recurrent Desmoplastic Small Round Cell Tumor, Refractory Desmoplastic Small Round Cell Tumor",
    "Refractory Synovial Sarcoma, Recurrent Synovial Sarcoma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Metastatic Carcinoma, Recurrent Carcinoma, Recurrent Breast Cancer, Recurrent Gastric (Stomach) Cancer",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Refractory Breast Cancer, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Refractory Ovarian Carcinoma, Refractory Urothelial Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Ovarian Carcinoma, Locally Advanced Urothelial Cancer, Locally Advanced Gastric Adenocarcinoma, Unresectable Triple-Negative Breast Carcinoma, Non-Small Cell Lung Cancer, Small Cell Lung Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML)",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma",
    "Metastatic Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Bladder Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer, Advanced Bladder Carcinoma, Bladder Disorder, Malignant Bladder Neoplasm, Locally Advanced Bladder Urothelial Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Pancreatic Carcinoma, Refractory Colorectal Cancer, Refractory Melanoma, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Metastatic Pancreatic Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Pancreatic Carcinoma, Metastatic Melanoma",
    "Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Refractory Gastric Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Advanced Lymphoma, Unresectable Lymphoma, Locally Advanced Lymphoma, Melanoma, Cutaneous (Skin) Melanoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Prostate Adenocarcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IIIB Colon Cancer, Stage IV Colon Cancer, Stage IVB Colon Cancer, Stage III Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colorectal Carcinoma, Metastatic Rectal Carcinoma, Refractory Rectal Carcinoma, Advanced Colorectal Carcinoma, Advanced Rectal Carcinoma, Advanced Colon Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVC Colon Cancer, Metastatic Colon Carcinoma, Stage IVA Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIA Colon Cancer, Stage IVA Colon Cancer, Stage IIIC Colon Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Unresectable Melanoma",
    "Unresectable Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Atypical Burkitt/Burkitt-Like Lymphoma, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Leukemia, Refractory Acute Leukemia, Recurrent Burkitt Leukemia, Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System, Recurrent High-Grade B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Acute Leukemia of Ambiguous Lineage, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Burkitt Lymphoma, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, B Lymphoblastic Leukemia/Lymphoma, Refractory T Lymphoblastic Leukemia/Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Burkitt Leukemia",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Recurrent Pancreatic Ductal Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Unresectable Bladder Urothelial Carcinoma, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Unresectable Urothelial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Stage III Renal Pelvis Cancer, Stage IVA Bladder Cancer, Stage III Bladder Cancer, Stage IIIC Lung Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Metastatic Unresectable Gastric (Stomach) Adenocarcinoma, Metastatic Endometrial Carcinoma, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Unresectable Malignant Solid Tumor",
    "Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Lung Small Cell Carcinoma, Extensive Stage Small Cell Lung Cancer",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Other Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Metastatic Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Recurrent Melanoma",
    "Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Stage IVA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Resectable Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer",
    "Refractory Follicular Lymphoma, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Follicular Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Malignant Gastrointestinal Neoplasm, Refractory Pancreatic Adenocarcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Refractory Gastric Adenocarcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Unresectable Malignant Solid Tumor, Metastatic Gastric Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Ovarian Carcinoma, Metastatic Ovarian Carcinoma, Stage IIIA2 Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostate Cancer",
    "Unresectable Colorectal Carcinoma, Locally Advanced Unresectable Cervical Carcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage III Cervical Cancer, Stage IVA Cervical Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Metastatic Bladder Urothelial Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Unresectable Bladder Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Breast Cancer, Unresectable Triple-Negative Breast Carcinoma, Stage IVA Lung Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Superficial Bladder Cancer",
    "Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IVB Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Gastric Carcinoma, Stage IIIC Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Stage IVB Gastric (Stomach) Cancer",
    "Refractory Lung Small Cell Carcinoma, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Melanoma, Refractory Gastric (Stomach) Cancer, Refractory Head and Neck Squamous Cell Cancer, Refractory Non-Small Cell Lung Cancer, Refractory Clear Cell Renal Cell Carcinoma, Refractory Triple-Negative Breast Carcinoma, Refractory Cervical Carcinoma",
    "Stage IIIA Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, HER2 Negative Breast Carcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma",
    "Malignant Solid Tumor",
    "Oral Cavity Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Head and Neck Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Hypopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Unresectable Oropharyngeal Squamous Cell Carcinoma, Stage IV Laryngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma",
    "Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Stage IVB Hepatocellular Cancer, Metastatic Malignant Neoplasm to the Liver",
    "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Anemia, Chronic Myelomonocytic Leukemia (CMML), Multiple Myeloma/Plasma Cell Myeloma, Myelodysplastic Syndrome",
    "Stage III Lung Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage III Colorectal (Colon or Rectal) Cancer",
    "High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Refractory Malignant Solid Tumor, Stage IVA Ovarian Cancer, Stage IIIA1 Fallopian Tube Cancer, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Stage IV Fallopian Tube Cancer, Stage IIIA2 Ovarian Cancer, Advanced Primary Peritoneal Carcinoma",
    "Anal Squamous Cell Cancer, Malignant Solid Tumor, Cutaneous Squamous Cell Carcinoma of the Head and Neck, Non-Small Cell Lung Cancer, Cutaneous (Skin) Melanoma, Urothelial Carcinoma, Skin Squamous Cell Cancer, Small Cell Lung Cancer, Renal Cell Cancer",
    "Metastatic Urothelial Cancer, Advanced Urothelial Cancer",
    "Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer",
    "Unresectable Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer",
    "Stage IV Pancreatic Cancer, Stage IIIC Lung Cancer, Stage IVA Pancreatic Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Triple-Negative Breast Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Locally Advanced Colorectal Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Refractory Pancreatic Carcinoma, Refractory Colorectal Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Refractory Lung Non-Squamous Non-Small Cell Carcinoma, Unresectable Pancreatic Cancer, Recurrent Pancreatic Cancer, Stage IVB Pancreatic Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Prostate Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Prostate Cancer, Refractory Gastroesophageal Junction Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome",
    "Stage II Lung Cancer, Stage IIIA Lung Cancer, Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Limited Stage Small Cell Lung Cancer",
    "Stage IIIC Lung Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IVB Pancreatic Cancer, Stage IVA Pancreatic Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage 0a Bladder Cancer, Stage 0is Bladder Cancer, Stage I Bladder Cancer, Superficial Bladder Urothelial Carcinoma, Bladder Urothelial Carcinoma In Situ, Superficial Bladder Cancer",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Locally Advanced Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IVB Lung Cancer, Stage IV Lung Cancer",
    "Refractory Malignant Skin Neoplasm, Recurrent Kidney Carcinoma, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Malignant Skin Neoplasm, Advanced Kidney Carcinoma, Advanced Malignant Skin Neoplasm, Refractory Kidney Carcinoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive Non-Hodgkin Lymphoma, Recurrent Aggressive Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IVA Lung Cancer, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML)",
    "Refractory Colorectal Cancer, Stage IIIC Rectal Cancer, Stage IVC Rectal Cancer, Stage IVA Colon Cancer, Stage IVC Colon Cancer, Stage IIIC Colon Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Stage IIIA Colon Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Rectal Cancer, Metastatic Colorectal Carcinoma, Unresectable Colon Adenocarcinoma, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IVB Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IV Rectal Cancer, Stage IVB Rectal Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Colon Cancer, Unresectable Rectal Adenocarcinoma",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Stage IIIB Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IVA Hepatocellular Cancer",
    "Unresectable Colorectal Adenocarcinoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Adenocarcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Advanced Colorectal Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Recurrent Colorectal Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Locally Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Unresectable Triple-Negative Breast Carcinoma, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IIIB Breast Cancer, Locally Advanced Triple-Negative Breast Carcinoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Resectable Lung Non-Small Cell Carcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer",
    "Unresectable Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Recurrent Melanoma, Locally Advanced Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Stage IV Renal Cell Cancer, Unresectable Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Metastatic Sarcomatoid Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Hereditary Clear Cell Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Von Hippel-Lindau Syndrome, Advanced Sarcomatoid Renal Cell Carcinoma, Unresectable Sarcomatoid Renal Cell Carcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm to the Leptomeninges, Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Metastatic Malignant Neoplasm to the Central Nervous System, Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Malignant Neoplasm, Metastatic Malignant Neoplasm, Advanced Malignant Neoplasm",
    "Stage IIIA Breast Cancer, Advanced Triple-Negative Breast Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IIIC Lung Cancer, Stage IIIC Breast Cancer, Stage III Lung Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIB Lung Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer",
    "Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Lymphoma, Acute Leukemia, Recurrent Chronic Lymphocytic Leukemia (CLL), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome, Mixed Phenotype Acute Leukemia",
    "Metastatic Paraganglioma, Locally Advanced Paraganglioma, Stage III Pancreatic Neuroendocrine Tumor, Stage III Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Locally Advanced Adrenal Gland Pheochromocytoma, Metastatic Pheochromocytoma, Advanced Adrenal Gland Pheochromocytoma, Metastatic Pancreatic Neuroendocrine Tumor, Locally Advanced Pancreatic Neuroendocrine Tumor, Stage IV Adrenal Gland Pheochromocytoma and Sympathetic Paraganglioma AJCC v8, Stage IV Pancreatic Neuroendocrine Tumor, Advanced Pancreatic Neuroendocrine Tumor, Advanced Paraganglioma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Stage IIA Pancreatic Cancer, Locally Advanced Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage II Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Recurrent Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer",
    "Stage IIIB Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIA Lung Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIB Lung Cancer, Advanced Colorectal Carcinoma, Stage IVB Lung Cancer",
    "Stage III Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma, Locally Advanced Pancreatic Carcinoma, Unresectable Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma",
    "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Classical Hodgkin Lymphoma",
    "Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma",
    "Advanced Malignant Solid Tumor, Glioma, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Unresectable Solid Tumor",
    "Metastatic Malignant Solid Tumor, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Microsatellite Stable Colorectal Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Metastatic Microsatellite Stable Ovarian Carcinoma, Advanced Microsatellite Stable Ovarian Carcinoma, Metastatic Microsatellite Stable Endometrial Carcinoma, Advanced Microsatellite Stable Endometrial Carcinoma, Unresectable Solid Tumor, Stage IIIB Ovarian Cancer, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Recurrent Glioblastoma, Brain Stem Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Spinal Cord Glioma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Stage IIIB Cutaneous (Skin) Melanoma",
    "Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Melanoma",
    "Glioblastoma, Supratentorial Glioblastoma, Recurrent Glioblastoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Metastatic Breast Carcinoma, Advanced Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Clear Cell Renal Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma",
    "Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer, Advanced Malignant Solid Tumor, Stage IV Breast Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Bladder Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IV Bladder Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Refractory Malignant Solid Tumor, Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Refractory Colorectal Cancer, Refractory Ovarian Carcinoma, Refractory Endometrial Carcinoma, Refractory Non-Small Cell Lung Cancer, Advanced Prostate Carcinoma, Advanced Endometrial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Hepatocellular Carcinoma, Advanced Colorectal Carcinoma, Advanced Ovarian Carcinoma, Refractory Triple-Negative Breast Carcinoma, Refractory Prostate Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Triple-Negative Breast Carcinoma",
    "Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Non-Small Cell Lung Cancer, Stage IVA Lung Cancer, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Lip and Oral Cavity Squamous Cell Cancer, Recurrent Nasal Cavity and Paranasal Sinus Squamous Cell Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Recurrent Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Unresectable Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Unresectable Malignant Solid Tumor, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Oral Cavity Squamous Cell Cancer, Refractory Sinonasal Squamous Cell Carcinoma, Advanced Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Unresectable Oral Cavity Squamous Cell Carcinoma, Lip and Oral Cavity Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Recurrent Malignant Glioma, Refractory Malignant Glioma, Diffuse Intrinsic Pontine Glioma",
    "Steroid Refractory Graft Versus Host Disease, Hematologic and Lymphocytic Disorder, Chronic Graft Versus Host Disease",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Advanced Colorectal Carcinoma",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Refractory Lymphoma, Recurrent Lymphoma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Osteosarcoma, Refractory Sarcoma, Recurrent Sarcoma, Recurrent Malignant Brain Neoplasm, Refractory Malignant Brain Neoplasm, Recurrent Hodgkin Lymphoma, Recurrent Ewing Sarcoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma, Refractory Hodgkin Lymphoma, Recurrent Neuroblastoma",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Stage IIIC Lung Cancer",
    "Metastatic Cutaneous Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Advanced Merkel Cell Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Neoplasm to the Lung, Metastatic Squamous Cell Carcinoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Malignant Neoplasm to the Skin, Metastatic Malignant Neoplasm in the Bladder, Metastatic Melanoma, Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm in the Stomach, Metastatic Malignant Neoplasm in the Uterine Cervix",
    "Glioblastoma, Malignant Glioma, Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma, Diffuse Astrocytoma, Anaplastic Astrocytoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Pancreatic Carcinoma, Refractory Colorectal Cancer, Refractory Melanoma, Refractory Gastric (Stomach) Cancer, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Refractory Ovarian Carcinoma, Refractory Bladder Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Refractory Fallopian Tube Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Bladder Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Esophageal Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Advanced Gastric Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Refractory Renal Cell Carcinoma, Locally Advanced Bladder Carcinoma, Locally Advanced Ovarian Carcinoma, Refractory Triple-Negative Breast Carcinoma, Locally Advanced Fallopian Tube Carcinoma, Advanced Bladder Carcinoma, Advanced Fallopian Tube Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Renal Cell Carcinoma, Refractory Esophageal Carcinoma, Advanced Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Melanoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Refractory Lymphoblastic Lymphoma, Pre-B Acute Lymphoblastic Leukemia, Hepatitis, Philadelphia-Positive Myelogenous Leukemia, Recurrent Lymphoblastic Lymphoma, Nonalcoholic Steatohepatitis",
    "Metastatic Urothelial Cancer, Stage III Renal Pelvis and Ureter Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis and Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Locally Advanced Urothelial Cancer",
    "Myelodysplastic Syndrome",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor, Unresectable Lymphoma, Glioma, Metastatic Malignant Neoplasm in the Brain, Advanced Malignant Solid Tumor, Stage IV Lymphoma, Unresectable Malignant Solid Tumor, Stage III Lymphoma",
    "Metastatic Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Unresectable Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Recurrent Lung Non-Small Cell Squamous Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Refractory Ovarian Carcinoma, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Refractory Ovarian Endometrioid Adenocarcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Refractory Endometrial Endometrioid Adenocarcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Recurrent Ovarian Cancer",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Unresectable Cutaneous (Skin) Melanoma, Refractory Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Cutaneous Melanoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Cutaneous (Skin) Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Waldenstrom Macroglobulinemia, Refractory Lymphoma, Recurrent Lymphoma, Refractory Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Unresectable Transitional Cell Cancer, Metastatic Transitional Cell Cancer, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Unresectable Urothelial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Metastatic Gastric Adenocarcinoma, Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Gastric Adenocarcinoma, Locally Advanced Urothelial Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma",
    "Metastatic Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Locally Advanced Malignant Solid Tumor, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Breast Cancer, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Hypopharyngeal Throat Squamous Cell Cancer, Refractory Laryngeal Throat Squamous Cell Cancer, Refractory Oral Cavity Squamous Cell Cancer, Refractory Oropharyngeal Throat Squamous Cell Cancer, Advanced Urothelial Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Refractory Urothelial Carcinoma, Metastatic Bladder Urothelial Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Pancreatic Adenocarcinoma, Locally Advanced Urothelial Cancer, Refractory Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Refractory Hepatocellular Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Advanced Breast Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Advanced Bladder Urothelial Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Hormone Receptor Negative Breast Carcinoma, Advanced Hepatocellular Carcinoma, HER2 Negative Breast Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Breast Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Triple-Negative Breast Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Refractory Colorectal Cancer, Metastatic Colorectal Carcinoma, Unresectable Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Refractory Lymphoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Lugano Classification Stage III Adult Lymphoma AJCC v8, Lugano Classification Stage IV Adult Lymphoma AJCC v8, Advanced Urothelial Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Lymphoma, Advanced Cervical Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Squamous Cell Carcinoma, Advanced Merkel Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Hepatocellular Carcinoma, HER2-Positive Breast Carcinoma, Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Marginal Zone Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Breast Adenocarcinoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Non-Hodgkin Lymphoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Urothelial Carcinoma",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma, Recurrent Systemic Anaplastic Large Cell Lymphoma, Refractory Systemic Anaplastic Large Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Uveal Melanoma, Advanced Melanoma",
    "Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma",
    "Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "Metastatic Digestive System Neuroendocrine Neoplasm, Locally Advanced Unresectable Digestive System Neuroendocrine Neoplasm",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Bone Cancer, Stage IV Bone Cancer, Stage IVA Bone Cancer, Stage IVB Bone Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Urothelial Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Gastric Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Soft Tissue Sarcoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Papillary Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Advanced Bone Sarcoma, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Gastric Carcinoma, Colon Cancer, Small Cell Lung Cancer, Metastatic Melanoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Anemia, Multiple Myeloma/Plasma Cell Myeloma, Extraosseous Plasmacytoma",
    "Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Refractory Breast Cancer, Refractory Melanoma, Locally Advanced Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Refractory Head and Neck Carcinoma, Refractory Non-Small Cell Lung Cancer, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Refractory Hepatocellular Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Neoplasm in the Head and Neck, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Hormone Receptor Negative Breast Carcinoma, Refractory Renal Cell Carcinoma, Metastatic Melanoma",
    "Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Head and Neck Squamous Cell Cancer, Unresectable Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Gastric Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Cutaneous Melanoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Cancer, Extensive Stage Small Cell Lung Cancer, Advanced Gastric Adenocarcinoma, Locally Advanced Cutaneous Melanoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Bladder Urothelial Cancer, Unresectable Transitional Cell Cancer, Stage IV Renal Pelvis and Ureter Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Bladder Urothelial Carcinoma, Unresectable Renal Pelvis and Ureter Urothelial Carcinoma, Recurrent Urothelial Cancer of the Renal Pelvis and Ureter",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Non-Small Cell Squamous Lung Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Head and Neck Squamous Cell Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer",
    "Recurrent Glioblastoma, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Recurrent Malignant Glioma, Recurrent Grade III Glioma",
    "Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Intrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Advanced Intrahepatic Cholangiocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Advanced Lung Carcinoma, Advanced Neuroendocrine Carcinoma, Advanced Breast Carcinoma, Advanced Cholangiocarcinoma, Advanced Gallbladder Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Advanced Hepatocellular Carcinoma",
    "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Bile Duct Carcinoma, Advanced Bile Duct Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Advanced Melanoma, Metastatic Gastric Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Lung Squamous Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Endometrial Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Advanced Papillary Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Advanced Gastric Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Advanced Esophageal Adenocarcinoma, Metastatic Melanoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Refractory Melanoma, Advanced Urothelial Cancer, Refractory Ovarian Carcinoma, Refractory Urothelial Carcinoma, Refractory Lung Small Cell Carcinoma, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Ovarian Carcinoma, Metastatic Melanoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Small Cell Neuroendocrine Prostate Cancer, Metastatic Prostate Neuroendocrine Carcinoma, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Adenocarcinoma, Advanced Lung Adenocarcinoma, Recurrent Lung Adenocarcinoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, HER2 Negative Breast Carcinoma",
    "Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Unresectable Urothelial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Metastatic Gastric Carcinoma, Locally Advanced Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Urothelial Cancer, Unresectable Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Metastatic Melanoma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Refractory Lymphoma, Recurrent Lymphoma, Refractory Malignant Brain Neoplasm, Refractory Meningioma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Meningioma, Recurrent Brain Neoplasm, Recurrent Neuroblastoma, Brain/Spinal Cord Tumor",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIA Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Esophageal Cancer, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Unresectable Malignant Solid Tumor, Metastatic Esophageal Carcinoma, Advanced Esophageal Carcinoma, Recurrent Mucosal Melanoma, Recurrent Acral Lentiginous Melanoma, Recurrent Esophageal Cancer, Recurrent Pancreatic Cancer, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Recurrent Ovarian Cancer, Recurrent Bladder Cancer, Recurrent Prostate Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Uterine (Including Endometrial) Cancer, Recurrent Cutaneous (Skin) Melanoma, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Essential Thrombocythemia",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Advanced Lymphoma",
    "Acute Lymphoblastic Leukemia (ALL), Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia (CML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma",
    "RSV Infection, Chronic Graft Versus Host Disease",
    "Waldenstrom Macroglobulinemia",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Urothelial Carcinoma, Refractory Cutaneous (Skin) Melanoma, Refractory Non-Small Cell Lung Cancer, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Urothelial Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Cutaneous Melanoma",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Metastatic Skin Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Pancreatic Carcinoma, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Refractory Colorectal Cancer, Refractory Lung Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Refractory Triple-Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Pancreatic Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Small Cell Lung Cancer",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Locally Recurrent Malignant Neoplasm",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Squamous Cell Cancer Metastatic to the Neck with Occult Primary, Recurrent Oropharyngeal Throat Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Unresectable Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma",
    "Refractory Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Recurrent Myelofibrosis, Refractory Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Colorectal Adenocarcinoma, Recurrent Colorectal Adenocarcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Non-Small Cell Lung Cancer, Stage II Lung Cancer",
    "Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Metastatic Colon Carcinoma, Metastatic Rectal Carcinoma, Advanced Colon Adenocarcinoma, Refractory Rectal Adenocarcinoma, Refractory Colon Adenocarcinoma, Advanced Rectal Adenocarcinoma, Stage IVC Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVC Colon Cancer",
    "Refractory Marginal Zone Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Marginal Zone Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Metastatic Hepatocellular Carcinoma, Stage IVB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage III Hepatocellular Cancer, Refractory Hepatocellular Carcinoma, Stage IIIB Hepatocellular Cancer, Locally Advanced Hepatocellular Carcinoma",
    "Refractory Indolent Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Refractory Breast Cancer, Stage III Prostate Cancer, Metastatic Pancreatic Carcinoma, Homologous Recombination Deficiency, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Refractory Pancreatic Carcinoma, Refractory Ovarian Carcinoma, Metastatic Breast Carcinoma, Metastatic Ovarian Carcinoma, Advanced Prostate Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Refractory Prostate Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Prostate Cancer, Stage IIIA1 Ovarian Cancer, Stage III Pancreatic Cancer, Advanced Ovarian Carcinoma, Stage IIIB Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Prostate Cancer",
    "Metastatic Triple-Negative Breast Carcinoma, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, HER2-Positive Breast Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Malignant Solid Tumor, Stage IV Breast Cancer, Stage IV Breast Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Advanced Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Advanced Malignant Solid Tumor, Stage IV Lung Cancer, Stage IVA Lung Cancer, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Advanced Synovial Sarcoma, Metastatic Synovial Sarcoma, Stage IVB Lung Cancer, Unresectable Synovial Sarcoma",
    "Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer",
    "Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Stage II Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis, Myelofibrosis",
    "Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Locally Advanced Breast Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Breast Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, HER2 Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Stage IVB Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Advanced Lung Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Stage IIIB Primary Peritoneal Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage III Breast Cancer, Stage IIIB Ovarian Cancer, Stage IV Breast Cancer, Stage IIIC Lung Cancer",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Refractory Colorectal Cancer, Refractory Gastric (Stomach) Cancer, Recurrent Sarcoma, Refractory Ovarian Carcinoma, Refractory Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer, Recurrent Prostate Cancer, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Stage IV Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Prostate Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Refractory Sarcoma, Refractory Prostate Carcinoma, Stage IVA Prostate Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Breast Carcinoma, Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Prostate Carcinoma, Refractory Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Colorectal Carcinoma, Advanced Liposarcoma, Refractory HER2 Negative Breast Carcinoma, Metastatic Liposarcoma, Metastatic Prostate Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Refractory Breast Cancer, Stage IIIC Prostate Cancer, Stage IIC Prostate Cancer, Stage IIIB Lung Cancer, HER2-Positive Breast Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Thrombotic Microangiopathy",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Recurrent Merkel Cell Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Locally Advanced Merkel Cell Carcinoma, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Locally Recurrent Merkel Cell Carcinoma, Extensive Stage Small Cell Lung Cancer, Metastatic Merkel Cell Carcinoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Advanced Urothelial Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Urothelial Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Urothelial Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage IVA Lung Cancer, Stage III Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage IIIA Lung Cancer, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Recurrent Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Stage IVB Lung Cancer, Refractory Lung Non-Small Cell Squamous Carcinoma, Refractory Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Stage IV Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Stage III Lung Cancer, Unresectable Lung Non-Small Cell Squamous Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage IV Renal Cell Cancer, Stage III Renal Cell Cancer",
    "Stage III Ovarian Cancer, Advanced Malignant Solid Tumor, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIA2 Ovarian Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA1 Ovarian Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, Metastatic Urothelial Cancer, Stage III Lung Cancer, Metastatic Colorectal Carcinoma, Stage IIIA Ovarian Cancer, Stage IVA Lung Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IIIB Ovarian Cancer, Metastatic Ovarian Carcinoma, Stage IV Renal Cell Cancer, Advanced Renal Cell Carcinoma, Advanced Urothelial Cancer, Metastatic Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Lung Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Locally Advanced Urothelial Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage IIIC Lung Cancer, Locally Advanced Malignant Solid Tumor, Locally Advanced Renal Cell Carcinoma, Locally Advanced Ovarian Carcinoma, Locally Advanced Colorectal Carcinoma, Advanced Ovarian Carcinoma",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVB Prostate Cancer, Stage IVA Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Breast Cancer, Stage III Gastric (Stomach) Cancer, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage IVB Gastric (Stomach) Cancer, Stage IIIC Breast Cancer, Stage IV Gastric (Stomach) Cancer, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Unresectable Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIB Breast Cancer, Stage III Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIC Gastric (Stomach) Cancer",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Recurrent Myelofibrosis, Refractory Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis",
    "Stage IV Lung Cancer, Stage IIIA Lung Cancer, Stage IIIA Breast Cancer, Refractory Gastric (Stomach) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Cervical Carcinoma, Recurrent Pancreatic Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Recurrent Endometrial Carcinoma, Stage IVA Ovarian Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Refractory Colorectal Cancer, Stage IVB Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIC Breast Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Cervical Cancer, Stage IVB Cervical Cancer, Stage IVA Cervical Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Refractory Endometrial Carcinoma, Stage IIIB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Lung Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Lung Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Appendix Adenocarcinoma, Advanced HER2 Negative Breast Carcinoma, Advanced Ovarian Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma, Refractory Cervical Carcinoma, Advanced Colorectal Carcinoma, Recurrent HER2 Negative Breast Carcinoma, Refractory HER2 Negative Breast Carcinoma, Refractory Esophageal Carcinoma, Stage III Lung Cancer, Advanced Endometrial Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Recurrent Ovarian Cancer, Advanced Pancreatic Adenocarcinoma, Refractory Pancreatic Adenocarcinoma, Recurrent Cervical Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Gastric (Stomach) Cancer, Advanced Esophageal Carcinoma, Refractory Appendix Adenocarcinoma, Recurrent Esophageal Cancer, Refractory Pseudomyxoma Peritonei, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Recurrent Malignant Solid Tumor, Stage IVB Lung Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage II Pancreatic Cancer, Stage IIIA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Ovarian Carcinoma, Stage IIIB Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Recurrent Pseudomyxoma Peritonei, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IV Cervical Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Refractory Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Breast Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Malignant Solid Tumor, Metastatic Hepatocellular Carcinoma, Refractory Cholangiocarcinoma, Advanced Cholangiocarcinoma, Unresectable Cholangiocarcinoma, Metastatic Malignant Neoplasm to the Liver, Unresectable Hepatocellular Cancer, Advanced Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Metastatic Cholangiocarcinoma, Stage III Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IV Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma",
    "Metastatic Head and Neck Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage IIIA Lung Cancer, Stage IVA Lung Cancer, Stage IIIA Breast Cancer, Stage IV Vulvar Cancer, Stage IVB Vaginal Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IV Cervical Cancer, Stage IVB Cervical Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Adenocarcinoma, Metastatic Endometrial Carcinoma, Refractory Pancreatic Adenocarcinoma, Advanced Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Refractory Cervical Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Refractory Vulvar Carcinoma, Advanced Triple-Negative Breast Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Metastatic Pancreatic Adenocarcinoma, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Vulvar Cancer, Recurrent Endometrial Carcinoma, Advanced Malignant Solid Tumor, Refractory Endometrial Carcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IIB Pancreatic Cancer, Stage IIIA Breast Cancer, Stage IVB Lung Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Refractory Head and Neck Carcinoma, Refractory Malignant Female Reproductive System Neoplasm, Stage IVA Cervical Cancer, Stage III Breast Cancer, Stage IV Vaginal Cancer, Stage IVA Vaginal Cancer, Stage III Breast Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IV Breast Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Lung Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage III Vulvar Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIA Pancreatic Cancer, Stage IIIB Breast Cancer, Refractory Malignant Solid Tumor, Stage IIIC Breast Cancer, Stage IIIA Vulvar Cancer, Stage III Pancreatic Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Cervical Cancer, Recurrent Lung Squamous Cell Carcinoma, Recurrent Lung Adenocarcinoma, Recurrent Vulvar Cancer, Recurrent Ovarian Cancer, Refractory Vaginal Carcinoma, Refractory Lung Squamous Cell Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Stage IIIC Gastric (Stomach) Cancer, Refractory Gastric Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Vulvar Carcinoma, Metastatic Vaginal Carcinoma, Stage IVA Ovarian Cancer, Recurrent Pancreatic Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Recurrent Gastric Adenocarcinoma, Stage IIIC Ovarian Cancer, Recurrent Malignant Female Reproductive System Neoplasm, Stage IVB Ovarian Cancer, Refractory Breast Cancer, Refractory Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Vulvar Cancer, Stage IIIA Gastric (Stomach) Cancer, Metastatic Lung Squamous Cell Carcinoma, Metastatic Cervical Carcinoma, Stage IVA Vulvar Cancer, Stage III Gastric (Stomach) Cancer, Stage III Vaginal Cancer, Stage IVB Vulvar Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer",
    "Refractory Endometrial Carcinoma, Stage IVA Gastric (Stomach) Cancer, Stage IV Lung Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Triple-Negative Breast Carcinoma, Refractory Gastric Adenocarcinoma, Recurrent Vulvar Cancer, Metastatic Vulvar Carcinoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IV Vaginal Cancer, Refractory Vaginal Carcinoma, Stage IVA Vulvar Cancer, Stage IV Cervical Cancer, Stage IVB Cervical Cancer, Stage IV Renal Cell Cancer, Stage IVA Ovarian Cancer, Recurrent Colon Cancer, Recurrent Ovarian Cancer, Recurrent Breast Cancer, Stage IVA Uterine (including Endometrial) Cancer, Recurrent Vaginal Cancer, Stage IVA Lung Cancer, Stage IV Ovarian Cancer, Refractory Breast Cancer, Recurrent Clear Cell Renal Cell Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Adenocarcinoma, Refractory Ovarian Carcinoma, Refractory Uterine Corpus Cancer, Stage IVB Ovarian Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Vaginal Cancer, Advanced Malignant Solid Tumor, Stage IVB Gastric (Stomach) Cancer, Stage IV Vulvar Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Uterine (Including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IVA Vaginal Cancer, Metastatic Triple-Negative Breast Carcinoma, Refractory Colon Carcinoma, Recurrent Gastric Adenocarcinoma, Refractory Vulvar Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Vaginal Carcinoma, Metastatic Ovarian Carcinoma, Recurrent Endometrial Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Colon Carcinoma, Refractory Cervical Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Metastatic Lung Adenocarcinoma, Metastatic Cervical Carcinoma, Stage IVA Cervical Cancer, Stage IVB Vulvar Cancer, Stage IVB Lung Cancer, Recurrent Lung Adenocarcinoma, Recurrent Cervical Cancer",
    "Urothelial Carcinoma, Stage IIIA Bladder Cancer, Stage II Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Recurrent Hepatosplenic T-Cell Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Recurrent Enteropathy-Associated T-Cell Lymphoma, Recurrent Anaplastic Large Cell Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Refractory Hepatosplenic T-Cell Lymphoma, Primary Cutaneous CD8-Positive Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma, Recurrent Follicular T-Cell Lymphoma, Refractory Follicular T-Cell Lymphoma, Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Refractory Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Refractory Anaplastic Large Cell Lymphoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Platinum-Resistant Primary Peritoneal Cancer, Stage IVB Prostate Cancer, Triple-Negative Breast Cancer, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage IVA Prostate Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Unresectable Malignant Solid Tumor, Metastatic Prostatic Adenocarcinoma",
    "Recurrent Breast Cancer, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Breast Cancer, HER2-Positive Breast Carcinoma",
    "Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma, Stage IV Pancreatic Cancer",
    "Myelodysplastic Syndrome",
    "Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Unresectable Breast Carcinoma, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Stage IIIA Breast Cancer",
    "B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Acute Lymphoblastic Leukemia (ALL), T Acute Lymphoblastic Leukemia",
    "Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Unresectable Melanoma, Advanced Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma",
    "Metastatic Synovial Sarcoma, Advanced Synovial Sarcoma, Recurrent Synovial Sarcoma, Unresectable Synovial Sarcoma",
    "Recurrent Grade 3a Follicular Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IV Lymphoplasmacytic Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Stage IV B-Cell Non-Hodgkin Lymphoma, Recurrent Lymphoplasmacytic Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Prostate Cancer, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage IV Pancreatic Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Pancreatic Carcinoma, Metastatic Prostate Cancer",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor, Metastatic Digestive System Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Locally Advanced Digestive System Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Unresectable Digestive System Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Chronic Lymphocytic Leukemia (CLL), B-Cell Non-Hodgkin Lymphoma, Grade 1 Follicular Lymphoma, Richter Syndrome, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mantle Cell Lymphoma, Splenic Marginal Zone Lymphoma, Grade 3a Follicular Lymphoma, Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Nodal Marginal Zone Lymphoma, Grade 2 Follicular Lymphoma",
    "Refractory Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Secondary Central Nervous System Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Central Nervous System Lymphoma",
    "Metastatic Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Gastric Adenocarcinoma",
    "Advanced Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer",
    "Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage II Breast Cancer, Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage I Breast Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement",
    "Non-Functioning Pancreatic Neuroendocrine Tumor, Functioning Pancreatic Neuroendocrine Tumor, Digestive System Neuroendocrine Tumor, Gastric Neuroendocrine Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Breast Cancer, Advanced Malignant Solid Tumor, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IIIA Breast Cancer, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Pancreatic Carcinoma, Stage IV Breast Cancer, Advanced Gastric Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Lymphoma, Stage III Lymphoma, Stage IV Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Esophageal Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, HER2-Positive Breast Carcinoma",
    "Vaso-Occlusive Crisis, Sickle Cell-SS Disease, Acute Chest Syndrome, Sickle Cell Disease, Bone Necrosis, Sickle Beta 0 Thalassemia",
    "Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Recurrent Bladder Urothelial Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Recurrent Urethral Urothelial Cancer, Locally Advanced Malignant Solid Tumor, Recurrent Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Recurrent Ureter Urothelial Cancer, Recurrent Renal Pelvis Urothelial Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Colon Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Sarcomatoid Renal Cell Cancer, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Colon Adenocarcinoma, Breast Adenocarcinoma, Stage III Oral Cavity Squamous Cell Cancer, Stage IV Oral Cavity Squamous Cell Cancer, Stage IVA Oral Cavity Squamous Cell Cancer, Stage IVB Oral Cavity Squamous Cell Cancer, Stage IVC Oral Cavity Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Stage IVC Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Squamous Cell Cancer, Stage IVB Oropharyngeal Throat Squamous Cell Cancer, Stage IVC Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Oropharyngeal Throat Squamous Cell Cancer, Recurrent Melanoma, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage IV Oropharyngeal Throat Squamous Cell Cancer, Stage III Hypopharyngeal Throat Squamous Cell Cancer, Stage IV Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage III Laryngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Metastatic Melanoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Urothelial Cancer, Stage IV Bladder Urothelial Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Rectal Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Unresectable Gastric (Stomach) Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Bladder Urothelial Carcinoma, Unresectable Lung Small Cell Carcinoma, Locally Advanced Unresectable Esophageal Adenocarcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Hypopharyngeal Throat Squamous Cell Cancer, Laryngeal Throat Squamous Cell Cancer, Oral Cavity Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Oropharyngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Metastatic Melanoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Malignant Solid Tumor, Unresectable Melanoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Advanced Hepatocellular Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Metastatic Prostate Cancer",
    "Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage IVB Hilar Cholangiocarcinoma, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Cholangiocarcinoma, Advanced Cholangiocarcinoma, Large Duct Intrahepatic Cholangiocarcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer",
    "Advanced Urothelial Cancer, Metastatic Urothelial Cancer, Unresectable Urothelial Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Urothelial Cancer, Unresectable Esophageal Cancer, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Unresectable Urothelial Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Urothelial Cancer, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Platinum Sensitive Ovarian Cancer, Unresectable Lung Small Cell Carcinoma, Unresectable Pancreatic Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Advanced Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Unresectable Cervical Carcinoma, Advanced Triple-Negative Breast Carcinoma, HER2-Positive Breast Carcinoma, Triple-Negative Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, HER2 Negative Breast Carcinoma, Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS), Breast Adenocarcinoma, Invasive Breast Cancer, Early-Stage Breast Cancer",
    "Advanced Malignant Solid Tumor, Advanced Lymphoma, Stage III Lymphoma, Stage IV Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Renal Cell Cancer, Metastatic Triple-Negative Breast Carcinoma, Unresectable Renal Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Stage IIIA Breast Cancer, Unresectable Lung Non-Small Cell Carcinoma, Recurrent Colorectal (Colon or Rectal) Cancer, Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Advanced Glioblastoma, Stage III Lung Cancer",
    "Stage IIIC Esophageal Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer",
    "Refractory Lymphoma, Recurrent Lymphoma, Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Non-Hodgkin Lymphoma, Refractory Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Waldenstrom Macroglobulinemia, Recurrent Acute Myeloid Leukemia (AML), FLT3 NP_004110.2:p.I836X, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Waldenstrom Macroglobulinemia",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage IV Pancreatic Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Advanced Renal Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Recurrent Pancreatic Adenocarcinoma, Metastatic Hypopharyngeal Carcinoma, Metastatic Oropharyngeal Carcinoma, Metastatic Laryngeal Carcinoma, Metastatic Lip and Oral Cavity Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Pancreatic Adenocarcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Gastric Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Advanced Glioblastoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Metastatic Pancreatic Adenocarcinoma, Recurrent Gastric (Stomach) Cancer",
    "Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer, Castration-Resistant Prostate Cancer",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Metastatic Unresectable Gastric (Stomach) Adenocarcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Advanced Digestive System Carcinoma, Metastatic Colorectal Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Pancreatic Carcinoma, Unresectable Pancreatic Cancer, Grade 3 Colorectal Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Advanced Melanoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Melanoma",
    "Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia with Multilineage Dysplasia, Refractory Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Refractory Marginal Zone Lymphoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Adenosquamous Carcinoma, Advanced Cervical Adenocarcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Microsatellite Stable Colorectal Carcinoma, Unresectable Cervical Squamous Cell Carcinoma, Unresectable Cervical Adenosquamous Carcinoma, Unresectable Cervical Adenocarcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Cervical Adenosquamous Carcinoma, Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Endometrial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Advanced Ovarian Carcinoma, Metastatic Breast Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Locally Advanced Endometrial Carcinoma, Triple-Negative Breast Cancer, Recurrent Breast Cancer, Advanced Breast Adenocarcinoma, Recurrent Ovarian Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Uterine (Including Endometrial) Cancer",
    "Invasive Pulmonary Aspergillosis, Aplastic Anemia, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome",
    "Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Refractory Pancreatic Carcinoma, Refractory Colorectal Cancer, Refractory Sarcoma, Metastatic Sarcoma, Advanced Sarcoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Pancreatic Carcinoma, Advanced Pancreatic Carcinoma, Unresectable Pancreatic Cancer, Colorectal (Colon or Rectal) Adenocarcinoma, Pleural Malignant Mesothelioma, Recurrent Pancreatic Cancer, Advanced Pleural Malignant Mesothelioma",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Metastatic Prostate Cancer in the Soft Tissue, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Carcinoma Metastatic in the Bone, Metastatic Prostatic Adenocarcinoma, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer",
    "Mantle Cell Lymphoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Anaplastic Large Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma, Anaplastic Large Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Renal Cell Cancer, Advanced Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Sarcomatoid Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, HER2 Negative Breast Carcinoma, Advanced Sarcomatoid Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Metastatic Prostatic Adenocarcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Breast Carcinoma",
    "Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer",
    "Stage IV Pancreatic Cancer, Unresectable Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer",
    "Stage II Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage II Cutaneous (Skin) Melanoma, Stage IIA Cutaneous (Skin) Melanoma, Cutaneous Melanoma of the Extremity, Invasive Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Tumor, Advanced Colorectal Carcinoma, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Gastrointestinal Stromal Tumor (GIST), Metastatic Lung Carcinoma, Advanced Lung Carcinoma, Metastatic Breast Carcinoma, Advanced Prostate Carcinoma, Advanced Breast Carcinoma, Advanced Gastrointestinal Stromal Tumor, Glioblastoma, Metastatic Prostate Cancer",
    "Stage III Hilar Cholangiocarcinoma, Stage IIIA Hilar Cholangiocarcinoma, Stage IIIB Hilar Cholangiocarcinoma, Stage IIIC Hilar Cholangiocarcinoma, Stage IV Hilar Cholangiocarcinoma, Stage IVA Hilar Cholangiocarcinoma, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IVB Hilar Cholangiocarcinoma, Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage III Lung Cancer, Stage IV Pleural Malignant Mesothelioma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Unresectable Pleural Malignant Mesothelioma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Cholangiocarcinoma, Unresectable Ovarian Serous Adenocarcinoma, Metastatic Ovarian Serous Adenocarcinoma, Unresectable Cholangiocarcinoma, Advanced Peritoneal Malignant Mesothelioma, Ovarian Serous Adenocarcinoma, Advanced Pleural Malignant Mesothelioma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome",
    "High Grade Fallopian Tube Serous Adenocarcinoma, High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Triple-Negative Breast Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Advanced Breast Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Metastatic Ovarian Carcinosarcoma, Advanced Ovarian Carcinosarcoma, Metastatic Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian Endometrioid Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Ovarian Cancer",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Refractory HER2 Negative Breast Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Breast Cancer, Recurrent HER2 Negative Breast Carcinoma, Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Anaplastic Pleomorphic Xanthoastrocytoma, Rosette-Forming Glioneuronal Tumor, Glioblastoma, Neurofibromatosis Type 1, Oligodendroglioma, Subependymal Giant Cell Astrocytoma, Ganglioglioma, Central Neurocytoma, Pilocytic Astrocytoma, Pleomorphic Xanthoastrocytoma, Anaplastic Oligodendroglioma, Anaplastic Ganglioglioma, Desmoplastic Infantile Ganglioglioma, Chordoid Glioma of the Third Ventricle, Astrocytoma, Cerebellar Liponeurocytoma, Gangliocytoma, Diffuse Astrocytoma, Dysplastic Cerebellar Gangliocytoma, Angiocentric Glioma, Papillary Glioneuronal Tumor, Extraventricular Neurocytoma, Desmoplastic Infantile Astrocytoma, Anaplastic Astrocytoma",
    "Mantle Cell Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Malignant Neoplasm to the Liver, Stage IV Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Advanced Carcinoma, Metastatic Carcinoma, Recurrent Carcinoma, Refractory Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Refractory Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Breast Cancer, Refractory Melanoma, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Sarcoma, Unresectable Sarcoma, Unresectable Melanoma, Refractory Endometrial Carcinoma, Refractory Bladder Cancer, Metastatic Sarcoma, Advanced Melanoma, Advanced Sarcoma, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Breast Carcinoma, Metastatic Bladder Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Advanced Prostate Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Unresectable Breast Carcinoma, Advanced Endometrial Carcinoma, Advanced Breast Carcinoma, Unresectable Bladder Carcinoma, Refractory Prostate Carcinoma, Advanced Bladder Carcinoma, Refractory Esophageal Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Squamous Cell Carcinoma, Refractory Lung Non-Small Cell Squamous Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Prostate Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Metastatic Melanoma, Metastatic Prostate Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia",
    "Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Metastatic Colon Adenocarcinoma, Metastatic Rectal Adenocarcinoma, Advanced Colon Adenocarcinoma, Advanced Rectal Adenocarcinoma",
    "Stage IVA Gastric (Stomach) Cancer, Stage IVB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IVB Gastric (Stomach) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Gastric (Stomach) Cancer, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Refractory Colorectal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Esophageal Adenocarcinoma, Advanced Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Recurrent Gastroesophageal Junction Adenocarcinoma, Stage IVB Gastric (Stomach) Cancer, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIIB Gastric (Stomach) Cancer, Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement, Recurrent Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Metastatic Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Recurrent Myeloid Neoplasm, Stage IV Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Locally Advanced Gastric Carcinoma, Recurrent Malignant Lymphoid Neoplasm, Advanced Gastric Carcinoma, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma",
    "Metastatic Prostate Cancer, Refractory Prostate Carcinoma, Stage IV Prostate Cancer, Castration-Resistant Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Myelodysplastic Syndrome, Myelodysplastic Syndrome with Excess Blasts, Secondary Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "High-Grade Treatment-Related Myeloid Neoplasm, Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Arising from Previous Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia Arising from Previous Myelodysplastic/Myeloproliferative Neoplasm",
    "Familial Adenomatous Polyposis",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Stage I Bladder Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IVA Bladder Cancer",
    "Advanced Malignant Solid Tumor, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Advanced Urothelial Cancer, Advanced Cervical Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Merkel Cell Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Skin Squamous Cell Carcinoma, Advanced Esophageal Squamous Cell Carcinoma, Advanced Nasopharyngeal Carcinoma, Advanced Malignant Mesothelioma",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Stage III Breast Cancer, Stage IV Lung Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IV Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage IVB Lung Cancer, Stage IVA Hepatocellular Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage III Major Salivary Gland Cancer, Stage IV Major Salivary Gland Cancer, Stage IVA Major Salivary Gland Cancer, Stage IVB Major Salivary Gland Cancer, Stage IVC Major Salivary Gland Cancer, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Hepatocellular Cancer, Stage IVA Lung Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Chordoma, Metastatic Hepatocellular Carcinoma, Locally Advanced Unresectable Pancreatic Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Bladder Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Salivary Gland Carcinoma, Locally Advanced Salivary Gland Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Unresectable Breast Carcinoma, Metastatic Merkel Cell Carcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Bladder Carcinoma, Locally Advanced Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Unresectable Bladder Carcinoma, Locally Advanced Endometrial Carcinoma, Unresectable Endometrial Carcinoma, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage IVB Ovarian Cancer, Stage 0is Bladder Cancer, Stage III Bladder Cancer, Stage IV Hepatocellular Cancer",
    "Myelodysplastic/Myeloproliferative Disease, Refractory Anemia, Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome, Myelodysplastic Syndrome with Ring Sideroblasts, Myelodysplastic Syndrome with Excess Blasts, Acute Myeloid Leukemia with Multilineage Dysplasia",
    "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Metastatic Urothelial Cancer, Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IVA Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Urothelial Cancer, Metastatic Renal Cell Cancer, Advanced Renal Cell Carcinoma, Metastatic Lung Carcinoma, Advanced Lung Carcinoma, Metastatic Breast Carcinoma, Metastatic Cervical Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Colorectal Carcinoma, Advanced Cervical Carcinoma, Advanced Esophageal Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Glioblastoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Recurrent Myelofibrosis, Refractory Myelofibrosis, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Unresectable Colorectal Carcinoma, Advanced Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), High-Grade Treatment-Related Myeloid Neoplasm",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Adrenal Cortex Cancer, Stage IV Adrenal Cortex Cancer, Unresectable Adrenal Cortex Carcinoma, Metastatic Adrenal Cortex Carcinoma",
    "High Grade Ovarian Serous Adenocarcinoma, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Primary Peritoneal Clear Cell Carcinoma, Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma",
    "Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Esophageal Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Bladder Cancer, Stage III Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Refractory Gastric (Stomach) Cancer, Refractory Breast Cancer, Unresectable Malignant Solid Tumor, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Ovarian Carcinoma, Refractory Bladder Cancer, Refractory Non-Small Cell Lung Cancer, Metastatic Cervical Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Recurrent Pancreatic Adenocarcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Bladder Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Esophageal Carcinoma, Advanced Cervical Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Advanced Esophageal Carcinoma, Refractory Pancreatic Adenocarcinoma, Unresectable Pancreatic Adenocarcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Ovarian Carcinoma, Refractory Skin Squamous Cell Carcinoma, Unresectable Ovarian Carcinoma, Unresectable Bladder Carcinoma, Advanced Skin Squamous Cell Carcinoma, Advanced Bladder Carcinoma, Refractory Cervical Carcinoma, Refractory Esophageal Carcinoma, Unresectable Cervical Carcinoma, Recurrent Esophageal Cancer, Malignant Exocrine Pancreas Neoplasm, Recurrent Breast Cancer, Recurrent Ovarian Cancer, Recurrent Bladder Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Cervical Cancer, Metastatic Pancreatic Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Lung Carcinoma, Locally Advanced Lung Carcinoma, Metastatic Gastric Carcinoma, Unresectable Lung Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Cholangiocarcinoma, Unresectable Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Locally Advanced Ovarian Carcinoma, Unresectable Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Cholangiocarcinoma, Unresectable Cholangiocarcinoma, Unresectable Pancreatic Cancer",
    "Ductal Carcinoma In Situ (DCIS), Invasive Breast Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Glioblastoma",
    "Choroid Melanoma, Intraocular Melanoma, Ocular Melanoma",
    "Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIIC Prostate Cancer, Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Locally Advanced Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma",
    "Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIB Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer",
    "Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis Transformation in Essential Thrombocythemia, Anemia, Chronic Myeloproliferative Disease",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Refractory Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Primary Myelofibrosis",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Locally Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma",
    "Stage IIIA Vulvar Cancer, Stage III Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage III Vaginal Cancer, Stage IV Vaginal Cancer, Stage IVA Vaginal Cancer, Stage IVB Vaginal Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage II Primary Peritoneal Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Refractory Ovarian Carcinoma, Refractory Uterine Corpus Cancer, Refractory Malignant Female Reproductive System Neoplasm, Refractory Primary Peritoneal Cancer, Refractory Fallopian Tube Cancer, Advanced Cervical Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Advanced Malignant Female Reproductive System Neoplasm, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Refractory Cervical Carcinoma, Advanced Vulvar Carcinoma, Advanced Vaginal Carcinoma, Advanced Uterine Corpus Cancer, Refractory Vulvar Carcinoma, Refractory Vaginal Carcinoma, Malignant Uterine Neoplasm, Stage IVA Ovarian Cancer",
    "Stage IV Renal Cell Cancer, Metastatic Gastric Carcinoma, Metastatic Renal Cell Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Metastatic Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Stage IV Hepatocellular Cancer, Metastatic Lung Non-Small Cell Carcinoma, Unresectable Hepatocellular Cancer, Metastatic Colorectal Carcinoma, Stage IIIB Hepatocellular Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Hepatocellular Cancer, Locally Advanced Unresectable Renal Cell Carcinoma, Stage IVA Hepatocellular Cancer, Unresectable Gastric Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Gastric Carcinoma, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Unresectable Malignant Solid Tumor, Stage IVA Lung Cancer, Stage III Renal Cell Cancer, Stage IVB Lung Cancer, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Hepatocellular Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Recurrent Malignant Glioma, Refractory Malignant Glioma, Metastatic Breast Carcinoma, Glioblastoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Prostate Cancer, Stage IV Prostate Cancer, Stage IV Breast Cancer, Malignant Solid Tumor, Stage IV Breast Cancer, Castration-Resistant Prostate Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Fallopian Tube Carcinoma, Metastatic Paranasal Sinus Squamous Cell Carcinoma, Stage IVA Nasopharyngeal Throat Cancer, Metastatic Malignant Solid Tumor, Stage IV Nasopharyngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IV Nasal Cavity and Paranasal Sinus Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IVB Laryngeal Throat Cancer, Advanced Ovarian Carcinoma, Recurrent Nasopharyngeal Squamous Cell Carcinoma, Refractory Fallopian Tube Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IVC Laryngeal Throat Cancer, Stage IVB Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Stage IV Fallopian Tube Cancer, Stage IVC Hypopharyngeal Throat Cancer, Metastatic Endometrial Carcinoma, Locally Advanced Endometrial Carcinoma, Stage IVA Laryngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Uterine (Including Endometrial) Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Stage IIIA2 Fallopian Tube Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IVB Primary Peritoneal Cancer, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Stage IIIA1 Fallopian Tube Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Primary Peritoneal Carcinoma, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Nasopharyngeal Throat Squamous Cell Cancer, Refractory Ovarian Carcinoma, Recurrent Paranasal Sinus Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Locally Advanced Malignant Solid Tumor, Stage IVA Uterine (including Endometrial) Cancer, Stage IIIC Ovarian Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Refractory Primary Peritoneal Cancer, Stage IVB Nasal Cavity and Paranasal Sinus Cancer, Stage IVA Nasal Cavity and Paranasal Sinus Cancer, Stage IVC Nasal Cavity and Paranasal Sinus Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer",
    "Stage IVA Lung Cancer, Metastatic Microsatellite Stable Colon Carcinoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Lung Small Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Alveolar Soft Part Sarcoma, Locally Advanced Neuroendocrine Neoplasm, Locally Advanced Gastric Adenocarcinoma, Locally Advanced Gastric Carcinoma, Metastatic Rectal Adenocarcinoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Lung Neuroendocrine Neoplasm, Metastatic Colorectal Carcinoma, Stage IV Lung Cancer, Stage IVB Lung Cancer, Metastatic Gastric Adenocarcinoma, Metastatic Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IVA Rectal Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Lung Cancer, Stage IV Rectal Cancer, Locally Advanced Digestive System Neuroendocrine Neoplasm, Advanced Malignant Solid Tumor, Stage IV Gastric (Stomach) Cancer, Stage IIIB Rectal Cancer, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Metastatic Gastroesophageal Junction Adenocarcinoma, Locally Advanced Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Metastatic Gastric Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Neuroendocrine Neoplasm, Locally Advanced Microsatellite Stable Colon Carcinoma, Locally Advanced Rectal Adenocarcinoma, Stage IIIC Rectal Cancer, Stage IVC Rectal Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IVB Rectal Cancer, Stage IIIB Lung Cancer, Locally Advanced Lung Neuroendocrine Neoplasm, Metastatic Digestive System Neuroendocrine Neoplasm, Metastatic Alveolar Soft Part Sarcoma, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Rectal Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Rectal Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage IIIB Bladder Cancer, Metastatic Ovarian Carcinoma, Stage IVA Bladder Cancer, Stage IIIC Breast Cancer, Stage IIIB Breast Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IV Prostate Cancer, Stage III Prostate Cancer, Stage IIIC Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Metastatic Bladder Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Stage IVB Lung Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer, Advanced Bladder Carcinoma, Advanced Ovarian Carcinoma, Castration-Resistant Prostate Cancer",
    "Locally Advanced Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma",
    "Colon Adenocarcinoma, Rectal Adenocarcinoma, Metastatic Colorectal Carcinoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Myelodysplastic/Myeloproliferative Disease, Myeloproliferative Neoplasm, Unclassifiable, Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, de novo Myelodysplastic Syndrome, Myeloid Neoplasm",
    "Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Refractory Myelodysplastic Syndrome",
    "Stage III Pleural Malignant Mesothelioma, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma",
    "Head and Neck Squamous Cell Carcinoma, Refractory Extracranial Malignant Solid Neoplasm, Advanced Extracranial Malignant Solid Neoplasm, Triple-Negative Breast Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Extracranial Malignant Solid Neoplasm, Non-Small Cell Lung Cancer, Clear Cell Renal Cell Cancer, Skin Squamous Cell Cancer, Liposarcoma, Undifferentiated Pleomorphic Sarcoma",
    "Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage III Ovarian Cancer, Stage IIIB Ovarian Cancer, Recurrent Malignant Solid Tumor, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVA Ovarian Cancer",
    "Recurrent Nodal Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Splenic Marginal Zone Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Refractory Grade 2 Follicular Lymphoma",
    "Stage 0 Pancreatic Cancer, Unresectable Pancreatic Adenocarcinoma, Stage IIB Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer, Stage I Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IB Pancreatic Cancer, Borderline Resectable Pancreatic Adenocarcinoma, Stage IA Pancreatic Cancer",
    "Metastatic Distal Bile Duct Adenocarcinoma, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Gallbladder Carcinoma, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Recurrent Pancreatic Ductal Adenocarcinoma, Stage IV Pancreatic Cancer, Recurrent Gallbladder Cancer, Stage IVA Gallbladder Cancer, Metastatic Head and Neck Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Gallbladder Cancer, Metastatic Pancreatic Ductal Adenocarcinoma, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Recurrent Anaplastic Astrocytoma, Metastatic Intrahepatic Cholangiocarcinoma, Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Extrahepatic (Distal) Bile Duct Cancer, Recurrent Glioblastoma, Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Head and Neck Squamous Cell Cancer, Recurrent Malignant Solid Tumor, Glioblastoma, Stage IVB Gallbladder Cancer, Refractory Malignant Solid Tumor, Metastatic Biliary Tract Carcinoma, Recurrent Biliary Tract Carcinoma, Metastatic Oropharyngeal Carcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Recurrent Esophageal Squamous Cell Cancer",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Advanced Renal Cell Carcinoma",
    "Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage IV Breast Cancer, HER2-Positive Breast Carcinoma, Refractory Breast Cancer, Metastatic Malignant Neoplasm in the Brain, Stage IV Breast Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma, Refractory Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Grade 3 Follicular Lymphoma, High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Chronic Lymphocytic Leukemia (CLL), Transformed Recurrent Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Grade 3b Follicular Lymphoma, Recurrent Double-Hit Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Grade 3b Follicular Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Advanced Ovarian Carcinoma, Stage IIIA1 Ovarian Cancer, Advanced Lung Non-Small Cell Carcinoma, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Metastatic Ovarian Carcinoma, Stage IIIA2 Ovarian Cancer, Stage IIIC Ovarian Cancer, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Malignant Solid Tumor, Stage IIIB Ovarian Cancer, Advanced Malignant Solid Tumor, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIC Lung Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage IVB Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IVA Ovarian Cancer, Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Advanced Malignant Solid Tumor, Recurrent Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Platinum Sensitive Ovarian Cancer, Advanced Lung Non-Small Cell Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Adenocarcinoma, Lung Adenocarcinoma, Stage IV Breast Cancer, Stage IV Non-Small Cell Lung Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer",
    "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Pleural Malignant Mesothelioma, Pleural Sarcomatoid Mesothelioma, Pleural Biphasic Mesothelioma, Stage III Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma",
    "Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Metastatic Head and Neck Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Advanced Head and Neck Cancer, Sacral Chordoma, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Refractory Soft Tissue Sarcoma, Recurrent Soft Tissue Sarcoma, Refractory Pancreatic Carcinoma, Metastatic Bile Duct Carcinoma, Advanced Bile Duct Carcinoma, Refractory Breast Cancer, Refractory Colorectal Cancer, Refractory Head and Neck Carcinoma, Metastatic Soft Tissue Sarcoma, Advanced Lymphoma, Metastatic Breast Carcinoma, Refractory Colon Carcinoma, Refractory Liver Carcinoma, Refractory Bile Duct Carcinoma, Recurrent Bile Duct Carcinoma, Metastatic Liver Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Colon Carcinoma, Metastatic Cholangiocarcinoma, Refractory Cholangiocarcinoma, Advanced Soft Tissue Sarcoma, Refractory Hepatocellular Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Recurrent Squamous Cell Carcinoma, Advanced Squamous Cell Carcinoma, Advanced Cholangiocarcinoma, Advanced Pancreatic Carcinoma, Advanced Colon Carcinoma, Advanced Hepatocellular Carcinoma, Refractory Squamous Cell Carcinoma, Recurrent Cholangiocarcinoma, Stage IV Breast Cancer, Recurrent Colon Cancer, Metastatic Squamous Cell Carcinoma, Stage IV Pancreatic Cancer, Recurrent Liver Cancer, Recurrent Head and Neck Carcinoma, Recurrent Pancreatic Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Pancreatic Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage III Colon Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IV Colon Cancer, Recurrent Hepatocellular Cancer, Stage III Liver Cancer, Stage III Liver Cancer, Stage III Liver Cancer, Stage III Liver Cancer, Stage IV Liver Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Cutaneous Melanoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Stage IIIA Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Metastatic Head and Neck Squamous Cell Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIB Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IIIC Esophageal Adenocarcinoma, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IIIC Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Glioma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Grade 3b Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3 Follicular Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Mediastinal (Thymic) Large B-Cell Lymphoma",
    "High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer, FIGO Stage IIIA Ovarian Cancer, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA1(i) Ovarian Cancer, FIGO Stage IIIA1(ii) Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer, FIGO Stage IIIC Ovarian Cancer, FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Ovarian Clear Cell Adenocarcinoma, Ovarian Seromucinous Carcinoma, Undifferentiated Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Cancer, Ovarian Adenocarcinoma, Ovarian Endometrioid Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Undifferentiated Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage IV Retroperitoneal Sarcoma, Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma, Unresectable Dedifferentiated Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma, Unresectable Soft Tissue Sarcoma, Metastatic Soft Tissue Sarcoma, Advanced Soft Tissue Sarcoma, Advanced Myxoid Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Advanced Leiomyosarcoma, Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Myxofibrosarcoma, Advanced Dedifferentiated Liposarcoma, Advanced Fibrosarcoma, Unresectable Fibrosarcoma, Unresectable Angiosarcoma, Unresectable Myxoid Liposarcoma, Advanced Angiosarcoma, Advanced Round Cell Liposarcoma, Unresectable Round Cell Liposarcoma, Advanced Myxofibrosarcoma, Pleomorphic Liposarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Angiosarcoma, Metastatic Fibrosarcoma, Metastatic Leiomyosarcoma",
    "Recurrent Glioblastoma, Malignant Solid Tumor, Refractory Glioblastoma, Malignant Brain Tumor, Metastatic Malignant Neoplasm in the Brain, MGMT-Unmethylated Glioblastoma, Leptomeningeal Neoplasm, Brain Glioblastoma, Brain Stem Glioblastoma",
    "Castration-Resistant Prostate Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Carcinoma, Refractory Lung Small Cell Carcinoma, Unresectable Lung Small Cell Carcinoma, Stage IV Follicular Lymphoma, Recurrent Follicular Lymphoma, Recurrent Prostate Cancer, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Stage III Follicular Lymphoma, Metastatic Prostate Cancer, Recurrent Small Cell Lung Cancer, Refractory Diffuse Large B-Cell Lymphoma, Extensive Stage Small Cell Lung Cancer",
    "Mucositis, Head and Neck Squamous Cell Carcinoma",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Unresectable Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Adenocarcinoma, Stage IIIA Lung Cancer",
    "Recurrent Primary Amyloidosis, Recurrent Waldenstrom Macroglobulinemia, Plasma Cell Leukemia, Non-Secretory Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Refractory Primary Amyloidosis, POEMS Syndrome, Refractory Waldenstrom Macroglobulinemia, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Breast Cancer, Triple-Negative Breast Cancer",
    "Metastatic Urothelial Cancer, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Recurrent Head and Neck Squamous Cell Cancer, Refractory Acute Myeloid Leukemia (AML), Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Ureter Cancer, Stage IV Ureter Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Acute Myeloid Leukemia (AML), Advanced Urothelial Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Metastatic Soft Tissue Sarcoma, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Melanoma, Advanced Soft Tissue Sarcoma, Advanced Gastric Carcinoma",
    "Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Esophageal Adenocarcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma, Diffuse Large B-Cell Lymphoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Esophageal Adenocarcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Colon Adenocarcinoma, Rectal Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Melanoma, Unresectable Malignant Solid Tumor, Unresectable Melanoma, Refractory Urothelial Carcinoma, Unresectable Urothelial Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Lung Adenocarcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Liposarcoma, Metastatic Dedifferentiated Liposarcoma, Locally Advanced Dedifferentiated Liposarcoma, Unresectable Malignant Peripheral Nerve Sheath Tumor, Unresectable Lung Adenocarcinoma, Well Differentiated Liposarcoma, Mediastinal Liposarcoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Cancer, Metastatic Malignant Peripheral Nerve Sheath Tumor, Metastatic Melanoma",
    "Recurrent Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Prostate Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Advanced Hepatocellular Carcinoma, Metastatic Prostatic Adenocarcinoma",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Refractory Marginal Zone Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Splenic Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Refractory Follicular Lymphoma",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Mixed Phenotype Acute Leukemia",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unresectable Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Urothelial Cancer, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Prostate Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Cholangiocarcinoma, Advanced Pancreatic Carcinoma, Advanced Leiomyosarcoma, Advanced Hepatocellular Carcinoma, Triple-Negative Breast Cancer, Advanced Liposarcoma, Metastatic Prostate Cancer",
    "Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Infiltrating Bladder Mixed Carcinoma, Bladder Urothelial Cancer",
    "Recurrent Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Carcinoma, Recurrent Biliary Tract Carcinoma, Metastatic Cholangiocarcinoma, Unresectable Colorectal Carcinoma, Metastatic Biliary Tract Carcinoma, Metastatic Gallbladder Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced Gallbladder Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma, Recurrent Gallbladder Cancer, Malignant Gastrointestinal Neoplasm, Unresectable Gallbladder Cancer, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Recurrent Non-Small Cell Lung Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Squamous Carcinoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Advanced Melanoma, Metastatic Melanoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIB Lung Cancer, Stage IIIA Lung Cancer, Resectable Lung Non-Small Cell Carcinoma",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Refractory Acute Myeloid Leukemia (AML), Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Leukemia, Refractory Acute Leukemia, Recurrent Neuroblastoma",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostatic Adenocarcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Head and Neck Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage III Rectal Cancer, Stage IIIA Rectal Cancer, Stage IIIB Rectal Cancer, Stage IIIC Rectal Cancer, Stage IV Rectal Cancer, Stage IVA Rectal Cancer, Stage IVB Rectal Cancer, Stage IVC Rectal Cancer, Stage III Vulvar Cancer, Stage IIIA Vulvar Cancer, Stage IIIB Vulvar Cancer, Stage IIIC Vulvar Cancer, Stage IV Vulvar Cancer, Stage IVA Vulvar Cancer, Stage IVB Vulvar Cancer, Stage III Vaginal Cancer, Stage IV Vaginal Cancer, Stage IVA Vaginal Cancer, Stage IVB Vaginal Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Recurrent Human Papillomavirus-Related Malignant Neoplasm, Locally Advanced Head and Neck Carcinoma, Metastatic Cervical Carcinoma, Metastatic Vaginal Carcinoma, Metastatic Vulvar Carcinoma, Metastatic Rectal Carcinoma, Locally Advanced Cervical Carcinoma, Metastatic Human Papillomavirus-Related Malignant Neoplasm, Locally Advanced Anal Carcinoma, Metastatic Anal Carcinoma, Locally Advanced Rectal Carcinoma, Locally Advanced Vulvar Carcinoma, Locally Advanced Vaginal Carcinoma, Locally Advanced Penile Carcinoma, Metastatic Penile Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Anal Canal Cancer, Recurrent Cervical Cancer, Recurrent Vaginal Cancer, Recurrent Penile Cancer, Recurrent Vulvar Cancer, Recurrent Rectal Cancer",
    "Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced HER2 Negative Breast Carcinoma",
    "Stage IIB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma, Stage IIB Cutaneous (Skin) Melanoma, Stage IIC Cutaneous (Skin) Melanoma",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Inflammatory Breast Cancer, Invasive Breast Cancer",
    "Metastatic Uveal Melanoma, Metastatic Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome, JAK2 Gene Mutation",
    "Stage IV Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Bladder Non-Invasive Papillary Urothelial Carcinoma, Bladder Papillary Urothelial Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Soft Tissue Sarcoma, Advanced Epithelioid Sarcoma",
    "Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Metastatic Malignant Neoplasm in the Supraclavicular Lymph Nodes, Esophageal Squamous Cell Cancer, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Refractory High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Advanced Breast Carcinoma, HER2 Negative Breast Carcinoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Recurrent Classical Hodgkin Lymphoma, Refractory Classical Hodgkin Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Unresectable Colorectal Carcinoma",
    "Metastatic Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Advanced Non-Squamous Non-Small Cell Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Unresectable Melanoma, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Refractory Lung Small Cell Carcinoma, Advanced Non-Small Cell Squamous Lung Cancer, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Adenosquamous Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Cervical Adenocarcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Unresectable Lung Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Squamous Carcinoma, Unresectable Lung Non-Small Cell Squamous Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Unresectable Laryngeal Squamous Cell Carcinoma, Metastatic Pharyngeal Squamous Cell Carcinoma, Advanced Pharyngeal Squamous Cell Carcinoma, Unresectable Cervical Squamous Cell Carcinoma, Unresectable Cervical Adenosquamous Carcinoma, Unresectable Cervical Adenocarcinoma, Advanced Cervical Squamous Cell Carcinoma, Advanced Cervical Adenosquamous Carcinoma, Recurrent Colorectal (Colon or Rectal) Cancer",
    "Superficial Bladder Urothelial Carcinoma, Carcinoma In Situ",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Higher Risk Myelodysplastic Syndrome",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Melanoma",
    "Stage IIIC1 Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer",
    "Unresectable Hypopharyngeal Squamous Cell Carcinoma, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Malignant Solid Tumor, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Unresectable Laryngeal Squamous Cell Carcinoma, Unresectable Oral Cavity Squamous Cell Carcinoma, Metastatic Laryngeal Throat Squamous Cell Cancer, Unresectable Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Lung Small Cell Carcinoma, Advanced Lung Small Cell Carcinoma, Recurrent Small Cell Lung Cancer",
    "Metastatic Malignant Neoplasm to Soft Tissues, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Metastatic Prostatic Adenocarcinoma, Stage IVB Prostate Cancer",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Unresectable Hepatocellular Cancer",
    "Metastatic Urothelial Cancer, Unresectable Urothelial Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer",
    "Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Unresectable Esophageal Squamous Cell Carcinoma, Locally Advanced Esophageal Squamous Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Unresectable Cutaneous (Skin) Melanoma, Advanced Melanoma, Unresectable Acral Lentiginous Melanoma, Unresectable Mucosal Melanoma",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Recurrent Ovarian Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Colorectal Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Stage IVA Cervical Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Metastatic Cervical Adenosquamous Carcinoma, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Recurrent Cervical Squamous Cell Cancer, Unresectable Cervical Adenosquamous Carcinoma, Recurrent Cervical Adenocarcinoma, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IV Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Cervical Carcinoma, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Unresectable Anal Squamous Cell Carcinoma, Unresectable Cervical Carcinoma, Unresectable Cervical Squamous Cell Carcinoma, Unresectable Cervical Adenocarcinoma, Recurrent Anal Canal Squamous Cell Carcinoma, Metastatic Anal Canal Squamous Cell Carcinoma, Unresectable Anal Canal Squamous Cell Carcinoma, Recurrent Cervical Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Stage IIIB Cervical Cancer",
    "Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Stage IV Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Stage IVA Cervical Cancer, Metastatic Cervical Adenosquamous Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Esophageal Squamous Cell Cancer, Advanced Malignant Solid Tumor, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Cervical Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Multiple Myeloma/Plasma Cell Myeloma, Diffuse Large B-Cell Lymphoma, Metastatic Melanoma, Stage IVB Esophageal Adenocarcinoma, Stage IV Gastric (Stomach) Cancer, Stage IVA Esophageal Adenocarcinoma, Stage IVB Cervical Cancer, Metastatic Gastric Carcinoma, Non-Hodgkin Lymphoma, Metastatic Esophageal Carcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Lung Cancer",
    "Recurrent Grade II Glioma, Low Grade Glioma",
    "Refractory Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma",
    "Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Unresectable Solid Tumor, Stage IIIA Non-Small Cell Lung Cancer, Advanced Malignant Solid Tumor, Stage III Non-Small Cell Lung Cancer",
    "Stage 0is Bladder Urothelial Cancer, Stage 0a Bladder Urothelial Cancer, Bladder Non-Invasive Papillary Urothelial Carcinoma, High Grade",
    "Myelodysplastic Syndrome",
    "Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Refractory Pancreatic Carcinoma, Bile Duct Cancer (including Cholangiocarcinoma), Recurrent Esophageal Cancer, Gastric (Stomach) Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma, Recurrent Pancreatic Cancer, Pancreatic Adenocarcinoma, Recurrent Colorectal (Colon or Rectal) Cancer, Metastatic Pancreatic Adenocarcinoma, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia (AML)",
    "Chronic Myelomonocytic Leukemia (CMML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Melanoma, Locally Advanced Melanoma, Unresectable Melanoma, Metastatic Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome",
    "Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Invasive Breast Cancer, Stage IIIC Breast Cancer",
    "Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma, Stage IV Breast Cancer, Breast Adenocarcinoma, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Advanced Breast Carcinoma, Recurrent Breast Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative, Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent High Risk Myelodysplastic Syndrome, Refractory High Risk Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent T Acute Lymphoblastic Leukemia, Refractory T Acute Lymphoblastic Leukemia, Recurrent Very High-Risk Myelodysplastic Syndrome, Refractory Very High-Risk Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm, Recurrent B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1, Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Chronic Myeloproliferative Disease, Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Acute Myeloid Leukemia (AML), Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Mantle Cell Lymphoma",
    "Resectable Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Tonsillar Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Soft Palate Cancer, Posterior Tongue Carcinoma",
    "Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Triple-Negative Breast Cancer, Invasive Breast Cancer",
    "Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Platinum-Resistant Primary Peritoneal Cancer",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Cancer",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Melanoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Advanced Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer",
    "Stage 0is Bladder Cancer, Stage I Bladder Cancer, Superficial Bladder Cancer, Bladder Urothelial Cancer, Stage I Bladder Cancer with Carcinoma In Situ",
    "Hepatocellular Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Resistant Prostate Carcinoma Refractory to Second-Generation Androgen Receptor Axis-Targeted Agents, Metastatic Prostate Cancer",
    "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Renal Cell Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Metastatic Gastric Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Colorectal Carcinoma, Clear Cell Renal Cell Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Malignant Solid Tumor, Symptomatic COVID-19 Infection Laboratory-Confirmed, Parainfluenza Virus Infection, Hematopoietic and Lymphoid Cell Neoplasm, Brain Tumor, Breast Neoplasm, Leukemia, Lung Neoplasm, Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Lower Respiratory Tract Infection",
    "Hepatocellular Cancer, Chronic Liver Disease, Cirrhosis, Hepatitis",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Renal Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Advanced Clear Cell Renal Cell Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma, Unresectable Triple-Negative Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Hepatocellular Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Recurrent Breast Cancer",
    "Advanced Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Refractory Pancreatic Carcinoma, Refractory Breast Cancer, Refractory Ovarian Carcinoma, Refractory Fallopian Tube Cancer, Refractory Non-Small Cell Lung Cancer, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Advanced Pancreatic Carcinoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Triple-Negative Breast Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Colorectal Cancer, Unresectable Malignant Solid Tumor, Refractory Cutaneous (Skin) Melanoma, Refractory Non-Small Cell Lung Cancer, Recurrent Pancreatic Ductal Adenocarcinoma, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Refractory Pleural Malignant Mesothelioma, Unresectable Pancreatic Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Ductal Adenocarcinoma, Advanced HER2 Negative Breast Carcinoma, Recurrent HER2 Negative Breast Carcinoma, Refractory HER2 Negative Breast Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Advanced Pleural Malignant Mesothelioma, Recurrent Pleural Malignant Mesothelioma, Recurrent Cutaneous (Skin) Melanoma",
    "Malignant Solid Tumor, Non-Small Cell Lung Cancer, Esophageal Cancer, Head and Neck Carcinoma, Urothelial Carcinoma, Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma",
    "Non-Small Cell Squamous Lung Cancer, Non-Squamous Non-Small Cell Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer",
    "Acute Myeloid Leukemia (AML), Blasts 20 Percent or More of Peripheral Blood White Cells, Blasts 20 Percent or More of Bone Marrow Nucleated Cells",
    "Refractory Marginal Zone Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Lymphoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Lymphoma, Unresectable Malignant Solid Tumor, Advanced Lymphoma, Unresectable Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Advanced Merkel Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Stage III Intrahepatic Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Ampulla of Vater Cancer, Stage IIIA Ampulla of Vater Cancer, Stage IIIB Ampulla of Vater Cancer, Stage IV Ampulla of Vater Cancer, Metastatic Bile Duct Carcinoma, Advanced Bile Duct Carcinoma, Locally Advanced Bile Duct Cancer, Metastatic Gallbladder Carcinoma, Advanced Gallbladder Carcinoma, Unresectable Ampulla of Vater Carcinoma, Locally Advanced Gallbladder Carcinoma, Unresectable Bile Duct Carcinoma, Metastatic Ampulla of Vater Carcinoma, Locally Advanced Ampulla of Vater Carcinoma, Advanced Ampulla of Vater Carcinoma, Unresectable Gallbladder Cancer",
    "Recurrent Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostate Cancer",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Classical Hodgkin Lymphoma, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Classical Hodgkin Lymphoma, Refractory Malignant Solid Tumor, Unresectable Head and Neck Squamous Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Gastric (Stomach) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Unresectable Cutaneous (Skin) Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Cervical Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Locally Advanced Cutaneous Melanoma, Unresectable Cervical Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Recurrent Gastric (Stomach) Cancer, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Splenic Marginal Zone Lymphoma, Refractory Splenic Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Endometrial Serous Adenocarcinoma, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Metastatic Triple-Negative Breast Carcinoma, Refractory Endometrial Serous Adenocarcinoma, Unresectable Ovarian Serous Adenocarcinoma, Metastatic Ovarian Serous Adenocarcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Refractory Triple-Negative Breast Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Metastatic Endometrial Serous Adenocarcinoma, Recurrent Triple-Negative Breast Carcinoma, Metastatic Fallopian Tube Serous Adenocarcinoma, Unresectable Fallopian Tube Serous Adenocarcinoma, Metastatic Primary Peritoneal Serous Adenocarcinoma, Unresectable Primary Peritoneal Serous Adenocarcinoma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma",
    "Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Recurrent Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVB Thyroid Gland Cancer, Undifferentiated (Anaplastic) Stage IVC Thyroid Gland Cancer, Refractory Pancreatic Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Refractory Glioblastoma, Refractory Breast Cancer, Refractory Colorectal Cancer, Refractory Gastric (Stomach) Cancer, Refractory Head and Neck Squamous Cell Cancer, Advanced Uveal Melanoma, Refractory Ovarian Carcinoma, Refractory Hepatocellular Carcinoma, Advanced Breast Carcinoma, Refractory Chordoma, Advanced Gastric Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Hormone Receptor Negative Breast Carcinoma, Refractory Triple-Negative Breast Carcinoma, Advanced Hepatocellular Carcinoma, HER2 Negative Breast Carcinoma, Refractory Thyroid Gland Anaplastic Carcinoma, Advanced Glioblastoma, Advanced Lung Squamous Cell Carcinoma, Refractory Lung Squamous Cell Carcinoma, Refractory Microsatellite Stable Colorectal Carcinoma, Advanced Chordoma, Refractory Anal Canal Squamous Cell Carcinoma, Refractory Uveal Melanoma, Advanced Thyroid Gland Anaplastic Carcinoma, Advanced Anal Canal Squamous Cell Carcinoma, Triple-Negative Breast Cancer, Stage IIIC Breast Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Microsatellite Stable Colorectal Carcinoma, Non-Small Cell Lung Cancer",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Indolent T-Cell Lymphoproliferative Disorder of the Gastrointestinal Tract, Adult T-Cell Leukemia/Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Enteropathy-Associated T-Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Follicular T-Cell Lymphoma, Hepatosplenic T-Cell Lymphoma, Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma",
    "Endometrial Cancer, Uterine Corpus Carcinosarcoma",
    "Mantle Cell Lymphoma",
    "Double-Hit Lymphoma, Triple-Hit Lymphoma, Recurrent High-Grade B-Cell Lymphoma with MYC, BCL2, and BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, B-Cell Non-Hodgkin Lymphoma, Grade 3 Follicular Lymphoma, Grade 1 Follicular Lymphoma, Recurrent Follicular Lymphoma, Grade 3a Follicular Lymphoma, Grade 3b Follicular Lymphoma, Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Grade 2 Follicular Lymphoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Unresectable Malignant Solid Tumor, Locally Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Colorectal Carcinoma, Metastatic Cholangiocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Melanoma, Metastatic Melanoma, Advanced Melanoma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma",
    "Stage IIIB Colorectal (Colon or Rectal) Cancer, Advanced Colorectal Carcinoma, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer",
    "Recurrent Desmoid-Type Fibromatosis, Refractory Desmoid-Type Fibromatosis, Deep Fibromatosis/Desmoid Tumor",
    "Metastatic Uveal Melanoma",
    "Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Stage IV Breast Cancer, Triple-Negative Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Ewing Sarcoma, Recurrent Ewing Sarcoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Unresectable Cutaneous (Skin) Melanoma, Advanced Non-Small Cell Squamous Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Unresectable Colorectal Carcinoma, Stage III Cutaneous (Skin) Melanoma, Advanced Cutaneous Melanoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer, Non-Small Cell Squamous Lung Cancer",
    "Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Recurrent Waldenstrom Macroglobulinemia, Refractory Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Double-Hit Lymphoma, Recurrent Double-Hit Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Richter Syndrome, Recurrent Marginal Zone Lymphoma",
    "Metastatic Malignant Solid Tumor, Metastatic Urothelial Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Advanced Urothelial Cancer, Unresectable Melanoma, Unresectable Urothelial Carcinoma, Advanced Melanoma, Metastatic Hepatocellular Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Adenocarcinoma, Advanced Hepatocellular Carcinoma, Unresectable Colorectal Adenocarcinoma, Unresectable Hepatocellular Cancer, Metastatic Melanoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Anemia, Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Chronic Myeloproliferative Disease",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Unresectable Hepatocellular Cancer",
    "Steroid Refractory Graft Versus Host Disease",
    "Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Recurrent Extranodal Diffuse Large B-Cell Lymphoma, Refractory Extranodal Diffuse Large B-Cell Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma, Refractory Waldenstrom Macroglobulinemia, Refractory Marginal Zone Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced B-Cell Neoplasm, Refractory Indolent Adult Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Follicular Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Non-Small Cell Lung Cancer, Unresectable Malignant Solid Tumor, Triple-Negative Breast Cancer",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Endometrial Serous Adenocarcinoma, Stage IA Uterine (including Endometrial) Cancer, Stage IB Uterine (including Endometrial) Cancer, Stage II Uterine (including Endometrial) Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Recurrent Endometrial Endometrioid Adenocarcinoma, Recurrent Endometrial Undifferentiated Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Advanced Endometrial Carcinoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Refractory Malignant Neoplasm, Recurrent Glioblastoma, Refractory Lymphoma, Recurrent Lymphoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Bone Cancer, Stage IV Bone Cancer, Stage IVA Bone Cancer, Stage IVB Bone Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Pancreatic Carcinoma, Refractory Glioblastoma, Refractory Breast Cancer, Refractory Sarcoma, Recurrent Sarcoma, Refractory Ovarian Carcinoma, Refractory Bladder Cancer, Metastatic Renal Cell Cancer, Metastatic Sarcoma, Advanced Renal Cell Carcinoma, Advanced Lymphoma, Advanced Sarcoma, Metastatic Breast Carcinoma, Recurrent Pancreatic Adenocarcinoma, Metastatic Bladder Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Refractory Pancreatic Adenocarcinoma, Advanced Pancreatic Adenocarcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Refractory Renal Cell Carcinoma, Advanced Bladder Carcinoma, Advanced Glioblastoma, Metastatic Glioblastoma, Breast Neoplasm, Colorectal Neoplasm, Glioblastoma, Lung Neoplasm, Pancreatic Neoplasm, Metastatic Malignant Neoplasm to the Bone, Metastatic Malignant Neoplasm, Bone Cancer, Recurrent Malignant Neoplasm, Malignant Glioma, Refractory Brain Neoplasm, Recurrent Pancreatic Cancer, Refractory Neoplasm, Recurrent Breast Cancer, Recurrent Renal Cell Cancer, Recurrent Ovarian Cancer, Recurrent Bladder Cancer, Refractory Non-Hodgkin Lymphoma, Metastatic Pancreatic Adenocarcinoma, Advanced Malignant Neoplasm, Bone Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Aggressive Prostate Adenocarcinoma, Recurrent Prostate Adenocarcinoma",
    "Metastatic Urothelial Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Recurrent Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Lugano Classification Stage III Adult Lymphoma AJCC v8, Lugano Classification Stage IV Adult Lymphoma AJCC v8, Refractory Melanoma, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Sarcoma, Recurrent Sarcoma, Locally Advanced Melanoma, Refractory Ovarian Carcinoma, Refractory Urothelial Carcinoma, Metastatic Renal Cell Cancer, Metastatic Sarcoma, Locally Advanced Sarcoma, Refractory Non-Small Cell Lung Cancer, Recurrent Clear Cell Renal Cell Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Lymphoma, Recurrent Melanoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer, Metastatic Melanoma",
    "Recurrent Waldenstrom Macroglobulinemia, Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Refractory Waldenstrom Macroglobulinemia, Recurrent Acute Lymphoblastic Leukemia, Refractory Marginal Zone Lymphoma, Recurrent Acute Myeloid Leukemia (AML), Richter Syndrome, Recurrent Follicular Lymphoma, Recurrent Burkitt Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Lymphoplasmacytic Lymphoma, Recurrent T-Cell Non-Hodgkin Lymphoma, Refractory T-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Recurrent Skin Squamous Cell Carcinoma, Metastatic Skin Squamous Cell Carcinoma, Refractory Melanoma, Metastatic Merkel Cell Carcinoma, Refractory Skin Squamous Cell Carcinoma, Recurrent Metastatic Skin Squamous Cell Carcinoma, Recurrent Metastatic Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Recurrent Melanoma, Metastatic Melanoma",
    "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IV Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA1 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVA2 Mycosis Fungoides and Sezary Syndrome AJCC v8, Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v8, Recurrent Sezary Syndrome, Refractory Sezary Syndrome, Recurrent Mycosis Fungoides, Refractory Mycosis Fungoides",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage IIA Lung Cancer, Non-Small Cell Lung Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Refractory Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Metastatic Lung Adenocarcinoma, Metastatic Endometrial Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Endometrial Carcinoma, Recurrent Lung Non-Small Cell Squamous Carcinoma, Refractory Lung Non-Small Cell Squamous Carcinoma, Unresectable Endometrial Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Lung Adenocarcinoma, Recurrent Small Cell Lung Cancer",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Breast Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Colorectal Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Melanoma, Metastatic Prostate Cancer",
    "Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Unresectable Hepatocellular Cancer",
    "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Malignant Solid Tumor, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Metastatic Malignant Solid Tumor, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Gastric (Stomach) Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Breast Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Breast Carcinoma, Recurrent Breast Cancer, Recurrent Gastric (Stomach) Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Recurrent Hepatocellular Cancer, Hepatocellular Cancer",
    "Metastatic Adenoid Cystic Cancer, Recurrent Adenoid Cystic Cancer, Unresectable Adenoid Cystic Carcinoma",
    "Recurrent Superficial Bladder Urothelial Carcinoma",
    "Recurrent Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Advanced Triple-Negative Breast Carcinoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma",
    "Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia-2",
    "Essential Thrombocythemia",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Refractory Cutaneous (Skin) Melanoma, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cutaneous Melanoma, Metastatic Colorectal Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Recurrent Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Malignant Skin Neoplasm, Advanced Cutaneous Melanoma, Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Refractory Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Triple-Negative Breast Carcinoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Carcinoma in the Skin, Recurrent Breast Cancer, Recurrent Cutaneous (Skin) Melanoma",
    "Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Acute Myelomonocytic Leukemia, Recurrent Acute Monoblastic and Monocytic Leukemia, Refractory Acute Monoblastic and Monocytic Leukemia, Refractory Acute Myelomonocytic Leukemia",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Refractory Gastric (Stomach) Cancer, Advanced Urothelial Cancer, Refractory Bladder Cancer, Refractory Urothelial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Gastroesophageal Junction Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Bladder Carcinoma",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Endometrioid Adenocarcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Advanced Endometrial Endometrioid Adenocarcinoma, Unresectable Endometrial Carcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "Stage IVA Esophageal Adenocarcinoma, Stage IVA Cervical Cancer, Refractory Melanoma, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC Breast Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Cutaneous (Skin) Melanoma, Metastatic Skin Squamous Cell Carcinoma, Stage IIIA Cutaneous (Skin) Melanoma, Metastatic Lung Small Cell Carcinoma, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Locally Advanced Cervical Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Urothelial Cancer, Stage IIIA Gastric (Stomach) Cancer, Advanced Urothelial Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIA Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IIIB Lung Cancer, Stage III Lung Cancer, Stage IVB Hepatocellular Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIA Esophageal Adenocarcinoma, Stage IV Uterine (including Endometrial) Cancer, Stage IV Renal Cell Cancer, Stage III Breast Cancer, Stage IV Cervical Cancer, Stage IIIB Breast Cancer, Stage IVB Cervical Cancer, Stage III Renal Cell Cancer, Stage IVB Uterine (including Endometrial) Cancer, Metastatic Endometrial Carcinoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Breast Cancer, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Breast Cancer, Metastatic Gastric Carcinoma, Stage IIIA Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Uterine (including Endometrial) Cancer, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Locally Advanced Malignant Solid Tumor, Stage IV Head and Neck Squamous Cell Cancer, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Hepatocellular Cancer, Refractory Gastric (Stomach) Cancer, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Refractory Endometrial Carcinoma, Refractory Urothelial Carcinoma, Platinum-Resistant Urothelial Carcinoma, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Refractory Lung Small Cell Carcinoma, Metastatic Renal Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Hepatocellular Carcinoma, Refractory Hepatocellular Carcinoma, Metastatic Merkel Cell Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Gastric Carcinoma, Refractory Skin Squamous Cell Carcinoma, Locally Advanced Merkel Cell Carcinoma, Refractory Merkel Cell Carcinoma, Refractory Renal Cell Carcinoma, Refractory Triple-Negative Breast Carcinoma, Advanced Skin Squamous Cell Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Endometrial Carcinoma, Refractory Cervical Carcinoma, Refractory Esophageal Carcinoma, Metastatic Melanoma, Stage IVA Uterine (including Endometrial) Cancer, Stage IVA Lung Cancer, Metastatic Cervical Carcinoma, Stage IIIB Breast Cancer, Refractory Head and Neck Squamous Cell Cancer, Stage IIIB Cervical Cancer, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Breast Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8",
    "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Malignant Solid Tumor, Unresectable Esophageal Cancer, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Unresectable Malignant Solid Tumor, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Unresectable Gastric (Stomach) Adenocarcinoma, Metastatic Esophageal Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Cholangiocarcinoma, Unresectable Colorectal Carcinoma, Metastatic Gallbladder Carcinoma, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer",
    "Unresectable Gastric Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Cervical Carcinoma, Stage IVB Cervical Cancer, Stage IVB Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Ovarian Cancer, Metastatic Breast Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Bladder Carcinoma, Stage III Bladder Cancer, Locally Advanced Lung Carcinoma, Locally Advanced Breast Carcinoma, Unresectable Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma, Unresectable Lung Carcinoma, Metastatic Biliary Tract Carcinoma, Stage IIIB Bladder Cancer, Metastatic Gastric Carcinoma, Metastatic Ovarian Carcinoma, Stage IVA Bladder Cancer, Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IVA Ovarian Cancer, Stage IV Bladder Cancer, Metastatic Lung Carcinoma, Metastatic Cervical Carcinoma, Metastatic Colorectal Carcinoma, Unresectable Bladder Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Pancreatic Carcinoma, Locally Advanced Endometrial Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Cervical Carcinoma, Unresectable Biliary Tract Carcinoma, Unresectable Pancreatic Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIB Ovarian Cancer, Locally Advanced Gastric Carcinoma, Stage IIIA Ovarian Cancer, Stage III Ovarian Cancer, Stage IVA Uterine (including Endometrial) Cancer, Unresectable Ovarian Carcinoma, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Locally Advanced Bladder Carcinoma, Locally Advanced Ovarian Carcinoma, Metastatic Endometrial Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Metastatic Colorectal Carcinoma, Locally Advanced Colorectal Carcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Refractory Non-Small Cell Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Endometrial Serous Adenocarcinoma, Endometrial Serous Adenocarcinoma",
    "Clinical Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage 0 Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage I Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage 0 Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage 0 Gastric (Stomach) Cancer, Stage I Gastric (Stomach) Cancer, Stage IA Gastric (Stomach) Cancer, Stage IB Gastric (Stomach) Cancer, Stage II Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Stage IIA Gastric (Stomach) Cancer, Stage IIB Gastric (Stomach) Cancer, Gastric (Stomach) Cancer, Gastroesophageal Junction Adenocarcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia (CMML), Recurrent Myeloproliferative Neoplasm, Refractory Myeloproliferative Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IIID Cutaneous (Skin) Melanoma, Refractory Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Melanoma, Stage III Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Unresectable Melanoma",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia",
    "Refractory Hematologic Malignancy, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Refractory Malignant Solid Tumor, Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Acute Adult T-Cell Leukemia/Lymphoma, Lymphomatous Adult T-Cell Leukemia/Lymphoma, Chronic Adult T-Cell Leukemia/Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Metastatic Prostatic Adenocarcinoma, Stage IV Prostate Adenocarcinoma, Recurrent Prostate Cancer, Metastatic Malignant Neoplasm to the Bone",
    "Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Refractory Malignant Neoplasm, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Neuroendocrine Neoplasm, Unresectable Lymphoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Unresectable Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm, Small Cell Lung Cancer, Recurrent Ovarian Cancer, Stage III Lymphoma, Stage IV Lymphoma, Locally Advanced Malignant Neoplasm",
    "Recurrent Prostate Cancer, Stage IV Prostate Cancer, Metastatic Prostate Cancer, Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor, Tenosynovial Giant Cell Tumor, Diffuse Type, Tenosynovial Giant Cell Tumor",
    "Stage II Renal Cell Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Sarcomatoid Renal Cell Cancer, Clear Cell Renal Cell Cancer",
    "Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Undifferentiated Esophageal Cancer, Esophageal Squamous Cell Cancer, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "Refractory Malignant Neoplasm, Refractory Neuroblastoma, Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Malignant Neoplasm, Recurrent Acute Lymphoblastic Leukemia (ALL), Recurrent Neuroblastoma, Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia (ALL), Refractory Non-Hodgkin Lymphoma, Recurrent Acute Myeloid Leukemia (AML), Recurrent Non-Hodgkin Lymphoma",
    "Refractory Neuroblastoma, Soft Tissue Tumor, Recurrent Neuroblastoma, Bone Neoplasm",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer in the Soft Tissue, Prostate Carcinoma Metastatic in the Bone, Prostate Adenocarcinoma, Metastatic Prostate Cancer",
    "Castration-Resistant Prostate Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Recurrent Endometrial Carcinoma, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Cervical Carcinoma, Advanced Endometrial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Malignant Uterine Neoplasm, Triple-Negative Breast Cancer, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Recurrent Renal Cell Cancer, Recurrent Bladder Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Metastatic Prostate Cancer, Recurrent Uterine (Including Endometrial) Cancer, Sarcoma, Advanced Malignant Neoplasm",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Marginal Zone Lymphoma, Recurrent Acute Myeloid Leukemia (AML), Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Adenocarcinoma, Locally Advanced Breast Adenocarcinoma, Advanced Breast Adenocarcinoma, Recurrent Breast Cancer",
    "Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia with BCR-ABL1",
    "Stage II Bladder Cancer, Stage IIIA Bladder Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, Recurrent High-Grade B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Refractory Grade 3b Follicular Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Richter Syndrome, Recurrent Follicular Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIB Breast Cancer, Stage IIIC Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Inflammatory Breast Cancer, Stage IIIC Breast Cancer, Breast Adenocarcinoma, Early-Stage Breast Cancer",
    "Metastatic Urothelial Cancer, Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Refractory Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Advanced Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma, Non-Hodgkin Lymphoma, Advanced Malignant Neoplasm, Metastatic Triple-Negative Breast Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Skin Squamous Cell Carcinoma, Refractory Melanoma, Refractory Bladder Cancer, Refractory Cutaneous (Skin) Melanoma, Advanced Melanoma, Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Bladder Carcinoma, Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Locally Advanced Unresectable Basal Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Locally Advanced Merkel Cell Carcinoma, Locally Advanced Bladder Carcinoma, Skin Basosquamous Cell Carcinoma, Stage III Skin Cancer, Stage IV Skin Cancer",
    "Recurrent Merkel Cell Cancer, Refractory Merkel Cell Carcinoma",
    "Recurrent Acute Lymphoblastic Leukemia, Refractory T Lymphoblastic Lymphoma, Recurrent T Lymphoblastic Leukemia/Lymphoma, Refractory B Lymphoblastic Lymphoma, Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent B Lymphoblastic Lymphoma",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Endometrial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Gastric Adenocarcinoma, Advanced Cutaneous Squamous Cell Carcinoma of the Head and Neck, Advanced Lung Adenocarcinoma, Fallopian Tube Cancer, Primary Peritoneal Cancer, Thyroid Gland Papillary Cancer, Ovarian Cancer, Advanced Pericardial Malignant Mesothelioma, Advanced Peritoneal Malignant Mesothelioma",
    "Hepatocellular Cancer, Hepatitis B Infection",
    "Malignant Neoplasm",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Lung Carcinoma Metastatic in the Brain",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer, Locally Advanced Breast Carcinoma, Recurrent Breast Cancer",
    "Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma",
    "Primary Central Nervous System Neoplasm, Advanced Malignant Solid Tumor, Anaplastic Large Cell Lymphoma, Metastatic Malignant Neoplasm to the Central Nervous System",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Transformed Mycosis Fungoides, Refractory Transformed Mycosis Fungoides, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Advanced Malignant Solid Tumor, Advanced Diffuse Large B-Cell Lymphoma",
    "Refractory Neuroblastoma, Recurrent Neuroblastoma",
    "Refractory Osteosarcoma, Recurrent Osteosarcoma",
    "Recurrent Head and Neck Squamous Cell Cancer, HPV16 Infection, Metastatic Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Metastatic Prostate Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Triple-Negative Breast Cancer",
    "Advanced Lung Non-Small Cell Carcinoma, Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage IIIB Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Non-Small Cell Lung Cancer",
    "Advanced Lung Non-Small Cell Carcinoma, Metastatic Primary Malignant Brain Neoplasm, Advanced Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Metastatic Malignant Solid Tumor, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IV Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Primary Malignant Brain Neoplasm, Metastatic Melanoma, Stage III Lung Cancer, Advanced Malignant Solid Tumor",
    "Stage IVA Lip and Oral Cavity Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis Transformation in Essential Thrombocythemia",
    "Recurrent Low Grade Ovarian Serous Adenocarcinoma",
    "Stage IVA Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage III Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Laryngeal Throat Cancer, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Metastatic Laryngeal Throat Squamous Cell Cancer, Locally Advanced Oral Cavity Squamous Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma",
    "Colorectal (Colon or Rectal) Cancer, Pancreatic Ductal Adenocarcinoma, Malignant Solid Tumor, Gallbladder Cancer, Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Non-Small Cell Lung Cancer, Malignant Ovarian Neoplasm, Bile Duct Cancer (including Cholangiocarcinoma)",
    "Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Nodal Peripheral T-Cell Lymphoma with TFH Phenotype, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Hepatosplenic T-Cell Lymphoma, Refractory Hepatosplenic T-Cell Lymphoma, Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified, Unresectable Lymphoma, Refractory Monomorphic Epitheliotropic Intestinal T-cell Lymphoma, Recurrent Subcutaneous Panniculitis-Like T-Cell Lymphoma, Refractory Subcutaneous Panniculitis-Like T-Cell Lymphoma, Mycosis Fungoides, Sezary Syndrome, Anaplastic Large Cell Lymphoma, Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma, Follicular T-Cell Lymphoma, Recurrent Adult T-Cell Leukemia/Lymphoma, Stage III Lymphoma, Stage IV Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Nasal Type Extranodal NK/T-Cell Lymphoma, Refractory Angioimmunoblastic T-Cell Lymphoma, Recurrent Angioimmunoblastic T-Cell Lymphoma, Refractory Enteropathy-Associated T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified, Recurrent Enteropathy-Associated T-Cell Lymphoma",
    "High-Risk Neuroblastoma, Metastatic Malignant Neoplasm to the Bone, Ganglioneuroblastoma, Recurrent Neuroblastoma, Refractory Neuroblastoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia",
    "Cytomegaloviral Infection",
    "Recurrent Bladder Urothelial Cancer, Stage 0a Bladder Cancer, Stage I Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage III Bladder Cancer, Stage IVA Bladder Cancer, Stage IV Bladder Cancer, Stage IVB Bladder Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Unresectable Pancreatic Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Lung Small Cell Carcinoma, Extensive Stage Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer",
    "Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-Cell Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Recurrent Lymphoproliferative Disorder, Recurrent EBV-Related Lymphoma, Refractory Lymphoproliferative Disorder, EBV-Related Lymphoproliferative Disorder, Refractory EBV-Related Lymphoma",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Resectable Lung Non-Small Cell Carcinoma, Non-Small Cell Lung Cancer, Stage IIB Lung Cancer",
    "Metastatic Urothelial Cancer, Advanced Urothelial Cancer, Unresectable Urothelial Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer",
    "Unresectable Ewing Sarcoma, Refractory Ewing Sarcoma, Refractory Myxoid Liposarcoma, Metastatic Myxoid Liposarcoma, Refractory Sarcoma, Unresectable Sarcoma, Metastatic Sarcoma, Refractory Desmoplastic Small Round Cell Tumor, Unresectable Myxoid Liposarcoma, Unresectable Desmoplastic Small Round Cell Tumor, Metastatic Desmoplastic Small Round Cell Tumor, Metastatic Ewing Sarcoma, Recurrent Ewing Sarcoma, Gilbert Syndrome",
    "Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Cholangiocarcinoma, Metastatic Cholangiocarcinoma",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase",
    "Advanced Malignant Solid Tumor, Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage III Hepatocellular Cancer, Stage IV Anal Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage IIIA Lung Cancer, Stage III Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Mismatch Repair Deficiency, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Refractory Melanoma, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Metastatic Uveal Melanoma, Advanced Uveal Melanoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Nasopharyngeal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Small Cell Carcinoma, Advanced Prostate Adenocarcinoma, Advanced Cervical Carcinoma, Recurrent Urothelial Cancer, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Lung Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Clear Cell Renal Cell Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Advanced Gastric Adenocarcinoma, Metastatic Primary Peritoneal Carcinoma, Advanced Hepatocellular Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Refractory Uveal Melanoma, Advanced Anal Canal Squamous Cell Carcinoma, Metastatic Vulvar Squamous Cell Carcinoma, Advanced Triple-Negative Breast Carcinoma, Metastatic Anal Canal Squamous Cell Carcinoma, Advanced Nasopharyngeal Carcinoma, Advanced Intrahepatic Cholangiocarcinoma, Non-Small Cell Lung Cancer, High-Frequency Microsatellite Instability, Penile Squamous Cell Cancer, Metastatic Melanoma, Metastatic Prostatic Adenocarcinoma",
    "Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Metastatic Cutaneous Melanoma, Cutaneous (Skin) Melanoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Stage IV Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Metastatic Urothelial Cancer, Metastatic Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Unresectable Malignant Solid Tumor, Refractory Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Recurrent Endometrial Carcinoma, Advanced Urothelial Cancer, Refractory Endometrial Carcinoma, Refractory Urothelial Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Triple-Negative Breast Carcinoma, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Advanced Cervical Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Recurrent Urothelial Cancer, Advanced Endometrial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Refractory Triple-Negative Breast Carcinoma, Refractory Cervical Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Cervical Cancer, Advanced Triple-Negative Breast Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Prostate Adenocarcinoma without Evidence of Neuroendocrine Differentiation, Metastatic Prostatic Adenocarcinoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Locally Advanced Pancreatic Ductal Adenocarcinoma, Unresectable Pancreatic Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Carcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Refractory Indolent Non-Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Recurrent Indolent Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Metastatic Breast Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Advanced Breast Carcinoma, Advanced Bladder Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma, Advanced Urethral Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma",
    "Advanced Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Refractory Colorectal Adenocarcinoma, Metastatic Colorectal Adenocarcinoma, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Myelodysplastic Syndrome",
    "Myelofibrosis Transformation in Essential Thrombocythemia, Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Secondary Myelofibrosis, Thrombocytopenia",
    "Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Advanced Breast Carcinoma, Recurrent Breast Cancer, Metastatic Breast Carcinoma, HER2 Negative Breast Carcinoma, Stage III Breast Cancer, Stage IIIC Breast Cancer",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Unresectable Gastric Carcinoma, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Stage III Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IVA Gastric (Stomach) Cancer, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Metastatic Gastric Carcinoma, Stage IV Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Disease, Myelofibrosis",
    "Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIB Breast Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IV Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Locally Advanced Melanoma, Metastatic Renal Cell Cancer, Metastatic Sarcoma, Locally Advanced Sarcoma, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Thyroid Gland Papillary Carcinoma, Metastatic Neuroendocrine Neoplasm, Metastatic Cholangiocarcinoma, Metastatic Salivary Gland Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Colorectal Carcinoma, Locally Advanced Ovarian Carcinoma, Locally Advanced Neuroendocrine Neoplasm, Locally Advanced Pancreatic Carcinoma, Locally Advanced Cholangiocarcinoma, Brain Tumor, Anaplastic Large Cell Lymphoma, Localized Brain Neoplasm, Locally Advanced Salivary Gland Carcinoma, Metastatic Melanoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Renal Cell Carcinoma",
    "Mycosis Fungoides, Sezary Syndrome",
    "Metastatic Malignant Neoplasm in the Brain, Stage IV Non-Small Cell Lung Cancer",
    "CCND1 Protein Overexpression, Mantle Cell Lymphoma",
    "Metastatic Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Unresectable Urothelial Carcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma",
    "Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Intrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Advanced Intrahepatic Cholangiocarcinoma, Combined Hepatocellular Cancer and Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Stage III Lung Cancer, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Breast Cancer, Refractory Lung Small Cell Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, Locally Advanced Breast Carcinoma, HER2 Negative Breast Carcinoma, Recurrent Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer",
    "Ann Arbor Stage III Hodgkin Lymphoma, Stage IA Hodgkin Lymphoma, Stage IIA Hodgkin Lymphoma, Stage IIB Hodgkin Lymphoma, Stage IIIA Hodgkin Lymphoma, Stage IIIB Hodgkin Lymphoma, Stage IVA Hodgkin Lymphoma, Stage IB Hodgkin Lymphoma, Stage IVB Hodgkin Lymphoma, Classical Hodgkin Lymphoma, Stage I Hodgkin Lymphoma, Stage II Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma",
    "B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma",
    "Recurrent Primary Peritoneal Low Grade Serous Adenocarcinoma, Recurrent Low Grade Ovarian Serous Adenocarcinoma, Recurrent Low Grade Fallopian Tube Serous Adenocarcinoma, Borderline Ovarian Serous Tumor",
    "Indolent Systemic Mastocytosis",
    "Advanced Malignant Solid Tumor, Stage III Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Non-Squamous Non-Small Cell Lung Cancer, Advanced Urothelial Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Sarcoma, Advanced Cervical Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Endometrial Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Colorectal Carcinoma, Advanced Pancreatic Carcinoma, Advanced Undifferentiated Pleomorphic Sarcoma, Advanced Gastric Adenocarcinoma, Advanced Hepatocellular Carcinoma, Advanced Myxofibrosarcoma, Head and Neck Squamous Cell Carcinoma, Triple-Negative Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML), Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Blasts 5 Percent or Less of Bone Marrow Nucleated Cells, Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Minimal Residual Disease",
    "Hepatocellular Cancer",
    "Advanced Malignant Solid Tumor, Refractory Lymphoma, Recurrent Lymphoma, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Cervical Adenosquamous Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Metastatic Cervical Carcinoma, Stage IVB Cervical Cancer, Metastatic Cervical Adenocarcinoma, Locally Advanced Cervical Adenocarcinoma, Locally Advanced Cervical Squamous Cell Carcinoma, Cervical Squamous Neoplasm, Endocervical Cancer, Recurrent Cervical Cancer",
    "Metastatic Malignant Neoplasm to the Central Nervous System, Malignant Central Nervous System Neoplasm",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Stage III Lung Cancer, Recurrent Lymphoma, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Refractory Non-Small Cell Lung Cancer, Advanced Lymphoma, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Advanced Diffuse Large B-Cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, Recurrent Non-Small Cell Lung Cancer, Indolent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma",
    "High Risk Myelodysplastic Syndrome, Very High Risk Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Mixed Phenotype Acute Leukemia, Acute Leukemia",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Recurrent Malignant Female Reproductive System Neoplasm, Metastatic Malignant Female Reproductive System Neoplasm, Advanced Malignant Female Reproductive System Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Neoplasm to Soft Tissues, Castration-Resistant Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer, Metastatic Malignant Neoplasm to the Bone, Metastatic Prostatic Adenocarcinoma",
    "Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Locally Advanced Pancreatic Carcinoma, Metastatic Pancreatic Carcinoma, Recurrent Pancreatic Cancer, Metastatic Pancreatic Adenocarcinoma",
    "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Unresectable Malignant Solid Tumor, Unresectable Melanoma, Advanced Melanoma, Advanced Lymphoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Unresectable Lymphoma, Metastatic Melanoma",
    "Recurrent Head and Neck Squamous Cell Cancer, Human Papillomavirus-Related Squamous Cell Carcinoma, Recurrent Malignant Neoplasm",
    "Locally Advanced Cervical Carcinoma, Cervical Squamous Cell Cancer, Cervical Adenosquamous Cancer, Endocervical Cancer, Stage IB2 Cervical Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage IIIB Cervical Cancer, Stage IIIA Cervical Cancer, Stage IVA Cervical Cancer, Stage III Cervical Cancer, Stage II Cervical Cancer",
    "Stage IV Pancreatic Cancer, Metastatic Pancreatic Carcinoma, Metastatic Pancreatic Adenocarcinoma",
    "Hepatocellular Cancer",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Recurrent Uterine Corpus Carcinosarcoma, Uterine Corpus Carcinosarcoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Stage III Gallbladder Cancer, Stage IIIA Gallbladder Cancer, Stage IIIB Gallbladder Cancer, Stage IV Gallbladder Cancer, Stage IVA Gallbladder Cancer, Stage IVB Gallbladder Cancer, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Metastatic Biliary Tract Carcinoma, Advanced Cholangiocarcinoma, Metastatic Gallbladder Carcinoma, Advanced Gallbladder Carcinoma, Locally Advanced Biliary Tract Carcinoma, Locally Advanced Gallbladder Carcinoma, Advanced Biliary Tract Carcinoma, Metastatic Intrahepatic Cholangiocarcinoma, Locally Advanced Intrahepatic Cholangiocarcinoma, Unresectable Cholangiocarcinoma, Unresectable Gallbladder Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma, HER2 Negative Breast Carcinoma, Advanced Breast Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Chronic Active EBV Infection of T-and NK-Cell Type, Systemic Form, Recurrent Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency, Refractory Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency, EBV-Related Sarcoma, EBV-Related Leiomyosarcoma, EBV-Related Post-Transplant Lymphoproliferative Disorder, Epstein-Barr Virus Infection",
    "Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Triple-Negative Breast Carcinoma, Advanced Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Locally Advanced Triple-Negative Breast Carcinoma",
    "Non-Small Cell Lung Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Metastatic Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma, Stage IV Hepatocellular Cancer, Unresectable Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Secondary Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Refractory Myelofibrosis, Chronic Myelomonocytic Leukemia (CMML), Myelofibrosis, Refractory Chronic Myelomonocytic Leukemia (CMML)",
    "Refractory B Acute Lymphoblastic Leukemia, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Advanced Hepatocellular Carcinoma, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IIIC Hepatocellular Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Recurrent Hepatocellular Cancer",
    "Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Anal Cancer, Stage IIIA Anal Cancer, Stage IIIB Anal Cancer, Stage IIIC Anal Cancer, Stage IV Anal Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Penile Cancer, Stage IIIA Penile Cancer, Stage IIIB Penile Cancer, Stage IV Penile Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Urothelial Cancer, Advanced Melanoma, Advanced Renal Cell Carcinoma, Advanced Neuroendocrine Carcinoma, Advanced Cervical Carcinoma, Basal Cell Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Clear Cell Renal Cell Carcinoma, Advanced Endometrial Carcinoma, Advanced Thymic Carcinoma, Advanced Malignant Thymoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Cholangiocarcinoma, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Eccrine Carcinoma, Prostate Adenocarcinoma, Mesothelioma, Adnexal Carcinoma, Nasopharyngeal Throat Cancer, Sebaceous Cancer, Pilomatrical Carcinoma, Trichilemmal Carcinoma, Vulvar Cancer, Small Cell Lung Cancer, Hidradenocarcinoma, Non-Small Cell Carcinoma, Triple-Negative Breast Cancer, Endometrial Cancer, Microcystic Adnexal Carcinoma, Penile Squamous Cell Cancer, Anal Squamous Cell Cancer, Salivary Gland Cancer",
    "High-Risk Neuroblastoma, Recurrent Neuroblastoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Malignant Solid Tumor, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Advanced Breast Carcinoma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Metastatic Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Graft Versus Host Disease",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Non-Small Cell Lung Cancer, Unresectable Melanoma, Metastatic Melanoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Cervical Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Prostate Carcinoma, Locally Advanced Unresectable Prostate Carcinoma, Advanced Cervical Carcinoma, Locally Advanced Cervical Carcinoma, Advanced Colorectal Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma, Prostate Carcinoma Metastatic in the Bone, Metastatic Prostate Cancer",
    "Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Castration-Sensitive Prostate Carcinoma, Advanced Prostate Adenocarcinoma, Metastatic Prostatic Adenocarcinoma, Castration-Resistant Prostate Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Pancreatic Ductal Adenocarcinoma, Shared Neoantigen-Positive Malignant Solid Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Acute Lymphoblastic Leukemia (ALL), Recurrent Acute Lymphoblastic Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Acute Leukemia, Recurrent Acute Myeloid Leukemia (AML), Refractory Mixed Phenotype Acute Leukemia, Refractory Acute Leukemia",
    "Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Recurrent Laryngeal Throat Squamous Cell Carcinoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma",
    "Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Platinum-Resistant Ovarian Cancer, Refractory Breast Cancer, Refractory Colorectal Cancer, Refractory Ovarian Carcinoma, Refractory Non-Small Cell Lung Cancer, Metastatic Breast Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Unresectable Breast Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Acral Lentiginous Melanoma, Unresectable Ovarian Carcinoma, Metastatic Acral Lentiginous Melanoma, Stage IVA Colorectal (Colon or Rectal) Cancer, Advanced Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer",
    "Refractory Marginal Zone Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3 Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Unresectable Pleural Malignant Mesothelioma, Advanced Pleural Malignant Mesothelioma",
    "Metastatic Cutaneous Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma",
    "Metastatic Breast Adenocarcinoma, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Locally Advanced Breast Adenocarcinoma, Recurrent Breast Adenocarcinoma, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, HER2 Negative Breast Carcinoma",
    "High Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Grade 3b Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Refractory Marginal Zone Lymphoma, Recurrent High-Grade B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Refractory High-Grade B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma Germinal Center B-Cell Type, Refractory Diffuse Large B-Cell Lymphoma Activated B-Cell Type, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma",
    "Leiomyosarcoma of Deep Soft Tissue, Unresectable Leiomyosarcoma, Atypical Intradermal Smooth Muscle Neoplasm, Leiomyosarcoma of Vessels, Stage III Bone Sarcoma, Stage IV Bone Sarcoma, Bone Leiomyosarcoma, Stage III Soft Tissue Sarcoma, Stage IV Soft Tissue Sarcoma, Metastatic Alveolar Soft Part Sarcoma, Metastatic Leiomyosarcoma, Recurrent Leiomyosarcoma, Metastatic Synovial Sarcoma, Recurrent Synovial Sarcoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Non-Small Cell Lung Cancer, Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Refractory Sarcoma, Advanced Melanoma, Advanced Synovial Sarcoma, Advanced Sarcoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Bone Sarcoma, Advanced Pancreatic Carcinoma, Advanced Liposarcoma, Leiomyosarcoma, Ewing Sarcoma, Osteosarcoma",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Unresectable Solid Tumor, Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor",
    "Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Prostate Adenocarcinoma, Castration-Resistant Prostate Cancer, Stage IVB Prostate Cancer",
    "Chronic Graft Versus Host Disease",
    "Stage III Nasopharyngeal Throat Cancer, Metastatic Urothelial Cancer, Stage IV Nasopharyngeal Throat Cancer, Stage IVA Nasopharyngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage III Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Stage IV Lung Cancer, Stage IVB Lung Cancer, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage III Breast Cancer, Stage IV Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IIIC Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Urothelial Cancer, Advanced Lymphoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Cervical Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Nasopharyngeal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Cervical Carcinoma, Classical Hodgkin Lymphoma, Triple-Negative Breast Cancer, Advanced Malignant Neoplasm",
    "Acute Graft Versus Host Disease",
    "Metastatic Cholangiocarcinoma, Advanced Cholangiocarcinoma, Unresectable Cholangiocarcinoma, Recurrent Cholangiocarcinoma",
    "Metastatic Malignant Solid Tumor, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML), Advanced Malignant Solid Tumor, Recurrent Chronic Myelomonocytic Leukemia, Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Acute Myeloid Leukemia (AML), Recurrent Adenoid Cystic Cancer, Recurrent Myelofibrosis, Refractory Myelofibrosis, Advanced Diffuse Large B-Cell Lymphoma, Refractory Adenoid Cystic Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Lung Adenocarcinoma, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia (AML)",
    "Multiple Myeloma/Plasma Cell Myeloma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor",
    "Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIA Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Metastatic Breast Carcinoma, Locally Advanced Unresectable Breast Carcinoma, Advanced Breast Carcinoma, Metastatic Endometrial Endometrioid Adenocarcinoma, Advanced Endometrial Endometrioid Adenocarcinoma, Locally Advanced Endometrial Endometrioid Adenocarcinoma",
    "Metastatic Thyroid Gland Medullary Carcinoma, Unresectable Thyroid Gland Medullary Carcinoma, Stage IVB Thyroid Gland Medullary Cancer, Stage IVC Thyroid Gland Medullary Cancer, Locally Advanced Thyroid Gland Medullary Carcinoma, Stage IVA Thyroid Gland Medullary Cancer, Stage III Thyroid Gland Medullary Cancer, Stage IV Thyroid Gland Medullary Cancer",
    "Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory B Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",
    "Glioblastoma, Recurrent Glioblastoma",
    "Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Hypopharyngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage IV Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVC Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Metastatic Oropharyngeal Throat Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Metastatic Hypopharyngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Recurrent Oropharyngeal Throat Squamous Cell Cancer",
    "Stage IIIA Breast Cancer, Stage IIIB Cervical Cancer, Stage IV Cervical Cancer, Stage IVA Cervical Cancer, Stage IIIB Breast Cancer, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Metastatic Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Locally Advanced Malignant Solid Tumor, Stage III Intrahepatic Bile Duct Cancer, Stage IIIA Intrahepatic Bile Duct Cancer, Stage IIIB Intrahepatic Bile Duct Cancer, Stage IV Intrahepatic Bile Duct Cancer, Stage III Extrahepatic (Distal) Bile Duct Cancer, Stage IIIA Extrahepatic (Distal) Bile Duct Cancer, Stage IIIB Extrahepatic (Distal) Bile Duct Cancer, Stage IV Extrahepatic (Distal) Bile Duct Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Cervical Cancer, Stage IIIA Cervical Cancer, Stage IVB Cervical Cancer, Metastatic Bile Duct Carcinoma, Unresectable Malignant Solid Tumor, Locally Advanced Bile Duct Cancer, Metastatic Breast Carcinoma, Metastatic Cervical Carcinoma, Locally Advanced Cervical Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Unresectable Lung Non-Squamous Non-Small Cell Carcinoma, Unresectable Bile Duct Carcinoma, Unresectable Cervical Carcinoma, Metastatic Primary Malignant Brain Neoplasm",
    "Unresectable Malignant Solid Tumor, Advanced Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Stage IVB Lung Cancer, Stage IV Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IVA Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Recurrent Ovarian Endometrioid Adenocarcinoma, Recurrent Ovarian Clear Cell Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Primary Peritoneal Clear Cell Carcinoma, Recurrent High Grade Ovarian Serous Adenocarcinoma, Recurrent Fallopian Tube Endometrioid Adenocarcinoma, Recurrent High Grade Fallopian Tube Serous Adenocarcinoma, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Recurrent Endometrioid Primary Peritoneal Carcinoma, Advanced Ovarian Carcinoma, Recurrent Platinum-Resistant Ovarian Carcinoma, Recurrent Platinum-Resistant Fallopian Tube Carcinoma, Recurrent Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Clear Cell Adenocarcinoma, Stage IV Non-Small Cell Lung Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage III Non-Small Cell Lung Cancer, Recurrent Non-Small Cell Lung Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Recurrent Colorectal (Colon or Rectal) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Refractory Marginal Zone Lymphoma, Refractory Indolent Adult Non-Hodgkin Lymphoma, Recurrent Follicular Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Indolent Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma",
    "Advanced Malignant Neoplasm, Lymphoma",
    "Advanced Malignant Solid Tumor, Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Thyroid Gland Papillary Cancer, Stage IV Thyroid Gland Papillary Cancer, Stage IVA Thyroid Gland Papillary Cancer, Stage IVB Thyroid Gland Papillary Cancer, Unresectable Malignant Solid Tumor, Advanced Neuroendocrine Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Malignant Bronchial Neoplasm, Locally Advanced Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Thyroid Gland Medullary Carcinoma, Unresectable Thyroid Gland Medullary Carcinoma, Papillary Adenocarcinoma, Colorectal Neoplasm, Digestive System Disorder, Digestive System Neoplasm, Head and Neck Neoplasm, Intestinal Neoplasm, Lung Neoplasm, Respiratory System Neoplasm, Thoracic Neoplasm, Thyroid Gland Neoplasm, Malignant Endocrine Neoplasm, Bronchogenic Lung Cancer, Primitive Neuroectodermal Tumor (PNET), Neuroendocrine Tumor",
    "Recurrent Cervical Squamous Cell Cancer, Recurrent Cervical Adenosquamous Cancer, Recurrent Cervical Adenocarcinoma, Metastatic Cervical Squamous Cell Carcinoma, Metastatic Cervical Adenocarcinoma, Metastatic Cervical Adenosquamous Carcinoma, Stage IV Cervical Cancer",
    "Myelodysplastic Syndrome",
    "Recurrent High-Grade B-Cell Lymphoma, Refractory High-Grade B-Cell Lymphoma, Recurrent Mature B-Cell Non-Hodgkin Lymphoma, Recurrent Grade 3b Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory Nodal Marginal Zone Lymphoma, Recurrent Nodal Marginal Zone Lymphoma, Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Follicular Lymphoma, Refractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Refractory Mature B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Resectable Head and Neck Squamous Cell Cancer, Stage III Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer, Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Advanced Head and Neck Squamous Cell Cancer, Advanced Hypopharyngeal Throat Squamous Cell Cancer",
    "Skin Squamous Cell Cancer",
    "Stage III Uterine (including Endometrial) Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Recurrent Endometrial Carcinoma, Advanced Endometrial Carcinoma",
    "Refractory Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor, Castration-Resistant Prostate Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage II Esophageal Squamous Cell Cancer, Stage IIA Esophageal Squamous Cell Cancer, Stage IIB Esophageal Squamous Cell Cancer, Stage III Esophageal Squamous Cell Cancer, Stage IIIA Esophageal Squamous Cell Cancer, Stage IIIB Esophageal Squamous Cell Cancer, Stage IV Esophageal Squamous Cell Cancer, Stage IVA Esophageal Squamous Cell Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Esophageal Squamous Cell Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IVC Colorectal (Colon or Rectal) Cancer, Stage IIA Pancreatic Cancer, Stage II Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Stage IV Prostate Cancer, Stage IVA Prostate Cancer, Stage IVB Prostate Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Stage IV Bladder Cancer, Stage IVA Bladder Cancer, Stage IVB Bladder Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Melanoma, Metastatic Gastric Carcinoma, Metastatic Bladder Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Advanced Prostate Carcinoma, Advanced Esophageal Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Colorectal Carcinoma, Metastatic Melanoma, Metastatic Pancreatic Adenocarcinoma, Metastatic Prostate Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "ISS Stage III Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIID Cutaneous (Skin) Melanoma, Advanced Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Advanced Lung Non-Small Cell Carcinoma, Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Metastatic Endometrial Endometrioid Adenocarcinoma, Advanced Endometrial Endometrioid Adenocarcinoma, Unresectable Hepatocellular Cancer, Metastatic Melanoma, Metastatic Lung Non-Small Cell Carcinoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IVB Lung Cancer",
    "High Grade Ovarian Serous Adenocarcinoma, Primary Peritoneal High Grade Serous Adenocarcinoma, High Grade Fallopian Tube Serous Adenocarcinoma, FIGO Stage III Ovarian Cancer, FIGO Stage IIIA Ovarian Cancer, FIGO Stage IIIA1 Ovarian Cancer, FIGO Stage IIIA2 Ovarian Cancer, FIGO Stage IIIB Ovarian Cancer, FIGO Stage IIIC Ovarian Cancer, FIGO Stage IVA Ovarian Cancer, FIGO Stage IVB Ovarian Cancer, Primary Peritoneal Carcinosarcoma, Primary Peritoneal Undifferentiated Carcinoma, Primary Peritoneal Clear Cell Carcinoma, Primary Peritoneal Endometrioid Adenocarcinoma, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Primary Peritoneal Adenocarcinoma, Advanced Ovarian Carcinosarcoma, Advanced Ovarian Endometrioid Adenocarcinoma, Advanced Ovarian Clear Cell Adenocarcinoma, Fallopian Tube Carcinosarcoma, Undifferentiated Ovarian Cancer, Fallopian Tube Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma, Undifferentiated Fallopian Tube Cancer, Ovarian Adenocarcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Metastatic Cholangiocarcinoma, Advanced Cholangiocarcinoma, Unresectable Cholangiocarcinoma, Chondrosarcoma, Glioma",
    "Stage IIIA Breast Cancer, Stage III Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor, Non-Small Cell Lung Cancer, Pancreatic Cancer",
    "Recurrent Fallopian Tube Cancer, Primary Peritoneal High Grade Serous Adenocarcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Malignant Solid Tumor, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Lung Adenocarcinoma, Metastatic Ovarian Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Recurrent Primary Peritoneal High Grade Serous Adenocarcinoma, Metastatic Primary Peritoneal Carcinoma, Recurrent Non-Small Cell Lung Cancer, Recurrent Ovarian Cancer",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Refractory Lymphoma, Recurrent Lymphoma, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Osteosarcoma, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Osteosarcoma, Recurrent Rhabdomyosarcoma",
    "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, CLDN18.2 Positive, Metastatic Gastric Adenocarcinoma, Locally Advanced Unresectable Gastric Adenocarcinoma, Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma, HER2/Neu Negative",
    "Metastatic Urothelial Cancer, Advanced Urothelial Cancer",
    "Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Recurrent Malignant Glioma, Malignant Glioma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Diffuse Intrinsic Pontine Glioma",
    "Stage IIIB Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm to the Central Nervous System, Recurrent Non-Small Cell Lung Cancer",
    "Mucosal Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Unresectable Cutaneous (Skin) Melanoma, Locally Advanced Melanoma, Unresectable Melanoma, Advanced Melanoma, Metastatic Cutaneous Melanoma, Recurrent Melanoma",
    "Locally Advanced Skin Squamous Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Stage II Pancreatic Cancer, Stage IIA Pancreatic Cancer, Stage IIB Pancreatic Cancer, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer, Stage III Pleural Malignant Mesothelioma, Stage IIIA Pleural Malignant Mesothelioma, Stage IIIB Pleural Malignant Mesothelioma, Stage IV Pleural Malignant Mesothelioma, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Stage III Fallopian Tube Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA1 Fallopian Tube Cancer, Stage IIIA2 Fallopian Tube Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIC Fallopian Tube Cancer, Stage IV Fallopian Tube Cancer, Stage IVA Fallopian Tube Cancer, Stage IVB Fallopian Tube Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Primary Peritoneal Cancer, Stage IVA Primary Peritoneal Cancer, Stage IVB Primary Peritoneal Cancer, Platinum-Resistant Ovarian Cancer, Metastatic Fallopian Tube Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Pancreatic Carcinoma, Locally Advanced Pancreatic Adenocarcinoma, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Advanced Pancreatic Adenocarcinoma, Peritoneal Epithelioid Mesothelioma, Advanced Pancreatic Carcinoma, Advanced Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma, Metastatic Pleural Malignant Mesothelioma, Locally Advanced Pancreatic Carcinoma, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Ovarian Carcinoma, Metastatic Peritoneal Malignant Mesothelioma, Pleural Epithelioid Mesothelioma, Advanced Peritoneal Malignant Mesothelioma, Metastatic Pancreatic Adenocarcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Advanced Pleural Malignant Mesothelioma",
    "Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer",
    "Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Recurrent Head and Neck Squamous Cell Cancer, Stage III Pancreatic Cancer, Stage III Lung Cancer, Stage IV Pancreatic Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage IIIA Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Soft Tissue Sarcoma of the Trunk and Extremities, Stage IIIB Soft Tissue Sarcoma of the Trunk and Extremities, Stage IV Soft Tissue Sarcoma of the Trunk and Extremities, Stage III Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIA Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IIIB Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage IV Gastric (Stomach) and Omental Gastrointestinal Stromal Tumor (GIST), Stage III Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IIIA Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IIIB Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage IV Small Intestinal, Esophageal, Colorectal, Mesenteric, and Peritoneal Gastrointestinal Stromal Tumor (GIST), Stage III Retroperitoneal Sarcoma, Stage IIIA Retroperitoneal Sarcoma, Stage IIIB Retroperitoneal Sarcoma, Stage IV Retroperitoneal Sarcoma, Advanced Head and Neck Squamous Cell Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Ovarian Cancer, Stage IIIA Ovarian Cancer, Stage IIIA1 Ovarian Cancer, Stage IIIA2 Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IV Ovarian Cancer, Stage IVA Ovarian Cancer, Stage IVB Ovarian Cancer, Metastatic Breast Carcinoma, Estrogen Receptor Negative, Progesterone Receptor Negative, Metastatic Pancreatic Carcinoma, Advanced Lung Small Cell Carcinoma, Advanced Soft Tissue Sarcoma, Advanced Breast Carcinoma, Advanced Ovarian Carcinoma, Locally Advanced Pancreatic Carcinoma, Advanced Diffuse Large B-Cell Lymphoma, Advanced Triple-Negative Breast Carcinoma, Squamous Cell Carcinoma, Leiomyosarcoma, Recurrent Follicular Lymphoma, HER2/Neu Negative, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma, Triple-Negative Breast Cancer, Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Mantle Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Non-Hodgkin Lymphoma, Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Stage III Diffuse Large B-Cell Lymphoma, Stage IV Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Advanced Malignant Neoplasm, Soft Tissue Sarcoma",
    "Metastatic Urothelial Cancer, Unresectable Urothelial Carcinoma, Recurrent Urothelial Cancer, Locally Advanced Urothelial Cancer",
    "BCLC Stage B Hepatocellular Cancer, BCLC Stage C Hepatocellular Cancer, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Hepatocellular Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage IV Renal Cell Cancer, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Hepatocellular Cancer",
    "Stage III Oropharyngeal (p16-Negative) Throat Cancer, Stage IVA Oropharyngeal (p16-Negative) Throat Cancer, Stage IVB Oropharyngeal (p16-Negative) Throat Cancer, Stage III Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage III Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Locally Advanced Laryngeal Squamous Cell Carcinoma, Locally Advanced Hypopharyngeal Squamous Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Refractory Malignant Solid Tumor, Stage III Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIA Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IIIB Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Refractory Gastric (Stomach) Cancer, Unresectable Malignant Solid Tumor, Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma), Refractory Endometrial Carcinoma, Advanced Endometrial Carcinoma, Advanced Breast Carcinoma, Advanced Gastric Carcinoma, Refractory Intrahepatic Cholangiocarcinoma",
    "Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Non-Small Cell Lung Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer",
    "Recurrent Malignant Solid Tumor, Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Recurrent Neuroblastoma",
    "Classical Hodgkin Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Head and Neck Squamous Cell Cancer, Stage IV Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Pathologic Stage III Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIA Merkel Cell Carcinoma AJCC v8, Pathologic Stage IIIB Merkel Cell Carcinoma AJCC v8, Pathologic Stage IV Merkel Cell Carcinoma AJCC v8, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Advanced Head and Neck Squamous Cell Cancer, Metastatic Skin Squamous Cell Carcinoma, Unresectable Malignant Solid Tumor, Metastatic Head and Neck Squamous Cell Cancer, Locally Advanced Melanoma, Unresectable Melanoma, Advanced Melanoma, Locally Advanced Skin Squamous Cell Carcinoma, Unresectable Skin Squamous Cell Carcinoma, Metastatic Merkel Cell Carcinoma, Locally Advanced Head and Neck Squamous Cell Carcinoma, Unresectable Merkel Cell Carcinoma, Advanced Merkel Cell Carcinoma, Locally Advanced Merkel Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma, Metastatic Malignant Neoplasm to the Liver, Metastatic Melanoma",
    "Stage I Prostate Cancer, Stage II Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer, Stage IIC Prostate Cancer, Stage III Prostate Cancer, Stage IIIA Prostate Cancer, Stage IIIB Prostate Cancer, Stage IIIC Prostate Cancer, Locally Advanced Prostate Carcinoma, Locally Advanced Prostate Adenocarcinoma, Prostate Adenocarcinoma",
    "Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Non-Small Cell Lung Cancer",
    "Advanced Synovial Sarcoma, Advanced Myxoid Liposarcoma",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma",
    "Glioblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome, Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Classical Hodgkin Lymphoma",
    "Refractory Lung Small Cell Carcinoma, Recurrent Small Cell Lung Cancer",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD",
    "Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Non-Small Cell Lung Cancer",
    "Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Metastatic Renal Cell Cancer, Metastatic Sarcomatoid Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Renal Cell Carcinoma, Locally Advanced Clear Cell Renal Cell Carcinoma, Metastatic Chromophobe Renal Cell Carcinoma, Metastatic Unclassified Renal Cell Carcinoma, Locally Advanced Papillary Renal Cell Carcinoma, Locally Advanced Sarcomatoid Renal Cell Carcinoma, Locally Advanced Unclassified Renal Cell Carcinoma, Locally Advanced Chromophobe Renal Cell Carcinoma",
    "Hemorrhagic Cystitis, BK Virus Infection",
    "Malignant Solid Tumor, Non-Small Cell Lung Cancer, Malignant Salivary Gland Tumor, Breast Cancer, Lung Cancer, Cervical Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Lymphoma, Advanced Melanoma, Neuroblastoma, Stage III Lymphoma, Stage IV Lymphoma, Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Recurrent Lymphoma, Stage III Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Recurrent Malignant Solid Tumor",
    "Supratentorial Glioblastoma, Diffuse Astrocytoma",
    "Metastatic Skin Squamous Cell Carcinoma, Locally Advanced Skin Squamous Cell Carcinoma, Advanced Skin Squamous Cell Carcinoma",
    "Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Gastric Adenocarcinoma, Unresectable Gastric Adenocarcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Neurofibromatosis Type 1, Plexiform Neurofibroma",
    "Malignant Solid Tumor, Metastatic Myxoid Liposarcoma, Unresectable Synovial Sarcoma, Advanced Synovial Sarcoma, Advanced Myxoid Liposarcoma, Unresectable Myxoid Liposarcoma, Metastatic Synovial Sarcoma",
    "Platinum-Resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Cancer, Platinum-Resistant Primary Peritoneal Cancer, Advanced Ovarian Carcinoma, Advanced Fallopian Tube Carcinoma, Advanced Primary Peritoneal Carcinoma",
    "AL Amyloidosis",
    "Hematologic and Lymphocytic Disorder, Chronic Graft Versus Host Disease",
    "Non-Hodgkin Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL), Waldenstrom Macroglobulinemia, Recurrent Chronic Lymphocytic Leukemia (CLL), Diffuse Large B-Cell Lymphoma",
    "Stage I Lung Cancer, Stage IA1 Lung Cancer, Stage IA2 Lung Cancer, Stage IA3 Lung Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Unresectable Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Stage III Hypopharyngeal Throat Cancer, Stage IV Hypopharyngeal Throat Cancer, Stage IVA Hypopharyngeal Throat Cancer, Stage IVB Hypopharyngeal Throat Cancer, Stage IVC Hypopharyngeal Throat Cancer, Locally Advanced Malignant Solid Tumor, Stage III Laryngeal Throat Cancer, Stage IV Laryngeal Throat Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage IIA Esophageal Adenocarcinoma, Stage IIB Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Stage II Esophageal Adenocarcinoma, Stage III Esophageal Adenocarcinoma, Stage IIIA Esophageal Adenocarcinoma, Stage IIIB Esophageal Adenocarcinoma, Stage IV Esophageal Adenocarcinoma, Stage IVA Esophageal Adenocarcinoma, Stage IVB Esophageal Adenocarcinoma, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8, Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage IVA Gastric (Stomach) Cancer, Stage IVB Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Locally Advanced Non-Squamous Non-Small Cell Lung Cancer, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Metastatic Triple-Negative Breast Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Metastatic Esophageal Carcinoma, Metastatic Hypopharyngeal Carcinoma, Metastatic Oropharyngeal Carcinoma, Metastatic Laryngeal Carcinoma, Metastatic Oral Cavity Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Lung Non-Small Cell Squamous Carcinoma, Locally Advanced Lung Non-Small Cell Squamous Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Gastric Carcinoma, Unresectable Triple-Negative Breast Carcinoma, Locally Advanced Laryngeal Carcinoma, Metastatic HER2-Negative Breast Carcinoma, Recurrent HER2 Negative Breast Carcinoma, Locally Advanced Esophageal Carcinoma, Locally Advanced Oropharyngeal Carcinoma, Recurrent Triple-Negative Breast Carcinoma, Locally Advanced Oral Cavity Carcinoma, Recurrent Lung Non-Small Cell Squamous Carcinoma, Elobixibat, Recurrent Esophageal Cancer, Recurrent Laryngeal Throat Cancer, Recurrent Oral Cavity Carcinoma, Recurrent Head and Neck Carcinoma, Recurrent Breast Cancer, Recurrent Oropharyngeal Throat Cancer, Recurrent Hypopharyngeal Throat Cancer",
    "Primary Central Nervous System Neoplasm, Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "AL Amyloidosis",
    "Primary Myelofibrosis, Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase, Myelofibrosis Transformation in Essential Thrombocythemia",
    "Stage IIIA Esophageal Cancer, Stage IIIB Esophageal Cancer, Stage IIIC Esophageal Cancer, Metastatic Urothelial Cancer, Recurrent Bladder Urothelial Cancer, Metastatic Head and Neck Cancer, Metastatic Malignant Solid Tumor, Recurrent Malignant Solid Tumor, Unresectable Solid Tumor, Unresectable Esophageal Cancer, Recurrent Urethral Urothelial Cancer, Castration-Resistant Prostate Cancer, Locally Advanced Malignant Solid Tumor, Recurrent Endometrial Carcinoma, Metastatic Bladder Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Metastatic Ureter Urothelial Cancer, Recurrent Renal Pelvis Urothelial Cancer, Recurrent Ureter Urothelial Cancer, Metastatic Gastroesophageal Junction Adenocarcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Metastatic Renal Cell Cancer, Locally Advanced Head and Neck Carcinoma, Metastatic Breast Carcinoma, Metastatic Gastric Carcinoma, Recurrent Gastroesophageal Junction Adenocarcinoma, Recurrent Clear Cell Renal Cell Carcinoma, Metastatic Hepatocellular Carcinoma, Unresectable Renal Cell Carcinoma, Unresectable Lung Non-Small Cell Carcinoma, Metastatic Ovarian Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Esophageal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Colorectal Carcinoma, Locally Advanced Unresectable Prostate Adenocarcinoma, Unresectable Urethral Urothelial Carcinoma, Unresectable Bladder Urothelial Carcinoma, Unresectable Ureter Urothelial Carcinoma, Unresectable Renal Pelvis Urothelial Carcinoma, Unresectable Breast Carcinoma, Unresectable Gastric Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma, Locally Advanced Breast Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Locally Advanced Gastric Carcinoma, Unresectable Head and Neck Carcinoma, Unresectable Clear Cell Renal Cell Carcinoma, Recurrent Differentiated Thyroid Gland Carcinoma, Locally Advanced Ovarian Carcinoma, Unresectable Hepatocellular Cancer, Stage IV Breast Cancer, Recurrent Esophageal Cancer, Stage IV Non-Small Cell Lung Cancer, Clear Cell Renal Cell Cancer, Stage IIIB Gastric (Stomach) Cancer, Stage IIIA Gastric (Stomach) Cancer, Stage IIIA Hepatocellular Cancer, Stage IIIB Hepatocellular Cancer, Stage IVA Hepatocellular Cancer, Stage IVB Hepatocellular Cancer, Stage III Renal Pelvis Cancer, Stage IV Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Ureter Cancer, Stage III Urethral Cancer, Stage IV Urethral Cancer, Stage IIIA Ovarian Cancer, Stage IIIB Ovarian Cancer, Stage IIIC Ovarian Cancer, Stage IIIA Uterine (including Endometrial) Cancer, Stage IIIB Uterine (including Endometrial) Cancer, Stage IIIC Uterine (including Endometrial) Cancer, Stage IVA Uterine (including Endometrial) Cancer, Stage IVB Uterine (including Endometrial) Cancer, Triple-Negative Breast Cancer, Recurrent Head and Neck Carcinoma, Stage IIIA Breast Cancer, Recurrent Breast Cancer, Stage III Non-Small Cell Lung Cancer, Stage IIIB Breast Cancer, Recurrent Non-Small Cell Lung Cancer, Recurrent Renal Cell Cancer, Stage III Ovarian Cancer, Stage IV Ovarian Cancer, Recurrent Ovarian Cancer, Recurrent Prostate Cancer, Recurrent Urothelial Cancer of the Renal Pelvis and Ureter, Recurrent Colorectal (Colon or Rectal) Cancer, Stage III Differentiated Thyroid Gland Cancer, Stage IVA Differentiated Thyroid Gland Cancer, Stage IVB Differentiated Thyroid Gland Cancer, Stage IVC Differentiated Thyroid Gland Cancer, Stage IIIC Gastric (Stomach) Cancer, Stage IIIA Colorectal (Colon or Rectal) Cancer, Stage IIIB Colorectal (Colon or Rectal) Cancer, Stage IIIC Colorectal (Colon or Rectal) Cancer, Stage IVA Colorectal (Colon or Rectal) Cancer, Stage IVB Colorectal (Colon or Rectal) Cancer, Stage IIIC Hepatocellular Cancer, Stage III Breast Cancer, Stage IIIC Breast Cancer, Stage III Prostate Cancer, Stage IV Prostate Cancer, Stage III Renal Cell Cancer, Stage IV Renal Cell Cancer, Stage III Bladder Urothelial Cancer, Stage IV Bladder Urothelial Cancer, Metastatic Prostate Cancer, Stage III Uterine (including Endometrial) Cancer, Stage IV Uterine (including Endometrial) Cancer, Stage III Esophageal Cancer, Stage IV Esophageal Cancer, Stage III Gastric (Stomach) Cancer, Stage IV Gastric (Stomach) Cancer, Stage III Colorectal (Colon or Rectal) Cancer, Stage IV Colorectal (Colon or Rectal) Cancer, Stage III Hepatocellular Cancer, Stage IV Hepatocellular Cancer, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage III Thyroid Gland Follicular Cancer, Recurrent Gastric (Stomach) Cancer, Recurrent Hepatocellular Cancer, Stage IIIC1 Uterine (including Endometrial) Cancer, Stage IIIC2 Uterine (including Endometrial) Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Lymphoproliferative Disorder, EBV-Related Post-Transplant Lymphoproliferative Disorder",
    "Unresectable Malignant Neoplasm, Metastatic Malignant Neoplasm, Advanced Malignant Neoplasm",
    "Recurrent Medulloblastoma, Recurrent Primary Central Nervous System Neoplasm, Refractory Central Nervous System Neoplasm, Recurrent Ewing Sarcoma, Recurrent Neuroblastoma, Recurrent Rhabdomyosarcoma, Recurrent Malignant Solid Tumor, Refractory Malignant Solid Tumor, Refractory Neuroblastoma, Recurrent Diffuse Intrinsic Pontine Glioma (DIPG), Refractory Diffuse Intrinsic Pontine Glioma (DIPG), Recurrent Rhabdoid Tumor, Refractory Rhabdomyosarcoma, Refractory Ewing Sarcoma, Refractory Medulloblastoma, Refractory Rhabdoid Tumor",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor",
    "Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage IIIB Lung Cancer, Stage IIIC Lung Cancer, Stage IV Lung Cancer, Stage IVA Lung Cancer, Stage IVB Lung Cancer, Metastatic Lung Non-Small Cell Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IIIA Bladder Cancer, Stage IIIB Bladder Cancer, Infiltrating Bladder Urothelial Carcinoma, Renal Pelvis and Ureter Urothelial Cancer",
    "Stage IIIA Cutaneous (Skin) Melanoma, Stage IIIB Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage III Cutaneous (Skin) Melanoma, Stage IIIC Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IV Cutaneous (Skin) Melanoma, Stage IIID Cutaneous (Skin) Melanoma",
    "Stage IVA Nasopharyngeal Throat Cancer, Stage IV Nasopharyngeal Throat Cancer, Pharyngeal Throat Squamous Cell Cancer, Stage IVA Laryngeal Throat Cancer, Stage IVC Lip and Oral Cavity Cancer, Stage IV Laryngeal Throat Cancer, Stage IVB Nasopharyngeal Throat Cancer, Stage III Nasopharyngeal Throat Cancer, Stage III Lip and Oral Cavity Cancer, Stage IV Lip and Oral Cavity Cancer, Stage IVA Lip and Oral Cavity Cancer, Stage IVB Lip and Oral Cavity Cancer, Stage IVB Laryngeal Throat Cancer, Stage IVC Laryngeal Throat Cancer, Recurrent Head and Neck Squamous Cell Cancer, Unresectable Head and Neck Squamous Cell Carcinoma, Advanced Head and Neck Squamous Cell Cancer, Metastatic Head and Neck Squamous Cell Cancer, Advanced Oral Cavity Squamous Cell Cancer, Metastatic Oral Cavity Squamous Cell Cancer, Advanced Nasopharyngeal Throat Squamous Cell Cancer, Metastatic Nasopharyngeal Throat Squamous Cell Cancer, Advanced Laryngeal Throat Squamous Cell Cancer, Metastatic Laryngeal Throat Squamous Cell Cancer, Metastatic Nasopharyngeal Carcinoma, Unresectable Nasopharyngeal Carcinoma, Recurrent Pharyngeal Throat Cancer, Recurrent Oral Cavity Squamous Cell Carcinoma, Squamous Cell Cancer of Unknown Primary Origin, Recurrent Laryngeal Throat Squamous Cell Carcinoma, Recurrent Nasopharyngeal Throat Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Undifferentiated Pleomorphic Sarcoma, Metastatic Myxofibrosarcoma, Locally Advanced Myxofibrosarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma",
    "Recurrent Anaplastic Astrocytoma, Anaplastic Astrocytoma",
    "Metastatic Malignant Solid Tumor, Locally Advanced Malignant Solid Tumor, Stage III Colon Cancer, Stage IIIA Colon Cancer, Stage IIIB Colon Cancer, Stage IIIC Colon Cancer, Stage IV Colon Cancer, Stage IVA Colon Cancer, Stage IVB Colon Cancer, Stage IVC Colon Cancer, Stage IB Lung Cancer, Stage II Lung Cancer, Stage IIA Lung Cancer, Stage IIB Lung Cancer, Stage III Lung Cancer, Stage IIIA Lung Cancer, Stage III Thyroid Gland Medullary Cancer, Stage IV Thyroid Gland Medullary Cancer, Stage IVA Thyroid Gland Medullary Cancer, Stage IVB Thyroid Gland Medullary Cancer, Stage IVC Thyroid Gland Medullary Cancer, Refractory Colon Carcinoma, Metastatic Colon Carcinoma, Refractory Adrenal Gland Pheochromocytoma, Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Thyroid Gland Medullary Carcinoma, Locally Advanced Adrenal Gland Pheochromocytoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Locally Advanced Colon Carcinoma, Metastatic Pheochromocytoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma, Refractory Small Lymphocytic Lymphoma",
    "Platinum-Resistant Ovarian Cancer, Recurrent Ovarian Cancer",
    "Malignant Neoplasm",
    "Metastatic Urothelial Cancer, Metastatic Urethral Urothelial Cancer, Metastatic Bladder Urothelial Cancer, Metastatic Renal Pelvis Urothelial Cancer, Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall, Metastatic Ureter Urothelial Cancer, Locally Advanced Urothelial Cancer, Recurrent Urothelial Cancer, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Infiltrating Bladder Urothelial Carcinoma with Squamous Differentiation, Stage III Renal Pelvis Cancer, Stage III Ureter Cancer, Stage IV Renal Pelvis Cancer, Stage IV Ureter Cancer, Infiltrating Ureter Urothelial Carcinoma with Squamous Differentiation, Stage III Urethral Cancer, Stage IV Urethral Cancer, Stage II Bladder Cancer, Stage III Bladder Cancer, Stage IV Bladder Cancer",
    "Metastatic Malignant Solid Tumor, Advanced Malignant Solid Tumor, Unresectable Malignant Solid Tumor",
    "Recurrent Glioblastoma, Recurrent Gliosarcoma, Glioblastoma, Gliosarcoma",
    "Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Metastatic Breast Carcinoma, Unresectable Breast Carcinoma, Locally Advanced Breast Carcinoma, Advanced Breast Carcinoma, HER2-Positive Breast Carcinoma",
    "Myelodysplastic Syndrome",
    "Ductal Carcinoma In Situ (DCIS), Lobular Carcinoma In Situ (LCIS)",
    "Oligodendroglioma, Recurrent Glioma, Astrocytoma, Grade II Glioma",
    "CNS 3, Acute Lymphoblastic Leukemia (ALL), Ph-Like Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia"
  ],
  "max_age_in_years": [
    999, 29, 999, 999, 999, 55, 999, 999, 35, 999, 22, 999, 999, 999, 999, 999,
    999, 999, 999, 45, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 35, 30, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 25, 999, 999,
    999, 999, 999, 999, 999, 999, 21, 999, 999, 999, 21, 21, 18, 999, 999, 999,
    999, 999, 30, 999, 21, 999, 999, 999, 999, 21, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 18, 999, 80, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 39, 999, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 25, 999, 999, 21, 999, 999, 999, 75,
    999, 999, 79, 30, 999, 999, 999, 30, 999, 999, 999, 999, 999, 18, 21, 21,
    999, 21, 21, 999, 999, 21, 21, 21, 21, 21, 999, 999, 999, 50, 30, 74, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 21, 25, 999, 45, 999, 999, 30, 999,
    21, 30, 21, 21, 21, 999, 999, 999, 21, 22, 3, 30, 999, 999, 21, 999, 2, 999,
    24, 999, 999, 999, 31, 999, 999, 999, 70, 999, 999, 999, 75, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 70, 40, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 39, 999, 999, 999, 999, 999, 999, 70,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 3, 999, 999, 69, 999, 45, 999, 999, 25, 999, 75, 999,
    999, 999, 999, 999, 999, 85, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 70, 999, 999,
    999, 999, 55, 999, 999, 21, 80, 999, 999, 999, 25, 65, 75, 999, 999, 999,
    999, 999, 100, 999, 999, 999, 999, 999, 999, 18, 999, 999, 999, 26, 999,
    999, 999, 75, 25, 999, 999, 999, 21, 65, 120, 20, 999, 35, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 70, 999,
    999, 999, 999, 75, 999, 30, 999, 999, 29, 999, 999, 999, 999, 999, 24, 999,
    999, 75, 999, 999, 99, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 75, 60, 999, 999, 99, 999, 20, 999, 21, 21, 21, 18, 999, 999, 999,
    999, 999, 999, 999, 75, 999, 999, 89, 999, 75, 21, 999, 999, 64, 999, 999,
    999, 999, 75, 999, 999, 22, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999,
    999, 75, 22, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 25, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 80, 50, 999, 999, 999, 65, 999, 999,
    999, 999, 999, 65, 999, 999, 70, 70, 999, 75, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 75, 79, 999, 999, 999, 999, 58, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 70, 999,
    999, 999, 999, 999, 65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 60,
    999, 999, 999, 999, 999, 999, 999, 80, 999, 999, 65, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 70, 40, 999, 999, 999,
    999, 999, 999, 39, 999, 999, 999, 999, 999, 999, 999, 999, 39, 70, 999, 999,
    999, 999, 999, 999, 75, 999, 99, 999, 999, 999, 75, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 26, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 76,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 59, 21,
    999, 999, 65, 999, 999, 999, 999, 999, 999, 999, 20, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 65, 77, 30, 999, 999, 999, 999, 75, 999, 999,
    999, 999, 999, 999, 999, 999, 80, 999, 999, 999, 70, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 85, 999, 999,
    999, 75, 999, 999, 999, 80, 80, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 99, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 29, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 25, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 21, 999, 999, 999, 21, 999, 999, 999, 70, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999,
    999, 999, 999, 19, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 80, 999, 999, 999, 999, 49, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 78, 70, 70, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 70, 999, 999, 24, 999, 999,
    100, 999, 70, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    75, 999, 999, 39, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 85, 999, 999, 999, 999, 999, 999,
    999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 89, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 79, 26, 999, 999, 999, 999, 999, 999, 21, 999, 999, 999, 30, 999, 999,
    75, 999, 999, 999, 999, 999, 999, 25, 999, 999, 999, 999, 999, 999, 999,
    999, 80, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 75, 80, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 60, 999, 17, 999, 999, 999, 29, 999, 60, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 35, 999, 999, 999, 999, 999, 70, 999, 999, 999, 999, 999,
    999, 21, 999, 999, 999, 999, 999, 999, 999, 21, 999, 999, 75, 999, 999, 25,
    999, 999, 999, 999, 75, 69, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999,
    65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 70, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 120, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999,
    999, 999, 999, 30, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999, 21, 999,
    999, 999, 999, 999, 26, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 80,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 25, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 25, 999, 999,
    999, 999, 999, 999, 65, 999, 999, 25, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 25, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 60, 999, 75, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 45, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 65, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999,
    21, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 90, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 45, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 999,
    999, 999, 85, 999, 999, 999, 999, 999, 30, 999, 999, 999, 999, 999, 999, 21,
    999, 999, 999, 24, 999, 21, 999, 999, 999, 999, 13, 75, 999, 999, 999, 999,
    999, 999, 70, 999, 999, 999, 999, 25, 999, 999, 999, 999, 25, 39, 999, 999,
    75, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 21, 50, 999, 999, 999, 999, 999, 85, 39, 23, 999, 19, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999,
    999, 999, 999, 999, 24, 999, 999, 999, 999, 999, 30, 999, 21, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 50, 999, 999, 999, 999, 999,
    999, 999, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 26, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 60, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 21, 999, 999, 999, 30, 18, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 65, 59, 18, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 20, 999, 999, 999, 999, 999, 999, 999, 30,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 45, 21, 999, 999, 30, 999, 999,
    65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 71, 999, 21, 70, 999, 19, 999,
    999, 74, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 40, 25, 999, 999,
    999, 75, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 70, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 50, 999, 999, 999, 75, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 99, 999, 999, 85, 999, 75, 999, 999,
    999, 999, 999, 75, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 40, 999,
    999, 999, 999, 999, 999, 22, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 65, 999, 999, 29, 999, 999, 999, 999,
    999, 30, 999, 999, 999, 59, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 31, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 89, 999, 999,
    999, 22, 999, 999, 999, 999, 999, 55, 999, 100, 999, 999, 999, 999, 30, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 21, 999, 999, 999, 999, 80, 80, 999, 999, 30, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 75, 999, 999, 999, 70, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 30, 999, 25, 999, 85, 999, 999, 999, 999, 999, 999,
    999, 999, 18, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 40, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 70, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 73, 999, 21, 999, 999, 999, 60, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 21, 999, 999, 21, 999, 999, 999, 999, 999, 60, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 39, 25, 999, 999, 999, 999, 999,
    999, 999, 75, 999, 999, 999, 999, 21, 999, 999, 999, 21, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 30,
    999, 999, 999, 999, 999, 80, 999, 39, 75, 999, 999, 999, 999, 18, 999, 21,
    999, 21, 999, 999, 21, 999, 999, 999, 22, 999, 999, 999, 999, 25, 999, 30,
    999, 999, 999, 999, 39, 999, 39, 1, 39, 999, 999, 999, 999, 999, 999, 9, 20,
    999, 999, 22, 80, 75, 999, 999, 999, 999, 999, 60, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 22,
    999, 999, 999, 999, 999, 999, 999, 999, 80, 999, 90, 999, 75, 999, 999, 18,
    999, 999, 999, 30, 70, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 70, 999, 999, 999, 999, 75, 21, 75, 999, 999, 73,
    999, 999, 999, 99, 999, 90, 999, 999, 999, 999, 99, 999, 999, 999, 999, 75,
    75, 999, 999, 999, 18, 69, 999, 999, 999, 999, 22, 999, 999, 999, 999, 90,
    999, 999, 80, 999, 999, 999, 999, 999, 999, 999, 21, 999, 999, 75, 40, 999,
    75, 999, 21, 999, 65, 49, 999, 999, 999, 999, 999, 69, 999, 999, 999, 999,
    999, 999, 999, 73, 999, 999, 999, 999, 999, 999, 31, 999, 999, 999, 75, 999,
    999, 999, 999, 65, 999, 999, 90, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 80, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 30, 999, 999,
    999, 64, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999, 999, 999, 99, 999,
    999, 999, 69, 999, 999, 999, 999, 999, 999, 85, 999, 65, 999, 999, 999, 999,
    50, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 65, 999, 999, 999, 49,
    999, 999, 999, 999, 85, 999, 999, 999, 999, 60, 999, 999, 999, 30, 999, 999,
    999, 999, 999, 75, 999, 31, 80, 999, 999, 999, 999, 85, 999, 999, 29, 999,
    30, 30, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 64, 999, 999,
    999, 18, 999, 999, 85, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 74, 79, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 85, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 18, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 130, 80, 999, 80, 999, 999, 999, 999, 999, 999, 89, 999,
    999, 80, 85, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 120, 999, 999, 999, 999, 999, 999, 999, 75, 999, 40, 999, 999, 999, 80,
    999, 999, 999, 999, 25, 999, 999, 75, 999, 999, 999, 999, 999, 17, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 130,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 100, 65,
    999, 999, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 80, 999, 999, 999, 999, 999, 999, 999, 130, 999, 999, 999,
    999, 999, 999, 120, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    95, 999, 999, 999, 999, 999, 999, 1, 999, 999, 999, 40, 999, 999, 999, 999,
    999, 999, 999, 21, 999, 999, 999, 999, 999, 999, 75, 101, 999, 999, 999,
    999, 999, 999, 999, 999, 60, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    75, 999, 999, 75, 999, 999, 999, 999, 999, 999, 75, 999, 999, 130, 70, 75,
    999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999,
    100, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 76, 999, 999, 999, 999, 999, 100, 80, 999,
    999, 999, 75, 99, 130, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 80, 999, 90, 999, 999, 999, 99, 999, 999, 130, 130, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 22, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 100, 999, 999, 75, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 130,
    999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 100, 17,
    999, 999, 999, 999, 130, 17, 999, 999, 130, 100, 999, 999, 999, 35, 999,
    999, 999, 50, 999, 999, 999, 999, 130, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 19, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 95, 999,
    999, 999, 999, 130, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 80, 999, 999, 999, 999, 999, 75, 21, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 65, 999, 999, 999, 999, 130, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 99, 999, 999, 99, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 30, 999, 999, 999, 999, 75, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 99, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 80,
    999, 999, 99, 999, 999, 999, 18, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 80, 99, 999, 25, 130, 999, 999, 999, 999, 999, 999, 999, 999,
    130, 999, 999, 999, 100, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 75, 999, 999, 99, 999, 999, 999, 999, 999, 999, 99, 999, 999, 999, 29,
    29, 999, 75, 70, 999, 999, 999, 999, 999, 999, 99, 999, 999, 999, 999, 120,
    120, 999, 95, 999, 999, 999, 999, 100, 999, 999, 130, 999, 130, 999, 80,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 101, 999, 99, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    130, 999, 999, 999, 120, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 120, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 18, 100,
    999, 999, 999, 999, 25, 999, 130, 999, 999, 21, 999, 75, 130, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999,
    999, 999, 999, 999, 999, 80, 999, 999, 999, 64, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 22, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75,
    999, 999, 999, 999, 100, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 100, 999, 999, 999, 999, 999, 999, 999, 99, 999, 999, 65,
    999, 999, 999, 999, 99, 17, 999, 999, 999, 999, 101, 999, 999, 120, 999, 99,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 999,
    45, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 130, 18, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 70, 999, 999, 999, 999, 85, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 18, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999, 999,
    999, 999, 80, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 120, 999, 999, 999, 999,
    70, 999, 999, 999, 120, 999, 65, 999, 999, 999, 999, 999, 130, 999, 85, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 75, 130,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 120, 65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 100,
    999, 999, 999, 999, 999, 999, 999, 75, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 100, 130, 999, 999, 999, 999, 999, 999, 999, 130, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 25, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 65, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 110, 999, 999, 999, 999, 999, 999, 999, 130,
    999, 999, 75, 999, 75, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 99,
    999, 999, 999, 999, 999, 999, 99, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 90, 999, 999, 999, 100,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 999, 999, 999, 999, 999,
    999, 80, 999, 101, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 120, 999, 999, 999,
    130, 200, 999, 999, 999, 21, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    25, 30, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 21,
    999, 999, 999, 999, 999, 110, 999, 25, 999, 999, 21, 25, 999, 999, 999, 999,
    999, 999, 999, 130, 999, 999, 999, 999, 999, 999, 999, 999, 30, 999, 21,
    999, 999, 999, 999, 999, 999, 999, 99, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 80, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 30, 150, 999, 999, 999, 21, 999, 65,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 150, 999, 999, 105, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 21, 75, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 120, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 130, 999, 120,
    999, 999, 999, 999, 110, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 21, 999, 999, 25, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    999, 18, 30, 75, 999, 999, 999, 75, 999, 999, 999, 999, 999, 25, 999, 70,
    999, 999, 999, 999, 17, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999,
    130, 100, 999, 999, 60, 999, 999, 999, 999, 999, 20, 100, 999, 25, 999, 999,
    999, 79, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 999, 99, 999, 21
  ],
  "min_age_in_years": [
    18, 1, 18, 18, 18, 18, 18, 18, 0, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 16, 18, 18, 18, 18, 18, 18,
    18, 1, 1, 4, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1,
    18, 18, 18, 18, 18, 18, 18, 16, 6, 18, 18, 18, 2, 1, 3, 18, 18, 18, 18, 18,
    1, 18, 3, 18, 18, 18, 18, 5, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 2,
    21, 18, 18, 18, 18, 18, 18, 18, 18, 18, 2, 18, 18, 18, 18, 1, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 3, 18, 18, 0, 18, 18, 18, 2, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 2, 18, 18, 0, 18, 18, 18, 18, 18, 18,
    18, 0, 18, 18, 75, 0, 18, 2, 18, 18, 18, 1, 1, 2, 18, 2, 1, 14, 18, 1, 1, 1,
    1, 1, 18, 18, 1, 0, 1, 45, 18, 18, 18, 18, 18, 60, 18, 18, 18, 1, 0, 18, 11,
    18, 18, 1, 18, 1, 0, 1, 1, 1, 18, 18, 18, 3, 0, 0, 0, 18, 18, 1, 18, 0, 18,
    1, 18, 18, 18, 1, 18, 18, 18, 50, 18, 18, 18, 50, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 0, 18, 35, 12, 18, 18, 18, 18, 18, 18, 18, 70, 18, 18,
    18, 18, 12, 70, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 12, 70, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 12, 1, 0, 18, 0, 0, 17, 1, 18, 19, 0, 18, 18, 18, 18, 2, 18, 0, 60,
    35, 18, 18, 18, 18, 60, 0, 0, 0, 18, 12, 18, 18, 18, 18, 15, 18, 0, 0, 18,
    18, 1, 8, 18, 18, 18, 18, 18, 18, 18, 0, 30, 18, 18, 18, 1, 18, 18, 18, 18,
    18, 12, 18, 18, 0, 18, 18, 0, 18, 18, 0, 18, 18, 18, 0, 18, 18, 18, 18, 4,
    18, 18, 18, 3, 1, 12, 1, 18, 3, 18, 18, 18, 18, 18, 18, 18, 18, 30, 18, 70,
    0, 50, 18, 18, 1, 18, 18, 18, 18, 0, 4, 18, 0, 18, 18, 1, 18, 18, 18, 18,
    16, 1, 18, 18, 0, 0, 18, 18, 18, 18, 18, 3, 0, 18, 18, 12, 18, 18, 18, 18,
    18, 0, 18, 18, 18, 18, 18, 1, 18, 1, 0, 0, 1, 18, 18, 18, 18, 18, 18, 18,
    12, 18, 18, 18, 14, 18, 2, 18, 18, 50, 18, 18, 18, 18, 0, 18, 18, 0, 18, 18,
    0, 18, 18, 18, 18, 21, 18, 18, 18, 0, 0, 18, 18, 18, 18, 18, 18, 15, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 1, 19, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18,
    18, 18, 30, 18, 18, 0, 18, 18, 0, 18, 15, 18, 18, 0, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 35, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 60, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 1,
    18, 18, 1, 18, 18, 21, 65, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 0, 19,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 0, 18, 18, 1, 18,
    0, 1, 18, 18, 18, 18, 18, 18, 18, 18, 3, 16, 21, 18, 19, 18, 40, 18, 18, 18,
    18, 0, 18, 18, 0, 18, 30, 18, 18, 18, 18, 18, 18, 12, 18, 18, 1, 0, 18, 18,
    0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 0,
    18, 18, 18, 50, 18, 18, 12, 0, 18, 12, 18, 18, 0, 18, 0, 18, 18, 18, 15, 18,
    1, 18, 18, 18, 18, 12, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 50, 18,
    18, 18, 18, 18, 18, 4, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19,
    21, 18, 18, 18, 2, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 40, 18, 21, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18,
    18, 0, 18, 18, 18, 18, 18, 18, 0, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 3, 18, 18, 18, 0, 18, 18, 18, 18, 18, 2, 18, 18, 18, 18, 21, 18, 18, 0,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 3, 18, 18, 0, 18, 18,
    18, 18, 12, 0, 18, 18, 18, 55, 18, 19, 40, 18, 18, 18, 70, 18, 18, 18, 18,
    18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    30, 18, 18, 18, 18, 0, 18, 18, 12, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    35, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1,
    18, 18, 18, 1, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 60, 18, 18, 18, 18, 18, 18, 15, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 19, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 50, 18, 18, 18, 18, 18, 65, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 12, 18, 18, 18, 18, 18, 18,
    1, 18, 18, 18, 18, 18, 0, 0, 1, 18, 18, 2, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 22, 18, 18, 12, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 12, 18, 3, 18, 18, 18, 0, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 0,
    12, 18, 18, 18, 18, 18, 40, 70, 18, 18, 18, 18, 2, 0, 16, 18, 18, 18, 18,
    18, 18, 0, 18, 18, 18, 18, 18, 3, 18, 18, 18, 18, 18, 4, 18, 0, 18, 18, 18,
    18, 18, 50, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 21, 18, 18, 18, 18, 18, 18, 18, 18, 1, 0, 18, 18, 24, 18, 18, 18, 18,
    18, 18, 0, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 15, 4, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 25, 18, 0, 18, 18, 18, 18, 18, 0,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 30, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 12, 0, 60, 18,
    18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 12, 21, 18, 18, 18, 18, 18, 18, 18, 2, 18, 18, 0, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18,
    65, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 4, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 50, 18, 40, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    0, 18, 18, 18, 18, 16, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18,
    18, 18, 18, 0, 18, 18, 18, 2, 18, 1, 0, 18, 18, 18, 1, 18, 18, 18, 18, 0,
    18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 1, 2, 18, 18, 18, 18, 18, 18,
    18, 70, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 50, 18, 18, 18, 18,
    18, 18, 18, 18, 0, 18, 18, 18, 18, 1, 1, 18, 18, 18, 18, 18, 35, 3, 0, 18,
    8, 12, 18, 18, 18, 0, 18, 18, 19, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 1, 21, 18, 0, 18, 15, 21, 30, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 16, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 19, 18, 18, 18, 1,
    18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 0, 18, 18, 18, 18,
    18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 1, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 65,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 10, 18, 18, 18, 1, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 70, 18, 6, 16, 18, 18, 1, 1, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 1, 18, 0, 18, 3, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    10, 1, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1,
    0, 18, 18, 6, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 22, 18, 18, 18, 18, 18, 18, 0, 0, 0, 0, 18, 0, 18, 18, 0, 18, 0,
    18, 18, 18, 0, 18, 45, 3, 0, 1, 2, 18, 65, 18, 12, 18, 18, 18, 18, 18, 18,
    3, 18, 18, 18, 18, 18, 18, 18, 18, 25, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 3, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 0, 18, 12, 18, 30, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 12,
    18, 18, 18, 18, 18, 18, 12, 18, 50, 18, 18, 18, 18, 6, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 16, 18, 1, 18, 40, 18, 18,
    18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 1, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 45, 70, 18, 18, 18, 18, 18, 10, 18,
    18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 60, 18, 18, 1, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 25, 18, 18, 18, 22, 18,
    12, 18, 1, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 1, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 30, 18, 0, 18, 1, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 0, 18,
    0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 21, 0, 1, 18, 18, 18, 21, 18, 18, 60,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 0, 18, 18, 3, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 13, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 16, 0, 18,
    18, 40, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 45, 18, 18, 18,
    18, 18, 1, 18, 18, 18, 0, 18, 18, 45, 1, 18, 18, 16, 18, 18, 0, 18, 0, 18,
    3, 18, 18, 0, 18, 18, 18, 1, 18, 18, 18, 18, 1, 18, 3, 18, 50, 18, 18, 3,
    18, 3, 0, 0, 18, 18, 18, 18, 18, 18, 0, 0, 0, 18, 12, 4, 1, 18, 0, 18, 18,
    18, 13, 18, 18, 18, 1, 25, 12, 19, 18, 16, 0, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 15, 18, 50, 18, 50, 18, 18, 1,
    18, 18, 18, 4, 3, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    10, 18, 18, 18, 18, 18, 18, 0, 3, 18, 18, 18, 50, 18, 18, 18, 18, 18, 18,
    18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 2, 40, 18, 18, 18,
    18, 0, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 2, 18,
    18, 18, 18, 18, 30, 22, 3, 18, 1, 18, 18, 21, 25, 18, 18, 18, 18, 18, 18,
    19, 18, 18, 18, 50, 18, 18, 18, 65, 18, 18, 0, 18, 18, 18, 45, 18, 18, 18,
    18, 21, 18, 18, 21, 18, 18, 18, 18, 18, 18, 18, 35, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 50, 18, 0, 18, 18, 18, 30, 18,
    18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 27, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 25,
    18, 18, 18, 18, 22, 50, 18, 18, 18, 18, 30, 18, 18, 18, 25, 18, 18, 0, 18,
    35, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 1, 18, 1, 18, 18,
    12, 18, 18, 21, 18, 18, 1, 18, 0, 0, 0, 18, 18, 18, 18, 18, 18, 18, 18, 65,
    18, 30, 18, 18, 18, 2, 55, 12, 18, 18, 18, 6, 5, 18, 18, 18, 18, 30, 18, 18,
    40, 18, 18, 18, 1, 50, 12, 18, 18, 12, 18, 0, 18, 18, 18, 18, 0, 18, 30, 21,
    0, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1,
    18, 12, 18, 0, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 30,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 12,
    18, 18, 18, 18, 16, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18,
    18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18,
    25, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 50, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18,
    18, 2, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 2, 18, 18, 11, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 22, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 16, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 50, 18, 5, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 16, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 50, 0, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 0, 16, 18, 18, 18, 18, 18, 18, 21, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 12,
    18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 3, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 25, 18, 18, 18, 18, 18, 18, 2, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 12, 1, 18, 18, 18, 18, 18, 18, 18, 18, 12,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 45, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 22, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18, 13, 18, 18, 10, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 1, 18, 18, 18, 18, 12, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 22, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 1, 12, 18, 18, 18, 18, 18, 18, 18, 12, 18,
    16, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 2, 18, 18, 18,
    18, 18, 2, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 15, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 0, 45, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 22, 18, 18, 16, 18, 18, 18, 18, 2, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 5, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 60, 18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 1, 65, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 15, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 16, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 16, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 8,
    18, 22, 1, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 6, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18,
    0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 1, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 1, 18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 2, 2, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 0, 55, 1, 16, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18,
    18, 21, 18, 65, 18, 18, 18, 18, 12, 18, 18, 18, 18, 1, 18, 18, 18, 18, 1,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 0,
    18, 18, 18, 18, 18, 18, 18, 0, 18, 18, 18, 1, 18, 18, 12, 12, 18, 18, 18,
    18, 0, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 12,
    18, 18, 18, 18, 18, 18, 18, 18, 12, 18, 18, 18, 18, 18, 0, 18, 18, 18, 18,
    18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 1, 18,
    18, 0, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 18, 0, 5, 18, 18, 18, 18, 10,
    18, 18, 18, 18, 18, 3, 18, 18, 18, 18, 0, 18, 1, 18, 18, 18, 18, 2, 10, 18,
    18, 2, 18, 18, 18, 18, 12, 18, 18, 18, 18, 0, 18, 2, 18, 18, 1, 18, 12, 18,
    18, 12, 18, 12, 18, 18, 0, 18, 18, 18, 18, 18, 40, 12, 1
  ],
  "disease_names_lead": [
    "Advanced Malignant Solid Tumor",
    "Recurrent Brain Neoplasm",
    "Stage IV Non-Small Cell Lung Cancer",
    "Rectal Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Relapsing-Remitting Multiple Sclerosis",
    "Metastatic Malignant Solid Tumor",
    "Endometrial Serous Adenocarcinoma",
    "Recurrent Osteosarcoma, Recurrent Neuroblastoma",
    "Lung Neuroendocrine Neoplasm",
    "Recurrent Medulloblastoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Cutaneous (Skin) Kaposi Sarcoma",
    "Neuroendocrine Tumor",
    "Recurrent AL Amyloidosis",
    "Peritoneal Malignant Mesothelioma",
    "Metastatic Malignant Solid Tumor",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Malignant Glioma",
    "Stage IV Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "HIV Infection, Anal Squamous Cell Cancer",
    "Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Plasmablastic Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Digestive System Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Recurrent Ovarian Cancer",
    "HIV Infection, Recurrent Non-Hodgkin Lymphoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Breast Carcinoma",
    "Recurrent Malignant Glioma",
    "Refractory Malignant Solid Tumor",
    "Stage IIID Cutaneous (Skin) Melanoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Melanoma",
    "Recurrent Osteosarcoma",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor",
    "Glioblastoma",
    "HIV Infection, High Grade Squamous Intraepithelial Neoplasia",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Advanced Urothelial Cancer, Advanced Malignant Solid Tumor",
    "Pancreatic Neuroendocrine Tumor",
    "Metastatic Neoplasm",
    "Metastatic Urothelial Cancer",
    "Advanced Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Adult T-Cell Leukemia/Lymphoma",
    "Unresectable Esophageal Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Malignant Solid Tumor",
    "Stage III Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Lymphoplasmacytic Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Cutaneous (Skin) Kaposi Sarcoma",
    "Metastatic Malignant Solid Tumor",
    "Gliosarcoma",
    "Metastatic Urothelial Cancer",
    "Anaplastic Astrocytoma, IDH-Mutant",
    "Recurrent Primary Central Nervous System Neoplasm",
    "Metastatic Melanoma",
    "Recurrent Glioblastoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Diffuse Intrinsic Pontine Glioma",
    "Recurrent Central Nervous System Neoplasm",
    "Recurrent Medulloblastoma, SHH-Activated",
    "Unresectable Malignant Solid Tumor",
    "Recurrent Sarcoma",
    "Stage IB2 Cervical Cancer, Stage II Vaginal Cancer",
    "Refractory Malignant Solid Tumor",
    "Non-Metastatic Breast Carcinoma",
    "Recurrent Malignant Glioma",
    "Metastatic Well Differentiated Neuroendocrine Neoplasm",
    "Recurrent Malignant Glioma",
    "Metastatic Breast Carcinoma",
    "Advanced Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Supratentorial Ependymoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage IV Lung Cancer",
    "Recurrent Meningioma",
    "Advanced Esophageal Adenocarcinoma",
    "Recurrent Mycosis Fungoides and Sezary Syndrome",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Head and Neck Squamous Cell Carcinoma",
    "Soft Tissue Sarcoma of the Trunk and Extremities",
    "Cutaneous (Skin) Kaposi Sarcoma",
    "Recurrent Grade III Glioma",
    "Primary Central Chondrosarcoma",
    "HIV Infection, Anal Intraepithelial Neoplasia",
    "Stage IIIA Penile Cancer",
    "AIDS-Related Lymphoma",
    "Recurrent Bladder Urothelial Cancer",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Acute Graft Versus Host Disease",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Central Nervous System Lymphoma",
    "Stage IA Pleural Malignant Mesothelioma",
    "Platinum-Resistant Ovarian Cancer",
    "Recurrent Glioblastoma",
    "Recurrent Malignant Solid Tumor",
    "HIV Infection, Recurrent Classical Hodgkin Lymphoma, Advanced Malignant Solid Tumor",
    "Stage III Hepatocellular Cancer",
    "Metastatic Urothelial Cancer",
    "Locally Recurrent Head and Neck Squamous Cell Carcinoma",
    "Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Thyroid Gland Cancer, Metastatic Renal Cell Cancer",
    "Glioma",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Non-Small Cell Squamous Lung Cancer",
    "Pleural Malignant Mesothelioma",
    "Advanced Renal Cell Carcinoma",
    "Osteosarcoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Central Nervous System Nongerminomatous Germ Cell Tumor",
    "Recurrent Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Hematologic and Lymphocytic Disorder",
    "Biochemically Recurrent Prostate Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Metastatic Pancreatic Adenocarcinoma",
    "Metastatic Alveolar Soft Part Sarcoma",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Primary Central Chondrosarcoma",
    "Endocervical Cancer, Vaginal Cancer",
    "Metastatic Breast Carcinoma",
    "Soft Tissue Sarcoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Solid Tumor",
    "Glioblastoma",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Anal Canal Squamous Cell Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Grade II Glioma",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Advanced Adrenal Gland Pheochromocytoma",
    "Juvenile Myelomonocytic Leukemia",
    "Oral Cavity Squamous Cell Cancer",
    "Bladder Urothelial Cancer",
    "Stage I Esophageal Adenocarcinoma",
    "B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",
    "Renal Pelvis and Ureter Urothelial Cancer",
    "Locally Advanced Rectal Adenocarcinoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "High-Risk Neuroblastoma",
    "Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Diffuse Large B-Cell Lymphoma",
    "Solid Tumor",
    "Stage III Cutaneous (Skin) Melanoma",
    "Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Papillary Craniopharyngioma",
    "Refractory B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma",
    "Cutaneous Angiosarcoma",
    "Deep Fibromatosis/Desmoid Tumor",
    "Advanced Malignant Solid Tumor",
    "Low Grade Glioma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Low Grade Glioma",
    "Advanced Malignant Solid Tumor",
    "Germ Cell Tumor",
    "Refractory T Lymphoblastic Lymphoma, Recurrent T Acute Lymphoblastic Leukemia",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Recurrent Non-Hodgkin Lymphoma",
    "Stage IB Cervical Cancer",
    "Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Cancer",
    "Recurrent Neuroblastoma",
    "Embryonal Rhabdomyosarcoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Lobular Carcinoma In Situ (LCIS)",
    "Recurrent Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
    "Metastatic HER2-Negative Breast Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Resectable Pancreatic Cancer",
    "Metastatic Urothelial Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Glioblastoma",
    "Locally Advanced Skin Squamous Cell Carcinoma",
    "Intracranial Meningioma",
    "Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Bladder Urothelial Cancer",
    "Malignant Germ Cell Tumor",
    "Recurrent Platinum-Resistant Ovarian Carcinoma",
    "Malignant Solid Tumor",
    "Neuroblastoma",
    "Stage II Nasopharyngeal Throat Cancer",
    "Advanced Malignant Solid Tumor",
    "Stage II Wilms Tumor",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Ependymoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Malignant Solid Tumor",
    "Inflammatory Breast Cancer",
    "Metastatic Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Medulloblastoma",
    "Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Hepatocellular Cancer",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer, Stage III Oral Cavity Squamous Cell Cancer",
    "Unresectable Melanoma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Resectable Pancreatic Adenocarcinoma",
    "Ganglioneuroblastoma, Neuroblastoma",
    "Extensive Stage Small Cell Lung Cancer",
    "B Acute Lymphoblastic Leukemia",
    "MGMT-Unmethylated Glioblastoma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Metastatic Pancreatic Adenocarcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Metastatic Renal Cell Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Non-Small Cell Lung Cancer",
    "Stage IA Breast Cancer",
    "Metastatic Genitourinary Tumor",
    "Stage II Prostate Adenocarcinoma",
    "Metastatic Thymic Carcinoma",
    "Pancreatic Neoplasm",
    "B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative",
    "Recurrent Anal Squamous Cell Carcinoma",
    "Recurrent Endometrial Carcinoma",
    "Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Bladder Urothelial Cancer",
    "Endometrial Endometrioid Adenocarcinoma",
    "Small Cell Lung Cancer",
    "Neuroendocrine Tumor",
    "Infiltrating Bladder Urothelial Carcinoma",
    "Stage II Gallbladder Cancer",
    "Mantle Cell Lymphoma",
    "Rhabdomyosarcoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Stage I Breast Cancer",
    "Recurrent Classical Hodgkin Lymphoma",
    "Metastatic Melanoma",
    "Unresectable Melanoma",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Metastatic Colorectal Adenocarcinoma",
    "Locally Advanced Urothelial Cancer",
    "Recurrent Follicular Lymphoma",
    "Recurrent Lung Non-Squamous Non-Small Cell Carcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Stage I Cervical Cancer",
    "Gastroesophageal Junction Adenocarcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Classical Hodgkin Lymphoma",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Metastatic Small Intestinal Adenocarcinoma",
    "Stage II HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Mantle Cell Lymphoma",
    "Stage IV Renal Cell Cancer",
    "Anal Canal Squamous Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Limited Stage Small Cell Lung Cancer",
    "Recurrent Meningioma",
    "Germ Cell Tumor",
    "Pathologic Stage I Merkel Cell Carcinoma AJCC v8",
    "Extensive Stage Small Cell Lung Cancer",
    "HER2-Positive Breast Carcinoma",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Metastatic Colorectal Adenocarcinoma",
    "Recurrent Uterine (Including Endometrial) Cancer",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Breast Adenocarcinoma",
    "Invasive Ovarian Micropapillary Serous Carcinoma",
    "Colon Adenocarcinoma",
    "Metastatic Pancreatic Adenocarcinoma",
    "Advanced Colorectal Carcinoma",
    "Stage III Lung Cancer",
    "Stage III Cutaneous (Skin) Melanoma",
    "Stage IIA Colon Cancer",
    "Invasive Breast Cancer",
    "Recurrent Non-Small Cell Lung Cancer",
    "Malignant Solid Tumor",
    "Stage I Breast Cancer",
    "Non-Squamous Non-Small Cell Lung Cancer",
    "Triple-Negative Breast Cancer",
    "Lymphoma, Refractory Malignant Solid Tumor",
    "Stage II Lung Cancer",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Grade I Lymphomatoid Granulomatosis",
    "Recurrent Neuroblastoma",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Hairy Cell Leukemia",
    "T Acute Lymphoblastic Leukemia",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma",
    "Myelodysplastic Syndrome, Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome with Excess Blasts",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Immune Dysregulation, Polyendocrinopathy, and Enteropathy X-Linked Syndrome",
    "Recurrent Hairy Cell Leukemia",
    "Recurrent B Acute Lymphoblastic Leukemia, Recurrent High-Grade B-Cell Lymphoma",
    "Pancreatic Adenocarcinoma",
    "Phyllodes Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Infectious Disorder",
    "Stage I Breast Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Pre-B Acute Lymphoblastic Leukemia",
    "Prostate Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1",
    "Stage I Grade 1 Follicular Lymphoma",
    "Benign Laryngeal Neoplasm",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Advanced Malignant Neoplasm",
    "Advanced Malignant Neoplasm",
    "Aplastic Anemia",
    "Metastatic Melanoma",
    "Refractory Hodgkin Lymphoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Myelofibrosis",
    "Smoldering Adult T-Cell Leukemia/Lymphoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Intraocular Retinoblastoma",
    "Primary Myelofibrosis",
    "de novo Myelodysplastic Syndrome",
    "Refractory Neuroblastoma",
    "Myelodysplastic Syndrome",
    "Metastatic Soft Tissue Sarcoma",
    "Stage I Renal Cell Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IVA Appendix Cancer",
    "Anemia",
    "Pancreatic Adenocarcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Myelodysplastic Syndrome",
    "Stage I Prostate Cancer",
    "Stage I Uveal Melanoma",
    "Advanced Hepatocellular Carcinoma",
    "Stage I Nasal Type NK/T-Cell Lymphoma",
    "Neuroblastoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Mixed Phenotype Acute Leukemia",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Kidney Oncocytoma",
    "Breast Cancer",
    "AIDS-Related Burkitt Lymphoma",
    "Stage 0 Bladder Urothelial Cancer",
    "Pancreatic Adenocarcinoma",
    "Cytomegaloviral Infection",
    "Refractory Lymphoma, Refractory Malignant Solid Tumor",
    "Stage IIIB Cutaneous (Skin) Melanoma",
    "Stage 2A Neuroblastoma",
    "Primary Myelofibrosis",
    "Advanced Malignant Neoplasm",
    "Metastatic Pheochromocytoma",
    "Recurrent Neuroblastoma",
    "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Stage IV Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Neurofibromatosis Type 1",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IV Oropharyngeal Throat Squamous Cell Cancer",
    "Primary Myelofibrosis",
    "Recurrent Brain Neoplasm",
    "Recurrent Neuroblastoma",
    "Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Breast Cancer",
    "Stage IV Inflammatory Breast Cancer",
    "Recurrent Malignant Solid Tumor",
    "Hematologic and Lymphocytic Disorder",
    "Locally Advanced Unresectable Soft Tissue Sarcoma",
    "Triple-Negative Breast Cancer",
    "B Acute Lymphoblastic Leukemia",
    "Pancreatic Cancer, Ovarian Cancer",
    "Stage IV Renal Cell Cancer",
    "Invasive Breast Cancer",
    "HIV Infection, Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Invasive Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "Stage I Indolent Non-Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "T-Cell Large Granular Lymphocyte Leukemia",
    "Recurrent Myelodysplastic Syndrome",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Stage IV Renal Cell Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Primary Immunodeficiency Syndrome",
    "Metastatic Colorectal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma",
    "Neuroblastoma",
    "Stage III Pleural Malignant Mesothelioma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Recurrent Hodgkin Lymphoma",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Sickle Cell-Thalassemia",
    "Stage IV Non-Small Cell Lung Cancer",
    "Prostate Adenocarcinoma",
    "Hematopoietic and Lymphoid System Neoplasm",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Endometrial Cancer",
    "Refractory Kaposi Sarcoma",
    "Myelodysplastic Syndrome, Lymphoblastic Lymphoma, Acute Myeloid Leukemia (AML), Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Breast Cancer",
    "Bronchiolitis Obliterans",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Triple-Negative Breast Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Recurrent Hodgkin Lymphoma",
    "Recurrent Brain Neoplasm",
    "Anal Intraepithelial Neoplasia",
    "Recurrent Malignant Peripheral Nerve Sheath Tumor",
    "Recurrent Soft Tissue Sarcoma",
    "Metastatic Melanoma",
    "Pleural Epithelioid Mesothelioma",
    "Recurrent Glioblastoma",
    "Malignant Solid Tumor",
    "Glioblastoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Stage IVB Colorectal (Colon or Rectal) Cancer",
    "Breast Adenocarcinoma",
    "Chronic Graft Versus Host Disease",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Ependymoma",
    "Head and Neck Squamous Cell Carcinoma",
    "Neuroblastoma",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Craniopharyngioma",
    "Recurrent Malignant Solid Tumor",
    "Unresectable Melanoma",
    "Stage IV Breast Cancer",
    "Stage I Oral Cavity Squamous Cell Cancer",
    "Stage III Ovarian Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Human Papillomavirus-Related Malignant Neoplasm",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Cervical Intraepithelial Neoplasia Grade 2/3",
    "Recurrent Hodgkin Lymphoma",
    "High Grade Vulvar Squamous Intraepithelial Lesion",
    "B Acute Lymphoblastic Leukemia",
    "Recurrent Acute Lymphoblastic Leukemia (ALL), Chronic Myelomonocytic Leukemia (CMML)",
    "Recurrent Primary Central Nervous System Neoplasm",
    "Stage IV Pancreatic Cancer",
    "Advanced Malignant Solid Tumor",
    "Human Papillomavirus-Related Malignant Neoplasm",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Metastatic Melanoma",
    "Primary Effusion Lymphoma",
    "Invasive Breast Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "POEMS Syndrome",
    "Stage IV Non-Small Cell Lung Cancer",
    "Severe Aplastic Anemia",
    "Castration-Resistant Prostate Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage III Prostate Adenocarcinoma",
    "Pleural Malignant Mesothelioma",
    "Cardiomyopathy",
    "Malignant Brain Glioma",
    "Inflammatory Breast Cancer",
    "Triple-Negative Breast Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML), Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Lymphoblastic Lymphoma, Acute Leukemia, Myelodysplastic Syndrome",
    "Primary Immunodeficiency Syndrome",
    "Head and Neck Squamous Cell Carcinoma",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Pancreatic Ductal Adenocarcinoma",
    "Malignant Mesothelioma",
    "Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Triple-Negative Breast Cancer",
    "Refractory Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma/Plasma Cell Myeloma, Refractory B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Melanoma",
    "Leptomeningeal Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Invasive Breast Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Pancreatic Carcinoma",
    "Stage IV Hepatocellular Cancer",
    "Advanced Digestive System Neuroendocrine Neoplasm",
    "Inherited Bone Marrow Failure Syndrome",
    "Recurrent Ovarian Serous Adenocarcinoma, Recurrent Lung Adenocarcinoma, Peritoneal Malignant Mesothelioma",
    "Recurrent Myelodysplastic Syndrome",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Esophageal Adenocarcinoma, Gastric (Stomach) Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML), Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Pancreatic Adenocarcinoma",
    "Recurrent Thymic Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Recurrent Non-Small Cell Lung Cancer",
    "Refractory Malignant Solid Tumor",
    "Gastric (Stomach) Adenocarcinoma",
    "Hematologic and Lymphocytic Disorder",
    "Metastatic Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Stage IIIA Non-Small Cell Lung Cancer, Stage III Esophageal Cancer",
    "Stage IIIC Breast Cancer",
    "Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma",
    "High Grade Anal Canal Intraepithelial Neoplasia",
    "Metastatic Breast Carcinoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Colorectal (Colon or Rectal) Adenocarcinoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Secondary Myelofibrosis",
    "Metastatic Endometrial Carcinoma",
    "Recurrent Follicular Lymphoma",
    "Breast Cancer",
    "Invasive Breast Cancer",
    "Castration-Resistant Prostate Cancer",
    "Non-Hodgkin Lymphoma",
    "Stage III Renal Cell Cancer",
    "Adrenal Cortex Cancer",
    "Pelvis Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Marginal Zone Lymphoma",
    "Stage III Esophageal Cancer",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Transformed Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Mantle Cell Lymphoma",
    "Stage I Non-Small Cell Lung Cancer",
    "Hematologic and Lymphocytic Disorder",
    "Stage IV Esophageal Cancer",
    "Recurrent Head and Neck Carcinoma",
    "Chondrosarcoma, Grade 3",
    "Metastatic Melanoma",
    "Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Malignant Female Reproductive System Neoplasm, Breast Cancer",
    "Stage IIIC Ovarian Cancer",
    "HER2-Positive Breast Carcinoma",
    "Supratentorial Glioblastoma",
    "Indolent Non-Hodgkin Lymphoma",
    "Stage IV Renal Cell Cancer",
    "Stage IV Inflammatory Breast Cancer",
    "Advanced Malignant Neoplasm",
    "Metastatic Pheochromocytoma",
    "Recurrent Malignant Female Reproductive System Neoplasm",
    "Metastatic Breast Carcinoma",
    "Stage I Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Abdominal Neuroendocrine Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Ductal Carcinoma In Situ (DCIS)",
    "Hepatocellular Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Metastatic Pancreatic Carcinoma, Metastatic Colorectal Carcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Acute Myeloid Leukemia (AML)",
    "Stage IV Non-Small Cell Lung Cancer",
    "Unresectable Malignant Solid Tumor",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Metastatic Breast Carcinoma",
    "Malignant Neoplasm",
    "Advanced Urothelial Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Stage III Ovarian Cancer",
    "Recurrent Ovarian Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Grade II Glioma",
    "Hepatocellular Cancer",
    "Recurrent Prostate Cancer",
    "EBV-Related Lymphoproliferative Disorder, Recurrent EBV-Related Lymphoma",
    "Superficial Bladder Cancer",
    "Refractory Hodgkin Lymphoma",
    "Hepatocellular Cancer",
    "Unresectable Malignant Gastric Neoplasm",
    "Stage IV Renal Cell Cancer",
    "Prostate Adenocarcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Pancreatic Ductal Adenocarcinoma",
    "Recurrent Meningioma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Metastatic Breast Carcinoma",
    "Hematopoietic and Lymphoid System Neoplasm",
    "Recurrent Glioblastoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Mantle Cell Lymphoma",
    "Recurrent Primary Amyloidosis",
    "Malignant Brain Tumor",
    "Recurrent Ovarian Cancer",
    "Advanced Well Differentiated Neuroendocrine Neoplasm",
    "Metastatic Breast Cancer in the Bone",
    "Unresectable Thymic Carcinoma",
    "Oligometastatic Prostate Carcinoma",
    "Stage IV Cutaneous (Skin) Melanoma",
    "Advanced Lung Non-Small Cell Carcinoma, Advanced Head and Neck Squamous Cell Cancer",
    "Hematologic and Lymphocytic Disorder",
    "Biochemically Recurrent Prostate Carcinoma",
    "Stage IIIB Ovarian Cancer",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Clear Cell Renal Cell Cancer",
    "Myelofibrosis, Myelodysplastic Syndrome",
    "Metastatic Angiosarcoma",
    "Classical Hodgkin Lymphoma",
    "Aplastic Anemia",
    "Soft Tissue Sarcoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Acute Myeloid Leukemia (AML)",
    "Invasive Breast Cancer",
    "Stage I Non-Small Cell Lung Cancer",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Bladder Urothelial Cancer",
    "Salivary Gland Cancer",
    "Liposarcoma",
    "Prostate Adenocarcinoma",
    "Metastatic Colorectal Carcinoma",
    "Stage IVB Cervical Cancer",
    "Stage III Adrenal Cortex Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Pancreatic Adenocarcinoma, Metastatic Colorectal Adenocarcinoma",
    "Metastatic Malignant Neoplasm to the Bone",
    "Refractory Adenovirus Infection",
    "Anal Squamous Cell Cancer",
    "Prostate Adenocarcinoma",
    "WHO Grade III Glioma",
    "Stage III Laryngeal Throat Squamous Cell Cancer",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Gastroesophageal Junction Adenocarcinoma",
    "Mycosis Fungoides",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Pancreatic Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Stage IV Cutaneous (Skin) T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Metastatic Prostatic Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor",
    "Advanced Prostate Carcinoma",
    "Lung Cancer",
    "Stage IIC Prostate Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Adenovirus Infection",
    "Recurrent Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Primary Central Nervous System Neoplasm",
    "Refractory Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Refractory Colorectal Cancer",
    "Metastatic Malignant Neoplasm",
    "Stage III Hepatocellular Cancer",
    "B Acute Lymphoblastic Leukemia",
    "Castration-Resistant Prostate Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Leukemia, Recurrent Leukemia",
    "Malignant Solid Tumor",
    "Astrocytoma",
    "Glioblastoma",
    "Stage I Prostate Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage I Breast Cancer",
    "Metastatic Thymic Carcinoma",
    "Metastatic Uveal Melanoma",
    "Metastatic Bone Sarcoma",
    "Bladder Urothelial Cancer",
    "Malignant Solid Tumor",
    "Prostate Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage III Non-Small Cell Lung Cancer",
    "Breast Cancer",
    "Malignant Neoplasm of the Thoracic Esophagus",
    "Metastatic Kidney Carcinoma",
    "Advanced Urothelial Cancer",
    "Small Cell Lung Cancer",
    "Gastric (Stomach) Adenocarcinoma, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8",
    "Stage II Esophageal Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Hodgkin Lymphoma",
    "Indolent B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Brain Neoplasm",
    "Stage IV Cutaneous (Skin) Melanoma",
    "Advanced Malignant Solid Tumor",
    "B-Cell Non-Hodgkin Lymphoma",
    "Prostate Adenocarcinoma",
    "Peritoneal Carcinomatosis",
    "Locally Advanced Soft Tissue Sarcoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Acute Myeloid Leukemia with t(9;11)(p21.3;q23.3); MLLT3-KMT2A",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Malignant Glioma",
    "Locally Advanced Rectal Carcinoma",
    "Stage III Hepatocellular Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Metastatic Basal Cell Carcinoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Invasive Ovarian Micropapillary Serous Carcinoma",
    "Hematologic and Lymphocytic Disorder",
    "Castration-Sensitive Prostate Carcinoma",
    "Supratentorial Glioblastoma",
    "Ductal Carcinoma In Situ (DCIS)",
    "Metastatic Pancreatic Adenocarcinoma",
    "Malignant Gastrointestinal Neoplasm",
    "Grade II Glioma",
    "Stage IV Prostate Cancer",
    "Unresectable Melanoma",
    "Non-Small Cell Lung Cancer",
    "Stage I Laryngeal Throat Squamous Cell Cancer",
    "Pancreatic Adenocarcinoma",
    "Refractory Barrett Esophagus",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Stage II Head and Neck Squamous Cell Cancer",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Stage IV Non-Small Cell Lung Cancer",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Fanconi Anemia, Acute Leukemia",
    "Recurrent Non-Small Cell Lung Cancer",
    "Prostate Small Cell Neuroendocrine Carcinoma, Bladder Small Cell Neuroendocrine Cancer",
    "High Grade Ovarian Serous Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Endometrial Adenocarcinoma, Recurrent Ovarian Cancer",
    "Glioblastoma",
    "Metastatic Kidney Medullary Carcinoma",
    "Localized Brain Neoplasm",
    "Pancreatic Ductal Adenocarcinoma",
    "Recurrent Osteosarcoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Biochemically Recurrent Prostate Carcinoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Recurrent Classical Hodgkin Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Leukoplakia",
    "Locally Advanced Malignant Solid Tumor",
    "Stage IV Pancreatic Cancer",
    "Metastatic Osteosarcoma",
    "Acute Lymphoblastic Leukemia (ALL), Hematopoietic and Lymphoid Cell Neoplasm",
    "Solid Tumor",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Stage II Breast Cancer",
    "Glioma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Follicular Lymphoma, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia (CLL)",
    "Chordoma",
    "Primary Myelofibrosis",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Breast Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Human Papillomavirus-Related Carcinoma",
    "BCLC Stage B Hepatocellular Cancer",
    "Metastatic Microsatellite Stable Colorectal Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia, Refractory Follicular Lymphoma",
    "Invasive Ductal Carcinoma, NOS",
    "Metastatic Pancreatic Adenocarcinoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Stage III Prostate Cancer",
    "Locally Advanced Soft Tissue Sarcoma",
    "Acute Myeloid Leukemia (AML)",
    "Stage IV Breast Cancer",
    "Lymphoproliferative Disorder",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Metastatic Soft Tissue Sarcoma",
    "Endometrial Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Malignant Mesothelioma",
    "Gastric Mucosa-Associated Lymphoid Tissue Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Breast Carcinoma",
    "Chronic Graft Versus Host Disease",
    "Anal Canal Squamous Cell Carcinoma",
    "Malignant Solid Tumor",
    "Stage III Uterine (including Endometrial) Cancer",
    "Mycosis Fungoides",
    "Malignant Solid Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Classical Hodgkin Lymphoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Cutaneous (Skin) Melanoma",
    "Stage IVB Lung Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Cigarette Smoking-Related Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Skin Squamous Cell Cancer",
    "Glioma",
    "Advanced Soft Tissue Sarcoma",
    "Malignant Leptomeningeal Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain",
    "Advanced Cutaneous Melanoma of the Extremity, Advanced Sarcoma of the Extremity",
    "Glioblastoma",
    "Breast Cancer",
    "Stage I Oropharyngeal Throat Squamous Cell Cancer",
    "Hypermutated Colorectal Carcinoma",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Neoplasm in the Brain",
    "Metastatic Urothelial Cancer",
    "Malignant Glioma",
    "Aggressive Non-Hodgkin Lymphoma",
    "Salivary Gland Cancer",
    "Castration-Resistant Prostate Cancer",
    "Myelodysplastic Syndrome, Hodgkin Lymphoma, Acute Lymphoblastic Leukemia (ALL)",
    "Advanced Malignant Solid Tumor",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIB Cutaneous (Skin) Melanoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Bladder Urothelial Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Locally Advanced Pancreatic Carcinoma",
    "Stage I Breast Cancer",
    "Stage IIIB Cutaneous (Skin) Melanoma",
    "Metastatic Breast Carcinoma",
    "Stage I Prostate Cancer",
    "Recurrent Central Nervous System Lymphoma",
    "Ovarian Cancer",
    "Localized Gastric Carcinoma",
    "Recurrent Classical Hodgkin Lymphoma",
    "Stage II Esophageal Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Hepatocellular Carcinoma",
    "Stage II Breast Cancer",
    "Stage IV Renal Cell Cancer",
    "Refractory Indolent Adult Non-Hodgkin Lymphoma",
    "Grade 1 Follicular Lymphoma",
    "High Grade Vulvar Squamous Intraepithelial Lesion",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Glioma, Invasive Breast Cancer",
    "Recurrent Prostate Cancer",
    "Cytomegaloviral Infection",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Pancreatic Cancer",
    "Hairy Cell Leukemia",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Anaplastic Kidney Wilms Tumor",
    "Hepatocellular Cancer",
    "Non-Small Cell Lung Cancer",
    "Stage I Soft Tissue Sarcoma of the Trunk and Extremities",
    "Non-Small Cell Lung Cancer",
    "Unresectable Pancreatic Cancer",
    "Stage IV Renal Cell Cancer",
    "Prostate Adenocarcinoma",
    "Extracranial Solid Tumor",
    "Endometrial Cancer",
    "Metastatic Thyroid Gland Medullary Carcinoma",
    "Metastatic Pheochromocytoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Hormone Receptor Positive Breast Carcinoma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Acute Myeloid Leukemia (AML)",
    "Burkitt Lymphoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Stage IIB Breast Cancer",
    "Metastatic Melanoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Malignant Solid Tumor",
    "Resectable Pancreatic Adenocarcinoma",
    "Digestive System Neuroendocrine Tumor",
    "Richter Syndrome",
    "Superficial Bladder Cancer",
    "Recurrent Head and Neck Carcinoma",
    "Malignant Solid Tumor",
    "Recurrent Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome",
    "Recurrent Malignant Glioma",
    "Unresectable Hepatocellular Cancer",
    "Prostate Adenocarcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Metastatic Melanoma",
    "Ductal Carcinoma In Situ (DCIS)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Malignant Brain Neoplasm",
    "Recurrent Malignant Solid Tumor",
    "Bladder Adenocarcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Bladder Urothelial Cancer",
    "Non-Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Cutaneous Angiosarcoma",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Hereditary Malignant Neoplasm",
    "Extensive Stage Small Cell Lung Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Grade III Glioma",
    "Lung Cancer",
    "Stage II Uterine (including Endometrial) Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Invasive Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Hepatocellular Cancer",
    "Stage III Ovarian Cancer",
    "Stage II Diffuse Large B-Cell Lymphoma",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Malignant Paraganglioma",
    "Recurrent Mantle Cell Lymphoma",
    "Unresectable Carcinoid Tumor",
    "Castration-Sensitive Prostate Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage I Uterine (including Endometrial) Cancer",
    "Advanced Melanoma",
    "Recurrent Myelodysplastic Syndrome",
    "Stage IV Lung Cancer",
    "Advanced Melanoma",
    "Invasive Breast Cancer",
    "Stage III Breast Cancer",
    "Recurrent Glioblastoma",
    "Invasive Breast Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Prostate Adenocarcinoma",
    "Malignant Female Reproductive System Neoplasm",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Oligodendroglioma",
    "Borderline Resectable Pancreatic Adenocarcinoma",
    "Unresectable Soft Tissue Sarcoma",
    "Essential Thrombocythemia",
    "Pancreatic Ductal Adenocarcinoma",
    "Bladder Urothelial Cancer",
    "Pancreatic Ductal Adenocarcinoma",
    "Invasive Breast Cancer",
    "Non-Neoplastic Hematologic and Lymphocytic Disorder",
    "Malignant Neoplasm",
    "Recurrent Hodgkin Lymphoma",
    "Multiple Myeloma/Plasma Cell Myeloma, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma",
    "Metastatic Prostate Cancer",
    "T-Cell Prolymphocytic Leukemia",
    "Metastatic Adenoid Cystic Cancer",
    "Breast Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Stage III Pancreatic Cancer",
    "Recurrent Glioblastoma, Breast Cancer",
    "Prostate Adenocarcinoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Breast Cancer",
    "Stage IIIA Lung Cancer",
    "Locally Advanced Urothelial Cancer",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Ductal Carcinoma In Situ (DCIS)",
    "Hereditary Breast and Ovarian Cancer Syndrome",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Recurrent Prostate Cancer",
    "Stage III Cutaneous (Skin) Melanoma",
    "MGMT-Unmethylated Glioblastoma",
    "Metastatic Microsatellite Stable Colorectal Carcinoma",
    "Glioblastoma",
    "Biochemically Recurrent Prostate Carcinoma",
    "Prostate Adenocarcinoma",
    "Metastatic Malignant Neoplasm to the Liver",
    "Metastatic Malignant Solid Tumor",
    "Peritoneal Desmoplastic Small Round Cell Tumor",
    "Hematopoietic and Lymphoid System Neoplasm",
    "Stage III Renal Cell Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Medulloblastoma",
    "Malignant Gastrointestinal Neoplasm",
    "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma",
    "Advanced Soft Tissue Sarcoma",
    "Clear Cell Renal Cell Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Laryngeal Throat Squamous Cell Cancer",
    "Prostate Cancer",
    "Castration-Resistant Prostate Cancer",
    "Gastric (Stomach) Adenocarcinoma",
    "Resectable Soft Tissue Sarcoma",
    "HER2 Negative Breast Carcinoma",
    "Malignant Genitourinary System Neoplasm",
    "Invasive Breast Cancer",
    "Advanced Non-Small Cell Squamous Lung Cancer",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Unresectable Esophageal Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Glioblastoma",
    "Metastatic High Grade Sarcoma",
    "Recurrent Mantle Cell Lymphoma",
    "Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Metabolic Bone Disorder",
    "Steroid Refractory Graft Versus Host Disease",
    "Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Recurrent Classical Hodgkin Lymphoma",
    "Recurrent Glioblastoma",
    "Unresectable Malignant Solid Tumor",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Essential Thrombocythemia",
    "Triple-Negative Breast Cancer",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent Meningioma",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Stage IB Esophageal Adenocarcinoma",
    "Recurrent Desmoplastic Small Round Cell Tumor",
    "Refractory Metastatic Pancreatic Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma, Recurrent Acute Myeloid Leukemia (AML), Recurrent Hodgkin Lymphoma, Hematopoietic and Lymphoid System Neoplasm",
    "Non-Squamous Non-Small Cell Lung Cancer",
    "Rectal Adenocarcinoma",
    "Stage III HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Borderline Resectable Pancreatic Adenocarcinoma",
    "Metastatic Gastric Carcinoma",
    "Metastatic Colorectal Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Prostatic Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Malignant Gastrointestinal Neoplasm",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Pancreatic Adenosquamous Cancer",
    "Advanced Malignant Solid Tumor",
    "Microsatellite Stable Colorectal Carcinoma, Pancreatic Adenocarcinoma",
    "Metastatic Breast Carcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Advanced Well Differentiated Neuroendocrine Neoplasm",
    "Resectable Lung Non-Small Cell Carcinoma, Resectable Hepatocellular Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Melanoma",
    "High Grade Cervical Intraepithelial Neoplasia",
    "Non-Hodgkin Lymphoma, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Recurrent Classical Hodgkin Lymphoma",
    "Recurrent Mature B-Cell Non-Hodgkin Lymphoma, Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Stage IIIB Cutaneous (Skin) Melanoma",
    "Invasive Breast Cancer",
    "Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Malignant Gastrointestinal Neoplasm",
    "Acute Myeloid Leukemia (AML)",
    "Prostate Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed, Malignant Solid Tumor",
    "Stage III Esophageal Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Neoplasm",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Resectable Pancreatic Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Malignant Gastrointestinal Neoplasm",
    "Chronic Myelomonocytic Leukemia (CMML), Recurrent Myelodysplastic Syndrome",
    "Recurrent Glioblastoma",
    "Colorectal Polyp",
    "Stage IIIC Gastric (Stomach) Cancer",
    "Recurrent Oropharyngeal Throat Cancer",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Gastric Adenocarcinoma",
    "Glioblastoma",
    "Metastatic Colorectal Carcinoma",
    "Recurrent Colorectal (Colon or Rectal) Cancer",
    "Recurrent Myeloid Neoplasm",
    "Head and Neck Squamous Cell Carcinoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Resectable Pancreatic Cancer",
    "Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Breast Carcinoma",
    "Prostate Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Epidermolysis Bullosa Dystrophica, Autosomal Recessive, Metastatic Skin Squamous Cell Carcinoma",
    "Diffuse Intrinsic Pontine Glioma",
    "Myelodysplastic Syndrome",
    "Metastatic Melanoma",
    "Acute Myeloid Leukemia (AML)",
    "Mantle Cell Lymphoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Acute Myeloid Leukemia (AML), Mantle Cell Lymphoma, Myelodysplastic Syndrome",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Diffuse Midline Glioma, H3 K27M-Mutant",
    "Malignant Abdominal Neoplasm",
    "Ocular Graft Versus Host Disease",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Non-Hodgkin Lymphoma",
    "Prostate Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Gastric Adenocarcinoma",
    "Non-Small Cell Lung Cancer",
    "Chronic Graft Versus Host Disease",
    "Malignant Abdominal Neoplasm",
    "Recurrent Malignant Brain Neoplasm",
    "Glioblastoma",
    "Triple-Negative Breast Cancer",
    "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Philadelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Recurrent T-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Neoplasm to the Spine",
    "Sarcoma of the Extremity",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Metastatic Gastric Adenocarcinoma",
    "Recurrent Glioblastoma",
    "Metastatic Malignant Digestive System Neoplasm",
    "Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Glioblastoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Renal Pelvis and Ureter Urothelial Cancer",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Aggressive Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Stage I Hepatocellular Cancer",
    "Myelodysplastic Syndrome",
    "Bronchiolitis Obliterans",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Locally Advanced High Grade Sarcoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection",
    "Fibrolamellar Cancer",
    "Stage I Breast Cancer",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Endometrial Carcinoma",
    "Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Skin Squamous Cell Cancer",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Stage II Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Metastatic Breast Carcinoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Essential Thrombocythemia",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Adenocarcinoma",
    "Diffuse Intrinsic Pontine Glioma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Renal Cell Cancer",
    "Castration-Sensitive Prostate Carcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Chondrosarcoma, Grade 2",
    "Acute Leukemia",
    "Chronic Myeloproliferative Disease",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Cancer-related Cognitive Difficulties, Malignant Solid Tumor",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Recurrent Rhabdomyosarcoma",
    "Primary Brain Neoplasm",
    "Prostate Adenocarcinoma",
    "Locally Advanced Intrahepatic Cholangiocarcinoma",
    "Kaposi Sarcoma",
    "Hormone Receptor Positive Breast Carcinoma",
    "Stage I Prostate Cancer",
    "Metastatic Breast Carcinoma",
    "Metastatic Cholangiocarcinoma",
    "Stage IIB Gastric (Stomach) Cancer",
    "T-Cell Prolymphocytic Leukemia",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Mucosal Melanoma",
    "Locally Advanced Thyroid Gland Carcinoma",
    "Recurrent Hairy Cell Leukemia",
    "Advanced Urothelial Cancer",
    "Basal Cell Carcinoma",
    "Refractory Hairy Cell Leukemia",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Hepatocellular Carcinoma",
    "Triple-Negative Breast Cancer",
    "Indolent B-Cell Non-Hodgkin Lymphoma",
    "Stage IV Lung Cancer",
    "Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Recurrent Malignant Brain Neoplasm",
    "Prostate Adenocarcinoma",
    "Castration-Resistant Prostate Cancer",
    "Monomorphic B-Cell Post-Transplant Lymphoproliferative Disorder",
    "Metastatic Neuroendocrine Neoplasm",
    "Hematologic and Lymphocytic Disorder",
    "Primary Immunodeficiency Syndrome",
    "Stage IV Lung Cancer",
    "Retinoblastoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Breast Carcinoma",
    "Stage I Breast Cancer",
    "Locally Advanced Rectal Carcinoma",
    "Hormone Receptor Positive Breast Carcinoma",
    "Metastatic Digestive System Cancer",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Primary Myelofibrosis",
    "Locally Advanced Clear Cell Renal Cell Carcinoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Extensive Stage Small Cell Lung Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Advanced Malignant Solid Tumor",
    "Head and Neck Squamous Cell Carcinoma",
    "Metastatic Cutaneous Melanoma",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Platinum Sensitive Ovarian Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed, Malignant Solid Tumor",
    "Unresectable Fibrolamellar Carcinoma",
    "Systemic Scleroderma",
    "Advanced Malignant Solid Tumor",
    "Stage IIIA Bladder Cancer",
    "Primary Myelofibrosis",
    "Bladder Urothelial Cancer",
    "Stage III Uterine (including Endometrial) Cancer",
    "Metastatic Malignant Solid Tumor",
    "Unresectable Clear Cell Renal Cell Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Metastatic Malignant Female Reproductive System Neoplasm",
    "Glioblastoma",
    "Non-Small Cell Lung Cancer",
    "Recurrent Cutaneous (Skin) Melanoma",
    "Stage I Head and Neck Squamous Cell Cancer",
    "Stage III Grade 1 Follicular Lymphoma",
    "Malignant Solid Tumor",
    "Chronic Myelomonocytic Leukemia-0",
    "Neuroendocrine Tumor",
    "Stage I Ovarian Cancer",
    "Metastatic Digestive System Cancer",
    "Malignant Brain Tumor",
    "Recurrent Cutaneous (Skin) Melanoma",
    "Biochemically Recurrent Prostate Carcinoma",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Unresectable Vulvar Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Human Papillomavirus-Related Malignant Neoplasm",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Liposarcoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Advanced Hepatocellular Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Malignant Solid Tumor",
    "Stage II Follicular Lymphoma",
    "Locally Advanced Unresectable Pancreatic Adenocarcinoma",
    "Advanced Head and Neck Squamous Cell Cancer",
    "Stage IA Breast Cancer",
    "Early-Stage Breast Cancer",
    "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma",
    "Breast Cancer",
    "Central Nervous System Lymphoma",
    "Recurrent Lymphoproliferative Disorder",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage III Cutaneous (Skin) Melanoma",
    "Prostate Cancer",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Malignant Solid Tumor",
    "Recurrent Ovarian Cancer, Recurrent Endometrial Carcinoma",
    "Unresectable Hepatocellular Cancer",
    "Stage I Renal Cell Cancer",
    "Ovarian Tumor",
    "Acute Myeloid Leukemia (AML), Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm",
    "Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Mantle Cell Lymphoma",
    "Glioblastoma",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Recurrent Glioblastoma",
    "Castration-Sensitive Prostate Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Double-Hit Lymphoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Invasive Breast Cancer",
    "Head and Neck Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Mantle Cell Lymphoma",
    "Locally Advanced Pancreatic Ductal Adenocarcinoma",
    "Metastatic Non-Small Cell Carcinoma",
    "Prostate Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Myelodysplastic Syndrome",
    "Acute Myeloid Leukemia with Gene Mutations",
    "Unresectable Melanoma",
    "Advanced Renal Cell Carcinoma, Advanced Melanoma",
    "Non-Small Cell Lung Cancer",
    "Stage III Hepatocellular Cancer",
    "Asymptomatic COVID-19 Infection Laboratory-Confirmed",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Non-Small Cell Lung Cancer",
    "Soft Tissue Sarcoma",
    "Bladder Urothelial Cancer",
    "B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Malignant Brain Tumor",
    "Gastroesophageal Junction Adenocarcinoma",
    "Locally Advanced Colorectal Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma",
    "Chronic Lymphocytic Leukemia (CLL), Acute Myeloid Leukemia (AML)",
    "Recurrent B Acute Lymphoblastic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma",
    "Stage IIIA Uterine (including Endometrial) Cancer, Stage I Cervical Cancer FIGO 2018",
    "Malignant Mesothelioma",
    "Metastatic Lung Small Cell Carcinoma",
    "Metastatic Malignant Female Reproductive System Neoplasm",
    "Diffuse Large B-Cell Lymphoma",
    "Primary Myelofibrosis",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Unresectable Hepatocellular Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Breast Adenocarcinoma",
    "Central Nervous System Germ Cell Tumor",
    "Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Gastric (Stomach) Adenocarcinoma",
    "Resectable Malignant Pleural Mesothelioma",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Melanoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Prostate Adenocarcinoma",
    "Recurrent Glioblastoma",
    "Recurrent Malignant Solid Tumor",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Breast Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Breast Adenocarcinoma",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Non-Small Cell Lung Cancer",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Unresectable Hepatocellular Cancer",
    "Non-Small Cell Lung Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Primary Myelofibrosis",
    "Unresectable Well Differentiated Neuroendocrine Neoplasm",
    "Metastatic Digestive System Neuroendocrine Neoplasm",
    "Hereditary Breast Cancer, Hereditary Ovarian Cancer",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Stage IV Lung Cancer",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Myelodysplastic Syndrome",
    "Metastatic Uveal Melanoma",
    "Metastatic Thyroid Gland Anaplastic Carcinoma",
    "Skin Basal Cell Cancer",
    "Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Glioblastoma",
    "Diffuse Large B-Cell Lymphoma",
    "Head and Neck Squamous Cell Carcinoma",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Early-Stage Breast Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Metastatic Melanoma",
    "Stage I Soft Tissue Sarcoma of the Trunk and Extremities",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Supratentorial Glioblastoma",
    "Locally Advanced Soft Tissue Sarcoma",
    "Pleural Malignant Mesothelioma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Melanoma",
    "Gastric (Stomach) Cancer",
    "Stage IA2 Lung Cancer",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Colorectal Carcinoma",
    "Refractory Follicular Lymphoma",
    "Metastatic Breast Carcinoma",
    "Glioblastoma",
    "Type 1 Diabetes Mellitus",
    "Melanoma",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Metastatic Colorectal Carcinoma",
    "Refractory Non-Hodgkin Lymphoma",
    "Unresectable Renal Cell Carcinoma",
    "Cigarette Smoking-Related Carcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Stage III Hepatocellular Cancer",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Platinum-Resistant Ovarian Cancer",
    "Digestive System Neuroendocrine Tumor",
    "Recurrent Small Cell Lung Cancer",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Human Papillomavirus (HPV)-Related Cervical Cancer",
    "Invasive Breast Cancer",
    "Monoclonal Gammopathy of Renal Significance",
    "Thoracic Esophagus Adenocarcinoma",
    "Metastatic Colorectal Carcinoma",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Secondary Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome",
    "Thyroid Gland Papillary Microcarcinoma",
    "Grade II Glioma",
    "Recurrent Malignant Head and Neck Neoplasm",
    "Prostate Adenocarcinoma",
    "Stage II Lung Cancer",
    "Mantle Cell Lymphoma",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer",
    "Malignant Solid Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Rectal Adenocarcinoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Melanoma",
    "Chronic Myelomonocytic Leukemia (CMML)",
    "Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia (CLL)",
    "Resectable Hepatocellular Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Meningioma",
    "Recurrent Metastatic Malignant Neoplasm in the Leptomeninges",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Recurrent Dedifferentiated Liposarcoma",
    "Non-Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Platinum-Resistant Ovarian Carcinoma",
    "Unresectable Ovarian Carcinoma, Unresectable Breast Carcinoma, Unresectable Pancreatic Cancer",
    "Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Locally Advanced Rectal Adenocarcinoma",
    "Triple-Negative Breast Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Esophageal Adenocarcinoma",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Malignant Neoplasm to the Liver",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Glioblastoma",
    "Metastatic Malignant Solid Tumor",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage I Cutaneous (Skin) Melanoma",
    "Neuroendocrine Cancer, Small Cell Lung Cancer",
    "Rectal Adenocarcinoma",
    "Metastatic Ovarian Carcinoma, Metastatic Prostate Cancer, Metastatic Breast Carcinoma",
    "Locally Advanced Intrahepatic Cholangiocarcinoma",
    "Advanced Skin Squamous Cell Carcinoma",
    "Influenza, Hematopoietic and Lymphoid Cell Neoplasm",
    "Cervical Intraepithelial Neoplasia",
    "Lung Cancer",
    "Metastatic Uveal Melanoma",
    "Recurrent Respiratory Papillomatosis",
    "Locally Recurrent Uterine Corpus Leiomyosarcoma",
    "Extensive Stage Small Cell Lung Cancer",
    "Metastatic Uveal Melanoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Brain Neoplasm",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia-1",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IIIA Breast Cancer",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Bile Duct Cancer (including Cholangiocarcinoma), Pancreatic Ductal Adenocarcinoma",
    "Myelodysplastic Syndrome",
    "Stage IIIB Cutaneous (Skin) Melanoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Basal Cell Carcinoma",
    "Refractory High-Grade B-Cell Lymphoma",
    "Stage I Mediastinal (Thymic) Large B-Cell Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like",
    "Recurrent Follicular Lymphoma, Recurrent Endometrial Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm",
    "Platinum-Resistant Ovarian Cancer",
    "AL Amyloidosis",
    "Metastatic Breast Carcinoma",
    "Diffuse Astrocytoma, IDH-Wildtype",
    "Malignant Thyroid Gland Neoplasm",
    "Metastatic Colorectal Carcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Gastric (Stomach) Adenocarcinoma",
    "Metastatic Breast Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Mantle Cell Lymphoma",
    "Triple-Negative Breast Cancer",
    "Metastatic Malignant Solid Tumor",
    "T-Cell Non-Hodgkin Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "BCLC Stage C Hepatocellular Cancer",
    "Advanced Malignant Digestive System Neoplasm",
    "Recurrent Ovarian Cancer",
    "Mantle Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Myelodysplastic Syndrome",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Nongerminomatous Germ Cell Tumor",
    "Diffuse Midline Glioma, H3 K27M-Mutant",
    "Stage II Ovarian Cancer",
    "Metastatic Skin Squamous Cell Carcinoma",
    "Skin Squamous Cell Cancer",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Locally Advanced Well Differentiated Neuroendocrine Neoplasm",
    "Recurrent Rectal Adenocarcinoma",
    "Mixed Phenotype Acute Leukemia",
    "Advanced Hepatocellular Carcinoma",
    "Locally Advanced Hepatocellular Carcinoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Non-Small Cell Lung Cancer",
    "Refractory Indolent Non-Hodgkin Lymphoma",
    "Recurrent Triple-Negative Breast Carcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Malignant Mesothelioma",
    "Stage IIA Breast Cancer",
    "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma",
    "Malignant Solid Tumor, Head and Neck Squamous Cell Carcinoma",
    "Metastatic Small Cell Neuroendocrine Prostate Cancer",
    "Recurrent Urothelial Cancer",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Triple-Negative Breast Cancer",
    "Stage 0 Breast Cancer",
    "Diffuse Large B-Cell Lymphoma",
    "Breast Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Advanced Urothelial Cancer",
    "Resectable Hepatocellular Cancer",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Locally Advanced Urothelial Cancer",
    "Recurrent Glioblastoma",
    "Pathologic Stage II Merkel Cell Carcinoma AJCC v8",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Refractory Hodgkin Lymphoma",
    "Recurrent Mantle Cell Lymphoma",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Stage I Cutaneous (Skin) Melanoma",
    "Refractory Malignant Germ Cell Tumor",
    "Metastatic Thyroid Gland Medullary Carcinoma",
    "Metastatic Urothelial Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Leukemia",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Pancreatic Ductal Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Differentiated Thyroid Gland Carcinoma",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Unresectable Pleural Malignant Mesothelioma",
    "Atypical Endometrial Hyperplasia",
    "Metastatic Breast Carcinoma",
    "Refractory Ewing Sarcoma, Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Melanoma",
    "Recurrent Endometrial Carcinoma",
    "Acute Graft Versus Host Disease",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Prostate Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Locally Advanced Kidney Carcinoma",
    "Low Grade Glioma",
    "Metastatic Breast Carcinoma",
    "Recurrent Extracranial Malignant Solid Neoplasm",
    "Neuroblastoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Borderline Resectable Pancreatic Adenocarcinoma",
    "Malignant Solid Tumor",
    "High-Risk Neuroblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Colorectal Adenocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Unresectable Melanoma",
    "Wilms Tumor",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Clinical Stage IIA Merkel Cell Carcinoma AJCC v8",
    "Prostate Cancer",
    "COVID-19, Lymphoma, Leukemia, Hematopoietic and Lymphoid System Neoplasm, Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Myelomonocytic Leukemia (CMML), Myelodysplastic Syndrome",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Unresectable Melanoma",
    "Stage II Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Breast Adenocarcinoma",
    "Recurrent Malignant Solid Tumor",
    "Diffuse Midline Glioma, H3 K27M-Mutant",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Undifferentiated Pleomorphic Sarcoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Breast Cancer, Colorectal (Colon or Rectal) Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Indolent B-Cell Non-Hodgkin Lymphoma",
    "Locally Advanced Angiosarcoma",
    "Malignant Solid Tumor",
    "Refractory Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia (CMML)",
    "Myeloid Leukemia",
    "Colorectal (Colon or Rectal) Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Prostate Cancer",
    "Breast Cancer",
    "Hormone Receptor Positive Breast Carcinoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Aggressive NK-Cell Leukemia, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Metastatic Skin Squamous Cell Carcinoma",
    "Unresectable Pleural Malignant Mesothelioma",
    "Prostate Adenocarcinoma",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "High Grade Ovarian Serous Adenocarcinoma",
    "HHV8-Positive Multicentric Castleman Disease",
    "Breast Cancer",
    "Hairy Cell Leukemia",
    "Malignant Solid Tumor",
    "KSHV Inflammatory Cytokine Syndrome",
    "Locally Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Pancreatic Cancer",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Glioblastoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Prostate Adenocarcinoma",
    "Leukemia, Hematopoietic and Lymphoid System Neoplasm, Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Chronic Graft Versus Host Disease",
    "Prostate Adenocarcinoma",
    "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
    "Metastatic Breast Carcinoma",
    "Stage I Prostate Adenocarcinoma",
    "Head and Neck Squamous Cell Carcinoma",
    "Stage IV Squamous Cell Lung Cancer",
    "Non-Hodgkin Lymphoma",
    "Refractory Adult T-Cell Leukemia/Lymphoma",
    "Recurrent Malignant Brain Neoplasm",
    "Stage IV Thyroid Gland Medullary Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor",
    "Stage IV Non-Small Cell Lung Cancer",
    "Adult T-Cell Leukemia/Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "High Grade Ductal Breast Carcinoma In Situ",
    "Triple-Negative Breast Cancer",
    "Stage IIIB Non-Small Cell Lung Cancer",
    "Stage II Bladder Cancer",
    "Recurrent Malignant Solid Tumor",
    "High Grade Cervical Squamous Intraepithelial Neoplasia",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Prostate Adenocarcinoma",
    "Clear Cell Renal Cell Cancer",
    "Metastatic Chordoma",
    "Bladder Urothelial Cancer",
    "Triple-Negative Breast Cancer",
    "Recurrent Triple-Negative Breast Carcinoma, Recurrent Ovarian Cancer, Endometrial Cancer",
    "Refractory B Acute Lymphoblastic Leukemia",
    "Invasive Breast Cancer",
    "Stage IV Lung Cancer",
    "Lymphoma",
    "Platinum-Resistant Ovarian Cancer",
    "Stage III Non-Small Cell Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Unresectable Merkel Cell Carcinoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Prostate Adenocarcinoma",
    "Breast Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Breast Adenocarcinoma",
    "Dedifferentiated Liposarcoma",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Malignant Glioma",
    "Advanced Non-Small Cell Squamous Lung Cancer",
    "Stage IV Bladder Urothelial Cancer",
    "Oral Cavity Squamous Cell Cancer",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Hepatocellular Carcinoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage IIIC Lung Cancer",
    "Refractory B Acute Lymphoblastic Leukemia",
    "Malignant Female Reproductive System Neoplasm",
    "Recurrent Neuroblastoma",
    "Advanced Malignant Solid Tumor",
    "Diffuse Large B-Cell Lymphoma",
    "Metastatic Breast Adenocarcinoma",
    "Stage IV Cutaneous (Skin) Melanoma",
    "Stage III Breast Cancer",
    "Stage IIIB Colorectal (Colon or Rectal) Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Neuroendocrine Tumor",
    "Recurrent Ovarian Cancer",
    "Recurrent Malignant Solid Tumor",
    "Skin Basal Cell Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Non-Hodgkin Lymphoma",
    "Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Prostate Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Severe Aplastic Anemia",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Advanced Urothelial Cancer",
    "Pancreatic Adenocarcinoma",
    "Rectal Adenocarcinoma",
    "HER2 Negative Breast Carcinoma",
    "Prostate Adenocarcinoma",
    "Recurrent Ovarian Cancer",
    "Stage IV Breast Cancer",
    "Stage I Breast Cancer",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Cervical Adenocarcinoma",
    "Stage IV Cutaneous (Skin) Melanoma",
    "Refractory Central Nervous System Neoplasm",
    "Metastatic Cervical Squamous Cell Carcinoma",
    "Cytomegaloviral Infection",
    "Non-Small Cell Lung Cancer",
    "Recurrent Endometrial Serous Adenocarcinoma",
    "Recurrent Extensive Stage Lung Small Cell Carcinoma",
    "Recurrent Glioblastoma",
    "Metastatic Malignant Solid Tumor",
    "Stage IV Head and Neck Squamous Cell Cancer",
    "Stage IV Lung Cancer",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Stage III Colorectal (Colon or Rectal) Cancer",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Recurrent Classical Hodgkin Lymphoma",
    "Metastatic Breast Carcinoma",
    "Stage IVA Prostate Cancer",
    "Glioblastoma",
    "Castration-Resistant Prostate Cancer",
    "Prostate Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Endometrial Serous Adenocarcinoma",
    "Oral Cavity Squamous Cell Cancer",
    "Lung Neoplasm",
    "Metastatic Melanoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Richter Syndrome",
    "Recurrent Osteosarcoma",
    "Rectal Adenocarcinoma",
    "Follicular Lymphoma",
    "Platinum-Resistant Ovarian Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Grade I Meningioma",
    "Metastatic Breast Carcinoma",
    "Non-Small Cell Lung Cancer",
    "Advanced Bile Duct Carcinoma",
    "Non-Small Cell Lung Cancer",
    "Stage III Breast Cancer",
    "Non-Small Cell Lung Cancer",
    "Glioblastoma",
    "Advanced Hepatocellular Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Platinum-Resistant Ovarian Cancer",
    "Low Grade Glioma",
    "Advanced Sarcoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Stage IV Lung Cancer",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Malignant Glioma",
    "Waldenstrom Macroglobulinemia",
    "Malignant Solid Tumor",
    "Resectable Undifferentiated Pleomorphic Sarcoma",
    "Locally Advanced Triple-Negative Breast Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Skin Squamous Cell Carcinoma",
    "Advanced Carcinoid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Neuroblastoma",
    "Metastatic Skin Squamous Cell Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Malignant Central Nervous System Neoplasm",
    "Intracranial Neoplasm",
    "Hepatocellular Cancer",
    "Stage IV Head and Neck Squamous Cell Cancer",
    "Stage IV Colon Cancer",
    "Chronic Graft Versus Host Disease",
    "Locally Advanced Malignant Solid Tumor",
    "Peritoneal Carcinomatosis",
    "Advanced Skin Squamous Cell Carcinoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma",
    "Lymphoblastic Lymphoma, Acute Lymphoblastic Leukemia (ALL)",
    "Recurrent Ependymoma",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Stage I HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Lung Cancer",
    "Malignant Gastrointestinal Neoplasm",
    "Malignant Solid Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Invasive Breast Cancer",
    "Advanced Leukemia",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Stage IV Ovarian Cancer",
    "Locally Advanced Cervical Squamous Cell Carcinoma",
    "Invasive Breast Cancer",
    "Recurrent Central Nervous System Lymphoma",
    "Extensive Stage Small Cell Lung Cancer",
    "Stage III Major Salivary Gland Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Chronic Myelogenous Leukemia (CML)",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent B Acute Lymphoblastic Leukemia",
    "Malignant Brain Glioma",
    "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
    "Recurrent Mantle Cell Lymphoma",
    "Recurrent Ewing Sarcoma",
    "Stage IV Pancreatic Cancer",
    "Recurrent Plasmablastic Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Urothelial Cancer",
    "Refractory Endometrial Carcinoma",
    "Locally Advanced Bladder Urothelial Carcinoma",
    "Castration-Resistant Prostate Cancer",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Pancreatic Ductal Adenocarcinoma, Malignant Lung Neoplasm",
    "Acute Myeloid Leukemia (AML)",
    "Stage IA Hepatocellular Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Castration-Resistant Prostate Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Head and Neck Carcinoma",
    "Metastatic Adenoid Cystic Cancer",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Melanoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Recurrent Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Prostate Cancer",
    "Advanced Salivary Gland Carcinoma",
    "Recurrent B Lymphoblastic Lymphoma, Recurrent B Acute Lymphoblastic Leukemia",
    "Advanced Head and Neck Squamous Cell Cancer",
    "Autoimmune Disease",
    "Lymphoproliferative Disorder",
    "Diffuse Large B-Cell Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Medulloblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Glioblastoma",
    "Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma",
    "Complex Endometrial Hyperplasia with Atypia",
    "Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Stage II Breast Cancer",
    "Glioblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent EBV-Related Lymphoma",
    "Recurrent Ovarian Cancer",
    "Stage I Breast Cancer",
    "Recurrent Primary Central Nervous System Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Myelodysplastic Syndrome",
    "Recurrent Osteosarcoma",
    "Recurrent Malignant Central Nervous System Neoplasm, Refractory Malignant Solid Tumor",
    "Recurrent Meningioma",
    "Stage IA Breast Cancer",
    "Metastatic Malignant Neoplasm to the Central Nervous System",
    "Aggressive Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Grade 1 Follicular Lymphoma",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Hodgkin Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Metastatic Malignant Neoplasm",
    "Recurrent Acute Lymphoblastic Leukemia, Recurrent Non-Hodgkin Lymphoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Unresectable Digestive System Adenocarcinoma",
    "Stage IIA Lung Cancer",
    "Soft Tissue Sarcoma",
    "HER2-Positive Breast Carcinoma",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "High Grade Vulvar Squamous Intraepithelial Lesion",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent B Acute Lymphoblastic Leukemia, Untreated Acute Lymphoblastic Leukemia (ALL)",
    "Metastatic Malignant Digestive System Neoplasm",
    "Castration-Resistant Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Digestive System Neoplasm",
    "Metastatic Breast Carcinoma",
    "Stage IV Lung Cancer",
    "Stage I Breast Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Oral Cavity Squamous Cell Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid System Neoplasm",
    "Locally Advanced Bile Duct Cancer",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Non-Small Cell Lung Cancer",
    "Recurrent Endometrial Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Ph-Like Acute Lymphoblastic Leukemia",
    "Stage IV Non-Small Cell Lung Cancer",
    "Anaplastic Large Cell Lymphoma",
    "Colorectal (Colon or Rectal) Adenocarcinoma",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Metastatic Ovarian Carcinoma, Metastatic Digestive System Cancer",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Recurrent Classical Hodgkin Lymphoma",
    "Castration-Sensitive Prostate Carcinoma",
    "Triple-Negative Breast Cancer",
    "Metastatic Prostate Cancer",
    "Recurrent Ovarian Cancer",
    "Metastatic Digestive System Neuroendocrine Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Endometrial Serous Adenocarcinoma",
    "Malignant Gastrointestinal Neoplasm",
    "Prostate Adenocarcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Stage IV Lung Cancer",
    "Resectable Malignant Pleural Mesothelioma",
    "Recurrent Glioma",
    "Metastatic Salivary Gland Carcinoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Breast Carcinoma",
    "Triple-Negative Breast Cancer",
    "Stage III Colorectal (Colon or Rectal) Cancer",
    "Stage IIIC Prostate Cancer",
    "Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
    "Metastatic Malignant Solid Tumor",
    "Viral Infection, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Hematopoietic and Lymphoid System Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Breast Cancer",
    "Advanced Cutaneous Melanoma",
    "Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Stage IIA Esophageal Adenocarcinoma",
    "Chronic Graft Versus Host Disease",
    "Rectal Adenocarcinoma",
    "Refractory Non-Hodgkin Lymphoma",
    "Stage IV Pancreatic Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma, Glioblastoma, IDH-Wildtype",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "High-Grade Treatment-Related Myeloid Neoplasm",
    "Stage IIA Prostate Cancer",
    "Waldenstrom Macroglobulinemia",
    "Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Resectable Skin Squamous Cell Carcinoma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Diffuse Large B-Cell Lymphoma",
    "Limited Stage Small Cell Lung Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Recurrent Osteosarcoma",
    "Recurrent Central Nervous System Lymphoma",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed",
    "Stage IA Breast Cancer",
    "Stage I Breast Cancer",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Stage II Pancreatic Cancer",
    "Hemophagocytic Lymphohistiocytosis",
    "Metastatic Soft Tissue Sarcoma",
    "Cervical Cancer, Endometrial Cancer",
    "Glioblastoma, IDH-Wildtype",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Lung Cancer",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Endometrial Cancer",
    "Stage III Cutaneous (Skin) Melanoma",
    "Stage IIIA Prostate Cancer",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Prostatic Adenocarcinoma",
    "Mantle Cell Lymphoma",
    "Recurrent Salivary Gland Cancer",
    "Recurrent Classical Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Dyskeratosis Congenita",
    "Recurrent Rhabdomyosarcoma, Recurrent Ewing Sarcoma",
    "Refractory Urothelial Carcinoma",
    "Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage I Breast Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Triple-Negative Breast Cancer",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Malignant Solid Tumor",
    "Stage IB Mycosis Fungoides and Sezary Syndrome",
    "Recurrent Classical Hodgkin Lymphoma",
    "Gastric (Stomach) Adenocarcinoma",
    "Stage I Breast Cancer",
    "Breast Adenocarcinoma",
    "Recurrent Endometrial Carcinoma",
    "Richter Syndrome",
    "Stage IV Non-Small Cell Lung Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage III Renal Cell Cancer",
    "Stage IB Gastric (Stomach) Cancer",
    "Acute Adult T-Cell Leukemia/Lymphoma",
    "Nasopharyngeal Throat Nonkeratinizing Cancer, Nasopharyngeal-Type Undifferentiated Carcinoma",
    "Invasive Breast Cancer",
    "Advanced Leukemia, Recurrent Leukemia",
    "Pancreatic Adenocarcinoma, Colorectal (Colon or Rectal) Adenocarcinoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Stage I Non-Small Cell Lung Cancer",
    "Metastatic Colorectal Carcinoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Recurrent Glioblastoma",
    "Recurrent Glioblastoma",
    "Stage IIIC Breast Cancer",
    "ENSAT Stage III Adrenal Cortex Cancer",
    "Metastatic Pancreatic Carcinoma",
    "Stage III Uterine (including Endometrial) Cancer",
    "Diffuse Large B-Cell Lymphoma Unclassifiable",
    "Hematopoietic and Lymphoid System Disorder, Cytomegaloviral Infection, Malignant Solid Tumor",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Hypereosinophilic Syndrome",
    "Advanced Malignant Solid Tumor",
    "Stage III Colorectal (Colon or Rectal) Cancer",
    "Mantle Cell Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Unresectable Melanoma",
    "Gastroesophageal Junction Adenocarcinoma",
    "Metastatic Bile Duct Carcinoma",
    "Stage IIIC Breast Cancer",
    "Recurrent Cervical Cancer",
    "Advanced Cholangiocarcinoma",
    "Recurrent Hepatocellular Cancer",
    "Stage IIIA Vulvar Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Biliary Tract Carcinoma",
    "Invasive Ductal Carcinoma, NOS",
    "Head and Neck Squamous Cell Carcinoma",
    "Metastatic Cutaneous Melanoma",
    "Stage II Lung Cancer",
    "Metastatic Pancreatic Carcinoma",
    "Metastatic Renal Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Acute Promyelocytic Leukemia with PML-RARA",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Malignant Female Reproductive System Neoplasm",
    "Metastatic Malignant Neoplasm",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Malignant Solid Tumor",
    "Invasive Breast Cancer",
    "Recurrent Endometrial Carcinoma",
    "Recurrent Glioblastoma",
    "Prostate Adenocarcinoma",
    "Metastatic Malignant Neoplasm in the Brain",
    "Myelodysplastic Syndrome, Acute Myeloid Leukemia (AML)",
    "Mantle Cell Lymphoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent T Lymphoblastic Leukemia/Lymphoma",
    "Acute Myeloid Leukemia (AML) Arising from Previous Myelodysplastic Syndrome",
    "Metastatic Malignant Neoplasm in the Brain",
    "Non-Small Cell Lung Cancer",
    "Non-Small Cell Lung Cancer",
    "Ocular Melanoma",
    "B Acute Lymphoblastic Leukemia, BCR-ABL1-Like",
    "Recurrent Gastric Adenocarcinoma",
    "Biochemically Recurrent Prostate Carcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Hematopoietic and Lymphoid System Neoplasm",
    "Chronic Myelomonocytic Leukemia (CMML)",
    "Recurrent Myelodysplastic Syndrome",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIA Breast Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IV Breast Cancer",
    "Castration-Sensitive Prostate Carcinoma",
    "Osteosarcoma",
    "Triple-Negative Breast Cancer",
    "Metastatic Colorectal Carcinoma",
    "Metastatic Colorectal Carcinoma",
    "Grade II Glioma",
    "Unresectable Leiomyosarcoma",
    "Neurofibromatosis Type 2",
    "Metastatic Pancreatic Carcinoma",
    "Recurrent Malignant Solid Tumor, Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Grade II Glioma",
    "Endometrial Endometrioid Adenocarcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Stage III Gastric (Stomach) Cancer",
    "Malignant Glioma",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Early-Stage Breast Cancer",
    "Recurrent Rectal Cancer, Recurrent Anal Canal Cancer",
    "Stage IV Prostate Cancer",
    "Triple-Negative Breast Cancer",
    "T Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia",
    "Advanced Malignant Solid Tumor",
    "Stage IIIC Breast Cancer",
    "Stage III Gastric (Stomach) Cancer",
    "Breast Adenocarcinoma",
    "Metastatic Breast Carcinoma",
    "Stage I Prostate Adenocarcinoma",
    "Metastatic Renal Cell Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Graft Versus Host Disease",
    "Recurrent Malignant Solid Tumor, Hematopoietic and Lymphoid System Neoplasm",
    "Non-Small Cell Lung Cancer",
    "Malignant Lung Neoplasm",
    "Metastatic Breast Carcinoma",
    "Recurrent Glioblastoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "HER2-Positive Breast Carcinoma",
    "Stage IIA Breast Cancer",
    "Metastatic Malignant Neoplasm in the Brain",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Stage IVA Appendix Cancer",
    "Ewing Sarcoma",
    "Central Nervous System Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Stage III Breast Cancer",
    "Metastatic Breast Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIB Esophageal Adenocarcinoma",
    "Lymphoma, Leukemia",
    "Locally Advanced Sarcoma",
    "Recurrent Germ Cell Tumor",
    "Ependymoma",
    "Ovarian Carcinosarcoma, Stage IV Uterine (including Endometrial) Cancer",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Refractory Malignant Germ Cell Tumor",
    "Stage I Uterine (including Endometrial) Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Stage I Bladder Cancer",
    "Bladder Urothelial Cancer",
    "Stage III Pancreatic Cancer",
    "Metastatic Urothelial Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent Central Nervous System Lymphoma",
    "Non-Small Cell Lung Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Advanced Renal Cell Carcinoma",
    "Triple-Negative Breast Cancer",
    "Endometrial Adenocarcinoma",
    "Recurrent Central Nervous System Lymphoma",
    "Borderline Resectable Pancreatic Adenocarcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Colon Adenocarcinoma",
    "Metastatic Triple-Negative Breast Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Biochemically Recurrent Prostate Carcinoma",
    "Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Recurrent Small Cell Lung Cancer",
    "Recurrent Malignant Ovarian Granulosa Cell Tumor",
    "Recurrent Malignant Solid Tumor, Refractory Lymphoma",
    "Pleural Malignant Mesothelioma",
    "Pituitary Gland Cancer, Pituitary Gland Adenoma",
    "Metastatic Renal Cell Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Endometrial Carcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Resectable Malignant Pleural Mesothelioma",
    "Locally Advanced Malignant Solid Tumor",
    "Plasmacytoma",
    "Metastatic Malignant Solid Tumor",
    "Undifferentiated (Anaplastic) Stage IVA Thyroid Gland Cancer",
    "Breast Cancer",
    "Resectable Soft Tissue Sarcoma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Metastatic Sarcoma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Malignant Solid Tumor",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Central Nervous System Lymphoma",
    "Marginal Zone Lymphoma",
    "Metastatic Colorectal Adenocarcinoma",
    "Thyroid Gland Follicular Cancer",
    "Triple-Negative Breast Cancer",
    "Lymphoma, Multiple Myeloma/Plasma Cell Myeloma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Endometrial Carcinoma",
    "Refractory Malignant Thyroid Gland Neoplasm",
    "Unresectable Leiomyosarcoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Malignant Solid Tumor",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Non-Small Cell Lung Cancer",
    "Breast Cancer",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Endometrial Cancer",
    "Metastatic Soft Tissue Sarcoma",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
    "Symptomatic COVID-19 Infection Laboratory-Confirmed, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Advanced Malignant Peripheral Nerve Sheath Tumor",
    "Metastatic Breast Carcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Unresectable Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v8",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Prostate Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IIIB Non-Small Cell Lung Cancer",
    "Stage III Ovarian Cancer",
    "Langerhans Cell Histiocytosis",
    "Recurrent T-Cell Non-Hodgkin Lymphoma",
    "Microinvasive Breast Carcinoma",
    "Recurrent Malignant Solid Tumor",
    "Stage IIIC Breast Cancer",
    "Glioblastoma",
    "Advanced Breast Carcinoma",
    "Recurrent Hodgkin Lymphoma",
    "Recurrent Head and Neck Carcinoma",
    "Stage IIB Hodgkin Lymphoma",
    "Endometrial Cancer",
    "Extensive Stage Small Cell Lung Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Richter Syndrome",
    "Triple-Negative Breast Cancer",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Mycosis Fungoides",
    "Primary Amyloidosis",
    "Refractory Classical Hodgkin Lymphoma",
    "Central Nervous System B-Cell Non-Hodgkin Lymphoma",
    "Nasal Type Extranodal NK/T-Cell Lymphoma",
    "Glioma",
    "Classical Hodgkin Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Lymphoma",
    "Recurrent Diffuse Large B-Cell Lymphoma, Refractory Mantle Cell Lymphoma",
    "Metastatic Breast Carcinoma",
    "Stage 0a Bladder Cancer",
    "Metastatic Adenoid Cystic Cancer",
    "Marginal Zone Lymphoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Non-Small Cell Lung Cancer",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Invasive Breast Cancer",
    "Neurofibromatosis Type 1",
    "Atypical Teratoid/Rhabdoid Tumor",
    "Recurrent Glioblastoma",
    "Salivary Gland Cancer",
    "Stage IA Breast Cancer",
    "T Acute Lymphoblastic Leukemia",
    "Metastatic Urothelial Cancer",
    "Unresectable Melanoma",
    "Stage IIIA Hepatocellular Cancer",
    "Recurrent Hodgkin Lymphoma",
    "Recurrent Malignant Brain Neoplasm",
    "Stage IV Breast Cancer",
    "Prostate Adenocarcinoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Neoplasm",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Stage IA Breast Cancer",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Metastatic Bladder Urothelial Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Stage I Hodgkin Lymphoma",
    "Clinical Stage III Merkel Cell Carcinoma AJCC v8",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "MGMT-Methylated Glioblastoma",
    "Recurrent Burkitt Lymphoma",
    "Prostate Adenocarcinoma",
    "Rhabdomyosarcoma",
    "Stage I Breast Cancer",
    "Stage IA Pleural Malignant Mesothelioma",
    "Stage IA Breast Cancer",
    "Recurrent Medulloblastoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Breast Carcinoma",
    "Classical Hodgkin Lymphoma",
    "Metastatic Lung Non-Small Cell Carcinoma, Metastatic Breast Carcinoma",
    "Invasive Breast Cancer",
    "Childhood Langerhans Cell Histiocytosis with Risk Organ Involvement",
    "Clear Cell Renal Cell Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Neuroendocrine Tumor",
    "Glioma",
    "Rectal Adenocarcinoma",
    "Stage IV Prostate Adenocarcinoma",
    "Malignant Glioma",
    "Metastatic Colorectal Carcinoma",
    "Advanced Gastroesophageal Junction Adenocarcinoma",
    "Locally Advanced Unresectable Colorectal Adenocarcinoma",
    "Malignant Glioma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Stage IV Breast Cancer",
    "Stage I Prostate Adenocarcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "B Acute Lymphoblastic Leukemia",
    "Breast Adenocarcinoma",
    "Refractory Soft Tissue Sarcoma",
    "Castration-Resistant Prostate Cancer",
    "Ductal Carcinoma In Situ (DCIS)",
    "Prostate Adenocarcinoma",
    "Metastatic Colon Adenocarcinoma",
    "Medulloblastoma",
    "HER2-Positive Breast Carcinoma",
    "Diffuse Intrinsic Pontine Glioma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Recurrent Osteosarcoma",
    "Non-Squamous Non-Small Cell Lung Cancer",
    "Stage IV Breast Cancer",
    "HER2-Positive Breast Carcinoma",
    "Metastatic Breast Carcinoma",
    "Stage I Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Central Nervous System Embryonal Tumor, Not Otherwise Specified",
    "Non-Neoplastic Hematologic and Lymphocytic Disorder",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Hepatocellular Cancer",
    "Brain Stem Glioma",
    "Bone Marrow Failure",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage II Prostate Adenocarcinoma",
    "Paranasal Sinus Adenoid Cystic Carcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Melanoma",
    "Recurrent Acute Leukemia",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Stage III Breast Cancer",
    "Metastatic Melanoma",
    "Recurrent Glioblastoma",
    "Recurrent Ovarian Cancer",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Fanconi Anemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Stage IA Pleural Malignant Mesothelioma",
    "HER2 Negative Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Cigarette Smoking-Related Carcinoma",
    "Stage III Laryngeal Throat Squamous Cell Cancer",
    "Liver Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Glioma",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Glioma",
    "Stage IV Cutaneous (Skin) Melanoma",
    "Triple-Negative Breast Cancer",
    "Recurrent Grade 1 Follicular Lymphoma",
    "Resectable Pancreatic Cancer",
    "Supratentorial Glioblastoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Hepatocellular Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Stage IIA Breast Cancer",
    "Stage I Breast Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Colorectal (Colon or Rectal) Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Non-Small Cell Lung Cancer",
    "High-Risk Neuroblastoma",
    "Recurrent Grade 1 Follicular Lymphoma",
    "Castration-Resistant Prostate Cancer",
    "Malignant Female Reproductive System Neoplasm",
    "Leukemia, Hematopoietic and Lymphoid System Disorder, Lymphoma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Recurrent Lymphoma, Metastatic Malignant Solid Tumor",
    "Recurrent Non-Hodgkin Lymphoma",
    "Myelodysplastic Syndrome",
    "Metastatic Uveal Melanoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Laryngeal Throat Squamous Cell Cancer",
    "Myelodysplastic Syndrome with Excess Blasts, Acute Lymphoblastic Leukemia (ALL)",
    "Lymphangioleiomyomatosis",
    "Recurrent Malignant Solid Tumor",
    "Hepatocellular Cancer",
    "High Grade Ovarian Serous Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Mantle Cell Lymphoma",
    "Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Hematologic and Lymphocytic Disorder",
    "Cigarette Smoking-Related Carcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Behavioral Disorder",
    "Metastatic Prostatic Adenocarcinoma",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Leukemia, Myelodysplastic Syndrome",
    "Malignant Glioma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Invasive Breast Cancer",
    "Refractory Malignant Solid Tumor",
    "Colorectal (Colon or Rectal) Cancer",
    "B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Glioblastoma",
    "Localized Pancreatic Adenocarcinoma",
    "Locally Advanced Pancreatic Ductal Adenocarcinoma",
    "Hereditary Female Breast Carcinoma",
    "Non-Small Cell Lung Cancer",
    "Malignant Solid Tumor",
    "Metastatic Renal Cell Cancer",
    "Ovarian Cancer",
    "Cervical Cancer",
    "Metastatic Melanoma",
    "Castration-Sensitive Prostate Carcinoma",
    "HER2 Negative Breast Carcinoma",
    "Recurrent Malignant Glioma",
    "Stage I Colorectal (Colon or Rectal) Cancer",
    "Recurrent Acute Myeloid Leukemia (AML), Hematopoietic and Lymphoid Cell Neoplasm",
    "Castration-Resistant Prostate Cancer",
    "Glioblastoma",
    "Unresectable Melanoma",
    "Recurrent Neuroblastoma",
    "Prostate Cancer",
    "Recurrent Head and Neck Carcinoma",
    "Locally Advanced Lung Carcinoma",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Merkel Cell Carcinoma",
    "Ependymoma",
    "Glottic Squamous Cell Carcinoma",
    "Secondary Lymphedema",
    "Head and Neck Squamous Cell Carcinoma",
    "Stage I Breast Cancer",
    "Stage II Breast Cancer",
    "Malignant Solid Tumor",
    "Monoclonal Gammopathy of Undetermined Significance",
    "Recurrent Hodgkin Lymphoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Castration-Resistant Prostate Cancer",
    "Advanced Gastroesophageal Junction Adenocarcinoma",
    "MGMT-Unmethylated Glioblastoma",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Pancreatic Adenocarcinoma",
    "Hepatocellular Cancer",
    "Adamantinomatous Craniopharyngioma",
    "Undifferentiated (Anaplastic) Thyroid Gland Cancer",
    "Stage III Colon Cancer",
    "Recurrent Glioblastoma",
    "Stage IB2 Cervical Cancer FIGO 2018",
    "Stage I Breast Cancer",
    "Endometrial Endometrioid Adenocarcinoma",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Diffuse Intrinsic Pontine Glioma",
    "Lung Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, HIV Infection",
    "Non-Malignant Neoplasm",
    "Primary Malignant Liver Neoplasm",
    "Cervical Cancer, Breast Cancer",
    "Anal Cancer",
    "Advanced Breast Carcinoma",
    "Recurrent Head and Neck Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Resectable Pancreatic Cancer",
    "Hepatocellular Cancer",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Colorectal (Colon or Rectal) Cancer",
    "Recurrent Glioblastoma",
    "Stage I Breast Cancer",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Invasive Breast Cancer",
    "Unresectable Colorectal Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Refractory Neuroblastoma",
    "Metastatic Triple-Negative Breast Carcinoma, Stage III Ovarian Cancer",
    "Stage I Breast Cancer",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Recurrent Ovarian Cancer",
    "Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Stage IB Cutaneous (Skin) Melanoma",
    "Cervical Cancer",
    "Recurrent Ovarian Cancer",
    "Unresectable Hepatocellular Cancer",
    "Prostate Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Resectable Soft Tissue Sarcoma",
    "Cigarette Smoking-Related Carcinoma",
    "Large Cell Neuroendocrine Carcinoma",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Prostate Cancer",
    "Cigarette Smoking-Related Carcinoma, HIV Infection",
    "Lung Cancer",
    "Metastatic Malignant Neoplasm to the Liver",
    "Prolonged Grief Disorder",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Cigarette Smoking-Related Carcinoma",
    "Platinum-Resistant Ovarian Cancer",
    "Recurrent Non-Hodgkin Lymphoma",
    "Non-Small Cell Lung Cancer, Esophageal Cancer",
    "Triple-Negative Breast Cancer",
    "Metastatic Colorectal Adenocarcinoma",
    "Castration-Sensitive Prostate Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Liver Cancer",
    "Locally Advanced Hepatocellular Carcinoma",
    "Oral Cavity Squamous Cell Cancer",
    "Colorectal (Colon or Rectal) Cancer",
    "EBV-Related Malignant Neoplasm",
    "Prostate Cancer",
    "Kaposi Sarcoma",
    "Cigarette Smoking-Related Carcinoma",
    "Adenoid Cystic Carcinoma",
    "Prostate Adenocarcinoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Resectable Pancreatic Ductal Adenocarcinoma",
    "Ovarian Cancer",
    "Rhabdomyosarcoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Uveal Melanoma",
    "Recurrent Colorectal Adenocarcinoma, Recurrent Malignant Ovarian Granulosa Cell Tumor, Recurrent Non-Small Cell Lung Cancer",
    "Barrett Esophagus",
    "Metastatic Malignant Solid Tumor",
    "Stage IV Prostate Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IIA Colon Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Lymphoma, Recurrent Acute Lymphoblastic Leukemia",
    "Stage II Breast Cancer",
    "Human Papillomavirus (HPV)-Related Cervical Cancer",
    "Neurofibromatosis Type 1",
    "Stage I Uterine (including Endometrial) Cancer",
    "Grade II Meningioma",
    "Non-Small Cell Lung Cancer",
    "BCLC Stage A Hepatocellular Cancer",
    "Esophageal Adenocarcinoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Malignant Neoplasm",
    "High Grade Vulvar Squamous Intraepithelial Lesion",
    "Pancreatic Mucinous-Cystic Neoplasm",
    "Obesity-Related Malignant Neoplasm",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Prostate Adenocarcinoma",
    "Metastatic Unresectable Malignant Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Metastatic Head and Neck Cancer, Stage IV Breast Cancer, Platinum-Resistant Ovarian Cancer",
    "Prostate Adenocarcinoma",
    "Cervical Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Ovarian Cancer",
    "Advanced Soft Tissue Sarcoma",
    "Metastatic Prostatic Adenocarcinoma",
    "Cervical Cancer, Human Papillomavirus Infection",
    "Ductal Carcinoma In Situ (DCIS)",
    "Castration-Resistant Prostate Cancer",
    "Bladder Urothelial Cancer",
    "Stage 0is Bladder Cancer",
    "Locally Advanced Prostate Carcinoma",
    "Colorectal (Colon or Rectal) Cancer",
    "Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Myeloma",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid System Neoplasm",
    "Malignant Glioma",
    "HIV Infection, Advanced Malignant Solid Tumor",
    "Cervical Cancer",
    "Multicentric Angiofollicular Lymphoid Hyperplasia",
    "Aggressive Variant Prostate Carcinoma",
    "Hepatocellular Cancer",
    "Cervical Cancer",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Hodgkin Lymphoma",
    "Hodgkin Lymphoma",
    "Diffuse Large B-Cell Lymphoma",
    "Prostate Adenocarcinoma",
    "Recurrent Glioblastoma",
    "Metastatic Breast Carcinoma",
    "Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Recurrent Ovarian Cancer",
    "Acute Myeloid Leukemia with Gene Mutations",
    "Refractory T Lymphoblastic Leukemia/Lymphoma",
    "Stage III Ovarian Cancer",
    "Metastatic Malignant Neoplasm in the Brain",
    "Hepatocellular Cancer",
    "Barrett Esophagus",
    "Stage IIIC Breast Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Stage III Cutaneous (Skin) Melanoma",
    "Recurrent Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Colorectal Adenoma",
    "Secondary Acute Myeloid Leukemia (AML)",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Prostate Cancer",
    "Breast Adenocarcinoma",
    "Pancreatic Intraductal Papillary-Mucinous Tumor",
    "Invasive Breast Cancer",
    "High Grade Anal Canal Intraepithelial Neoplasia, HIV Infection",
    "Refractory Malignant Solid Tumor, Advanced Leukemia",
    "Soft Tissue Sarcoma of the Trunk and Extremities",
    "Refractory Adenovirus Infection",
    "Refractory Cytomegalovirus Infection",
    "Epstein-Barr Virus Infection",
    "Giant Cell Tumor of Bone",
    "Breast Cancer",
    "Head and Neck Carcinoma",
    "Stage IV Pancreatic Cancer",
    "Prostate Adenocarcinoma",
    "HER2-Positive Breast Carcinoma",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Central Nervous System Lymphoma",
    "Chronic Myeloproliferative Disease",
    "Cervical Cancer",
    "Esophageal Squamous Intraepithelial Neoplasia",
    "Triple-Negative Breast Cancer",
    "Advanced Sarcoma",
    "Neurofibroma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Peripheral Nerve Sheath Tumor",
    "Lung Neoplasm",
    "Malignant Neoplasm",
    "Metastatic Prostatic Adenocarcinoma",
    "Neurofibromatosis Type 2, Acoustic Schwannoma",
    "Stage III Soft Tissue Sarcoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Prostate Adenocarcinoma",
    "Stage IA Breast Cancer",
    "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma",
    "Pancreatic Cancer",
    "Recurrent Meningioma",
    "Invasive Breast Cancer",
    "Breast Cancer",
    "Ductal Carcinoma In Situ (DCIS)",
    "Recurrent Soft Tissue Sarcoma",
    "Central Nervous System B-Cell Non-Hodgkin Lymphoma",
    "Neurofibromatosis Type 1",
    "Ovarian Cancer",
    "Metastatic Malignant Solid Tumor, Multiple Myeloma/Plasma Cell Myeloma, B-Cell Non-Hodgkin Lymphoma",
    "Triple-Negative Breast Cancer",
    "Stage IV Non-Small Cell Lung Cancer",
    "Undifferentiated Pleomorphic Sarcoma",
    "Oligometastatic Malignant Solid Neoplasm",
    "Invasive Lobular Breast Carcinoma",
    "Atypical Endometrial Hyperplasia",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML)",
    "Stage III Oropharyngeal Throat Squamous Cell Cancer",
    "Hematopoietic and Lymphoid System Disorder",
    "Stage II Breast Cancer",
    "Prostate Adenocarcinoma",
    "Stage IIIC Breast Cancer",
    "Metastatic Breast Carcinoma",
    "Stage III Hepatocellular Cancer",
    "Stage IV Pancreatic Cancer",
    "Stage I Prostate Cancer",
    "Viral Infection",
    "Stage I Oropharyngeal Throat Squamous Cell Cancer",
    "Metastatic Urothelial Cancer",
    "Refractory Non-Hodgkin Lymphoma",
    "Locally Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Stage II Pancreatic Cancer",
    "Pancreatic Ductal Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Chronic Eosinophilic Leukemia",
    "Community-Acquired Pneumonia",
    "Recurrent Gastroesophageal Junction Adenocarcinoma",
    "Myelodysplastic Syndrome, Recurrent Acute Leukemia",
    "Advanced Malignant Solid Tumor",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Low Grade Glioma",
    "Pancreatic Adenocarcinoma",
    "Catheter-Related Infection",
    "Advanced Malignant Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Stage IV Non-Small Cell Lung Cancer",
    "Sarcoma",
    "Advanced Malignant Solid Tumor, Advanced Diffuse Large B-Cell Lymphoma",
    "Stage III Hepatocellular Cancer",
    "Non-Small Cell Lung Cancer",
    "Hematologic and Lymphocytic Disorder",
    "Metastatic Hepatocellular Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "High-Risk Neuroblastoma",
    "Refractory Barrett Esophagus",
    "Triple-Negative Breast Cancer",
    "Advanced Melanoma",
    "Idiopathic Thrombocytopenic Purpura",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Advanced Malignant Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Stage III Lung Cancer",
    "Non-Small Cell Lung Cancer",
    "Metastatic Colorectal Carcinoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Urothelial Cancer",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Stage II Breast Cancer",
    "Transplant-Associated Thrombotic Microangiopathy",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Neoplasm",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Malignant Solid Tumor",
    "Fungal Infection",
    "Viral Infection",
    "Recurrent Nasal Type Extranodal NK/T-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Sickle Cell Disease",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Stage III Ovarian Cancer",
    "Endogenous Cushing Syndrome",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Head and Neck Carcinoma",
    "Invasive Breast Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Malignant Salivary Gland Tumor",
    "Advanced Malignant Neoplasm",
    "Recurrent Glioblastoma",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Lymphoma, Advanced Malignant Solid Tumor",
    "Hepatocellular Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Platinum-Resistant Ovarian Carcinoma",
    "Advanced Urothelial Cancer",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Superficial Bladder Cancer",
    "Recurrent High Grade Ovarian Serous Adenocarcinoma",
    "Clostridium difficile Colitis",
    "Kaposi Sarcoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Hepatocellular Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Malignant Solid Tumor",
    "Pleural Malignant Mesothelioma",
    "Recurrent Mantle Cell Lymphoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Retroperitoneal Sarcoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Idiopathic Thrombocytopenic Purpura",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Gastroesophageal Junction Adenocarcinoma",
    "Recurrent Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Cervical Squamous Cell Carcinoma In Situ, Human Papillomavirus Infection",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Warm Antibody Autoimmune Hemolytic Anemia",
    "Locally Advanced Melanoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Congenital Neutropenia",
    "Lymphedema",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor",
    "Breast Adenocarcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Locally Advanced Malignant Solid Tumor",
    "Metastatic Adrenal Cortex Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Resectable Pancreatic Adenocarcinoma",
    "Hormone Receptor Positive Breast Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Endometrial Carcinoma",
    "Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Stage IIB Lung Cancer",
    "Fungal Infection",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Idiopathic Thrombocytopenic Purpura",
    "Multiple Myeloma/Plasma Cell Myeloma, Follicular Lymphoma, Chronic Lymphocytic Leukemia (CLL), Hematopoietic and Lymphoid Cell Neoplasm",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Breast Cancer",
    "Gastroesophageal Reflux Disease",
    "Stage IIIB Cutaneous (Skin) Melanoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent AL Amyloidosis",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Oropharyngeal Throat Cancer",
    "Primary Myelofibrosis",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Stage IIIA Lung Cancer, Stage IIIA1 Ovarian Cancer",
    "Castration-Resistant Prostate Cancer",
    "Refractory Severe Aplastic Anemia",
    "Advanced Malignant Solid Tumor",
    "Rectal Adenocarcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Indolent Non-Hodgkin Lymphoma",
    "Hemophilia A",
    "Advanced Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Sickle Cell Disease",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Refractory Diffuse Large B-Cell Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "HER2-Positive Breast Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Platinum-Resistant Ovarian Cancer",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Acromegaly",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Bladder Neoplasm",
    "Advanced Gastrointestinal Stromal Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Solid Tumor",
    "HER2-Positive Breast Carcinoma",
    "Recurrent Primary Central Nervous System Neoplasm",
    "Lung Neoplasm, Gastric Neoplasm",
    "Primary Myelofibrosis",
    "HIV Infection",
    "Advanced Malignant Solid Tumor",
    "Recurrent Primary Myelofibrosis",
    "Hepatocellular Cancer",
    "Primary Myelofibrosis",
    "Advanced Triple-Negative Breast Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "PIK3CA-Related Overgrowth Spectrum",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Clear Cell Sarcoma of Soft Tissue",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Glioma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Myelodysplastic Syndrome",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Primary Myelofibrosis",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Ovarian Tumor, Breast Neoplasm",
    "Non-Small Cell Lung Cancer",
    "Breast Cancer",
    "Advanced Soft Tissue Sarcoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Extensive Stage Small Cell Lung Cancer",
    "Metastatic Colorectal Carcinoma, Metastatic Lung Non-Small Cell Carcinoma",
    "Extensive Stage Small Cell Lung Cancer",
    "Recurrent Ovarian Cancer",
    "Recurrent Follicular Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Primary Myelofibrosis",
    "Recurrent Non-Hodgkin Lymphoma, Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Mantle Cell Lymphoma",
    "Tenosynovial Giant Cell Tumor",
    "HER2-Positive Breast Carcinoma",
    "Extensive Stage Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Esophageal Cancer",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Glioblastoma",
    "Refractory Hematologic Malignancy",
    "Locally Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Advanced Melanoma",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Recurrent Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Diffuse Large B-Cell Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Head and Neck Carcinoma",
    "Parkinson's Disease",
    "Advanced Malignant Solid Tumor",
    "Recurrent Osteosarcoma",
    "Follicular Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Myelodysplastic Syndrome",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Diffuse Large B-Cell Lymphoma, Not Otherwise Specified",
    "Advanced Cutaneous Melanoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Primary Myelofibrosis",
    "Advanced Malignant Solid Tumor",
    "B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Soft Tissue Sarcoma",
    "Metastatic Urothelial Cancer",
    "Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Monoclonal Mast Cell Activation Syndrome, Indolent Systemic Mastocytosis",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma, Unresectable Pleural Malignant Mesothelioma",
    "Metastatic Malignant Solid Tumor, Non-Hodgkin Lymphoma",
    "Locally Advanced Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Metastatic Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Small Lymphocytic Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Dedifferentiated Liposarcoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Acute Promyelocytic Leukemia with PML-RARA",
    "Acute Myeloid Leukemia (AML)",
    "Locally Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Epstein-Barr Virus-Associated Lymphoproliferative Disease with Primary Immunodeficiency, EBV-Related Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Non-Hodgkin Lymphoma, Multiple Myeloma/Plasma Cell Myeloma, Chronic Leukemia",
    "Advanced Malignant Solid Tumor",
    "Recurrent Glioblastoma",
    "Tenosynovial Giant Cell Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Stage 0 Breast Cancer",
    "Neuroblastoma",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Refractory Non-Hodgkin Lymphoma",
    "Recurrent Malignant Solid Tumor, Refractory Multiple Myeloma/Plasma Cell Myeloma, Refractory Myelodysplastic Syndrome",
    "Locally Advanced Malignant Solid Tumor",
    "Stage IIIA Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Non-Hodgkin Lymphoma, Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Triple-Negative Breast Cancer",
    "Severe Combined Immunodeficiency",
    "Herpes Simplex Virus Infection",
    "Advanced Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Mucosal Melanoma",
    "Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Digestive System Carcinoma",
    "Malignant Central Nervous System Neoplasm",
    "Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Head and Neck Squamous Cell Carcinoma",
    "Recurrent Endometrial Carcinoma",
    "Unresectable Malignant Mesothelioma",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain",
    "Stage IVA Lung Cancer, Stage IV Head and Neck Squamous Cell Cancer",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Stage III Ovarian Cancer",
    "Non-Small Cell Lung Cancer",
    "Stage IV Lung Cancer",
    "Breast Cancer, Non-Small Cell Lung Cancer",
    "Unresectable Esophageal Squamous Cell Carcinoma",
    "Advanced Hepatocellular Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Hepatocellular Carcinoma",
    "Recurrent Glioblastoma",
    "Non-Small Cell Lung Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Digestive System Disorder",
    "Advanced Malignant Solid Tumor",
    "Stage IV Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Advanced Bile Duct Carcinoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Stage IV Ovarian Cancer",
    "Metastatic Basal Cell Carcinoma",
    "Advanced Malignant Neoplasm",
    "Malignant Solid Tumor",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Leukemia, Lymphoma",
    "Recurrent Glioblastoma",
    "Advanced Breast Adenocarcinoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Medulloblastoma",
    "Primary Myelofibrosis",
    "Advanced Lymphoma, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "HER2-Positive Breast Carcinoma",
    "Metastatic Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Chronic Lymphocytic Leukemia (CLL), Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Hepatocellular Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Waldenstrom Macroglobulinemia",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Breast Carcinoma",
    "Metastatic Malignant Solid Tumor, Refractory Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Neoplasm in the Brain",
    "Recurrent Cervical Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Glioblastoma",
    "Advanced Merkel Cell Carcinoma",
    "Recurrent Respiratory Papillomatosis, Human Papillomavirus Infection",
    "Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Ovarian Carcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "COVID-19, Lymphopenia",
    "Locally Advanced Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Colorectal Adenocarcinoma",
    "Metastatic Anal Canal Squamous Cell Carcinoma",
    "Stage IIA Colon Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent T-Cell Prolymphocytic Leukemia",
    "Advanced Malignant Solid Tumor",
    "Tenosynovial Giant Cell Tumor",
    "Recurrent Non-Hodgkin Lymphoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Transplant-Associated Thrombotic Microangiopathy",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML)",
    "Triple-Negative Breast Cancer",
    "Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Gastric Adenocarcinoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Lung Non-Squamous Non-Small Cell Carcinoma",
    "HER2-Positive Breast Carcinoma",
    "Sickle Cell Disease",
    "Platelet Disorder",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Recurrent Myelofibrosis",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Melanoma",
    "Muscle Invasive Bladder Urothelial Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Gastroesophageal Junction Adenocarcinoma",
    "Advanced Ovarian Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Ovarian Carcinoma, Advanced Renal Cell Carcinoma",
    "Unresectable Malignant Solid Tumor, Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Non-Hodgkin Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Diffuse Intrinsic Pontine Glioma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), B-Cell Neoplasm, Recurrent Small Lymphocytic Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Endometrial Serous Adenocarcinoma, Recurrent Endometrial Serous Adenocarcinoma",
    "Prostate Adenocarcinoma",
    "Recurrent Osteosarcoma",
    "Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Advanced Malignant Digestive System Neoplasm",
    "HER2-Positive Breast Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Uveal Melanoma",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Non-Squamous Non-Small Cell Lung Cancer",
    "Early-Stage Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "AL Amyloidosis",
    "Lymphoma, Advanced Malignant Solid Tumor",
    "Advanced Melanoma, Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Aggressive Systemic Mastocytosis, Mast Cell Leukemia",
    "Advanced HER2 Positive Breast Carcinoma",
    "Advanced Cutaneous Melanoma",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Locally Advanced Malignant Neoplasm",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Malignant Female Reproductive System Neoplasm",
    "Recurrent Glioblastoma",
    "Advanced Skin Squamous Cell Carcinoma",
    "Prostate Adenocarcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Acute Lymphoblastic Leukemia (ALL)",
    "Locally Advanced Malignant Solid Tumor",
    "Bladder Urothelial Cancer",
    "Stage IIIB Non-Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Neuroblastoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Refractory Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Bladder Urothelial Cancer",
    "Castration-Resistant Prostate Cancer",
    "Stage IV Lung Cancer",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Glioblastoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Refractory Mature B-Cell Non-Hodgkin Lymphoma",
    "Advanced Breast Adenocarcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Locally Advanced Unresectable Gastric Adenocarcinoma",
    "Advanced Microsatellite Stable Colorectal Carcinoma",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "High Grade Cervical Squamous Intraepithelial Neoplasia",
    "Advanced Malignant Solid Tumor",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Liver Cancer",
    "Metastatic Leiomyosarcoma",
    "Advanced Malignant Solid Tumor",
    "Warm Antibody Autoimmune Hemolytic Anemia",
    "Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Advanced Ovarian Serous Adenocarcinoma",
    "Metastatic Esophageal Adenocarcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Malignant Solid Tumor",
    "Bladder Urothelial Cancer",
    "Locally Advanced Pancreatic Carcinoma",
    "Metastatic Urothelial Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Unresectable Pancreatic Adenocarcinoma",
    "Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Metastatic Small Cell Neuroendocrine Prostate Cancer",
    "Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Malignant Solid Tumor",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "High-Risk Neuroblastoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Locally Advanced Breast Carcinoma, Locally Advanced Lung Non-Small Cell Carcinoma",
    "Head and Neck Carcinoma",
    "Advanced Malignant Solid Tumor",
    "RSV Infection",
    "Locally Advanced Breast Adenocarcinoma",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Ewing Sarcoma",
    "Metastatic Colorectal Carcinoma",
    "Castration-Resistant Prostate Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Gastric Adenocarcinoma",
    "Advanced Malignant Digestive System Neoplasm",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Recurrent Desmoplastic Small Round Cell Tumor",
    "Recurrent Synovial Sarcoma",
    "Metastatic Carcinoma",
    "Refractory Malignant Solid Tumor",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Advanced Malignant Solid Tumor, Advanced Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Prostate Adenocarcinoma",
    "Advanced Colorectal Carcinoma",
    "Refractory Melanoma",
    "Advanced Melanoma",
    "Refractory Classical Hodgkin Lymphoma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Extensive Stage Small Cell Lung Cancer",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Locally Advanced Gastric Adenocarcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Metastatic Malignant Solid Tumor, Recurrent Non-Hodgkin Lymphoma",
    "Malignant Gastrointestinal Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Superficial Bladder Cancer",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Malignant Solid Tumor",
    "Stage IIIA Breast Cancer",
    "B Acute Lymphoblastic Leukemia",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Malignant Solid Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Metastatic Hepatocellular Carcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Advanced Urothelial Cancer",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Limited Stage Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Superficial Bladder Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Recurrent Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Melanoma",
    "Refractory Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Metastatic Colorectal Carcinoma",
    "Advanced Hepatocellular Carcinoma",
    "Advanced Colorectal Adenocarcinoma",
    "Recurrent Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Metastatic Melanoma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Lymphoma, Acute Leukemia, Myelodysplastic Syndrome",
    "Advanced Pancreatic Neuroendocrine Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Pancreatic Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Pancreatic Ductal Adenocarcinoma",
    "Classical Hodgkin Lymphoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Microsatellite Stable Endometrial Carcinoma, Microsatellite Stable Colorectal Carcinoma, Advanced Microsatellite Stable Ovarian Carcinoma",
    "Recurrent Glioblastoma",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Melanoma",
    "Advanced Lung Non-Small Cell Carcinoma, Advanced Melanoma",
    "Advanced Malignant Solid Tumor",
    "Glioblastoma",
    "Unresectable Melanoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Breast Carcinoma",
    "Smoldering Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Glioma",
    "Hematologic and Lymphocytic Disorder",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Castration-Resistant Prostate Cancer",
    "Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Metastatic Cutaneous Melanoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Neoplasm",
    "Malignant Glioma",
    "Advanced Malignant Solid Tumor",
    "Pre-B Acute Lymphoblastic Leukemia",
    "Metastatic Urothelial Cancer",
    "Myelodysplastic Syndrome",
    "Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Ovarian Cancer, Recurrent Endometrial Carcinoma",
    "Primary Myelofibrosis",
    "Unresectable Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Lymphoma",
    "Unresectable Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Follicular Lymphoma",
    "Locally Advanced Malignant Solid Tumor",
    "Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Stage III Bladder Cancer",
    "Recurrent Classical Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent T-Cell Non-Hodgkin Lymphoma",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Metastatic Digestive System Neuroendocrine Neoplasm",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Colorectal (Colon or Rectal) Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Bladder Urothelial Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor, Recurrent Central Nervous System Lymphoma",
    "Advanced Intrahepatic Cholangiocarcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Non-Small Cell Squamous Lung Cancer",
    "Advanced Non-Small Cell Squamous Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Breast Carcinoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Locally Advanced Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm, Refractory Malignant Solid Tumor",
    "Stage I Prostate Cancer",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Essential Thrombocythemia",
    "Advanced Malignant Solid Tumor, Advanced Lymphoma",
    "Refractory Chronic Myelogenous Leukemia (CML)",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "RSV Infection",
    "Waldenstrom Macroglobulinemia",
    "Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Skin Squamous Cell Carcinoma, Metastatic Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Pancreatic Ductal Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Oropharyngeal Throat Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer",
    "Unresectable Renal Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Recurrent Myelofibrosis",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Metastatic Colon Carcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Stage IV Head and Neck Squamous Cell Cancer",
    "Metastatic Hepatocellular Carcinoma",
    "Refractory Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor, Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Advanced Colorectal Carcinoma",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Diffuse Large B-Cell Lymphoma Activated B-Cell Type",
    "Myelofibrosis",
    "Stage III Ovarian Cancer, Stage III Breast Cancer, Stage IIIA Lung Cancer",
    "Recurrent Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Thrombotic Microangiopathy",
    "Primary Myelofibrosis",
    "Metastatic Merkel Cell Carcinoma, Extensive Stage Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML), Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Clear Cell Renal Cell Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Metastatic Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Refractory Myelofibrosis",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Monomorphic Epitheliotropic Intestinal T-cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Pancreatic Adenocarcinoma",
    "Myelodysplastic Syndrome",
    "Metastatic Breast Carcinoma",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Refractory Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Melanoma",
    "Advanced Synovial Sarcoma",
    "Stage IV B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Waldenstrom Macroglobulinemia",
    "Metastatic Malignant Solid Tumor",
    "Stage III Renal Cell Cancer",
    "Metastatic Malignant Solid Tumor",
    "Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement",
    "Digestive System Neuroendocrine Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Sickle Cell Disease",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Cholangiocarcinoma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Unresectable Urothelial Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "HER2 Negative Breast Carcinoma",
    "Advanced Lymphoma, Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Refractory Lymphoma, Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Triple-Negative Breast Cancer",
    "Metastatic Prostate Cancer",
    "Advanced Digestive System Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor, Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Malignant Solid Tumor",
    "Invasive Pulmonary Aspergillosis",
    "Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Mantle Cell Lymphoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor, Non-Hodgkin Lymphoma, Hematopoietic and Lymphoid Cell Neoplasm",
    "Unresectable Malignant Solid Tumor",
    "Stage IV Lung Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Stage II Cutaneous (Skin) Melanoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Pleural Malignant Mesothelioma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Primary Myelofibrosis",
    "Recurrent Ovarian Cancer",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Astrocytoma",
    "Mantle Cell Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Stage IV Colorectal (Colon or Rectal) Cancer",
    "Advanced Carcinoma",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Advanced Colon Adenocarcinoma, Advanced Rectal Adenocarcinoma",
    "Metastatic Gastric Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Familial Adenomatous Polyposis",
    "Advanced Malignant Solid Tumor",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Advanced Malignant Solid Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Metastatic Malignant Solid Tumor",
    "Myelodysplastic Syndrome",
    "Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML), Recurrent Myelodysplastic Syndrome",
    "Refractory Myelofibrosis",
    "Locally Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Adrenal Cortex Carcinoma",
    "Platinum-Resistant Ovarian Cancer",
    "Unresectable Melanoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Invasive Breast Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Glioblastoma",
    "Choroid Melanoma",
    "Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Castration-Resistant Prostate Cancer",
    "Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Chronic Myeloproliferative Disease",
    "Primary Myelofibrosis",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Locally Advanced Clear Cell Renal Cell Carcinoma",
    "Refractory Malignant Female Reproductive System Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Metastatic Colorectal Carcinoma",
    "Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Renal Cell Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Extracranial Malignant Solid Neoplasm",
    "Advanced Malignant Solid Tumor",
    "Recurrent Grade 1 Follicular Lymphoma",
    "Unresectable Pancreatic Adenocarcinoma",
    "Recurrent Malignant Solid Tumor",
    "Stage IV Renal Cell Cancer",
    "Metastatic Malignant Solid Tumor",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "HER2-Positive Breast Carcinoma",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Refractory Diffuse Large B-Cell Lymphoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Unresectable Pleural Malignant Mesothelioma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Esophageal Squamous Cell Carcinoma, Stage IIIA Gastric (Stomach) Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Glioma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Ovarian Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Malignant Solid Tumor",
    "Metastatic Soft Tissue Sarcoma",
    "Recurrent Glioblastoma",
    "Recurrent Small Cell Lung Cancer",
    "Head and Neck Squamous Cell Carcinoma",
    "Unresectable Melanoma",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Breast Cancer, Advanced Ovarian Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Refractory Marginal Zone Lymphoma, Refractory Follicular Lymphoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Solid Tumor",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Mixed Phenotype Acute Leukemia",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Bladder Urothelial Cancer",
    "Malignant Gastrointestinal Neoplasm",
    "Malignant Solid Tumor",
    "Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Stage IV Lung Cancer",
    "Metastatic Melanoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Resectable Lung Non-Small Cell Carcinoma",
    "Recurrent Malignant Solid Tumor, Refractory Acute Leukemia",
    "Metastatic Prostatic Adenocarcinoma",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Stage IIB Cutaneous (Skin) Melanoma",
    "Invasive Breast Cancer",
    "Metastatic Melanoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Metastatic Breast Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Bladder Non-Invasive Papillary Urothelial Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Soft Tissue Sarcoma",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Esophageal Adenocarcinoma",
    "Primary Myelofibrosis",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Classical Hodgkin Lymphoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Superficial Bladder Urothelial Carcinoma",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Refractory Myelodysplastic Syndrome",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Endometrial Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Small Cell Carcinoma",
    "Castration-Sensitive Prostate Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Castration-Sensitive Prostate Carcinoma",
    "Metastatic Cutaneous Squamous Cell Carcinoma of the Head and Neck",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Locally Advanced Hepatocellular Carcinoma",
    "Recurrent Urothelial Cancer",
    "Unresectable Esophageal Squamous Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Melanoma",
    "Recurrent Ovarian Cancer",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma, Locally Advanced Colorectal Carcinoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Stage IV Cervical Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Multiple Myeloma/Plasma Cell Myeloma, Non-Hodgkin Lymphoma, Advanced Malignant Solid Tumor",
    "Low Grade Glioma",
    "Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Bladder Non-Invasive Papillary Urothelial Carcinoma, High Grade",
    "Myelodysplastic Syndrome",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Acute Myeloid Leukemia (AML)",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Melanoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Myelodysplastic Syndrome",
    "Stage III Breast Cancer",
    "Breast Adenocarcinoma",
    "Triple-Negative Breast Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Stage III Breast Cancer",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Refractory Acute Lymphoblastic Leukemia (ALL), Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Acute Myeloid Leukemia (AML)",
    "Mantle Cell Lymphoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Triple-Negative Breast Cancer",
    "Stage III Ovarian Cancer",
    "Locally Advanced Unresectable Pancreatic Adenocarcinoma",
    "Metastatic Clear Cell Renal Cell Carcinoma",
    "Metastatic Melanoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Stage IV HPV-Mediated (p16-Positive) Oropharyngeal Throat Cancer",
    "Superficial Bladder Cancer, Stage 0is Bladder Cancer",
    "Hepatocellular Cancer",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Colorectal Carcinoma",
    "Chronic Lymphocytic Leukemia (CLL)",
    "Malignant Solid Tumor",
    "Hepatocellular Cancer",
    "Unresectable Triple-Negative Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Triple-Negative Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Acute Myeloid Leukemia (AML)",
    "Recurrent Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor, Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Merkel Cell Carcinoma",
    "Advanced Bile Duct Carcinoma",
    "Recurrent Non-Small Cell Lung Cancer",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Advanced Skin Squamous Cell Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Primary Myelofibrosis",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Metastatic Colorectal Carcinoma",
    "Endometrial Cancer",
    "Mantle Cell Lymphoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Melanoma",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Advanced Colorectal Carcinoma",
    "Deep Fibromatosis/Desmoid Tumor",
    "Metastatic Uveal Melanoma",
    "Stage IV Breast Cancer",
    "Advanced Malignant Solid Tumor",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Ewing Sarcoma",
    "Metastatic Malignant Solid Tumor",
    "Non-Small Cell Lung Cancer",
    "Refractory Neuroblastoma",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Myelofibrosis",
    "Stage IV Hepatocellular Cancer",
    "Steroid Refractory Graft Versus Host Disease",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Stage IV Uterine (including Endometrial) Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Neoplasm",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Aggressive Prostate Adenocarcinoma",
    "Lymphoma, Locally Advanced Malignant Solid Tumor",
    "Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Melanoma",
    "Refractory Mycosis Fungoides",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Non-Small Cell Lung Cancer",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Metastatic Hepatocellular Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Hepatocellular Cancer",
    "Metastatic Adenoid Cystic Cancer",
    "Recurrent Superficial Bladder Urothelial Carcinoma",
    "Stage IIIA Breast Cancer",
    "Myelodysplastic Syndrome",
    "Essential Thrombocythemia",
    "Advanced Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Monoblastic and Monocytic Leukemia",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Endometrial Endometrioid Adenocarcinoma",
    "Recurrent Diffuse Large B-Cell Lymphoma",
    "Locally Advanced Malignant Solid Tumor",
    "Unresectable Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Metastatic Malignant Solid Tumor",
    "Refractory Non-Small Cell Lung Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Recurrent Endometrial Serous Adenocarcinoma",
    "Gastric (Stomach) Cancer",
    "Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Unresectable Melanoma",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Recurrent Hematopoietic and Lymphoid Cell Neoplasm",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Non-Hodgkin Lymphoma",
    "Castration-Resistant Prostate Cancer",
    "Recurrent Lymphoma, Locally Advanced Malignant Solid Tumor",
    "Prostate Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Clear Cell Renal Cell Cancer",
    "Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma",
    "Refractory Malignant Neoplasm",
    "Refractory Neuroblastoma",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Neoplasm",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Diffuse Large B-Cell Lymphoma",
    "Recurrent Breast Cancer",
    "Acute Lymphoblastic Leukemia (ALL)",
    "Bladder Carcinoma Infiltrating the Muscle of the Bladder Wall",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Early-Stage Breast Cancer",
    "Advanced Malignant Neoplasm",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Refractory Merkel Cell Carcinoma",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Advanced Malignant Solid Tumor",
    "Hepatocellular Cancer",
    "Malignant Neoplasm",
    "Locally Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Metastatic Breast Carcinoma",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Peripheral T-Cell Lymphoma, Not Otherwise Specified",
    "Advanced Malignant Solid Tumor",
    "Recurrent Neuroblastoma",
    "Recurrent Osteosarcoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Castration-Resistant Prostate Cancer",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Triple-Negative Breast Cancer",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Primary Myelofibrosis",
    "Recurrent Low Grade Ovarian Serous Adenocarcinoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia (CLL)",
    "Unresectable Lymphoma, Advanced Malignant Solid Tumor",
    "High-Risk Neuroblastoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Recurrent Acute Lymphoblastic Leukemia",
    "Cytomegaloviral Infection",
    "Recurrent Bladder Urothelial Cancer",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Locally Advanced Unresectable Pancreatic Adenocarcinoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Small Cell Lung Cancer",
    "Recurrent Non-Small Cell Lung Cancer",
    "Angioimmunoblastic T-Cell Lymphoma",
    "Recurrent EBV-Related Lymphoma, EBV-Related Lymphoproliferative Disorder",
    "Non-Small Cell Lung Cancer",
    "Metastatic Urothelial Cancer",
    "Recurrent Ewing Sarcoma",
    "Stage IV Intrahepatic Bile Duct Cancer (Cholangiocarcinoma)",
    "Primary Myelofibrosis",
    "Advanced Malignant Solid Tumor",
    "Cutaneous (Skin) Melanoma",
    "Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer",
    "Locally Advanced Pancreatic Ductal Adenocarcinoma",
    "Multiple Myeloma/Plasma Cell Myeloma, Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Gastric Carcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Myeloid Leukemia (AML)",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Refractory Grade 1 Follicular Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Colorectal Adenocarcinoma",
    "Myelodysplastic Syndrome",
    "Primary Myelofibrosis",
    "Advanced Breast Carcinoma",
    "Metastatic Gastroesophageal Junction Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Colorectal Carcinoma",
    "Recurrent Platinum-Resistant Ovarian Carcinoma",
    "Myelofibrosis",
    "Locally Advanced Malignant Solid Tumor",
    "Mycosis Fungoides",
    "Stage IV Non-Small Cell Lung Cancer",
    "Mantle Cell Lymphoma",
    "Metastatic Urothelial Cancer",
    "Advanced Intrahepatic Cholangiocarcinoma",
    "Stage IIIA Lung Cancer",
    "Recurrent Malignant Solid Tumor",
    "Classical Hodgkin Lymphoma",
    "B-Cell Non-Hodgkin Lymphoma",
    "Recurrent Low Grade Ovarian Serous Adenocarcinoma",
    "Indolent Systemic Mastocytosis",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Hepatocellular Cancer",
    "Advanced Malignant Solid Tumor, Recurrent Lymphoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Recurrent Cervical Cancer",
    "Malignant Central Nervous System Neoplasm",
    "Advanced Malignant Solid Tumor, Advanced Lymphoma",
    "Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Castration-Resistant Prostate Cancer",
    "Metastatic Pancreatic Adenocarcinoma",
    "Metastatic Lung Non-Squamous Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Human Papillomavirus-Related Squamous Cell Carcinoma",
    "Locally Advanced Cervical Carcinoma",
    "Metastatic Pancreatic Adenocarcinoma",
    "Hepatocellular Cancer",
    "Recurrent Endometrial Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Biliary Tract Carcinoma",
    "Advanced Breast Carcinoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Epstein-Barr Virus Infection",
    "Stage IIA Breast Cancer",
    "Advanced Breast Carcinoma",
    "Non-Small Cell Lung Cancer",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Hepatocellular Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia (AML)",
    "Myelofibrosis",
    "Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent B Acute Lymphoblastic Leukemia",
    "Advanced Hepatocellular Carcinoma",
    "Pancreatic Adenocarcinoma",
    "Advanced Malignant Solid Tumor",
    "High-Risk Neuroblastoma",
    "Advanced Malignant Solid Tumor",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Chronic Graft Versus Host Disease",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Advanced Malignant Solid Tumor",
    "Refractory Acute Leukemia",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Locally Advanced Breast Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent B-Cell Non-Hodgkin Lymphoma",
    "Unresectable Pleural Malignant Mesothelioma",
    "Unresectable Cutaneous (Skin) Melanoma",
    "Locally Advanced Breast Adenocarcinoma",
    "Refractory B-Cell Non-Hodgkin Lymphoma",
    "Refractory Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia (CLL)",
    "Recurrent Leiomyosarcoma",
    "Metastatic Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Unresectable Solid Tumor",
    "Castration-Resistant Prostate Cancer",
    "Chronic Graft Versus Host Disease",
    "Advanced Malignant Neoplasm",
    "Acute Graft Versus Host Disease",
    "Advanced Cholangiocarcinoma",
    "Hematopoietic and Lymphoid Cell Neoplasm, Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Acute Myeloid Leukemia (AML)",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Advanced Malignant Solid Tumor",
    "Metastatic Breast Carcinoma",
    "Stage III Thyroid Gland Medullary Cancer",
    "Metastatic Malignant Solid Tumor",
    "Recurrent B Acute Lymphoblastic Leukemia",
    "Recurrent Glioblastoma",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Unresectable Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Recurrent Marginal Zone Lymphoma",
    "Advanced Malignant Neoplasm",
    "Unresectable Malignant Solid Tumor",
    "Stage IV Cervical Cancer",
    "Myelodysplastic Syndrome",
    "Refractory Mature B-Cell Non-Hodgkin Lymphoma",
    "Resectable Head and Neck Squamous Cell Cancer",
    "Skin Squamous Cell Cancer",
    "Recurrent Endometrial Carcinoma",
    "Recurrent Non-Hodgkin Lymphoma",
    "Advanced Malignant Solid Tumor",
    "Unresectable Malignant Solid Tumor",
    "ISS Stage III Multiple Myeloma/Plasma Cell Myeloma",
    "Malignant Solid Tumor",
    "Advanced Ovarian Carcinoma",
    "Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Breast Carcinoma",
    "Unresectable Malignant Solid Tumor",
    "Malignant Solid Tumor",
    "Recurrent Lymphoma, Refractory Malignant Solid Tumor",
    "Locally Advanced Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Advanced Urothelial Cancer",
    "Recurrent Malignant Solid Tumor",
    "Recurrent Non-Small Cell Lung Cancer",
    "Advanced Melanoma",
    "Locally Advanced Skin Squamous Cell Carcinoma",
    "Stage IV Ovarian Cancer, Stage IIIA Pleural Malignant Mesothelioma, Stage IIA Pancreatic Cancer",
    "Metastatic Head and Neck Squamous Cell Cancer",
    "Advanced Malignant Neoplasm",
    "Unresectable Urothelial Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Refractory Malignant Solid Tumor",
    "Classical Hodgkin Lymphoma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Prostate Adenocarcinoma",
    "Stage IV Lung Cancer",
    "Advanced Synovial Sarcoma",
    "Advanced Lung Non-Small Cell Carcinoma",
    "Advanced Clear Cell Renal Cell Carcinoma",
    "Glioblastoma",
    "Refractory Multiple Myeloma/Plasma Cell Myeloma",
    "Recurrent Acute Myeloid Leukemia (AML)",
    "Classical Hodgkin Lymphoma",
    "Recurrent Small Cell Lung Cancer",
    "Acute Myeloid Leukemia (AML) with FLT3/ITD",
    "Non-Small Cell Lung Cancer",
    "Locally Advanced Renal Cell Carcinoma",
    "Hemorrhagic Cystitis",
    "Malignant Solid Tumor",
    "Recurrent Lymphoma, Recurrent Malignant Solid Tumor",
    "Supratentorial Glioblastoma",
    "Advanced Skin Squamous Cell Carcinoma",
    "Unresectable Gastroesophageal Junction Adenocarcinoma",
    "Recurrent Multiple Myeloma/Plasma Cell Myeloma",
    "Plexiform Neurofibroma",
    "Advanced Synovial Sarcoma",
    "Advanced Ovarian Carcinoma",
    "AL Amyloidosis",
    "Hematologic and Lymphocytic Disorder",
    "Small Lymphocytic Lymphoma",
    "Unresectable Lung Non-Small Cell Carcinoma",
    "Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Locally Advanced Malignant Solid Tumor",
    "Acute Myeloid Leukemia (AML)",
    "AL Amyloidosis",
    "Primary Myelofibrosis",
    "Locally Advanced Malignant Solid Tumor",
    "EBV-Related Post-Transplant Lymphoproliferative Disorder",
    "Advanced Malignant Neoplasm",
    "Recurrent Malignant Solid Tumor",
    "Advanced Malignant Solid Tumor",
    "Metastatic Lung Non-Small Cell Carcinoma",
    "B Acute Lymphoblastic Leukemia",
    "Infiltrating Bladder Urothelial Carcinoma",
    "Stage III Cutaneous (Skin) Melanoma",
    "Recurrent Head and Neck Squamous Cell Cancer",
    "Multiple Myeloma/Plasma Cell Myeloma",
    "Metastatic Undifferentiated Pleomorphic Sarcoma",
    "Anaplastic Astrocytoma",
    "Locally Advanced Malignant Solid Tumor",
    "Recurrent Chronic Lymphocytic Leukemia (CLL), Recurrent Small Lymphocytic Lymphoma",
    "Recurrent Ovarian Cancer",
    "Malignant Neoplasm",
    "Metastatic Bladder Urothelial Cancer",
    "Advanced Malignant Solid Tumor",
    "Glioblastoma",
    "HER2-Positive Breast Carcinoma",
    "Myelodysplastic Syndrome",
    "Ductal Carcinoma In Situ (DCIS)",
    "Grade II Glioma",
    "Ph-Like Acute Lymphoblastic Leukemia"
  ],
  "brief_title": [
    "Trametinib in Treating Patients with Advanced Cancer with or without Hepatic Dysfunction",
    "Pembrolizumab in Treating Younger Patients with Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma",
    "Comparing Standard Treatment Alone to Radiation Therapy with or without Surgery with Standard Treatment for Patients with Limited Metastatic Non-Small Cell Lung Cancer",
    "Talimogene Laherparepvec, Chemotherapy, and Radiation Therapy before Surgery in Treating Patients with Locally Advanced or Metastatic Rectal Cancer",
    "Durvalumab in Combination with Chemotherapy in Treating Patients with Advanced Solid Tumors, (DURVA+ study)",
    "Best Available Therapy Versus Autologous Hematopoetic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)",
    "Testing the Sequential Combination of the Anti-cancer Drugs Olaparib followed by Adavosertib (AZD1775) in Patients with Advanced Solid Tumors with Selected Mutations and PARP Resistance, STAR Study",
    "Testing the Response to the Anti-cancer Drug, Triapine, in Uterine Cancers Using Markers from the Tissue at the Time of Hysterectomy",
    "Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults with Relapsed / Refractory Osteosarcoma and Neuroblastoma, The GD2-CAR PERSIST Trial",
    "Testing Lutetium Lu 177 Dotatate in Patients with Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors",
    "Testing a New Anti-Cancer Drug, 131I-Omburtamab, in Recurrent Medulloblastoma or Ependymoma",
    "Measuring the Effects of Talazoparib in Patients with Advanced Cancer and DNA Repair Variations",
    "Testing the Addition of an Anti-cancer drug, BAY1895344, with Radiation Therapy to the Usual Pembrolizumab Treatment for Recurrent Head and Neck Cancer",
    "Pomalidomide Treatment in Patients with Kaposi Sarcoma",
    "Testing the Addition of An Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors",
    "Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain Amyloidosis",
    "Chemotherapy with or without Immunotherapy for Peritoneal Mesothelioma",
    "Atezolizumab in Treating Patients with Cancer following Adoptive Cell Transfer",
    "Ropidoxuridine and Whole Brain Radiation Therapy in Treating Patients with Brain Metastases",
    "Identify a Dose of Regadenoson That Will Open the Blood-Brain Barrier in Patients with Gliomas",
    "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) after Initial Chemotherapy in a Phase Ib / II Trial for Advanced HER2 Positive Breast Cancer",
    "Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab with or without Ipilimumab) in Patients with Advanced Solid Cancers That Have Changes in the following Genes: PIK3CA and PTEN",
    "Surgery in Treating Patients with Early Stage Anal Canal or Perianal Cancer and HIV Positive",
    "Atezolizumab, Gemcitabine, Oxaliplatin, and Rituximab in Treating Patients with Relapsed or Refractory Transformed Diffuse Large B-Cell Lymphoma",
    "CB-839 HCl in Combination with Carfilzomib and Dexamethasone in Treating Patients with Recurrent or Refractory Multiple Myeloma",
    "A Study of Daratumumab and Dose-Adjusted EPOCH in Plasmablastic Lymphoma",
    "Testing the Biological Effects of DS-8201a on Patients with Advanced Cancer",
    "Testing the Addition of an Anticancer Drug, BAY 1895344, to the Usual Chemotherapy with FOLFIRI in Advanced or Metastatic Cancers of the Stomach and Intestines",
    "Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers with Expansion in Patients with Endometrial Cancer",
    "Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma",
    "Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer",
    "Gene Therapy in Treating Patients with Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant",
    "Blinatumomab and Nivolumab with or without Ipilimumab in Treating Patients with Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia",
    "Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma",
    "A Study of a New Drug Combination, Copanlisib and Fulvestrant, in Advanced Breast Cancer",
    "Binimetinib and Encorafenib in Treating Patients with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or Other Primary Brain Tumor",
    "Testing the Combination of New Anti-cancer Drug Peposertib with Avelumab and Radiation Therapy for Advanced / Metastatic Solid Tumors and Hepatobiliary Malignancies",
    "Testing Treatment with Encorafenib and Binimetinib before Surgery for Melanoma with Lymph Node Involvement",
    "Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer",
    "Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma that has Progressed on the Usual Treatment",
    "Testing the Combination of Two Immunotherapy Drugs (Magrolimab and Dinutuximab) in Patients with Relapsed or Refractory Neuroblastoma or Relapsed Osteosarcoma",
    "Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors",
    "Safety Study of Cord Blood Units for Stem Cell Transplants",
    "Ipilimumab and Decitabine in Treating Patients with Relapsed or Refractory Myelodysplastic Syndrome or Acute Myeloid Leukemia",
    "Testing a New Chemotherapy Drug, KRT-232 (AMG-232) in Combination with Decitabine in Patients with Acute Myeloid Leukemia",
    "PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors with PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery",
    "Lisavanbulin and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma",
    "VGX-3100 and Electroporation in Treating Patients with HIV-Positive High-Grade Anal Lesions",
    "Pevonedistat and Belinostat in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors with Emphasis on Urothelial Cancer",
    "Testing the Use of Chemotherapy after Surgery for High-Risk Pancreatic Neuroendocrine Tumors",
    "Pembrolizumab in Treating Patients with HIV and Relapsed, Refractory, or Disseminated Malignant Neoplasms",
    "Testing Olaparib in Patients with Advanced or Metastatic (Cancer That Has Spread) Bladder Cancer with DNA-Repair Genetic Changes",
    "Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients with Advanced Solid Tumors with Selected Mutations",
    "Testing the Addition of Copanlisib to Usual Treatment (Fulvestrant and Abemaciclib) in Metastatic Breast Cancer",
    "Using the Anticancer Drug Olaparib to Treat Relapsed / Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome with an Isocitrate Dehydrogenase (IDH) Mutation",
    "Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment (“EPOCH”) for Adult T-Cell Leukemia-Lymphoma (ATL)",
    "Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients with Incurable Esophageal and Gastroesophageal Junction Cancers",
    "Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients with Relapsed / Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study",
    "Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome",
    "Testing the Addition of a New Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia / Lymphoplasmacytic Lymphoma",
    "Pembrolizumab and Ziv-aflibercept in Treating Patients with Advanced Solid Tumors",
    "sEphB4-HSA in Treating Patients with Kaposi Sarcoma",
    "Pembrolizumab and Recombinant Interleukin-12 in Treating Patients with Solid Tumors",
    "Testing the Ability of AMG 232 (KRT 232) to get into the Tumor in Patients with Brain Cancer",
    "Atezolizumab and CYT107 in Treating Participants with Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma",
    "CB-839 with Radiation Therapy and Temozolomide in Treating Patients with IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma",
    "Volitinib in Treating Patients with Recurrent or Refractory Primary CNS tumors",
    "Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients with Selected Unresectable or Metastatic Cancers",
    "Bemcentinib in Treating Patients with Recurrent Glioblastoma Undergoing Surgery",
    "Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma",
    "Testing the Drug, Panobinostat, for Patients with Diffuse Intrinsic Pontine Glioma",
    "CD40 Agonistic Monoclonal Antibody APX005M in Treating Pediatric Patients with Recurrent or Refractory Brain Tumors",
    "CX-4945 in Treating Patients with Recurrent SHH Medulloblastoma",
    "Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, with a Specific Focus on Patients with Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer",
    "Testing the Anti-cancer Drug, Rogaratinib (BAY 1163877), for Treatment of Advanced Sarcoma with Alteration in Fibroblast Growth Factor Receptor (FGFR 1-4), and in Patients with SDH-deficient Gastrointestinal Stromal Tumor (GIST)",
    "Triapine with Chemotherapy and Radiation Therapy in Treating Patients with IB2-IVA Cervical or Vaginal Cancer",
    "Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors",
    "Testing the Addition of an Anti-cancer Drug, Berzosertib, to the Usual Treatment (Radiation Therapy) for Chemotherapy-Resistant Triple-Negative and Estrogen and / or Progesterone Receptor Positive, HER2 Negative Breast Cancer",
    "Testing the Safety and Benefit of Adding Hydroxychloroquine to Dabrafenib and / or Trametinib in Children with Recurrent or Progressive Low Grade or High Grade Brain Tumor with Specific Genetic Mutations",
    "Testing the Addition of an Anti-cancer Drug, Triapine, to the Usual Radiation-Based Treatment (Lutetium Lu 177 Dotatate) for Neuroendocrine Tumors",
    "Testing INCB007839 in Patients with Recurrent, Progressive High-Grade Glioma",
    "Testing the Addition of Copanlisib to Eribulin for the Treatment of Advanced-Stage Triple Negative Breast Cancer",
    "Testing the Addition of M3814 (Peposertib) to Radiation Therapy for Patients with Advanced Head and Neck Cancer Who Cannot Take Cisplatin",
    "Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients with Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial",
    "A Phase 2 Study of Cediranib in Combination with Olaparib in Advanced Solid Tumors",
    "Optune Delivered Electric Field Therapy in Treating Children with Recurrent, Progressive, or Refractory High-Grade Glioma or Supratentorial Ependymoma",
    "Atezolizumab and Cobimetinib in Treating Patients with Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer",
    "Telaglenastat Hydrochloride and Osimertinib in Treating Patients with EGFR-Mutated Stage IV Non-small Cell Lung Cancer",
    "Nivolumab and Multi-fraction Stereotactic Radiosurgery with or without Ipilimumab in Treating Patients with Recurrent Grade II-III Meningioma",
    "Testing the Addition of the Anti-cancer Viral Therapy Telomelysin to Chemoradiation for Patients with Advanced Esophageal Cancer and Are Not Candidates for Surgery",
    "Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned after Treatment or Does Not Respond to Treatment",
    "M6620 and Irinotecan Hydrochloride in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
    "Testing the Addition of an Individualized Vaccine to Nab-Paclitaxel, Durvalumab and Tremelimumab and Chemotherapy in Patients with Metastatic Triple Negative Breast Cancer",
    "Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer",
    "Talimogene Laherparepvec and Radiation Therapy in Treating Patients with Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery",
    "Nelfinavir Mesylate in Treating Patients with Kaposi Sarcoma",
    "Testing the Safety of the Study Drug Pamiparib (BGB-290) When Given with Different Doses of the Usual Chemotherapy (Temozolomide) for Patients with Recurrent Glioma Having the IDH1 / 2 Genetic Change",
    "Testing Atezolizumab in Patients >= 2 Years Old with Newly Diagnosed, Unresectable, or Metastatic Clear Cell Sarcoma or Chondrosarcoma",
    "Imiquimod, Fluorouracil, or Observation in Treating Patients with High-Grade Anal Squamous Skin Lesions Who Are HIV-Positive",
    "ILND Surgery Alone or after Chemotherapy with or without Radiation Therapy in Treating Patients with Advanced Penile Cancer",
    "Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients with HIV-Positive Stage II-IV Diffuse Large B-Cell Lymphomas",
    "Atezolizumab with or without Eribulin Mesylate in Treating Patients with Recurrent Locally Advanced or Metastatic Urothelial Cancer",
    "Testing AZD1775 in Advanced Solid Tumors that have a Mutation called SETD2",
    "Talimogene Laherparepvec and Nivolumab in Treating Patients with Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers",
    "Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men with Advanced Prostate Cancer with Bone Metastasis",
    "Infliximab and Intravenous Immunoglobulin Therapy in Treating Patients with Steroid-Refractory Pneumonitis",
    "Radiation Medication (Radium-223 dichloride) versus Radium-223 dichloride plus Radiation Enhancing Medication (M3814) versus Radium-223 dichloride plus M3814 plus Avelumab (a type of immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy",
    "Treatment of GVHD in Hematopoietic Stem Cell Transplant (HSCT) Recipients Using AAT Plus Corticosteroids (CS) Compared With Corticosteroids Alone",
    "Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients with an IDH2 Mutation",
    "Testing the Addition of Lenalidomide and Nivolumab to the Usual Treatment for Primary CNS Lymphoma",
    "Testing the Addition of Targeted Radiation Therapy to Surgery and the Usual Chemotherapy Treatment (Pemetrexed and Cisplatin [or Carboplatin]) for Stage I-IIIA Malignant Pleural Mesothelioma",
    "Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients with Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Testing the Addition of the Immune Therapy Drugs, Tocilizumab and Atezolizumab, to Radiation Therapy for Recurrent Glioblastoma",
    "Selinexor in Treating Younger Patients with Recurrent or Refractory Solid Tumors or High-Grade Gliomas",
    "Nivolumab and Ipilimumab in Treating Patients with HIV Associated Relapsed or Refractory Classical Hodgkin Lymphoma or Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
    "Radiation Therapy with Protons or Photons in Treating Patients with Liver Cancer",
    "Tazemetostat and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Urothelial Carcinoma",
    "Birinapant and Intensity Modulated Re-Irradiation Therapy in Treating Patients with Locally Recurrent Head and Neck Squamous Cell Carcinoma",
    "Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma",
    "Testing the Addition of Radium Therapy (Radium-223 Dichloride) to the Usual Chemotherapy Treatment (Paclitaxel) for Advanced Breast Cancer That Has Spread to the Bones",
    "Cancer and Blood Pressure Management, CARISMA Study",
    "Proton Beam or Intensity-Modulated Radiation Therapy in Preserving Brain Function in Patients with IDH Mutant Grade II or III Glioma",
    "Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer",
    "Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients with Advanced Squamous Cell Non-small Cell Lung Cancer",
    "Pembrolizumab with or without Anetumab Ravtansine in Treating Patients with Mesothelin-Positive Pleural Mesothelioma",
    "Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, the RadiCaL Study",
    "Trastuzumab Deruxtecan for the Treatment of HER2+ Newly Diagnosed or Recurrent Osteosarcoma",
    "Savolitinib in Treating Patients with MET Amplified Metastatic or Unresectable Colorectal Cancer",
    "A Study of a New Way to Treat Children and Young Adults with a Brain Tumor Called NGGCT",
    "Randomized Trial of Topotecan With M6620, an ATR Kinase Inhibitor, in Small Cell Lung Cancers and Small Cell Cancers Outside of the Lungs",
    "Testing Whether Cancers with Specific Mutations Respond Better to Glutaminase Inhibitor, Telaglenastat Hydrochloride, Anti-Cancer Treatment, BeGIN Study",
    "Clinical Transplant-Related Long-term Outcomes of Alternative Donor Allogeneic Transplantation (BMT CTN 1702)",
    "Treating Prostate Cancer That Has Come Back after Surgery with Apalutamide and Targeted Radiation Using PET / CT Imaging",
    "Testing the Addition of Whole Brain Radiotherapy Using a Technique That Avoids the Hippocampus to Stereotactic Radiosurgery in Patients with Cancer That Has Spread to the Brain and Come Back in Other Areas of the Brain after Earlier Stereotactic Radiosurgery",
    "Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer",
    "Testing Atezolizumab and Bevacizumab in People with Advanced Alveolar Soft Part Sarcoma",
    "Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations",
    "Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma",
    "Testing the Addition of a New Anti-Cancer Drug, Triapine, to the Usual Chemotherapy Treatment (Cisplatin) during Radiation Therapy for Advanced-stage Cervical and Vaginal Cancers",
    "Testing Olaparib Either Alone or in Combination with Atezolizumab in BRCA Mutant Non-HER2-positive Breast Cancer",
    "MDM2 Inhibitor AMG-232 (KRT-232) and Radiation Therapy in Treating Patients with Soft Tissue Sarcoma",
    "Nivolumab in Treating Patients with Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer",
    "Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma",
    "Testing the Addition of an Anti-Cancer Immunotherapy Drug, Avelumab, to Gemcitabine and Carboplatin Chemotherapy Prior to Surgery in Muscle Invasive Urinary Tract Cancer vs. Surgery Alone in Patients Who Are Not Able to Receive Cisplatin Therapy, SWOG GAP Trial",
    "Nivolumab with or without Ipilimumab in Treating Patients with Refractory Metastatic Anal Canal Cancer",
    "Stereotactic Radiosurgery or Hippocampus Avoidance Whole-Brain Radiation Therapy with Memantine in Treating Patients with 5-15 Brain Metastases",
    "A Study to Compare Treatment with the Drug Selumetinib Alone versus Selumetinib and Vinblastine in Patients with Recurrent or Progressive Low-Grade Glioma",
    "Comparing Photon Therapy to Proton Therapy to Treat Patients with Lung Cancer",
    "Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer",
    "Trametinib in Treating Patients with Relapsed or Refractory Juvenile Myelomonocytic Leukemia",
    "Comparing an Alternative Surgical Procedure, Sentinel Lymph Node (SLN) Biopsy, with Standard Neck Dissection for Patients with Early-Stage Oral Cavity Cancer",
    "A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which has Spread to the Lymph Nodes (The INSPIRE Study)",
    "Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer",
    "Testing the Use of Steroids and Tyrosine Kinase Inhibitors with Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults",
    "Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy before Surgery for Patients with High-Grade Upper Urinary Tract Cancer",
    "Testing Nivolumab and Ipilimumab with Short-Course Radiation in Advanced Rectal Cancer",
    "Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Added to Radiation or Given by Itself Compared to the Usual Treatment of Chemotherapy with Radiation after Surgery for Recurrent Head and Neck Squamous Cell Carcinoma",
    "Treatment with Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination with Irinotecan and Temozolomide after Intensive Therapy for People with High-Risk Neuroblastoma (NBL)",
    "Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) after Surgery for Men with High-Risk Prostate Cancer, The ERADICATE Study",
    "Testing the Addition of Ixazomib to Lenalidomide in Patients with Evidence of Residual Multiple Myeloma, OPTIMUM Trial",
    "Testing CC-486 (Oral Azacitidine) plus the Standard Drug Therapy in Patients 75 years or Older with Newly Diagnosed Diffuse Large B Cell Lymphoma",
    "Larotrectinib in Treating Patients with Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia",
    "A Study Evaluating Whether Pembrolizumab Alone or in Combination with CMP-001 Improves Efficacy in Patients with Operable Melanoma",
    "Nivolumab in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma",
    "Vemurafenib and Cobimetinib in Treating Patients with BRAF V600E Mutation Positive Craniopharyngioma",
    "Venetoclax and Vincristine Liposomal in Treating Patients with Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia",
    "Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma",
    "A Study of a New Drug, Nirogacestat, for Treating Desmoid Tumors that Cannot be Removed by Surgery",
    "Olaparib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)",
    "A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients with Low-Grade Glioma",
    "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients",
    "A Study of the Drugs Selumetinib versus Carboplatin / Vincristine in Patients with Neurofibromatosis and Low-Grade Glioma",
    "Vemurafenib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)",
    "Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors",
    "Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients with Relapsed / Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)",
    "Ensartinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)",
    "Larotrectinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with NTRK Fusions (A Pediatric MATCH Treatment Trial)",
    "Erdafitinib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with FGFR Mutations (A Pediatric MATCH Treatment Trial)",
    "Samotolisib in Treating Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with TSC or PI3K / MTOR Mutations (A Pediatric MATCH Treatment Trial)",
    "Palbociclib in Treating Patients with Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders with Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)",
    "Chemotherapy and Pelvic Radiation Therapy with or without Additional Chemotherapy in Treating Patients with High-Risk Early-Stage Cervical Cancer after Radical Hysterectomy",
    "Chemotherapy before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients with Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery",
    "Irinotecan Hydrochloride, Temozolomide, and Dinutuximab with or without Eflornithine in Treating Patients with Relapsed or Refractory Neuroblastoma",
    "A Study to Compare Early Use of Vinorelbine and Maintenance Therapy for Patients with High Risk Rhabdomyosarcoma",
    "A Study to Compare Blinatumomab Alone to Blinatumomab with Nivolumab in Patients Diagnosed with First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL)",
    "Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer",
    "Ibrutinib before and after Stem Cell Transplant in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma",
    "Testing Sacituzumab Govitecan Therapy in Patients with HER2-Negative Breast Cancer and Brain Metastases",
    "Single Fraction Stereotactic Radiosurgery or Three to Five Fraction Stereotactic Radiosurgery in Treating Patients with Brain Metastasis That Has Been Removed By Surgery",
    "A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer Who Have a BRCA1, BRCA2 or PALB2 Mutation, The APOLLO Trial",
    "Comparing the New Anti-cancer Drug Eribulin with or without Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer",
    "Daunorubicin and Cytarabine with or without Uproleselan in Treating Older Adult Patients with Acute Myeloid Leukemia Receiving Intensive Induction Chemotherapy",
    "A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients with Recurrent Glioblastoma with Elevated Mutational Burden",
    "Testing what Happens when an Immunotherapy Drug (Avelumab) Is Added to a Usual Drug Treatment (Cetuximab) Compared to Avelumab by Itself in the Treatment of Advanced Squamous Cell Carcinoma of the Skin (cSCC)",
    "Observation or Radiation Therapy in Treating Patients with Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery",
    "Inotuzumab Ozogamicin in Treating Younger Patients with B-Lymphoblastic Lymphoma or Relapsed or Refractory CD22 Positive B Acute Lymphoblastic Leukemia",
    "Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients with Chronic Phase Chronic Myeloid Leukemia",
    "Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder Cancer",
    "Accelerated or Standard BEP Chemotherapy in Treating Patients with Intermediate or Poor-Risk Metastatic Germ Cell Tumors",
    "Comparison of Standard of Care Treatment with a Triplet Combination of Targeted Immunotherapeutic Agents",
    "Evaluation of Dosing Procedures of Chemotherapy Treatment (Carboplatin) with the Contrast Agent Iohexol",
    "Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People with High-Risk Neuroblastoma (NBL)",
    "Individualized Treatment in Treating Patients with Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA",
    "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients with Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)",
    "A Study of Combination Chemotherapy for Patients with Newly Diagnosed DAWT and Relapsed FHWT",
    "Ivosidenib in Treating Patients with Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with IDH1 Mutations (A Pediatric MATCH Treatment Trial)",
    "Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders with HRAS Gene Alterations, a Pediatric MATCH Treatment Trial",
    "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders with Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial",
    "Radiation Therapy with or without Olaparib in Treating Patients with Inflammatory Breast Cancer",
    "Genetic Testing in Guiding Treatment for Patients with Brain Metastases",
    "CASPAR, A Clinical Study Evaluating The Benefit of Adding Rucaparib to Enzalutamide for Men with Metastatic Prostate Cancer That Has Become Resistant To Testosterone-Deprivation Therapy",
    "Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma",
    "A Study to Compare Standard Chemotherapy to Therapy with CPX-351 and / or Gilteritinib for Patients with Newly Diagnosed AML with or without FLT3 Mutations",
    "Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients with Down Syndrome",
    "Cisplatin and Combination Chemotherapy in Treating Children and Young Adults with Hepatoblastoma or Liver Cancer After Surgery",
    "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer",
    "Testing the Combination of Dabrafenib and Trametinib with or without Hydroxychloroquine in Patients with Stage IIIC or IV BRAF V600E / K Melanoma with Elevated LDH",
    "Imatinib Mesylate and Combination Chemotherapy in Treating Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
    "Testing the Use of the Usual Chemotherapy before and after Surgery for Removable Pancreatic Cancer",
    "Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients with Non-high Risk Neuroblastoma",
    "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial",
    "Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients with High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy",
    "Testing the Use of the Immunotherapy Drugs Ipilimumab and Nivolumab plus Radiation Therapy Compared to the Usual Treatment (Temozolomide and Radiation Therapy) for Newly Diagnosed MGMT Unmethylated Glioblastoma",
    "Testing Pembrolizumab with Existing Cancer Therapy in Patients with Evidence of Residual Chronic Myelogenous Leukemia",
    "Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients with Pancreatic Cancer That Has Spread with Inherited BRCA Mutations",
    "A Study to Investigate Blinatumomab in Combination with Chemotherapy in Patients with Newly Diagnosed B-Lymphoblastic Leukemia",
    "Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy with or without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial",
    "Testing the Effects of Early Treatment with Venetoclax and Obinutuzumab versus Delayed Treatment with Venetoclax and Obinutuzumab for Newly Diagnosed Patients with High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Do Not Have Symptoms, the EVOLVE CLL / SLL Study",
    "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients with Early Non-small Cell Lung Cancer",
    "Testing the Usual Treatment of Radiation Therapy and Hormonal Therapy to Hormonal Therapy alone for Low-Risk, Early Stage Breast Cancer, the DEBRA Trial",
    "Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) with One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors",
    "Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients with Stage IIA-B Prostate Cancer",
    "Carboplatin and Paclitaxel with or without Ramucirumab in Treating Patients with Locally Advanced, Recurrent, or Metastatic Thymic Cancer That Cannot Be Removed by Surgery",
    "Comparing Two Methods to Follow Patients with Pancreatic Cysts",
    "Inotuzumab Ozogamicin and Blinatumomab in Treating Patients with Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia",
    "EA2176: Phase 3 Clinical Trial of Carboplatin and Pacliitaxel + / - Nivolumab in Metastatic Anal Cancer Patients",
    "Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer",
    "Osimertinib with or without Bevacizumab as Initial Treatment for Patients with EGFR-Mutant Lung Cancer",
    "Chemoradiotherapy with or without Atezolizumab in Treating Patients with Localized Muscle Invasive Bladder Cancer",
    "Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer",
    "Testing Whether the Use of Brain Scans Alone Instead of Brain Scans plus Preventive Brain Radiation Affects Lifespan in Patients with Small Cell Lung Cancer",
    "Testing Cabozantinib in Patients with Advanced Pancreatic Neuroendocrine and Carcinoid Tumors",
    "Gemcitabine Hydrochloride and Cisplatin in Treating Patients with Invasive Bladder Urothelial Cancer",
    "Comparison of Chemotherapy before and after Surgery versus after Surgery Alone for the Treatment of Gallbladder Cancer, OPT-IN Trial",
    "Rituximab with or without Stem Cell Transplant in Treating Patients with Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission",
    "Combination Chemotherapy with or without Temsirolimus in Treating Patients with Intermediate Risk Rhabdomyosarcoma",
    "Comparing the Outcome of Standard Systemic Therapy Only versus Standard Systemic therapy with either Surgery or Radiation Therapy, for Patients with Advanced Prostate cancer",
    "Regional Radiation Therapy with or without Whole Breast Irradiation in Treating Patients with Estrogen Receptor Positive, HER2 Negative Low Risk Breast Cancer Who Have Undergone Breast Conserving Surgery or Mastectomy",
    "Brentuximab Vedotin and Nivolumab with or without Ipilimumab in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma",
    "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma with Brain Metastases",
    "Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients with Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial",
    "De-intensified Radiation Therapy with Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients with Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer",
    "Combination Chemotherapy, Bevacizumab, and / or Atezolizumab in Treating Patients with Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study",
    "Trying to Find the Correct Length of Treatment with Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma",
    "Obinutuzumab with or without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients with Relapsed or Refractory Grade I-IIIa Follicular Lymphoma",
    "Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)",
    "Testing the Effects of MK-3475 (Pembrolizumab) with or without the Usual Chemotherapy Treatment for Patients 70 Years of Age and Older with Advanced Non-small Cell Lung Cancer",
    "Radiation Therapy with or without Chemotherapy in Patients with Stage I-IIA Cervical Cancer Who Previously Underwent Surgery",
    "Nivolumab and Ipilimumab in Treating Patients with Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery",
    "Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults with Newly Diagnosed B Acute Lymphoblastic Leukemia",
    "Testing the Addition of Daratumumab-Hyaluronidase to Enhance Therapeutic Effectiveness of Lenalidomide in Smoldering Multiple Myeloma, The DETER-SMM Trial",
    "Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma",
    "Testing The Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients with Chronic Lymphocytic Leukemia",
    "Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers",
    "Testing Immunotherapy versus Observation in Patients with HPV Throat Cancer",
    "Radiation Therapy with or without Cisplatin in Treating Patients with Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery",
    "A Comparison of Three Chemotherapy Regimens for Patients with Newly Diagnosed Mantle Cell Lymphoma",
    "Immunotherapy with Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab with Cabozantinib for Patients with Advanced Kidney Cancer, The PDIGREE Study",
    "Lower-Dose Chemoradiation in Treating Patients with Early-Stage Anal Cancer, the DECREASE Study",
    "Testing the Use of Combination Therapy in Adult Patients with Newly Diagnosed Multiple Myeloma, the EQUATE Trial",
    "Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia",
    "Chemoradiation with or without Atezolizumab in Treating Patients with Limited Stage Small Cell Lung Cancer",
    "Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas",
    "Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients with Germ Cell Tumors",
    "Pembrolizumab Compared to Standard of Care Observation in Treating Patients with Completely Resected Stage I-III Merkel Cell Cancer, STAMP Study",
    "Testing Maintenance Therapy for Small Cell Lung Cancer in Patients with SLFN11 Positive Biomarker",
    "T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial",
    "A Phase II / III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients with Advanced Melanoma",
    "Vitamin D3 with Chemotherapy and Bevacizumab in Treating Patients with Advanced or Metastatic Colorectal Cancer, SOLARIS Trial",
    "Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib alone in Recurrent or Refractory Endometrial Cancer following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone",
    "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer",
    "Testing the Addition of a New Drug, Daratumumab / rHuPH20, to the Usual Treatment (Lenalidomide) as Post-stem Cell Transplant Treatment for Multiple Myeloma, DRAMMATIC Study",
    "Testing the Drug Atezolizumab or Placebo with Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer",
    "Letrozole with or without Paclitaxel and Carboplatin in Treating Patients with Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Combination Chemotherapy with or without Atezolizumab in Treating Patients with Stage III Colon Cancer and Deficient DNA Mismatch Repair",
    "Comparing Two Treatment Combinations, Gemcitabine and Nab-Paclitaxel with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan for Older Patients with Pancreatic Cancer That Has Spread",
    "Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients with Locally Advanced or Metastatic HER2 / Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery",
    "Testing the Addition of an Antibody to Standard Chemoradiation followed by the Antibody for One Year to Standard Chemoradiation followed by One Year of the Antibody in Patients with Unresectable Stage III Non-Small Cell Lung Cancer",
    "A Study to Compare the Administration of Pembrolizumab after Surgery Versus Administration both before and after Surgery for High-Risk Melanoma",
    "Circulating Tumor DNA Testing in Predicting Treatment for Patients with Stage IIA Colon Cancer After Surgery, COBRA Trial",
    "Testing the Ability to Decrease Chemotherapy in Patients with HER2-Positive Breast Cancer Who Have No Remaining Cancer at Surgery after Limited Pre-operative Chemotherapy and HER2-Targeted Therapy",
    "Biomarker-Driven Therapy and Immunotherapy in Screening Participants with Recurrent or Stage IV Non-Small Cell Lung Cancer (The Expanded Lung-MAP Screening Trial)",
    "Nivolumab and Ipilimumab in Treating Patients with Rare Tumors",
    "Lymph Node Dissection and Radiation Therapy in Treating Patients with Breast Cancer Previously Treated with Chemotherapy and Surgery",
    "Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer",
    "Doxorubicin Hydrochloride and Cyclophosphamide Followed by Paclitaxel with or without Carboplatin in Treating Patients with Triple-Negative Breast Cancer",
    "Targeted Therapy Directed by Genetic Testing in Treating Patients with Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)",
    "Crizotinib in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)",
    "Genetic Testing in Screening Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)",
    "Treatment and Natural History Study of Lymphomatoid Granulomatosis",
    "Iobenguane I-131 in Treating Patients with Recurrent Neuroblastoma, Malignant Pheochromocytoma, or Malignant Paraganglioma",
    "Busulfan, Melphalan, and Fludarabine Phosphate Followed by Donor Umbilical Cord Blood Transplant in Treating Younger Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome",
    "Cladribine and Rituximab in Treating Patients with Hairy Cell Leukemia",
    "Combination Chemotherapy and Nelarabine in Treating Patients with T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
    "Peripheral Blood Stem Cell Transplant in Treating Patients with Acute Myeloid Leukemia",
    "Docetaxel, Cisplatin and Fluorouracil in Treating Patients with Previously Untreated Stage II-IV Nasal Cavity and Paranasal Sinus Cancer",
    "Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients with Hematologic Disease",
    "Fludarabine Phosphate, Cytarabine, Filgrastim-sndz, Gemtuzumab Ozogamicin, and Idarubicin Hydrochloride in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Standardization of CD3+ T Cell Dose for Patients Undergoing Donor Stem Cell Transplants",
    "Reduced Intensity Conditioning Regimen for the Treatment of Non-Malignant Disorders",
    "Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia",
    "Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation",
    "Vaccine Therapy and Cyclophosphamide in Treating Patients with Pancreatic Cancer",
    "Radiation Therapy in Treating Patients Who Have Undergone Surgery For Phyllodes Tumors",
    "Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency",
    "Radiation Therapy in Treating Patients with Stage 0-II Breast Cancer",
    "Cyclophosphamide in Treating Patients with Hematological Malignancies after Undergoing Donor Stem Cell Transplant",
    "Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia",
    "MRI-Mapped Dose-Escalated Salvage Radiotherapy for the Treatment of Prostate Cancer after Surgery, the MAPS Study",
    "Ixazomib Citrate in Treating Patients with Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib",
    "Combination Chemotherapy and Ponatinib Hydrochloride in Treating Patients with Acute Lymphoblastic Leukemia",
    "Radiation Therapy and Rituximab in Treating Patients with Stage I-II Grade 1 or Grade 2 Follicular Lymphoma",
    "Transoral Robotic Surgery in Treating Patients with Benign or Malignant Tumors of the Head and Neck",
    "Cladribine, Cytarabine, and Decitabine in Treating Patients with Untreated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Bevacizumab and Temsirolimus Alone or in Combination with Valproic Acid or Cetuximab in Treating Patients with Advanced or Metastatic Malignancy or Other Benign Disease",
    "Vandetanib and Everolimus in Treating Patients with Advanced or Metastatic Cancer",
    "Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and / or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients with Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome",
    "Stereotactic Radiosurgery in Treating Patients with Greater Than 3 Melanoma Brain Metastases",
    "Gemcitabine Hydrochloride, Clofarabine, and Busulfan before Donor Stem Cell Transplant in Treating Patients with Refractory B-Cell or T-Cell Non-Hodgkin Lymphoma or Hodgkin Lymphoma",
    "Brentuximab Vedotin with or without Nivolumab in Treating Patients with Relapsed or Refractory CD30+ Lymphoma",
    "Sotatercept in Treating Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis or Anemia",
    "Ruxolitinib for Adult T-Cell Leukemia",
    "Sirolimus and Auranofin in Treating Patients with Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer",
    "Ipilimumab and Imatinib Mesylate in Treating Patients with Metastatic or Unresectable Solid Tumors",
    "Ponatinib Hydrochloride as Second Line Therapy in Treating Patients with Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib",
    "Reduced-Intensity Conditioning before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies",
    "Combination Chemotherapy in Treating Patients with Newly Diagnosed, Previously Untreated Intraocular Retinoblastoma",
    "Ruxolitinib Phosphate and Azacytidine in Treating Patients with Myelofibrosis or Myelodysplastic Syndrome / Myeloproliferative Neoplasm",
    "Chemotherapy in Treating Patients with Myelodysplastic Syndrome before Donor Stem Cell Transplant",
    "MIBG for Refractory Neuroblastoma and Pheochromocytoma",
    "Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations",
    "Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients with Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery",
    "Radiosurgery in Treating Patients with Stage I Kidney Cancer",
    "Radiosurgery before Surgery in Treating Patients with Brain Metastases That Can Be Removed by Surgery",
    "Combination Chemotherapy in Treating Patients with Metastatic Appendiceal Cancer",
    "Nonmyeloablative Donor Stem Cell Transplant in Treating Patients with Congenital Anemias including Sickle Cell Disease and Thalassemia",
    "Combination Chemotherapy before and after Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery",
    "Fractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis",
    "CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant",
    "Curcumin in Treating Patients with Prostate Cancer That Was Removed by Surgery",
    "Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma",
    "Radiolabeled Glass Beads for the Treatment of Patients with Advanced or Metastatic and Unresectable Hepatocellular Cancer",
    "Combination Chemotherapy and Radiation Therapy in Treating Patients with Newly Diagnosed Stage I-II Nasal NK Cell Lymphoma",
    "Proton Beam Radiation Therapy in Treating Patients with Neuroblastoma or Ganglioneuroblastoma",
    "Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia",
    "Organ-Sparing Marrow-Targeted Irradiation before Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies",
    "Lenalidomide in Treating Patients with High Risk Acute Myeloid Leukemia in Remission",
    "Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients with Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia",
    "Cellular Immunotherapy in Treating Patients with High-Risk Acute Lymphoblastic Leukemia",
    "Genetically Modified T-cell Immunotherapy in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Technetium Tc-99m Sestamibi SPECT / CT Imaging in Treating Patients with Kidney Cancer",
    "Ropivacaine Hydrochloride via Paravertebral Blocks before Surgery in Decreasing Pain in Patients with Breast Cancer",
    "Dose Adjusted EPOCH Regimen in Combination with Ofatumumab or Rituximab in Treating Patients with Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia",
    "Cabazitaxel, Gemcitabine, and Cisplatin in Treating Patients with BCG Solution-Refractory Non-muscle Invasive Urothelial Carcinoma of the Bladder",
    "Radiation Therapy and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Pancreatic Cancer",
    "Donor Cytomegalovirus-Specific Cytotoxic T-Lymphocytes in Treating Patients with a Persistent Cytomegalovirus Infection",
    "Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors",
    "Dabrafenib and Trametinib before and after Surgery in Treating Patients with Stage IIIB-C Melanoma with BRAF V600 Mutation",
    "Reduced-Dose Radiation Therapy after Chemotherapy and Surgery in Treating Patients with High-Risk Neuroblastoma",
    "JAK Inhibitor before Donor Stem Cell Transplant in Treating Patients with Primary or Secondary Myelofibrosis",
    "Talazoparib in Treating Patients with Recurrent, Refractory, Advanced, or Metastatic Cancers and Alterations in the BRCA Genes",
    "Cabozantinib S-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery",
    "Genetically Modified T-Cell Immunotherapy in Treating Patients with Recurrent or Refractory Neuroblastoma",
    "Bosutinib and Inotuzumab Ozogamicin in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia",
    "Stereotactic Body Radiation Therapy in Treating Patients with Stage IV Oncogene-Driven Non-small Cell Lung Cancer Receiving Selected Targeted Therapy",
    "Ceritinib and Everolimus in Treating Patients with Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer",
    "Intensity Modulated Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients with Relapsed Hematologic Cancers Undergoing a Second or above Donor Stem Cell Transplant",
    "Peginterferon alfa-2b in Treating Younger Patients with Recurrent or Refractory and Radiographically or Clinically Progressive Pilocytic Astrocytomas and Optic Pathway Gliomas",
    "Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation",
    "Mitomycin in Treating Patients with P16 Positive Oropharyngeal or P16 Negative Head and Neck Cancer That is Resistant to Platin, Fluorouracil, Cetuximab, and Taxane",
    "P1101 in Treating Patients with Myelofibrosis",
    "MRI-Guided Laser Heat Ablation in Treating Younger Patients with Brain Tumors",
    "Iobenguane I-131 in Treating Patients with Recurrent or Refractory Neuroblastoma or Non-neuroblastic Iobenguane Avid Tumors",
    "Combination Nilotinib and Paclitaxel in Adults With Relapsed Solid Tumors",
    "Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients with Advanced, Recurrent, or Refractory Solid Tumors",
    "Stereotactic Radiosurgery Dose Escalation in Treating Patients with Brain Metastases",
    "PLX3397 in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN)",
    "Nivolumab and Azacitidine with or without Ipilimumab in Treating Patients with Refractory / Relapsed or Newly Diagnosed Acute Myeloid Leukemia",
    "Talazoparib in Treating Patients with BRCA1 and BRCA2 Wild-Type, Metastatic or Recurrent, Triple-Negative or HER2-Negative Breast Cancer or Other Solid Tumors",
    "Pembrolizumab in Treating Patients with Stage IV Metastatic or Recurrent Inflammatory Breast Cancer or Triple-Negative Breast Cancer Who Have Achieved Clinical Response or Stable Disease to Prior Chemotherapy",
    "Afatinib Dimaleate and Capecitabine in Treating Patients with Advanced Refractory Solid Tumors, Pancreatic Cancer or Biliary Cancer",
    "Natural Killer Cell-Enriched Donor Cell Infusions with or without TLR9 Agonist DUK-CPG-001 in Treating Patients with Hematologic Disease after Donor Stem Cell Transplant",
    "Talimogene Laherparepvec and Preoperative Radiation Therapy in Treating Patients with Locally Advanced Soft Tissue Sarcoma That Cannot Be Removed by Surgery",
    "Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients with Locally Advanced TNBC with Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative",
    "Blinatumomab in Treating Patients with B-cell Acute Lymphoblastic Leukemia with Minimal Residual Disease",
    "Rapid Pancreatic and Ovarian MR Imaging in Screening Patients with BRCA Mutation Undergoing Breast MRI",
    "Stereotactic Ablative Radiation Therapy in Treating Patients with Kidney Cancer Undergoing Surgery",
    "Tamoxifen Citrate or Aromatase Inhibitor in Treating Elderly Patients with Estrogen Receptor Positive Breast Cancer That Can Be Removed by Surgery",
    "Cytotoxic T Lymphocytes in Treating Patients with Malignancies with BK and / or JC Virus",
    "Single-Fraction Partial Breast Radiation Therapy before Surgery in Treating Patients with Early Stage Breast Cancer",
    "Phase I / II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and / or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...",
    "Ultra Low Dose Orbital Radiation Therapy in Treating Patients with Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma",
    "Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed / Refractory Hematologic Malignancies or High Risk Solid Tumors",
    "Romidepsin in Conditioning and Maintenance in Patients with T-cell Leukemia or Lymphoma Undergoing Donor Stem Cell Transplant",
    "Nivolumab and / or Ipilimumab with or without Azacitidine in Treating Patients with Myelodysplastic Syndrome",
    "Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma",
    "Stereotactic Body Radiation Therapy in Treating Patients with Metastatic or Recurrent Kidney Cancer",
    "Reduced Intensity Chemotherapy and Radiation Therapy before Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies",
    "Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies",
    "Personalized Peptide Vaccine in Treating Patients with Advanced Pancreatic Cancer or Colorectal Cancer",
    "High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk Neuroblastoma",
    "Transarterial Chemoperfusion: Cisplatin, Methotrexate, Gemcitabine for Unresectable Pleural Mesothelioma",
    "Combination Chemotherapy and Binimetinib in Treating Patients with RAS Positive Metastatic Colorectal Cancer",
    "RNA CART-19 Cells and Cyclophosphamide for the Treatment of Recurrent or Refractory Hodgkin Lymphoma",
    "Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia",
    "Riociguat in Treating Patients with Sickle Cell Diseases",
    "Pembrolizumab and Vorinostat in Treating Patients with Stage IV Non-small Cell Lung Cancer",
    "Ibrutinib Given before Surgery in Treating Patients with Prostate Cancer",
    "Cobimetinib in Treating Patients with Histiocytic Disorders",
    "Genetically Engineered Cells (CART22 T Cells) for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in Pediatric Patients",
    "Selective Surgical Staging in Predicting Lymph Node Removal in Patients with Endometrial Cancer Undergoing Surgery",
    "Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma",
    "Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning for the Treatment of Blood Diseases",
    "Exemestane in Treating Post-menopausal Patients with Recurrent or Advanced Non-small Cell Lung Cancer",
    "Quantitative Cardiac Magnetic Resonance Imaging in Finding Heart Complications in Patients with Breast Cancer Receiving Chemotherapy",
    "Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation",
    "Guadecitabine and Donor Lymphocyte Infusion in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing after Allogeneic Stem Cell Transplant",
    "Enzalutamide and Paclitaxel before Surgery in Treating Patients with Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer",
    "Dasatinib and Venetoclax in Treating Patients with Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia",
    "CD30 Receptor-Activated T-cells in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Non-Hodgkin Lymphoma",
    "Radiation Therapy in Treating Patients with Recurrent Brain Tumors Who Have Undergone Previous Radiation Therapy",
    "Photodynamic Therapy, Gliolan, and Vitamin D3 for the Treatment of Carcinoma In-situ, High-Grade Anal Dyplasia, or Microinvasive Anal Cancer",
    "Vaccine Therapy in Treating Patients with Malignant Peripheral Nerve Sheath Tumor That is Recurrent or Cannot Be Removed by Surgery",
    "Hypofractionated Radiation for Preoperative Treatment of Patients with Sarcoma",
    "CD40 Agonistic Monoclonal Antibody APX005M and Pembrolizumab in Treating Patients with Stage III-IV Melanoma",
    "Pembrolizumab in Treating Patients with Malignant Pleural Mesothelioma That Can Be Removed by Surgery",
    "Dose Escalation Trial of Re-irradiation in Good Prognosis Recurrent Glioblastoma",
    "Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients with Spine Metastases at Risk for Compressing the Spinal Cord",
    "Disulfiram and Copper Gluconate with Radiation Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma That Can Be Removed by Surgery",
    "Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation with or without Anti-Thymocyte Globulin before Donor Umbilical Cord Blood Transplant in Treating Patients with Hematologic Cancer",
    "Filgrastim, Cladribine, Cytarabine, and Mitoxantrone with Sorafenib in Treating Patients with Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Liver Surgery and Chemotherapy in Treating Patients with Colorectal Cancer with Liver Metastases That Can Be Removed by Surgery and Lung Metastases That Cannot Be Removed by Surgery",
    "Pembrolizumab and Nab-paclitaxel in Treating Patients with HER2-Negative Metastatic Breast Cancer",
    "Study of Baricitinib, a JAK1 / 2 Inhibitor, in Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation",
    "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed / Refractory Small Cell Lung Cancer",
    "Sargramostim and Trastuzumab in Treating Younger Patients with Recurrent Ependymoma",
    "Pembrolizumab, Cisplatin, and Intensity Modulated Radiation Therapy in Treating Patients with Previously Untreated Stage III-IVb Head and Neck Cancer",
    "Next Generation Personalized Neuroblastoma Therapy with Ribociclib and Ceritinib, Trametinib, or HDM2 Inhibitor HDM201 in Treating Younger Patients with High-Risk Neuroblastoma",
    "Blinatumomab and T Cell Depleted Donor Blood Cell Transplant in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancy after a Previous Transplant",
    "Intensity-Modulated Proton Therapy after Limited Surgery or Radical Surgery in Treating Younger Patients with Craniopharyngioma",
    "Durvalumab for the Treatment of Relapsed or Refractory Solid Tumors, Lymphoma, or Central Nervous System Tumors",
    "Azacitidine and Pembrolizumab in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery",
    "Rebastinib Tosylate and Paclitaxel or Eribuilin Mesylate in Treating Patients with HER2 Negative Metastatic Breast Cancer",
    "Durvalumab before Surgery in Treating Patients with Oral Cavity or Oropharynx Cancer",
    "Pembrolizumab, Paclitaxel, and Carboplatin for the Treatment of Stage III-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome",
    "E7 TCR T Cells for Human Papillomavirus-Associated Cancers",
    "Continuous 24h Intravenous Infusion of Mithramycin, an Inhibitor of Cancer Stem Cell Signaling, in People With Primary Thoracic Malignancies or Carcinomas, Sarcomas or Germ Cell Neoplasms With Pleuropulmonary Metastases",
    "Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients with Blood Cancer Undergoing Donor Stem Cell Transplant",
    "Imiquimod with or without 9-Valent HPV Vaccine in Treating Patients with High-Grade Pre-neoplastic Cervical Lesions",
    "Carfilzomib and Umbralisib in Treating Patients with Relapsed or Refractory Lymphoma",
    "Ultrasonic Aspiration versus CO2 Laser Ablation for the Treatment of High-Grade Vulvar Intraepithelial Neoplasia",
    "Blinatumomab, Inotuzumab Ozogamicin, and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia",
    "Partially HLA-Mismatched Related Donor Stem Cell Transplant Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection in Treating Patients with Hematologic Malignancies",
    "Cabozantinib S-malate in Treating Children with Recurrent or Refractory Central Nervous System Tumors",
    "Whipple Procedure or Distal Pancreatectomy and Hepatectomy in Treating Patients with Metastatic Pancreatic Cancer",
    "Palbociclib with Cisplatin or Carboplatin in Treating Patients with Advanced Solid Tumors",
    "HPV-related Oropharyngeal and Uncommon Cancers Screening",
    "Nintedanib Alone followed by Nintedanib, Gemcitabine Hydrochloride, and Nab-paclitaxel in Treating Participants with Locally Advanced or Metastatic Pancreatic Adenocarcinoma",
    "Nivolumab with Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients with BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma",
    "Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma",
    "Fulvestrant and Tamoxifen Citrate in Treating Patients with Estrogen Receptor Positive Metastatic Breast Cancer",
    "Fludarabine Phosphate, Busulfan, Rabbit Anti-thymocyte Globulin, Tacrolimus, and Methotrexate in Treating Participants with Blood Cancer Undergoing Stem Cell Transplant",
    "Ixazomib Citrate, Lenalidomide, and Dexamethasone in Treating Patients with POEMS Syndrome",
    "Bemcentinib and Docetaxel in Treating Patients with Stage IV Non-small Cell Lung Cancer",
    "Fludarabine-Based Conditioning before Donor Bone Marrow Transplant in Patients with Acquired Aplastic Anemia or Inherited Bone Marrow Failure Syndromes",
    "PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer",
    "Nimotuzumab and Nivolumab in Treating Patients with Advanced Non-small Cell Lung Cancer or Squamous Cell Head and Neck Cancer",
    "Apalutamide with or without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients with High-Risk Prostate Cancer Undergoing Surgery",
    "Pembrolizumab after Radiation Therapy in Treating Patients with Pleural Malignant Mesothelioma",
    "Donor Bone Marrow Derived Mesenchymal Stem Cells in Controlling Heart Failure in Patients with Cardiomyopathy Caused by Anthracyclines",
    "Expedited Laser Interstitial Thermal Therapy, Radiation Therapy, and Temozolomide in Treating Patients with Newly Diagnosed High Grade Glioma",
    "Pembrolizumab in Treating Patients with Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy",
    "Pembrolizumab with and without Intra-operative Radiation Therapy in Treating Patients with Triple Negative Breast Cancer",
    "Afatinib Dimaleate and Cetuximab as Second-Line Treatment in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer",
    "FASN Inhibitor TVB-2640 in Treating Patients with Colon or Other Cancers That Can Be Removed by Surgery",
    "Pembrolizumab in Treating Patients with Acute Myeloid Leukemia, Myelodysplastic Syndrome, or B Cell Lymphomas after Donor Stem Cell Transplant",
    "Reduced Intensity Conditioning and Stem Cell Transplant in Treating Patients with Blood Cancer",
    "A Donor Stem Cell Transplant (Alpha / Beta T Cell and CD19+ B Cell Depleted Stem Cells) in Treating Patients with Primary Immunodeficiencies",
    "Cisplatin and Intensity-Modulated Radiation Therapy in Treating Patients with Locally Advanced Head and Neck Squamous Cell Carcinoma",
    "Nab-paclitaxel / Rituximab-coated Nanoparticle AR160 in Treating Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma, LS1681 Trial",
    "Epacadostat, Pembrolizumab, and CRS-207 with or without Cyclophosphamide and a Vaccine (GVAX Pancreas Vaccine) in Treating Patients with Metastatic Pancreatic Cancer",
    "Brentuximab Vedotin in Treating Patients with CD30+ Malignant Mesothelioma That Cannot Be Removed by Surgery",
    "Durvalumab with or without Lenalidomide in Treating Patients with Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma",
    "Pembrolizumab and Ruxolitinib Phosphate in Treating Patients with Metastatic Stage IV Triple Negative Breast Cancer",
    "Brentuximab Vedotin, Cyclosporine, and Verapamil Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma",
    "Sapanisertib and Metformin in Treating Patients with Advanced or Metastatic Relapsed or Refractory Cancers",
    "Donor Nicotinamide Expanded-Natural Killer Cells Followed by IL-2 in Treating Patients with Relapsed or Refractory Multiple Myeloma or CD20 Positive Non-Hodgkin Lymphoma",
    "Pembrolizumab and Ibrutinib in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery",
    "Intravenous and Intrathecal Nivolumab in Treating Patients with Leptomeningeal Disease",
    "Single or Multi-fraction Stereotactic Radiosurgery in Treating Patients with Solid Tumors and Spine Metastasis",
    "Hydroxychloroquine Sulfate, Everolimus, or the Combination in Preventing Recurrence in Patients with Breast Cancer",
    "Donor Stem Cell Transplant in Treating Patients with High Risk Hematologic Malignancies",
    "Ultrasound-Guided Verteporfin Photodynamic Therapy for the Treatment of Unresectable Solid Pancreatic Tumors or Advanced Pancreatic Cancer, VERTPAC-02 Study",
    "Sorafenib Tosylate and Hydroxychloroquine Sulfate in Treating Patients with Advanced or Metastatic Liver Cancer",
    "Pembrolizumab and Lanreotide Acetate in Treating Patients with Gastroenteropancreatic Neuroendocrine Tumors That Are Recurrent, Metastatic, or Cannot Be Removed by Surgery",
    "Unrelated and Partially Matched Related Donor Peripheral Blood Stem Cell Transplant with TCR alpha / beta+ T Cell and B Cell Depletion for the Treatment of Patients with Acquired or Inherited Bone Marrow Failure",
    "Human Chimeric Antigen Receptor Modified T-Cells with or without Cyclophosphamide in Treating Patients with Mesothelin-Expressing Cancers",
    "Pyrimethamine for the Treatment of Relapsed or Azanucleosides Refractory Intermediate or High-Risk Myelodysplastic Syndrome",
    "STAT Inhibitor OPB-111077, Decitabine, and Venetoclax in Treating Patients with Acute Myeloid Leukemia That Is Refractory, Relapsed, or Newly Diagnosed and Ineligible for Intensive Chemotherapy",
    "Pembrolizumab in Treating Patients with Locally Advanced Esophageal and Gastric Cancer",
    "Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants with Refractory and Advanced or Metastatic Solid Tumors with EGFR Mutation / Amplification, HER2 Mutation / Amplification, or HER3 / 4 Mutation or KRAS Mutation",
    "Poziotinib in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer with EGFR or HER2 Exon 20 Mutation",
    "Daratumumab in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia, T Acute Lymphoblastic Leukemia / Lymphoma, or High-Risk Myelodysplastic Syndrome",
    "Cytokine Induced Memory-like Natural Killer Cell Therapy after Donor Stem Cell Transplant in Treating Children and Young Adults with Relapsed Acute Myeloid Leukemia",
    "Hypofractionated Stereotactic Body Radiation Therapy and Fluorouracil or Capecitabine with or without Zoledronic Acid in Treating Patients with Locally Advanced Pancreatic Cancer",
    "A Pilot Study to Investigate the Safety and Clinical Activity of Avelumab (MSB0010718C) in Thymoma and Thymic Carcinoma After Progression on Platinum-Based Chemotherapy",
    "Broad-Spectrum Antibiotics in Treating Fever and Neutropenia in Patients Undergoing Stem Cell Transplant",
    "Trametinib and Paclitaxel in Treating Patients with Metastatic Anaplastic Thyroid Cancer That Cannot Be Removed by Surgery",
    "Talimogene Laherparepvec in Treating Patients with Locally Advanced, Metastatic, or Refractory Pancreatic Cancer That Cannot Be Removed by Surgery",
    "Panitumumab with or without Trametinib in Treating Patients with Stage IV Colorectal Cancer",
    "Pembrolizumab after Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Recurrent Non-small Cell Lung Cancer",
    "Genomic Testing and Molecular Tumor Board-Recommended Targeted Therapy in Treating Patients with Refractory or Rare Cancer",
    "Heated Intraperitoneal Chemotherapy and Gastrectomy for Gastric Cancer With Positive Peritoneal Cytology",
    "Haploidentical Stem Cell Selection using Miltenyi CliniMACS CD34 Reagent System in Treating Participants with High-Risk Hematologic Disorders",
    "Aerosol Gemcitabine in Treating Participants with Solid Tumors and Lung Metastases",
    "Azacitidine and Pembrolizumab in Treating Patients with Myelodysplastic Syndrome",
    "Pulsed Low Dose Radiation Therapy and Chemotherapy in Reducing the Rates of Severe Acute Esophagitis in Patients with Stage IIIA Non-small Cell Lung Cancer and Stage IB-IIIC Esophageal Cancer",
    "Paclitaxel before Surgery in Treating Patients with Breast Cancer",
    "Umbilical Cord Blood Transplant with Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients with Leukemia or Lymphoma",
    "Artesunate in Treating Patients with High-Grade Anal Intraepithelial Neoplasia",
    "Neratinib and Paclitaxel with or without Pertuzumab and Trastuzumab before Combination Chemotherapy in Treating Patients with Metastatic or Locally Advanced Breast Cancer",
    "huJCAR014 CAR-T Cells in Treating Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
    "Nivolumab, Ipilimumab, and Radiation Therapy in Treating Patients with Colorectal or Pancreatic Cancer",
    "Blinatumomab in Treating Patients with Pre B-Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) Undergoing Stem Cell Transplant",
    "Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients with Secondary Myelofibrosis",
    "VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Stage IV or Recurrent Endometrial Cancer",
    "Personalized Synthetic Long Peptide Vaccine and Nivolumab in Treating Patients with Grade 1-3a Follicular Lymphoma",
    "Stellate Ganglion Blockade with Bupivacaine Hydrochloride in Reducing Hot Flashes in Hispanic Patients with Breast Cancer",
    "Imipramine before Surgery in Treating Patients with Previously Untreated Invasive Breast Cancer",
    "Enzalutamide and Niclosamide in Treating Patients with Recurrent or Metastatic Castration-Resistant Prostate Cancer",
    "Chemotherapy with or without Total Body Irradiation before Stem Cell Transplant in Treating Patients with Hodgkin or Non-Hodgkin Lymphoma",
    "Nivolumab with or without Ipilimumab in Treating Patients with Metastatic or Advanced Kidney Cancer",
    "Cytoreductive Surgery and Heated Cisplatin in Treating Patients with Adrenocortical Cancer",
    "Tranexamic Acid in Reducing Blood Loss in Patients with Pelvic Tumors Undergoing Hemipelvectomy Surgery",
    "Venetoclax and Ibrutinib in Treating Patients with High-Risk Chronic Lymphocytic Leukemia",
    "Palbociclib and Sorafenib, Decitabine, Dexamethasone or Venetoclax in Treating Patients with Recurrent or Refractory Leukemia",
    "Idelalisib in Treating Participants with Indolent or Transformed Indolent Non-Hodgkin Lymphoma after Autologous Stem Cell Transplant",
    "Vascular-Targeted Photodynamic Therapy with Padeliporfin in Treating Dysphagia in Patients with Stage IV Esophageal Cancer",
    "Combination Chemotherapy in Treating Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma / Leukemia, or Double-Hit Lymphoma / Leukemia",
    "Vactosertib and Pomalidomide in Treating Patients with Relapsed or Relapsed and Refractory Multiple Myeloma",
    "Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients with Philadelphia Chromosome-Positive and / or BCR-ABL Positive Acute Lymphoblastic Leukemia",
    "Selinexor and Combination Chemotherapy in Treating Patients with Advanced B Cell Non-Hodgkin Lymphoma or Newly Diagnosed Diffuse Large B Cell Lymphoma",
    "Ibrutinib and Pembrolizumab in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma",
    "Nivolumab with or without Ipilimumab or Chemotherapy in Treating Patients with Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer",
    "Umbilical Cord-Derived Stem Cells in Treating Patients with High Risk or Steroid Refractory Acute Graft Versus Host Disease",
    "Chemotherapy with or without Radiation or Surgery in Treating Participants with Oligometastatic Esophageal or Gastric Cancer",
    "Stereotactic Body Radiation Therapy or Intensity Modulated Radiation / Proton Therapy in Treating Patients with Recurrent Head and Neck Cancer",
    "Zoledronic Acid before and after Surgery in Treating Patients with Grade I-III Chondrosarcoma",
    "Bevacizumab and Atezolizumab with or without Cobimetinib in Treating Patients with Untreated Melanoma Brain Metastases",
    "Atezolizumab with Chemotherapy in Treating Patients with Anaplastic or Poorly Differentiated Thyroid Cancer",
    "Lisdexamfetamine for the Improvement of Executive Function in Women who have Undergone Risk-Reducing Bilateral Salpingo-Oophorectomy, IMPRES Study",
    "Hyperthermic Intraperitoneal Chemotherapy in Improving Quality of Life in Patients with Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "T-DM1 Alone Versus T-DM1 and Metronomic Temozolomide in Secondary Prevention of HER2-Positive Breast Cancer Brain Metastases Following Stereotactic Radiosurgery",
    "Pembrolizumab and Standard Therapy in Treating Patients with Glioblastoma",
    "Obinutuzumab and Ibrutinib as Front Line Therapy in Treating Patients with Indolent Non-Hodgkin's Lymphomas",
    "Cabozantinib S-malate and Avelumab in Treating Participants with Metastatic Kidney Cancer",
    "Atezolizumab, Cobimetinib, and Eribulin in Treating Patients with Chemotherapy Resistant Metastatic Inflammatory Breast Cancer",
    "Combination Chemotherapy and Bevacizumab with the NovoTTF-100L(P) System in Treating Participants with Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer",
    "Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma / Paraganglioma",
    "Paclitaxel, Carboplatin, and Galunisertib in Treating Patients with Newly Diagnosed, Persistent, or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Carcinosarcoma",
    "Alpelisib and Enzalutamide in Treating Patients with Androgen Receptor and PTEN Positive Metastatic Breast Cancer",
    "Ibrutinib in Treating Participants with Early Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Pembrolizumab and External Beam Radiation Therapy in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma",
    "Entinostat in Treating Patients with Relapsed or Refractory Stage IV Abdominal Neuroendocrine Tumor That Cannot Be Removed by Surgery",
    "Venetoclax with Combination Chemotherapy in Treating Patients with Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia",
    "Intensity-Modulated Radiation Therapy in Treating Patients with HPV-Positive Oropharyngeal Cancer",
    "Intraoperative Radiation Therapy in Preventing Breast Cancer Recurrence in Patients with Ductal Carcinoma in Situ",
    "Nivolumab with or without Ipilimumab in Treating Patients with Resectable Liver Cancer",
    "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed / Refractory B-cell Lymphoma",
    "Trifluridine and Tipiracil Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients with Colorectal or Pancreatic Cancer with Liver Metastases",
    "Genu-Sparing Whole-Brain Radiotherapy in Preserving Cognition and Neuropsychiatric Functioning in Patients with Solid Tumors with Brain Metastases",
    "Cytarabine, Idarubicin and Liposome-encapsulated Daunorubicin-Cytarabine, or Venetoclax, Azacitidine, and Decitabine in Treating Older Patients with Acute Myeloid Leukemia",
    "Pevonedistat and Docetaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer",
    "Oral Decitabine and Tetrahydrouridine as Epigenetic Priming for, Pembrolizumab-Mediated Immune Checkpoint Blockade in Patients With Inoperable, or Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancers and Esophageal Carcinomas",
    "Autologous CD19 / CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia",
    "High-Intensity Focused Ultrasound and Pembrolizumab in Treating Patients with Metastatic or Unresectable Breast Cancer",
    "Aprepitant or Fosaprepitant in Combination with Dexamethasone and Ondansetron in Preventing Nausea and Vomiting in Patients with Cancer Receiving Carboplatin-Based Chemotherapy",
    "Nab-Paclitaxel and Pembrolizumab in Treating Participants with Recurrent Unresectable Locally Advanced or Metastatic Urothelial Cancer",
    "Pembrolizumab, Aspirin, and Clopidogrel Bisulfate in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "Nivolumab, Paclitaxel, and Carboplatin with or without Ipilimumab in Treating Patients with High Grade Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Fostamatinib Disodium and Paclitaxel in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Sorafenib, Busulfan and Fludarabine in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant",
    "Intensity-Modulated Stereotactic Radiation Therapy in Treating Patients with Grade II-IV Glioma",
    "Meclizine in Treating Participants with Liver Carcinoma",
    "Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy",
    "Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas",
    "Durvalumab and Vicineum in Subjects With High-Grade Non-Muscle-Invasive Bladder Cancer Previously Treated With Bacillus Calmette-Guerin (BCG)",
    "Olaparib and High-Dose Chemotherapy in Treating Patients with Relapsed or Refractory Lymphomas Undergoing Stem Cell Transplant",
    "Transarterial Chemoembolization in Treating Patients with Liver Cancer and Elevated Bilirubin",
    "EUS-Guided Gastroenterostomy or Enteral Stenting for the Palliation of Malignant Gastric Outlet Obstruction",
    "Aldesleukin and Pembrolizumab in Treating Patients with Advanced or Metastatic Kidney Cancer",
    "Poly ICLC in Treating Patients with Prostate Cancer before Radical Prostatectomy",
    "Ipilimumab and Nivolumab in Treating Patients with Stage IIIB, Stage IV, or Recurrent Non-small Cell Lung Cancer",
    "Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients with Philadelphia Chromosome-Positive and / or BCR-ABL Positive, or Relapsed / Refractory, Acute Lymphoblastic Leukemia",
    "Pembrolizumab and Azacitidine in Treating Patients with Advanced Pancreatic Cancer after Failure of First-Line Therapy",
    "Avelumab and Hypofractionated Proton Radiation Therapy before Surgery in Treating Patients with Recurrent Radiation-Refractory Meningioma",
    "Pembrolizumab and Radiation Therapy in Treating Patients with Relapsed or Refractory Stage I-III Multiple Myeloma",
    "EGFR-BATs in Treating Participants with Locally Advanced or Metastatic Pancreatic Cancer",
    "A Specialized Type of Immune Cells (HER2Bi-Armed Activated T Cells) and Pembrolizumab in Treating Patients with Metastatic Breast Cancer",
    "Irradiated Donor Cells following Stem Cell Transplant in Controlling Cancer in Patients with Hematologic Malignancies",
    "Laser Interstitial Thermal Therapy and Pembrolizumab in Treating Patients with Recurrent Glioblastoma",
    "A Phase I / II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients with Relapsed or Refractory B Cell Non-Hodgkin Lymphomas",
    "Ibrutinib in Treating Participants with Untreated High Risk Smoldering Mantle Cell Lymphoma",
    "Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refectory Amyloid Light Chain Amyloidosis",
    "Proton Beam Radiation Therapy in Evaluating Local Control, Quality of Life, and Toxicities in Patients with Brain Tumors",
    "Defactinib Hydrochloride, Carboplatin, and Paclitaxel in Treating Patients with Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Pembrolizumab and Lenvatinib in Treating Patients with Metastatic Well-Differentiated Neuroendocrine Cancer",
    "Merestinib in Treating Patients with Breast Cancer Metastatic in the Bone",
    "Pembrolizumab in Treating Participants with Unresectable Thymoma or Thymic Cancer",
    "Radium Ra 223 Dichloride and External Beam Radiation Therapy in Treating Patients with Prostate Cancer Metastatic in the Bone",
    "Pembrolizumab with or without Metformin in Treating Patients with Stage III-IV Melanoma",
    "Nivolumab, Pembrolizumab, or Atezolizumab and Standard Radiation Therapy or Stereotactic Body Radiation Therapy in Treating Patients with Advanced or Metastatic Non-small Cell Lung Cancer or Head and Neck Squamous Cell Carcinoma",
    "Donor Stem Cell Transplant in Treating Patients with Blood Cancer",
    "Combination Immunotherapy in Biochemically Recurrent Prostate Cancer",
    "Hyperthermic Intraperitoneal Chemotherapy in Treating Patients with Stage IIIB-IIIC Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Lenvatinib and Pembrolizumab in Treating Patients with Metastatic or Recurrent Gastric or Gastroesophageal Cancer",
    "Lenvatinib and Everolimus before Surgery in Treating Patients with Locally Advanced or Metastatic Kidney Cancer",
    "Selumetinib and Azacitidine in Treating Patients with Myelodysplastic Syndrome, Myelodysplastic / Myeloproliferative Neoplasm, and Myelofibrosis",
    "Eribulin Mesylate in Treating Patients with Locally Advanced or Metastatic Angiosarcoma or Epithelioid Hemangioendothelioma",
    "Doxorubicin Hydrochloride, Pembrolizumab, Vinblastine, and Dacarbazine in Treating Patients with Classical Hodgkin Lymphoma",
    "Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients with Blood Cancer",
    "Pembrolizumab and Radiation Therapy in Treating Patients with Intermediate or High-Grade Soft Tissue Sarcoma",
    "Fecal Microbiota Transplant and Pembrolizumab in Treating Patients with Stage III-IV Melanoma",
    "Thiotepa, Fludarabine Phosphate, and Melphalan Hydrochloride in Treating Patients with Blood Cancer Undergoing Donor Stem Cell Transplant",
    "Hypofractionated Radiation Therapy in Treating Patients with Stage 0-IIB Breast Cancer",
    "Stereotactic Body Radiation Therapy followed by Surgery in Treating Patients with Stage I-IIIA Non-small Cell Lung Cancer",
    "Low-Impact Physical Activity for the Improvement of Quality of Life in Patients with Advanced Non-small Cell Lung Cancer",
    "Bendamustine Hydrochloride and Melphalan before Stem Cell Transplant in Treating Elderly Patients with Multiple Myeloma or Relapsed or Refractory B-cell Lymphoma",
    "Atezolizumab and PGV001 in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer",
    "Pembrolizumab and Docetaxel in Treating Participants with Poorly Chemo-Responsive and Unresectable Thyroid and Salivary Gland Cancers",
    "Eribulin Mesylate and Radiation Therapy in Treating Patients with Retroperitoneal Liposarcoma That Can Be Removed by Surgery",
    "Radium Ra 223 Dichloride, Hormone Therapy and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Prostate Cancer",
    "Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver",
    "Pembrolizumab, Bevacizumab, and Standard Chemotherapy for the Treatment of Recurrent, Persistent, or Stage IVB Cervical Cancer",
    "Cabozantinib in Treating Patients with Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma",
    "Lenalidomide with or without an Allogeneic Myeloma Vaccine and Prevnar-13 in Treating Patients with Newly Diagnosed, Recurrent, or Refractory Multiple Myeloma",
    "Durvalumab, MVA-BN-CV301, FPV Vaccine CV301, and Capecitabine with or without Bevacizumab in Treating Patients with Metastatic Colorectal or Pancreatic Cancer",
    "Stereotactic Radiosurgery in Reducing Pain in Cancer Patients with Bone Metastases",
    "A Form of Immunotherapy (Adoptive T Cell Therapy) in Treating Patients with Adenovirus Infection after Stem Cell Transplant",
    "MnSOD Mimetic BMX-001 in Treating Patients with Anal Cancer Undergoing Radiation Therapy and Chemotherapy",
    "Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy",
    "Memory-Enriched T Cells in Treating Patients with Recurrent or Refractory Grade III-IV Glioma",
    "Palbociclib and Intensity-Modulated Radiation Therapy with Cisplatin or Cetuximab in Treating Patients with Head and Neck Squamous Cell Cancer",
    "OX40, Venetoclax, Avelumab, Glasdegib, Gemtuzumab Ozogamicin, and Azacitidine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia",
    "Pembrolizumab in Treating Patients with Metastatic or Unresectable Gastroesophageal Adenocarcinoma",
    "Ultra Low Dose Radiation Therapy in Treating Patients with Mycosis Fungoides",
    "Rituximab, Pembrolizumab, and Obinutuzumab in Treating Patients with Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma",
    "Venetoclax and Decitabine in Treating Participants with Relapsed / Refractory Acute Myeloid Leukemia or Relapsed High-Risk Myelodysplastic Syndrome",
    "Niraparib and Ipilimumab or Nivolumab in Treating Patients with Locally Advanced or Metastatic Pancreatic Cancer Who Are Stable after Platinum-Based Therapy",
    "Apatinib and Pembrolizumab in Treating Participants with Advanced Cancers",
    "Brentuximab Vedotin and Lenalidomide in Treating Patients with Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma",
    "Fractionated Stereotactic Radiation Therapy in Treating Cancer Patients with Brain Metastases",
    "Rucaparib Camsylate in Treating Patients with Metastatic or Biochemically Recurrent Prostate Cancer",
    "Melphalan Hydrochloride in Treating Participants with Newly-Diagnosed Multiple Myeloma Undergoing Donor Stem Cell Transplantation",
    "Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults with Relapsed or Refractory Solid Tumors",
    "Exercise Intervention with or without Internet-Based Cognitive Behavior Therapy in Reducing Fatigue in Patients with Advanced Prostate Cancer",
    "Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer",
    "High Dose Rate Brachytherapy in Treating Patients with Prostate Cancer",
    "Donor T Cell Therapy in Treating Immunocompromised Patients with Adenovirus-Related Disease",
    "Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients with Recurrent or Refractory Malignant Solid Tumors",
    "Donor Stem Cell Transplant in Treating Younger Patients with Hematologic Malignancies or Myelodysplasia",
    "Ribociclib, Gemcitabine Hydrochloride, Trametinib, and Sonidegib in Treating Patients with Refractory or Recurrent Brain Cancers",
    "Pembrolizumab and Clostridium Novyi-NT Spores in Treating Patients with Advanced, Refractory Solid Tumors",
    "Early Palliative Care in Improving Recovery and Quality of Life in Patients with Cancer Undergoing Abdominal Surgery, the SCOPE Trial",
    "M7824 in Treating Patients with Metastatic or Unresectable Color or Rectal Cancer with Microsatellite Instability",
    "DNA Plasmid-encoding Interleukin-12 / HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients with Recurrent or Metastatic Human Papillomavirus Associated Cancers",
    "Sorafenib and Nivolumab as First-Line Therapy in Treating Patients with Unresectable, Locally Advanced or Metastatic Liver Cancer",
    "Inotuzumab Ozogamicin in Treating Patients with B-cell Acute Lymphocytic Leukemia with Positive Minimal Residual Disease",
    "Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients with Metastatic Castration Resistant Prostate Cancer with Homologous Recombination DNA Repair Deficiency",
    "Daratumumab and Ibrutinib in Treating Patients with Symptomatic Chronic Lymphocytic Leukemia",
    "CD19 / CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19 / CD22-expressing B Cell Malignancies",
    "LN-145 or LN-145-S1 in Treating Patients with Relapsed or Refractory Ovarian Cancer, Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas",
    "NOVOTTF-200A for the Treatment of Recurrent WHO Grade III Malignant Astrocytoma",
    "Tinostamustine with or without Radiation Therapy in Treating Patients with Newly Diagnosed MGMT-Unmethylated Glioblastoma",
    "Intra-Urethral Radiotransponder Beacon Guided Stereotactic Body Radiation Therapy in Treating Patients with Prostate Cancer",
    "Pevonedistat and Low Dose Cytarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Selective Use of Observation in HER-2 Positive Breast Cancer Participants Who Have Undergone Lumpectomy and Lymph Node Biopsy and Achieved Pathologic Complete Response after Chemotherapy",
    "Pembrolizumab and Sunitinib Malate in Treating Participants with Refractory Metastatic or Unresectable Thymic Cancer",
    "Cyclophosphamide, Fludarabine, Tumor Infiltrating Lymphocytes, and Aldesleukin in Treating Patients with Metastatic Uveal Melanoma",
    "Gemcitabine Hydrochloride and Ascorbic Acid in treating Participants with Locally Advanced, Unresectable, or Metastatic Soft Tissue or Bone Sarcomas",
    "Urinary Diversion (Intra-Corporal or Extra-Corporal) after Robot Assisted Radical Cystectomy for the Treatment of Bladder Cancer",
    "Epacadostat in Treating Patients with Resectable Solid Tumors",
    "Fluorine F 18 DCFPyL PET / CT in Detecting High-Grade Prostate Cancer in Patients with Elevated PSA",
    "Palbociclib and Dexamethasone in Treating Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
    "Cyclophosphamide, Fludarabine Phosphate, and Total Body Radiation, before Donor Stem Cell Transplant in Treating Participants with Blood Disorders and Blood Cancers",
    "Radiation Therapy and Chemotherapy in Treating Patients with Stage II-IV Non-small Cell Lung Cancer and the Effect of Treatment on Patient-Reported Outcomes",
    "Contrast Enhanced Spectral Mammography and Magnetic Resonance Imaging in Detecting Breast Cancer",
    "Proton Beam Radiation Therapy in Treating Patients with Stage II or III Esophageal Cancer",
    "Gemcitabine and Avelumab in Treating Patients with Advanced Kidney Cancer",
    "Neutron Radiation Therapy and Pembrolizumab in Treating Participants with Advanced Urothelial Carcinoma",
    "Stereotactic Radiosurgery followed by Tumor Treating Fields Therapy in Treating Participants with Small Cell Lung Cancer with Brain Metastases",
    "Fluorouracil, Leucovorin, Oxaliplatin and Pembrolizumab in Treating Patients with Resectable Gastroesophageal Junction and Stomach Adenocarcinoma",
    "Avelumab and Chemoradiation in Treating Patients with Stage II-III Esophageal and Gastroesophageal Junction Cancer That Can Be Removed by Surgery",
    "Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Leukemia or Myelodysplastic Syndrome",
    "Nivolumab and Low Dose Radiation Therapy in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma",
    "Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases",
    "HER2-Specific CAR T Cell Immunotherapy in Treating Patients with Recurrent or Refractory Central Nervous System Tumors",
    "Trametinib and Ceritinib for the Treatment of Refractory, Unresectable Stage IIIC-IV Melanoma",
    "APX005M, Nivolumab, and Cabiralizumab in Treating Patients with Advanced Melanoma, Non-small Cell Lung Cancer or Renal Cell Cancer Who Have Progressed on Anti-PD1 / PDL-1 Therapy",
    "Tailored Prednisone Reduction in Preventing Hyperglycemia in Patients with B-Cell Non-Hodgkin Lymphoma Receiving Combination Chemotherapy Treatment",
    "Flutamide in Treating Patients with Prostate Cancer on Androgen Suppression Undergoing Brachytherapy",
    "Nivolumab with or without Ipilimumab in Treating Patients with Recurrent or High Grade Gynecologic Cancer with Metastatic Peritoneal Carcinomatosis",
    "High Dose Ascorbate and Radiation Therapy before Surgery in Treating Patients with Stage IIB-IV Soft Tissue Sarcomas of Extremity, Trunk, and Retroperitoneum",
    "Stereotactic Radiosurgery in Treating Participants with Brain Metastases and Studying Their Neurocognitive Decline",
    "Pembrolizumab and Blinatumomab in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia",
    "Nintedanib and Azacitidine in Treating Participants with HOX Gene Overexpression Relapsed or Refractory Acute Myeloid Leukemia",
    "Venetoclax and Ibrutinib in Treating in Patients with Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations",
    "Ibrutinib and Pembrolizumab in Treating Patients with High Risk Chronic Lymphocytic Leukemia",
    "Ruxolitinib and Radiation Therapy with or without Temozolomide in Treating Patients with Newly Diagnosed Grade III Glioma or Glioblastoma",
    "Epacadostat with Standard Chemoradiation Therapy before Surgery in Treating Patients with Locally Advanced Rectal Cancer",
    "Pembrolizumab and Bavituximab in Treating Participants with Locally Advanced or Metastatic Liver Cancer",
    "Regorafenib and Methotrexate in Treating Participants with Recurrent or Metastatic Non-Small Cell Lung Cancer",
    "Nivolumab with or without Ipilimumab or Relatlimab in Treating Patients with Unresectable, Metastatic, or Refractory Basal Cell Carcinoma",
    "Nivolumab and Ramucirumab for the Treatment of Recurrent, Advanced, or Metastatic Non-Small Cell Lung Cancer",
    "Fulvestrant and Abemaciclib in Treating Patients with Stage III- IV Low Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "T Cells (EAGD T-Cells) after Stem Cell Transplantation and Post-transplant Cyclophosphamide for the Treatment of Blood Cancers",
    "Rucaparib in Treating Patients with Non-metastatic, Hormone-Sensitive Prostate Cancer",
    "Ibrutinib and Radiation Therapy with or without Temozolomide in Treating Participants with Newly Diagnosed Methylated or Unmethylated Glioblastoma",
    "Palbociclib before Surgery in Treating Patients with Stage 0-I Ductal Breast Carcinoma in Situ",
    "Gemcitabine, Nab-paclitaxel, Capecitabine, Cisplatin, and Irinotecan in Treating Patients with Pancreatic Cancer That Has Spread to Other Places in the Body",
    "Cabozantinib and Durvalumab with or without Tremelimumab in Treating Patients with Stage III-IV Gastroesophageal Cancer and Other Gastrointestinal Malignancies",
    "MRI Perfusion or 2-HG MR Spectroscopy in Imaging Patients with Grade II-IV Gliomas Undergoing Image-Guided Surgery",
    "Nivolumab with Radiation Therapy and Androgen Deprivation Therapy in Treating Patients with Gleason Group 5 Prostate Cancer",
    "Encorafenib, Binimetinib, and Nivolumab for the Treatment of BRAF Mutant Stage IIIC-IV Melanoma",
    "Vancomycin and Stereotactic Body Radiation Therapy in Treating Participants with Early-Stage Non-small Cell Lung Cancer",
    "Stereotactic Ablative Radiotherapy in Treating Patients with Stage I-II Glottic Larynx Cancer",
    "Niraparib after Previous Chemotherapy for the Treatment of Pancreatic Cancer, NIRA-PANC Study",
    "Nitrous Oxide For Endoscopic Ablation of Refractory Barrett's Esophagus (NO FEAR-BE)",
    "Atorvastatin in Treating Patients with p53-Mutant and Wild-Type Malignant Solid Tumors or Recurrent Hematologic Malignancies",
    "Omacetaxine and Azacitidine in Treating Participants with High Grade Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Cemiplimab in Treating Patients with Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer before Surgery",
    "Bethanechol before Surgery in Treating Patients with Resectable Pancreatic Cancer",
    "5-AZA and ATRA in Treating Patients with PSA-only Recurrent Prostate Cancer",
    "Venetoclax and Azacitidine in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia",
    "SJCAR19 and Combination Chemotherapy in Treating Younger Patients with CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia",
    "Nivolumab, Ipilimumab, and Paclitaxel in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer",
    "Venetoclax, Ponatinib, and Dexamethasone in Patients with Philadelphia Chromosome or BCR-ABL Positive Relapsed or Refractory Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia",
    "Alpha / Beta T Cell Depleted Stem Cell Transplant in Treating Patients with Fanconi Anemia",
    "Durvalumab, Tremelimumab, and Selumetinib in Treating Patients with Recurrent or Stage IV Non-small Cell Lung Cancer",
    "Pembrolizumab with Combination Chemotherapy in Treating Patients with Locally Advanced or Metastatic Small Cell / Neuroendocrine Cancers of Urothelium or Prostate",
    "MOv19-BBz CAR T Cells with or without Cyclophosphamide and Fludarabine in Treating Patients with Recurrent High Grade Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Venetoclax, Cladribine, Low Dose Cytarabine, and Azacitidine in Treating Patients with Previously Untreated Acute Myeloid Leukemia",
    "Niraparib and Copanlisib in Treating Patients with Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "OKN-007 and Temozolomide in Treating Patients with Grade III-IV Glioblastoma Multiforme Undergoing Adjuvant Concomitant Radiotherapy",
    "Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients with Locally Advanced or Metastatic Kidney Cancer",
    "Ketogenic Diet in Treating Pediatric Patients with Brain Tumors Undergoing Chemotherapy",
    "mDC3 / 8-KRAS Vaccine and Cyclophosphamide in Treating Patients with Resectable Stage I-III Pancreatic Cancer",
    "Gemcitabine, Docetaxel, and Hydroxychloroquine in Treating Participants with Recurrent or Refractory Osteosarcoma",
    "Nivolumab and Ipilimumab after Donor Stem Cell Transplant in Treating Patients with High Risk Refractory or Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "pTVG-HP and Nivolumab in Treating Patients with High-Risk PSA-Recurrent Prostate Cancer",
    "Alpelisib in Treating Patients with Transorally Resectable HPV-Associated Stage I-IVA Oropharyngeal Cancer",
    "ATLCAR.CD30.CCR4 with or without ATLCAR.CD30 in Treating Patients with Relapsed or Refractory CD30+ Hodgkin Lymphoma or Cutaneous T-cell Lymphoma",
    "High Dose Ascorbic Acid and Low Dose Melphalan in Treating Patients with Relapsed and Refractory Multiple Myeloma",
    "Pembrolizumab in Treating Participants with Leukoplakia",
    "Nivolumab and Relatlimab in Treating Patients with Locally Advanced or Metastatic Mismatch Repair Deficient Solid Tumors Resistant to Prior PD-L1 Therapy",
    "iExosomes in Treating Participants with Metastatic Pancreas Cancer with KrasG12D Mutation",
    "CycloSam and External Beam Radiotherapy for the Treatment of High Risk Osteosarcoma and Other Solid Tumors Metastatic to Bone",
    "Intravenous Ascorbic Acid Followed by Oral Ascorbic Acid in Treating Inflammation after Donor Stem Cell Transplant in Patients with Hematological Malignancies",
    "A Study of EGFR806 CAR T-Cell Immunotherapy for Treating Children and Young Adults with Recurrent / Refractory Solid Tumors",
    "Denosumab and Pembrolizumab or Nivolumab in Treating Patients with Stage III-IV Cutaneous or Mucosal Melanoma",
    "M7824 in Treating Patients with Stage II-III HER2 Positive Breast Cancer",
    "Awake or Asleep Craniotomy for the Treatment of Non-Eloquent Gliomas",
    "Daratumumab and Hyaluronidase-fihj and Pomalidomide for the Treatment of Relapsed Multiple Myeloma after Stem Cell Transplant",
    "Cytokine-Treated Veto Cells in Treating Patients with Hematologic Malignancies following Stem Cell Transplant",
    "Nivolumab and Relatlimab in Treating Patients with Advanced Chordoma",
    "Selinexor in Treating Patients with Myelofibrosis Intolerant or Resistant to JAK1 / 2 Inhibitors",
    "Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants with Relapsed, Refractory or Untreated Acute Myeloid Leukemia",
    "Edetate Calcium Disodium or Succimer in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy",
    "Personalized Vaccine in Treating Patients with Smoldering Multiple Myeloma",
    "A Vaccine (VRP-HER2) and Pembrolizumab in Treating Patients with Locally Recurrent or Metastatic HER2-Overexpressing Breast Cancer",
    "Milademetan Tosylate and Low-Dose Cytarabine with or without Venetoclax in Treating Participants with Recurrent or Refractory Acute Myeloid Leukemia",
    "MRI-Guided Brachytherapy in Treating Participants with HPV-Associated Stage IB2-IVA Cervical or Stage II-IVA Vaginal Cancer",
    "Durvalumab and Tremelimumab in Treating Patients with Liver Cancer Undergoing Drug-Eluting Bead Transarterial Chemoembolization",
    "Nivolumab and Relatlimab in Treating Patients Microsatellite Stable Advanced Colorectal Cancer",
    "Chimeric Antigen Receptor (CAR)-T Cell Therapy for Patients with Blood Cancer",
    "Accelerator Based Stereotactic Body Radiation Therapy after Surgery in Treating Patients with Early Stage Breast Cancer",
    "Bemcentinib with Nab-Paclitaxel, Gemcitabine, and Cisplatin in Treating Patients with Metastatic or Recurrent Pancreatic Cancer",
    "Proliferation Saturation Index Determined Radiation Therapy in Treating Patients with Head and Neck Cancer",
    "Civasheet and Surgical Removal of Prostate with or without External Beam Radiation Therapy in Treating Participants with Intermediate or High Risk Prostate Cancer",
    "Nanoparticle Albumin-Bound Rapamycin and Pazopanib Hydrochloride in Treating Patients with Advanced Nonadipocytic Soft Tissue Sarcomas",
    "Quizartinib, Decitabine, and Venetoclax in Treating Patients with Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome",
    "Her2-BATs for the Treatment of Breast Cancer Leptomeningeal Metastases",
    "Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and / or Dysregulation",
    "Ipilimumab and Nivolumab in Treating Patients with Recurrent Extensive Stage Small Cell Lung Cancer",
    "Itacitinib in Treating Patients with Refractory Metastatic / Advanced Tissue Sarcomas",
    "Megestrol Acetate with or without Pterostilbene in Treating Patients with Endometrial Cancer Undergoing Hysterectomy",
    "Autologous CAR138 T-cells in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Liposome-encapsulated Daunorubicin-Cytarabine and Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome",
    "Light Dosimetry for Photodynamic Therapy with Porfimer Sodium in Treating Patients with Malignant Mesothelioma or Non-small Cell Lung Cancer with Pleural Disease Undergoing Surgery",
    "Ultra Low-Dose Radiation Therapy in Treating Patients with Stage I-IV Stomach MALT Lymphoma",
    "Enasidenib and Azacitidine in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation",
    "Olaparib, Palbociclib, and Fulvestrant in Treating Patients with BRCA Mutation-Associated, Hormone Receptor-Positive, and HER2-Negative Advanced Breast Cancer",
    "Ibrutinib and Rituximab for Steroid-Refractory or Dependent Chronic GVHD",
    "LET-IMPT and Standard Chemotherapy in Treating Patients with Newly Diagnosed Stage I-III Anal Canal Squamous Cell Cancer",
    "Ifetroban in Treating Patients with Malignant Solid Tumors at High Risk of Metastatic Recurrence",
    "Pembrolizumab and Chemotherapy in Treating Patients with High-Grade Obesity-Driven Endometrial Cancer",
    "Pembrolizumab in Treating Patients with Stage IB-IV Mycosis Fungoides",
    "HER2-CAR T cells and Chemotherapy in Treating Patients with Recurrent Brain or Leptomeningeal Metastases",
    "Specialized Immune Cells (iC9-CAR19 T Cells) in Treating with Patients with Relapsed or Refractory B-Cell Lymphoma",
    "Itacitinib and Everolimus in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma",
    "ADCT-602 in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
    "CPI-613 and Combination Chemotherapy in Treating Patients with Locally Advanced Pancreatic Cancer",
    "MoleMapper, Visiomed, and Confocal Microscopy in Screening Participants for Melanoma",
    "Bronchoscopic Laser Ablation of Peripheral Lung Tumors",
    "CS1-CAR T Therapy following Chemotherapy in Treating Patients with Relapsed or Refractory CS1 Positive Multiple Myeloma",
    "Liraglutide and Smoking Cessation Behavioral Counseling in Helping Smokers to Quit Smoking",
    "2-Step Approach to Stem Cell Transplant in Treating Patients with Hematological Malignancies",
    "Talimogene Laherparepvec in Treating Patients with Cutaneous Squamous Cell Cancer",
    "Nivolumab in Patients With IDH-Mutant Gliomas With and Without Hypermutator Phenotype",
    "APX005M and Doxorubicin in Treating Patients with Advanced Soft Tissue Sarcoma",
    "Avelumab and Whole-Brain Radiation Therapy in Treating Patients with Leptomeningeal Disease",
    "ALRN-6924 and Paclitaxel in Treating Patients with Advanced, Metastatic, or Unresectable Solid Tumors",
    "Fractionated Stereotactic Radiation Therapy in Treating Cancer Patients with Brain Metastases That Has Not Been Removed by Surgery",
    "CBL0137 in Treating Patients with Advanced Extremity Melanoma or Sarcoma",
    "Escitalopram in Treating Cognitive Dysfunction in Patients with Grade IV Glioma",
    "A Multi-Modality Surveillance Program in Screening Women at High Risk for Breast Cancer",
    "Radiation Therapy in Treating Patients with p16 Positive Oropharyngeal Squamous Cell Cancer",
    "Mature Dendritic Cell Vaccine in Treating Patients with Stage I-II Resected Hypermutated Colorectal Cancer",
    "Venetoclax and Quizartinib in Treating Patients with FLT3-mutated Recurrent or Refractory Acute Myeloid Leukemia",
    "Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients with Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or High-Risk Myeloproliferative Neoplasm",
    "Pre-operative SRS or Post-operative SRS in Treating Cancer Patients with Brain Metastases",
    "Pemetrexed and Avelumab in Treating Patients with MTAP-Deficient Metastatic Urothelial Cancer",
    "Whole Brain Radiation Therapy with Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients with Glioblastoma",
    "Nivolumab with DA-REPOCH Chemotherapy Regimen in Treating Patients with Aggressive B-Cell Non-Hodgkin's Lymphoma",
    "Nivolumab and Ipilimumab and Stereotactic Body Radiation Therapy in Treating Patients with Salivary Gland Cancers",
    "Enzalutamide with Venetoclax in Treating Patients with Metastatic Castration Resistant Prostate Cancer",
    "Itacitinib in Reducing the Incidence of Graft Versus Host Disease in Patients with Hematologic Cancers Undergoing Donor Stem Cell Transplant",
    "TAK-659 and Paclitaxel in Treating Patients with Advanced Solid Tumors",
    "Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with High-Risk Multiple Myeloma",
    "Pembrolizumab in Treating Patients with Stage IIB or IIC Melanoma Undergoing Surgery and Sentinel Lymph Node Biopsy",
    "Minnelide for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "TAS-102 in Treating Patients with Locally Advanced Unresectable or Metastatic Bladder Cancer",
    "Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Entinostat and Pembrolizumab in Treating Patients with Stage III-IV Melanoma",
    "Immunotherapy (BMS-813160 and Nivolumab) with or without a Vaccine (GVAX) after Chemotherapy and Radiation Therapy for the Treatment of Unresectable, Locally Advanced Pancreatic Cancer",
    "Topical Caffeine Compound for the Reduction of Complications in Patients with Stage 0-III Breast Cancer Undergoing Radiation Therapy, ReDCoAT Study",
    "VX15 / 2503 with or without Ipilimumab and / or Nivolumab in Treating Patients with Resectable Stage IIIB-D Melanoma",
    "RNA Expression and Molecular Subtype Analysis to Optimize Novel Therapy for Metastatic Breast Cancer, HARMONY Study",
    "Curcumin in Preventing Progression in Low-Risk Localized Prostate Cancer Patients Undergoing Active Surveillance",
    "Nivolumab and Ibrutinib in Treating Patients with Relapsed or Refractory Central Nervous System Lymphoma",
    "Low-Dose Aspirin in Decreasing Inflammation in Patients Undergoing Gynecologic Surgery",
    "Nivolumab, Ipilimumab and Chemoradiation in Treating Patients with Resectable Gastric Cancer",
    "Umbralisib and Pembrolizumab in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma",
    "Atezolizumab, Oxaliplatin, and Fluorouracil in Treating Patients with Esophageal or Gastroesophageal Cancer",
    "SOR-C13 in Treating Patients with Advanced Refractory Solid Tumors",
    "Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers",
    "Intensity Modulated Radiation Therapy or 3-Dimensional Conformal Radiation Therapy in Treating Patients with Lymph-Node Positive Breast Cancer",
    "Olaparib for Treatment of Metastatic Kidney Cancer in Patients with DNA Repair Gene Mutations, the ORCHID Study",
    "Flt3L, Radiation Therapy, Poly-ICLC, and Pembrolizumab in Treating Patients with Refractory Indolent Non-Hodgkin's Lymphoma, Metastatic Breast Cancer, or Head and Neck Cancer",
    "Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular Lymphoma",
    "Artesunate Ointment in Treating Patients with High-Grade Vulvar Intraepithelial Neoplasia",
    "Modified Immune Cells (huCART19) in Treating Pediatric Patients with Relapsed or Refractory Very High-Risk B Acute Lymphoblastic Leukemia",
    "Ketoconazole before Surgery in Treating Patients with Recurrent Glioma or Breast Cancer Metastatic to the Brain",
    "Surgery and Radiation Therapy in Treating Patients with Recurrent Prostate Cancer that Has Spread to Other Parts of the Body",
    "A Type of Immunotherapy (CMV Specific T Cells) in Treating CMV Infection in Pediatric and Adult Immunocompromised Patients or Stem Cell Transplant Recipients",
    "Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients with HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma",
    "Olaparib and Durvalumab in Treating Patients with Metastatic Triple Negative Breast Cancer",
    "Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers",
    "Title: Moxetumomab Pasudotox-tdfk (Lumoxiti ) and Rituximab (Rituxan ) for Relapsed Hairy Cell Leukemia",
    "TVB-2640 for the Treatment of Patients with Metastatic or Advanced KRAS Mutant Non-Small Cell Lung Cancers",
    "Low-Intensity Chemotherapy and Venetoclax in Treating Patients with Relapsed or Refractory B- or T-Cell Acute Lymphoblastic Leukemia",
    "CD45RA Depleted T Cell Infusion after Alpha / Beta Depleted Stem Cell Transplant for the Reduction of Complications in Patients at Risk for Viral or Fungal Infections",
    "Pencil Beam Scanning Proton Beam Radiation Therapy in Treating Patients with Kidney Tumors",
    "Stereotactic Body Radiation Therapy in Treating Patients with Liver Cancer",
    "Durvalumab and Proton Beam Radiation Therapy for the Treatment of Stage IIA-IIIC Non-small Cell Lung Cancer, PARTICLE-D Study",
    "Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients with Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk",
    "Papaverine Hydrochloride and Stereotactic Body Radiation Therapy in Treating Patients with Non-small Cell Lung Cancer or Lung Metastases",
    "Trametinib and Hydroxychloroquine in Treating Patients with Locally Advanced or Metastatic and Unresectable Pancreatic Cancer",
    "CBM588, Nivolumab, and Ipilimumab in Treating Patients with Stage IV or Advanced Kidney Cancer",
    "Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients with Erectile Dysfunction after Radiation Therapy for Prostate Cancer",
    "SD-101 and BMS-986178 in Treating Patients with Advanced or Metastatic Solid Malignancies",
    "Mirvetuximab Soravtansine for the Treatment of Folate Receptor-Alpha Positive Persistent or Recurrent Endometrial Cancer",
    "Ponatinib for the Treatment of Advanced and Metastatic Medullary Thyroid Cancer",
    "Axitinib in Treating Patients with Metastatic, Recurrent, or Primary Unresectable Pheochromocytoma or Paraganglioma",
    "Vorinostat in Preventing Graft Versus Host Disease in Children, Adolescents, and Young Adults Undergoing Blood and Bone Marrow Transplant",
    "Pembrolizumab and Vactosertib in Treating Colorectal Cancer with Resectable Hepatic Metastases",
    "Venetoclax in Combination with Decitabine for the Treatment of High-Risk Acute Myeloid Leukemia",
    "CPX-351 and Palbociclib in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia",
    "Stem Cell Transplant with Chemotherapy and Selected Use of Blinatumomab in Treating Patients with Blood Cancer",
    "Inotuzumab Ozogamicin and Vincristine Sulfate Liposome in Treating Patients with Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia",
    "Ipatasertib in Combination with Carboplatin, Carboplatin / Paclitaxel, or Capecitabine / Atezolizumab in Treating Patients with Metastatic Triple Negative Breast Cancer",
    "Palbociclib, Bosutinib, and Fulvestrant for the Treatment of Metastatic Hormone Receptor Positive and HER2 Negative Breast Cancer Refractory to Aromatase Inhibitors",
    "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients with Leukemia or Lymphoma Undergoing Stem Cell Transplantation",
    "Azacitidine, Venetoclax, and Pevonedistat in Treating Patients with Newly Diagnosed Acute Myeloid Leukemia",
    "Rituximab Hyaluronidase in Combination with Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda",
    "Immunotherapy with or without Stereotactic Body Radiation Therapy after First-line Systemic Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer",
    "High Dose Vitamin A Compound in Treating Patients with Resectable Non-small Cell Lung Cancer",
    "Atorvastatin in Treating Patients with Stage IIb-III Triple Negative Breast Cancer Who Did Not Achieve a Pathologic Complete Response after Receiving Neoadjuvant Chemotherapy",
    "Low Dose Ipilimumab with Pembrolizumab in Treating Patients with Melanoma that Has Spread to the Brain",
    "Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial",
    "Immunotherapy (Nivolumab) for the Treatment of Untreated or Recurrent Head and Neck Cancer in Patients Undergoing Surgery",
    "A Vaccine (SurVaxM) in Treating Patients with Metastatic Neuroendocrine Tumors",
    "Proton Therapy and Combination Chemotherapy for the Treatment of Resectable Pancreatic Cancer, PROTON-PANC Study",
    "Abemaciclib in Treating Patients with Advanced, Refractory, and Unresectable Digestive System Neuroendocrine Tumors",
    "Duvelisib and Nivolumab in Treating Patients with Richter Syndrome or Transformed Follicular Lymphoma",
    "Avelumab and Bacille Calmette-Guerin for the Treatment of Recurrent Non-muscle Invasive Bladder Cancer, ABC Study",
    "Stereotactic Body Radiation Therapy Using HyperArc in Treating Patients with Recurrent Head and Neck Cancer",
    "Stereotactic MRI-Guided Focused Ultrasound Mesencephalotomy for Pain Palliation in Head & Neck Cancer",
    "CPX-351 in Treating Patients with Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Oncolytic Adenovirus DNX-2401 in Treating Patients with Recurrent High-Grade Glioma",
    "Radioembolization for HCC Patients with Personalized Yttrium-90 Dosimetry for Curative Intent (RAPY90D)",
    "Aspirin and Rintatolimod with or without Interferon-alpha 2b in Treating Patients with Prostate Cancer Before Surgery",
    "Antiandrogen Therapy and SBRT in Treating Patients with Recurrent, Metastatic Prostate Cancer",
    "Tumor Treating Fields Therapy, Nivolumab, and Ipilimumab in Treating Patients with Melanoma Brain Metastasis",
    "Breast Surgery Alone versus Radiotherapy before Breast Surgery in Treating Patients with Ductal Carcinoma in Situ",
    "Carfilzomib-Based Chemotherapy before Autologous Stem Cell Transplant for the Treatment of Multiple Myeloma",
    "Oncolytic HSV-1 G207 in Patients with Recurrent or Refractory Cerebellar Brain Tumors",
    "Durvalumab and Tremelimumab in Treating Patients with Somatically Hypermutated Recurrent or Refractory Solid Tumors",
    "Durvalumab and Standard Chemotherapy before Surgery in Treating Patients with Variant Histology Bladder Cancer",
    "Inotuzumab Ozogamicin in Treating Patients with MRD Positive CD22+ Relapsed B Cell Acute Lymphoblastic Lymphoma",
    "Pemigatinib before Surgery for the Treatment of Recurrent Low- or Intermediate Risk Non-Muscle Invasive Bladder Cancer",
    "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy with Chemotherapy and Durvalumab in Treating Patients with Inoperable Stage IIB, IIIA, and select IIIB and IIIC Non-small Cell Lung Cancer",
    "Neratinib and Divalproex Sodium in Treating Patients with Advanced Solid Tumors or RAS-Mutated Cancers",
    "Paclitaxel and Radiation Therapy in Treating Patients with Cutaneous Angiosarcoma",
    "Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma",
    "Identification of Genetic Mutations in Patients with Suspected Hereditary Cancers",
    "Durvalumab with or without Tremelimumab or Olaparib after Thoracic Radiation Therapy in Treating Patients with Extensive Stage-Small Cell Lung Cancer",
    "Adoptive Cellular Therapy (PRGN-3006 T Cells) in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Convection-Enhanced Delivery of Topotecan in Treating Patients with Recurrent or Progressive WHO Grade III-IV Glioma",
    "Tobacco Treatment in Helping Current Smokers Quit Smoking",
    "Frontline Immunotherapy Combined with Radiation and Chemotherapy in High Risk Endometrial Cancer, FIERCE Study",
    "ONC 201 Maintenance Therapy for the Treatment of Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome after Donor Stem Cell Transplant",
    "MRI-Guided Accelerated Partial Breast Irradiation in Treating Patients with Early Breast Cancer",
    "Daratumumab, Ixazomib, and Dexamethasone with or without Bortezomib in Treating Patients with Newly Diagnosed Multiple Myeloma",
    "Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) after High-Dose External Beam Radiation Therapy in Treating Patients with Unresectable Liver Cancer",
    "Olaparib in Treating Patients with Newly Diagnosed BRCA-Mutant Ovarian, Primary Peritoneal, or Fallopian Cancer before Surgery",
    "Split-Dose R-CHOP for Older Adults with Diffuse Large B-cell Lymphoma",
    "Carboplatin, Paclitaxel, and Nivolumab Induction Therapy followed by Chemoradiation for the Treatment of Locally Advanced, HPV Negative Head and Neck Cancer, DEPEND Trial",
    "Lanreotide for the Treatment of Metastatic or Unresectable Pheochromocytoma or Paraganglioma, the LAMPARA Study",
    "Venetoclax and Acalabrutinib in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma",
    "Lenvatinib and Everolimus in Treating Patients with Advanced, Unresectable Carcinoid Tumors",
    "Androgen Deprivation Therapy (Leuprolide and Degarelix) and Chemoimmunotherapy (Cemiplimab and Docetaxel) for the Treatment of Metastatic Hormone-Sensitive Prostate Cancer",
    "Ruxolitinib Cream in Treating Non-sclerotic Chronic Cutaneous Graft Versus Host Disease in Patients Who Have Undergone a Stem Cell Transplant",
    "TSR-042 and Radiation for the Treatment of Stage I-II Endometrial Cancer",
    "Cabozantinib and Pembrolizumab for the Treatment of Stage IIIC-IV Melanoma",
    "CPX-351 in Treating Patients with Myelodysplastic Syndromes after Hypomethylating Agent Failure",
    "Rucaparib and Nivolumab in Treating Patients with Stage IV Extensive Stage Small Cell Lung Cancer",
    "HU14.18-IL2, Radiation Therapy, Nivolumab and Ipilimumab in Treating Patients with Stage IV or Unresectable Melanoma",
    "Capecitabine and Radiation Therapy after Surgery in Treating Patients with Non-Metastatic Invasive Breast cancer",
    "Ipatasertib with Aromatase Inhibitor, Fulvestrant, and / or Palbociclib in Treating Patients with Hormone Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer",
    "MBG453, Spartalizumab, and Stereotactic Radiosurgery for the Treatment of Recurrent Glioblastoma",
    "Ketogenic Diet with Letrozole in Treating Patients with Estrogen Receptor Positive Breast Cancer",
    "Durvalumab and Tremelimumab in Combination with Platinum-based Chemotherapy for the Treatment of Patients with Untreated Extensive-Stage Small Cell Lung Cancer",
    "Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS)",
    "Immediate Prostatectomy versus Cabozantinib Followed by Prostatectomy in Patients with Intermediate-High or High-Risk Prostate Cancer, The SPARC Study",
    "Talazoparib and Radiation Therapy in Treating Patients with Locally Recurrent Gynecologic Cancers",
    "Pembrolizumab and Decitabine in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome That Is Newly-Diagnosed, Recurrent, or Refractory",
    "Abemaciclib in Treating Patients with Recurrent Oligodendroglioma",
    "Nivolumab in Combination with Chemotherapy before Surgery in Treating Patients with Borderline Resectable Pancreatic Cancer",
    "Hypofractionated Radiation Therapy in Treating Patients with Unresectable or Metastatic Soft Tissue Sarcoma",
    "CPAP in Treating Obstructive Sleep Apnea in Patients with Polycythemia Vera or Essential Thrombocythemia",
    "FOLFIRINOX Chemotherapy Before Surgery in Treating Patients with Non-Metastatic Pancreatic Cancer",
    "Pembrolizumab with or without Entinostat in Treating Patients with Bladder Urothelial Cancer",
    "Atezolizumab with or without PEGPH20 before and after Surgery for the Treatment of Stage I-II Resectable Pancreatic Cancer",
    "Curcumin for the Treatment of Stage I-III Invasive Breast Cancer in Patients Undergoing Surgery",
    "Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Thiotepa in Treating Patients with Non-malignant Disorders",
    "Copaxone for the Treatment of Percutaneously Accessible Tumors",
    "Pembrolizumab and CMP-001 for the Treatment of Relapsed and Refractory Lymphomas",
    "Optimizing PTCy Dose and Timing",
    "Resistance Training with or without Creatine Monohydrate Supplement in Improving Body Composition and Health Outcomes in Patients with Metastatic Prostate Cancer",
    "Itacitinib and Alemtuzumab in Treating Patients with T-Cell Prolymphocytic Leukemia",
    "Axitinib and Avelumab in Treating Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma",
    "An Investigational Surgical Procedure (Vascularized Lymph Node Transfer) in Reducing the Risk of Lymphedema in Patients with Breast Cancer Undergoing Breast Reconstruction",
    "Pembrolizumab for the Treatment of PD-L1 Gene-Altered Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Inotuzumab Ozogamicin and Chemotherapy in Treating Patients with Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia",
    "Modified FOLFIRINOX and Stereotactic Body Radiation Therapy for the Treatment of Patients with Non-Metastatic Unresectable Pancreatic Cancer",
    "Sacituzumab Govitecan in Treating Patients with Breast Cancer Brain Metastasis or Recurrent Glioblastoma",
    "Erdafitinib and Abiraterone Acetate or Enzalutamide in Treating Patients with Double Negative Prostate Cancer",
    "Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma",
    "Comprehensive Genetic Assessment, Risk and Education among Women at Intermediate or High Risk of Breast Cancer, CARE at Mammography Study",
    "Durvalumab and Radiation Therapy for the Treatment of Stage IIIA-B Non-small Cell Lung Cancer",
    "Avelumab in Combination with AXL Inhibitor AVB-S6-500 for the Treatment of Locally Advanced, Unresectable, or Metastatic Urothelial Cancer",
    "Targeted PARP or MEK / ERK Inhibition in Patients With Pancreatic Cancer",
    "An Investigational Graft Processing Procedure (ApoGraft) for the Prevention of Acute Graft Versus Host Disease in Patients Undergoing Stem Cell Transplant",
    "Modified Immune Cells (CD19 / CD20 CAR-T Cells) in Treating Patients with Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
    "Topical Afimoxifene in Treating Patients with Breast Cancer Who Have Undergone Radiation Therapy on One Breast",
    "Genetic Testing in Families with an Identified Mutation Associated with Hereditary Gynecologic Cancers",
    "Abemaciclib for the Treatment of Rb Wild-Type Refractory or Relapsed Extensive Stage Small Cell Lung Cancer",
    "Hydroxychloroquine for the Treatment of Recurrent, Oligometastatic Prostate Cancer",
    "Nivolumab with or without Ipilimumab after Surgery for the Treatment of Resectable Stage III Melanoma",
    "Personalized DNA Vaccine for the Treatment of Newly Diagnosed Glioblastoma",
    "Encorafenib, Cetuximab, and Nivolumab in Treating Patients with Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer",
    "Short Course Chemo-Radiation Therapy for the Treatment of Newly Diagnosed Glioblastoma",
    "Nivolumab for the Treatment of DNA Repair-Mutated, Biochemically Recurrent Prostate Cancer, The NivoCure Trial",
    "Immunotherapy (Atezolizumab) and Vaccines (MVA-BN-Brachyury and PROSTVAC) for the Treatment of Intermediate-Risk and High-Risk Localized Prostate Cancer, the AtezoVax Study",
    "SBRT with MRI Guidance in Treating Patients with Liver Metastases",
    "BMS-986156, Ipilimumab, and Nivolumab with or without Stereotactic Body Radiation Therapy in Treating Patients with Advanced or Metastatic Lung / Chest or Liver Cancers",
    "A Study of the Drug 131I-Omburtamab in People with Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum",
    "Bendamustine with or without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant",
    "Cabozantinib in Treating Patients with Locally Advanced Non-metastatic Kidney Cancer",
    "PLX51107 and Azacitidine in Treating Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Prexasertib with Cyclophosphamide or Gemcitabine in Treating Children and Adolescents with Recurrent or Refractory Medulloblastoma",
    "Octreotide, Dexamethasone, and Metoclopramide in Treating Patients with Inoperable Malignant Bowel Obstruction",
    "LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)",
    "Doxorubicin, AGEN1884, and AGEN2034 for the Treatment of Advanced or Metastatic Soft Tissue Sarcoma",
    "Neoadjuvant Spartalizumab and Canakinumab for the Treatment of Patients with Localized Kidney Cancer, SPARC-1 Trial",
    "Modified Immune Cells (CD19-CD22 CAR T cells) in Treating Patients with Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma",
    "Cisplatin, Docetaxel, and Pembrolizumab in Treating Patients with Stage II-III Laryngeal Cancer",
    "Niraparib before Surgery in Treating Patients with Unfavorable Intermediate or High Risk Localized Prostate Cancer and DNA Damage Response Defects",
    "sEphB4-HSA in Treating Patients with Metastatic Castration-Resistant Prostate Cancer",
    "Intraperitoneal and Intravenous Paclitaxel Chemotherapy With Oral Capecitabine for Gastric Adenocarcinoma With Peritoneal Carcinomatosis",
    "Gemcitabine and Docetaxel with Radiation Therapy before Surgery for the Treatment of High Grade and Greater than 5 cm Soft Tissue Sarcoma of the Extremities",
    "Aspirin, Tamoxifen, and Combination Chemotherapy for the Treatment of ER Positive, HER2 Negative Stage I-III Breast Cancer",
    "Fecal Microbiota Transplantation in Treating Immune-Checkpoint Inhibitor Induced-Diarrhea or Colitis in Genitourinary Cancer Patients",
    "Single Fraction Stereotactic Breast Irradiation for the Treatment of Early Stage Breast Cancer",
    "Nivolumab and Oxaliplatin with or without Ipilimumab for the Treatment of Advanced Squamous or Non-squamous Non-small Cell Lung Cancer",
    "Intravenous Vitamin C with Gemcitabine and Carboplatin for the Treatment of Patients with Bladder Cancer who Cannot Receive Cisplatin, A Forgotten Group Study",
    "Accelerated Hypofractionated Intensity Modulated Radiation Therapy and Combination Chemotherapy for the Treatment of Unresectable Esophageal or Gastroesophageal Junction Cancer",
    "Cladribine, Idarubicin, Cytarabine, and Quizartinib in Treating Patients with Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Vyxeos in Treating Patients with Intermediate and High-Risk Acute Myeloid Leukemia Who Have Failed an Initial Cycle of Standard Cytarabine and Daunorubicin Chemotherapy",
    "Combination Chemotherapy with Gemtuzumab Ozogamicin for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "Regorafenib for the Treatment of Bevacizumab Refractory Recurrent Glioblastoma",
    "Lymphodepletion with Adoptive Cell Therapy and High-Dose IL-2 for the Treatment of Metastatic Soft Tissue Sarcoma in Young Adult Patients",
    "Ultra Low Dose Radiation Delivered before or after Chemotherapy-Free Targeted Therapy in Treating Patients with Relapsed or Refractory Mantle Cell Lymphoma",
    "Vaccine Response With NT-I7",
    "Ivosidenib and Nivolumab for the Treatment of IDH1 Mutant Glioma and Advanced Solid Tumors",
    "Azacitidine and Venetoclax in Treating Patients with Acute Myeloid Leukemia in Remission",
    "OsteoCrete in Filling Bone Voids in Participants with Bone Voids or Defects",
    "Itacitinib and Tocilizumab for the Treatment of Steroid Refractory Acute Graft versus Host Disease",
    "Topical Tazarotene 0.1% Gel for the Prevention of Regorafenib-Induced Hand-Foot-Skin Reactions",
    "Single Fraction Stereotactic Body Radiation Therapy after Surgery in Treating Patients with Non-small Cell Lung Cancer",
    "Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients with Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas",
    "Abemaciclib and Bevacizumab for the Treatment of Recurrent Glioblastomas with Loss of CDKN2A / B or Gain of CDK4 / 6",
    "Pexmetinib with Nivolumab or Ipilimumab for the Treatment of Advanced Melanoma, Kidney Cancer, or Solid Tumors",
    "Nivolumab Alone or in Combination with Relatlimab or Ipilimumab for the Treatment of Resectable Stage III-IVA Head and Neck Cancer",
    "LSD1 Inhibitor IMG-7289 for the Treatment of Essential Thrombocythemia",
    "Chemokine Modulation Therapy and Standard Chemotherapy before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer",
    "Immunotherapy (Atezolizumab and Varlilumab) in Combination with Radiation Therapy for the Treatment of Advanced Unresectable Non-small Cell Lung Cancer",
    "Lutathera for the Treatment of Inoperable, Progressive Meningioma after External Beam Radiation Therapy",
    "Pembrolizumab before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers",
    "Genetically Engineered Cells (ATLCAR.CD30 T Cells) for the Treatment of Relapsed or Refractory CD30 Positive Peripheral T Cell Lymphoma",
    "Isatuximab, Bendamustine, and Prednisone for the Treatment of Refractory Multiple Myeloma",
    "Autologous CD22 Chimeric Antigen Receptor (CAR) T Cells for the Treatment of Recurrent or Refractory B Cell Malignancies or Acute Lymphoblastic Leukemia",
    "Pembrolizumab for the Treatment of Resectable Early Stage Gastroesophageal or Gastic Cancer",
    "Prexasertib and Irinotecan for the Treatment of Relapsed or Refractory Desmoplastic Small Round Cell Tumor or Rhabdomyosarcoma",
    "Galeterone Alone or Combined with Gemcitabine for the Treatment of Refractory Metastatic Pancreatic Adenocarcinoma",
    "Giving Chemotherapy and rATG for a Shortened Amount of Time before a Donor Stem Cell Transplantation for the Treatment of Patients with Blood Cancers",
    "Atezolizumab and Bevacizumab for the Treatment of EGFR Mutant Stage IV Non-small Cell Non-squamous Lung Cancer",
    "TAS-102 with Concurrent Radiation for the Treatment of Untreated Resectable Stage II-III Rectal Cancer",
    "Radiation Therapy and Cisplatin with or without Cetuximab in Treating Patients with HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma",
    "Losartan and Hypofractionated Radiation Therapy after Chemotherapy for the Treatment of Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer, the SHAPER Study",
    "Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Stomach Cancer with Peritoneal Metastases",
    "Immunotherapy (Durvalumab) Combined with Radiation Therapy (Yttrium-90 Radioembolization) for the Treatment of Colorectal Cancer Metastatic to the Liver, iRE-C Trial",
    "Minimal Residual Disease Detection to Guide Post-Transplant Maintenance Therapy in Multiple Myeloma",
    "Nivolumab and Radium-223 for the Treatment of Metastatic Castration Resistant Prostate Cancer",
    "Precision Medicine for the Treatment of Cancer in Patients with Identified Actionable Mutations",
    "A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma",
    "Modified Immune Cells (LN-145) for the Treatment of Pretreated Metastatic Triple Negative Breast Cancer",
    "NIAGEN for the Alleviation of Chemotherapy-Induced Peripheral Neuropathy in Cancer Survivors",
    "Immunotherapy (Pembrolizumab or Nivolumab) with Metformin or Rosiglitazone for the Treatment of Advanced Solid Tumors",
    "Retifanlimab for the Treatment of Unresectable or Metastatic Pancreatic Cancer",
    "Focused Ultrasound Ablation and PD-1 Antibody Blockade for the Treatment of Advanced Solid Tumors",
    "KRAS Peptide Vaccine, Nivolumab, and Ipilimumab for the Treatment of Resected Pancreatic Cancer or MSS Colorectal Cancer",
    "Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer",
    "Ramucirumab and Pembrolizumab for the Treatment of EGFR Mutant Recurrent or Metastatic Non-small Cell Lung Cancer",
    "Tamoxifen for the Treatment of Hormone Receptor Positive, Well Differentiated Neuroendocrine Tumors, the HORMONET Study",
    "Nivolumab and BMS-813160 or BMS-986253 for the Treatment of Resectable Non-small Cell Lung Cancer or Liver cancer",
    "Venetoclax and Azacitidine for the Treatment of Acute Myeloid Leukemia in the Post-Transplant Setting",
    "Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome",
    "NovoTTF-200A and Pembrolizumab for the Treatment of Newly Diagnosed Melanoma Brain Metastasis",
    "A Vaccine (9pNGVL4aCRTE6E7L2 HPV DNA Vaccine) for the Treatment of HPV16 Positive High-Grade Cervical Intraepithelial Lesions",
    "Baricitinib for the Prevention of Graft Versus Host Disease in Patients with Hematological Malignancies after Peripheral Blood Donor Stem Cell Transplantation",
    "Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) following CAR-T Cell Therapy for the Treatment of Relapsed / Refractory Classical Hodgkin Lymphoma",
    "Genetically Engineered Cells (CAR-37 T Cells) for the Treatment of Relapsed or Refractory CD37 Positive Hematologic Malignancies",
    "Dostarlimab Alone or in Combination with Cobolimab for the Treatment of Resectable Stage III or IV Melanoma",
    "RBX7455 before Surgery for the Treatment of Operable Breast Cancer",
    "Azacitidine, Venetoclax, and Gilteritinib in Treating Patients with Recurrent / Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome / Myeloproliferative Neoplasm",
    "Osimertinib and Ipilimumab for the Treatment of EGFR-Mutated Metastatic Non-small Cell Lung Cancer",
    "Ulixertinib and Hydroxychloroquine for the Treatment of Advanced MAPK-Mutated Gastrointestinal Cancers",
    "Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia / Myeloproliferative Disease",
    "Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for the Treatment of Intermediate Risk Prostate Cancer",
    "A Study of Anakinra to Prevent or Treat Severe Side Effects for Patients Receiving CAR-T Cell Therapy and to Treat Systemic Inflammation Associated with COVID-19",
    "Fluorouracil, Oxaliplatin, Liposomal Irinotecan with or without Trastuzumab for the First Line Treatment of Advanced Esophageal or Gastric Adenocarcinoma",
    "Escalation of Daratumumab Frequency for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Pembrolizumab and Bavituximab for the Treatment of Progressive Recurrent or Metastatic Head and Neck Squamous Cell Cancer",
    "Cryoablation for the Treatment of Metastatic Cancer",
    "Daratumumab and Dexamethasone with or without Lenalidomide or Bortezomib for the Treatment of Newly Diagnosed Multiple Myeloma in Older Adults",
    "Copanlisib and Combination Chemotherapy for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma or Relapsed Grade 3b Follicular Lymphoma",
    "Th-1 Dendritic Cell Vaccine After Standard Chemotherapy and Surgery in Treating Patients with Pancreatic Cancer",
    "Comparing Length of Treatment with Immunotherapy in Patients with Advanced Solid Tumors",
    "Oxaliplatin and mFOLFIRI Regimen for the Treatment of Unresectable Peritoneal Carcinomatosis from Colorectal or Appendiceal Cancer",
    "Venetoclax and Azacitidine for the Treatment of High-Risk Recurrent or Refractory Myelodysplastic Syndrome",
    "D2C7-IT and Atezolizumab for the Treatment of Recurrent Glioblastoma",
    "Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations in Patients with Advanced Colorectal Polyps",
    "Magnetic Resonance-Guided Radiation Therapy before Surgery for the Treatment of Stage I-III Gastric Cancer",
    "Celecoxib through Surgery and Radiation Therapy for the Treatment of Advanced Head and Neck Cancer",
    "Staggered Chemo-Immunotherapy (Pemetrexed and Carboplatin with Durvalumab) for the Treatment of Metastatic Non-squamous Non-small Cell Lung Cancer",
    "Umbralisib for the Treatment of Treatment Naive Chronic Lymphocytic Leukemia",
    "Cabozantinib and Pembrolizumab for the Treatment of Metastatic or Recurrent Gastric or Gastroesophageal Adenocarcinoma",
    "Drug Resistant Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma in Patients Receiving Maintenance Temozolomide",
    "VB-111 in Combination With Nivolumab in People With Metastatic Colorectal Cancer (mCRC)",
    "Temozolomide and Olaparib for the Treatment of MGMT Promoter Hypermethylated Relapsed or Refractory Colorectal Cancer",
    "NTX-301 for the Treatment of Relapsed or Refractory Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Abemaciclib for the Treatment of HPV-Negative Stage I-IVA Head and Neck Cancer Undergoing Surgery",
    "Acalabrutinib and Venetoclax with or without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers",
    "Minimally Invasive versus Open Pancreaticoduodenectomy for the Treatment of Periampullary or Pancreatic Tumors",
    "Venetoclax for the Treatment of Stage IB-IV Cutaneous T Cell Lymphoma",
    "FES-PET / CT Scans for the Optimization of Tamoxifen Dose in Patients with Estrogen Receptor Positive, ESR1 Mutant Metastatic or Unresectable Breast Cancer",
    "Fluciclovine (FACBC) PET / CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study",
    "68Ga-HBED-CC PSMA-PET / MRI for the Definition of Radiation Treatment in Patients with Prostate Cancer",
    "Rigosertib for the Treatment of Recessive Dystrophic Epidermolysis Bullosa Associated Unresectable, Locally Advanced, or Metastatic Squamous Cell Skin Cancer",
    "Genetically Engineered Cells (B7-H3-Specific CAR T Cells) in Treating Pediatric Patients with Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, or Recurrent or Refractory Central Nervous System Tumors",
    "Azacitidine and Decitabine for the Treatment of Myelodysplastic Syndrome or Other Related Cancers",
    "Nivolumab plus Talazoparib for the Treatment of Unresectable or Metastatic Melanoma in Patients with Mutations in BRCA or BRCA-ness",
    "Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia",
    "Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell Lymphoma",
    "Radiation Therapy (Hypofractionated Proton Beam Therapy or IMRT) for the Treatment of Recurrent, Oligometastatic Prostate Cancer following Primary Localized Treatment",
    "Reduced-Intensity Fludarabine, Melphalan, and Total Body Irradiation for the Treatment of Blood Cancer in Patients Undergoing Donor Stem Cell Transplant",
    "CM4620 for the Reduction of the Severity of Acute Pancreatitis Due to Treatment with Asparaginase in Patients with Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma, the CRSPA Study",
    "Donor Stem Cell Transplant with Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies",
    "CPX-351 or CLAG-M Regimen for the Treatment of Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms in Medically Less-Fit Patients",
    "Continuous Infusion Chemotherapy (CI-CLAM) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Other High-Grade Myeloid Neoplasms",
    "GD2CART for the Treatment of H3K27M Mutated Diffuse Intrinsic Pontine Glioma or Spinal Diffuse Midline Glioma",
    "Contrast-Enhanced CBCT during Radiation Therapy in Patients with Abdominal or Pelvic Tumors",
    "Vigamox for the Treatment for Ocular Graft-Versus-Host Disease",
    "Reduce Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed Multiple Myeloma",
    "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients with Hematologic Malignancies",
    "Radium-223 in Biochemically Recurrent Prostate Cancer",
    "Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia",
    "Paclitaxel, Pembrolizumab, and Olaparib for the Treatment of Previously Treated Advanced Stomach Cancer",
    "Dose De-escalated Stereotactic Body Radiation Therapy for the Treatment of Centrally Located Non-small Cell Lung Cancer",
    "Leflunomide in Treating Patients with Steroid Dependent Chronic Graft Versus Host Disease",
    "Heated Intra-peritoneal Chemotherapy with Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Abdominal or Pelvic Tumors in Pediatric Patients, T.O.A.S.T. I.T. Study",
    "Chimeric Antigen Receptor (CAR) T Cells with a Chlorotoxin Tumor-Targeting Domain for the Treatment of MPP2+ Recurrent or Progressive Glioblastoma or Brain Tumors",
    "Selinexor (KPT-330) in Combination With Temozolomide and Radiation Therapy in Patients With Newly Diagnosed Glioblastoma",
    "Nab-paclitaxel and Alpelisib for the Treatment of Anthracycline Refractory Triple Negative Breast Cancer with PIK3CA or PTEN Alterations",
    "Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "ABL001 for the Treatment of Chronic Myeloid Leukemia in Patients Who Are on Therapy with Tyrosine Kinase Inhibitor",
    "CPI-613 and Bendamustine for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma",
    "Single- or Two-Fraction Spine Stereotactic Radiosurgery for the Treatment of Vertebral Metastases",
    "Cabozantinib with Radiation Therapy for the Treatment of Sarcomas of the Extremities",
    "Donor Natural Killer Cell Therapy in Treating Patients with Recurrent or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Bintrafusp Alfa and Stereotactic Body Radiation Therapy for the Treatment of Recurrent or Second Primary Head and Neck Squamous Cell Cancer",
    "Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer",
    "Niraparib and Tumor-Treating Fields for the Treatment of Recurrent Glioblastoma",
    "Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers",
    "GLIADEL or Stereotactic Radiosurgery after Surgery for the Treatment of Metastatic Brain Tumor",
    "Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors",
    "Ragifilimab and Retifanlimab in Combination with Stereotactic Radiosurgery for the Treatment of Recurrent Glioblastoma",
    "Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent Non-small Cell Lung Cancer",
    "Infigratinib before Surgery for the Treatment of Upper Tract Urothelial Cancer",
    "Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT Study",
    "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Untreated Aggressive Large B-cell Lymphoma",
    "Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients with FGFR Gene Mutations",
    "Yttrium-90 Radiation Segmentectomy versus Stereotactic Body Radiation Therapy for the Treatment of Early Stage Liver Cancer",
    "Canakinumab for the Treatment of Low or Intermediate Risk Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia",
    "Itacitinib for the Treatment of Bronchiolitis Obliterans Syndrome after Donor Hematopoietic Cell Transplant",
    "UCD19 CAR T Cells for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
    "DCC-3014 and Avelumab for the Treatment of Locally Advanced or Metastatic High-Grade Sarcoma",
    "HIV-Specific T-Cell Therapy (DD HST-NEETs) for the Treatment of HIV-Infected Individuals on Antiretroviral Therapy following Donor Bone Marrow Transplantation, The alloRESIST Trial",
    "FLC Peptide Vaccine Combined with Nivolumab and Ipilimumab for the Treatment of Patients with Fibrolamellar Cancer",
    "Rifaximin for the Treatment of Gastrointestinal Toxicities Related to Pertuzumab-Based Therapy in Patients with Stage I-III HER2 Positive Breast Cancer",
    "Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia",
    "Sacituzumab Govitecan for the Treatment of Persistent or Recurrent Endometrial Cancer",
    "mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone with Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma",
    "Pramlintide for the Treatment of Resectable Skin Squamous Cell Cancer",
    "Pembrolizumab with or without Chemotherapy for the Treatment of Non-small Cell Lung Cancer",
    "Mogamulizumab and Low-Dose Total Skin Electron Beam Therapy for the Treatment of Stage IB-IV Mycosis Fungoides and Sezary Syndrome",
    "Aromatase Inhibitor Therapy with or without Fulvestrant for the Treatment of HR Positive Metastatic Breast Cancer with an ERS1 Activating Mutation, the INTERACT Study",
    "Acalabrutinib and Anti-CD19 CAR T-cell therapy for the Treatment of B-cell Lymphoma",
    "An Enzyme Inhibitor, Bomedemstat, for the Treatment of Essential Thrombocythemia or Polycythemia Vera That Has Failed at Least One Standard Therapy",
    "Total Marrow and Lymphoid Irradiation as Conditioning Regimen before Hematopoietic Cell Transplantation in Patients with Myelodysplastic Syndrome or Acute Leukemia",
    "Rigosertib and Nivolumab Combination Therapy for the Treatment of Stage IV Lung Adenocarcinoma Patients with KRAS Mutation Who Progressed on First-Line Treatment",
    "Convection-Enhanced Delivery of MTX110 and Gadolinium for the Treatment of Diffuse Midline Glioma",
    "Avelumab and M6620 for the Treatment of DDR Deficient Metastatic or Unresectable Solid Tumors",
    "Lenvatinib and Pembrolizumab for the Treatment of Locally Advanced or Metastatic Non-clear Cell Kidney Cancer, LENYKN Study",
    "Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer",
    "Genetically Modified Cells (CART19) for the Treatment of Pediatric B cell Acute Lymphoblastic Leukemia",
    "AG-120 in People with IDH1 Mutant Chondrosarcoma",
    "Total Body Irradiation using Intensity Modulated Radiation Therapy (IMRT) (VMAT or Tomotherapy) for the Prevention of Pulmonary Toxicities in Patients Undergoing Donor Stem Cell Transplant",
    "Decitabine with Ruxolitinib or Fedratinib for the Treatment of Accelerated / Blast Phase Myeloproliferative Neoplasms",
    "Necitumumab and Trastuzumab in Combination with Osimertinib for the Treatment of Refractory EGFR-Mutated Stage IV Non-small Cell Lung Cancer",
    "Niraparib Maintenance for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "Lorlatinib with Crizotinib, Binimetinib, or TNO155 for the Treatment of Refractory Stage IV Non-small Cell Lung Cancer with ALK or ROS1 Gene Rearrangement",
    "Eryaspase and Modified FOLFIRINOX for the Treatment of Locally Advanced, Metastatic, or Unresectable Pancreatic Cancer",
    "Repetitive Transcranial Magnetic Stimulation for the Treatment of Post-chemotherapy Cognitive Impairment",
    "Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain",
    "MR Guided HIFU for the Treatment of Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer",
    "Abemaciclib and Androgen Deprivation Therapy for the Treatment of Localized High-Risk or Locally Advanced Prostate Cancer",
    "Mocetinostat and Vinorelbine for the Treatment of Locally Advanced Unresectable or Metastatic, Refractory or Relapsed Rhabdomyosarcoma in Children, Adolescents, and Young Adults",
    "Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients",
    "Degarelix Acetate alone or in combination with Immunotherapy (BMS-986218) before Surgery for the Treatment of High Risk Localized Prostate Cancer",
    "Durvalumab and SNDX-6352 with Chemoembolization or Radioembolization for the Treatment of Intrahepatic Cholangiocarcinoma",
    "NHS-IL12 Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma",
    "Neo-adjuvant Abemaciclib with Fulvestrant for the Treatment of Hormone Receptor Positive Stage I-III Breast Cancer",
    "Augmented Bladder Neck Reconstruction for the Improvement of Urinary Function after Radical Prostatectomy",
    "Abemaciclib Monotherapy in Treating Older Patients with Hormone Receptor Positive Metastatic Breast Cancer",
    "Pembrolizumab and Olaparib for the Treatment of Metastatic Bile Duct Cancer",
    "Laparoscopic HIPEC with Chemoradiation as First Line Treatment in Treating Patients with Local Regional Advanced Gastric Cancer",
    "Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients with Hematological Malignancies Treated with Alemtuzumab",
    "Intraoperative Imaging of Lung Nodules by SGM-101",
    "Tagraxofusp in Treating Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm after Stem Cell Transplant",
    "CD123-Directed Autologous T-Cell Therapy for the Treatment of Relapsed or Refractory Acute Myelogenous Leukemia, CATCH-AML Study",
    "Pembrolizumab and Hypofractionated Radiation Therapy after Surgery for the Treatment of Mucosal Melanoma",
    "Lenvatinib before Surgery for the Treatment of Locally Advanced or Recurrent Invasive Thyroid Cancer",
    "Binimetinib for People With Relapsed / Refractory BRAF Wild Type Hairy Cell Leukemia and Variant",
    "Intermittent Checkpoint Inhibitor Therapy for the Treatment of Advanced or Metastatic Urothelial Cancer",
    "Pembrolizumab before and after Surgery for the Treatment of Resectable Basal Cell Cancer of the Head and Neck",
    "Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed / Refractory HCL",
    "Nivolumab with Relatlimab or Ipilimumab for the Treatment of Recurrent and / or Metastatic Head and Neck Squamous Cell Cancer",
    "Modified Chemotherapy Regimen and Gemtuzumab Ozogamicin for the Treatment of Newly Diagnosed Acute Myeloid Leukemia in Pediatric Patients",
    "Amplitude-Modulated Electromagnetic Fields and Regorafenib as Second-Line Therapy for the Treatment of Patients with Advanced Hepatocellular Carcinoma",
    "Chemotherapy and Nivolumab Alone or in Combination with Cabiralizumab for the Treatment of Stage II-III Triple-Negative Breast Cancer",
    "Duvelisib Maintenance after Autologous Stem Cell Transplant for the Treatment of T-Cell or Indolent B-Cell Lymphoma",
    "Carboplatin, Paclitaxel, and Ramucirumab for the Treatment of Stage IV or Recurrent Non-squamous Non-Small Cell Lung Cancer",
    "Brentuximab Vedotin for the Treatment of CD30 Positive T-Cell Lymphomas in Patients after Stem Cell Transplant, BRENTICON-T Study",
    "WP1066 for the Treatment of Recurrent or Refractory and Progressive Malignant Brain Tumors",
    "Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load",
    "Omeprazole and Cabazitaxel for the Treatment of Docetaxel- and Castration- Resistant Prostate Cancer",
    "Rituximab and Acalabrutinib for the Treatment of Newly Diagnosed B Cell Post-Transplant Lymphoproliferative Disorder",
    "Capecitabine and Temozolomide with A Specific Form of Radiation Therapy (Transarterial Radioembolization) for the Treatment of Unresectable Grade II Neuroendocrine Tumors with Liver Metastases",
    "Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients with Acute leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation",
    "Allogeneic Hematopoietic Stem Cell Transplant for People With Primary Immunodeficiency Diseases",
    "Docetaxel, Ramucirumab, and Pembrolizumab for the Treatment of Metastatic or Recurrent Non-small Cell Lung Cancer in Patients who have Progressed on Platinum-Doublet and PD-1 / PD-L1 Blockade Therapy",
    "Intra-arterial Chemotherapy (Melphalan) for the Treatment of Retinoblastoma",
    "Anti-IL-8 (BMS-986253) for Hospitalized Patients with COVID-19",
    "Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma with Kidney Failure",
    "Endocrine Therapy and Abemaciclib for the Treatment of Locally Advanced, Unresectable or Metastatic ER+ / HER2- Breast Cancer",
    "Genetic Counseling using an Artificial Intelligence Program (ChatBot) in Women with Stage 0-III Breast Cancer",
    "Pembrolizumab with Chemotherapy and Radiation Therapy before Surgery for the Treatment of Stage II-IV Rectal Cancer",
    "Breast Radiotherapy (SABER) for the Treatment of Hormone Receptor Positive HER2 Negative Early Stage Breast Cancer",
    "gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study",
    "A Vaccine (ISA101b) and Pembrolizumab with Cisplatin and IMRT for the Treatment of Intermediate Risk HPV-16 Associated Head and Neck Squamous Cell Carcinoma",
    "Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis",
    "Pembrolizumab with or without Axitinib for the Treatment of Locally Advanced or Metastatic Clear Cell Kidney Cancer in Patients Undergoing Surgery",
    "ADMIRAL Trial: Adaptive Mediastinal Radiation with Chemo-Immunotherapy",
    "Baricitinib, Placebo and Antiviral Therapy for the Treatment of Patients with Moderate and Severe COVID-19",
    "Vorolanib and Atezolizumab for the Treatment of Extensive-Stage Small Cell Lung Cancer",
    "Pembrolizumab and QUAD SHOT Radiation Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Head and Neck Squamous Cell Cancer",
    "Ivermectin, Camostat Mesilate, Artemisia Annua, and Artesunate for the Treatment of High Risk COVID19 Infection",
    "A Study of Rituximab or Tocilizumab for Cancer Patients that Develop Immunotherapy-Related Side Effects Requiring Prolonged Steroid Use",
    "Cetuximab after Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer",
    "Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma",
    "CLAG-M Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia",
    "Delayed Initiation of Olaparib Maintenance Therapy for the Treatment of Platinum Sensitive Recurrent Ovarian Cancer",
    "Rintatolimod and IFN alpha-2b for the Treatment of COVID-19 Infection in Cancer Patients",
    "Nivolumab, Fluorouracil, and Interferon Alpha 2B for the Treatment of Unresectable Fibrolamellar Cancer",
    "Total Body Irradiation Using Intensity Modulated Radiation Therapy and Cyclophosphamide prior to Stem Cell Transplant for the Treatment of Severe Systemic Sclerosis",
    "Low-dose Radiation and Aminolevulinic Acid for the Treatment of Advanced or Metastatic Solid Tumors",
    "Pembrolizumab and Combination Chemotherapy before Surgery for the Treatment of Muscle-Invasive Bladder Cancer",
    "Peritransplant Ruxolitinib for Patients with Primary and Secondary Myelofibrosis",
    "Gemcitabine and Docetaxel for the Treatment of Patients with Bladder Cancer",
    "Short Course Radiation Therapy after Surgery for the Treatment of Endometrial Cancer in Patients Receiving Chemotherapy, DeCRESCEndo Trial",
    "DS3201 and Ipilimumab for the Treatment of Metastatic Prostate, Urothelial and Renal Cell Cancers",
    "Lenvatinib and Pembrolizumab before Surgery for the Treatment of Locally Advanced Non-Metastatic Kidney Cancer",
    "Sirolimus for the Treatment of Metastatic Mismatch Repair Deficient Solid Tumors after Progression on Immunotherapy",
    "Imatinib for the Treatment of COVID-19 in Hospitalized Adults",
    "Brachytherapy and Durvalumab with or without Tremelimumab for the Treatment of Patients with Platinum-Resistant, Refractory, Recurrent, or Metastatic Gynecological Malignancies",
    "Partial Brain Radiation Therapy, Temozolomide, Chloroquine, and Tumor Treating Fields Therapy for the Treatment of Newly Diagnosed Glioblastoma",
    "Hypofractionated Radiotherapy for the Treatment of Stage II-III Non-small Cell Lung Cancer Patients Who Decline or Are Ineligible for Surgery or Chemotherapy",
    "CMP-001 and Nivolumab before Surgery for the Treatment of Stage IIIB / C / D Melanoma",
    "Hypofractionated Radiation Therapy after Surgery for the Treatment of Stage I-IVB Head and Neck Cancer",
    "Acalabrutinib, Lenalidomide, and Rituximab for the Treatment of CD20 Positive Stage III-IV, Grade 1-3a Follicular Lymphoma",
    "Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients with Genitourinary Cancer or Melanoma",
    "Cobimetinib for the Treatment of RAS Pathway-Mutated Newly Diagnosed or Refractory Chronic Myelomonocytic Leukemia",
    "Cabozantinib for the Treatment of High Grade Neuroendocrine Neoplasms",
    "Second Look Laparoscopic Surgery with Heated Chemotherapy for the Treatment of Patients with Stage I-IVA Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "CISH Inactivated Tumor-Infiltrating Lymphocytes for the Treatment of Metastatic Gastrointestinal Epithelial Cancer",
    "Frameless Single versus Multifraction Radiosurgery in Patients with Brain Cancer Receiving Immunotherapy, MIGRAINE Study",
    "Talimogene laherparepvec before Surgery for the Treatment of High-Risk and Treatment-Naive Recurrent Melanoma",
    "Epidiolex in Prostate Cancer Patients with Rising PSA",
    "AGEN1884 and AGEN2034 in Combination with Cisplatin and Gemcitabine for the Treatment of Muscle-invasive Bladder Cancer before Radical Cystectomy",
    "Cisplatin, Pembrolizumab and Radiation Therapy for the Treatment of Unresectable, Recurrent or Metastatic Vulvar Squamous Cell Cancer",
    "Anakinra for the Reduction of CAR-T Toxicity in Patients with Relapsed or Refractory Large B-cell Lymphoma",
    "HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1 / TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers",
    "Magrolimab, Azacitidine, and Venetoclax for the Treatment of Acute Myeloid Leukemia",
    "Palbociclib and Retifanlimab (INCMGA00012) for the Treatment of Metastatic or Unresectable Liposarcoma",
    "Ibrutinib for the Treatment of COVID-19 in Patients Requiring Hospitalization",
    "Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver Cancer",
    "Itacitinib and Extracorporeal Photopheresis for First-Line Treatment of Chronic Graft Versus Host Disease, the FLIGHT Trial",
    "An Early Phase Study of Venetoclax, Lenalidomide, and Rituximab / Hyaluronidase in Slow-Growing Lymphomas That Have Come Back after Treatment or Have Not Responded to Treatment",
    "Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel",
    "Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma",
    "Pulsed Low-Dose-Rate Radiation for the Treatment of Pancreatic Cancer",
    "Quad-Shot Radiation Therapy in Combination with Pembrolizumab for the Treatment of Locally Advanced, Locally Recurrent, or Metastatic Head and Neck Cancer",
    "Preoperative Use of Radiation to Enhance the Effectiveness of Immune Checkpoint Blockade Therapy in Operable Breast Cancer",
    "Aerobic Therapy to Improve Cardiovascular Health in Post-Menopausal Women after Treatment for Early Stage Breast Cancer",
    "Zanubrutinib and Rituximab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "A Study of Platelet-rich Plasma (PRP) Treatment for Hair Loss after Cancer Therapy in Women with Breast Cancer",
    "Acalabrutinib and Durvalumab for the Treatment of Primary or Secondary Central Nervous System Lymphoma",
    "Leflunomide for the Treatment of Relapsed or Refractory CD30+ Lymphoproliferative Disorders",
    "19(T2)28z1xx Chimeric Antigen Receptor (CAR) T Cells for the Treatment of B-Cell Cancers",
    "Nivolumab and Hydroxychloroquine or Nivolumab, Ipilimumab, and Hydroxychloroquine for the Treatment of Stage III-IV Melanoma",
    "External Beam Radiation Therapy and MRI-Guided High Dose Brachytherapy for the Treatment of Unfavorable-Intermediate and High-Risk Prostate Cancer",
    "Ipatasertib in Combination with Docetaxel for the Treatment of Non-small Cell Lung Cancer",
    "Sirolimus and Metronomic Chemotherapy for the Treatment of High-Risk Solid Tumors in Children, AflacST1903 Study",
    "Abemaciclib for the Treatment of Recurrent Ovarian or Endometrial Cancer",
    "Cabozantinib, Ipilimumab, Nivolumab, and Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma",
    "Interstitial Brachytherapy for the Treatment of Unresectable / Unablatable Kidney Cancer",
    "Transvaginal Ultrasonography in Screening Participants for Ovarian Cancer",
    "RGI-2001 for the Prevention of Graft Versus Host Disease in Patients with Hematological Malignancies after Stem Cell Transplantation",
    "Radiation Therapy for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma after CAR T Cell Therapy",
    "Tumor Treating Fields, Stereotactic Radiosurgery, and Temozolomide for the Treatment of Newly Diagnosed Glioblastoma",
    "Precision Oncology in Advanced Pancreatic Cancer",
    "Mycophenolate Mofetil Combined with Radiation Therapy for the Treatment of Recurrent Glioblastoma or Gliosarcoma",
    "Cabozantinib, Abiraterone, and Nivolumab for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, CABIOS Trial",
    "Romiplostim for the Treatment of Inherited and Acquired Disorders of Hematopoietic Failure",
    "Polatuzumab Vedotin and Combination Chemotherapy for the Treatment of Previously Untreated Double or Triple Hit Lymphoma",
    "Osimertinib in Combination with Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer",
    "Abemaciclib and Niraparib before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer",
    "Low-Level Laser for the Treatment of Head and Neck Chronic Lymphedema",
    "Melphalan before Stem Cell Transplant for the Treatment of Multiple Myeloma",
    "B7H3 CAR T Cell Immunotherapy for the Treatment of Children and Young Adults with Recurrent or Refractory Solid Tumors",
    "Modified Immune Cells (CD19 CAR T cells) and Acalabrutinib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
    "NBTXR3 Activated by Radiation Therapy for the Treatment of Locally Advanced or Borderline-Resectable Pancreatic Cancer",
    "Local Consolidative Radiotherapy for the Treatment of Patients with Oligoprogressive Metastatic Non-small Cell Lung Cancer on Immune Checkpoint Inhibitors",
    "Hypofractionated Radiation Therapy for the Treatment of Localized, Intermediate, or High Risk Prostate Cancer",
    "Azacitidine, Venetoclax, and Trametinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Higher-Risk Myelodysplastic Syndrome",
    "CDX-301, CDX-1140, and Stereotactic Body Radiation Therapy versus Standard Therapy the Treatment of Advanced Non-Small Cell Lung Cancer",
    "Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic / Myeloproliferative Neoplasm with FLT3 or CBL Mutations",
    "CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Nivolumab plus Axitinib for the Treatment of Stage III or IV Melanoma",
    "APX005M, Nivolumab and Ipilimumab for the Treatment of Stage III or IV Melanoma or Locally Advanced Unresectable or Metastatic Renal Cell Cancer",
    "Ketorolac before Surgery for the Treatment of Stage I-II Non-small Cell Lung Cancer or Stage III Renal Cell Cancer",
    "Cabozantinib for the Treatment of Liver Cancer with Child Pugh Class B Cirrhosis after First-Line Therapy",
    "Analysis of Coronavirus Disease 19 (COVID-19) Convalescent Plasma",
    "Cirmtuzumab and Venetoclax as Consolidation Therapy for the Treatment of Patients with Small Lymphocytic Lymphoma / Chronic Lymphocytic Leukemia Previously Treated with Venetoclax",
    "Niraparib and Neratinib for the Treatment of Advanced Solid Tumors or Platinum-Resistant Ovarian Cancer",
    "Infigratinib in Combination with Tamoxifen for the Treatment of Hormone Receptor-Positive, HER2-Negative Metastatic or Locally Recurrent Unresectable Breast Cancer",
    "Acalabrutinib and Obinutuzumab for the Treatment of Chronic Lymphocytic Leukemia",
    "NBTXR3 and Radiation Therapy for the Treatment of Inoperable Recurrent Non-small Cell Lung Cancer",
    "Hypofractionated Radiotherapy Followed by Immediate Surgery for the Treatment of Soft Tissue Sarcomas",
    "Risk Enabled Therapy after Neoadjuvant Immunochemotherapy for the Treatment of Bladder Cancer",
    "Ublituximab and Umbralisib for the Treatment of Treatment-Naive Follicular or Marginal Zone Lymphoma",
    "Leflunomide, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Total Body Irradiation with Linac Based Volumetric Modulated Arc Therapy for the Treatment of Hematologic Malignancies in Patients Undergoing Donor Stem Cell Transplant",
    "Chemotherapy and CAR-T Cell Immunotherapy (Brain Tumor‐Specific Immune Cells) for the Treatment of IL13Ralpha2 Positive Recurrent or Refractory Brain Tumors",
    "Pembrolizumab and Trastuzumab after Surgery for the Treatment of Patients with HER2 Positive Esophagogastric Tumors",
    "Trifluridine / Tipiracil in Combination with Talazoparib for the Treatment of Patients with Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer",
    "Pitavastatin and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia or Acute Myeloid Leukemia",
    "A Study of 131-I Apamistamab and CAR T-cell Therapy in Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma",
    "Granulocyte Colony Stimulating Factor Stimulated Imaging for Radiation Treatment Planning in Patients with Stage I-IIIC1 Cervical or Stage IIIA-IIIC1 Endometrial Cancer",
    "Olaparib for the Treatment of Homologous Recombination Deficient Malignant Mesothelioma",
    "Stereotactic Radiosurgery for the Treatment of Patients with Small Cell Lung Cancer Brain Metastasis",
    "Single Fraction or Multi-fraction Palliative Radiation Therapy for the Improvement of Quality of Life in Patients with Metastatic Gynecologic Cancers",
    "Zandelisib and R-CHOP for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma",
    "Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis",
    "TP-0903 for the Treatment of FLT3 Mutated Acute Myeloid Leukemia",
    "Y-90 SIRT and SBRT for the Treatment of Unresectable Liver Cancer",
    "Disulfiram and Copper Gluconate for the Treatment of Recurrent or Refractory Multiple Myeloma",
    "A Vaccine (MV-s-NAP) for the Treatment of Patients with Invasive Metastatic Breast Cancer",
    "Chemotherapy and Donor Stem Transplant for the Treatment of Patients with High Grade Brain Cancer",
    "Pembrolizumab and Chemoradiotherapy for the Treatment of Unresectable Gastroesophageal Cancer",
    "Psilocybin Enhanced Group Psychotherapy in Patients with Cancer, HOPE Study",
    "Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma",
    "Poly-ICLC Vaccine before Surgery for the Treatment of Malignant Pleural Mesothelioma",
    "CPX-351 versus Immediate Stem Cell Transplantation for the Treatment of High-Grade Myeloid Cancers with Measurable Residual Disease",
    "Tavokinogene Telseplasmid plus Electroporation in Combination with Nivolumab for the Treatment of Resectable Locally-Regionally Advanced Melanoma",
    "Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia",
    "[18F]FLOR (FC303) PET / CT Scan for the Detection of Prostate Cancer",
    "Blood-Brain Barrier Opening with the SonoCloud-9 Implantable Ultrasound Device and Nab-Paclitaxel for the Treatment of Recurrent Glioblastoma",
    "Donor Stem Cell Transplant after Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults",
    "Leflunomide for the Treatment of Severe COVID‐19 in Patients with a Concurrent Malignancy",
    "Effect of DIEP Flap Neurotization on Sensory Restoration after Breast Reconstruction",
    "ERK1 / 2 Inhibitor LY3214996 and Abemaciclib for the Treatment of Advanced, Metastatic, or Unresectable Cancer Harboring Mutations in BRAF, RAF1, MEK1 / 2, ERK1 / 2, and NF1",
    "Polatuzumab Vedotin, Bendamustine, and Rituximab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Platelet Rich Plasma for the Treatment of Genitourinary Syndrome of Menopause in Patients with Stage 0-III Breast Cancer",
    "CDX-301 and CDX-1140 for the Treatment of Patients with Resectable Pancreatic Cancer",
    "Olaparib (LYNPARZA) Plus Durvalumab (IMFINZI) in EGFR-Mutated Adenocarcinomas That Transform to Small Cell Lung Cancer (SCLC) and Other Neuroendocrine Tumors",
    "NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine / Nab-Paclitaxel before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer",
    "Study of Atezolizumab and Bevacizumab With Y-90 TARE in Patients With Unresectable Hepatocellular Carcinoma (HCC)",
    "Temozolomide with Osimertinib or Lorlatinib for the Treatment of Stage IV Non-small Cell Lung Cancer in Patients with CNS Progression on Either Osimertinib or Lorlatinib",
    "Immunotherapy (Cemiplimab and Motixafortide) and Chemotherapy (Gemcitabine and Nab-Paclitaxel) for the Treatment of Stage IV Pancreatic Cancer, the Chemo4METPANC Trial",
    "Fostamatinib Alone or in Combination with Ruxolitinib for Treatment of Patients with Intermediate- or High-Risk Myelofibrosis with Severe Thrombocytopenia",
    "Telotristat and Lutetium Lu 177 Dotatate for the Treatment of Metastatic or Unresectable Well Differentiated Neuroendocrine Tumors",
    "Lutathera for the Treatment of Unresectable Gastroenteropancreatic Neuroendocrine Tumors That Have Spread to the Liver",
    "Genetic Counseling and Testing in Latina Women At-Risk of Hereditary Breast and Ovarian Cancer",
    "Genetically Engineered Cells (UCD19 CAR-T Cells) for the Treatment of Recurrent or Refractory B-cell Acute Lymphoblastic Leukemia or B-cell Non-Hodgkin Lymphoma",
    "Osimertinib and Abemaciclib for the Treatment of Stage IV or Recurrent Non-small Cell Lung Cancer with EGFR Activating Mutations with Osimertinib Resistance",
    "Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
    "Venetoclax and Azacitidine for the Treatment of Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Nivolumab and Relatlimab for the Treatment of Metastatic Uveal Melanoma",
    "Abemaciclib for the Treatment of Unresectable or Metastatic Anaplastic / Undifferentiated Thyroid Cancer",
    "Use of Jet-Injection in Photodynamic Therapy for Basal Cell Carcinoma",
    "Palliative Lattice Stereotactic Body Radiation therapy for the Treatment of Sarcoma, Thoracic, Abdominal, or Pelvic Cancer",
    "MCARH109 CAR Modified T cells for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Nedisertib and Radiation Therapy, Followed by Temozolomide for the Treatment of Patients with Newly Diagnosed MGMT Unmethylated Glioblastoma or Gliosarcoma",
    "FT596 and Rituximab after Autologous Blood Stem Cell Transplant for the Treatment of Diffuse Large B-cell Lymphoma or High-Grade B-cell Lymphoma",
    "Alisertib and Pembrolizumab for the Treatment of Patients with Rb-deficient Head and Neck Squamous Cell Cancer",
    "Donor-Derived 19-28z CAR T cells following Allogeneic Transplant for the Treatment of CD19 Malignancies",
    "MRD Adapted Therapy with Venetoclax, Obinutuzumab, and Acalabrutinib for the Treatment of High- or Intermediate-Risk Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Diabetes Prevention Program (METFIT) in Reducing Insulin Resistance in Stage I-III Breast Cancer Survivors",
    "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer",
    "High-Dose Interleukin-2, Ipilimumab and Nivolumab for the Treatment of Patients with Stage III-IV Melanoma",
    "Hypofractionated Radiation Therapy before Surgery for the Treatment of Localized, Resectable Soft Tissue Sarcoma of the Extremity and Superficial Trunk",
    "Cord Blood-Derived Mesenchymal Stem Cells for the Treatment of COVID-19 Related Acute Respiratory Distress Syndrome",
    "Induction Chemotherapy Followed by Risk and Response-Stratified Treatment in Patients with HPV+ Oropharyngeal Squamous Cell Cancer",
    "Multiparametric MR-Guided High Dose Adaptive Radiotherapy and Temozolomide for the Treatment of Newly Diagnosed Grade IV Gliomas",
    "Retifanlimab with Gemcitabine and Docetaxel in Patients with Advanced Soft Tissue Sarcoma",
    "Assessing the Safety of Modified T Cells for Mesothelioma",
    "CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma",
    "De-intensified Hypofractionated Radiation Therapy for the Treatment of Human Papilloma Virus-Associated Oropharynx Cancer, HYHOPE Trial",
    "Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma",
    "Intraperitoneal Docetaxel in Combination with mFOLFOX6 for the Treatment of Gastric Cancer Patients with Peritoneal Carcinomatosis",
    "Durvalumab for the Treatment of Patients with Stage IA2-III Non-small Cell Lung Cancer who Have Minimal Residual Disease",
    "Personalized Treatment following Chemoradiotherapy and Immunotherapy for the Treatment of Stage III Non-small Cell Lung Cancer",
    "Anti-EGFR Therapy for the Treatment of Select Patients with Metastatic Colorectal Cancer",
    "Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma",
    "Radiation Therapy Followed by Trastuzumab and Pertuzumab for the Treatment of HER2 Positive Breast Cancer that has Spread to the Leptomeninges",
    "Verteporfin for the Treatment of Recurrent High Grade EGFR-Mutated Glioblastoma",
    "A Vaccine (PIpepTolDC) for the Treatment of Patients with Type 1 Diabetes",
    "Nodal Radiation Therapy for Sentinel Lymph Node Positive Melanoma",
    "Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma",
    "SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial",
    "Re-Priming Radiation Therapy for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma after Incomplete Response after CAR-T Therapy",
    "Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer",
    "Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial",
    "64Cu-DOTA-pembrolizumab PET for the Study of PD1 Expression",
    "Durvalumab and Tremelimumab after Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer",
    "Durvalumab and Topotecan for the Treatment of Relapsed or Refractory Small Cell Lung Cancer",
    "Lapatinib and Paclitaxel for the Treatment of Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer",
    "Peptide Receptor Radionuclide Therapy before and after Surgery for the Treatment of Metastatic, WHO Grade 1 or 2, SSTR Positive, Gastroenteropancreatic Neuroendocrine Tumor",
    "Lurbinectedin, Nivolumab, and Ipilimumab for the Treatment of Patients with Relapsed or Refractory Small Cell Lung Cancer",
    "Viral Therapy (CG0070) and Immunotherapy (Nivolumab) for the Treatment of Cisplatin Ineligible Patients with Muscle Invasive Bladder Cancer",
    "Project Self in Improving Cervical Cancer Screening Rates in Hispanic and African American Women",
    "Neoadjuvant Letrozole with or without Abemaciclib in Hormone Receptor Positive Breast Cancer",
    "Isatuximab for the Treatment of Monoclonal Gammopathy of Renal Significance",
    "NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer",
    "LY3214996 and Cetuximab Alone or in Combination with Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer",
    "Low-Dose-Rate Brachytherapy and Nivolumab for the Treatment of Stage III-IV Cutaneous Melanoma",
    "Non-engrafting, CD8 Depleted Donor Lymphocyte Infusion for the Treatment of Myelodysplastic Syndrome after First Therapy or Secondary Acute Myeloid Leukemia",
    "Laser Ablation for the Treatment of Papillary Thyroid Microcarcinoma",
    "Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas",
    "Tazemetostat and Pembrolizumab for the Treatment of Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Cancer",
    "Germline DNA-Based Radiosensitivity Biomarker Influence on Toxicity following Prostate Radiotherapy, GARUDA Trial",
    "Durvalumab and Tremelimumab for the Treatment of Stage II-IIIB Non-small Cell Lung Cancer",
    "Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients with Mantle Cell Lymphoma",
    "IFN-Gamma for the Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed after Donor Blood Transplant",
    "Bintrafusp Alfa (M7824) and M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer",
    "Tobacco Treatment Optimization and Preferences during Concurrent Cancer Treatment",
    "Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma",
    "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer",
    "Chemotherapy (mFOLFOX) and Short-Course Radiotherapy for the Treatment of Resectable Rectal Cancer",
    "Olaparib with Pembrolizumab and Carboplatin as First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "Chemotherapy and Cord Blood Transplant in Children and Young Adults with Blood Cancers or Non-malignant Disorders",
    "Encorafenib, Nivolumab, and Ipilimumab with or without Binimetinib for the Treatment of BRAF-Mutant Unresectable or Metastatic Melanoma",
    "Venetoclax in Combination with ASTX727 for the Treatment of Treatment-Naive High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients with Chronic Lymphocytic Leukemia",
    "Nivolumab Alone or in Combination with Relatlimab for the Treatment of Resectable Hepatocellular Carcinoma",
    "Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia",
    "Stereotactic Radiosurgery and Immunotherapy (Pembrolizumab) for the Treatment of Recurrent Meningioma",
    "Brain Tumor-Specific Immune Cells (IL13Ralpha2-CAR T Cells) for the Treatment of Leptomeningeal Glioblastoma, Ependymoma, or Medulloblastoma",
    "Gallium Ga 68-DOTA-5G and Lutetium Lu 177-DOTA-ABM-5G in Diagnosing and Treating Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer",
    "Oleclumab and Durvalumab for the Treatment of Recurrent, Refractory, or Metastatic Sarcoma",
    "Glucarpidase for the Improvement of Methotrexate Toxicity and Detection in Central Nervous System Involvement of Aggressive Lymphoma",
    "Lower Doses of CPX-351 for the Treatment of Older Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Testing CAR-T Cell Therapy in Recurrent Epithelial Ovarian Cancer",
    "Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer",
    "Pembrolizumab, Dabrafenib, and Trametinib before Surgery for the Treatment of BRAF V600E-Mutated Anaplastic Thyroid Cancer",
    "Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides",
    "Chemotherapy with Radiation for the Treatment of Rectal Cancer",
    "Vitamin D Supplementation for the Improvement of Pathologic Complete Response in Vitamin D Deficient Patients Receiving Neoadjuvant Chemotherapy for Operable Triple Negative Breast Cancer",
    "Belantamab Mafodotin as Pre- and Post- Autologous Stem Cell Transplant Consolidation and Maintenance for the Treatment of Multiple Myeloma",
    "Flotetuzumab for the Treatment of Relapsed or Refractory Advanced CD123-Positive Hematological Malignancies",
    "Propranolol and Chemoradiation Therapy for the Treatment of Patients with Esophageal Cancer",
    "huCART19-IL18 Cells for the Treatment of Relapsed or Refractory CD19+ Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia",
    "Combined Infusion System to Deliver Chemotherapy Regionally to the Liver",
    "Talazoparib, Radiation Therapy, and Atezolizumab for the Treatment of gBRCA 1 / 2 Negative, PD-L1 Positive, Metastatic Triple-Negative Breast Cancer, TARA Study",
    "A Pilot Study of Ketogenic Diet and Metformin in Glioblastoma: Feasibility and Metabolic Imaging",
    "Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial",
    "Lamivudine in Combination with Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer",
    "Intralesional Influenza Vaccine for the Treatment of Stage I, II, and IV Melanoma",
    "Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas",
    "Short Course Radiation Therapy and Combination Chemotherapy for the Treatment of Stage II-III Rectal Cancer",
    "Talazoparib and Belinostat for the Treatment of Metastatic or Unresectable Breast Cancer, Metastatic Castration Resistant Prostate Cancer, or Metastatic Ovarian Cancer",
    "Hypofractionated Radiation Therapy and Bintrafusp Alfa for the Treatment of Advanced Intrahepatic Cholangiocarcinoma",
    "Neoadjuvant Atezolizumab for the Treatment of Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma",
    "Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients",
    "Pembrolizumab for the Treatment of Cervical Intraepithelial Neoplasia",
    "4D CBCT and Intrafractional CBCT Scan for the Determination of Radiation Treatment Planning in Patients Receiving Radiation Therapy for the Treatment of Lung Cancer",
    "Defactinib and VS-6766 for the Treatment of Patients with Metastatic Uveal Melanoma",
    "Adjuvant PRGN-2012 in Adult Patients With Recurrent Respiratory Papillomatosis",
    "Cytoreductive Surgery with Gemcitabine Followed by Dacarbazine for the Treatment of Locally Recurrent Uterine Leiomyosarcoma",
    "Olaparib and Durvalumab with Carboplatin, Etoposide, and / or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial",
    "Transarterial Chemoembolization for the Treatment of Uveal Melanoma with Liver Metastases",
    "SAR439459 and Cemiplimab for the Treatment of Advanced or Unresectable Solid Tumors, Strategic Alliance, TACTIC TRIAL",
    "ONC206 for the Treatment of Newly Diagnosed or Recurrent Diffuse Midline Gliomas or Other Recurrent Primary Malignant Brain Tumors",
    "Human Anti-CD19 Chimeric Antigen Receptor T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma, Acute Lymphoblastic Leukemia and Chronic Lymphocytic Leukemia",
    "Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia",
    "Binimetinib and Hydroxychloroquine for the Treatment of Patients with Advanced KRAS Mutant Non-Small Cell Lung Cancer, UPCC 21520 The LIMIT KRAS Mutant NSCLC Trial",
    "Onapristone and Fulvestrant for Patients with ER-Positive, HER2 Negative Metastatic Breast Cancer",
    "Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed / Refractory B-cell Lymphoma",
    "A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP",
    "SP-420 for the Treatment of Transfusional Iron Overload in Patients with Myelodysplastic Syndrome, Myelofibrosis, or Sickle Cell Disease",
    "Adjuvant Therapy Based on Pathologic Response after Neoadjuvant Encorafenib and Binimetinib for the Treatment of Stage IIIB-IV Melanoma",
    "SARS-CoV-2 Specific Immune Cells (Cytotoxic T Lymphocytes) for the Treatment of COVID-19 in Patients with Cancer",
    "Metformin and Digital Lifestyle Intervention (Noom) for the Prevention of Diabetes in Childhood Cancer Survivors with Prediabetes, PREDM Study",
    "Optical Coherence Tomography Guided Laser for the Treatment of Basal Cell Cancer",
    "Pneumococcal 13-Valent Conjugate Vaccine before and after CD19-Targeted CAR T Cell Immunotherapy for the Treatment of Relapsed or Refractory B Cell Lymphoma",
    "PACIFIC: Primary Mediastinal large B-cell lymphoma treated with Antibody therapy, Checkpoint Inhibitor in Frontline with ImmunoChemotherapy",
    "Venetoclax and ASTX727 for the Treatment of Relapsed, Refractory, or Newly Diagnosed Acute Myeloid Leukemia",
    "Chemotherapy-free Induction Regimen and Inotuzumab Ozogamicin for the Treatment of Ph+ Acute Lymphoblastic Leukemia",
    "Copanlisib and a Ketogenic Diet for the Treatment of Relapsed or Refractory Follicular Lymphoma or Endometrial Cancer",
    "DS-1594b with or without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia",
    "Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis",
    "Immunotherapy (NHS-IL12 & Bintrafusp Alfa) and Radiation Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer, the REINA Trial",
    "Tadalafil, Radiation therapy and Temozolomide for the Treatment of IDH-Wild Type Grade III-IV Astrocytoma",
    "Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer",
    "Riluzole in Combination with mFOLFOX6 and Bevacizumab in Treating Patients with Metastatic Colorectal Cancer",
    "MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer",
    "Intravenous Leucovorin, Fluorouracil, Paclitaxel and Intraperitoneal Paclitaxel for the Treatment of Stomach Cancer with Peritoneal Carcinomatosis, STOPGAP Study",
    "Alpelisib in Combination with Hormone Therapy for the Treatment of Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic or Unresectable Breast Cancer",
    "Selinexor, Pomalidomide, and Dexamethasone with or without Carfilzomib for the Treatment of Patients with Relapsed Refractory Multiple Myeloma, The SCOPE Trial",
    "Acalabrutinib and Rituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
    "Adjuvant Capecitabine in Treating Patients with Stage I-II Triple-Negative Breast Cancer and Residual Disease",
    "Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors",
    "Romidepsin and Parsaclisib for the Treatment of Relapsed or Refractory T-Cell Lymphomas",
    "Decitabine / Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia",
    "BO-112 and Pembrolizumab for the Treatment of PD-1 / PD-L1 Refractory Liver Cancer",
    "Flat Dose or Weight-Based Dose of Mitomycin during Cytoreductive Surgery for the Treatment of Advanced Gastrointestinal Malignancy",
    "Lenvatinib, Pembrolizumab, and Paclitaxel for the Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma",
    "Anti-CTLA4-NF mAb (BMS986218), Nivolumab, and Stereotactic Body Radiation Therapy for the Treatment of Metastatic Solid malignancies",
    "Bintrafusp Alfa and Pimasertib for the Treatment of Patients with Brain Metastases",
    "Zimberelimab, Domvanalimab, and Etrumadenant for the Treatment of Previously Treated Metastatic Non-small Cell Lung Cancer",
    "Brentuximab Vedotin and Pembrolizumab in Treating Patients with Recurrent Peripheral T-Cell Lymphoma",
    "Canakinumab and Darbepoetin Alfa for the Treatment of Lower-Risk Myelodysplastic Syndromes in Patients Who Have Failed Erythropoietin Stimulating Agents",
    "Pevonedistat and Pembrolizumab for the Treatment of dMMR / MSI-H Metastatic or Locally Advanced Unresectable Solid Tumor",
    "Rapid-infusion Isatuximab in Relapsed / Refractory Multiple Myeloma",
    "Etoposide or Observation for the Treatment of Relapsed Metastatic Germ-Cell Tumor Following High-dose Chemotherapy",
    "Focused Ultrasound with Panobinostat for the Treatment of Diffuse Midline Gliomas",
    "Artemisia Annua Decaf Coffee for the Treatment of Stage II-IV Ovarian Cancer",
    "Ruxolitinib for the Treatment of Solid Organ Transplant Recipients with Advanced Skin Squamous Cell Cancer",
    "Pembrolizumab for the Treatment of PD-1 Naive Cutaneous Squamous Cell Carcinoma",
    "Mesothelin-Specific T-Cells (FH-TCR-TMSLN) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma",
    "Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients with Metastatic Neuroendocrine Tumor",
    "Hypofractionated Pencil-Beam Scanning Intensity-Modulated Proton Therapy for the Treatment of Recurrent Rectal Cancer, IMPARC Study",
    "Blinatumomab for Treatment of Relapsed or Refractory Mixed Phenotypic Acute Leukemia",
    "Futibatinib and Pembrolizumab for the Treatment of Advanced or Metastatic FGF19 Positive BCLC Stage A, B, or C Liver Cancer",
    "Atezolizumab and Bevacizumab for the Treatment of Locally Advanced, Metastatic, or Unresectable Child-Pugh B7 Liver Cancer, The AB7 Trial",
    "Nab-Paclitaxel and Nivolumab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma",
    "Re-irradiation with NBTXR3 in Combination with Pembrolizumab for the Treatment of Inoperable Locoregional Recurrent Head and Neck Squamous Cell Cancer",
    "Photodynamic Therapy to Amplify the Response to Immunotherapy in Patients with Non-small Cell Lung Cancer with Pleural Disease",
    "Acalabrutinib and Duvelisib for the Treatment of Relapsed / Refractory Indolent Non-Hodgkin Lymphoma",
    "Niraparib, Dostarlimab, and Radiation Therapy for the Treatment Metastatic PD-L1 Negative or Immunotherapy-Refractory Triple Negative Breast Cancer, the NADiR Study",
    "Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer",
    "Intratumor Injection of Anti-Mesothelin Immunotoxin LMB-100 With Ipilimumab in Malignant Mesothelioma",
    "Avelumab or Hydroxychloroquine with or without Palbociclib for the Treatment of Stage II-III Breast Cancer, PALAVY Study",
    "Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia / Lymphoma",
    "Nivolumab in Combination with BMS-986253 or Cabiralizumab Before Surgery for the Treatment of Newly Diagnosed Surgically Resectable, Recurrent or Metastatic Head and Neck Cancer, SPARK2 Study",
    "Pembrolizumab and Lenvatinib in Advanced / Metastatic Neuroendocrine Prostate Cancer",
    "Propranolol Hydrochloride and Pembrolizumab for the Treatment of Recurrent or Metastatic Urothelial Cancer",
    "Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients with Treated Secondary Acute Myeloid Leukemia",
    "Genomically Directed Therapy with Capecitabine after Surgery for the Treatment of Residual Stage I-III Invasive Triple Negative Breast Cancer, PERSEVERE study",
    "Single Fraction Accelerated Partial Breast Irradiation or Five Fraction Accelerated Partial Breast Irradiation for the Treatment of Low-risk Stage 0 and I Breast Cancer",
    "Zanubrutinib in Combination with R-CHOP (ZaRCHOP) for Newly Diagnosed Diffuse Large B-Cell Lymphoma",
    "Supplemental Screening for Breast Cancer with Abbreviated Breast Magnetic Resonance for Black Women with Increased Breast Density",
    "E7777 to Enhance Regulatory T-Cell Depletion Prior to Tisagenlecleucel for the Treatment of Relapsed / Refractory Diffuse Large B-Cell Lymphoma",
    "Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma",
    "Neoadjuvant Stereotactic Beam Radiation Therapy Followed by Atezolizumab and Bevacizumab for the Treatment of Resectable Liver Cancer",
    "First Line Chemotherapy (Carboplatin and Paclitaxel) and Immunotherapy (Pembrolizumab) for the Treatment of Locally Advanced or Metastatic Head and Neck Squamous Cell Carcinoma",
    "NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer",
    "Cemiplimab, Low-Dose Paclitaxel and Carboplatin for the Treatment of Recurrent / Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "Ipilimumab, Nivolumab, and Sacituzumab Govitecan for the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma",
    "Imipramine Hydrochloride and Lomustine for the Treatment of Recurrent Glioblastoma",
    "Lenvatinib and Pembrolizumab Before Surgery for the Treatment of Stage II-IV Merkel Cell Cancer",
    "Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers",
    "Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer",
    "Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined with BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma",
    "Interrogating Biological Signaling Pathway Dysregulations and In Vitro Screening with Personalized Therapies in Relapsed or Refractory Mantle Cell Lymphoma, MCL MATCH Trial",
    "Personalized r-ATG for the Improvement of Survival through Enhanced Immune Reconstitution in Patients with Acute Leukemia or Myelodysplastic Syndrome Undergoing Ex-Vivo CD34-Selected Allogeneic-HCT, (PRAISE-IR)",
    "The Impact of an Antibiotic (Cefazolin) before Surgery on the Microbiome in Patients with Stage I-II Melanoma",
    "Cabozantinib for the Treatment of Incurable Refractory Germ Cell Tumors",
    "CART-GFRa4 Cells after Lymphodepletion for the Treatment of Medullary Thyroid Cancer",
    "Cabozantinib in Combination with Enfortumab Vedotin for Locally Advanced or Metastatic Urothelial Cancer",
    "Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors",
    "Genetically Engineered Cells (CD19- CAR.CD45RA-Negative T-cells) for the Treatment of Relapsed and / or Refractory CD19-Positive Leukemia",
    "Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Lenvatinib and Pembrolizumab Maintenance Therapy for the Treatment of Patients of Advanced Unresectable Pancreatic Cancer",
    "Belantamab Mafodotin, Lenalidomide, and Daratumumab for the Treatment of Relapsed, Refractory, or Previously Untreated Multiple Myeloma",
    "Radiation Therapy and Radioactive Iodine for the Treatment of Recurrent Papillary or Follicular Thyroid Cancer",
    "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC after Chemoradiation and Anti-PD-L1 Therapy",
    "Radiosurgery before Surgery for the Treatment of Brain Metastases",
    "Pembrolizumab and Intensity-Modulated Pleural Radiation Therapy for the Treatment of Unresectable Malignant Pleural Mesothelioma",
    "Levonorgestrel-Releasing Intrauterine System or Megestrol Acetate for the Treatment of Atypical Endometrial Hyperplasia",
    "Neratinib and Fulvestrant for the Treatment of HR+ / HER2- Metastatic Breast Cancer",
    "Onivyde in Combination with Talazoparib or Temozolomide for the Treatment of Recurrent or Refractory Solid Tumors and Ewing Sarcoma",
    "Plinabulin in Combination with Radiation / Immunotherapy in Patients with Select Advanced Cancers after Progression on PD-1 or PD-L1 Targeted Antibodies",
    "Nilotinib, Trametinib, and Dabrafenib for the Treatment of BRAF V600 Mutant Metastatic or Unresectable Melanoma",
    "Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer",
    "Novel BET Inhibitor PLX51107 for Steroid-Refractory Acute GVHD",
    "KPT-9274 for the Treatment of Recurrent and Refractory Acute Myeloid Leukemia",
    "Extremely Hypofractionated Intensity Modulated Stereotactic Body Radiotherapy for the Treatment of Prostate Cancer with Rising PSA after Radical Prostatectomy, EXCALIBUR Study",
    "Liposomal Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin for the treatment of Relapsed Refractory Pediatric Patients with Acute Myeloid Leukemia",
    "All-Trans Retinoic Acid (ATRA) and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer",
    "Reduced Dose Radiation Therapy and Chemotherapy after Surgery for the Treatment of HPV Caused Throat Cancer",
    "Reduction of Donor Blood Transfusion in Patients During Surgery for in Patients with Locally Advanced Kidney Cancer",
    "Mirdametinib for the Treatment of Low-Grade Glioma",
    "Stereotactic Radiosurgery, Abemaciclib, and Endocrine Therapy for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer Brain Metastases",
    "A Study of Codrituzumab in Children and Young Adults with Relapsed or Refractory Solid Tumors",
    "Bivalent Vaccine, OBT-821, and Beta-glucan with or without Granulocyte-Macrophage Colony Stimulating Factor for the Treatment of High-Risk Neuroblastoma",
    "Bempegaldesleukin Combined with Palliative Radiation Therapy and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab before Surgery for the Treatment of in Resectable / Borderline Resectable Primary Pancreatic Cancer",
    "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma",
    "N9 Chemotherapy for the Treatment of High-Risk Neuroblastoma",
    "Panobinostat in Combination with Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed / Refractory Multiple Myeloma",
    "Cabozantinib and Nivolumab for the Treatment of Refractory Metastatic Microsatellite Stable Colorectal Cancer",
    "Uproleselan, Azacitidine, and Venetoclax for the Treatment of Treatment Naive Acute Myeloid Leukemia",
    "Ipilimumab and Nivolumab for the Treatment of Stage III-IV Unresectable Metastatic Melanoma",
    "Proton Beam Radiation Therapy after Surgery for the Treatment of Favorable Histology Wilms Tumor",
    "Bintrafusp Alfa with Pemetrexed and Platinum-Based Chemotherapy for the Treatment of Locally Advanced or Metastatic Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer",
    "Neoadjuvant Cemiplimab for the Treatment of Stage I-II Merkel Cell Carcinoma",
    "Comparison of the Pharmacokinetics of Intravenous and Intra-Arterial Infusions of a Radioligand in Patients with Prostate Cancer",
    "SARS-CoV-2 Vaccine (COH04S1) versus Emergency Use Authorization SARS-COV-2 Vaccine for the Treatment of COVID-19 in Patients with Blood Cancer",
    "Decitabine and Cedazuridine as Maintenance Therapy following Allogeneic Hematopoietic Cell Transplantation for the Treatment of Myeloid Neoplasms",
    "Rituximab and High-Dose Methylprednisolone prior to Venetoclax for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Imipenem, Cilastatin Sodium, and Relebactam Monohydrate for the Treatment of Cancer Patients with Febrile Neutropenia",
    "Palbociclib, Bortezomib, Dexamethasone, and Doxorubicin for the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia, RELPALL2 Study",
    "Axitinib and Ipilimumab for the Treatment of Advanced Melanoma",
    "A Study of MRI-guided High-dose Radiation Therapy in Prostate Cancer",
    "Leflunomide for the Treatment of PTEN-Null Advanced Solid Tumors",
    "Axillary Dissection after Neoadjuvant Systemic Therapy for the Treatment of Breast Cancer with Advanced Nodal Disease",
    "A Study of Repotrectinib in Combination with Chemotherapy in Children and Young Adults with Solid Tumor Cancer",
    "Combination Therapy for the Treatment of Diffuse Midline Gliomas",
    "ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Dupilumab in Combination with Immunotherapy for the Treatment of Relapsed, Refractory, or Metastatic Non-small Cell Lung Cancer",
    "Donor Gamma Delta T-Cell Infusion for the Treatment of Acute Myeloid Leukemia in Patients at High Risk of Relapse after Allogeneic Hematopoietic Stem Cell Transplant",
    "Sintilimab for the Treatment of Locally Advanced, Metastatic, Recurrent, or Unresectable Undifferentiated Pleomorphic Sarcoma, SiARa Cancer Study",
    "Effect of Withdrawal Time on Cancer Detection Rate for Screening Colonoscopy",
    "Hypofractionated Radiation Therapy for the Treatment of Relapsed or Refractory Hodgkin or Non-Hodgkin Lymphoma",
    "TriPRIL CAR T Cells for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Incorporating ePrognosis for the Encouragement of Smarter Screening for Breast and Colorectal Cancer in Older Adults",
    "Vyxeos and Gilteritinib for the Treatment of Relapsed or Refractory FLT-3 Mutated Acute Myeloid Leukemia",
    "Sintilimab for the Treatment of Patients with Unresectable, Locally Advanced, Recurrent, or Metastatic Cancer of Unknown Primary, SiARa-CUP Study",
    "ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma",
    "Sintilimab for the Treatment of Locally Advanced, Metastatic, or Recurrent Angiosarcoma, the SiARa Cancer Study",
    "Evaluating the Feasibility of a Novel Surface Image Guidance System for Adaptive Stereotactic Body Radiation Therapy",
    "Fostamatinib for the Treatment of Lower-risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia who have Failed Therapy with Hypomethylating Agents",
    "Anti-Leukemia Immune Responses after Irradiation of Extramedullary Tumors",
    "Vitamin D, Aspirin, Exercise, and Low Saturated Fat Foods for the Treatment of Colorectal Cancer Patients with Minimal Residual Disease, DAILY Study",
    "IACS-6274 with or without Pembrolizumab for the Treatment of Advanced Solid Tumors",
    "Novel Synthetic T2W MR Imaging and Spin Parameter Mapping Techniques for Screening Prostate Cancer",
    "Intensive Lymphedema Screening in Reducing the Development Rate of Lymphedema in Breast Cancer Patients",
    "Capecitabine and Cemiplimab for the Treatment of Hormone Receptor Positive Locally Advanced, Unresectable, or Metastatic Invasive Breast Cancer",
    "Colon Cancer Education in Screening High-Risk Colon Cancer",
    "Duvelisib in Combination with Oral Azacitidine for the Treatment of Lymphoid Malignancy",
    "Afatinib for the Treatment of Advanced Cutaneous Squamous Cell Carcinoma",
    "A Study of Pembrolizumab and Cryoablation in Patients with Unresectable Mesothelioma",
    "Stereotactic Body Radiotherapy and 177Lu-PSMA-617 for the Treatment of Oligometastatic Prostate Cancer",
    "CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer",
    "A Cancer Vaccine (Labvax 3(22)-23) and GM-CSF for the Treatment of Advanced Stage Adenocarcinoma",
    "Pembrolizumab and Lenvatinib for the Treatment of Serous Ovarian Cancer Patients",
    "Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity",
    "Collection of Biological Specimens with or without Fine Needle Aspiration in Predicting Short Term Risk in Patients with High Risk for Breast Cancer",
    "Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia",
    "A Study of Patients Receiving High-Dose Rate Brachytherapy",
    "History of the KSHV Inflammatory Cytokine Syndrome (KICS)",
    "Pazopanib and Abexinostat in Treating Patients with Metastatic Solid Tumors",
    "Cyclophosphamide or Thalidomide after Stem Cell Transplant in Treating Younger Patients with Solid Tumors",
    "Donor Bone Marrow Transplant in Treating Patients with High-Risk Solid Tumors",
    "Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma",
    "NanoKnife Irreversible Electroporation System in Treating Patients with Locally Advanced Pancreatic Cancer That Cannot Be Removed by Surgery",
    "Transoral Robotic Surgery Alone, with Radiation, or with Radiation and Cisplatin in Treating Patients with Stage I-IVa HPV Positive Oropharyngeal Cancer",
    "Vaccine Therapy, Radiation Therapy, Pembrolizumab, and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma",
    "TAA-Specific Cytotoxic T-Lymphocytes in Treating Participants with Multiple Myeloma",
    "MRI-directed High Dose Radiation Therapy in Addition to Standard Radiation for the Treatment of Prostate Cancer, the Miami BLaStM Trial",
    "Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies",
    "Donor Partial Immune Cell Depletion for the Treatment of Hematologic Malignancies",
    "SVN53-67 / M57-KLH Peptide Vaccine in Treating Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance Therapy",
    "DXA and pQCT in Measuring Bone Mineral Density in Younger Cancer Survivors with a History of Bone Fractures after Treatment",
    "Mesenchymal Stem Cell Transplant in Treating Patients with Acute or Chronic Graft-Versus-Host Disease",
    "Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer",
    "Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of gFOLFIRINOX in Treating Patients with Locally Advanced Gastroesophageal or Stomach Cancer",
    "High-Dose Methotrexate in Treating Patients with Breast Cancer and Leptomeningeal Metastasis",
    "Stereotactic Body Radiation Therapy with Boost Using Urethral-Sparing Intensity-Modulated Radiation Therapy Planning in Treating Patients with Prostate Cancer",
    "Stereotactic or Hypofractionated Radiation Therapy in Treating Patients with Recurrent or Metastatic Head and Neck Cancer",
    "A Phase II Trial of AZD1775 plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer",
    "Cholecalciferol in Treating Patients with Newly Diagnosed Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia with Vitamin D Deficiency",
    "Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Mature T Cell Lymphoma",
    "Mebendazole in Treating Patients with Recurrent, Refractory, or Progressive Pediatric Brain Tumors",
    "Regorafenib in Treating Patients with Metastatic Medullary and Differentiated Radioiodine Refractory Thyroid Cancer",
    "Nintedanib, Idarubicin Hydrochloride, and Cytarabine in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia",
    "Pembrolizumab and Bevacizumab in Treating Patients with Metastatic Melanoma or Non-small Cell Lung Cancer with Untreated Brain Metastases",
    "Nivolumab and Radiation Therapy with or without Ipilimumab in Treating Patients with Brain Metastases from Non-small Cell Lung Cancer",
    "Belinostat and Zidovudine for the Treatment of HTLV-I Positive T-Cell Leukemia or Lymphoma",
    "Frameless Stereotactic Radiosurgery with or without Margins in Treating Brain Metastases in Cancer Patients",
    "NFKB2 Rearrangement in Guiding Treatment with Ixazomib Citrate and Dexamethasone or Ixazomib Citrate, Dexamethasone and Lenalidomide in Patients with Relapsed or Refractory Multiple Myeloma",
    "Pembrolizumab with or without mRNA 2752 in Treating Patients with High Grade Ductal Breast Carcinoma In Situ",
    "Carboplatin and Paclitaxel with or without Panitumumab in Treating Patients with Invasive Triple Negative Breast Cancer",
    "Durvalumab as First Line Therapy in Treating Patients with Stage IIIB-IV Non-small Cell Lung Cancer",
    "Celecoxib, Gemcitabine Hydrochloride, and Cisplatin in Treating Participants with Bladder Cancer before Surgery",
    "Modified Immune Cells (GPC3-CAR T cells) for the Treatment of Relapsed or Refractory Pediatric Solid Tumors",
    "Curcumin in Treating HIV Infected and Uninfected Women with High Grade Cervical Squamous Intraepithelial Neoplasia",
    "Combination Chemotherapy and Radiation Therapy in Treating Patients with Locally Advanced HPV Positive Oropharynx Cancer",
    "Oligomeric Procyanidin Complex in Treating Patients with Prostate Cancer Receiving Androgen Deprivation Therapy",
    "NeoVax, a Personalized Neoantigen Cancer Vaccine, with or without Ipilimumab in Treating Patients with Stage III or IV Kidney Cancer",
    "Nivolumab with or without Stereotactic Radiosurgery in Treating Patients with Recurrent or Metastatic Chordoma",
    "An Additional Bladder Biopsy before Surgery in Diagnosing Patients with Non-muscle Invasive Bladder Cancer",
    "Online Genetics Educational Video with or without Pre- and / or Post-Telephone Genetics Counseling in Assessing Cancer-Risk Distress in Patients with Triple Negative Breast Cancer",
    "Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients with FRalpha-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer",
    "Ibrutinib and Blinatumomab in Treating Patients with Relapsed or Refractory B Acute Lymphoblastic Leukemia",
    "Nab-Paclitaxel and Pembrolizumab in Treating Patients with Hormone Receptor-Positive Breast Cancer before Surgery",
    "Atezolizumab in Treating Patients with Stage IIIB-IV Non-small Cell Lung Cancer",
    "Nivolumab and Lenalidomide in Treating Patients with Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma",
    "Durvalumab and Tremelimumab in Treating Patients with Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "Afatinib and Necitumumab in Treating Patients with EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer",
    "Venetoclax and Combination Chemotherapy in Treating Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Nivolumab and Ipilimumab with or without Stereotactic Body Radiation Therapy in Treating Patients with Recurrent or Stage IV Merkel Cell Cancer",
    "Heated Chemotherapy Solution (Hyperthermic Intraperitoneal Chemotherapy) Using Mitomycin-C or Melphalan in Treating Patients with Colorectal Peritoneal Carcinomatosis Undergoing Surgery",
    "Pembrolizumab and Radiation Therapy in Treating Patients with Head and Neck Squamous Cell Carcinoma",
    "Grape Seed Extract in Treating Patients with Asymptomatic or Minimally Symptomatic Prostate Cancer",
    "Incidence and Severity of Diarrhea in Patients with Stage II-IIIC HER2 Positive Breast Cancer Treated with Trastuzumab and Neratinib",
    "Inotuzumab Ozogamicin in Treating Patients with Acute Lymphocytic Leukemia and Non-Hodgkin's Lymphoma after Transplant",
    "Pembrolizumab and Binimetinib in Treating Patients with Locally Advanced or Metastatic Triple Negative Breast Cancer",
    "Ribociclib and Everolimus in Treating Patients with Locally Advanced, Metastatic, or Refractory Dedifferentiated Liposarcoma or Leiomyosarcoma",
    "Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery",
    "rQNestin34.5v.2 with or without Cyclophosphamide in Treating Patients with Recurrent Malignant Glioma",
    "Palbociclib with or without Binimetinib or Binimetinib Alone in Treating Patients with Advanced KRAS Mutant Non-small Cell Lung Cancer",
    "Nivolumab in Treating Patients with Stage II-IV Muscle-Invasive Bladder, Urethra, or Ureter Cancer That Have Undergone Chemoradiotherapy",
    "Multimodality Therapy before and after Surgery in Patients with Squamous Cell Carcinoma of the Head and Neck",
    "Whole Brain Radiation Therapy with Simultaneous Integrated Boost in Treating Patients with Brain Metastases from Solid Tumors",
    "Venetoclax and Cytarabine with or without Idarubicin Hydrochloride in Treating Pediatric Patients with Refractory or Relapsed Acute Myeloid Leukemia",
    "TTI-101 in Treating Patients with Locally Advanced, Inoperable, Metastatic, or Refractory Solid Tumors",
    "Cabozantinib in Treating Patients with Refractory Multiple Myeloma Resistant to Carfilzomib",
    "Sorafenib and Pembrolizumab in Treating Patients with Advanced or Metastatic Liver Cancer",
    "Ipilimumab, Nivolumab, and Stereotactic Body Radiation Therapy in Treating Patients with Stage IV Non-small Cell Lung Cancer",
    "Durvalumab and Radiation Therapy with or without Tremelimumab in Treating Patients with Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery",
    "CD19 / CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults with Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia",
    "Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Gynecologic Cancer That Is Metastatic or Cannot Be Removed by Surgery",
    "Modified Immune Cells (GD2 Specific Chimeric Antigen Receptor and IL-15 Expressing Autologous Natural Killer T-Cells) in Treating Children with Relapsed or Refractory Neuroblastoma",
    "Abemaciclib in Treating Patients with Advanced Solid Tumors with CCND1 / 2 / 3 and CDK4 / 6 Genetic Alterations",
    "Circulating Tumor DNA Monitoring and Nivolumab Treating Patients with Diffuse Large B-Cell Lymphoma",
    "Addition of Simvastatin to Dual Anti-HER2 Therapy for the Treatment of HER2-Positive Metastatic Breast Cancer, SIMPHONY Study",
    "Propranolol Hydrochloride and Pembrolizumab in Treating Patients with Stage IIIC-IV Melanoma That Cannot Be Removed by Surgery",
    "Pembrolizumab and Fulvestrant in Treating Patients with Hormone Receptor Positive, HER2 Negative Advanced or Metastatic Breast Cancer",
    "Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients with Microsatellite Stable Colorectal Cancer that Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery",
    "Stereotactic Radiosurgery before Resection in Treating Patients with Solid Tumor Brain Metastases",
    "Ascorbic Acid and Combination Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma or Clonal Cytopenia of Undetermined Significance",
    "Pembrolizumab in Treating Patients with Metastatic, Recurrent or Locally Advanced Cancer and Genomic Instability",
    "Ascorbic Acid in Treating Patients with Intermediate or High Risk Myelodysplastic Syndrome with TET2 Mutations",
    "Pembrolizumab and Liver-Directed Therapy or Peptide Receptor Radionuclide Therapy in Treating Patients with Well-Differentiated Neuroendocrine Tumors and Symptomatic and / or Progressive Liver Metastases",
    "AZD6738 and Olaparib in Treating Patients with Recurrent High Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "Nivolumab after Bone Marrow Transplant in Treating Children or Young Adult Patients with High Risk, Recurrent or Refractory Solid Tumors",
    "Vitamin D Given before Photodynamic Therapy When Treating Patients with Basal Cell Cancer in Basal Cell Nevus Syndrome",
    "Venetoclax, Rituximab, and Rituximab and Hyaluronidase Human in Treating Participants with Recurrent or Refractory Chronic Lymphocytic Leukemia",
    "Pevonedistat and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma",
    "Venetoclax and Azacitidine in Treating Patients with Recurrent, Refractory, or Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm",
    "Muscadine Grape Extract in Treating Participants with Prostate Cancer on Androgen Deprivation Therapy",
    "Daratumumab, Carfilzomib, Lenalidomide, and Low-dose Dexamethasone in Treating Participants with Newly-diagnosed, Multiple Myeloma",
    "Apalutamide with or without Stereotactic Body Radiation Therapy in Treating Participants with Castration-Resistant Prostate Cancer",
    "Nab-paclitaxel followed by Gemcitabine Hydrochloride in Treating Pediatric Participants with Newly-Diagnostic, Relapsed or Refractory Solid Tumors",
    "Reduced Intensity Chemotherapy and Total Body Irradiation before TCR-alpha / beta+ T-lymphocytes Donor Transplant in Treating Participants with High-Risk Myeloid Diseases",
    "Venetoclax and Romidepsin in Treating Patients with Recurrent or Refractory Mature T-Cell Lymphoma",
    "Cabozantinib and Pembrolizumab as First Line Therapy in Treating Patients with Cisplatin-Ineligible Metastatic, Locally Advanced, or Unresectable Urothelial Cancer",
    "Carbon Ion or Conventional Photon Radiation Therapy and Chemotherapy in Treating Patients with Locally Advanced, Unresectable Pancreatic Cancer",
    "Preservation of Organs in Participants with Early Rectal Cancer",
    "Talimogene Laherparepvec with Chemotherapy or Endocrine Therapy in Treating Patients with Metastatic, Unresectable, or Recurrent HER2- Negative Breast Cancer",
    "External Beam Radiotherapy in Treating Participants with Metastatic Castration-Resistant Prostate Cancer",
    "Adavosertib with or without Olaparib in Treating Patients with Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "M7824 and Eribulin Mesylate in Treating Patients with Metastatic Triple Negative Breast Cancer",
    "5 Fraction Stereotactic Partial Breast Irradiation Using the GammaPod System in Treating Patients with Stage 0-IIa Breast Cancer",
    "Abexinostat and Pembrolizumab in Treating Patients with MSI-High Locally Advanced or Metastatic Solid Tumors",
    "Dexamethasone, Carfilzomib, and Nivolumab with Pelareorep in Treating Patients with Relapsed Multiple Myeloma",
    "Bendamustine, Rituximab, and Venetoclax in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia",
    "Ceritinib and Docetaxel in Treating Patients with Stage IIIB / IV ALK-Negative and EGFR Wild-Type Non-small Cell Lung Cancer",
    "Venetoclax, Busulfan, Fludarabine, Azacitidine, Decitabine, and Cedazuridine in Treating Patients with High Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Myelodysplastic / Myeloproliferative Neoplasm Overlap Syndromes Undergoing Donor Stem Cell Transplantation",
    "Stereotactic Body Radiation Therapy and Atezolizumab in Treating Patients with Recurrent, Persistent, or Metastatic Cervical, Vaginal, or Vulvar Cancer",
    "A Vaccine (6MHP) with or without CDX-1127 for the Treatment of Stage IIB-IV Melanoma",
    "EGFR806-Specific CAR T Cell in Treating Patients with Recurrent or Refractory Pediatric Central Nervous System Tumors",
    "Niraparib and Radiotherapy for the Treatment of Stage IIIC2-IV Invasive Cervical Cancer, The NIVIX Trial",
    "Donor CMV Specific CTLs in Treating CMV Reactivation or Infection in Patients who have Undergone Stem Cell Transplant or Solid Organ Transplant",
    "Osimertinib and Stereotactic Body Radiation Therapy in Treating Patients with EGFR Mutant Advanced Non-small Cell Lung Cancer",
    "Adavosertib in Treating Patients with Recurrent Uterine Serous Carcinoma or Uterine Carcinosarcoma",
    "Talazoparib and Low-Dose Temozolomide in Treating Patients with Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer",
    "Individualized Therapy in Treating Patients with Recurrent Resectable Glioblastoma or Gliosarcoma",
    "Ceralasertib with or without Olaparib in Treating Patients with Locally Advanced or Metastatic Solid Tumors",
    "Pepinemab with or without Ipilimumab and / or Nivolumab in Treating Patients with Stage I-IVA Head and Neck Squamous Cell Cancer",
    "Local Consolidative Therapy and Brigatinib in Treating Patients with Stage IV or Recurrent Non-small Cell Lung Cancer",
    "Atezolizumab with or without Tocilizumab, Tiragolumab, or Other Immune Modulating-Agents in Treating Patients with Head and Neck Squamous Cell Cancer",
    "Venetoclax in Combination with Intensive Chemotherapy in Treating Patients with Acute Myelogenous Leukemia",
    "Copanlisib and Nivolumab in Treating Patients with Microsatellite Stable Relapsed, Refractory, Metastatic, or Unresectable Solid Tumors or Colorectal Cancer",
    "Pembrolizumab with or without Defactinib before and after Surgery for the Treatment of Resectable Stage I-IIB Pancreatic Ductal Adenocarcinoma",
    "Gemcitabine, Bendamustine Hydrochloride, and Nivolumab in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma",
    "Paxalisib and Trastuzumab in Treating Patients with HER2 Positive Breast Cancer Brain Metastases",
    "Conventional Androgen Deprivation Therapy with or without Abiraterone, Prednisone, and Apalutamide for the Treatment of High Risk Prostate Cancer after Radiation and Male Hormone Deprivation Therapy",
    "18F-DOPA-PET / MRI Scan in Imaging Elderly Patients with Newly Diagnosed Grade IV Malignant Glioma or Glioblastoma during Planning for a Short Course of Proton Beam Radiation Therapy",
    "Olaparib and Ceralasertib in Treating Patients with Metastatic Castration-Resistant Prostate Cancer",
    "Atezolizumab with or without Tocilizumab or Etrumadenant in Treating Men with Localized Prostate Cancer before Radical Prostatectomy",
    "Metformin, Nelfinavir, and Bortezomib in Treating Patients with Relapsed and / or Refractory Multiple Myeloma",
    "Niraparib, Temozolomide and Atezolizumab in Treating Patients with Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer with a Complete or Partial Response to Platinum-Based First-Line Chemotherapy",
    "Mirvetuximab Soravtansine and Pembrolizumab for the Treatment of Microsatellite Stable Advanced or Recurrent Endometrial Cancer",
    "Nivolumab and BMS986205 in Treating Patients with Stage II-IV Squamous Cell Cancer of the Head and Neck",
    "Prophylactic Risedronate in Reducing Rapid Bone Loss in Patients with Peripheral Lung Tumors Who Are Undergoing SBRT",
    "Modified Virus VSV-IFNbetaTYRP1 in Treating Patients with Stage III-IV Melanoma",
    "Ruxolitinib and Venetoclax in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia",
    "ASTX727 for the Treatment of Advanced, Unresectable, or Metastatic Solid Tumors",
    "Radiation Therapy in Treating Patients with HPV-Associated Head and Neck Cancers after Surgery",
    "Copanlisib and Nivolumab in Treating Patients with Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma",
    "Losartan and Sunitinib for the Treatment of Relapsed or Refractory Osteosarcoma",
    "Radiation Therapy and Chemotherapy in Treating Patients with Stage I-IIIB Rectal Cancer",
    "Umbralisib and Rituximab as Initial Therapy for Follicular Lymphoma and Marginal Zone Lymphoma",
    "Olaparib and Entinostat in Treating Patients with Recurrent, Platinum-Refractory or Resistant Ovarian, Primary Peritoneal, or Fallopian Tube Cancers",
    "Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients with Acute Leukemia",
    "177Lu-DOTATATE in Treating Patients with Progressive or High-Risk Grade I-III Meningioma",
    "Talazoparib for the Treatment of BRCA 1 / 2 Mutant Metastatic Breast Cancer",
    "Brigatinib and Binimetinib in Treating Patients with Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer",
    "Fluorouracil, Leucovorin, and Nanoliposomal Irinotecan for the Treatment of Previously Treated Advanced Biliary Tract Cancer, NAPOLI-2 Study",
    "Ipilimumab and Nivolumab in Combination with Radiation Therapy in Treating Patients with Stage II-III Non-small Cell Lung Cancer",
    "Screening MRI Scan for the Imaging of Metastatic, Unresectable, or Recurrent Breast Cancer",
    "Pembrolizumab Every 12 Weeks versus Every 3 Weeks in Treating Patients with Non-small Cell Lung Cancer",
    "Nivolumab, BMS-986205, and Radiation Therapy with or without Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma",
    "Nivolumab with or without BMS-986253 for the Treatment of Advanced Liver Cancer",
    "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma in Elderly Patients",
    "ONC201 and Paclitaxel in Treating Patients with Platinum-Resistant Refractory or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Hippocampal-Avoidance Using Intensity-Modulated Radiation Therapy for the Treatment of Low-Grade Glioma",
    "Trabectedin and Olaparib in Treating Patients with Advanced Unresectable or Metastatic Sarcoma",
    "LY3214996 for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia in Patients who are not Candidates for Standard Therapy",
    "Alisertib and Osimertinib for the Treatment of EGFR-Mutated Stage IV Lung Cancer",
    "Genetically Engineered Cells (CD22-CAR T Cells) for the Treatment of Recurrent or Refractory B Cell Malignancies",
    "Genetically Engineered Cells (C7R-GD2.CAR T Cells) for the Treatment of Patients with GD2-Expressing High Grade Glioma or Diffuse Intrinsic Pontine Glioma, The GAIL-B Trial",
    "Dasatinib for the Treatment of Waldenstrom Macroglobulinemia in Patients Progressing on Ibrutinib",
    "Stereotactic Magnetic Resonance Guided Adaptive Radiation Therapy for the Treatment of Cancer, SMART Study",
    "Focused Ultrasound for the Promotion of Immune Responses for Resectable Undifferentiated Pleomorphic Sarcoma",
    "Sitravatinib for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer",
    "Daratumumab, Lenalidomide, Dexamethasone and Bortezomib for the Treatment of Patients with Newly Diagnosed Multiple Myeloma",
    "Talimogene Laherparepvec and Panitumumab for the Treatment of Locally Advanced or Metastatic Squamous Cell Carcinoma of the Skin",
    "Cabozantinib and Nivolumab for the Treatment of Advanced Carcinoid Tumors",
    "Acalabrutinib for the Treatment of Chronic Graft Versus Host Disease",
    "Cobimetinib, Atezolizumab, and Hydroxychloroquine for the Treatment of Metastatic or Unresectable KRAS-Mutated Malignancies, MEKiAUTO Study",
    "Vaccine Therapy (GVAX), Nivolumab, and Ipilimumab for the Treatment of Relapsed or Refractory Neuroblastoma",
    "Cemiplimab for the Treatment of Immunocompromised Patients with Unresectable Locally Recurrent and / or Metastatic Cutaneous Squamous Cell Carcinoma",
    "Donor Stem Cell Transplant after TCR Alpha-Beta+ T Cells / CD19+ B Cell Depletion for the Treatment of Children and Young Adults with Malignant or Non-malignant Hematological Disorders",
    "CPX-351 for the Treatment of Secondary Acute Myeloid Leukemia in Patients Younger than 60 Years Old",
    "Intensity Modulated Proton Therapy in Treating Younger Patients with Cancer of the Central Nervous System",
    "Hypofractionated Proton or Photon Radiation Therapy for the Treatment of Brain Tumors, the HiPPI Study",
    "Abbreviated MRI versus Standard Ultrasound for Hepatocellular Carcinoma Screening and Surveillance in Patients with Cirrhosis",
    "CIML NK Cells and Nogapendekin Alfa Alone or in Combination with Ipilimumab for the Treatment of Recurrent or Metastatic Head and Neck Cancer",
    "TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer",
    "Front Line Ibrutinib for Newly Diagnosed Chronic Graft-Versus Host Disease",
    "Standard Interval Dosing Compared to Extended Interval Dosing of Nivolumab or Pembrolizumab for the Treatment of Locally Advanced or Metastatic Cancer",
    "PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients with Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer",
    "Cemiplimab for the Treatment of Advanced or Metastatic Cutaneous Squamous Cell Cancer in Selected Organ Transplant Recipients, CONTRAC study",
    "Donor Mesenchymal Stromal Cells for the Treatment of COVID-19 Induced Acute Respiratory Distress Syndrome",
    "Image Guided Radiation Therapy with MRI for the Treatment of Cancer, CONFIRM Study",
    "CMP-001 and INCAGN01949 for the Treatment of Patients with Stage IV Pancreatic Cancer and Other Cancers Except Melanoma",
    "Hypertension Intervention for the Reduction of Osteonecrosis in Children with Acute Lymphoblastic Leukemia or Lymphoma",
    "Sargramostim in Increasing Infiltration of Immune Cells in Younger Patients with Incompletely Resected or Recurrent Ependymoma",
    "INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study",
    "Study of Mucosal Sparing Adjuvant Radiotherapy after Surgical Exploration in HPV+ Head and Neck Cancer of Unknown Primaries",
    "Combined Deep Inspiration Breath Hold-Expiration Planning Technique in Patients with Lung Tumors in Close Proximity to the Chest Wall",
    "Dose-Adjustment Algorithm for the Prevention of Cytopenia-Related FOLFOX Chemotherapy Delays during Treatment of Gastrointestinal System Cancer",
    "Magnetic Resonance Imaging Simulation for the Planning of Radiation Therapy in Cancer Patients, JUMP Study",
    "Acalabrutinib for the Treatment of Relapsed / Refractory Primary or Secondary CNS Lymphomas",
    "Trastuzumab Deruxtecan alone or in combination with Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer",
    "Modified Immune Cells (CD22-Specific CAR T Cells) for the Treatment of Refractory or Recurrent CD22+ Leukemia or Lymphoma, Plat-07 Study",
    "Venetoclax and Copanlisib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Minimally Invasive Surgery after Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial",
    "A Vaccine (PDS0101) and Chemoradiation for the Treatment of Stage IB3-IVA Cervical Cancer, the IMMUNOCERV Trial",
    "Niraparib and Dostarlimab as Neoadjuvant Treatment for Patients with BRCA-Mutated Stage I-III Breast Cancer",
    "Axicabtagene Ciloleucel for the Treatment of Relapsed / Refractory Primary or Secondary Central Nervous System Lymphoma",
    "Atezolizumab, Carboplatin and Etoposide for the Treatment of Extensive Stage Small Cell Lung Cancer with Untreated, Asymptomatic Brain Metastases",
    "Trastuzumab Emtansine and Chemoradiation for the Treatment of HER2-Positive, Resectable Stage II-IVB Salivary Gland Cancer",
    "Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated, Relapsed, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Tyrosine Kinase Inhibitor Cessation for Chronic Myeloid Leukemia Patients With Stable Molecular Response",
    "T-allo10 Infusion Therapy to Prevent Graft Versus Host Disease and Improve Potential Immune Reconstitution in Patients who received Hematopoietic Stem Cell Transplantation",
    "Larotrectinib for Treatment of Children with Newly-Diagnosed High-Grade Glioma with NTRK Fusion",
    "Chemotherapy followed by Chemoradiation for the Treatment of Locally Advanced Esophagogastric Cancer",
    "Polatuzumab Vedotin, Venetoclax, and Rituximab and Hyaluronidase Human for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",
    "Cabozantinib, Topotecan, and Cyclophosphamide for the Treatment of Relapsed or Refractory Ewing Sarcoma or High-Grade Osteosarcoma",
    "Modified Chemotherapy Alternated with Biweekly Gemcitabine plus Nab-Paclitaxel for the Treatment of Stage IV Pancreatic Cancer",
    "Belantamab Mafodotin for the Treatment of Relapsed or Refractory Plasmablastic Lymphoma or ALK+ Large B-cell Lymphoma",
    "Immunosuppression-Free Regulatory T Cell Graft-Engineered Haploidentical Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Copanlisib and Ibrutinib or Acalabrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia",
    "Pembrolizumab and Cryoablation for the Treatment of Patients with Metastatic Urothelial Cancer",
    "Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer",
    "Sacituzumab Govitecan and Enfortumab Vedotin for the Treatment of Locally Advanced or Metastatic Urothelial Cancer",
    "Abemaciclib with or without Atezolizumab for the Treatment of Metastatic Castration Resistant Prostate Cancer",
    "Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for the Treatment of High-Risk Smoldering Multiple Myeloma, B- PRISM Study",
    "Stereotactic Magnetic Resonance-Guided Adaptive Radiation Therapy with or without AGuIX for the Treatment of Central Lung Tumors and Locally Advanced Pancreatic Ductal Adenocarcinoma",
    "Venetoclax and Azacitidine for the Treatment of Fit Adults with Newly Diagnosed Acute Myeloid Leukemia",
    "Stereotactic Body Proton Radiotherapy for the Treatment of Liver Cancer",
    "Accelerated Dose Venetoclax Ramp-Up for the Treatment of Newly Diagnosed, Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, SAVE Study",
    "Talazoparib and Tazemetostat for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC",
    "Customized 3D Printed Oral Stents during Head and Neck Radiotherapy",
    "Stereotactic Body Radiation Therapy for the Treatment of Oligometastatic Adenoid Cystic Cancer, SOLAR Study",
    "Brain-Directed Stereotactic Radiation Therapy with or without AGulX Gadolinium-Based Nanoparticles for the Treatment of Brain Metastases",
    "Troriluzole, Ipilimumab, and Nivolumab for the Treatment of Melanoma Brain Metastases Previous Treated with Anti-PD-1 Therapy",
    "Risk-Adapted Radiation and Chemotherapy for the Treatment of Human Papillomavirus-Positive Oropharyngeal Cancer",
    "Paxalisib for the Treatment of Recurrent or Refractory Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System",
    "Acalabrutinib for the Treatment of Recurrent or Refractory Central Nervous System Lymphoma",
    "Androgen Ablation Therapy with or without Niraparib after Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer",
    "Elraglusib and Carboplatin for the Treatment of Recurrent, Unresectable, Advanced, or Metastatic Salivary Gland Cancer",
    "Venetoclax and Inotuzumab Ozogamicin for the Treatment of Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia",
    "Duvelisib and Docetaxel for the Treatment of Recurrent, Metastatic, or Advanced Head and Neck Squamous Cell Carcinoma",
    "Autologous Peripheral Blood Stem Cell Transplant for Neurologic Autoimmune Diseases",
    "Laboratory-Treated T Cells in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Recurrent or Refractory B-Cell Lymphoma or Multiple Myeloma",
    "Risk-Adapted Therapy in Treating Young Patients with Mature B-Cell Lymphoma or Leukemia",
    "Donor Stem Cell Transplant in Treating Patients With Hematological Malignancies",
    "Stereotactic Radiosurgery in Treating Patients with Oligometastatic Disease",
    "Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma and ATRT",
    "Carfilzomib, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Pulse Reduced Dose-Rate Radiation Therapy and Bevacizumab in Treating Patients with Recurrent Glioblastoma or Anaplastic Glioma Previously Treated with Radiation Therapy, Temozolomide, and / or Bevacizumab",
    "Genetically Modified T-Cells in Treating Patients With Advanced Non-Hodgkin's Lymphoma",
    "Metformin Hydrochloride and Levonorgestrel-Releasing Intrauterine System in Treating Patients with Atypical Endometrial Hyperplasia or Endometrial Cancer",
    "CD19.CAR T Cells in Treating Participants with CD19 Positive Malignancies after Stem Cell Transplant",
    "Anastrozole or Letrozole before Surgery in Treating Patients with Hormone Receptor Positive Stage II-III Breast Cancer That Can Be Removed by Surgery",
    "Temozolomide and Targeted or Standard Brain Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma Multiforme",
    "Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "LMP1 / BARF1 / EBNA1-Specific Cytotoxic T-Lymphocytes with or without Cyclophosphamide and Fludarabine in Treating Participants with EBV-Positive Lymphoma",
    "MV-NIS or Investigator's Choice Chemotherapy in Treating Patients with Ovarian, Fallopian, or Peritoneal Cancer",
    "Intraoperative Radiation Therapy in Treating Patients with Early Stage Breast Cancer Undergoing Breast Conserving Surgery",
    "HER2-Specific T Cells in Treating Participants with Recurrent or Refractory HER2-Positive Glioblastoma",
    "Donor-Derived Tumor-Associated Antigen-Specific T Cells in Treating Participants with Relapsed or Refractory acute myeloid leukemia or myelodysplastic syndrome",
    "Humanized Monoclonal Antibody 3F8 and Sargramostim in Treating Patients with Recurrent Osteosarcoma",
    "Abemaciclib and Radiation Therapy in Treating Younger Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent or Refractory Solid Tumors, or Malignant Brain Tumors",
    "Nivolumab with or without Ipilimumab in Treating Patients with Recurrent High-Grade Meningioma",
    "Fulvestrant and Palbociclib in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery",
    "Palbociclib in Treating Patients with Recurrent Brain Metastases with Alterations in the CDK Pathway",
    "CD30 CAR T Cells with or without Cyclophosphamide and Fludarabine in Treating Participants with Relapsed or Refractory CD30 Positive Lymphoma",
    "Merestinib in Treating Patients with Advanced Non-small Cell Lung Cancer with MET Exon 14 Mutations or Solid Tumors with NTRK Rearrangements",
    "Ibrutinib and Venetoclax in Treating Patients with Relapsed or Refractory Follicular Lymphoma",
    "Isatuximab with or without Lenalidomide in Treating Patients with High Risk Smoldering Plasma Cell Myeloma",
    "Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients with Refractory or Relapsed Hodgkin Lymphoma",
    "Phenformin Hydrochloride in Combination with BRAF Inhibitor and MEK Inhibitor in Treating Patients with Stage III-IV BRAF V600E / K-Mutated Melanoma",
    "Palbociclib and Gedatolisib in Treating Patients with Advanced Solid Tumors or Lung, Pancreatic, or Head and Neck Cancer",
    "CD5.CAR / 28 T Cells, Cyclophosphamide, and Fludarabine in Treating Participants with Recurrent T-Cell Malignancies Expressing the CD5 Antigen",
    "Ceritinib and Trametinib in Treating Patients with ALK Positive Stage IIIB-IV Non-small Cell Lung Cancer",
    "Pembrolizumab and Hsp90 inhibitor XL888 in Treating Patients with Advanced Gastrointestinal Cancer",
    "Stereotactic Body Radiation Therapy with or without Nivolumab in Treating Patients with Stage I-IIA or Recurrent Non-small Cell Lung Cancer",
    "Durvalumab, Tremelimumab, and Radiation Therapy in Treating Participants with High Risk Soft-Tissue Sarcoma",
    "Atezolizumab, Paclitaxel, Trastuzumab, and Pertuzumab in Treating Patients with HER2 Positive Breast Cancer That Is Locally Recurrent, Metastatic, or Cannot Be Removed by Surgery",
    "Ruxolitinib in Treating Patients with Head and Neck Cancer That Can Be Removed by Surgery",
    "Niraparib and Carboplatin in Treating Patients with Homologous Recombination Deficient Advanced Solid Tumors",
    "Pembrolizumab, Guadecitabine, and Mocetinostat in Treating Patients with Stage IIIb-IV Non-small Cell Lung Cancer",
    "Cyclophosphamide and IRX-2 in Treating Women with Cervical Squamous Intraepithelial Neoplasia 3 or Squamous Vulvar Intraepithelial Neoplasia 3",
    "Pembrolizumab and Umbralisib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Non-Hodgkin Lymphoma",
    "Venetoclax and Combination Chemotherapy in Treating Patients with Recurrent or Refractory B or T Cell Acute Lymphoblastic Leukemia",
    "Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients with Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer",
    "Enzalutamide with or without Radium Ra 223 Dichloride in Patients with Metastatic, Castration-Resistant Prostate Cancer",
    "Daratumumab after Stem Cell Transplant in Treating Patients with Multiple Myeloma",
    "TAS102 and Liposomal Irinotecan in Treating Patients with Gastrointestinal Cancers That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery",
    "Atezolizumab, Pertuzumab, and High-Dose Trastuzumab in Treating Patients with Her2-Positive Breast Cancer with Central Nervous System Metastases",
    "Osimertinib in Treating Participants with Stage IV Non-Small Cell Lung Cancer with Uncommon EGFR Mutations",
    "Simvastatin in Treating Patients with Stage I-II Breast Cancer",
    "Abatacept, Ixazomib Citrate, and Dexamethasone in Treating Patients with Multiple Myeloma Resistant to Chemotherapy",
    "Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery",
    "Ivosidenib and Venetoclax with or without Azacitidine in Treating Patients with IDH1 Mutated Hematologic Malignancies",
    "Durvalumab, Tremelimumab, and Radiation Therapy in Treating Patients with Unresectable, Locally Advanced, or Metastatic Hepatocellular Carcinoma or Biliary Tract Cancer",
    "Acalabrutinib with or without Obinutuzumab in Treating Patients with Early-Stage Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Pembrolizumab and Radiation Therapy in Treating Patients with Locally Advanced Non-small Cell Lung Cancer",
    "Atezolizumab and Bevacizumab in Treating Patients with Advanced, Recurrent, or Refractory Endometrial Cancer",
    "FID-007 in Treating Participants with Advanced Solid Tumors",
    "Ruxolitinib in Combination with Standard Chemotherapy in Treating Adolescents and Young Adults with Ph-Like Acute Lymphoblastic Leukemia",
    "Osimertinib in Treating Patients with Stage IV EGFR-Mutant Non-small Cell Lung Cancer",
    "Pembrolizumab and Pralatrexate in Treating Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas",
    "Chemotherapy and / or Metastasectomy in Treating Patients with Metastatic Colorectal Adenocarcinoma with Lung Metastases",
    "Nab-Paclitaxel, Gemcitabine, and Hypofractionated Ablative Proton Therapy in Treating Patients with Locally Advanced Pancreatic Cancer",
    "Talimogene Laherparepvec for the Treatment of Peritoneal Surface Malignancies, TEMPO Study",
    "Dabrafenib, Trametinib, and Spartalizumab in Treating Patients with BRAFV600E Mutant Metastatic Colorectal Cancer",
    "Dose-Reduced Consolidation Radiation Therapy in Treating Patients with Stage I-IV Diffuse Large B-cell Lymphoma",
    "Nivolumab and Ruxolitinib in Treating Patients with Relapsed or Refractory Classic Hodgkin Lymphoma",
    "Nivolumab and Degarelix with or without BMS-986253 in Treating Patients with Hormone-Sensitive Prostate Cancer",
    "Leflunomide in Treating Patients with Previously Treated Metastatic Triple Negative Breast Cancer",
    "Sacituzumab Govitecan in Treating Patients with Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation Androgen Receptor-Directed Therapy",
    "Pembrolizumab in Treating Participants with Recurrent Ovarian Cancer",
    "Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients with Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin",
    "Oncolytic Adenovirus CAdVEC and HER2 Specific CAR T Cells for the Treatment of Advanced or Refractory HER2 Positive Solid Tumors, VISTA Study",
    "Pre-Operative or Post-Operative Stereotactic Radiosurgery in Treating Patients with Operative Metastatic Brain Tumors",
    "ANCHOR Cells for the Treatment of Patients with Relapsed or Refractory CD19-Positive B-Cell Lymphoma or Leukemia, ANCHOR Study",
    "Standard Dose Fractionation Regimens for Vaginal Brachytherapy in Treating Sexual Dysfunction in Patients with Stage I-II Endometrial Cancer After Surgery",
    "6-Hour Oxaliplatin in Preventing Nerve Damage in Patients with Advanced or Metastatic Gastrointestinal Cancer",
    "Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients with Hormone-Naive Metastatic Prostate Cancer",
    "Evaluation of Response to Abiraterone Acetate, Prednisone, and Androgen Deprivation Therapy by Race or Ethnicity in Patients with Metastatic Prostate Cancer",
    "Niraparib and Osimertinib in Treating Patients with Stage IV EGFR-Mutated Non-small Cell Lung Cancer",
    "Nivolumab with or without Ipilimumab before Surgery for the Treatment of Resectable Stage I-III Malignant Pleural Mesothelioma",
    "ASTX727 for the Treatment of IDH Mutant Recurrent Glioma",
    "Goserelin Acetate and Pembrolizumab in Treating Patients with Advanced Androgen-Receptor Positive Salivary Gland Cancer",
    "Intermittent Duvelisib Dosing in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Talazoparib and Avelumab for the Treatment of Advanced Breast Cancer, the TALAVE study",
    "Abemaciclib in Treating Patients with Surgically Resectable, Chemotherapy Resistant, Triple Negative Breast Cancer",
    "Niraparib and Panitumumab in Treating Patients with Advanced or Metastatic Colorectal Cancer",
    "Conventional or Hypofractionated Radiation Therapy in Treating Patients with Prostate Cancer",
    "Pembrolizumab and Combination Chemotherapy (R-CHOP) for the Treatment of Non-germinal Center Diffuse Large B Cell Lymphoma or High-Grade B Cell Lymphoma",
    "Sonidegib and Pembrolizumab in Treating Patients with Advanced Solid Tumors",
    "Partially HLA-matched Multivirus-specific Cytotoxic T-Lymphocytes for the Treatment of EBV, CMV, Adenovirus, BK, or JC Virus Infections after Donor Stem Cell Transplant",
    "Sacituzumab Govitecan and Talazoparib for the Treatment of Stage IV Triple-Negative Breast Cancer",
    "Ruxolitinib, Decitabine, and Donor Lymphocyte Infusion in Treating Patients with Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome after Stem Cell Transplant",
    "Single-Fraction SBRT versus Standard Palliative Radiation Therapy in Treating Patients with Metastatic Cancer",
    "Contrast-Enhanced Mammography for the Improvement of Surveillance in Women with a Personal History of Breast Cancer",
    "Nivolumab, Ipilimumab, and Cabozantinib in Stage IIIB-D or Stage IV Unresectable Advanced Melanoma",
    "Use of Trifluridine / Tipiracil and Oxaliplatin as Induction Chemotherapy for the Treatment of Resectable Esophageal or Gastroesophageal Junction (GEJ) Adenocarcinoma",
    "Glasdegib for Chronic Graft-Versus-Host Disease",
    "APX005M, mFOLFOX Chemotherapy, and Radiation Therapy for the Treatment of Stage II-III Rectal Cancer, The INNATE Trial",
    "Axicabtagene Ciloleucel and Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity in Recurrent or Refractory B Cell Lymphoma Patients",
    "Siltuximab and Spartalizumab in Treating Participants with Metastatic Pancreatic Cancer",
    "WSD0922-FU for the Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer with Central Nervous System Metastases",
    "Modified Immune Cells (CLL-1 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Expressing Cll-1 Antigen, CARMEN Study",
    "CPX-351 and Glasdegib for the Treatment of Therapy-Related Acute Myeloid Leukemia",
    "Comparison of High-Dose Rate Brachytherapy and Stereotactic Ablative Radiotherapy as Monotherapy for the Treatment of Localized Prostate Cancer",
    "Ibrutinib and Venetoclax for the Treatment of Patients with MYD88-Mutated Waldenstrom Macroglobulinemia",
    "Donor CD30.CAR-EBVST in Patients with Relapsed or Refractory CD-30 Positive Lymphomas",
    "Infliximab or Corticosteroids for the Treatment of Ipilimumab Colitis",
    "A PD-1 Checkpoint Inhibitor (Cemiplimab) before Surgery for the Treatment of High-Risk Localized, Locally Recurrent, or Regionally Advanced Resectable Skin Cancer",
    "Nivolumab and Cabozantinib Prior to Nephrectomy for the Treatment of Metastatic Kidney Cancer",
    "Parsaclisib plus the Standard Drug Therapy in Patients with Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma",
    "Intensity-Modulated Proton Therapy in Treating Patients with Limited Stage or Extensive Stage Small Cell Lung Cancer",
    "Nivolumab, Ipilimumab, and Radiation Therapy for the Treatment of Metastatic Microsatellite Stable Pancreatic Cancer",
    "Olaparib and Ceralasertib for the Treatment of Patients with Recurrent or Refractory Osteosarcoma with or without Suspected Lung Metastases",
    "Pembrolizumab, Ibrutinib, and Rituximab for the Treatment of Recurrent Primary Central Nervous System Lymphoma",
    "Best Supportive Care with or without Low Dose Whole Lung Radiation Therapy for the Treatment of COVID-19 Infection",
    "Preoperative Chemotherapy, Pembrolizumab, and No, Low, or High Dose Radiation for the Treatment of Node-Positive, HER2-Negative Breast Cancer, P-RAD",
    "Assessing the Rate of Complications in X-Ray Therapy versus Proton Beam Radiation Therapy after Breast Conserving Surgery or Mastectomy in Treating Patients with Breast Cancer",
    "Niraparib and Dostarlimab for the Treatment of Germline or Somatic BRCA1 / 2 and PALB2 Mutated Metastatic Pancreatic Cancer",
    "Paricalcitol and Hydroxychloroquine in Combination with Gemcitabine and Nab-Paclitaxel for the Treatment of Advanced or Metastatic Pancreatic Cancer",
    "Response-Adapted Ruxolitinib-Containing Regimen for the Treatment of Hemophagocytic Lymphohistiocytosis",
    "Cabozantinib, Nivolumab, and Ipilimumab for the Treatment of Metastatic or Unresectable, Refractory Soft Tissue Sarcoma",
    "Comparison of Acute Toxicities between Patients Treated with Protons or Intensity Modulated Radiation Therapy after Surgery for the Treatment of Endometrial or Cervical Cancer",
    "Nivolumab Alone or in Combination with Ipilimumab before Surgery for the Treatment of Surgically Accessible Relapsed IDH-Wildtype Glioblastoma",
    "Abemaciclib with or without MK-6482 for the Treatment of Advanced Kidney Cancer",
    "Brigatinib before Brain Irradiation Trial for the Treatment of Brain Metastases from ALK+ Lung Cancer, the B3i Trial",
    "Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed / Refractory Diffuse Large B-Cell Lymphoma",
    "Whole Pelvic Hypofractionated Radiotherapy for the Treatment of Women with Endometrial Cancer",
    "Pembrolizumab and Sargramostim for the Treatment of Stage III or IV Unresectable or Metastatic Melanoma",
    "Proton Radiation Therapy for the Treatment of Patients with High Risk Prostate Cancer",
    "Pembrolizumab and Lenvatinib for the Treatment of Solid Tumor with Leptomeningeal Metastases",
    "Neratinib for the Treatment of Metastatic Castration Resistant Prostate Cancer and Increased HER2 Signaling",
    "Acalabrutinib, Venetoclax, and Obinutuzumab for the treatment of Relapsed or Refractory and Previously Untreated Mantle Cell Lymphoma",
    "Pemetrexed and Pembrolizumab for the Treatment of Recurrent and / or Metastatic Salivary Gland Cancer",
    "Ipilimumab and Nivolumab for the Treatment of Relapsed or Refractory Classic Hodgkin Lymphoma",
    "Niraparib for the Treatment of Tumors Metastatic to the Central Nervous System",
    "Local Consolidative Therapies for the Treatment of Metastatic Colorectal Cancer",
    "Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita",
    "Olaparib and Temozolomide with or without Irinotecan Hydrochloride in Treating Patients with Recurrent or Metastatic Ewing Sarcoma or Rhabdomyosarcoma Previously Treated with Chemotherapy",
    "Afatinib Dimaleate in Treating Patients with Advanced Refractory Urothelial Cancer",
    "OKT3 / Humanized 3F8 Bispecific Antibody-Activated T Lymphocytes, Aldesleukin, and Sargramostim in Treating Younger Patients with GD2-Positive Metastatic, Recurrent or Refractory Solid Tumors",
    "Isatuximab, Standard and High-Dose Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Hypofractionated Regional Nodal Radiation Therapy in Treating Older Patients with Breast Cancer Who Have Undergone Surgery",
    "Docetaxel and Capecitabine in Treating Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "Carboplatin with or without Everolimus in Treating Patients with Metastatic Triple Negative Breast Cancer",
    "Enzalutamide with or without Ribociclib in Treating Patients with Metastatic Castrate-Resistant, Chemotherapy Naive Prostate Cancer That Retains Retinoblastoma Expression",
    "Sirolimus and Metronomic Chemotherapy in Treating Younger Patients with Recurrent and / or Refractory Solid or Central Nervous System Tumors",
    "Romidepsin and Brentuximab Vedotin in Treating Patients with Cutaneous T-Cell Lymphoma",
    "Ibrutinib in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma",
    "Combination Chemotherapy and Pembrolizumab in Treating Patients with Previously Untreated Localized Gastric or Gastroesophageal Junction Cancer",
    "Intraoperative Electron Beam Radiotherapy Boost in Treating Patients with Stage I-II Breast Cancer Undergoing Surgery with Reconstruction",
    "Pembrolizumab, Decitabine, and Standard Chemotherapy before Surgery in Treating Patients with Locally Advanced HER2-Negative Breast Cancer",
    "A Phase II, Two-Arm Study of Everolimus and Letrozole, + / - Ribociclib (Lee011) in Patients with Advanced or Recurrent Endometrial Carcinoma",
    "Venetoclax, Rituximab, and Combination Chemotherapy in Treating Patients with Richter Syndrome",
    "Selinexor and Docetaxel in Treating Participants with Stage IV KRAS Mutant Non-Small Cell Lung Cancer",
    "Tagraxofusp-erzs, Azacitidine and Venetoclax for the Treatment of Untreated, Relapsed, or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Axitinib and Nivolumab in Treating Patients with Advanced Kidney Cancer",
    "Pembrolizumab, Capecitabine, and Radiation Therapy in Treating Patients with Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer",
    "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients with Adult T-Cell Leukemia / Lymphoma",
    "Nivolumab and Chemoradiotherapy in Treating Patients with Stage II-IVB Nasopharyngeal Cancer",
    "Ribociclib in Treating Patients with Estrogen Receptor Positive Breast Cancer",
    "Autologous CD19 / CD22 Chimeric Antigen Receptor T-cells in Treating Patients with Recurrent or Refractory Leukemia",
    "Pepinemab with or without Ipilimumab or Nivolumab in Treating Patients with Stage I-III Pancreatic Cancer That Can Be Removed by Surgery or Stage IV Colorectal Cancer with Liver Metastasis That Can Be Removed by Surgery",
    "Osimertinib and Selumetinib in Treating Participants with Stage IV EGFR Mutant Non-Small Cell Lung Cancer",
    "Osimertinib in Treating Patients with Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer before Surgery",
    "Palbociclib and Cetuximab in Treating Participants with Metastatic Colorectal Cancer and Non-Mutated KRAS, NRAS, and BRAF Genes",
    "Intensity-Modulated Radiation Therapy and Nivolumab in Treating Participants with Recurrent or Second Primary Head and Neck Squamous Cell Cancer",
    "INCMGA0012, Bevacizumab, and Radiation Therapy with or without Epacadostat for the Treatment of Patients with Recurrent Gliomas",
    "Nivolumab in Treating Patients with Recurrent or Progressive IDH-Mutant Gliomas",
    "Avelumab and Endocrine Therapy with or without Palbociclib in Treating Patients with Stage I-III Estrogen Receptor Positive Breast Cancer",
    "Mitotane with or without Cisplatin and Etoposide after Surgery in Treating Patients with Stage I-III Adrenocortical Cancer with High Risk of Recurrence",
    "Niraparib in Treating Patients with Advanced, Metastatic, or Unresectable Pancreatic Cancer with Homologous Recombination DNA Repair Deficiencies",
    "Rucaparib in Treating Patients with Stage III, IV or Endometrial Cancer That Has Either Spread or Has Come Back After Prior Treatment",
    "Nivolumab and Combination Chemotherapy in Treating Patients with Diffuse Large B-Cell Lymphoma",
    "Letermovir in Treating Patients with Resistant Cytomegalovirus Infection or Disease with Organ Dysfunction",
    "Carfilzomib or Bortezomib with Lenalidomide and Dexamethasone in Treating Patients with Newly Diagnosed Multiple Myeloma, COBRA Study",
    "Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults with Blood Cancers Undergoing Donor Stem Cell Transplant",
    "Ruxolitinib in Treating Patients with Hypereosinophilic Syndrome or Primary Eosinophilic Disorders",
    "Binimetinib and Encorafenib in Treating Patients with Genetically Changed (Non-V600 Activating BRAF Mutant) Metastatic or Advanced Malignant Tumors",
    "Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients with Advanced or Metastatic Colorectal Cancer",
    "Bendamustine, Obinutuzumab, and Venetoclax in Treating Patients with Mantle Cell Lymphoma",
    "Venetoclax and Selinexor in Treating Patients with Relapsed or Refractory High Risk Hematologic Malignancies",
    "Inotuzumab Ozogamicin with Standard Chemotherapy Regimen for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia",
    "Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Unresectable Stage IIIb-IV Melanoma",
    "FLOT and Chemoradiation before Surgery for the Treatment of Resectable Esophageal or Gastroesophageal Junction Cancer",
    "Olaparib in Treating Patients with Metastatic Biliary Tract Cancer with Aberrant DNA Repair Gene Mutations",
    "Telehealth in Improving Adherence to Endocrine Therapy in Patients with Hormone Receptor Positive Stage 0-III Breast Cancer Who Have Underwent Surgery",
    "Niraparib and Dostarlimab for the Treatment of Recurrent or Progressive Cervical Cancer, STAR Study",
    "Gemcitabine and Cisplatin with Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma",
    "Pembrolizumab for the Treatment of Relapsed or Refractory Pediatric Liver Cancer",
    "Nelfinavir, Cisplatin, and External Beam Radiation Therapy for the Treatment of Locally Advanced Vulvar Cancer That Cannot Be Removed by Surgery",
    "Daratumumab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Gemcitabine and Cisplatin with or without Devimistat as First Line Therapy for the Treatment of Advanced Unresectable Biliary Tract Cancer, BilT-04 Trial",
    "Single Dose Preoperative Breast Stereotactic Body Radiation Therapy Using GammaPod for the Treatment of Early Stage Breast Cancer",
    "Hypofractionated Radiation Therapy in Treating Elderly Patients with Head and Neck Squamous Cell Cancer",
    "Atezolizumab and Bevacizumab for the Treatment of Stage III-IV Cutaneous Melanoma",
    "Combination Chemotherapy and Atezolizumab for the Treatment of Stage IB-IIIA Non-small Cell Lung Cancer",
    "LY3214996 Alone or in Combination with Hydroxychloroquine for the Treatment of Pancreatic Cancer",
    "Cabozantinib, Nivolumab, and Ipilimumab for the Treatment of Metastatic Non-clear Cell Renal Cell Cancer",
    "A Study of Mirdametinib on Its Own or in Combination with Fulvestrant in Patients with Advanced Solid Tumor Cancer",
    "Tretinoin and Arsenic Trioxide with or without Gemtuzumab Ozogamicin in Treating Patients with Previously Untreated Acute Promyelocytic Leukemia",
    "Pazopanib Hydrochloride and Bevacizumab in Treating Patients with Previously Untreated Metastatic Kidney Cancer",
    "Biospecimen Collection and Testing for the Prevalence of Anal Dysplasia and Anal Cancer in Patients with Cervical, Vaginal and Vulvar Dysplasia and Cancer",
    "Molecular Profiling and Targeted Therapy in Treating Patients with Metastatic Cancer",
    "Neoadjuvant Immunotherapy in Treating Patients with Stage IB-IIIA Non-small Cell Lung Cancer That Can Be Removed by Surgery",
    "Selinexor with Multiple Standard Chemotherapy or Immunotherapy Regimens in Treating Patients with Advanced Malignancies",
    "Salvage Radiation Therapy in Treating Patients with Metastatic Cancer That Has Progressed after Systemic Immunotherapy",
    "Fimepinostat in Treating Younger Patients with Relapsed or Refractory Solid Tumors, Central Nervous System Tumors, or Lymphoma",
    "Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients with Invasive Breast Cancer",
    "Avelumab, Talazoparib, and Axitinib in Treating Patients with MSS, MSI-H, and POLE-Mutated Recurrent or Persistent Endometrial Cancer",
    "Abemaciclib in Treating Patients with Recurrent Glioblastoma",
    "Olaparib in Treating Patients with High-Risk, Biochemically-Recurrent Prostate Cancer Who Have Undergone Surgery",
    "Whole-Brain Radiotherapy or Stereotactic Radiosurgery in Treating Patients with 5-20 Metastatic Malignant Tumors in the Brain",
    "Ruxolitinib Phosphate in Treating Older Patients with Acute Myeloid Leukemia in Complete Remission or Myelodysplastic Syndrome after Donor Stem Cell Transplant",
    "Bendamustine and Obinutuzumab in Treating Patents with Previously Untreated Mantle Cell Lymphoma",
    "Pembrolizumab in Treating Patients with Histiocyte / Dendritic Cell Tumors or Relapsed or Refractory Aggressive Lymphomas",
    "Everolimus, Nelarabine, Cyclophosphamide, and Etoposide Phosphate in Treating Patients with Relapsed or Refractory T Cell Lymphoblastic Leukemia or Lymphoma",
    "Pevonedistat, Cytarabine, and Idarubicin in Treating Patients with Acute Myeloid Leukemia",
    "Stereotactic Radiosurgery in Treating Patients with Small Cell Cancer and 1-10 Brain Metastases",
    "Nivolumab and Ipilimumab with or without Local Consolidation Therapy in Treating Patients with Stage IV Non-Small Cell Lung Cancer",
    "Osimertinib, Surgery, and Radiation Therapy in Treating Patients with Stage IIIB or IV Non-small Cell Lung Cancer with EGFR Mutations, NORTHSTAR Study",
    "Ipilimumab and Nivolumab in Treating Patients with High-Risk Ocular Melanoma",
    "ABL001, Dasatinib, and Prednisone in Treating Patients with BCR-ABL Positive B-Cell Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia",
    "Nivolumab with or without Relatlimab in Treating Advanced Esophageal or Gastric Cancer",
    "Nivolumab in Treating Patients with High-Risk Biochemically Recurrent Prostate Cancer",
    "Regorafenib and Pembrolizumab in Treating Participants with Advanced or Metastatic Colorectal Cancer",
    "Ruxolitinib Phosphate in Treating Patients with Bronchiolitis Obliterans Syndrome after Donor Stem Cell Transplant",
    "Ruxolitinib in Treating Patients with Chronic Myelomonocytic Leukemia",
    "AZD6738 for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Progressing on Standard Therapy",
    "Daratumumab, Pomalidomide, and Dexamethasone in Treating Patients with Relapsed Multiple Myeloma",
    "Docetaxel and Trastuzumab before Surgery for the Treatment of HER2-Positive Stage II-III Breast Cancer in Nigerian Women, the ARETTA Trial",
    "CPX-351 and Gemtuzumab Ozogamicin in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia",
    "Talazoparib and Gedatolisib in Treating Patients with Advanced Triple Negative or BRCA1 / 2 Positive, HER2 Negative Breast Cancer",
    "Carboplatin, Cabazitaxel and Abiraterone in Treating Patients with Metastatic Castration Sensitive Prostate Cancer",
    "Glucarpidase after High-Dose Methotrexate in Patients with Osteosarcoma",
    "Avelumab with Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Patients with Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer",
    "Pemigatinib for the Treatment of Metastatic or Unresectable Colorectal Cancer Harboring FGFR Alterations",
    "TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study",
    "Laser Interstitial Thermal Therapy and Hypofractionated Radiation Therapy for the Treatment of Recurrent or Progressive Grade II-IV Glioma",
    "Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma",
    "Innovative Trial for Understanding the Impact of Targeted Therapies in Neurofibromatosis Type 2, The INTUITT-NF2 Trial",
    "Binimetinib and Encorafenib for the Treatment of Pancreatic Cancer in Patients with a Somatic BRAF V600E Mutation",
    "Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Relapsed or Refractory INI-1 Negative Cancer",
    "Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab for the Treatment of Newly Diagnosed, Transplant-Eligible Multiple Myeloma",
    "Trametinib and Everolimus for the Treatment of Pediatric and Young Adult Patients with Recurrent Low Grade Gliomas",
    "Concurrent Intensity-Modulated Proton Beam Therapy and High-Dose Chemotherapy for the Treatment of Loco-regionally Advanced Endometrioid Endometrial Cancer, the \"UPPROACH\" Approach Study",
    "Study of Benralizumab in People with Skin Side Effects Caused by Cancer Therapies",
    "Radiation Therapy Avoiding the Contralateral Neck for the Treatment of Patients with p16-Positive Oropharyngeal Squamous Cell Cancer, SAVER Study",
    "Ramucirumab and Trifluridine / Tipiracil or Paclitaxel for the Treatment of Patients with Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer",
    "Laser Interstitial Thermal Therapy and Hypofractionated Radiation Therapy for the Treatment of Newly Diagnosed High-Grade Gliomas",
    "Cemiplimab with Chemotherapy and Immunotherapy (Cetuximab) for the Treatment of Resectable, Locally Advanced Head and Neck Squamous Cell Cancer",
    "Radiation Therapy and Sequential or Concurrent Combination Chemotherapy in Treating Patients with Early Stage Breast Cancer",
    "High-Dose-Rate Brachytherapy and Chemotherapy in Treating Patients with Locally Recurrent or Residual Rectal or Anal Cancer Undergoing Non-operative Management",
    "Enzalutamide with or without Galunisertib in Treating Patients with Metastatic Castrate Resistant Prostate Cancer",
    "Carboplatin and Gemcitabine Hydrochloride with or without Pembrolizumab in Treating Patients with Metastatic Triple-Negative Breast Cancer",
    "Combination Chemotherapy in Treating Patients with Acute Lymphoblastic Leukemia or Lymphoma",
    "Epacadostat and Sirolimus in Treating Participants with Advanced Cancer",
    "Chemotherapy with or without Metformin Hydrochloride in Treating Patients with HER2 Positive Breast Cancer That Can Be Removed by Surgery",
    "Combination Chemotherapy and Nab-Paclitaxel in Treating Patients with Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer That Cannot Be Removed by Surgery",
    "Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in Treating Participants with HR-Positive, HER2-Positive Metastatic Breast Cancer",
    "PARP Inhibitor (Niraparib) and Trastuzumab for the Treatment of Metastatic HER2+ Breast Cancer",
    "Stereotactic Ablative Body Radiotherapy with or without Neurovascular Sparing in Reducing Erectile Dysfunction in Patients with Localized Prostate Cancer",
    "Cabozantinib or Sunitinib Malate in Treating Participants with Metastatic Variant Histology Renal Cell Carcinoma",
    "Acalabrutinib, Venetoclax, and Obinutuzumab in Treating Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Treating Patients with Multiple Myeloma That Has Come Back or Does Not Respond to Treatment",
    "Ruxolitinib in Treating Patients with Sclerotic Chronic Graft-Versus-Host Disease after Failure of Systemic Glucocorticoids",
    "ALRN-6924 in Treating Children with Recurrent or Refractory Solid Tumors, Brain Tumors, or Lymphoma",
    "Blood Plasma Assessment for Guiding Treatment Using Pembrolizumab with or without Doublet Chemotherapy in Patients with Stage IV Non-small Cell Lung Cancer",
    "Ultrasound-Guided Serratus Anterior Plane Block for Additional Pain Relief after Lung Surgery",
    "T-DM1 with or without Abemaciclib for the Treatment of HER2-Positive Metastatic Breast Cancer",
    "Ofranergene Obadenovec before and after Surgery for the Treatment of Patients with Resectable or Recurrent Glioblastoma",
    "The Combination of Venetoclax and Obinutuzumab in Patients with Chronic Lymphocytic Leukemia (CLL)",
    "Hormonal Therapy after Pertuzumab and Trastuzumab for the Treatment of Hormone Receptor Positive, HER2 Positive Breast Cancer, the ADEPT study",
    "Study of a Shortened Radiation Therapy Schedule in Patients with Breast Cancer, the FAST-R Trial",
    "Cs131 Brachytherapy for the Treatment of Recurrent Brain Metastases",
    "A Simplified Workflow for Lung Cancer Radiation Target Review with Radiology for the Treatment of Locally Advanced Lung Cancer",
    "Mitomycin C or Floxuridine and Leucovorin during or after Surgery in Treating Patients with Appendiceal, Colon, or Rectal Cancer",
    "Irinotecan Hydrochloride, Temozolomide, and Combination Chemotherapy in Treating Patients with Newly Diagnosed Ewing Sarcoma",
    "Ibrutinib with or without Methotrexate, Rituximab, Vincristine, and Procarbazine in Treating Patients with Newly Diagnosed or Refractory / Recurrent Primary or Secondary Central Nervous System Lymphoma",
    "Trastuzumab Emtansine in Treating Patients with HER2 Amplified or Mutant Advanced Cancers",
    "Palbociclib and Fulvestrant in Treating Patients with Hormone Receptor-Positive, HER2-Negative Metastatic or Locally Advanced Breast Cancer",
    "Pembrolizumab, Endocrine Therapy, and Palbociclib in Treating Postmenopausal Patients with Newly Diagnosed Metastatic Stage IV Estrogen Receptor Positive Breast Cancer",
    "Denosumab in Treating Patients with Multiple Myeloma with Kidney Insufficiency",
    "Citarinostat and PVX-410 with or without Lenalidomide in Treating Patients with Smoldering Multiple Myeloma",
    "Durvalumab, an Anti-PDLI Antibody, Tremelimumab, an Anti-CTLA4 Antibody, and Chemoradiation before Surgery for Esophageal Cancer",
    "Ruxolitinib in Treating Patients with Relapsed or Refractory T-cell or NK Cell Lymphoma",
    "Talimogene Laherparepvec and Pembrolizumab in Treating Patients with Locally Advanced or Metastatic Sarcoma",
    "Durvalumab and Tremelimumab in Treating Patients with Relapsed or Refractory Germ Cell Tumors",
    "Immune Checkpoint Inhibitor Nivolumab in People With Recurrent Select Rare CNS Cancers",
    "Nivolumab in Treating Patients with Metastatic or Recurrent Uterine Cancer",
    "Radiation Therapy in Combination with Durvalumab for the Treatment of Locally Advanced Pancreatic Cancer",
    "18F-FMISO PET / CT in Diagnosing Patients with HPV Associated Squamous Cell Carcinoma",
    "Nivolumab and Ipilimumab in Treating Patients with Advanced Rare Genitourinary Tumors",
    "Short Course Vaginal Cuff Brachytherapy in Treating Patients with Stage I-II Endometrial Cancer",
    "Daratumumab and Lenalidomide in Treating Patients with Minimal Residual Disease Positive Multiple Myeloma after Induction Therapy with or without High-Dose Chemotherapy with Stem Cell Support",
    "Pembrolizumab as First-Line Therapy in Treating Participants with High-Risk Non-Muscle-Invasive Bladder Cancer",
    "Nivolumab with or without Ipilimumab before Surgery in Treating Patients with Muscle Invasive Bladder Cancer or High Grade Urothelial Cancer of the Upper Urinary Tract",
    "Hypofractionated Ablative Intensity-Modulated Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients with Potentially Resectable Locally Advanced Pancreatic Cancer",
    "Tremelimumab in Treating Patients with Previously Treated Metastatic Urothelial Cancer",
    "Osimertinib, Carboplatin, Cisplatin, and Etoposide in Treating Patients with Metastatic Non-small Cell Lung Cancer with EGFR, RB1, and P53 Mutations",
    "Copanlisib and Ibrutinib in Treating Patients with Recurrent or Refractory Primary Central Nervous System Lymphoma",
    "Nivolumab and Vorolanib in Treating Patients with Non-Small Cell Lung Cancer and Refractory Thoracic Tumors",
    "Ruxolitinib and Tyrosine Kinase Inhibitors for the Treatment of Recurrent Chronic Phase-Chronic Myeloid Leukemia",
    "Nivolumab and Cabozantinib S-malate in Treating Patients with Advanced or Metastatic Kidney Cancer",
    "Pembrolizumab, Carboplatin and Docetaxel in Treating Patients with Stage I-III Triple-Negative Breast Cancer before Surgery",
    "Fulvestrant and Abemaciclib in Treating Patients with Hormone Receptor Positive Recurrent or Refractory Endometrial Cancer",
    "Ibrutinib, Rituximab, and Lenalidomide in Treating Patients with Refractory or Recurrent, Primary or Secondary Central Nervous System Lymphoma",
    "Electron Beam Intraoperative Radiation Therapy after Chemoradiation in Treating Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer",
    "Dacomitinib with or without Osimertinib in Treating Patients with Metastatic EGFR Mutant Lung Cancers with Disease Progression on Osimertinib",
    "Colesevelam in Treating Lenalidomide-Associated Diarrhea in Patients with Multiple Myeloma",
    "Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer",
    "Early Stereotactic Body Radiation Therapy or High-Dose Radiotherapy in Treating Patients with Metastatic Breast or Non-small Cell Lung Cancer",
    "Olaparib and Durvalumab in Treating Patients with Non-metastatic Prostate Cancer",
    "Aerobic Training in Supporting Patients with Solid Tumors before Surgery, PRESTO 1 study",
    "Study of Pembrolizumab Following Surgery in Patients with High Number of Genetic Changes (Microsatellite Instability High) Solid Tumors",
    "DS-3201b and Irinotecan in Treating Patients with Recurrent Small Cell Lung Cancer",
    "Extended-Release Onapristone with or without Anastrozole in Treating Patients with Progesterone Receptor Positive Recurrent Ovarian, Primary Peritoneal, or Endometrial Cancer",
    "BMS-986158 for the Treatment of Recurrent or Refractory Solid Tumors, Central Nervous System Tumors, or Lymphoma",
    "A Vaccine (Galinpepimut-S) with Nivolumab for the Treatment of Patients with WT1-Expressing Malignant Pleural Mesothelioma",
    "Immunotherapy (Nivolumab and Ipilimumab) for the Treatment of Aggressive Pituitary Tumors",
    "Talazoparib and Avelumab for the Treatment of Metastatic Renal Cell Carcinoma",
    "Ixazomib, Pomalidomide, and Dexamethasone for the Treatment of Recurrent or Refractory Multiple Myeloma",
    "Nivolumab with or without BMS-986205 (Linrodostat) for the Treatment of Recurrent or Persistent Endometrial Cancer or Carcinosarcoma",
    "Nivolumab, Docetaxel, and Androgen Deprivation Therapy for the Treatment of Metastatic, Hormone-Sensitive Prostate Cancer with DNA Damage Repair Defects or Inflamed Tumors",
    "A Vaccine (Personalized Cancer Vaccine RO7198457), Atezolizumab, and Combination Chemotherapy for the Treatment of Resectable Stage I-III Pancreatic Cancer",
    "Nivolumab and Combination Chemotherapy before Surgery for the Treatment of Resectable Pleural Malignant Mesothelioma",
    "Dostarlimab before Chemoradiotherapy and Surgery for the Treatment of Locally Advanced Mismatch Repair Deficiency or Microsatellite Instability Solid Tumors",
    "A Study of Lenalidomide and CC-486 with Radiation Therapy for the Treatment of Plasmacytoma, LENZART Study",
    "GDC-0084 and Radiation Therapy for the Treatment of Solid Tumor Brain Metastases or Leptomeningeal Metastases with PI3K Pathway Mutations",
    "Study of Cemiplimab Combined with Dabrafenib and Trametinib in People with Anaplastic Thyroid Cancer",
    "Immediate Lymphatic Reconstruction after Axillary Lymph Node Dissection for the Decrease in Incidence of Lymphedema in Patients with Breast Cancer",
    "Dose Reduction of Postoperative Radiation for Treatment of Soft Tissue Sarcoma of the Arms and Legs",
    "Blinatumomab in Combination with Tyrosine Kinase Inhibitor Therapy for the Treatment of Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia",
    "A Study of Pembrolizumab plus Local Chemotherapy using Isolated Limb Infusion (ILI) for Patients with Sarcoma in the Arm or Leg",
    "Talazoparib and Axitinib for the Treatment of Metastatic or Unresectable Kidney Cancer",
    "Proton Craniospinal Radiation Therapy versus Partial Photon Radiation Therapy for Leptomeningeal Metastasis from Solid Tumors",
    "Radiation Therapy to Relieve Symptoms in Patients with Advanced Non-Small Cell Lung Cancer",
    "Nivolumab for People with Newly Diagnosed Primary Central Nervous System Lymphoma following Completion of First-Line Chemotherapy",
    "Rituximab and Venetoclax in the Front Line for the Treatment of Marginal Zone Lymphoma",
    "Temozolomide, Cisplatin, and Nivolumab for the Treatment of Patients with MMR-Proficient Locally Advanced, Unresectable or Metastatic Colorectal Cancer",
    "Vemurafenib plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers",
    "Testing the Addition of Pembrolizumab to Sacituzumab Govitecan for the Treatment of PD-L1 Negative Locally Advanced Unresectable or Metastatic Triple Negative Breast Cancer, Saci-IO TNBC Study",
    "Using Romiplostim to Treat Low Platelet Counts following Chemotherapy and Stem Cell Transplant in Patients with Blood Cancer",
    "A Study of Health-Related Quality of Life in Patients with Multiple Myeloma Receiving Daratumumab or Lenalidomide",
    "ZW25 for the Treatment of HER2 Overexpressed Recurrent or Refractory Endometrial Cancers and Carcinosarcomas",
    "PDR001 Combination Therapy for the Treatment of Radioiodine-Refractory Thyroid Cancer",
    "A Study of Rucaparib and Nivolumab in Patients with Leiomyosarcoma",
    "Study of Ipilimumab after Stem Cell Transplantation in Patients with Relapsed / Refractory Multiple Myeloma",
    "Pembrolizumab and Olaparib for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency or Exceptional Treatment Response to Platinum-Based Therapy",
    "Romiplostim for the Prevention of Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors",
    "Pembrolizumab and Ablative Radiotherapy with or without Olaparib for the Treatment of Metastatic Triple-Negative Breast Cancer",
    "A Time-Limited Approach to Treatment with Ibrutinib for Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Treating Early-Stage Non-small Cell Lung Cancer with Durvalumab and Radiation Therapy",
    "Comparing Two Different Surgical Techniques for Breast Reconstruction",
    "A Study on Limiting Treatment Time with Acalabrutinib Combined with Obinutuzumab in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "A Study of Nivolumab Combined with FOLFOX and Regorafenib in Patients Who Have HER2-Negative Metastatic Esophagogastric Cancer",
    "Study of a Geriatric Assessment to Plan a Treatment Approach for Older People with Various Blood Disorders",
    "Radiation and Dostarlimab after Surgery for the Treatment of Endometrial Cancer",
    "Lenvatinib and Pembrolizumab in People with Advanced Soft Tissue Sarcoma",
    "Study of Avelumab and / or Radiation Therapy for Treatment of Stage III-IV Merkel Cell Carcinoma",
    "Aerobic Exercise Therapy in Cancer Patients Hospitalized for COVID-19",
    "ASTX727 for the Treatment of Malignant Nerve Sheath Tumors with PRC2 Mutation Loss",
    "Onapristone Extended-Release, Letrozole, and Palbociclib for the Treatment of Unresectable or Metastatic Estrogen Receptor Positive, Progesterone Receptor Positive, HER2 Negative Breast Cancer",
    "Stool Transplant to Control Treatment-Related Diarrhea",
    "Gemcitabine and Oxaliplatin Chemotherapy with or without a Floxuridine and Dexamethasone Pump in Patients with Cholangiocarcinoma that Cannot Be Removed with Surgery",
    "Canakinumab with Chemoradiation and Durvalumab for the Treatment of Stage IIIA-C Non-Small Cell Lung Cancer, CHORUS Study",
    "Testing an Herbal Pain Relief Patch to Reduce Pain in Cancer Survivors",
    "The Effect of Electroacupuncture on Nerve Pain Caused by Chemotherapy (Chemotherapy-Induced Peripheral Neuropathy)",
    "Pembrolizumab in Combination with Gemcitabine in Patients with Advanced Mycosis Fungoides and Sezary Syndrome",
    "Amivantamab and Lazertinib for the Treatment of Metastatic EGFR-Mutant Non-small Cell Lung Cancer",
    "Fluorescent Imaging of Nerves with Illuminare-1 during Surgery",
    "A Study of Reduced-Dose Radiation in Patients with Metastatic Tumors with a Genetic Change",
    "A Study of E7820 in Patients with Relapsed or Refractory Bone Marrow (Myeloid) Cancers",
    "A Study of Stereotactic Body Radiation Therapy and Surgical Stabilization for Patients with Cancer That Has Spread to the Bone",
    "Cabozantinib-s-malate in Treating Patients with Non-small Cell Lung Cancer That Is Metastatic or Cannot Be Removed by Surgery",
    "Azacitidine, Entinostat, and Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer",
    "Adavosertib before Surgery in Treating Patients with Advanced High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Cytarabine or Vinblastine Sulfate and Prednisone in Treating Patients with Langerhans Cell Histocytosis",
    "Duvelisib and Romidepsin or Bortezomib in Treating Patients with Relapsed or Refractory T-cell Lymphoma",
    "Ruxolitinib in Preventing Breast Cancer in Patients with High Risk and Precancerous Breast Lesions",
    "Neratinib in Treating Pediatric Patients with Recurrent or Refractory Solid Tumors or Lymphoma",
    "Hypofractionated Radiation Therapy in Treating Patients with Stage II-III Breast Cancer Undergoing Total Nodal Irradiation",
    "Acetazolamide Sodium and Temozolomide in Treating Adult Patients with Newly Diagnosed MGMT Promoter-Methylated IDH Wildtype Glioblastoma",
    "Carboplatin with or without Pembrolizumab in Treating Patients with Advanced Breast Cancer with Locally Recurrent Chest Wall Disease That Cannot Be Removed by Surgery",
    "Pembrolizumab and Involved Site Radiation Therapy in Treating Patients with Early Stage Relapsed or Refractory Hodgkin Lymphoma",
    "Proton Re-Irradiation Therapy in Treating Patients with Recurrent Head and Neck Cancer",
    "Doxorubicin, Vinblastine, Dacarbazine, Brentuximab Vedotin, and Nivolumab in Treating Patients with Stage I-II Hodgkin Lymphoma",
    "Ketogenic Diet in Evaluating Metabolomic and Tissue Effects in Overweight or Obese Patients with Stage I-IVB Endometrial Cancer",
    "Olaparib and Low Dose Radiation Therapy in Treating Patients with Extensive Stage Small Cell Lung Cancer",
    "FORRDuvelisib and Venetoclax in Treating Patients with Richter's Syndrome or Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma",
    "Rucaparib Camsylate and Radiation Therapy in Treating Patients with Triple Negative Breast Cancer or Hormone Receptor Positive Breast Cancer",
    "Losartan and Nivolumab in Combination with Combination Chemotherapy and SBRT in Treating Patients with Localized Pancreatic Cancer",
    "Combination Immunotherapy (Nivolumab and Ipilimumab) in Treating Patients with CDK12 Loss and Metastatic Prostate Cancer or Other Metastatic Cancers, IMPACT Study",
    "Reduced Brentuximab Vedotin Doses in Treating Patients with Stage IB-IV Mycosis Fungoides, Sezary Syndrome, and Lymphomatoid Papulosis",
    "Ixazomib and Dexamethasone in Treating Patients with Immunoglobulin Light Chain Amyloidosis",
    "Second-Line Pembrolizumab in Combination with Gemcitabine, Vinorelbine, and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma",
    "Glucarpidase in Treating Patients with Central Nervous System B-Cell Non-Hodgkin Lymphoma",
    "Pembrolizumab in Treating Patients with Untreated Nasal Type Extranodal NK / T-Cell Lymphoma",
    "BGB-290 and Temozolomide in Treating Adolescents and Young Adults with IDH1 / 2-Mutant Newly Diagnosed or Recurrent Grade I-IV Gliomas",
    "Combination Chemotherapy in Treating Patients with Classical Hodgkin Lymphoma",
    "Zanubrutinib, Obinutuzumab, and Venetoclax in Treating Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma and Mantle Cell Lymphoma",
    "Abexinostat and Ibrutinib in Treating Patients with Recurrent or Refractory Diffuse Large B-cell Lymphoma or Mantle Cell Lymphoma",
    "Exercise Intervention with Concurrent First-Line Therapy in Treating Patients with Hormone Receptor Positive Metastatic Breast Cancer",
    "Bacillus Calmette-Guerin (BCG) Vaccine and Gemcitabine for the Treatment of BCG-Relapsing High-Grade Non-Muscle Invasive Bladder Cancer",
    "Lenvatinib and Pembrolizumab for the Treatment of Recurrent or Metastatic Adenoid Cystic Carcinoma or Other Salivary Gland Cancers",
    "Ibrutinib and Rituximab for the Treatment of Treatment Naive Marginal Zone Lymphoma",
    "Study of Abiraterone, Atezolizumab, GnRH Analog, and Radiation Therapy for the Treatment of Men with Newly Diagnosed Metastatic Hormone-sensitive Prostate Cancer, SAABR Study",
    "Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone for the Treatment of Newly Diagnosed Multiple Myeloma",
    "Pembrolizumab versus Observation after Surgery for the Treatment of Stage I Non-small Cell Lung Cancer",
    "Assessing Minimal Residual Disease to Minimize Exposure in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Who Have Been Treated with Venetoclax, Veneto-STOP Study",
    "Sacituzumab Govitecan Alone or in Combination with Pembrolizumab for the Treatment of Hormone Receptor+, HER2-, and PD-L1+ Metastatic Breast Cancer",
    "Cabozantinib S-malate in Treating Patients with Plexiform Neurofibromas or Neurofibromatosis Type 1",
    "Alisertib Alone or in Combination with Chemotherapy and Radiation Therapy in Treating Younger Patients with Recurrent, Progressive, or Newly Diagnosed Central Nervous System Atypical Teratoid Rhabdoid Tumors or Extra-Central Nervous System Malignant Rhabdoid Tumors",
    "Pembrolizumab in Treating Patients with Recurrent Malignant Glioma with a Hypermutator Phenotype",
    "Proton Beam or Photon-Based Intensity-Modulated Radiation Therapy in Treating Patients with Salivary Gland Cancer, Skin Cancer, or Melanoma",
    "Eliminating Surgery after Systemic Therapy in Treating Patients with HER2 Positive or Triple Negative Breast Cancer",
    "Risk Classification Schemes in Identifying Better Treatment Options for Children and Adolescents with Acute Lymphoblastic Leukemia",
    "Atezolizumab, Gemcitabine Hydrochloride, and Cisplatin as First-Line Therapy in Treating Patients with Locally Advanced or Metastatic Urothelial Cancer",
    "Ipilimumab and Nivolumab in Treating Patients with Stage III-IV Melanoma That Cannot Be Removed by Surgery",
    "Nivolumab and Drug Eluting Bead Transarterial Chemoembolization in Treating Patients with Liver Cancer",
    "Pembrolizumab and Entinostat in Treating Patients with Relapsed or Refractory Classical Hodgkin Lymphoma",
    "Abemaciclib in Treating Patients with Recurrent Brain Tumors",
    "Capecitabine and Neratinib in Treating Patients with HER2 Positive Stage IV Breast Cancer",
    "Apalutamide, Abiraterone Acetate, Prednisone, and Radiation Therapy in Treating Patients with Prostate Cancer",
    "Cabozantinib S-malate and Cetuximab in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer",
    "Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Cancer with Limited Progression on Immune Checkpoint Inhibitors",
    "Low-Dose Radiotherapy in Treating Painful Bone Metastases in Patients with Multiple Myeloma",
    "Determining Whether Durvalumab in Combination with Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer",
    "Talazoparib and Temozolomide in Treating Patients with Metastatic Castration Resistant Prostate Cancer with No Mutations in DNA Damage Repair",
    "Study of 3-Day Partial Breast Radiation Therapy for the Treatment of Stage I Breast Cancer",
    "R-ICE and Lenalidomide in Treating Patients with First-Relapse / Primary Refractory Diffuse Large B-Cell Lymphoma",
    "Recombinant EphB4-HSA Fusion Protein and Pembrolizumab in Treating Patients with Metastatic or Recurrent Urothelial Cancer That Is Refractory to Certain Chemotherapy Drugs",
    "Pembrolizumab in Treating Patients with Recurrent Stage III-IVB Head and Neck Squamous Cell Cancer",
    "Nivolumab and Combination Chemotherapy in Treating Patients with Untreated Stage III-IV Classical Hodgkin Lymphoma",
    "Adjuvant Avelumab in Merkel Cell Cancer",
    "Ribociclib in Combination with Everolimus and Dexamethasone in Treating Children and Young Adults with Relapsed or Refractory Acute Lymphoblastic Leukemia",
    "Nivolumab, Hypofractionated Stereotactic Radiosurgery, and Bevacizumab in Treating Patients with Recurrent MGMT Methylated Glioblastoma",
    "CPI-613 in Treating Patients with Relapsed or Refractory Burkitt Lymphoma / Leukemia or High-Grade B-cell Lymphoma with MYC, BCL2, and / or BCL6 Gene Rearrangements",
    "Darolutamide and Radiation Therapy for the Treatment of Prostate Cancer, the INTREPiD Trial",
    "Evolutionary Inspired Therapy for the Treatment of Fusion Positive Newly Diagnosed or Metastatic Rhabdomyosarcoma",
    "Trastuzumab Emtansine Followed by Trastuzumab versus Paclitaxel in Combination with Trastuzumab for the Treatment of HER2-Positive Stage I Breast Cancer, ATEMPT 2.0 Trial",
    "Surgery, Chemotherapy, and Intensity Modulated Radiation Therapy in Treating Patients with Stage I-III Pleural Mesothelioma",
    "Intraoperative Radiation Therapy in Treating Patients with Breast Cancer Undergoing Breast-Conserving Surgery",
    "MV-NIS in Treating Children and Young Adults with Recurrent Medulloblastoma or Atypical Teratoid Rhabdoid Tumors",
    "Carfilzomib, Lenalidomide, Dexamethasone, Daratumumab, Melphalan, and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Radiation Therapy, Palbociclib, and Hormone Therapy in Treating Breast Cancer Patients with Bone Metastasis",
    "Brentuximab Vedotin and Nivolumab in Treating Patients with Early Stage Classic Hodgkin Lymphoma",
    "Stereotactic Body Radiotherapy in Treating Patients with Oligometastatic Breast Cancer or Metastatic Non-small Cell Lung Cancer",
    "Paclitaxel and Pertuzumab with Margetuximab or Trastuzumab for the Treatment of HER2-Positive Stage II-III Invasive Breast Cancer, The MARGOT Trial",
    "LCH-IV, International Collaborative Treatment Protocol for Children and Adolescents With Langerhans Cell Histiocytosis",
    "Nivolumab with or without Ipilimumab as Front Line Therapy in Treating Patients with Advanced Kidney Cancer",
    "Azacitidine or Decitabine in Epigenetic Priming in Patients with Newly Diagnosed Acute Myeloid Leukemia",
    "Embolization Therapy with or without Chemotherapy in Controlling Liver Metastases in Patients with Neuroendocrine Tumor Metastases to the Liver That Cannot Be Removed by Surgery",
    "H3.3K27M-specific Peptide Vaccine and Poly ICLC with or without Nivolumab in Treating Patients with Newly Diagnosed HLA-A2 Positive, H3.3K27M Positive Diffuse Intrinsic Pontine Glioma or Other Newly Diagnosed Gliomas",
    "Transanal Total Mesorectal Excision with Laparoscopic Assistance in Treating Patients with Rectal Cancer",
    "Surgical Removal of Prostate Tumor and Antiandrogen Therapy with or without Docetaxel in Treating Men with Newly Diagnosed Metastatic Prostate Cancer",
    "Molecular Profiling in Creating a Personalized Treatment Plan in Children and Young Adults with High Grade Glioma",
    "Panitumumab, Regorafenib, or TAS-102, in Treating Patients with Metastatic and / or Unresectable RAS Wild-Type Colorectal Cancer",
    "Rucaparib and Ramucirumab with or without Nivolumab for the Treatment of Stage III-IV Gastric, Esophageal, or Esophageal Adenocarcinoma",
    "Regorafenib, with Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer",
    "Immunotherapy (Nivolumab and Ipilimumab) before and after Surgery for the Treatment of Recurrent or Progressive High Grade Glioma in Children and Young Adults",
    "Osimertinib Alone or with Chemotherapy for EGFR-Mutant Lung Cancers",
    "Neratinib, Capecitabine, and Trastuzumab Emtansine in Treating Patients with HER2-Positive Breast Cancer That Has Spread to the Brain",
    "Proton Beam or Intensity-Modulated Radiation Therapy in Treating Patients with Low or Low-Intermediate Risk Prostate Cancer",
    "Stem Cell Mobilization in Treating Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma following High-Dose Therapy and Autologous Stem Cell Transplant",
    "The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL",
    "Fulvestrant or Exemestane with or without Ribociclib in Patients with Recurrent, Unresectable, or Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer",
    "Nab-Paclitaxel and Gemcitabine Hydrochloride in Treating Teenagers or Young Adults with Recurrent or Refractory Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma, or Soft Tissue Sarcoma",
    "Abiraterone Acetate, Olaparib, and Prednisone in Treating Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects",
    "Hypofractionated Partial Breast Irradiation in Treating Patients with Early Stage Breast Cancer",
    "Muscadine Plus in Treating Rising PSA Levels in Men Carrying a Specific Gene Variant (Alanine / Alanine SOD2 Genotype) Following Initial Therapy for Prostate Cancer",
    "Genetic Testing in Screening Patients with Metastatic or Unresectable Colon or Rectal Cancer for a COLOMATE Trial",
    "Clinical and Molecular Risk-Directed Craniospinal Irradiation and Combination Chemotherapy in Treating Younger Patients with Newly Diagnosed Medulloblastoma",
    "T-DM1 and Palbociclib in Treating Patients with Metastatic HER2 Positive Breast Cancer",
    "Fimepinostat in Treating Patients with Newly Diagnosed Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma, or Recurrent High-Grade Glioma",
    "Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia",
    "Nivolumab with or without Azacitidine in Treating Patients with Recurrent Resectable Osteosarcoma",
    "Carboplatin, Pemetrexed, and Bevacizumab with or without Atezolizumab for the Treatment of Stage IV Non-squamous Non-small Cell Lung Cancer",
    "Olaparib in Treating Patients with Metastatic Breast Cancer with DNA Repair Gene Mutations",
    "Trastuzumab, Vinorelbine Tartrate, and Avelumab with or without Utomilumab in Treating Patients with HER2-Positive Metastatic Breast Cancer",
    "Fulvestrant with or without Palbociclib and Avelumab in Treating Patients with Hormone Receptor Positive, HER2 Negative Metastatic or Recurrent Breast Cancer That Cannot Be Removed by Surgery Previously Treated with CDK and Endocrine Therapy",
    "Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer",
    "Docetaxel with or without Radium Ra 223 Dichloride in Treating Patients with Metastatic Castration-Resistant Prostate Cancer",
    "Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Embryonal Tumors",
    "Campath / Fludarabine / Melphalan Transplant Conditioning for Non-Malignant Diseases",
    "Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematologic Malignancies",
    "Oncolytic HSV-1 rRp450 in Treating Patients with Primary Liver Cancer or Liver Metastases",
    "HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and Poly-ICLC in Treating Children with Newly Diagnosed High-Grade Glioma, Brainstem Glioma, or Recurrent Unresectable Low-Grade Glioma",
    "Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells",
    "Low-Dose Donor Bone Marrow Transplant in Treating Patients with Hematologic Malignancies",
    "Combined Vaccine Therapy in Treating Patients with Metastatic Solid Tumors",
    "Epstein-Barr Virus Specific Cytotoxic T-Cells in Treating Patients with Relapsed Acute Lymphoblastic Leukemia Who Have Undergone Donor Stem Cell Transplant",
    "Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer",
    "Intensity-Modulated or Proton Beam Radiation Therapy Together with or without Cisplatin in Treating Patients with Stage III-IVB Paranasal Sinus and Nasal Cavity Cancer",
    "Image-Guided, Intensity-Modulated Photon or Proton Beam Radiation Therapy in Treating Patients with Stage II-IIIB Non-small Cell Lung Cancer",
    "Conventional and Regulatory T Cells in Treating Patients with Advanced Hematologic Malignancies Undergoing T Cell-Depleted Donor Stem Cell Transplant",
    "Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients with Stage III or Metastatic Melanoma",
    "Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation",
    "Quizartinib with Azacitidine or Cytarabine in treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Cytokine-Induced Memory-Like NK Cells in Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Duloxetine Hydrochloride in Reducing Pain in Patients with Stage 0-III Breast Cancer and Chronic Pain",
    "Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients with Stage III-IV Melanoma",
    "IL-12-Expressing HSV-1 in Treating Patients with Recurrent or Progressive Glioblastoma, Anaplastic Astrocytoma, or Gliosarcoma",
    "MV-NIS Infected Mesenchymal Stem Cells in Treating Patients with Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer",
    "Total Marrow and Lymphoid Irradiation and Chemotherapy before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Lymphocytic or Myelogenous Leukemia",
    "HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy",
    "Chemotherapy With or Without Porfimer Sodium-Based Photodynamic Therapy During Surgery in Treating Patients With Malignant Pleural Mesothelioma",
    "Vaccine Therapy in Treating Patients with HER2-Negative Stage III-IV Breast Cancer",
    "Sapanisertib and Ziv-Aflibercept in Treating Patients with Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery",
    "Bupropion in Promoting Smoking Cessation in Pregnant Women",
    "Nelfinavir Mesylate and Chemoradiotherapy in Treating Patients With Locally Advanced, Human Papilloma Virus Negative, Squamous Cell Carcinoma of the Larynx",
    "The HeLiX (Hemorrhage During Liver Resection: traneXamic Acid) Trial",
    "Selinexor and Ibrutinib in Treating Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma",
    "D2C7-IT via Convection-Enhanced Delivery in Treating Patients with Recurrent Malignant Glioma",
    "Activated Immune Cells in Treating Patients with Hematologic Cancers That Have Relapsed after Donor Stem Cell Transplant",
    "Vaccine Therapy and Poly-ICLC in Treating Younger Patients with Recurrent Low-Grade Gliomas that Cannot Be Removed by Surgery",
    "Dabrafenib Mesylate, Trametinib, and 6 Melanoma Helper Peptide Vaccine in Treating Patients with Stage IIIB-IV Melanoma",
    "Personalized Vaccine Therapy in Treating Patients with Triple-Negative Breast Cancer",
    "Rituximab and Pembrolizumab with or without Lenalidomide in Treating Patients with Relapsed Follicular Lymphoma and Diffuse Large B-Cell Lymphoma",
    "Vaccine Therapy with or without Nivolumab or Urelumab before and after Surgery in Treating Patients with Stage I-IIB Pancreatic Cancer That Can Be Removed by Surgery",
    "Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme",
    "Hu8F4 in Treating Patients with Advanced Hematologic Malignancies",
    "Radiation Therapy in Treating Patients with Hepatocellular Carcinoma, Cholangiocarcinoma, or Liver Metastasis Who Have Impaired Liver Function",
    "Genetically Modified T-Cell Therapy in Treating Patients with Advanced ROR1+ Malignancies",
    "Personalized NK Cell Therapy after Chemotherapy and Cord Blood Transplant in Treating Patients with Myelodysplastic Syndrome, Leukemia, Lymphoma or Multiple Myeloma",
    "Disseminated Tumor Cells in Blood and Bone Marrow Samples from Patients Previously Treated for Breast Cancer",
    "Trial to Compare Radiation Fibrosis With Five Versus Three Fractions",
    "Cytokine-Induced Killer Cells after Donor Stem Cell Transplant in Treating Patients with Refractory or Relapsed Acute Myeloid Leukemia",
    "Enhanced Prevention Program in Improving Colorectal Health",
    "Gemcitabine and Nab-Paclitaxel with or without Pharmacological Ascorbate in Treating Patients with Metastatic Pancreatic Cancer",
    "High Doses of Vitamin C with Chemotherapy and Radiation Therapy in Treating Patients with Non-Small Cell Lung Cancer",
    "Phase I Study of 131-I mIBG Followed by Nivolumab & Dinutuximab Beta Antibodies in Children With Relapsed / Refractory Neuroblastoma",
    "TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients with Relapsed or Refractory Grade 1-3A Follicular Lymphoma",
    "Enzalutamide and Indomethacin in Treating Patients with Recurrent or Metastatic Castration-Resistant Prostate Cancer",
    "Magnetic Resonance Imaging-Guided Brachytherapy in Treating Patients with Gynecologic Cancers",
    "Cyclophosphamide and Bendamustine after Donor Bone Marrow Transplant in Preventing GVHD in Patients with Leukemia or Lymphoma",
    "Autologous IC9-CAR19 T cells in Treating Patients with Recurrent or Refractory Acute Lymphoblastic Leukemia",
    "Study to Test the Safety of an Experimental Drug, LMP744, in Patients with Relapsed Solid Tumors or Lymphomas",
    "Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients with Non-Hodgkin Lymphoma",
    "Glutaminase Inhibitor CB-839 and Azacitidine in Treating Patients with Advanced Myelodysplastic Syndrome",
    "Autologous CD8+ SLC45A2-Specific T Lymphocytes with Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients with Metastatic Uveal Melanoma",
    "MDC3 / 8 Vaccines in Treating Patients with Stage III-IV Melanoma",
    "Stereotactic Hypofractionated Radioablative Therapy Treating Participants with Squamous Cell Laryngeal Cancer",
    "211^At-BC8-B10 before Donor Stem Cell Transplant in Treating Patients with High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome, or Mixed-Phenotype Acute Leukemia",
    "Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease Trial",
    "Selumetinib and Olaparib in Treating Participants with Relapsed or Refractory and Advanced Endometrial, Ovarian, or Other Solid Tumors with RAS Pathway Alterations",
    "Perflutren Protein-Type A Microspheres and Contrast-Enhanced Ultrasound in Improving Response to Radioembolization Therapy in Patients with Liver Cancer",
    "PTC596 in Treating Patients with Newly Diagnosed Unresectable Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Receiving Chemotherapy",
    "Belimumab in Preventing Chronic Graft Versus Host Disease after Donor Stem Cell Transplant in Patients with Hematologic Malignancies",
    "Patient-Derived Xenografts in Personalizing Treatment for Patients with Relapsed / Refractory Mantle Cell Lymphoma",
    "Magnetic Resonance Imaging-Guided Intensity Modulated Radiation Therapy in Treating Participants with Human Papillomavirus Positive Oropharyngeal Cancer",
    "Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR after a Myeloablative Conditioning Regimen to Treat Patients with Advanced Cancer",
    "Comparison of Triple GVHD Prophylaxis Regimens for Nonmyeloablative or Reduced Intensity Conditioning Unrelated Mobilized Blood Cell Transplantation",
    "EVarQuit: Extended Pre-quit Varenicline to Assist in Quitting Smoking",
    "Glutaminase Inhibitor CB-839, Panitumumab, and Irinotecan Hydrochloride in Treating Patients with Metastatic and Refractory RAS Wildtype Colorectal Cancer",
    "Enhancing & Mobilizing the POtential for Wellness & Emotional Resilience Among Surrogate Decision-Makers of ICU Patients",
    "Systemic and Tumor-Directed Therapy for Oligometastatic Prostate Cancer",
    "Personalized Exercise Program in Improving Cancer Treatment in Patients with Stage I-IIIA Non-small Cell Lung Cancer or Secondary Lung Cancer That Can Be Removed by Surgery",
    "HA-1 T TCR T cell Immunotherapy for the Treatment of Patients with Relapsed or Refractory Acute Leukemia after Donor Stem Cell Transplant",
    "Adoptive Cellular Therapy in Pediatric Patients With High-grade Gliomas",
    "HERV-E TCR Transduced CD8+ / CD34+ T-cells in Treating Patients with Metastatic Clear Cell Renal Cell Cancer",
    "HER2 Directed Dendritic Cell Vaccine, Trastuzumab, Pertuzumab, and Chemotherapy in Treating Participants with Stage II-III HER-2 Positive Breast Cancer",
    "Recombinant Human Interleukin-15, Nivolumab, and Ipilimumab in Treating Patients with Metastatic or Refractory Solid Tumors",
    "A Patient-centered Intervention Using Technology to Reduce Colorectal Cancer Disparities in Primary Care",
    "TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients with Low-Grade B-Cell Non-Hodgkin Lymphomas",
    "Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast Cancer",
    "Personalized Radiation Therapy in Treating Patients with Grade IV Glioblastoma",
    "A Study of the Safety and Activity of Liposomal Irinotecan in Combination With the 5-FU and Oxaliplatin in the Preoperative Treatment of Pancreatic Adenocarcinoma",
    "CCR2 / CCR5 Antagonist BMS-813160, Nivolumab, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer",
    "Intelligent Tutoring System Intervention in Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer",
    "CCL21-Gene Modified Dendritic Cell Vaccine and Pembrolizumab in Treating Patients with Stage IV Non-small Cell Lung Cancer",
    "African American Families Fighting Parental Cancer Together",
    "Stereotactic Body Radiation Therapy in Treating Patients with Oligometastatic Renal Cell Carcinoma",
    "Fluorine F 18 Fluorthanatrace PET / CT in Treating Patients with Primary or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer",
    "Ipilimumab and Nivolumab with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma",
    "Antiandrogen Therapy, Abiraterone Acetate, and Prednisone with or without Neutron Radiation Therapy in Treating Patients with Prostate Cancer",
    "Nivolumab, Ipilimumab, and Bicalutamide in Human Epidermal Growth Factor (HER) 2 Negative Breast Cancer Patients",
    "Genetically Engineered Virus (C134) for the Treatment of Recurrent Malignant Glioma",
    "Marine Omega 3 Fatty Acid in Treating Patients with Stage I-III Colorectal Cancer or Colorectal Mass or Polyp Undergoing Surgery",
    "211At-BC8-B10 followed by Donor Stem Cell Transplant in Treating Patients with Relapsed or Refractory High-Risk Acute Leukemia or Myelodysplastic Syndrome",
    "Enzalutamide and Relacorilant in Treating Patients with Metastatic Castration Resistant Prostate Cancer",
    "A Vaccine (pp65 Loaded DC Vaccine) with or without Varlilumab in Treating Patients with Glioblastoma",
    "Rituximab and Hyaluronidase Human in Treating Patients with Unresectable Stage III-IV Melanoma Undergoing Nivolumab and Ipilimumab Therapy",
    "Modified Immune Cells (Autologous iC9.GD2.CAR.IL-15 T cells) for Treating Patients with Relapsed or Refractory High Risk Neuroblastoma, Ganglioneuroblastoma, or Osteosarcoma",
    "Decision Coaching Program in Improving Health Decisions in Black Male Patients Undergoing Screening for Prostate Cancer",
    "Porfimer Sodium Interstitial Photodynamic Therapy with or without Standard of Care Chemotherapy in Treating Patients with Locally Advanced or Recurrent Head and Neck Cancer",
    "Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients with Locally Advanced Lung Cancer or Advanced Cancer Obstructing the Airway",
    "Fractionated Docetaxel and Radium 223 in Metastatic Castration-Resistant Prostate Cancer",
    "Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients with Metastatic or Unresectable Merkel Cell Cancer",
    "LET Optimized IMPT in Treating Pediatric Patients with Ependymoma",
    "Vocal-cord vs. Complete Laryngeal Radiotherapy for Early Glottic Cancer",
    "Fluid Measurements and MRI in Determining Biomarkers of Lymphatic Dysfunction in Patients with Breast Cancer",
    "Cetuximab in Treating Patients with Head and Neck Squamous Cell Carcinoma",
    "Hydroxychloroquine, Palbociclib, and Letrozole before Surgery in Treating Patients with Estrogen Receptor Positive, HER2 Negative Breast Cancer",
    "Converting HR+ Breast Cancer Into an Individualized Vaccine",
    "Brief Behavioral Treatment for Insomnia in Cancer Survivors",
    "Rifaximin in Treating Patients with Monoclonal Gammopathy",
    "Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma",
    "Coping Skills Training and Activity Coaching Intervention (HCT Symptoms and Steps) for Symptom Management and Daily Steps in Stem Cell Transplant Patients",
    "PSCA-CAR T Cells in Treating Patients with PSCA+ Metastatic Castration Resistant Prostate Cancer",
    "Phase 2 Study of Telomelysin (OBP-301) in Combination With Pembrolizumab in Esophagogastric Adenocarcinoma",
    "A Vaccine (pp65 Loaded DC Vaccine) for the Treatment of Newly-Diagnosed Grade IV Unmethylated Glioma, I-ATTAC Study",
    "Neoantigen Vaccine (NeoVax plus Montanide) in Combination with Nivolumab and Ipilimumab for the Treatment of Unresectable Melanoma",
    "Neoantigen Peptide Vaccine for the Treatment of Pancreatic Cancer",
    "Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant",
    "Tocilizumab in Treating Children and Adolescents with Newly-Diagnosed, Recurrent, or Progressive Adamantinomatous Craniopharyngioma",
    "Dabrafenib, Trametinib, and IMRT in Treating Patients with BRAF Mutated Anaplastic Thyroid Cancer",
    "The Exercise And Colorectal Cancer Treatment Trial",
    "IL13Ralpha2-Targeted Chimeric Antigen Receptor (CAR) T Cells with or without Nivolumab and Ipilimumab in Treating Patients with Recurrent or Refractory Glioblastoma",
    "FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery",
    "Carvedilol in Reducing the Risk of Cardiotoxicity in Patients with Stage I-III Breast Cancer Treated with Doxorubicin and / or Trastuzumab",
    "HIIT before Surgery in Improving Outcomes in Patients with Endometrial Cancer",
    "Bronchoscopic Cryo-Immunotherapy for the Treatment of Advanced Unresectable Non-small Cell Lung Cancer",
    "Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG",
    "An Investigational Scan (Stationary Digital Chest Tomosynthesis) for the Detection of Lung Lesions",
    "Cord Blood Transplant with OTS for the Treatment of HIV Positive Hematologic Cancers",
    "Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases",
    "Software-Aided Imaging (Morfeus) for Confirming Tumor Coverage with Ablation in Patients with Liver Tumors",
    "Tailored Navigation Intervention to Improve Breast and Cervical Screening in Southeast Asian Women",
    "The Prevent Anal Cancer Palpation Study",
    "Olaparib with Cediranib or Ceralasertib for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer",
    "CLR 131 and External Beam Radiation Therapy for the Treatment of Patients with Recurrent Head and Neck Cancer",
    "Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) after Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors",
    "Binimetinib and Hydroxychloroquine in Treating Patients with KRAS Mutant Metastatic Pancreatic Cancer",
    "Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate",
    "Fecal Microbiota Transplantation for the Treatment of High-Risk Acute Graft-versus-Host Disease after Donor Hematopoietic Cell Transplantation",
    "Neoadjuvant Chemotherapy and Digoxin for the Treatment of Resectable Pancreatic Cancer",
    "An Intraoperative Guidance Platform for Patients Undergoing Radio Frequency Ablation for Liver Cancer",
    "Plerixafor and Cemiplimab for the Treatment of Metastatic Pancreatic Cancer",
    "Fentanyl Buccal Tablet or Morphine for Exertional Dyspnea in Cancer Patients",
    "Virtual Human Delivered Nutrition Module for Colorectal Cancer Prevention",
    "Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma",
    "Nilotinib in Preventing Paclitaxel-Induced Peripheral Neuropathy in Patients with Stage I-III Breast Cancer",
    "T Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain for the Treatment of Relapsed or Refractory B cell Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma",
    "Endocrine Therapy before Surgery and Radiation Therapy for the Treatment of Geriatric, Estrogen Receptor Positive Stage I Breast Cancer",
    "Hepatic Arterial Infusion Using Codman Catheter / Synchromed Pump for the Treatment of Unresectable Colorectal Cancer Liver Metastases or Unresectable Intrahepatic Cholangiocarcinoma",
    "Green Tea Catechins for the Prevention of Prostate Cancer Progression in Men on Active Surveillance",
    "Eflornithine (DFMO) and Etoposide for Relapsed / Refractory Neuroblastoma",
    "Ribociclib In Combination with Belinostat in Patients with Metastatic Triple Negative Breast Cancer or Recurrent Platinum-Resistant Ovarian Cancer, Charge Study",
    "Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy before Surgery for the Treatment of Patients with Breast Cancer",
    "Stereotactic Body Radiotherapy and Defactinib for the Treatment of Locally Advanced Pancreatic Adenocarcinoma",
    "Stool DNA to Improve Colorectal Cancer Screening Among Alaska Native People",
    "Zafirlukast for the Treatment of Tumor-Marker Only Relapsed Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer",
    "Sequential High Dose Testosterone and Enzalutamide Compared with Enzalutamide Alone for the Treatment of Asymptomatic Metastatic Castration Resistant Prostate Cancer, STEP-UP Study",
    "Enhanced Melanoma Vaccine for the Treatment of Stage IIB-IV Melanoma",
    "Increasing Cervical Cancer Screening Uptake Among Emergency Department Patients",
    "Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Yttrium-90 Microsphere Radioembolization for Enabling Resection of Liver Cancer",
    "Study of PSMA PET / MR Guided Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost (SBRT-SIB) for High-Intermediate and High Risk Prostate Cancer",
    "Tasquinimod Alone and in Combination with Standard Therapy for the Treatment of Relapsed or Refractory Multiple Myeloma",
    "Daratumumab, Azacitidine, and Dexamethasone for the Treatment of Patients with Recurrent or Refractory Multiple Myeloma Previously Treated with Daratumumab",
    "Nivolumab and BO-112 before Surgery for the Treatment of Resectable Soft Tissue Sarcoma",
    "The Positively Quit Trial for Smoking Cessation",
    "Next Generation Sequencing-Based Stratification of Front Line Therapy for the Treatment of Metastatic and / or Unresectable High Grade Neuroendocrine Cancer, Precision-Nec Study",
    "Pancreatic Adenocarcinoma Signature Stratification for Treatment",
    "ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "Prostate Screening for Men with Inherited Risk of Developing Aggressive Prostate Cancer, PATROL Study",
    "Nicotine Replacement Therapy, Varenicline, and Contingency Management for the Cessation of Tobacco Use in Patients with Human Immunodeficiency Virus",
    "Design and Implementation of Scalable Decision Support and Shared Decision Making for Lung Cancer Screening",
    "99mTc MAA SPECT / CT Scan for Treatment Planning for Radioembolization in the Treatment of Unresectable Metastases in the Liver",
    "Naltrexone Treatment for Prolonged Grief Disorder (PGD)",
    "Flotetuzumab for the treatment of Relapsed Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Following Allogeneic Hematopoietic Cell Transplantation",
    "Metabolism Informed Smoking Treatment for Smoking Cessation in Medicaid and Medicare Patients",
    "Genetically Modified Cells (FT516), Interleukin-2, and Enoblituzumab for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Low-Dose Selinexor and Choline Salicylate for the Treatment of Patients with Residual, Relapsed or Refractory Non-Hodgkin Lymphoma",
    "Autologous Lymphocyte Infusions after Chemotherapy and / or Radiation Therapy for Immune Reconstitution in Patients with Stage II-IVA Non-small Cell Lung Cancer or Esophageal Cancer",
    "A Vaccine (Alpha-Lactalbumin) for the Treatment of Stage II-III Triple-Negative Breast Cancer",
    "Fecal Microbiota Transplant and Re-introduction of Anti-PD-1 Therapy (Pembrolizumab or Nivolumab) for the Treatment of Metastatic Colorectal Cancer in Anti-PD-1 Non-responders",
    "Talazoparib with Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer",
    "Addition of Cord Blood Tissue-Derived Mesenchymal Stromal Cells to Ruxolitinib for the Treatment of Steroid-Refractory Acute Graft Versus Host Disease",
    "Azacitidine and Romidepsin for the Treatment of Relapse or Refractory Peripheral T-cell Lymphoma",
    "Surveys, Blood Testing, and Fibroscan in Screening for Liver Fibrosis and Liver Cirrhosis",
    "Electromagnetic Fields for the Treatment of Locally Advanced or Metastatic Liver Cancer",
    "Topical Imiquimod 5% Cream for The Treatment of Stage I-II Oral Cancer",
    "Screening More Patients for Colorectal Cancer through Adapting and Refining Targeted Evidence-Based Interventions in Rural settings, SMARTER CRC",
    "Pomalidomide and Nivolumab for the Treatment of Virus-Associated Malignancies with or without HIV",
    "68Ga-PSMA-11 PET in Surgery Guidance in Prostate Cancer",
    "Abemaciclib for the Treatment of Patients with HIV-Associated and HIV-Negative Kaposi Sarcoma",
    "Mindfulness-based Smoking Cessation Enhanced With Mobile Technology",
    "AL101 before Surgery for the Treatment of Notch Activated Adenoid Cystic Cancer",
    "Neoadjuvant Dietary Intervention in Intermediate Risk Prostate Cancer",
    "CpG-STAT3 siRNA CAS3 / SS3 and Localized Radiation Therapy for the Treatment of Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma",
    "A Study to Determine if the Drug, Pyrvinium Pamoate, is Safe and Tolerable in Patients with Pancreatic Cancer",
    "Aspirin for the Improvement of Immunological Features of Ovarian Tumors in Patients Receiving Neoadjuvant Chemotherapy",
    "Proton Beam Radiation Therapy in Treating Patients with Previously Untreated Childhood Rhabdomyosarcoma",
    "Veliparib and Dinaciclib in Treating Patients with Advanced Solid Tumors",
    "Vorinostat in Treating Patients with Metastatic Melanoma of the Eye",
    "TRC102 and Temozolomide in Treating Patients with Relapsed Solid Tumors or Lymphomas",
    "High-Resolution Microendoscopy or Standard Endoscopy in Diagnosing Esophageal Cancer in Participants with Barrett Esophagus",
    "Trametinib and Navitoclax in Treating Patients with Advanced or Metastatic Solid Tumors",
    "Testosterone Therapy Followed by Enzalutamide or Abiraterone Acetate in Treating Patients with Prostate Cancer That Is Progressing on Combined Androgen Therapies",
    "Wild-Type Reovirus in Combination with Carfilzomib and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma",
    "Transcriptional Targets of Vitamin D in Patients with Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases Receiving Preoperative Cholecalciferol",
    "Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies",
    "Mammaglobin-A DNA Vaccine in Treating Patients with Newly Diagnosed Breast Cancer Undergoing Endocrine Therapy or Chemotherapy before Surgery",
    "A Vaccine (TA-CIN) as Adjuvant Therapy in Treating Patients with HPV16 Related Stage IB1-IV Cervical Cancer",
    "Selumetinib in Treating Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas That Cannot Be Removed by Surgery",
    "Trial of Cisplatin Plus Radiation Followed by Carbo and Taxol Vs. Sandwich Therapy of Carbo and Taxol Followed Radiation Then Further Carbo and Taxol",
    "Increased Dose IMPT in Treating Patients with High-Grade Meningiomas",
    "4-Dimensional Computed Tomography in Improving Treatment Plan in Patients with Non-small Cell Lung Cancer or Lung Metastasis Undergoing Radiation Therapy",
    "Glypican 3-Specific Chimeric Antigen Receptor Expressing T Cells for the Treatment of Unresectable, Metastatic, or Recurrent Liver Cancer",
    "Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma",
    "Androgen Deprivation Therapy, Pembrolizumab, and Stereotactic Body Radiation Therapy with or without TLR9 Agonist SD-101 in Treating Patients with Metastatic Prostate Cancer",
    "VSV-hIFNbeta-NIS with or without Ruxolitinib Phosphate in Treating Patients with Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia, or T-cell Lymphoma",
    "General Anesthetics in CAncer REsection Surgery (GA-CARES) Trial",
    "HPV Vaccine Therapy in Interrupting Progression in Patients with High-Grade Vulvar or Anal Lesions",
    "CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts",
    "Home Intervention for Reducing Sugary Drinks and Obesity in Hispanic Women and Infants, MAMITA Study",
    "Personalized Neoantigen Cancer Vaccine with and without Low-Dose Cyclophosphamide or Pembrolizumab for the Treatmen IGHV Unmutated Chronic Lymphocytic Leukemia.",
    "Focal Salvage HDR Brachytherapy for Locally Recurrent Prostate Cancer in Patients Treated With Prior Radiotherapy",
    "Celiac Plexus Radio-Surgery for Pain Management",
    "Aza-TdC in Treating Patients with Advanced or Refractory Solid Tumors",
    "Nicotinamide Riboside in Reducing Paclitaxel or Nab-paclitaxel Induced Peripheral Neuropathy in Patients with Stage IV Breast Cancer or Platinum-resistant Recurrent Ovarian, Peritoneal, Endometrial, Fallopian Tube, or Head and Neck Cancer",
    "177Lu-PSMA-617 and Pembrolizumab in Treating Patients with Metastatic Castration-Resistant Prostate Cancer",
    "Mailed Self-Sample HPV Testing to Increase Cervical Cancer Screening among Minority / Underserved Women in an Integrated Safety Net Healthcare System",
    "T Cell-Depleted Donor Lymphocyte Infusion and Ipilimumab in Treating Patients with Myeloid Disease Relapse after Donor Stem Cell Transplant",
    "NeoVax and Nivolumab for the Treatment of Patients with Newly-Diagnosed, Stage IIIC or IV or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration",
    "Vaccine Therapy (pTVG-HP DNA Vaccine with or without pTVG-AR DNA Vaccine) and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",
    "Cervical Cancer Screen-and-Treat Strategy with HPV Self-testing and Thermocoagulation for the Detection and Treatment of Cervical Lesions",
    "A Vaccine (H2NVAC) before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ",
    "Opaganib and Androgen Antagonists for the Treatment of Patients with Metastatic Castration Resistant Prostate Cancer",
    "Study of CAbozantinib in Combination With AtezolizumaB for Muscle-Invasive BladdEr Cancer",
    "Encapsulated Rapamycin for the Treatment of Non-Muscle Invasive Bladder Cancer",
    "Implantable Microdevice for the Evaluation of Drug Response in Patients with Prostate Cancer",
    "Scaling Colorectal Cancer Screening Through Outreach, Referral, and Engagement (SCORE) Intervention for the Reduction of Colorectal Cancer Burden in Vulnerable Populations",
    "Managing Pain Caused by Chemotherapy in People with Myeloma or Lymphoma, OPTIMAL-HiChemo Study",
    "Identifying and Caring for Individuals with Inherited Cancer Syndrome",
    "Effect of Perampanel on Peritumoral Hyperexcitability and Seizure Control in Patients with Newly Diagnosed High Grade Glioma",
    "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients with Advanced Cancer and HIV",
    "Evidence-Based Approach for the Improvement of Cervical Cancer Screening in Asian American Women",
    "Rituximab with or without Etoposide for the Treatment of Multicentric Castleman Disease",
    "Cabazitaxel, Carboplatin, and Cetrelimab followed by Niraparib with or without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer",
    "Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC)",
    "Prevention and Early Detection of Cervical Cancer through Self-Administered Screening",
    "177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu-J591) and Ketoconazole in Patients With Prostate Cancer",
    "T-Lymphocytes in Treating Patients with Active or Relapsed Hodgkin Lymphoma or Non-Hodgkin Lymphoma",
    "Modified T-Cells in Treating Patients With Epstein-Barr Virus Positive Lymphoma.",
    "Cholecalciferol in Improving Survival in Patients with Newly Diagnosed Cancer with Vitamin D Insufficiency",
    "Hypofractionated Radiation Therapy for the Treatment of Prostate Cancer",
    "Liposomal Rhenium Re 186 in Treating Patients with Recurrent Glioblastoma",
    "Alternating Estradiol and Aromatase Inhibitor Therapies for the Treatment of ER+ / HER2- Advanced or Metastatic Breast Cancer, POLLY Study",
    "Ibrutinib, Temozolomide, Etoposide, Pegylated Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Rituximab in Treating Patients with Primary Central Nervous System Lymphoma",
    "Avatar-Directed Chemotherapy in Treating Patients with Ovarian, Primary Peritoneal, or Fallopian Tube Cancer",
    "Mutation Clearance in Improving Risk Assessment for Patients with Acute Myeloid Leukemia in Remission",
    "CXCR4 Antagonist BL-8040 and Nelarabine in Treating Patients with Relapsed or Refractory T-Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma",
    "Bevacizumab in Treating Patients with Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
    "Pembrolizumab with or without Stereotactic Radiosurgery in Treating Patients with Central Nervous System Metastases",
    "Paediatric Hepatic International Tumour Trial",
    "Non-endoscopic Screening and Surveillance in Patients with Barrett’s Esophagus",
    "FASN Inhibitor TVB-2640 and Trastuzumab in Combination with Paclitaxel or Endocrine Therapy for the Treatment of HER2 Positive Metastatic Breast Cancer",
    "Alectinib and Cobimetinib in Treating Patients with Advanced ALK-Rearranged Non-small Cell Lung Cancer",
    "Pembrolizumab in Treating Patients with Metastatic Castration Resistant Prostate Cancer with or without DNA Damage Repair Defects",
    "Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients with High-Risk Stage III Melanoma",
    "Modified Immune Cells (C7R-GD2.CART) for the Treatment of GD2 Positive Relapsed or Refractory Solid Cancers",
    "Dendritic Cell / AML Fusion Cell Vaccine with or without Decitabine in Treating Patients with Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant",
    "Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia / Lymphoma",
    "Linaclotide in Treating Patients with Stages 0-3 Colorectal Cancer",
    "Talazoparib for the Treatment of Cohesin-Mutated Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "Cell Therapy (CIML NK Cells) for the Treatment of Recurrent Myeloid Disease after Donor Blood Stem Cell Transplant",
    "SABR with or without Radium-223 for the Treatment of Metastatic Prostate Cancer",
    "TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients with Residual Disease after Chemotherapy and Surgery",
    "Sulindac in Preventing Progression to Pancreatic Cancer in Patients with Intraductal Papillary Mucinous Neoplasms, The 3PC Trial",
    "Anastrozole and Letrozole after Surgery for the Treatment of Stage I-III Breast Cancer",
    "High Resolution Microendoscopy for the Diagnosis of Anal High Grade Intraepithelial Lesions among People Living with HIV",
    "Carfilzomib in Combination With Cyclophosphamide and Etoposide for Children",
    "Preoperative vs Postoperative IMRT for Extremity / Truncal STS",
    "Adenovirus-specific Cytotoxic T-lymphocytes for Refractory Adenovirus Infection",
    "Virus Specific Cytotoxic T-Lymphocytes (CTLs) for Refractory Cytomegalovirus (CMV)",
    "EBV-specific Cytotoxic T-lymphocytes (CTLs) for Refractory EBV Infection",
    "Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone",
    "Combined Breast MRI and Biomarker Strategies in Identifying High-risk Breast Cancer Patients",
    "PRO-ACTIVE: Prophylactic Swallow Intervention for Patients Receiving Radiotherapy for Head and Neck Cancer",
    "Paricalcitol, Gemcitabine Hydrochloride, and Nab-Paclitaxel in Treating Patients with Metastatic Pancreatic Cancer",
    "Fluciclovine F18 or Gallium Ga 68-labeled PSMA-11 PET / CT in Enhancing Outcomes in Patients with Prostate Adenocarcinoma",
    "Carvedilol for the Treatment of Heart Disease in Patients with New or Locally Recurrent Breast Cancer Receiving Trastuzumab, TACTIC Study",
    "Estradiol in Treating Patients with ER Beta Positive, Triple Negative Locally Advanced or Metastatic Breast Cancer",
    "Phase II Study of Short Course FOLFOX Chemotherapy With Either Nivolumab or Nivolumab + Radiation in the First Line Treatment of Metastatic or Unresectable Gastroesophageal Cancers (BMS Protocol CA209-76L)",
    "Nivolumab Consolidation in Older (≥ 65) Patients With Primary CNS Lymphoma",
    "Ruxolitinib and Enasidenib for the Treatment of Accelerated or Blast-Phase Myeloproliferative Neoplasm or Chronic-Phase Myelofibrosis with an IDH2 Mutation",
    "Multilevel HPV Self-Testing Intervention for the Increase of Cervical Cancer Screening among Women in Appalachia",
    "High Resolution Microendoscopy with Proflavine Hemisulfate in Diagnosing Squamous Cell Cancer of the Esophagus in Participants Undergoing Standard Chromoendoscopy",
    "Molecular Testing and Imaging in Improving Response in Patients with Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative",
    "Pexidartinib and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery",
    "INFUSE Bone Graft in Treating Patients with Tibial Pseudarthrosis and Neurofibromatosis 1 Undergoing Surgery",
    "Vaccine Therapy in Treating Patients with Acute Myeloid Leukemia following Chemotherapy-Induced Remission",
    "SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors",
    "Biomarker Analysis in Blood, Sputum, Exhaled breath, and Urine Samples from Participants with Lung Nodule",
    "Ketoconazole in Treating Participants with Ongoing EGFR Inhibitor-Induced Rash",
    "A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 Inactivation",
    "Crizotinib for the Treatment of Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma",
    "SARC024: A Blanket Protocol to Study Oral Regorafenib in Patients With Selected Sarcoma Subtypes",
    "Trametinib with or without Dabrafenib Mesylate in Treating Patients with BRAF, KRAS, or NRAS Gene Mutation and Recurrent Multiple Myeloma",
    "Testing Experimental PET / CT Imaging for High Risk Prostate Cancer",
    "Study of the Body’s Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women with Hormone Receptor Positive Stage I-III Breast Cancer",
    "Ruxolitinib and Duvelisib for the Treatment of Relapsed or Refractory T- or NK-Cell Lymphoma",
    "Biomarker Analysis in Improving Screening in Patients with or at High Risk of Developing Pancreatic Cancer",
    "Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients with Recurrent or Progressive Grade 2 or 3 Meningioma",
    "Vaccine Therapy in Preventing Recurrence in Patients with Her-2 Positive Stage I-III Breast Cancer",
    "Women Informed to Screen Depending on Measures of Risk (Wisdom Study)",
    "Conjugated Estrogens / Bazedoxifene in Treating Patients with Ductal Carcinoma in Situ Undergoing Surgery",
    "Image-Guided Intensity-Modulated Proton or Photon Beam Radiation Therapy with Boost in Treating Patients with Primary or Locally Recurrent Soft Tissue Sarcoma",
    "Maintenance Obinutuzumab in Treating Patients with Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response",
    "Binimetinib for the Treatment of Neurofibromatosis Type 1 Associated Plexiform Neurofibromas, PNOC010 Study",
    "CA-125 Algorithm in Early Screening for Ovarian Cancer in Low Risk Postmenopausal Participants",
    "TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer",
    "Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients with Triple Negative Breast Cancer",
    "Comprehensive Genomic Analysis in Tissue Samples from Patients with Recurrent or Stage IV Non-small Cell Lung Cancer",
    "A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity",
    "Systemic Therapy with or without Local Consolidative Therapy in Treating Patients with Oligometastatic Solid Tumor",
    "Tamoxifen Citrate, Anastrozole, or Fulvestrant in Treating Patients with Stage I-III Invasive Lobular Breast Cancer",
    "Levonorgestrel-Releasing Intrauterine System with or without Everolimus in Treating Patients with Atypical Hyperplasia or Stage IA Grade 1 Endometrial Cancer",
    "Myeloma-Developing Regimens Using Genomics (MyDRUG)",
    "Study of Biomarker-Based Treatment of Acute Myeloid Leukemia",
    "Intensity-Modulated Proton Beam Therapy or Intensity-Modulated Photon Therapy in Treating Patients with Stage III-IVB Oropharyngeal Cancer",
    "Safety Study of Unlicensed, Investigational Cord Blood Units Manufactured by the NCBP for Unrelated Transplantation",
    "I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer",
    "A Prospective Comparative Study of Outcomes With Proton and Photon Radiation in Prostate Cancer",
    "Proton Beam Radiation Therapy or Photon Beam Radiation Therapy in Treating Patients with Non-Metastatic Breast Cancer, A Radiotherapy Comparative Effectiveness (RadComp) Consortium Trial",
    "A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies",
    "A Study to Assess PV-10 Chemoablation of Cancer of the Liver",
    "Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer",
    "Study of NanoKnife for Ablation of Prostate Cancer in Intermediate Risk Patients",
    "Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation",
    "Post-operative Adjuvant Treatment for HPV-positive Tumours (PATHOS)",
    "An Efficacy and Safety Study of Erdafitinib (JNJ-42756493) in Participants With Urothelial Cancer",
    "Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects",
    "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors",
    "A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed / Refractory Synovial Sarcoma",
    "Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive Malignancies",
    "LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer",
    "Study of Favezelimab (MK-4280) as Monotherapy and in Combination With Pembrolizumab (MK-3475) With or Without Chemotherapy or Lenvatinib (MK-7902) AND Favezelimab / Pembrolizumab (MK-4280A) as Monotherapy in Adults With Advanced Solid Tumors (MK-4280-001)",
    "PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies",
    "Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia",
    "A Study of Regorafenib in Refractory Advanced Gastro-Oesophageal Cancer",
    "Pharmacological Study of Intravenous OTS167 in Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Advanced Myelodysplastic Syndromes, Advanced Myeloproliferative Neoplastic Disorders, or Advanced Chronic Myelogenous Leukemia",
    "A Phase 1, Open-Label, Dose-Escalation Study of NEV801, Administered to Patients With Advanced Cancers",
    "Phase I / II, First in Human, Dose Escalation Trial of TL 895 in Subjects With Relapsed / Refractory Chronic Lymphocytic Leukemia or Relapsed / Refractory Small Lymphocytic Lymphoma",
    "Vinblastine + / - Bevacizumab in Children With Unresectable or Progressive Low Grade Glioma (LGG)",
    "Initial Feasibility Study to Treat Borderline Resectable Pancreatic Cancer With a Planar LDR Source",
    "Mino-Lok Therapy (MLT) for the Treatment of CRBSI / CLABSI",
    "A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers",
    "Ribociclib (LEE011) Rollover Study for Continued Access",
    "A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study",
    "A Study of ABBV-927 and ABBV-181, an Immunotherapy, in Participants With Advanced Solid Tumors",
    "SEL24 / MEN1703 in Patients With Acute Myeloid Leukemia",
    "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving INC280 Treatment as Single Agent or in Combination With Other Treatments.",
    "Trial of NanoPac® in Subjects With Locally Advanced Pancreatic Adenocarcinoma",
    "Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).",
    "Dose-Escalation and Expansion Trial of NC-6300 in Patients With Advanced Solid Tumors or Soft Tissue Sarcoma",
    "A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma",
    "Combination of TATE and PD-1 Inhibitor in Liver Cancer",
    "Feasibility Study to Treat Lung Cancer With the Permanently Implantable LDR CivaSheet®",
    "Study of ASTX727 vs IV Decitabine in MDS, CMML, and AML",
    "Study of GNS561 in Patients With Liver Cancer",
    "Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule",
    "A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)",
    "Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and / or Bone Marrow",
    "Endorotor Resection In Refractory Barrett's Dysplasia Patients",
    "A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer",
    "Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors",
    "A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)",
    "ABI-009 (Nab-rapamycin) in Combination With FOLFOX and Bevacizumab as First-line Therapy in Patients With Advanced or Metastatic Colorectal Cancer",
    "Phase I Study of RiMO-301 With Radiation in Advanced Tumors",
    "An Investigational Immunotherapy Study of BMS-986299 Alone and in Combination With Nivolumab and Ipilimumab in Participants With Solid Cancers That Have Spread or Cannot be Removed",
    "A Study of ZN-e4 in Subjects With Epidermal Growth Factor Receptor Mutated Non-Small Cell Lung Cancer",
    "A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer",
    "Study of Neratinib +Trastuzumab or Neratinib + Cetuximab in Patients With KRAS / NRAS / BRAF / PIK3CA Wild-Type Metastatic Colorectal Cancer by HER2 Status",
    "A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Non-Hodgkin Lymphomas and Participants With DLBCL",
    "A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer",
    "Study of NEO-201 in Solid Tumors Expansion Cohorts",
    "Trial to Determine the Efficacy and Safety of JCAR017 in Adult Subjects With Aggressive B-Cell Non-Hodgkin Lymphoma",
    "A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline / Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer",
    "Eculizumab to Treat Thrombotic Microangiopathy / Atypical Hemolytic Uremic Syndrome -Associated Multiple Organ Dysfunction Syndrome in Hematopoietic Stem Cell Transplant Recipients",
    "A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors",
    "A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors",
    "A Study to Evaluate MEDI5752 in Subjects With Advanced Solid Tumors",
    "Oral AMXT 1501 Dicaprate in Combination With DFMO",
    "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.",
    "A Phase I / Ib Study of NZV930 Alone and in Combination With PDR001 and / or NIR178 in Patients With Advanced Malignancies.",
    "Evaluation of Safety and Efficacy of KPG-121 Plus Enzalutamide, Abiraterone or Apalutamide in CRPC Patients",
    "GEN1029 (HexaBody®-DR5 / DR5) Safety Trial in Patients With Malignant Solid Tumors",
    "Evaluate F901318 Treatment of Invasive Fungal Infections in Patients Lacking Treatment Options",
    "Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation / Infection or Prophylaxis",
    "A Study of CS1001 in Subjects With Relapsed or Refractory Extranodal Natural Killer / T Cell Lymphoma(ENKTL)",
    "Ph I / II Trial of Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC",
    "A Study to Assess the Safety, Tolerability, and Efficacy of BIVV003 for Autologous Hematopoietic Stem Cell Transplantation in Patients With Severe Sickle Cell Disease",
    "A Study of Subcutaneous Nivolumab Monotherapy With or Without Recombinant Human Hyaluronidase PH20 (rHuPH20)",
    "Study of TRPH-222 in Patients With Relapsed and / or Refractory B-Cell Lymphoma",
    "A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer",
    "A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome",
    "Study to Evaluate the Safety, Tolerability,Pharmacokinetics, and Antitumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate Alone and in Combination With Darolutamide, in Patients With Metastatic Castration Resistant Prostate Cancer",
    "A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients",
    "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)",
    "Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).",
    "A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed / Refractory (r / r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)",
    "Safety and Efficacy of Repeat Administration of Ad / PNP and Fludarabine Phosphate in Patients With Local Head / Neck Cancer",
    "MEN1611 With Trastuzumab (+ / - Fulvestrant) in Metastatic Breast Cancer",
    "LCI-HEM-MYE-CRD-004 (MMRC-073 CARJAK): Study of CRD for Carfilzomib-Refractory Multiple Myeloma",
    "An Open-label, Dose Escalation Trial to Evaluate the Safety and Pharmacokinetics of HMPL-523 in Patients With Lymphoma",
    "Study of CPI-100 in Patients With Advanced Tumors",
    "APG-115 in Salivary Gland Cancer Trial",
    "Safety and Efficacy of KY1044 and Atezolizumab in Advanced Cancer",
    "TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab",
    "Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed / Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers",
    "Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors",
    "SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas",
    "ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma",
    "Study of the Safety and Pharmacokinetics of BGB-283 (Lifirfenib) and PD-0325901 (Mirdametinib) in Participants With Advanced or Refractory Solid Tumors",
    "Modified Immune Cells (Autologous CAR T Cells) in Treating Patients With Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer",
    "KHK2455 (IDO Inhibitor) Plus Avelumab in Adult Subjects With Advanced Bladder Cancer",
    "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC",
    "A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)",
    "Safety and Efficacy of OT-82 in Participants With Relapsed or Refractory Lymphoma",
    "HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)",
    "Intravesical Photodynamic Therapy (PDT) in BCG Refractory / Intolerant Non-Muscle Invasive Bladder Cancer (NMIBC) Patients",
    "Cancer Stem Cell Assay Directed Chemotherapy in Recurrent Platinum Resistant Ovarian Cancer",
    "An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection",
    "A Study of sEphB4-HSA in Kaposi Sarcoma",
    "Phase Ib Study of TNO155 in Combination With Spartalizumab or Ribociclib in Selected Malignancies",
    "YIV-906 (Formerly PHY906 / KD018) With Sorafenib in HBV(+) Hepatocellular Carcinoma (HCC)",
    "Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia Patients",
    "Evaluate Eribulin ORA in Subjects With Solid Tumors",
    "MTG201 Plus Nivolumab in Patients With Relapsed Pleural Mesothelioma",
    "A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r / r B-Cell Malignancies",
    "ATL001 in Patients With Advanced Unresectable or Metastatic NSCLC",
    "Registry of Sarcoma Patients Treated With Permanently Implantable LDR CivaSheet®",
    "Multi-center, Open-label, Phase 1b Study in Patients With Relapsed / Refractory Multiple Myeloma (RRMM)",
    "Study of Oral SKI-O-703, SYK Inhibitor, in Patients With Persistent and Chronic Immune Thrombocytopenia (ITP)",
    "Rollover Study for Continued Safety and Tolerability in Subjects Treated With Spartalizumab Alone or in Combination With Other Study Treatments",
    "Dose-Escalation and Efficacy Study of LAE001 / Prednisone Plus Afuresertib Patients With m-CRPC",
    "Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma",
    "A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies",
    "Phase 1 / 2 Study of OBI-999 in Patients With Advanced Solid Tumors",
    "Study of Molecular Response Adaptive Immuno-Chemotherapy in Patients With NSCLC",
    "Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2 / 3)",
    "US Study of UM171-Expanded CB in Patients With High Risk Leukemia / Myelodysplasia",
    "Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)",
    "Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia",
    "A Phase I / II Trial Investigating LOAd703 in Combination With Atezolizumab in Malignant Melanoma",
    "Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (MK-3475-A31 / KEYNOTE-A31) in Advanced or Metastatic Malignancy",
    "A Study of Melphalan, BCNU, Vitamin B12b, Vitamin C, and Stem Cell Infusion in People With Advanced Pancreatic Cancer and BRCA Mutations",
    "A Study of Mavorixafor in Participants With Severe Congenital Neutropenia and Chronic Neutropenia Disorders",
    "ConMed HelixAR™ ElectroSurgical Generator With Argon Beam Coagulation Technology Study",
    "Study in Relapsed / Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Patients to Determine the Recommended Dose of CYAD-02",
    "M1774 in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)",
    "A Study of ZN-c5 in Participants With Breast Cancer",
    "A Study to Evaluate the Safety and Efficacy of Polatuzumab Vedotin in Combination With Rituximab, Gemcitabine and Oxaliplatin Compared to Rituximab, Gemcitabine and Oxaliplatin Alone in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Study of NMS-03305293 in Pts With Selected Advanced / Metastatic Solid Tumors",
    "A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma / Paraganglioma",
    "Safety of ABM-1310 in Patients With Advanced Solid Tumors",
    "A Study of Live Biotherapeutic Product MRx0518 With Hypofractionated Radiation Therapy in Resectable Pancreatic Cancer",
    "A Study to Determine Safety and Tolerability of GMI-1359 in Subjects With HR+ Metastatic Breast Cancer",
    "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors",
    "Dendritic Cell Immunotherapy Plus Standard Treatment of Advanced Renal Cell Carcinoma",
    "ENB003 Plus Pembrolizumab Phase 1b / 2a in Solid Tumors",
    "SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma",
    "A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia",
    "A Study of BI-1206 in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (KEYNOTE-A04)",
    "Effects of Intravenous GC4419 on the Incidence and Severity of Esophagitis Due to Chemoradiotherapy for Lung Cancer",
    "Open-label Study of APX001 for Treatment of Patients With Invasive Mold Infections Caused by Aspergillus or Rare Molds",
    "First-in-Human Study of ICT01 in Patients With Advanced Cancer",
    "SX-682 Treatment in Subjects With Myelodysplastic Syndrome Who Had Disease Progression or Are Intolerant to Prior Therapy",
    "Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy",
    "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318 in Participants With Advanced Solid Tumors",
    "A Study of TAK-079 in Adults With Persistent / Chronic Primary Immune Thrombocytopenia",
    "Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects",
    "A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR) / Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation",
    "A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer",
    "Efficacy of EsoGuard on Samples Collected Using EsoCheck Versus EGD for the Diagnosis of BE",
    "Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C / KEYMAKER-U02)",
    "Study of a Triple Combination Therapy, DTRM-555, in Patients With R / R CLL or R / R Non-Hodgkin's Lymphomas",
    "Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis",
    "Vopratelimab (JTX-2011) Alone and in Combination With Anti-PD-1 or Anti-CTLA-4 in Subjects With Advanced and / or Refractory Solid Tumors",
    "TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia",
    "Determining Swallow Outcomes in Head & Neck Lymphedema Subjects Receiving Early Intervention With Pneumatic Compression",
    "A Study of APG-1252 in Patients With Myelofibrosis Who Progressed After Initial Therapy",
    "A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS",
    "Study of Lorlatinib In Participants With Anaplastic Lymphoma Kinase (ALK) -Positive NSCLC",
    "AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)",
    "Study of NEROFE, a Novel Hormone-Peptide in Adult Patients With Advanced MDS and AML",
    "SAR408701 in Combination With Ramucirumab in Pre-treated Patients With Non-Squamous Non-small Cell Lung Cancer (NSQ NSCLC)",
    "First-in-Human Study of XMT-1592 in Patients With Ovarian Cancer and NSCLC Likely to Express NaPi2b",
    "Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer",
    "REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy",
    "ZZ06 in Adult Patients With Advanced EGFR Positive Solid Tumor Malignancies",
    "SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer",
    "A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors",
    "Dose De-escalation Study of the PI3k Alpha / Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed / Refractory Indolent Lymphoma",
    "A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors",
    "NBE-002 in Patients With Advanced Solid Tumors",
    "A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed / Refractory Diffuse Large B-cell Lymphoma",
    "A Phase 1, Multi-Center, Safety, Dose Escalation, Pharmacokinetics of INV-1120 in Adult Patients Advanced Solid Tumors",
    "Study of Safety and Efficacy of Genome-edited Hematopoietic Stem and Progenitor Cells in Sickle Cell Disease (SCD)",
    "Evaluation of GLR2007 for Advanced Solid Tumors",
    "Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors",
    "Hemopurifier Plus Pembrolizumab in Head and Neck Cancer",
    "First in Human Study of M6223",
    "A Study of BLYG8824A in Participants With Locally Advanced or Metastatic Colorectal Cancer",
    "A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors",
    "Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed / Refractory Multiple Myeloma",
    "A Study of Ponatinib With Chemotherapy in Children, Teenagers, and Adults With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia",
    "Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R / R DLBCL or R / R CLL",
    "DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer",
    "A Dose-Escalation Study of SPYK04 in Patients With Locally Advanced or Metastatic Solid Tumors (With Expansion).",
    "A Study of ZN-c3 in Patients With Platinum-Resistant Ovarian Cancer",
    "Study of Sitravatinib, Nivolumab and Ipilimumab in Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies",
    "A Study of V937 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced / Metastatic Solid Tumors (V937-013)",
    "A Study to Assess the Safety, Tolerability, and Efficacy of IONIS-GHR-LRx Administered in Patients With Acromegaly",
    "A Study to Evaluate MEDI5752 and Axitinib in Subjects With Advanced Renal Cell Carcinoma",
    "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC (CARMEN-LC05)",
    "Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors",
    "A Drug-Drug Interaction Study to Evaluate the Effect of Ripretinib on the Pharmacokinetics of a CYP2C8 Probe Substrate in Patients With Advanced GIST",
    "A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat",
    "A Phase 1b / 2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer",
    "Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms",
    "Study of ECHELON ENDOPATH(TM) Staple Line Reinforcement",
    "To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)",
    "Study to Evaluate the Safety of a Gene and Cell Therapy Product in Participants With HIV That is Well-Controlled on Antiretroviral Therapy",
    "Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Solid Tumors Malignancies",
    "A Study to Evaluate Safety and Efficacy of Selinexor Versus Treatment of Physician's Choice in Participants With Previously Treated Myelofibrosis",
    "The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy (#HOPE4LIVER)",
    "A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment",
    "A Study of Fruquintinib in Combination With Tislelizumab in Advanced Triple Negative Breast Cancer",
    "A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer",
    "Study Assessing the Efficacy, Safety and PK of Alpelisib (BYL719) in Pediatric and Adult Patients With PIK3CA-related Overgrowth Spectrum",
    "A First-in-Human Study of CDK-002 (exoSTING) in Subjects With Advanced / Metastatic, Recurrent, Injectable Solid Tumors",
    "A Study of ALKS 4230 (Nemvaleukin Alfa) on the Tumor Microenvironment",
    "To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue",
    "NT-I7 in Combination With Nivolumab in Advanced Gastric, Gastro-Esophageal Junction or Esophageal Adenocarcinoma",
    "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer",
    "LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)",
    "Safety, Dose Tolerance, Pharmacokinetics, and Pharmacodynamics Study of CPX-POM in Patients With Advanced Solid Tumors",
    "Convection-enhanced Delivery of OS2966 for Patients With High-grade Glioma Undergoing a Surgical Resection",
    "Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan-hziy in Participants With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment",
    "A Study of TP-0184 to Treat Anemia in Adults With IPSS-R Low or Intermediate Risk MDS",
    "A Phase 3 Trial of Epcoritamab in R / R DLBCL",
    "To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and / or Fedratinib Monotherapy (LIMBER-213)",
    "Autologous Memory-like NK Cell Therapy With BHV-1100 (Formerly KP1237), Low Dose IL-2 in Multiple Myeloma Patients",
    "Phase 1 Trial of LVGN7409 (CD40 Agonist Antibody) as Single Agent and Combination Therapies in Advanced or Metastatic Malignancy",
    "A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline / TESARO-sponsored Niraparib Study",
    "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.",
    "DuraSorb® in Prosthetic Breast Reconstruction",
    "A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma",
    "A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors",
    "A Study of ION537 in Patients With Molecularly Selected Advanced Solid Tumors",
    "Phase 1b Study of AEVI-007 in Subjects With Relapsed or Refractory Multiple Myeloma",
    "Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies",
    "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation",
    "M1231 in Participants With Solid Tumors",
    "Evaluation of the Efficacy and Safety of ANB019 in the Treatment of Acneiform Rash",
    "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer",
    "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC",
    "A Study of BMS-986012 in Combination With Carboplatin, Etoposide, and Nivolumab as First-line Therapy in Extensive-stage Small Cell Lung Cancer",
    "First-in-Human Evaluation of GRN-300 in Subjects With Recurrent Ovarian, Primary Peritoneal, and Fallopian Tube Cancers.",
    "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide in Patients With Follicular Lymphoma After at Least One Line of Systemic Therapy",
    "DNX-2440 for Resectable Colorectal Liver Metastasis",
    "An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions",
    "A Dose Escalation and Cohort Expansion Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors or Non-Hodgkin Lymphoma",
    "Study of AMG 994 Monotherapy and AMG 994 and AMG 404 Combination Therapy in Participants With Advanced Solid Tumors",
    "Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)",
    "An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee",
    "A Study of Trastuzumab Emtansine in Combination With Atezolizumab or Placebo as a Treatment for Participants With Human Epidermal Growth Factor 2 (HER2)-Positive and Programmed Death-ligand 1 (PD-L1)-Positive Locally Advanced (LABC) or Metastatic Breast Cancer (MBC)",
    "Study of AZD2811 + Durvalumab in ES-SCLC",
    "Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of GS-3583 in Participants With Advanced Solid Tumors",
    "ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)",
    "Onvansertib in Combination With Nanoliposomal Irinotecan, Leucovorin, and Fluorouracil for Second-Line Treatment of Participants With Metastatic Pancreatic Ductal Adenocarcinoma",
    "A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)",
    "First in Human Study of UCT-01-097 in Participants With Advanced Solid Tumors",
    "A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme",
    "A Study of HMPL-306 in Advanced Hematological Malignancies With mIDH",
    "A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC)",
    "Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma",
    "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory NHL, RT, MM, T-PLL, Acute Leukemia (AML, ALL), MDS, MDS / MPN, and MF",
    "Phase 1a and Phase 2 Study for PK, PD, Safety and Preliminary Efficacy of ST-067",
    "Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia",
    "A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)",
    "Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1",
    "Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Percutaneously Accessible Advanced Solid Tumors (ATLAS-IT-05)",
    "A Study Evaluating an Advanced Pneumatic Compression Device Versus Usual Care for Treatment of Head and Neck Lymphedema",
    "Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease",
    "Study to Compare the Effects of Repeated Doses of an Investigational New Drug and a Placebo on Appetite in Advanced Cancer and Anorexia",
    "SARC038: Phase 2 Study of Regorafenib and Nivolumab in Osteosarcoma",
    "Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia",
    "A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread",
    "Phase Ib Study of Select Drug Combinations in Patients With Lower Risk MDS",
    "Pepinemab in Combination With Pembrolizumab in Advanced, Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",
    "Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients",
    "Nemvaleukin Alfa (ALKS 4230) Monotherapy in Patients With Advanced Cutaneous Melanoma or Advanced Mucosal Melanoma - ARTISTRY-6",
    "A Study of HC-5404-FU to Establish the Maximum Tolerated Dose (MTD)",
    "Study of ASP7517 Alone and With Pembrolizumab in Participants With Advanced Solid Tumors Expressing WT1 Antigen",
    "Registrational Trial to Compare Effectiveness of Two Digital Software Medical Devices as Adjunctive Oncology Treatment",
    "Capivasertib + Palbociclib + Fulvestrant for HR+ / HER2- Advanced Breast Cancer (CAPItello-292).",
    "Study of AZD0466 Monotherapy or in Combination in Patients With Advanced Haematological Malignancies",
    "A Phase 1 / 2 Study Evaluating MCLA-129, a Human Anti-EGFR and Anti-c-MET Bispecific Antibody, in Patients With Advanced NSCLC and Other Solid Tumors",
    "Study of KRT-232 or TL-895 in Janus Associated Kinase Inhibitor Treatment-Naïve Myelofibrosis",
    "First-in-human Study of M4076 in Advanced Solid Tumors (DDRiver Solid Tumors 410)",
    "Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma",
    "A Study of DT2216 in Relapsed / Refractory Malignancies",
    "Study of Liposomal Annamycin for the Treatment of Subjects With Soft-Tissue Sarcomas (STS) With Pulmonary Metastases",
    "Trilaciclib, a CDK 4 / 6 Inhibitor, in Patients With Advanced / Metastatic Bladder Cancer Receiving Chemotherapy Then Avelumab",
    "Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors",
    "SY-1425 Plus Venetoclax / Azacitidine in Participants With Newly Diagnosed AML",
    "A Study Evaluating the Safety, Pharmacokinetics, and Activity of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis",
    "A Study to Evaluate KIN-2787 in Subjects With BRAF Mutation Positive Solid Tumors",
    "Study of NGM707 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies",
    "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma",
    "ALPN-202 With PD-1 Inhibition in Advanced Malignancies",
    "Study of XB002 in Subjects With Solid Tumors",
    "Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC",
    "A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (Intrinsic)",
    "A Study of NB003 in Patients With Advanced Malignancies",
    "Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants",
    "A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer",
    "Study of Fosciclopirox in Patients With Relapsed / Refractory Acute Myeloid Leukemia",
    "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)",
    "A Study to Assess the Effect of Capivasertib on Midazolam in Patients With Advanced Solid Tumours",
    "Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin",
    "A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL)",
    "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)",
    "Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and / or Refractory Multiple Myeloma",
    "Double / Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors",
    "Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)",
    "Treatment of Milademetan Versus Trabectedin in Patient With Dedifferentiated Liposarcoma",
    "A Multiple Dose Study to Evaluate Safety, Tolerability, PK, and Efficacy of SER-155 in Adults Undergoing HSCT",
    "A Study for Oral SY-2101 for Participants With Acute Promyelocytic Leukemia",
    "Study of GDX012 in Patients With MRD Positive AML",
    "Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients",
    "XmAb®20717 Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer",
    "An Open-Label, Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed / Refractory Lymphomas",
    "Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed / Refractory HER2 Expressing Solid Tumors",
    "Study of Oral LOXO-338 in Patients With Advanced Blood Cancers",
    "A Study of NB004 in Patients With Advanced Solid Tumors",
    "A Study to Evaluate Safety and Efficacy of ACT001 and Anti-PD-1 in Patients With Surgically Accessible Recurrent Glioblastoma Multiforme",
    "Study of Vimseltinib for Tenosynovial Giant Cell Tumor",
    "A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol)",
    "A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer",
    "Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer",
    "Pediatric Precision Laboratory Advanced Neuroblastoma Therapy",
    "Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed / Refractory Hematologic Malignancies",
    "Pharmacokinetic Study of PM01183 in Combination With Irinotecan in Patients With Selected Solid Tumors",
    "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158 / KEYNOTE-158)",
    "Phase I Dose Escalation Study for VIP152 in Patients With Advanced Cancer",
    "Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed / Refractory Cancer Indications",
    "A Phase 1 Trial of a Novel XPO1 Inhibitor in Patients With Advanced Solid Tumors",
    "Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors",
    "INTense ExeRcise for surviVAL Among Men With Metastatic Prostate Cancer (INTERVAL - GAP4)",
    "An Open-label, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of GSK3326595 in Participants With Solid Tumors and Non-Hodgkin's Lymphoma",
    "Safety and Efficacy of MAK683 in Adult Patients With Advanced Malignancies",
    "Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer",
    "JSP191 Antibody Targeting Conditioning in SCID Patients",
    "Trial on Efficacy and Safety of Pritelivir Tablets for Treatment of Acyclovir-resistant Mucocutaneous HSV (Herpes Simplex Virus) Infections in Immunocompromised Subjects",
    "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed / Refractory Non-Hodgkin's Lymphomas",
    "PEN-866 in Patients With Advanced Solid Malignancies",
    "Ipilimumab and Nivolumab as Adjuvant Treatment of Mucosal Melanoma",
    "A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies",
    "An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment",
    "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer",
    "DM-CHOC-PEN Plus Radiation for Brain Tumors",
    "Phase I / II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL / SLL and NHL",
    "Effects of Hyperbaric Oxygen (HBO) on Blood Count Recovery After Autologous Hematopoietic Stem Cell (HSPC) Transplant for Multiple Myeloma",
    "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic or Inoperable Locally Advanced Triple-Negative Breast Cancer",
    "FS118 First in Human Study in Patients With Advanced Malignancies",
    "A Phase I Study of BTRC4017A in Participants With Locally Advanced or Metastatic HER2-Expressing Cancers",
    "This Study Aims to Find the Best Dose of BI 907828 in Patients With Different Types of Advanced Cancer (Solid Tumors)",
    "A Study of Atezolizumab (Anti-Pd-L1 Antibody) as Adjuvant Therapy After Definitive Local Therapy in Patients With High-Risk Locally Advanced Squamous Cell Carcinoma of the Head and Neck",
    "ONC201 in Recurrent or Metastatic Type II Endometrial Cancer Endometrial Cancer",
    "Phase II Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma",
    "Pharmacokinetic and Safety Study of MRX-2843 in Adults With Relapsed / Refractory Advanced and / or Metastatic Solid Tumors",
    "Oral TrkA Inhibitor VMD-928 for Treatment of Advanced Adult Solid Tumors or Lymphoma",
    "A Phase I / II Study of OBI-3424 in Subjects With Advanced Solid Tumors",
    "Study to Evaluate the Safety and Efficacy of a Combination of Favezelimab (MK-4280) and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies (MK-4280-003)",
    "Study of A166 in Patients With Relapsed / Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene",
    "A Trial for Treatment of Cancer Patients With Multiple Brain Metastases Undergoing Whole-Brain Radiotherapy",
    "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC",
    "A Safety and Tolerability Study of NC318 in Subjects With Advanced or Metastatic Solid Tumors",
    "Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.",
    "MGC018 With or Without MGA012 in Advanced Solid Tumors",
    "Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients",
    "A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "A Study to Evaluate the Efficacy and Safety of Anamorelin HCl for the Treatment of Malignancy Associated Weight Loss and Anorexia in Adult Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "A Study to Allow Continued Dosing and / or Follow-up of Patients Who Have Had Previous Exposure to Poziotinib",
    "Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma",
    "Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Subjects With Advanced HCC Who Have Not Received Previous Systemic Anticancer Therapy",
    "Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers",
    "A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCC",
    "Study to Evaluate Ibudilast and TMZ Combo Treatment in Newly Diagnosed and Recurrent Glioblastoma",
    "Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1 / ERBB Gene Fusions",
    "A Study to Assess the Efficacy and Safety of IMAB362 in Combination With Nab-Paclitaxel and Gemcitabine (Nab-P + GEM) as First Line Treatment in Subjects With Claudin 18.2 (CLDN18.2) Positive, Metastatic Pancreatic Adenocarcinoma",
    "A Study of TAK-954 to Treat Gastrointestinal Dysfunction in Adults After Surgery",
    "Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors",
    "Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC",
    "AMG 404 in Patients With Advanced Solid Tumors.",
    "Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed / Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia",
    "Venetoclax and Lintuzumab-Ac225 in AML Patients",
    "A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors",
    "Daratumumab Retreatment in Participants With Multiple Myeloma Who Have Been Previously Treated With Daratumumab",
    "First-in-Human Study of EOS100850 in Patients With Cancer",
    "Durvalumab or Placebo in Combination With Gemcitabine / Cisplatin in Patients With 1st Line Advanced Biliary Tract Cancer (TOPAZ-1)",
    "Study of the Combination of Binimetinib and Encorafenib in Adolescent Patients With Unresectable or Metastatic BRAF V600-mutant Melanoma",
    "Investigation of 2X-121 in Patients With Advanced Ovarian Cancer Selected by the 2X-121 DRP®",
    "Treatment Duration Increment and Pharmacodynamic Study of CX-4945 in Patients With Basal Cell Carcinoma (BCC)",
    "A Clinical Trial to Evaluate AZD7648 Alone and in Combination With Other Anti-cancer Agents in Patients With Advanced Cancers.",
    "Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Non-small Cell Lung Cancer (NSCLC), Ovarian Cancer, or Breast Cancer",
    "A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)",
    "Trial of DFP-14927 in Advanced Solid Tumors",
    "A Study in Patients With Different Types of Advanced Cancer (Solid Tumors) to Test Different Doses of BI 907828 in Combination With BI 754091 (Ezabenlimab) and 754111 or BI 907828 in Combination With BI 754091 (Ezabenlimab)",
    "Study of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed / Refractory Acute Myeloid Leukemia",
    "Study of ASTX295 in Patients With Solid Tumors With Wild-Type p53",
    "A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors",
    "A Study of FF-10850 Topotecan Liposome Injection in Advanced Solid Tumors",
    "Testosterone Replacement in Male Cancer Survivors With Fatigue and Low Testosterone",
    "GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma",
    "A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials",
    "A First-in-Humans Dose Finding Study for an Aryl Hydrocarbon Receptor Inhibitor (AhRi) in Patients With Advanced Cancer",
    "Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113",
    "Durvalumab Long-Term Safety and Efficacy Study",
    "GEN1042 Safety Trial and Anti-tumor Activity in Subjects With Malignant Solid Tumors",
    "PCI Treatment / Gemcitabine & Chemotherapy vs Chemotherapy Alone in Patients With Inoperable Extrahepatic Bile Duct Cancer",
    "Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment",
    "First-in-Human, Phase 1b / 2a Trial of a Multipeptide Therapeutic Vaccine in Patients With Progressive Glioblastoma",
    "A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has Spread",
    "A Study of Intratumoral / Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced / Metastatic or Recurrent Malignancies (V938-001)",
    "A Study to Find the Best Dose of BI 1387446 Alone or in Combination With Ezabenlimab (BI 754091) in Patients With Different Types of Advanced or Metastatic Cancer (Solid Tumors)",
    "Study to Compare the Effects of Drug Darolutamide and Drug Enzalutamide on Physical Function, Including Balance and Daily Activity, in Patients With Castration-resistant Prostate Cancer (CRPC)",
    "Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Subjects",
    "177Lu-DTPA-Omburtamab Radioimmunotherapy for Recurrent or Refractory Medulloblastoma",
    "A Study of Oral TP-3654 in Patients With Myelofibrosis",
    "An Open-label Study of ALPN-202 in Subjects With Advanced Malignancies",
    "A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABSK-021 in Patients With Advanced Solid Tumor",
    "Study of Alpelisib (BYL719) in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy in Patients With HER2-positive Advanced Breast Cancer With a PIK3CA Mutation",
    "A Study of ZW25 (Zanidatamab) With Palbociclib Plus Fulvestrant in Patients With HER2+ / HR+ Advanced Breast Cancer",
    "Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced / Metastatic Solid Tumors",
    "Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma (NHL)",
    "A Safety and Efficacy Study Evaluating CTX120 in Subjects With Relapsed or Refractory Multiple Myeloma",
    "An Open-Label Dose-Escalation Study to Evaluate XmAb24306 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors",
    "GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC",
    "A First-in-human Study of Multiple Doses of BB-1701 in Subjects With Locally Advanced / Metastatic HER2 Positive Solid Tumors",
    "APG-2575 Single Agent or in Combination With Ibrutinib or Rituximab in Patients With Waldenström Macroglobulinemia",
    "Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma",
    "DRAGON 1- Training, Accreditation, Implementation and Safety Evaluation of Combined PVE / HVE",
    "Study of CRX100 in Patients With Advanced Solid Tumors",
    "Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced / Metastatic Solid Tumors",
    "Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+ / HER2- Breast Cancer",
    "A Study of IMC-002 in Subjects With Metastatic or Locally Advanced Solid Tumors and Relapsed or Refractory Lymphomas",
    "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors",
    "The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC",
    "COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies",
    "Post-Surgical Stereotactic Radiotherapy (SRT) Versus GammaTile",
    "A Study of AK104, a PD-1 / CTLA-4 Bispecific Antibody in Subjects With Recurrent / Metastatic Cervical Cancer",
    "PRO-MERIT (Prostate Cancer Messenger RNA Immunotherapy)",
    "Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma",
    "Domatinostat in Combination With Avelumab in Patients With Advanced Merkel Cell Carcinoma Progressing on Anti-PD-(L)1",
    "INO-3107 With Electroporation (EP) in Participants With HPV-6- and / or HPV-11-Associated Recurrent Respiratory Papillomatosis (RRP)",
    "First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL",
    "Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer",
    "A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed / Refractory Diffuse Large B-Cell Lymphoma",
    "First In Human Study With ABBV-CLS-579 When Given Alone Or In Combination With Programmed Cell Death-1 Inhibitor In Participants With Locally Advanced Or Metastatic Tumors",
    "Safety and Efficacy Study of SAR442720 in Combination With Pembrolizumab in Advanced Malignancies",
    "InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic Patients With COVID-19 Infection ( ILIAD-7-US-O )",
    "A Study to Test Different Doses of BI 764532 in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for Delta-Like Ligand 3 (DLL3).",
    "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer",
    "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma",
    "Descartes-11 Consolidation Treatment in Patients With High-Risk Multiple Myeloma Who Have Residual Disease After Induction Therapy",
    "A Study of the PD-L1xCD27 Bispecific Antibody CDX-527 in Patients With Advanced Malignancies",
    "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors",
    "A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013 / E7080)",
    "A Study of the Safety and Tolerance of CAN04 in Combination With Pembrolizumab in Subjects With Solid Tumors",
    "BNT151 as a Monotherapy and in Combination With Other Anti-cancer Agents in Patients With Solid Tumors",
    "Efficacy and Safety of Olaparib (MK-7339) With or Without Bevacizumab Compared to Bevacizumab With a Fluoropyrimidine in Unresectable or Metastatic Colorectal Cancer (CRC) (MK-7339-003 / LYNK-003)",
    "Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303 / InterAACT 2).",
    "A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer",
    "Trial of ZN-A-1041 Enteric Capsules in Patients With HER2-Positive Advanced Solid Tumors",
    "A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With T-PLL",
    "Safety and Efficacy Study Of CFI-402411 in Subjects With Advanced Solid Malignancies",
    "Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib",
    "Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma",
    "Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD1-refractory / Relapsed, Unresectable Stage III or IV Melanoma",
    "A Study of PRT1419 in Patients With Relapsed / Refractory Hematologic Malignancies",
    "Ravulizumab in Thrombotic Microangiopathy After Hematopoietic Stem Cell Transplant",
    "Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma",
    "Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)",
    "A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer",
    "A Study of GFH009 in Patients With Hematologic Malignancies",
    "A Study of TNB-486 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma",
    "Derazantinib Alone or in Combination With Paclitaxel, Ramucirumab or Atezolizumab in Gastric Adenocarcinoma",
    "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC",
    "Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma",
    "A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin / Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin / Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05)",
    "A Study of FT-4202 in Adults and Adolescents With Sickle Cell Disease (HIBISCUS)",
    "Thrombosomes® in Bleeding Thrombocytopenic Patients Study",
    "Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC",
    "Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer",
    "KRT-232 in Combination With TL-895 for the Treatment of R / R MF and KRT-232 for the Treatment of JAKi Intolerant MF",
    "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies",
    "A Study of JNJ-69086420, an Actinium-225-Labeled Antibody Targeting Human Kallikrein-2 (hK2) for Advanced Prostate Cancer",
    "Dose-escalation Study of Safety of PBCAR19B in Participants With CD19-expressing Malignancies",
    "BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors",
    "Encorafenib and Binimetinib Plus Pembrolizumab Versus Pembrolizumab for BRAF V600E / K Positive Melanoma",
    "A Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder",
    "SAR408701 in Patients With CEACAM5-positive Advanced Solid Tumors",
    "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors",
    "ARX517 in Subjects With Advanced Solid Tumor",
    "Efficacy and Safety of Lenvatinib (E7080 / MK-7902) Plus Pembrolizumab (MK-3475) Plus Chemotherapy in Participants With Advanced / Metastatic Gastroesophageal Adenocarcinoma (MK-7902-015 / E7080-G000-321 / LEAP-015)",
    "EP0057 in Combination With Olaparib in Advanced Ovarian Cancer",
    "A Dose Escalation / Expansion Study of ERAS-601 in Patients With Advanced or Metastatic Solid Tumors",
    "Patritumab Deruxtecan in Combination With Osimertinib in Subjects With Locally Advanced or Metastatic EGFR-mutated Non-Small Cell Lung Cancer",
    "A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies",
    "Study of TJ210001 Administered in Subjects With Relapsed or Refractory Advanced Solid Tumors",
    "CAB-AXL-ADC Safety and Efficacy Study in Adults With NSCLC",
    "Safety, Tolerability, and Pharmacokinetics of CAL056 Mesylate in Patients With Resistant or Refractory Solid Tumors",
    "Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",
    "A Study of U3-1402 in Subjects With Metastatic Breast Cancer",
    "TH1902 in Patients With Advanced Solid Tumors",
    "A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors",
    "Dose Escalation Trial of BNT152+153 in Patients With Cancer",
    "A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors",
    "A Study of ADI-001 in B Cell Malignancies",
    "Study of TT-00420 Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors",
    "AGENT-797 in Patients With Relapsed / Refractory Multiple Myeloma",
    "Study to Assess the Safety and Tolerability of CFT7455 in Relapsed / Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma",
    "TAS-117 in Patients With Advanced Solid Tumors Harboring Germline PTEN Mutations",
    "A Study of BXQ-350 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) or Diffuse Midline Glioma (DMG)",
    "Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.",
    "Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia",
    "Study Evaluating the Safety of KITE-222 in Participants With Relapsed / Refractory Acute Myeloid Leukemia",
    "PF-07284892 in Participants With Advanced Solid Tumors",
    "Study to Evaluate Adverse Events and Change in Disease Activity When Intravenous (IV) Infusion of ABBV-927 is Administered in Combination With IV Modified FOLFIRINOX (mFFX) With or Without IV Budigalimab Compared to mFFX in Adult Participants With Untreated Pancreatic Cancer Metastasis",
    "A Study of JNJ-75276617 in Participants With Acute Leukemia",
    "A Study of ZN-c3 in Women With Recurrent or Persistent Uterine Serous Carcinoma",
    "Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC",
    "A Study of ZN-c3 in Combination With Gemcitabine in Subjects With Osteosarcoma",
    "Study of Magrolimab Combination Therapy in Participants With Head and Neck Squamous Cell Carcinoma",
    "A Study of the Safety and PK of PCS6422 (Eniluracil) With Capecitabine in Patients With Advanced, Refractory GI Tract Tumors",
    "A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy",
    "Study of Sitravatinib With or Without Other Anticancer Therapies Receiving Clinical Benefit From Parent Study",
    "A Safety, Tolerability and PK Study of DCC-3116 in Patients With RAS or RAF Mutant Advanced or Metastatic Solid Tumors.",
    "A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab in Participants With Advanced Solid Tumors",
    "Study of TJ033721 in Subjects With Advanced or Metastatic Solid Tumors",
    "Study of PBI-200 in Subjects With NTRK-Fusion-Positive Solid Tumors",
    "CMP-001 in Combination With IV PD-1-Blocking Antibody in Subjects With Certain Types of Advanced or Metastatic Cancer",
    "Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma",
    "Study to Evaluate Safety and Tolerability of CC-91633 (BMS-986397) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-Risk Myelodysplastic Syndromes",
    "A Study of ERAS-007 in Patients With Advanced Non-Small-Cell Lung Cancer",
    "A Study Evaluating the Efficacy and Safety of Adjuvant Giredestrant Compared With Physician's Choice of Adjuvant Endocrine Monotherapy in Participants With Estrogen Receptor-Positive, HER2-Negative Early Breast Cancer (lidERA Breast Cancer)",
    "Phase 1b / 2 Study of Futibatinib in Combination With Binimetinib in Patients With Advanced KRAS Mutant Cancer",
    "A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis",
    "A Study to Investigate Fadraciclib (CYC065), in Subjects With Advanced Solid Tumors and Lymphoma",
    "A Study of SEA-CD40 Given With Other Drugs in Cancers",
    "(Apex) CGT9486 in Patients With Advanced Systemic Mastocytosis",
    "A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer",
    "ITIL-168 in Advanced Melanoma",
    "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors",
    "A Study to Evaluate the Safety, Tolerability and Preliminary Anti-tumor Activity of NT-I7 (Efineptakin Alfa) Post-Tisagenlecleucel (Kymriah®) in Relapsed / Refractory Large B-cell Lymphoma Subjects",
    "A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands",
    "A Study of APTO-253 in Patients With Relapsed or Refractory AML or MDS",
    "Phase 1 / 2a / 3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)",
    "Safety and Efficacy Study in Recurrent Grade IV Glioma",
    "Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",
    "Pivotal Study of MRI-guided Transurethral Ultrasound Ablation in Patients With Localized Prostate Cancer",
    "Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and / or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors",
    "A Study of PTX-200 (Triciribine) Plus Cytarabine in Refractory or Relapsed Acute Leukemia",
    "Study to Assess Safety, Tolerability and Clinical Activity of BGB-290 in Combination With Temozolomide (TMZ) in Participants With Locally Advanced or Metastatic Solid Tumors",
    "Trial of Intravesical Measles Virotherapy in Patients With Bladder Cancer Who Are Undergoing Radical Cystectomy",
    "A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)",
    "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors, Colorectal, and Breast Cancer",
    "131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System / Leptomeningeal Metastases",
    "CD19 / 22 CAR T Cells (AUTO3) for the Treatment of Diffuse Large B Cell Lymphoma",
    "A Study of PLX2853 in Advanced Malignancies.",
    "A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors",
    "ADAPT-BLADDER: Modern Immunotherapy in BCG-Relapsing Urothelial Carcinoma of the Bladder",
    "Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer",
    "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC",
    "Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies",
    "A Phase 1 Dose-escalation Study of FF-10832 for Treatment of Solid Tumors",
    "TCR-engineered T Cells in Solid Tumors: IMA202-101",
    "A First-in-Human Study of D-0502 Alone and in Combination With Palbociclib in Women With Advanced or Metastatic ER-Positive and HER2-Negative Breast Cancer",
    "QUILT 2.023: A Study of N-803 in Combination With Current Standard of Care vs Standard of Care as First-Line Treatment for Patients With Stage 3 or 4 NSCLC.",
    "Assessment of Safety and Feasibility of ExAblate Blood-Brain Barrier (BBB) Disruption",
    "Study of Oraxol and Pembrolizumab in Subjects With Advanced Solid Tumors",
    "This Study Aims to Find and Test a Safe Dose of BI 905677 in Patients With Different Types of Cancer (Solid Tumours)",
    "Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients",
    "Study of AZD9833 Alone or in Combination in Women With Advanced Breast Cancer.",
    "Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors",
    "Treatment With Nivolumab and Ipilimumab or Nivolumab Alone According to the Percentage of Tumoral CD8 Cells in Advanced Metastatic Cancer",
    "A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as First-line Treatment of Subjects With Claudin (CLDN) 18.2-Positive, HER2-Negative, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",
    "Grapiprant and Pembrolizumab in Patients With Advanced or Progressive MSS Colorectal Cancer",
    "TCR-engineered T Cells in Solid Tumors",
    "Platform Trial Evaluating Safety and Efficacy of BI 754091 Anti- PD-1 Based Combination Therapies in PD-(L)1 naïve and PD- (L)1 Pretreated Patient Populations With Advanced / Metastatic Solid Tumours.",
    "REVEAL 2 Trial (Evaluation of VGX-3100 and Electroporation for the Treatment of Cervical HSIL)",
    "Study of Avelumab-M3814 Combinations",
    "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer",
    "Ablation Confirmation Study",
    "A Study of PTC596 (Unesbulin) in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)",
    "A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors",
    "A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of wAIHA",
    "A Study in Patients Previously Enrolled in a Genentech and / or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study",
    "A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced / Metastatic Solid Tumors",
    "Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations",
    "A Trial Evaluating TG4050 in Ovarian Carcinoma.",
    "A Study Evaluating Safety and Efficacy of Niraparib in Patients With Previously Treated Metastatic Esophageal / Gastroesophageal Junction / Proximal Gastric Adenocarcinoma",
    "Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
    "A Dose Escalation Study Of PF-06939999 In Participants With Advanced Or Metastatic Solid Tumors",
    "A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer",
    "Liposomal Irinotecan in Combination With Oxaliplatin, Leucovorin, and 5-fluorouracil for Patients With Locally Advanced Pancreatic Carcinoma:",
    "Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)",
    "A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors",
    "Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors.",
    "A Pivotal Study of Safety and Effectiveness of NanoKnife IRE for Stage 3 Pancreatic Cancer",
    "A Study to Evaluate Immune Biomarker Modulation in Response to VTX-2337 in Combination With an Anti- PD-1 Inhibitor in Head and Neck Cancer",
    "A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.",
    "A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Rituximab in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R / R NHL)",
    "A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma",
    "An Investigational Immunotherapy Study of BMS-986301 Alone or in Combination With Nivolumab, and Ipilimumab in Participants With Advanced Solid Cancers",
    "Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Subjects With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax",
    "RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome",
    "67Cu-SARTATE™ Peptide Receptor Radionuclide Therapy Administered to Pediatric Patients With High-Risk, Relapsed, Refractory Neuroblastoma",
    "A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery",
    "Dose-escalation Study of Safety of PBCAR20A in Subjects With r / r NHL or r / r CLL / SLL",
    "DS8201a and Pembrolizumab in Participants With Locally Advanced / Metastatic Breast or Non-Small Cell Lung Cancer",
    "A Phase 1 Open-Label, Dose Escalation Study to Determine the Optimal Dose, Safety, and Activity of AAV2hAQP1 in Subjects With Radiation-Induced Parotid Gland Hypofunction and Xerostomia",
    "A First-in-Human, Phase 1 Study of JAB-3312 in Adult Patients With Advanced Solid Tumors",
    "Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV)",
    "Phase 2 Study of Amcenestrant (SAR439859) Versus Physician's Choice in Locally Advanced or Metastatic ER-positive Breast Cancer",
    "Safety and Preliminary Efficacy of OBT076 in Recurrent / Metastatic CD205+ Solid Tumors and HER2-neg Breast Cancer",
    "SARC037: A Phase I Study to Evaluate the Safety of Trabectedin in Combination With Irinotecan in Ewing Sarcoma Patients",
    "Phase 1b / 2 Study of Rivoceranib and Trifluridine / Tipiracil for Metastatic Colorectal Cancer",
    "First-in-human Study of CCW702 in Patients With Metastatic Castration Resistant Prostate Cancer",
    "Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma",
    "Evaluating Safety and Efficacy of SB 11285 Alone and in Combination With Atezolizumab in Patients With Advanced Solid Tumors",
    "Phase 1 Study of SQ3370 in Patients With Advanced Solid Tumors",
    "A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation)",
    "Study of AMG 199 in Subjects With MUC17-Positive Solid Tumors Including Gastric, Gastroesophageal Junction, Colorectal, and Pancreatic Cancers",
    "A Study to Find a Safe and Effective Dose of BI 905711 in Patients With Advanced Gastrointestinal Cancer",
    "Dose-escalation Study of Oral Administration of LP-108 in Patients With Relapsed or Refractory Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)",
    "Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC",
    "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Desmoplastic Small Round Cell Tumor",
    "CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma",
    "A First in Human Study of BAY2701439 to Look at Safety, How the Body Absorbs, Distributes and Excretes the Drug, and How Well the Drug Works in Participants With Advanced Cancer Expressing the HER2 Protein",
    "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable / Metastatic Solid Tumors, Refractory to Standard Therapies",
    "Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL",
    "Master Protocol for the Phase 1 Study of Cell Therapies in Multiple Myeloma",
    "A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML)",
    "Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma",
    "A Phase 1a / b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma",
    "A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome",
    "Study of Safety, Pharmacokinetics, and Antitumor Activity of BGB-3245 in Participants With Advanced or Refractory Tumors",
    "Study of AMG 910 in Subjects With CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma",
    "A Phase I / Ib Study of NIZ985 Alone and in Combination With Spartalizumab",
    "Antigen-specific T Cell Therapy for AML or MDS Patients With Relapsed Disease After Allo-HCT",
    "PK and Dose Escalation and Expansion Study of DST-2970",
    "A Study of Select Drug Combinations in Adult Patients With Advanced / Metastatic BRAF V600 Colorectal Cancer",
    "Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A / KEYMAKER-U02)",
    "Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B / KEYMAKER-U02)",
    "Tislelizumab in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma",
    "The WWRD Study: AVM0703 for Treatment of Leukemia or Lymphoma",
    "Study of SRF617 in Patients With Advanced Solid Tumors",
    "Phase 1a / 1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid Tumors",
    "A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers",
    "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas",
    "Study of AMG 256 in Adult Subjects With Advanced Solid Tumors",
    "A Study to Find the Maximum Tolerated Dose (MTD) of SYN125 in People With Solid Tumors and the MTD of SYN125 With a Fixed Dose of SYN004 in People With Cancer of the Internal or External Lining of the Body.",
    "Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies",
    "Ph1b / 2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2+ Gastric Cancer (DESTINY-Gastric03)",
    "Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma",
    "Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)",
    "Evaluate the Safety and Clinical Activity of HH2853",
    "Claudin18.2 CAR-T (CT041) in Patients With Gastric or Pancreatic Cancer",
    "A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors",
    "Oral EPI-7386 in Patients With Metastatic Castration-Resistant Prostate Cancer",
    "AN0025 and Pembrolizumab Combination in Advanced Solid Tumors",
    "Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors",
    "Study of CG0070 Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin",
    "Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants With Advanced / Metastatic Non-small Cell Lung Cancer",
    "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers",
    "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer",
    "A Study of MRG002 in Patients With HER2-Positive Advanced Solid Tumors and Locally Advanced or Metastatic Gastric / Gastroesophageal Junction (GEJ) Cancer",
    "First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours",
    "A Dose Escalation / Expansion Study of Oral OP-1250 in Subjects With Advanced and / or Metastatic HR+, HER2- Breast Cancer",
    "Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)",
    "Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)",
    "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)",
    "Instylla HES Hypervascular Tumor Pivotal Study",
    "A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1",
    "A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread",
    "The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy",
    "To Assess the Safety and Tolerability of INCB000928 in Participants With Myelodysplastic Syndromes or Multiple Myeloma.",
    "Study to Evaluate D-1553 in Subjects With Solid Tumors",
    "Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors.",
    "TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy",
    "Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma",
    "Datopotamab Deruxtecan (Dato-DXd) in Combination With Durvalumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung04)",
    "Tomivosertib With Anti-PD-(L)1 in Subjects With NSCLC. 1st Line Therapy or Progressing on 1st Line Anti-PD-(L)1 Therapy",
    "First-in-Human Study of IMGC936 in Patients With Advanced Solid Tumors",
    "NKX101, Intravenous Allogeneic Engineered Natural Killer Cells, in Adults With AML or MDS",
    "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013 / KEYLYNK-013)",
    "REGN7075 in Combination With Cemiplimab in Adult Participants With Advanced Solid Tumors",
    "FT819 in Subjects With B-cell Malignancies",
    "AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer.",
    "Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer",
    "A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed / Refractory B Cell Non-Hodgkin Lymphoma",
    "A Study of T-DXd for the Treatment of Solid Tumors Harboring HER2 Activating Mutations",
    "A Study of TAR-200 in Combination With Cetrelimab, TAR-200 Alone, or Cetrelimab Alone in Participants With Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Intravesical Bacillus Calmette-Guerin Who Are Ineligible for or Elected Not to Undergo Radical Cystectomy",
    "FS120 First in Human Study in Patients With Advanced Malignancies",
    "Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants",
    "NL-201 in Patients With Relapsed or Refractory Cancer",
    "A Study of Atezolizumab Plus Tiragolumab and Atezolizumab Plus Placebo as First-Line Treatment in Participants With Recurrent / Metastatic PD-L1 Positive Squamous Cell Carcinoma of the Head and Neck",
    "Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation",
    "AB-101 as Monotherapy and In Combination With Rituximab in Patients With Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma",
    "Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)",
    "Study of Mana 312 (Multi Tumor-Associated Antigen T Cells) in Adults With AML / MDS After HSCT",
    "Study of RET Inhibitor TAS0953 / HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities",
    "177Lu-PSMA-617 vs. Androgen Receptor-directed Therapy in the Treatment of Progressive Metastatic Castrate Resistant Prostate Cancer",
    "Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D / KEYMAKER-U02)",
    "A Study of CFI-400945 With or Without Azacitidine or Decitabine in Patients With AML, MDS or CMML",
    "Phase III Study of Trifluridine / Tipiracil in Combination With Bevacizumab vs Trifluridine / Tipiracil Single Agent in Patients With Refractory Metastatic Colorectal Cancer",
    "Safety and Efficacy of Coformulated Pembrolizumab / Quavonlimab (MK-1308A) in Combination With Lenvatinib (E7080 / MK-7902) in Advanced Hepatocellular Carcinoma (MK-1308A-004)",
    "Trastuzumab Deruxtecan in Participants With HER2-overexpressing Advanced or Metastatic Colorectal Cancer",
    "Dose Escalation of RMC-5552 Monotherapy in Relapsed / Refractory Solid Tumors",
    "Study of Magrolimab Combinations in Participants With Myeloid Malignancies",
    "A Study of TransCon TLR7 / 8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors",
    "Trilaciclib, a CDK 4 / 6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)",
    "A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer",
    "A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Atezolizumab in Patients With NRAS-mutant Advanced Melanoma.",
    "A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)",
    "A Study of TPX-0131, a Novel Oral ALK Tyrosine Kinase Inhibitor, in Patients With ALK+ Advanced or Metastatic NSCLC",
    "Safety and Efficacy of bb2121 (Ide-cel) Combinations in Multiple Myeloma",
    "A Study of MPT-0118 in Subjects With Advanced or Metastatic Refractory Solid Tumors",
    "A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers",
    "HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide",
    "Belzutifan / MK-6482 for the Treatment of Advanced Pheochromocytoma / Paraganglioma (PPGL) or Pancreatic Neuroendocrine Tumor (pNET) (MK-6482-015)",
    "A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE)",
    "Study of RP-3500 With Niraparib or Olaparib in Advanced Solid Tumors",
    "Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Pancreatic Adenocarcinoma",
    "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation",
    "A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer",
    "A Study of Brentuximab Vedotin With Hodgkin Lymphoma (HL) and CD30-expressing Peripheral T-cell Lymphoma (PTCL)",
    "Study to Investigate the Safety and Tolerability of Odronextamab in Patients With CD20+ B-Cell Malignancies",
    "A Study of PLX8394 as a Single Agent in Patients With Advanced Unresectable Solid Tumors",
    "A Study to Evaluate the Safety and Tolerability of ETC-1922159 as a Single Agent and in Combination With Pembrolizumab in Advanced Solid Tumours",
    "Oral ONC201 in Recurrent GBM, H3 K27M Glioma, and Midline Glioma",
    "A Multi-Center, Open-Label Study of Surufatinib (HMPL-012) in Patients With Advanced Solid Tumors",
    "PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma",
    "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma",
    "Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors",
    "A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma Following Initial Therapy",
    "SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab",
    "TCR-engineered T Cells in Solid Tumors (ACTengine IMA201-101)",
    "Trial of H3B-6545, in Women With Locally Advanced or Metastatic Estrogen Receptor-positive, HER2 Negative Breast Cancer",
    "Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant",
    "A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma",
    "PRS-343 in HER2-Positive Solid Tumors",
    "A Study Evaluating the Safety and Pharmacokinetics of Orally Administered SM08502 in Subjects With Advanced Solid Tumors",
    "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab",
    "A Study of DSP-0509 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile",
    "ONC201 in Pediatric H3 K27M Gliomas",
    "Safety and Efficacy of Efavaleukin Alfa in Subjects With Steroid Refractory Chronic Graft Versus Host Disease",
    "A Safety Study of NUC-3373 in Combination With Standard Agents Used in Colorectal Cancer Treatment",
    "Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC",
    "Brief Title: Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC / UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer Acronym: CANOPY-A",
    "An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread",
    "Dose Escalation Study of CLR 131 in Children, Adolescents, and Young Adults With Relapsed or Refractory Malignant Tumors Including But Not Limited to Neuroblastoma, Rhabdomyosarcoma, Ewings Sarcoma, and Osteosarcoma",
    "A Study Of The Selective PKC-β Inhibitor MS- 553",
    "A Global Study to Assess the Effects of Osimertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer (LAURA)",
    "Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB / C Melanoma Patients",
    "NBTXR3 Activated by Radiotherapy for Patients With Advanced Cancers Treated With An Anti-PD-1 Therapy",
    "A Phase 1b Study of PTC596 in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma and High Grade Glioma",
    "Study of ADCT-301 in Patients With Selected Advanced Solid Tumors",
    "A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed / Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients",
    "Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer",
    "Efficacy and Safety Study of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low or Intermediate Risk Myelodysplastic Syndromes (MDS) in ESA Naïve Subjects Who Require Red Blood Cell Transfusions",
    "A Phase 1 Study to Evaluate FN-1501 Monotherapy in Patients With Advanced Solid Tumors and R / R AML",
    "Study of Ibrutinib in Combination With Revlimid / Dexamethasone in Relapsed / Refractory Multiple Myeloma",
    "Hepatic Impairment Study for Lorlatinib in Cancer Patients",
    "Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors",
    "Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody Drug Conjugate in Ovarian & Endometrial Cancers",
    "A Safety Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib With Concomitant Luspatercept for Subjects With Anemia",
    "MGD019 DART® Protein in Unresectable / Metastatic Cancer",
    "Study of PTC299 (Emvododstat) in Relapsed / Refractory Acute Leukemias",
    "Trial to Evaluate the Safety and Pharmacokinetics of HMPL-689 in Patients With Lymphomas",
    "Study of INBRX-105 in Patients With Solid Tumors",
    "Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of ABBV-151 as a Single Agent and in Combination With ABBV-181 in Participants With Locally Advanced or Metastatic Solid Tumors",
    "Onvansertib in Combination With FOLFIRI and Bevacizumab for Second Line Treatment of Metastatic Colorectal Cancer Patients With a Kras Mutation",
    "FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors",
    "First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)",
    "Study of CTX-471 in Patients Post PD-1 / PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies",
    "Assess the Anti-Tumor Activity and Safety of Odronextamab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
    "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-927 With ABBV-368, Budigalimab (ABBV-181) and / or Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors",
    "A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",
    "A Study of Bispecific Antibody MCLA-145 in Patients With Advanced or Metastatic Malignancies",
    "Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866 / KEYNOTE-866)",
    "A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma",
    "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ / 11 Mutations or PRKC Fusions",
    "A Dose Escalation Study Evaluating CPI-818 in Relapsed / Refractory T-Cell Lymphoma",
    "This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.",
    "Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET",
    "A Study of PSB205 in Subjects With Advanced Solid Tumors",
    "An Investigational Immunotherapy Study of BMS-986288 Alone and in Combination With Nivolumab in Advanced Solid Cancers",
    "A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR) / Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)",
    "Study of Lenalidomide / Ixazomib / Dexamethasone / Daratumumab in Transplant-Ineligible Patients With Newly Diagnosed MM",
    "Safety and Efficacy Study of IMSA101 in Refractory Malignancies",
    "A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors",
    "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
    "Derazantinib and Atezolizumab in Patients With Urothelial Cancer",
    "Study of BGB-A1217 in Combination With Tislelizumab in Advanced Solid Tumors",
    "A Study of PRT811 in Participants With Advanced Solid Tumors, CNS Lymphoma and Gliomas",
    "Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements",
    "A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy",
    "A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)",
    "Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.",
    "Anti-CD137 Monoclonal Antibody in Patients With Advanced Cancer",
    "Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and / or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007 / KEYLYNK-007)",
    "Study Evaluating Safety and Efficacy of UCART Targeting CS1 in Patients With Relapsed / Refractory Multiple Myeloma (MELANI-01)",
    "Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.",
    "A Study of ZN-c3 in Participants With Solid Tumors",
    "KEYMAKER-U01 Substudy 2: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Treatment-naïve Participants With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Positive Advanced Non-small Cell Lung Cancer (NSCLC ) (MK-3475-01B / KEYMAKER-U01B)",
    "KEYMAKER-U01 Substudy 3: Efficacy and Safety Study of Pembrolizumab (MK-3475) When Used With Investigational Agents in Participants With Advanced Non-small Cell Lung Cancer (NSCLC), Previously Treated With Anti-programmed Cell Death Receptor Ligand 1 (PD-L1) Therapy (MK-3475-01C / KEYMAKER-U01C)",
    "Study of Tazemetostat With Enzalutamide or Abiraterone / Prednisone in Subjects With Castration Resistant Prostate Cancer Who Have Not Received Chemotherapy",
    "Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression",
    "A Study Evaluating the Efficacy and Safety of Inavolisib + Palbociclib + Fulvestrant vs Placebo + Palbociclib + Fulvestrant in Patients With PIK3CA-Mutant, Hormone Receptor-Positive, Her2-Negative, Locally Advanced or Metastatic Breast Cancer",
    "A Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-368 Plus Tilsotolimod and Other Therapy Combinations in Participants With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma",
    "Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)",
    "9-ING-41 in Pediatric Patients With Refractory Malignancies.",
    "An Extension Study MRI / US Fusion Imaging and Biopsy in Combination With Nanoparticle Directed Focal Therapy for Ablation of Prostate Tissue",
    "A Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of KD033 in Subjects With Metastatic or Locally Advanced Solid Tumors.",
    "Study of GNX102 in Patients With Advanced Solid Tumors",
    "RLY-1971 in Subjects With Advanced or Metastatic Solid Tumors",
    "IMG-7289 in Patients With Essential Thrombocythemia",
    "A Trial of ZL-1201 in Subjects With Advanced Cancer",
    "Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL",
    "Expanded Access of Omidubicel, for Allogeneic Transplantation in Patients With Hematological Malignancies",
    "Study to Evaluate Monotherapy and Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer",
    "Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV",
    "A Study of Mavorixafor in Combination With Ibrutinib in Participants With Waldenstrom's Macroglobulinemia (WM) Whose Tumors Express Mutations in MYD88 and CXCR4",
    "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",
    "An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors",
    "NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors",
    "A Study of Osimertinib With or Without Chemotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer",
    "A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors",
    "Study of Efficacy and Safety of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)",
    "A Study of ION251 Administered to Patients With Relapsed / Refractory Multiple Myeloma",
    "A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent / Metastatic HPV16 Positive OPC",
    "Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CC-94676 in Subjects With Metastatic Castration-Resistant Prostate Cancer",
    "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)",
    "A Study of DSP107 Alone and in Combination With Atezolizumab for Patients With Advanced Solid Tumors",
    "CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies",
    "Safety and Tolerability Study of Oral ABBV-744 Tablet Alone or in Combination With Oral Ruxolitinib Tablet or Oral Navitoclax Tablet in Adult Participants With Myelofibrosis",
    "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors",
    "A Study to Evaluate NT219 Alone and in Combination With ERBITUX® (Cetuximab) in Adults With Advanced Solid Tumors and Head and Neck Cancer",
    "Phase 1 Study of CI-8993 Anti-VISTA Antibody in Patients With Advanced Solid Tumor Malignancies",
    "Phase 1 / 2 Study of SBRT With or Without GC4711 for NSCLC",
    "A Study to Evaluate U3-1402 in Subjects With Advanced or Metastatic Colorectal Cancer",
    "Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T",
    "A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10 / KEYNOTE B10)",
    "Study of ET140203 T Cells in Adults With Advanced Hepatocellular Carcinoma (ARYA-1)",
    "Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed / Refractory Non-Hodgkin Lymphoma",
    "A Trial of AMXI-5001 for Treatment in Patients With Advanced Malignancies",
    "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Solid Tumors (MK-2140-002)",
    "Study of Tepotinib Combined With Cetuximab in Participants With Left-Sided RAS / BRAF Wild Type Metastatic Colorectal Cancer (PERSPECTIVE)",
    "Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL",
    "Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and / or LAGE-1a Positive Advanced Solid Tumors",
    "Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)",
    "A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB Subtype DLBCL (ACE-LY-312)",
    "To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)",
    "PF-07104091 as a Single Agent and in Combination Therapy",
    "Phase I Study of IGM-8444 as a Single Agent and in Combination in Subjects With Relapsed and / or Refractory Solid Cancers",
    "PLX2853 in Combination With Abiraterone Acetate and Prednisone and in Combination With Olaparib in Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
    "Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors",
    "Study of Ravulizumab in Pediatric Participants With HSCT-TMA",
    "A Study to Evaluate Safety and Efficacy of Selinexor in Combination With Ruxolitinib in Participants With Myelofibrosis",
    "Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer",
    "GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy",
    "Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors",
    "A Study of MEDI9253 in Combination With Durvalumab in Select Solid Tumors",
    "Phase 2 Trial of MRTX849 Monotherapy and in Combination With Pembrolizumab for NSCLC With KRAS G12C Mutation KRYSTAL-7",
    "FT538 in Subjects With Advanced Hematologic Malignancies",
    "Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)",
    "Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors",
    "Safety and Efficacy of Therapies for Metastatic Castration-resistant Prostate Cancer (mCRPC)",
    "Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)",
    "Study Evaluating mCRPC Treatment Using PSMA [Lu-177]-PNT2002 Therapy After Second-line Hormonal Treatment",
    "Oral Axl / Mer / CSF1R Selective Tyrosine Kinase Inhibitor in Patients With Advanced Solid Tumor",
    "Safety and Activity Study of HER2-Targeted Dual Switch CAR-T Cells (BPX-603) in Subjects With HER2-Positive Solid Tumors",
    "Study of TL-895 in Subjects With Myelofibrosis",
    "A Study of SGN-STNV in Advanced Solid Tumors",
    "TL-895 and KRT-232 Study in Acute Myeloid Leukemia",
    "A Study of CC-95266 in Subjects With Relapsed and / or Refractory Multiple Myeloma",
    "Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)",
    "Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced / Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy",
    "A Phase 1a / 1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors",
    "A Study of PY314 in Subjects With Advanced Solid Tumors",
    "Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15 / KEYNOTE-B15 / EV-304)",
    "Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1 / 2 Dual Inhibitor, for Relapsed / Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)",
    "Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors",
    "TAC T-cells for the Treatment of HER2-positive Solid Tumors",
    "LUT014 for the Reduction of Dose-Limiting Acneiform Lesions Associated With EGFRI Treatment of mCRC",
    "A Study of HMPL-306 in Advanced Solid Tumors With IDH Mutations",
    "Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic Adenocarcinoma",
    "SY-1425 Plus Azacitidine in Participants With Newly Diagnosed RARA-positive Higher-Risk Myelodysplastic Syndrome",
    "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer",
    "Calaspargase Pegol in Adults With ALL",
    "FHD-286 in Subjects With Advanced Hematologic Malignancies",
    "FLX475 in Combination With Ipilimumab in Advanced Melanoma",
    "FHD-609 in Subjects With Advanced Synovial Sarcoma",
    "A Phase I / II Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma",
    "A Phase 1 Study of AMG 330 in Subjects With Myeloid Malignancies",
    "Study of TAS3681 in Metastatic Castration Resistant Prostate Cancer",
    "Safety and Activity Study of PSCA-Targeted CAR-T Cells (BPX-601) in Subjects With Selected Advanced Solid Tumors",
    "Study of Talimogene Laherparepvec In Children With Advanced Non-CNS Tumors",
    "Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML",
    "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers",
    "An Investigational Immuno-therapy Study of BMS-986207 Given Alone and in Combination With Nivolumab or With Nivolumab and Ipilimumab in Solid Cancers That Are Advanced or Have Spread",
    "Study to Evaluate Safety and Tolerability of XmAb13676 in Patients With CD20-expressing Hematologic Malignancies",
    "Study of CLR 131 in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia",
    "Study of Vibostolimab Alone and in Combination With Pembrolizumab in Advanced Solid Tumors (MK-7684-001)",
    "A Study to Test Combination Treatments in People With Advanced Renal Cell Carcinoma",
    "To Evaluate the Safety, Tolerability, and Pharmacokinetics of Inavolisib Single Agent in Participants With Solid Tumors and in Combination With Endocrine and Targeted Therapies in Participants With Breast Cancer",
    "A Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid / Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)",
    "Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients",
    "A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed / Refractory B-Cell Non-Hodgkin's Lymphoma",
    "A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors",
    "Study of MK-2118 Administered as Intratumoral Injection as Monotherapy and in Combination With Pembrolizumab (MK-3475) or by Subcutaneous Injection in Combination With Pembrolizumab in the Treatment of Adults With Advanced / Metastatic Solid Tumors or Lymphomas (MK-2118-001)",
    "Study Investigating the Efficacy of Crenolanib With Chemotherapy vs Chemotherapy Alone in R / R FLT3 Mutated AML",
    "A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)",
    "Haploidentical Bone Marrow Transplantation in Sickle Cell Patients (BMT CTN 1507)",
    "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors",
    "Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Participants With Resected Solid Tumors and in Combination With Pembrolizumab in Participants With Unresectable Solid Tumors",
    "An Investigational Immunotherapy Study of BMS-986249 Alone and in Combination With Nivolumab in Solid Cancers That Are Advanced or Have Spread",
    "A Study of ABC294640 (Yeliva ®) Alone and in Combination With Hydroxychloroquine Sulfate in Treatment of Patients With Advanced Cholangiocarcinoma",
    "An Investigational Immuno-therapy Study Of Nivolumab In Combination With Trametinib With Or Without Ipilimumab In Participants With Previously Treated Cancer of the Colon or Rectum That Has Spread",
    "A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations",
    "VAY736 in Combination With Ibrutinib in Patients With CLL on Ibrutinib",
    "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)",
    "Study of Neoadjuvant Chemotherapy Plus Trastuzumab and Pertuzumab in HER2-Negative Breast Cancer Patients With Abnormal HER2 Signaling",
    "Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss",
    "An Investigational Immunotherapy Study of BMS-986258 Alone and in Combination With Nivolumab in Participants With Solid Cancers That Are Advanced or Have Spread",
    "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours",
    "Safety, Tolerability and Pharmacokinetics of an Anti-PD-1 Monoclonal Antibody in Subjects With Advanced Malignancies",
    "A Trial of TTI-622 in Patients With Advanced Hematologic Malignancies",
    "APG-2575 Study of Safety, Tolerability ,PK / PD in Patients With Hematologic Malignancies",
    "To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed / Refractory Multiple Myeloma (RRMM)",
    "Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)",
    "Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC",
    "A Phase 1 Study of FOR46 in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
    "A Study of RGX-202-01 as a Single Agent and as Combination Therapy in Patients With Advanced Gastrointestinal Malignancies",
    "Phase 1, First-in-human Study of Oral TP-1287 in Patients With Advanced Solid Tumors",
    "Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)",
    "Study of APVO436 in Patients With AML or MDS",
    "A Study of TAK-981 in Participants With Relapsed / Refractory Solid Tumors or Non-Hodgkin Lymphoma (NHL)",
    "COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors.",
    "Study to Evaluate the Safety and Efficacy of the Coadministration of Ibrexafungerp (SCY-078) With Voriconazole in Patients With Invasive Pulmonary Aspergillosis",
    "Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly / Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma",
    "Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas",
    "Efficacy and Safety of Olaparib (MK-7339) in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer (MK-7339-002 / LYNK-002)",
    "A Phase 1 Study of [225Ac]-FPI-1434 Injection",
    "Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641 / KEYNOTE-641)",
    "Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age",
    "Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLL",
    "Durvalumab and Tremelimumab for Pediatric Malignancies",
    "A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors",
    "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer",
    "Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine",
    "Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma",
    "A Dose Escalation and Cohort Expansion Study of Subcutaneously-Administered Cytokine ALKS 4230 (Nemvaleukin Alfa) as a Single Agent and in Combination With Anti-PD-1 Antibody (Pembrolizumab) in Subjects With Select Advanced or Metastatic Solid Tumors (ARTISTRY-2)",
    "Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors (ILLUMINATE-206)",
    "[177Lu]-NeoB in Patients With Advanced Solid Tumors and With [68Ga]-NeoB Lesion Uptake",
    "Phase 1 / 2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer",
    "A Study of JNJ-67571244 in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)",
    "Study of ORIC-101 in Combination With Anticancer Therapy",
    "Assess the Safety, Tolerability Oral PU-H71 in Subjects Taking Ruxolitinib",
    "Effect of Tumor Treating Fields (TTFields, 200 kHz) Concomitant With Weekly Paclitaxel for the Treatment of Recurrent Ovarian Cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3)",
    "ORIN1001 in Patients With Advanced Solid Tumors and Relapsed Refractory Metastatic Breast Cancer",
    "Study of REGN5678 (Anti-PSMAxCD28) With Cemiplimab (Anti-PD-1) in Patients With Metastatic Castration-resistant Prostate Cancer",
    "Pediatric Long-Term Follow-up and Rollover Study",
    "Study Comparing Zanubrutinib + Rituximab Versus Bendamustine + Rituximab in Participants With Untreated Mantle Cell Lymphoma",
    "FT516 in Subjects With Advanced Hematologic Malignancies",
    "A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma",
    "Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer",
    "First in Human Study With NG-641, an Oncolytic Transgene Expressing Adenoviral Vector",
    "RBN-2397, an Oral PARP7 Inhibitor, in Patients With Solid Tumors , FIH, MAD Study",
    "First In Human (FIH) Study of REGN5459 in Adult Patients With Relapsed or Refractory Multiple Myeloma (MM)",
    "Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies",
    "A Study of Subcutaneous Daratumumab Regimens in Combination With Bispecific T Cell Redirection Antibodies for the Treatment of Participants With Multiple Myeloma",
    "Platform Study of Belantamab Mafodotin as Monotherapy and in Combination With Anti-cancer Treatments in Participants With Relapsed / Refractory Multiple Myeloma (RRMM) (DREAMM 5)",
    "Study of DS-7300a in Participants With Advanced Solid Malignant Tumors",
    "Phase 1 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)",
    "FOLFOXIRI Plus Panitumumab in Metastatic RAS Wild-type, Left-sided Colorectal Cancer",
    "Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.",
    "A Dose-escalation Study to Evaluate the Safety and Clinical Activity of PBCAR269A, With or Without Nirogacestat, in Study Participants With Relapsed / Refractory Multiple Myeloma",
    "Futibatinib in Patients With Specific FGFR Aberrations",
    "Study of APG-2575 as a Single Agent or in Combination With Other Therapeutic Agents for CLL / SLL",
    "Study of AMG 509 in Subjects With Metastatic Castration-Resistant Prostate Cancer",
    "A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)",
    "A Safety Study of SEA-CD70 in Patients With Myeloid Malignancies",
    "GPS Compared With BAT in AML CR2 / CR2p",
    "Trial of eRapa to Prevent Progression in Familial Adenomatous Polyposis Patients Under Active Surveillance",
    "KAZ954 Alone and With PDR001, NZV930 and NIR178 in Advanced Solid Tumors",
    "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992 / KEYNOTE-992)",
    "Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors",
    "FT596 as a Monotherapy and in Combination With Anti-CD20 Monoclonal Antibodies",
    "Intravenous TAEK-VAC-HerBy Vaccine Alone and in Combination Treatment in HER2 Cancer Patients",
    "A Study of ASTX030 (Cedazuridine in Combination With Azacitidine) in MDS, CMML, or AML",
    "Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant / Intolerant Ph + Chronic Myeloid Leukemia\",",
    "Study to Assess AFM24 in Advanced Solid Cancers",
    "Dose Escalation / Expansion Trial of CA-4948 as Monotherapy and in Combination With Azacitidine or Venetoclax in Patients With AML or MDS",
    "Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms",
    "Study of TBio-6517, Given Intratumorally, Alone or in Combination With Pembrolizumab, in Solid Tumors",
    "Natural Killer Cell (CYNK-001) Infusions in Adults With AML",
    "BCMA-directed CAR-T Cell Therapy in Adult Patients With Relapsed and / or Refractory Multiple Myeloma",
    "Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production",
    "Study With Afuresertib and Paclitaxel in Platinum Resistant Ovarian",
    "UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma",
    "A Study of SGN-B6A in Advanced Solid Tumors",
    "A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors",
    "Breast Cancer Locator Guided vs. Wire Localized Partial Mastectomy for Breast Cancer",
    "A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function",
    "Exablate Blood-Brain Barrier Disruption for the Treatment of rGBM in Subjects Undergoing Carboplatin Monotherapy",
    "Phase 2 Trial to Evaluate Safety and Efficacy of AU-011 Via Suprachoroidal Administration in Subjects With Primary Indeterminate Lesions and Small Choroidal Melanoma",
    "A Study of TAK-676 and TAK-676 in Combination With Pembrolizumab in Adults With Advanced Solid Tumors",
    "JSP191 Antibody Conditioning Regimen in MDS / AML Subjects Undergoing Allogenic Hematopoietic Stem Cell Transplantation",
    "Study of AO-176 as Monotherapy and in Combination With Bortezomib / Dexamethasone in Relapsed / Refractory Multiple Myeloma",
    "Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC",
    "Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy",
    "INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders",
    "Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed / Refractory Myelofibrosis",
    "A Study of CG-806 in Patients With Relapsed or Refractory Acute Myeloid Leukemia",
    "A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)",
    "PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer",
    "First-In-Human Dose-Escalation Study of STP1002 in Patients With Advanced-Stage Solid Tumors",
    "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions",
    "Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors",
    "A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma",
    "COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors.",
    "A Study of FT-7051 in Men With MCRPC",
    "Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors",
    "INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors",
    "A Study of Belzutifan (MK-6482) in Combination With Lenvatinib Versus Cabozantinib for Treatment of Renal Cell Carcinoma (MK-6482-011)",
    "Trilaciclib, a CDK 4 / 6 Inhibitor, in Patients Receiving FOLFOXIRI / Bevacizumab for Metastatic Colorectal Cancer (mCRC):",
    "Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed / Refractory Chronic Lymphocytic Leukemia",
    "Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B)",
    "A Study of TAS1553 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia (AML) and Other Myeloid Neoplasms",
    "APR-548 in Combination With Azacitidine for the Treatment of TP53 Myelodysplastic Syndromes (MDS)",
    "Study to Evaluate VT3989 in Patients With Metastatic Solid Tumors Enriched for Tumors With NF2 Gene Mutations",
    "Study of JTX 8064, as Monotherapy and in Combination With a PD-1 Inhibitor, in Adult Subjects With Advanced Refractory Solid Tumors",
    "A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors",
    "A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed / Refractory (R / R) Follicular Lymphoma or Marginal Zone Lymphoma.",
    "Phase 2b Study of GC4711 in Combination With SBRT for Nonmetastatic Pancreatic Cancer",
    "A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors",
    "Pembrolizumab Plus Lenvatinib for First-line Advanced / Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)",
    "This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects With Any Progressive Locally Advanced or Metastatic Solid Tumors",
    "MGTA-145 + Plerixafor in the Mobilization of HSCs for Allogeneic Transplant in Hematologic Malignancies",
    "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion",
    "ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)",
    "A Study of NX-2127 in Adults With Relapsed / Refractory B-cell Malignancies",
    "(SYMPHONY) Phase 1 / 2 Study Targeting EGFR Resistance Mechanisms in NSCLC",
    "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.",
    "Ascending Doses of Ceralasertib in Combination With Chemotherapy and / or Novel Anti Cancer Agents",
    "Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment Refractory / Intolerant CML Failing ≥3 Prior CML Therapies",
    "AMG 176 First in Human Trial in Subjects With Relapsed or Refractory Multiple Myeloma and Subjects With Relapsed or Refractory Acute Myeloid Leukemia",
    "Ph 2 / 3 Study in Subjects With MPM to Assess ADI-PEG 20 With Pemetrexed and Cisplatin",
    "A Phase 1 / 2 Safety Study of Intratumorally Dosed INT230-6",
    "First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Participants With Advanced Solid Tumors",
    "Bempegaldesleukin and Pembrolizumab With or Without Chemotherapy in Locally Advanced or Metastatic Solid Tumors",
    "Dose Escalation Study of Teclistamab, a Humanized BCMA*CD3 Bispecific Antibody, in Participants With Relapsed or Refractory Multiple Myeloma",
    "A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 in Participants With Refractory Multiple Myeloma (MM)",
    "A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G / GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer)",
    "A Study to Assess AMG 701 Montherapy, or in Combination With Pomalidomide, With or Without, Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma",
    "ONC201 in Adults With Recurrent H3 K27M-mutant Glioma",
    "Study of ISB 1342, a CD38 / CD3 Bispecific Antibody, in Subjects With Previously Treated Multiple Myeloma",
    "A Safety and Efficacy Trial of JCAR017 Combinations in Subjects With Relapsed / Refractory B-cell Malignancies (PLATFORM)",
    "Study of GEN-1 With NACT for Treatment of Ovarian Cancer (OVATION 2)",
    "Dose Escalation Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma",
    "A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers",
    "Treatment of Metastatic Soft Tissue Sarcoma (STS) Patients (FIBROSARC USA)",
    "A Study to Assess the Safety and Tolerability of AZD1390 Given With Radiation Therapy in Patients With Brain Cancer",
    "PF-06821497 Treatment Of Relapsed / Refractory SCLC, Castration Resistant Prostate Cancer, and Follicular Lymphoma",
    "Treatment of Radiation and Cisplatin Induced Toxicities With Tempol",
    "Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
    "Efficacy and Safety Study of Tisotumab Vedotin for Patients With Solid Tumors",
    "Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma",
    "A Safety, Pharmacokinetic, Pharmacodynamic and Anti-Tumor Study of PF-06873600 as a Single Agent and in Combination With Endocrine Therapy",
    "A Study Exploring the Safety and Tolerability of INCB081776 in Participants With Advanced Malignancies",
    "PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL",
    "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)",
    "A Safety Study of SEA-BCMA in Patients With Multiple Myeloma",
    "A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors",
    "Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma",
    "PF-06952229 Treatment in Adult Patients With Advanced Solid Tumors",
    "A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer",
    "Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)",
    "ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head / Neck Cancer for Patients Who Have Failed at Least Two Lines of Therapy",
    "A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers",
    "A Study of Neoadjuvant / Adjuvant Durvalumab for the Treatment of Patients With Resectable Non-small Cell Lung Cancer",
    "A Phase 1 Study of Engineered Donor Grafts (OrcaGraft / Orca-Q) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies",
    "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers",
    "TPST-1120 as Monotherapy and in Combination With Nivolumab in Subjects With Advanced Cancers",
    "Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905 / KEYNOTE-905 / EV-303)",
    "A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer",
    "A Study of mRNA-5671 / V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)",
    "CD19-specific CAR-T Cells in CLL / SLL and DLBCL",
    "Safety and Efficacy of IMC-C103C as Monotherapy and in Combination With Atezolizumab",
    "Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)",
    "Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080 / MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008 / E7080-G000-316 / LEAP-008)",
    "A Study to Assess Safety and Efficacy of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-PD-1 Treatment",
    "First-in-human Single Agent Study of SAR442085 in Relapsed or Refractory Multiple Myeloma",
    "A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer",
    "A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed / Refractory Acute Leukemias or Solid Tumors",
    "Study of ORIC-101 in Combination With Enzalutamide",
    "A Phase 1 / 2a Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer",
    "Study of SQZ-PBMC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors",
    "Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug",
    "Effectiveness Study of Nivolumab Compared to Placebo in Prevention of Recurrent Melanoma After Complete Resection of Stage IIB / C Melanoma",
    "Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer",
    "IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma",
    "An Open-Label, Multicenter, Phase 1b / 2 Study of the Safety and Efficacy of KRT-232 When Administered Alone and in Combination With Low-Dose Cytarabine (LDAC) or Decitabine in Patients With Acute Myeloid Leukemia (AML)",
    "Phase 1 / 1b Study of Oral PMD-026 in Patients With Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer",
    "A Study of MBG453 in Combination With Azacitidine and Venetoclax in AML Patients Unfit for Chemotherapy",
    "KEYMAKER-U01 Substudy 1: Efficacy and Safety Study of Pembrolizumab (MK-3475) Plus Chemotherapy When Used With Investigational Agents in Treatment-naïve Participants With Advanced Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A / KEYMAKER-U01A)",
    "Sasanlimab (PF-06801591) in Combination With BCG or as Single Agent in Participants With High-Risk Non-Muscle Invasive Bladder Cancer",
    "A Phase 1 / 2 Open-label, Multicenter, Dose Escalation and Dose Expansion Study of the Safety, Tolerability, and PK of HPN217 in Patients With R / R MM",
    "Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma",
    "A Study of Nivolumab Plus Bempegaldesleukin (Bempeg / NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer.",
    "Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975 / KEYNOTE-975)",
    "Actuate 1901: 9-ING-41 in Myelofibrosis",
    "A Study of CC-97540, CD19-targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma",
    "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors",
    "Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint Inhibitors",
    "Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed / Refractory Hodgkin Lymphoma (CHARIOT)",
    "A Study of TAS1440 With ATRA in Subjects With r / r AML",
    "Phase 1 / 2 Study in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL 2",
    "A Study of TAK-981 Given With Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors",
    "Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-Guerin",
    "Study of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic Syndrome",
    "A Study of Evorpacept (ALX148) With Azacitidine for Higher Risk Myelodysplastic Syndrome (ASPEN-02)",
    "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations",
    "Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy.",
    "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors.",
    "Study in Patients With Advanced Cancers Associated With Expression of DLL3 Who Have Failed Standard Available Therapy",
    "Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency",
    "Study of RP-3500 in Advanced Solid Tumors",
    "A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)",
    "Ph1 Study of SL-172154 Administered Intratumorally in Subjects With Squamous Cell Carcinoma of the Head and Neck or Skin",
    "Antigen-specific T Cell Therapy for Patients With Relapsed Refractory Multiple Myeloma",
    "A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (Morpheus-Liver)",
    "Study of Sacituzumab Govitecan-hziy (IMMU-132) Versus Treatment of Physician's Choice in Participants With Metastatic or Locally Advanced Unresectable Urothelial Cancer",
    "A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy",
    "A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer",
    "LUMINOS-102: PVSRIPO With or Without Immune Checkpoint Blockade in Patients With Advanced PD-1 Refractory Melanoma",
    "Study of REGN5668 Administered in Combination With Cemiplimab or REGN4018 in Adult Women With Recurrent Ovarian Cancer.",
    "Study of NKTR 255 in Combination With Cetuximab in Solid Tumors",
    "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-LUNG01)",
    "Pharmacokinetics, Safety, and Efficacy of ASTX727 in Combination With Venetoclax in Acute Myeloid Leukemia (AML)",
    "RTX-321 Monotherapy in Patients With HPV 16+ Tumors",
    "Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer",
    "A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma",
    "A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies",
    "A Study to Evaluate DAY101 in Pediatric and Young Adult Patients With Relapsed or Progressive Low-Grade Glioma",
    "DALY 2.0 USA / MB-CART2019.1 for DLBCL",
    "A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors",
    "A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer",
    "Study to Evaluate Imetelstat (GRN163L) in Subjects With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)",
    "CGX1321 in Subjects With Advanced Solid Tumors and CGX1321 With Pembrolizumab in Subjects With Advanced GI Tumors (Keynote 596)",
    "Open-label Study of FT-2102 With or Without Azacitidine or Cytarabine in Patients With AML or MDS With an IDH1 Mutation",
    "A Study of H3B-8800 in Participants With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia",
    "Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)",
    "Tavo and Pembrolizumab in Patients With Stage III / IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment",
    "Study Evaluating Safety and Efficacy of UCART123 in Patients With Relapsed / Refractory Acute Myeloid Leukemia",
    "Efficacy and Safety of FG-4592 for Treatment of Anemia in Patients With Lower Risk MDS With Low Red Blood Cell Transfusion Burden",
    "A Study of Multiple Immunotherapy-Based Treatment Combinations in Hormone Receptor (HR)-Positive Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer",
    "Phase 1 / 2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer",
    "Safety and Efficacy of SGN-LIV1A Plus Pembrolizumab for Patients With Locally-Advanced or Metastatic Triple-Negative Breast Cancer",
    "A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma",
    "Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer",
    "A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL",
    "Study of IMGN632 in Patients With Untreated BPDCN and Relapsed / Refractory BPDCN",
    "Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma",
    "SBRT + / - Pembrolizumab in Patients With Local-Regionally Recurrent or Second Primary Head and Neck Carcinoma",
    "Study of Adagloxad Simolenin (OBI-822) / OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC",
    "Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer",
    "Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer",
    "A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinoma (ccRCC) (MK-6482-003)",
    "A Study of NKTR-214 Combined With Nivolumab vs Nivolumab Alone in Participants With Previously Untreated Inoperable or Metastatic Melanoma",
    "A Study of FOR46 in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)",
    "Phase 1 Study of BAY1905254 - An Early Clinical Research Study to Evaluate a New Drug Called Bapotulimab (BAY1905254) in the Expansion Cohort in Combination With Pembolizumab in Head and Neck Cancer That Has Returned or is Discovered to be Metastatic and is Expressing PDL1.",
    "A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC",
    "Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676 / KEYNOTE-676)",
    "A Global Study to Evaluate Transarterial Chemoembolization (TACE) in Combination With Durvalumab and Bevacizumab Therapy in Patients With Locoregional Hepatocellular Carcinoma",
    "Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC",
    "Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers",
    "Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V)",
    "Phase III DAS181 Lower Tract PIV Infection in Immunocompromised Subjects (Substudy: DAS181 for COVID-19): RCT Study",
    "Case-Control Study of the Glycotest™ HCC Panel vs AFP for the Detection of Early-stage Hepatocellular Carcinoma",
    "Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma (MARIO-3)",
    "Phase 1 Study of TPX-0022, a MET / CSF1R / SRC Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in MET",
    "Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC",
    "A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers",
    "A Study of SGN-CD228A in Advanced Solid Tumors",
    "Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors",
    "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA / B Non-Small Cell Lung Cancer",
    "A Phase 1b Master Trial to Investigate CPX-351 in Subjects With Previously Untreated Acute Myeloid Leukemia",
    "A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed / Refractory Non-Hodgkin Lymphoma",
    "Phase 1 Study to Determine the MTD, Safety, Tolerability, PK and Preliminary Anti-tumor Effects of LNS8801alone and With Pembrolizumab",
    "Study of Intratumorally Administered Stimulator of Interferon Genes (STING) Agonist E7766 in Participants With Advanced Solid Tumors or Lymphomas - INSTAL-101",
    "Immuno-Oncology Drugs Elotuzumab, Anti-LAG-3 and Anti-TIGIT",
    "Immunotherapy With IFx-Hu2.0 Vaccine for Advanced Non-melanoma Skin Cancers",
    "Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer",
    "An Efficacy and Safety Study of Cofetuzumab Pelidotin in Participants With PTK7-Expressing, Recurrent Non-Small Cell Lung Cancer",
    "P-PSMA-101 CAR-T Cells in the Treatment of Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",
    "A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer",
    "Study of Bcl-2 Inhibitor BGB-11417 in Participants With Mature B-Cell Malignancies",
    "Study of AMG 650 in Adult Participants With Advanced Solid Tumors",
    "Safety and Efficacy Study of AVB-S6-500 in Patients With Advanced Clear Cell Renal Cell Carcinoma",
    "A Phase 1B Study of RP1 in Transplant Patients With Advanced Cutaneous Squamous Cell Carcinoma",
    "RTX-240 Monotherapy and in Combination With Pembrolizumab",
    "Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors",
    "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation",
    "Study of PF-07265807 in Participants With Metastatic Solid Tumors.",
    "An Open-Label, Multicenter, Phase 1b / 2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib",
    "A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM)",
    "A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression",
    "BRAF V600E-mutant Colorectal Cancer Study of Encorafenib Taken With Cetuximab Plus or Minus Chemotherapy (BREAKWATER)",
    "Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)",
    "Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)",
    "Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma",
    "LYT-200 Alone and in Combination With Chemotherapy or Anti-PD-1 in Patients With Metastatic Solid Tumors",
    "CMP-001 in Combination With Nivolumab Compared to Nivolumab Monotherapy in Subjects With Advanced Melanoma",
    "A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab / Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)",
    "Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation (KRYSTAL-10)",
    "A Study of AL102 in Patients With Progressing Desmoid Tumors",
    "FHD-286 in Subjects With Metastatic Uveal Melanoma",
    "A Safety Study of SGN-LIV1A in Breast Cancer Patients",
    "A Phase 1 Study Evaluating the Safety, PK, and Clinical Effects of PT-112 in Subjects With Advanced Solid Tumors",
    "Selinexor and Backbone Treatments of Multiple Myeloma Patients",
    "TK216 in Patients With Relapsed or Refractory Ewing Sarcoma",
    "A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)",
    "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)",
    "NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)",
    "A Study of Nemtabrutinib (MK-1026) (ARQ 531) in Participants With Selected Hematologic Malignancies",
    "A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors",
    "A Safety and Efficacy Study to Evaluate Luspatercept in Subjects With Myeloproliferative Neoplasm-associated Myelofibrosis Who Have Anemia With and Without Red Blood Cell-transfusion Dependence",
    "Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",
    "Neihulizumab (AbGn-168H) in Patients With Steroid-refractory Acute Graft-versus-host Disease or Treatment-refractory Acute Graft-versus-host Disease",
    "A Study of CA-4948 in Patients With Relapsed or Refractory Hematologic Malignancies",
    "A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",
    "Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies",
    "CAB-ROR2-ADC Safety and Efficacy Study in Patients With TNBC or Head & Neck Cancer (Ph1) and NSCLC or Melanoma (Ph2)",
    "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495 / KEYNOTE-495)",
    "Maintenance With Selinexor / Placebo After Combination Chemotherapy in Participants With Endometrial Cancer [SIENDO]",
    "Dose Escalation of RMC-4630 Monotherapy in Relapsed / Refractory Solid Tumors",
    "9-ING-41 in Patients With Advanced Cancers",
    "Safety and Effectiveness of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood",
    "A Study of Salvage Radiotherapy With or Without Enzalutamide in Recurrent Prostate Cancer Following Surgery",
    "RPTR-147 in Patients With Selected Solid Tumors and Lymphomas",
    "A Study of Zilovertamab Vedotin (MK-2140) (VLS-101) in Participants With Hematologic Malignancies (MK-2140-001)",
    "Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer",
    "High-Risk Skin Cancers With Atezolizumab Plus NT-I7",
    "IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma",
    "Clinical Trial to Evaluate CT053 in Patients With Relapsed and / or Refractory Multiple Myeloma (LUMMICAR STUDY 2)",
    "Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867 / KEYNOTE-867)",
    "A Study of MEDI1191 in Sequential and Concurrent Combination With Durvalumab in Subjects With Advanced Solid Tumors.",
    "A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid Tumors",
    "Study of Sacituzumab Govitecan-hziy in Metastatic Solid Tumors",
    "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors",
    "A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma",
    "Study of MT-5111 in HER2-positive Solid Tumors",
    "A Trial of CPX-351 Lower Intensity Therapy (LIT) Plus Venetoclax as First Line Treatment for Subjects With AML",
    "A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations",
    "A Study of Atezolizumab Plus Bevacizumab Versus Active Surveillance as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Surgical Resection or Ablation",
    "Phase 2 Study to Evaluate the Efficacy and Safety of Rivoceranib in Subjects With Recurrent or Metastatic ACC",
    "A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)",
    "Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss",
    "Study of Efficacy and Safety of MBG453 in Combination With Azacitidine in Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)",
    "Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance",
    "Phase 1 Study of Oral TP-1454",
    "Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and / or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors",
    "IO-202 as Monotherapy in Patients in AML and CMML",
    "Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012 / KEYLYNK-012)",
    "Phase 1 / 2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies",
    "Abemaciclib and Letrozole to Treat Endometrial Cancer",
    "Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed / Refractory DLBCL",
    "Dose Escalation of DF6002 in Patients With Advanced Solid Tumors, and Expansion in Selected Indications",
    "Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers",
    "A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors",
    "Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations",
    "GMCI Plus Standard of Care Immune Checkpoint Inhibitor for Stage III / IV NSCLC",
    "Umbrella Study of Sasanlimab Combined With Targeted Therapies in Participants With Non-Small Cell Lung Cancer",
    "A Study of Adavosertib as Treatment for Uterine Serous Carcinoma",
    "Assessing Durvalumab and FLOT Chemotherapy in Resectable Gastric and Gastroesophageal Junction Cancer",
    "Study of Oral LY3410738 in Patients With Advanced Hematologic Malignancies With IDH1 or IDH2 Mutations",
    "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer",
    "CMP-001 in Combination With Nivolumab in Subjects With Advanced Melanoma",
    "Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia",
    "A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumors",
    "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer",
    "DS-3201b in Participants With Lymphomas",
    "Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365 / KEYNOTE-365)",
    "A Study of RGX-104 in Patients With Advanced Solid Malignancies and Lymphoma",
    "A Study of Rucaparib Versus Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency",
    "Study of DCC-3014 in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor",
    "A Study Comparing Nivolumab, Nivolumab in Combination With Ipilimumab and Placebo in Participants With Localized Kidney Cancer Who Underwent Surgery to Remove Part of a Kidney",
    "APX005M With Concurrent Chemoradiation for Resectable Esophageal and Gastroesophageal Junction Cancers",
    "A Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies",
    "MIBG With Dinutuximab + / - Vorinostat",
    "Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPC",
    "CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers",
    "A Study of Venetoclax and Dexamethasone Compared With Pomalidomide and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma",
    "A Phase 1 Study of Voruciclib in Subjects With B-Cell Malignancies or AML",
    "A Study of ZN-c5 in Subjects With Breast Cancer",
    "A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia",
    "A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC",
    "Dose-escalation Study of Safety of PBCAR0191 in Patients With r / r NHL and r / r B-cell ALL",
    "Study of Pembrolizumab (MK-3475) Versus Placebo in Combination With Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy in the Treatment of Early-Stage Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (ER+ / HER2-) Breast Cancer (MK-3475-756 / KEYNOTE-756)",
    "Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies",
    "First in Human (FIH) Study of REGN5458 in Patients With Relapsed or Refractory Multiple Myeloma",
    "Study of RP1 Monotherapy and RP1 in Combination With Nivolumab",
    "This Study Evaluates KRT-232, a Novel Oral Small Molecule Inhibitor of MDM2, for the Treatment of Patients With (p53WT) Merkel Cell Carcinoma Who Have Failed Anti-PD-1 / PD-L1 Immunotherapy",
    "PO Ixazomib in Combination With Chemotherapy for Childhood Relapsed or Refractory Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma",
    "AO-176 in Multiple Solid Tumor Malignancies",
    "Safety and Efficacy of Pembrolizumab (MK-3475) Versus Placebo as Adjuvant Therapy in Participants With Hepatocellular Carcinoma (HCC) and Complete Radiological Response After Surgical Resection or Local Ablation (MK-3475-937 / KEYNOTE-937)",
    "Pan Tumor Nivolumab Rollover Study",
    "Study of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)",
    "A Study of TAS-120 in Patients With Metastatic Breast Cancer",
    "A Study of Osimertinib With or Without Chemotherapy as 1st Line Treatment in Patients With Mutated Epidermal Growth Factor Receptor Non-Small Cell Lung Cancer (FLAURA2)",
    "A Phase 1 / 2 Trial of ARV-471 Alone and in Combination With Palbociclib (IBRANCE®) in Patients With ER+ / HER2- Locally Advanced or Metastatic Breast Cancer",
    "A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations",
    "Phase II Study to Assess AFM13 in Patients With R / R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides",
    "A Study of CPI-0209 in Patients With Advanced Tumors",
    "A Study of LY3295668 Erbumine in Participants With Relapsed / Refractory Neuroblastoma",
    "A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma",
    "Study of PDS0101 and Pembrolizumab Combination I / O in Subjects With HPV16 + Recurrent and / or Metastatic HNSCC",
    "Adenosine Receptor Antagonist Combination Therapy for Metastatic Castrate Resistant Prostate Cancer",
    "A Study of CC-98633, BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells, in Subjects With Relapsed and / or Refractory Multiple Myeloma",
    "A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function",
    "A Study of AL101 Monotherapy in Patients With Notch Activated Triple Negative Breast Cancer",
    "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)",
    "A FIH Study of PF-07284890 in Participants With BRAF V600 Mutant Solid Tumors With and Without Brain Involvement",
    "Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer",
    "Study of CPI-0610 in Myelofibrosis (MF)",
    "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation",
    "CMP-001 in Combination With Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma",
    "A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors",
    "Study of RP-6306 in Advanced Solid Tumors",
    "Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation",
    "A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)",
    "Phase 1-2 Study of ASTX660 in Subjects With Advanced Solid Tumors and Lymphomas",
    "Immunotherapy of Relapsed Refractory Neuroblastoma With Expanded NK Cells",
    "Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia",
    "Vincristine Sulfate Liposome Injection (Marqibo®) in Combination With UK ALL R3 Induction Chemotherapy for Children, Adolescents, and Young Adults With Relapsed ALL",
    "A Study of Maribavir Compared to Valganciclovir to Treat Cytomegalovirus Infections in People Who Have Received Stem Cell Transplants",
    "QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer",
    "A Study of ONO-7475 in Patients With Acute Leukemias",
    "Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC",
    "Dose-Escalation Study of Cevostamab in Participants With Relapsed or Refractory Multiple Myeloma (R / R MM)",
    "P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM)",
    "Study Evaluating Safety, Tolerability and PK of AMG 757 in Adults With Small Cell Lung Cancer",
    "Phase II Umbrella Study of Novel Anti-cancer Agents in Patients With NSCLC Who Progressed on an Anti-PD-1 / PD-L1 Containing Therapy",
    "A Study of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)",
    "Dose Escalation & Expansion Study of Oral VRx-3996 & Valganciclovir in Subjects With EBV-Associated Lymphoid Malignancies",
    "Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant / Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671 / KEYNOTE-671)",
    "Study of Sacituzumab Govitecan-hziy in Metastatic Urothelial Cancer",
    "Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas",
    "A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma",
    "KRT-232 Versus Best Available Therapy for the Treatment of Subjects With Myelofibrosis Who Are Relapsed or Refractory to JAK Inhibitor Treatment",
    "A Study of XmAb®22841 Monotherapy & in Combination w / Pembrolizumab in Subjects w / Selected Advanced Solid Tumors",
    "An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)",
    "Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer",
    "GEN1046 Safety Trial in Patients With Malignant Solid Tumors",
    "Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd / 3rd / 4th Salvage",
    "Study of I-131-1095 Radiotherapy in Combination With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer Who Are Chemotherapy Naive and Have Progressed on Abiraterone",
    "Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Locally Advanced Pancreatic Cancer",
    "A Study to Determine the Recommended Dose and Regimen and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)",
    "Combination Margetuximab, INCMGA00012, MGD013, and Chemotherapy Phase 2 / 3 Trial in HER2+ Gastric / GEJ Cancer (MAHOGANY)",
    "NKTR-255 in Relapsed / Refractory Multiple Myeloma & Non-Hodgkin Lymphoma",
    "Study of DF1001 in Patients With Advanced Solid Tumors",
    "A Study of ASTX660 as a Single Agent and in Combination With ASTX727 in Subjects With Relapsed / Refractory Acute Myeloid Leukemia (AML)",
    "A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma",
    "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.",
    "Study in Subjects With Relapsed / Refractory Follicular Lymphoma",
    "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors",
    "A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer",
    "Study Of Venetoclax Tablet With Intravenous or Subcutaneous Azacitidine to Assess Change in Disease Activity In Adult Participants With Newly Diagnosed Higher-Risk Myelodysplastic Syndrome",
    "Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis",
    "Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer",
    "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer",
    "The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a p53 Y220C Mutation",
    "An Open Label Study Evaluating the Efficacy and Safety of AB928 Based Treatment Combinations in Patients With Metastatic Colorectal Cancer.",
    "AVB-S6-500 / Placebo in Combination With Paclitaxel in Patients With Platinum-Resistant Recurrent Ovarian Cancer",
    "A Phase 2 Study of CPI-0610 With and Without Ruxolitinib in Patients With Myelofibrosis",
    "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1 / 2 / 3 (Trk A / B / C), ROS1, or ALK Gene Rearrangements (Fusions)",
    "Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL",
    "Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC).",
    "A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL",
    "Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the Standard of Care Chemotherapy Alone in Treatment of Participants With Untreated Inoperable or Metastatic Urothelial Cancer",
    "Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma",
    "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer",
    "A Study With ABBV-155 Alone and in Combination With Taxane Therapy in Adults With Relapsed and / or Refractory Solid Tumors",
    "Clinical Trial of Brentuximab Vedotin in Classical Hodgkin Lymphoma",
    "A Study to Evaluate the Safety and Efficacy of Mosunetuzumab (BTCT4465A) in Combination With Polatuzumab Vedotin in B-Cell Non-Hodgkin Lymphoma",
    "Ribociclib and Letrozole Treatment in Ovarian Cancer",
    "(PIONEER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, Versus Placebo in Patients With Indolent Systemic Mastocytosis",
    "A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)",
    "Nivolumab in Combination With 5-azacytidine in Childhood Relapsed / Refractory AML",
    "Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment",
    "TTX-030 Single Agent and in Combination With Immunotherapy or Chemotherapy for Patients With Advanced Cancers",
    "A Study of CG-806 in Patients With Relapsed or Refractory CLL / SLL or Non-Hodgkin's Lymphomas",
    "RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer",
    "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors",
    "Study of TJ011133 in Participants With Relapsed / Refractory Advanced Solid Tumors and Lymphoma",
    "A Study of Engineered Donor Grafts (TregGraft / Orca-T) in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies",
    "A Study to Evaluate Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor",
    "First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia",
    "A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer",
    "A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies",
    "TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations",
    "Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies",
    "A Study of TheraT® Vector(s) Expressing HPV 16+ in Patients With HPV 16+ Confirmed Cancers",
    "Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18 / KEYNOTE-A18 / ENGOT-cx11 / GOG-3047)",
    "A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer",
    "Safety and Efficacy of Lenvatinib (E7080 / MK-7902) With Pembrolizumab (MK-3475) in Combination With Transarterial Chemoembolization (TACE) in Participants With Incurable / Non-metastatic Hepatocellular Carcinoma (MK-7902-012 / E7080-G000-318 / LEAP-012)",
    "Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer",
    "Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors",
    "A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers",
    "Study of Trastuzumab Deruxtecan (T-DXd) vs Investigator's Choice Chemotherapy in HER2-low, Hormone Receptor Positive, Metastatic Breast Cancer",
    "Efficacy of MT-401 in Patients With AML Following Stem Cell Transplant",
    "A Study to Evaluate Tabelecleucel in Participants With Epstein-barr Virus-associated Diseases",
    "DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer",
    "Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer",
    "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V or Other KRAS-Mutant Non-Small Cell Lung Cancer",
    "MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb",
    "Regorafenib Plus Pembrolizumab in Patients With Advanced or Spreading Liver Cancer Who Have Been Previously Treated With PD-1 / PD-L1 Immune Checkpoint Inhibitors",
    "JAB-3312 Activity in Adult Patients With Advanced Solid Tumors",
    "Flotetuzumab in Primary Induction Failure (PIF) or Early Relapse (ER) Acute Myeloid Leukemia (AML)",
    "Tagraxofusp (SL-401) in Patients With CMML or MF",
    "Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed / Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed / Refractory B-Cell Non-Hodgkin Lymphoma",
    "AFPᶜ³³²T in Advanced HCC",
    "Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)",
    "A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors",
    "A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects",
    "A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors",
    "An Efficacy and Safety Study of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma",
    "Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy",
    "Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors",
    "Osimertinib Plus Savolitinib in EGFRm+ / MET+ NSCLC Following Prior Osimertinib",
    "A Study of ASP1951 in Subjects With Advanced Solid Tumors",
    "Trial of ARV-110 in Patients With Metastatic Castration Resistant Prostate Cancer",
    "A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens",
    "A Study of SNDX-5613 in R / R Leukemias Including Those With an MLLr / KMT2A Gene Rearrangement or NPM1 Mutation",
    "A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080 / MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R / M HNSCC) (LEAP-010) (MK-7902-010)",
    "A Study to Assess Overall Response Rate by Inducing an Inflammatory Phenotype in Metastatic BReast cAnCEr With the Oncolytic Reovirus PeLareorEp in CombinaTion With Anti-PD-L1 Avelumab and Paclitaxel - BRACELET-1 Study",
    "A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies",
    "A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)",
    "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma",
    "Study of Efficacy and Safety of LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma",
    "A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)",
    "Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (TRANSCEND-NHL-001)",
    "A Study of ME-401 in Subjects With CLL / SLL, FL, and B-cell Non-Hodgkin's Lymphoma",
    "Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS)",
    "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors",
    "Phase 2 CAB-AXL-ADC Safety and Efficacy Study in Adult and Adolescent Patients With Sarcoma",
    "Study of ASTX029 in Subjects With Advanced Solid Tumors",
    "Study of HPN424 in Patients With Advanced Prostate Cancer",
    "GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease",
    "Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab",
    "A Study to Evaluate the Safety, Tolerability, PK, PD, and Clinical Activity of EQ001 in Subjects With aGVHD",
    "Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions / Translocations",
    "A Study of PRT543 in Participants With Advanced Solid Tumors and Hematologic Malignancies",
    "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)",
    "REGN5093 in Patients With MET-Altered Advanced Non-Small Cell Lung Cancer",
    "IMGN632 as Monotherapy or With Venetoclax and / or Azacitidine for Patients With CD123-Positive Acute Myeloid Leukemia",
    "A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma",
    "Study of TPX-0046, A RET / SRC Inhibitor in Adult Subjects With Advanced Solid Tumors Harboring RET Fusions or Mutations",
    "A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer",
    "A Study of Selpercatinib (LY3527723) in Participants With RET-Mutant Medullary Thyroid Cancer",
    "TTX-030 in Combination With Immunotherapy and / or Chemotherapy in Subjects With Advanced Cancers",
    "A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL)",
    "A Study of Selinexor in Combination With Standard of Care Therapy for Newly Diagnosed or Recurrent Glioblastoma",
    "Lenvatinib (E7080 / MK-7902) in Combination With Pembrolizumab (MK-3475) vs. Standard Chemotherapy and Lenvatinib Monotherapy in Participants With Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma That Progressed After Platinum Therapy and Immunotherapy (MK-7902-009 / E7080-G000-228 / LEAP-009)",
    "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations",
    "Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study",
    "HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer",
    "Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors",
    "Trial of Magrolimab (Hu5F9-G4) in Combination With Rituximab or Rituximab + Chemotherapy in Participants With Relapsed / Refractory B-cell Non-Hodgkin's Lymphoma",
    "Study of REGN3767 (Anti-LAG-3) With or Without REGN2810 (Anti-PD1) in Advanced Cancers",
    "Phase 1 / 2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors",
    "Study of LN-145, Autologous Tumor Infiltrating Lymphocytes in the Treatment of Patients With Cervical Carcinoma",
    "Phase 1-2 Study of Low Dose ASTX727 (ASTX727 LD) in Lower Risk MDS",
    "GEN3013 Trial in Patients With Relapsed, Progressive or Refractory B-Cell Lymphoma",
    "Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)",
    "Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma",
    "A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer",
    "A Safety and Efficacy Study Evaluating CTX110 in Subjects With Relapsed or Refractory B-Cell Malignancies (CARBON)",
    "Study of NGM120 in Subjects With Advanced Solid Tumors and Pancreatic Cancer Using Combination Therapy",
    "A Study to Evaluate Rucaparib in Patients With Solid Tumors and With Deleterious Mutations in HRR Genes",
    "A Study to Evaluate the Safety of bb2121 in Subjects With High Risk, Newly Diagnosed Multiple Myeloma (NDMM)",
    "Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients",
    "Oregovomab Plus Chemo in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer Following Optimal Debulking Surgery",
    "Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations",
    "A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer",
    "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion",
    "First-in-Human Study of XMT-1536 in Cancers Likely to Express NaPi2b",
    "Safety, Tolerability, Efficacy and Pharmacokinetics of Copanlisib in Pediatric Patients",
    "A Phase 3 Efficacy, Safety and Tolerability Study of Zolbetuximab (Experimental Drug) Plus mFOLFOX6 Chemotherapy Compared to Placebo Plus mFOLFOX6 as Treatment for Gastric and Gastroesophageal Junction (GEJ) Cancer",
    "Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma",
    "REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma",
    "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells Specific in NY-ESO-1 / LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab",
    "A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.",
    "Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630 / KEYNOTE-630)",
    "Study of HPN536 in Patients With Advanced Cancers Associated With Mesothelin Expression",
    "A Phase 1 Study in Patients With HPV16+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma",
    "A Phase 1 / 2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors",
    "Enfortumab Vedotin and Pembrolizumab vs. Chemotherapy Alone in Untreated Locally Advanced or Metastatic Urothelial Cancer",
    "Study of SRF388 in Patients With Advanced Solid Tumors",
    "A Study of Debio 1143 (Xevinapant) in Combination With Platinum-Based Chemotherapy and Standard Fractionation Intensity-Modulated Radiotherapy in Participants With Locally Advanced Squamous Cell Carcinoma of the Head and Neck, Suitable for Definitive Chemoradiotherapy",
    "First-in-Human Study of Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients With ICC and Other Advanced Solid Tumors",
    "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer",
    "Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And / Or Who Have No Satisfactory Treatment Options",
    "A Study of Nivolumab Plus Brentuximab Vedotin in Patients Between 5 and 30 Years Old, With Hodgkin's Lymphoma (cHL), Relapsed or Refractory From First Line Treatment",
    "Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed / Refractory Acute Myeloid Leukemia",
    "Intratumoral Cavrotolimod Combined With Pembrolizumab or Cemiplimab in Patients With Merkel Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, or Other Advanced Solid Tumors",
    "A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy",
    "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer",
    "Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid / Round Cell Liposarcoma",
    "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer",
    "A Study of Belzutifan (MK-6482) Versus Everolimus in Participants With Advanced Renal Cell Carcinoma (MK-6482-005)",
    "Pivotal, Randomized, Open-label Study of Optune® (Tumor Treating Fields) Concomitant With RT & TMZ for the Treatment of Newly Diagnosed GBM",
    "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma",
    "Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies",
    "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667 / KEYNOTE-667)",
    "A Study of ABBV-011 Alone and in Combination With Budigalimab (ABBV-181) in Participants With Relapsed or Refractory Small Cell Lung Cancer",
    "Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia",
    "A Study of Alectinib, Entrectinib, Vemurafenib Plus Cobimetinib, or Pralsetinib in Patients With Resectable Stages II-III Non-Small Cell Lung Cancer With ALK, ROS1, NTRK, BRAF V600, or RET Molecular Alterations",
    "A Study of Atezolizumab in Combination With Cabozantinib Compared to Cabozantinib Alone in Participants With Advanced Renal Cell Carcinoma After Immune Checkpoint Inhibitor Treatment",
    "Study to Evaluate Viralym-M (ALVR105) for the Treatment of Virus-Associated Hemorrhagic Cystitis (HC)",
    "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations",
    "A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051 / KEYNOTE-051)",
    "A Trial of Enzastaurin Plus Temozolomide During and Following Radiation Therapy in Patients With Newly Diagnosed Glioblastoma With or Without the Novel Genomic Biomarker, DGM1",
    "Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer",
    "A Study of DKN-01 in Combination With Tislelizumab ± Chemotherapy in Patients With Gastric or Gastroesophageal Cancer",
    "Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)",
    "MEK Inhibitor Mirdametinib (PD-0325901) in Patients With Neurofibromatosis Type 1 Associated Plexiform Neurofibromas",
    "Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and / or LAGE-1a Positive Solid Tumors",
    "A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression",
    "A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis",
    "A Study of Axatilimab at 3 Different Doses in Patients With Chronic Graft Versus Host Disease (cGVHD)",
    "A Study of Oral LOXO-305 in Patients With Previously Treated CLL / SLL or NHL",
    "Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients",
    "A Phase 1 / 2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of AMG 510 in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)",
    "A Study to Evaluate Enfortumab Vedotin in Subjects With Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)",
    "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements",
    "Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML",
    "A Study to Evaluate the Effectiveness and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis",
    "A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis",
    "Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors",
    "Tabelecleucel for Solid Organ or Allogeneic Hematopoietic Cell Transplant Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) After Failure of Rituximab or Rituximab and Chemotherapy",
    "Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study (MK-3475-587 / KEYNOTE-587)",
    "Study Of Palbociclib Combined With Chemotherapy In Pediatric Patients With Recurrent / Refractory Solid Tumors",
    "Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)",
    "Phase 2 Study of Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation",
    "Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients",
    "Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations",
    "Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence",
    "Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy",
    "A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous Stem Cell Transplant",
    "ENVASARC: Envafolimab And Envafolimab With Ipilimumab In Patients With Undifferentiated Pleomorphic Sarcoma Or Myxofibrosarcoma",
    "Study to Evaluate Eflornithine + Lomustine vs Lomustine in Recurrent Anaplastic Astrocytoma (AA) Patients",
    "A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer",
    "Study Evaluating Safety and Efficacy of JCAR017 in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)",
    "A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)",
    "Long-Term Follow-up Protocol for Subjects Treated With Gene-Modified T Cells",
    "A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer",
    "Phase 1 / 2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
    "A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma",
    "A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer",
    "Magrolimab + Azacitidine Versus Azacitidine + Placebo in Untreated Participants With Myelodysplastic Syndrome (MDS)",
    "Comparing an Operation to Monitoring, With or Without Endocrine Therapy (COMET) Trial For Low Risk DCIS",
    "Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)",
    "A Phase 2 Study of Ruxolitinib With Chemotherapy in Children With Acute Lymphoblastic Leukemia"
  ],
  "phase": [
    "I",
    "I",
    "II_III",
    "I",
    "II",
    "III",
    "I",
    "O",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "II",
    "II_III",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "II",
    "NA",
    "II",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "III",
    "III",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "III",
    "II",
    "I",
    "III",
    "II",
    "II",
    "I",
    "I",
    "III",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "III",
    "III",
    "I_II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "III",
    "III",
    "III",
    "II",
    "II",
    "II_III",
    "II",
    "III",
    "III",
    "III",
    "II",
    "II",
    "II",
    "III",
    "III",
    "II_III",
    "II",
    "II",
    "III",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "III",
    "II",
    "III",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "III",
    "II",
    "III",
    "III",
    "II",
    "III",
    "II",
    "III",
    "II_III",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "III",
    "II",
    "I",
    "III",
    "II_III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "III",
    "III",
    "II_III",
    "II_III",
    "II",
    "III",
    "III",
    "III",
    "II_III",
    "III",
    "II_III",
    "II",
    "II",
    "III",
    "III",
    "III",
    "III",
    "III",
    "II",
    "III",
    "II",
    "II",
    "II",
    "III",
    "III",
    "III",
    "III",
    "III",
    "III",
    "III",
    "II",
    "II_III",
    "III",
    "III",
    "III",
    "III",
    "I_II",
    "II",
    "II",
    "II_III",
    "III",
    "III",
    "II",
    "II",
    "II",
    "III",
    "II_III",
    "III",
    "III",
    "III",
    "III",
    "II",
    "II_III",
    "II",
    "II",
    "III",
    "II",
    "III",
    "II",
    "III",
    "II",
    "III",
    "III",
    "II",
    "III",
    "II_III",
    "III",
    "II",
    "II",
    "III",
    "III",
    "III",
    "III",
    "II",
    "II",
    "III",
    "II",
    "II_III",
    "II",
    "II_III",
    "II",
    "III",
    "III",
    "III",
    "II",
    "III",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II_III",
    "II",
    "II",
    "I_II",
    "NA",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "I_II",
    "NA",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "I",
    "I",
    "I",
    "III",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "NA",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "NA",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "NA",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I_II",
    "III",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "NA",
    "I_II",
    "II",
    "I_II",
    "II",
    "O",
    "II",
    "I",
    "O",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "O",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "O",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "III",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "O",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "IV",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "NA",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "O",
    "I",
    "II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "O",
    "I_II",
    "I_II",
    "II",
    "I",
    "NA",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "NA",
    "NA",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "O",
    "I_II",
    "I",
    "I",
    "II",
    "I_II",
    "O",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "NA",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "NA",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "I",
    "III",
    "III",
    "NA",
    "II",
    "I",
    "II",
    "NA",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I_II",
    "NA",
    "I_II",
    "O",
    "O",
    "II",
    "II",
    "NA",
    "I",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "NA",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "O",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "NA",
    "I_II",
    "II",
    "I",
    "I_II",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "O",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "NA",
    "NA",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "NA",
    "II",
    "I",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "NA",
    "III",
    "II",
    "O",
    "I_II",
    "II",
    "O",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "O",
    "II",
    "O",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "NA",
    "O",
    "II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I",
    "II",
    "I_II",
    "I",
    "III",
    "NA",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "NA",
    "I",
    "I",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "NA",
    "I",
    "I",
    "O",
    "IV",
    "I",
    "I",
    "II",
    "II",
    "O",
    "O",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "O",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "O",
    "II",
    "O",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "I_II",
    "O",
    "I",
    "II",
    "NA",
    "II",
    "I",
    "II",
    "O",
    "II",
    "II",
    "NA",
    "II",
    "I_II",
    "O",
    "I",
    "I",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "I",
    "I",
    "O",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "O",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "I",
    "I",
    "III",
    "I",
    "I_II",
    "I",
    "NA",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "III",
    "I",
    "O",
    "II",
    "II",
    "O",
    "I",
    "O",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "O",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "I",
    "O",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "NA",
    "II",
    "I",
    "I",
    "I",
    "I",
    "O",
    "II",
    "I",
    "II",
    "II",
    "O",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "I_II",
    "I",
    "NA",
    "IV",
    "I",
    "II",
    "I_II",
    "II",
    "O",
    "II",
    "I_II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "IV",
    "NA",
    "I",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "I_II",
    "O",
    "I",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "II",
    "III",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "O",
    "I",
    "NA",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "NA",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "O",
    "II",
    "I",
    "I",
    "NA",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "NA",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II_III",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "O",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "III",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "NA",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "II",
    "NA",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "O",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "I",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "IV",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "NA",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I_II",
    "NA",
    "O",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "II",
    "I",
    "NA",
    "I",
    "O",
    "O",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "O",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "III",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "NA",
    "I",
    "NA",
    "I_II",
    "I_II",
    "O",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "NA",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "O",
    "I",
    "III",
    "II",
    "I_II",
    "I_II",
    "I",
    "O",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "NA",
    "I_II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "O",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "O",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I",
    "NA",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I",
    "II",
    "NA",
    "I",
    "I",
    "NA",
    "I",
    "II",
    "I_II",
    "II",
    "NA",
    "I",
    "NA",
    "NA",
    "I",
    "NA",
    "NA",
    "I",
    "NA",
    "I",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "NA",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "O",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I",
    "NA",
    "NA",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "O",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "III",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "O",
    "II",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "NA",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "NA",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "NA",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "IV",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "O",
    "II",
    "O",
    "NA",
    "II",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "III",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "III",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "O",
    "I",
    "O",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "III",
    "I",
    "III",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "III",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "NA",
    "II",
    "II",
    "I_II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "O",
    "I",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "NA",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "O",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II_III",
    "I",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "O",
    "II",
    "NA",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "O",
    "II",
    "III",
    "II",
    "II",
    "O",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "II",
    "III",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "I",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "O",
    "III",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "O",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "NA",
    "III",
    "II",
    "II",
    "O",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "III",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "IV",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II_III",
    "II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II_III",
    "III",
    "NA",
    "II",
    "II",
    "O",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "III",
    "IV",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "III",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "III",
    "I",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "II",
    "NA",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "NA",
    "I",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "NA",
    "I",
    "I_II",
    "III",
    "I",
    "II",
    "I",
    "I",
    "O",
    "II",
    "I",
    "II",
    "III",
    "I_II",
    "NA",
    "II",
    "III",
    "I",
    "I",
    "I",
    "O",
    "I",
    "NA",
    "I",
    "I",
    "O",
    "II",
    "I_II",
    "NA",
    "I",
    "NA",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "NA",
    "II",
    "I_II",
    "I",
    "I_II",
    "I",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "NA",
    "I",
    "I",
    "NA",
    "I",
    "II",
    "II",
    "I",
    "I",
    "III",
    "O",
    "I",
    "NA",
    "I",
    "NA",
    "I",
    "O",
    "I",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "NA",
    "NA",
    "II",
    "I",
    "I",
    "I",
    "III",
    "O",
    "II",
    "NA",
    "II",
    "II",
    "NA",
    "I",
    "I",
    "I",
    "NA",
    "I",
    "II",
    "II",
    "I",
    "II",
    "II",
    "NA",
    "II",
    "I",
    "II",
    "I_II",
    "NA",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "III",
    "NA",
    "II",
    "II",
    "NA",
    "NA",
    "NA",
    "O",
    "IV",
    "II",
    "III",
    "I",
    "I",
    "II",
    "I",
    "NA",
    "II",
    "O",
    "II",
    "NA",
    "II",
    "O",
    "NA",
    "I",
    "II",
    "I_II",
    "NA",
    "I",
    "NA",
    "I",
    "I",
    "NA",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "O",
    "I",
    "I",
    "I",
    "II",
    "III",
    "I",
    "NA",
    "I",
    "II",
    "II",
    "I",
    "IV",
    "IV",
    "III",
    "NA",
    "O",
    "I_II",
    "NA",
    "I",
    "II",
    "I",
    "NA",
    "I",
    "I",
    "II",
    "II",
    "NA",
    "I",
    "II",
    "II",
    "II",
    "I",
    "NA",
    "III",
    "NA",
    "I_II",
    "I",
    "NA",
    "II",
    "II",
    "O",
    "NA",
    "II",
    "I",
    "I",
    "NA",
    "III",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "III",
    "NA",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "O",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "III",
    "II",
    "II",
    "II",
    "III",
    "NA",
    "NA",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "II",
    "NA",
    "II",
    "NA",
    "I_II",
    "II",
    "II",
    "II",
    "NA",
    "O",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "NA",
    "II",
    "II",
    "NA",
    "II",
    "I_II",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "NA",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II_III",
    "II",
    "II",
    "NA",
    "III",
    "II",
    "I",
    "III",
    "NA",
    "II",
    "III",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "IV",
    "III",
    "I_II",
    "I",
    "I_II",
    "II",
    "I_II",
    "III",
    "I_II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "III",
    "I_II",
    "II",
    "II",
    "II",
    "III",
    "I_II",
    "I",
    "I_II",
    "II",
    "NA",
    "III",
    "I",
    "I_II",
    "I_II",
    "I",
    "I",
    "I_II",
    "III",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "III",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "I",
    "III",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I",
    "II",
    "III",
    "II",
    "II",
    "I",
    "II",
    "III",
    "I",
    "II",
    "I_II",
    "I_II",
    "IV",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "II_III",
    "I_II",
    "I",
    "I",
    "I",
    "NA",
    "I",
    "I",
    "I",
    "III",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I",
    "III",
    "I",
    "NA",
    "I_II",
    "II",
    "I",
    "I_II",
    "I_II",
    "NA",
    "I_II",
    "I_II",
    "IV",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "III",
    "I_II",
    "II_III",
    "I",
    "I_II",
    "I_II",
    "I",
    "NA",
    "I",
    "I",
    "I_II",
    "III",
    "I_II",
    "I_II",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "NA",
    "III",
    "I",
    "I_II",
    "II",
    "NA",
    "III",
    "I_II",
    "I",
    "II",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "NA",
    "I",
    "I",
    "I",
    "I_II",
    "III",
    "II",
    "I_II",
    "I",
    "II",
    "III",
    "NA",
    "III",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I",
    "III",
    "I",
    "III",
    "I",
    "I",
    "II",
    "II",
    "III",
    "II",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "III",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "NA",
    "I",
    "I",
    "II",
    "I",
    "III",
    "I",
    "I_II",
    "III",
    "II",
    "I",
    "I_II",
    "NA",
    "III",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "II",
    "I",
    "II_III",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "I",
    "III",
    "III",
    "I",
    "I",
    "I",
    "II",
    "III",
    "I",
    "I",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "III",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "NA",
    "I",
    "I_II",
    "I",
    "I_II",
    "III",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "III",
    "I",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "III",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "I_II",
    "III",
    "III",
    "III",
    "II",
    "III",
    "III",
    "I_II",
    "III",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "III",
    "I",
    "II",
    "I",
    "I_II",
    "III",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "II",
    "I_II",
    "III",
    "I",
    "I",
    "IV",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "II",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "III",
    "NA",
    "I",
    "I",
    "III",
    "I",
    "I",
    "III",
    "I",
    "III",
    "II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "III",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "III",
    "III",
    "II",
    "I",
    "II",
    "I_II",
    "IV",
    "I",
    "II",
    "I",
    "III",
    "I",
    "III",
    "I",
    "I",
    "I",
    "I_II",
    "II",
    "I",
    "II",
    "III",
    "II_III",
    "II",
    "I",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "III",
    "II",
    "I",
    "I",
    "III",
    "II",
    "I",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "III",
    "I",
    "I",
    "II",
    "I",
    "II",
    "III",
    "I_II",
    "II",
    "I",
    "III",
    "II_III",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "I_II",
    "III",
    "I_II",
    "III",
    "I_II",
    "II",
    "II",
    "I_II",
    "II",
    "I",
    "I",
    "I",
    "I",
    "III",
    "I_II",
    "II",
    "NA",
    "I",
    "I_II",
    "I_II",
    "I",
    "II_III",
    "I",
    "II_III",
    "I_II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "NA",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "III",
    "I",
    "I",
    "II",
    "III",
    "I",
    "I_II",
    "NA",
    "I",
    "I",
    "III",
    "IV",
    "I_II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "III",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "III",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I",
    "III",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "I_II",
    "II",
    "III",
    "III",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "III",
    "I",
    "III",
    "I_II",
    "I",
    "I_II",
    "IV",
    "II",
    "III",
    "NA",
    "II",
    "I_II",
    "NA",
    "I_II",
    "I_II",
    "I",
    "I",
    "II",
    "I",
    "II",
    "I_II",
    "I",
    "III",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "I",
    "II",
    "II",
    "I",
    "II_III",
    "I",
    "II",
    "III",
    "I_II",
    "II",
    "I",
    "I_II",
    "III",
    "I_II",
    "I_II",
    "III",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "III",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "III",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "I",
    "I",
    "III",
    "III",
    "I",
    "I",
    "I",
    "IV",
    "III",
    "III",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "III",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I",
    "III",
    "II",
    "I_II",
    "I",
    "II",
    "III",
    "I",
    "I_II",
    "III",
    "II",
    "I_II",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "III",
    "III",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "I_II",
    "I_II",
    "II_III",
    "I",
    "I",
    "I",
    "NA",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "III",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "II",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "I",
    "IV",
    "I_II",
    "I",
    "I_II",
    "II",
    "II",
    "I",
    "I",
    "I",
    "III",
    "III",
    "II",
    "I",
    "I_II",
    "I",
    "III",
    "I_II",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "III",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "I",
    "III",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "III",
    "I_II",
    "II_III",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "II",
    "III",
    "I",
    "I",
    "I",
    "III",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "I_II",
    "III",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "O",
    "I_II",
    "I",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "II",
    "I_II",
    "I",
    "II",
    "I",
    "III",
    "II",
    "III",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "I",
    "I",
    "I",
    "III",
    "I_II",
    "I_II",
    "IV",
    "III",
    "I",
    "I",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I",
    "II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "III",
    "I",
    "III",
    "II",
    "O",
    "III",
    "I",
    "I",
    "I_II",
    "II_III",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I",
    "NA",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "I_II",
    "III",
    "III",
    "I_II",
    "III",
    "I",
    "II",
    "I_II",
    "I",
    "III",
    "I_II",
    "II",
    "I_II",
    "I",
    "I_II",
    "I",
    "III",
    "III",
    "I_II",
    "I_II",
    "I",
    "I",
    "I",
    "I",
    "I",
    "III",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I",
    "II_III",
    "I_II",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I",
    "II",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "II",
    "I",
    "I",
    "II",
    "II",
    "II",
    "I",
    "II",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "I_II",
    "I",
    "II_III",
    "II",
    "III",
    "I",
    "III",
    "I",
    "I",
    "I",
    "III",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "III",
    "I",
    "I",
    "III",
    "I_II",
    "I",
    "I_II",
    "I",
    "I",
    "III",
    "III",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "III",
    "I_II",
    "III",
    "III",
    "III",
    "II",
    "I",
    "I",
    "I_II",
    "II",
    "I",
    "I_II",
    "I_II",
    "II",
    "I",
    "I_II",
    "I",
    "II",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "III",
    "I",
    "I_II",
    "I_II",
    "III",
    "III",
    "II",
    "II",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "I",
    "III",
    "I",
    "I",
    "II",
    "II",
    "I",
    "I_II",
    "II_III",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "I",
    "III",
    "I_II",
    "I_II",
    "I_II",
    "II",
    "II",
    "III",
    "I_II",
    "II",
    "II",
    "III",
    "I_II",
    "II",
    "II",
    "III",
    "I",
    "I",
    "II",
    "III",
    "III",
    "I",
    "I",
    "II_III",
    "III",
    "NA",
    "II",
    "I",
    "III",
    "I",
    "I",
    "I",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "III",
    "I",
    "I",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "I",
    "I",
    "I_II",
    "I",
    "II",
    "III",
    "III",
    "III",
    "I_II",
    "I_II",
    "II_III",
    "III",
    "III",
    "II_III",
    "I",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "III",
    "I",
    "I_II",
    "I",
    "II",
    "III",
    "I",
    "I_II",
    "I_II",
    "I",
    "I_II",
    "II",
    "III",
    "I",
    "I_II",
    "I_II",
    "II",
    "I",
    "I",
    "I_II",
    "I_II",
    "II",
    "I",
    "III",
    "I",
    "I",
    "II",
    "I",
    "I_II",
    "I",
    "I",
    "II",
    "III",
    "II",
    "II",
    "III",
    "III",
    "III",
    "I",
    "I",
    "I",
    "III",
    "I_II",
    "II",
    "III",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "I_II",
    "II",
    "III",
    "I",
    "II",
    "II",
    "I",
    "I",
    "I_II",
    "I",
    "I_II",
    "I",
    "III",
    "I_II",
    "III",
    "II",
    "I",
    "I",
    "III",
    "I",
    "III",
    "I",
    "I_II",
    "III",
    "III",
    "I_II",
    "III",
    "I",
    "I_II",
    "II",
    "II",
    "I_II",
    "I_II",
    "III",
    "II",
    "II",
    "II",
    "III",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "II",
    "II",
    "I_II",
    "I",
    "I",
    "II",
    "II",
    "I",
    "III",
    "III",
    "II",
    "II",
    "I",
    "I",
    "I",
    "I_II",
    "I_II",
    "I",
    "III",
    "I",
    "III",
    "II_III",
    "I_II",
    "III",
    "I",
    "I_II",
    "I",
    "II",
    "II",
    "I_II",
    "III",
    "II",
    "I",
    "III",
    "II_III",
    "I",
    "II",
    "III",
    "I_II",
    "III",
    "II",
    "III",
    "I_II",
    "II_III",
    "I",
    "I_II",
    "I",
    "III",
    "I_II",
    "III",
    "I_II",
    "III",
    "III",
    "III",
    "III",
    "II_III",
    "I_II",
    "I_II",
    "III",
    "I_II",
    "II",
    "III",
    "III",
    "III",
    "III",
    "II",
    "II",
    "I",
    "II",
    "I_II",
    "II",
    "II",
    "I",
    "I_II",
    "III",
    "I",
    "I",
    "II",
    "I_II",
    "I",
    "I",
    "I_II",
    "I_II",
    "III",
    "I",
    "III",
    "I",
    "I_II",
    "III",
    "III",
    "III",
    "III",
    "II",
    "II",
    "III",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "II",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "III",
    "I",
    "II",
    "I",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "I_II",
    "I_II",
    "III",
    "II",
    "I",
    "II",
    "III",
    "II",
    "III",
    "I",
    "I",
    "III",
    "I_II",
    "I_II",
    "I_II",
    "I_II",
    "II_III",
    "I_II",
    "I_II",
    "III",
    "I",
    "II",
    "I_II",
    "I_II",
    "II",
    "I_II",
    "I",
    "III",
    "I",
    "I_II",
    "I_II",
    "II",
    "II",
    "II",
    "II",
    "I",
    "I_II",
    "I",
    "I_II",
    "II",
    "I_II",
    "I_II",
    "III",
    "III",
    "III",
    "I",
    "I_II",
    "II",
    "I",
    "II",
    "III",
    "I",
    "II",
    "I_II",
    "I_II",
    "I_II",
    "III",
    "II",
    "I_II",
    "I_II",
    "II",
    "III",
    "I_II",
    "I",
    "I_II",
    "III",
    "I",
    "III",
    "I",
    "I",
    "I_II",
    "II",
    "III",
    "I_II",
    "III",
    "II",
    "II",
    "I",
    "III",
    "NA",
    "I_II",
    "I",
    "II",
    "I",
    "II",
    "II",
    "III",
    "III",
    "II",
    "I_II",
    "III",
    "II",
    "II",
    "III",
    "II",
    "II",
    "III",
    "III",
    "II",
    "I_II",
    "III",
    "I_II",
    "II",
    "I_II",
    "III",
    "III",
    "III",
    "I_II",
    "III",
    "III",
    "II",
    "I_II",
    "II",
    "II",
    "III",
    "III",
    "II",
    "III",
    "II",
    "III",
    "I_II",
    "I_II",
    "III",
    "II_III",
    "I_II",
    "I_II",
    "II_III",
    "III",
    "III",
    "NA",
    "III",
    "II"
  ],
  "study_source": [
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "National",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Institutional",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Externally Peer Reviewed",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial",
    "Industrial"
  ],
  "biomarker_exc_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR T790M Mutation Negative (EGFR NP_005219.2:p.T790M Negative; Receptor Tyrosine-Protein Kinase erbB-1 T790M Negative; EGFR NP_005219.2:p.Thr790Met Negative; Proto-Oncogene c-ErbB-1 T790M Negative; EGFR Thr790Met Negative; Epidermal Growth Factor Recept",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 19 Deletion Mutation (C126892) | EGFR NP_005219.2:p.L858R (C98515) | EGFR NP_005219.2:p.L861Q (C98497) | EGFR NP_005219.2:p.G719X (C107154) | ALK Gene Rearrangement (C129574)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR T790M (T790M EGFR Gene Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 20 Mutation (HER1 Exon 20; PIG61 Exon 20; Epidermal Growth Factor Receptor Gene Exon 20 Mutation; ERBB1 Exon 20; ERBB Exon 20 Mutation; mENA Exon 20; ERBB Exon 20; ERBB1 Exon 20 Mutation; HER1 Exon 20 Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR T790M (T790M EGFR Gene Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR T790M (T790M EGFR Gene Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Fusion Gene Positive (Anaplastic Lymphoma Receptor Tyrosine Kinase Fusion Gene Alteration Positive; CD246 Fusion Gene Positive; ALK Fusion Gene Present; ALK Gene Fusion; Anaplastic Lymphoma Kinase Fusion Gene Positive; ALK Fusion Oncogene Positive; An",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Sensitizing EGFR Gene Mutation (C153232) | Sensitizing ALK Gene Mutation (C147074) | Sensitizing ROS1 Gene Mutation (C171079) | Sensitizing BRAF Gene Mutation (C171078)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Mutation (CD246 Gene Mutation; Anaplastic Lymphoma Kinase Receptor Gene Mutation; Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (Anaplastic Lymphoma Kinase Gene Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Translocation (Anaplastic Lymphoma Receptor Tyrosine Kinase Gene Translocation; Anaplastic Lymphoma Kinase Gene Translocation; ALK Gene Translocation; CD246 Gene Translocation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating KRAS Mutation (v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog Activating Mutation; KRAS-2 Activating Mutation; KRAS Proto-Oncogene, GTPase Activating Mutation; KRAS Activating Mutation; KRAS2 Activating Mutation; c-K-ras Activating Mutati",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | ALK Gene Mutation (C81945) | ROS1 Gene Mutation (C130952) | MET Gene Mutation (C39788) | BRAF Gene Mutation (C40430)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HLA-A*0205 Positive Cells Present (HLA-A*02:05 Positive Cells Present; HLA-A*02:05 Positive; HLA-A*0205 Positive; HLA-A0205 Positive)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "BRAF Gene Mutation Negative (v-raf Murine Sarcoma Viral Oncogene Homolog B1 Gene Mutation Negative; BRAF Mutation Negative; BRAF Wildtype; BRAF wt; B-RAF Gene Mutation Negative; B-RAF1 Gene Mutation Negative)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ROS1 Gene Mutation (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation; MCF3 Gene Mutation; ROS Gene Mutation; ROS1 Mutation; c-ros-1 Gene Mutation)",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ROS1 Gene Mutation (ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Mutation; MCF3 Gene Mutation; ROS Gene Mutation; ROS1 Mutation; c-ros-1 Gene Mutation)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Stable (MSS)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS Gene Rearrangement",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ROS1 Gene Rearrangement (ROS Gene Rearrangement; c-ros-1 Gene Rearrangement; MCF3 Gene Rearrangement; ROS Proto-Oncogene 1, Receptor Tyrosine Kinase Gene Rearrangement; ROS1 Rearrangement)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "biomarker_inc_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR exon 21 L858R mutation (C98516:C98517:C98518:C9851) | Activating EGFR Gene Mutation Negative (C134494) | EGFR Exon 19 Deletion (C126892) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS NP_004976.2:p.G12C (C98365)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Sensitizing EGFR Mutation Negative (C160967) | ALK Gene Rearrangement Negative (C134487)",
    "",
    "",
    "TP53 Negative (C156049)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "ALK Positive (C128831) | ALK Translocation (C129703) | ALK Gene Rearrangement (C129574)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Translocation (C129572) | ROS1 Translocation (C129704) | ROS1 Gene Mutation (C130952) | EGFR Gene Mutation (C98357) | ALK Gene Mutation (C81945) | ALK Positive (C128831) | ALK Translocation (C129703) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "ALK Positive (C128831) | ROS1 Gene Rearrangement (C130236) | ALK Gene Rearrangement (C129574) ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Castration Levels of Testosterone (C129259)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | ALK Gene Mutation (C81945) | ALK Positive (C128831) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ERBB2 Gene Mutation (C96866) | EGFR Exon 20 Mutation (C128663) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Folate Receptor Alpha Positive (C131327)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361) | ALK Gene Mutation (C81945) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "BRCA1 Gene Mutation (C19635) | BRCA2 Gene Mutation (C19636)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "RB1 Gene Mutation Negative (C153496)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Sensitizing EGFR Gene Mutation (C153232)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Triple-Negative Breast Cancer Finding (C71428) | Estrogen Receptor Negative (C15493) | HER2/Neu Negative (C68749) | Progesterone Receptor Negative (C15497) | Microsatellite Instability (C36318) | MMR Mutation (C133706)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Folate Receptor Alpha Positive (C131327)",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Protein Deficiency (C137827)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 19 Gene Mutation (C128662) | EGFR Exon 21 Gene Mutation (C128666) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Folate Receptor Alpha Positive (C131327) | Microsatellite Stable (C131459)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831) | ROS1 Gene Rearrangement (C130236)",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 19 Deletion (C126892) | EGFR Exon 21 L861Q Mutation (C98497) | EGFR NP_005219.2:p.L833F (C163746) | EGFR NP_005219.2:p.V769L (C163752) | EGFR exon 18 G719X (C107154) | EGFR S768I (C125209:C125210) | EGFR T790M (C98504:C98503) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MET Exon 14 Mutation (C127129) | NTRK1 Gene Rearrangement (C46006) | NTRK2 Gene Rearrangement (C131321) | NTRK3 Gene Rearrangement (C131325)",
    "",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361) | PTEN Loss (C96270) | PIK3CA Gene Mutation (C96271) | HPV Negative (C131488)",
    "",
    "ROS1 Gene Rearrangement (C130236) | ALK Gene Rearrangement (C129574) | ALK Positive (C128831)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR S768I (C125209:C125210) | EGFR Exon 21 L861Q Mutation (C98497) | EGFR exon 18 G719X (C107154) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 19 Deletion (C126892) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating EGFR Gene Mutation (C92172) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712) | PD-L1 Positive (C128554) | ALK Gene Mutation (C81945) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501) | BRAF Gene Mutation (C40430)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating EGFR Gene Mutation (C92172) | EGFR Gene Amplification (C36649) | IDH Gene Family Wildtype (C136567) | EGFRvIII (C101139:C101140) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Ganglioside GD2 Positive (C129573)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating EGFR Gene Mutation (C92172) | EGFR Exon 19 Deletion (C126892) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "EGFR T790M (T790M EGFR Gene Mutation) | EGFR Exon 19 Deletion (C126892) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Positive (C134501) | EGFR Gene Mutation (C98357)  ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ROS1 Gene Mutation (C130952) | RET Gene Mutation (C43293)",
    "EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR T790M (C98504:C98503) | EGFR Exon 19 Deletion (C126892) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Mutation (C81945) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HER2 Amplification (C36638) | ERBB2 Gene Mutation (C96866) | Activating ERBB2 Mutation (C129700) | HER2/Neu Positive (C68748)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating EGFR Gene Mutation (C92172) | TP53 Gene Alteration Positive (C157565) | RB1 Gene Alteration Positive (C157566) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating EGFR Gene Mutation (C92172) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "Triple-Negative Breast Cancer Finding (C71428) | EGFR Gene Mutation Negative (C148091) | ALK Gene Rearrangement Negative (C134487) | HER2/Neu Negative (C68749) | Progesterone Receptor negative (C15497) | ROS1 Gene Rearranagement Negative (C147054) | Estrogen Receptor Negative (C15493)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MET Overexpression Positive (C148403) | AXL Overexpression Positive (C148406) | AXL Gene Amplification (C141275) | MET Gene Amplification (C43532) | KIF5B-RET Fusion (C114800:C114799) | ROS1 Fusion (C131071) | MET Gene Mutation (C39788) | AXL Gene Mutation (C141276) | NTRK1 Fusion (C131070) | RET Fusion (C131069)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428) | Progesterone Receptor Negative (C15497) | Estrogen Receptor Negative (C15493)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 21 Gene Mutation (C128666) | EGFR Gene Mutation Negative (C148091) | EGFR Exon 19 Gene Mutation (C128662) ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ROR1 Positive (C142123)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "BRAF V600E Mutation (Serine/Threonine-Protein Kinase B-raf Val600Glu; …) (C98342)",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361) | NRAS Gene Mutation (C41381)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NTRK2 Fusion Positive (C132235) | NTRK3 Fusion Positive (C132236) | NTRK1 Fusion (C131070)",
    "HLA-A*0201 Positive (C69178)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Exon 19 Deletion (C126892) | EGFR exon 18 G719X (C107154) | EGFR Gene Mutation (C98357) | EGFR Exon 21 L861Q Mutation (C98497) | EGFR T790M Mutation Negative (C131326) | EGFR Positive (C134501)",
    "ALK Positive (C128831) | ALK Gene Rearrangement (C129574)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831)",
    "",
    "TP53 wt Allele (C52271) | HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428) | HPV Positive (C128839) | Progesterone Receptor Negative (C15497) | Estrogen Receptor Negative (C15493)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MDM2 Gene Amplification (C36681) | TP53 wt Allele (C52271)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "CD274 (C96024)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 20 Insertion (C125605) | NRG1 Gene Fusion Positive (C164193) | Activating ERBB2 Mutation (C129700) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501) | ERBB2 Gene Mutation (C96866)",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Activating Mutation (C92172) | EGFR Gene Mutation (C98357) | c-MET Gene Amplification (C43532)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Stable (MSS) (C131459)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "BRAF Gene Mutation (C40430)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712) | HLA-A*02 Positive (C69408) | BRCA1 Gene Mutation (C19635) | BRCA2 Gene Mutation (C19636)",
    "",
    "",
    "HLA-A*0202 Positive Cells Present (C147058) | PD-L1 Positive (C128554)",
    "",
    "",
    "HLA Phenotype Positive (C154157)",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HER2/Neu Positive (C68748) | ERBB2 Gene Mutation (C96866) | ALK Gene Mutation (C81945) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501) | BRAF V600E Mutation (C98342) | ROS1 Fusion (C131071)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "KRAS Gene Mutation (C41361)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NRAS Gene Mutation (C41381) | BRAF Gene Mutation (C40430) | KRAS Gene Mutation (C41361)",
    "KRAS NP_004976.2:p.G12C (KRAS NP_004976.2:p.Gly12Cys; KRAS p.G12C; Ki-Ras G12C; KRAS Gly12Cys; K-Ras 2 G12C; KRAS G12C; KRAS G12C Mutation; c-K-ras G12C; GTPase KRas G12C; KRAS p.Gly12Cys)",
    "",
    "",
    "HLA-A*0201 Positive (C69178)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428) | Estrogen Receptor Negative (C15493) | Progesterone Receptor Negative (C15497)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HER2/Neu Negative (C68749) | Estrogen Receptor Negative (C15493) | Triple-Negative Breast Cancer Finding (C71428) | Progesterone Receptor Negative (C15497)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Progesterone Receptor Negative (C15497) | Estrogen Receptor Negative (C15493)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EPHA2 Protein Overexpression (C131065)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK wt Allele (C51738) | KRAS Wildtype (C52546) | EGFR wt Allele (C51744) | ROS1 Fusion Negative (C142839) | HER2/Neu Positive (C68748) | ERBB2 Gene Mutation (C96866)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Triple-Negative Breast Cancer Finding (C71428) | Progesterone Receptor Negative (C15497) | HER2/Neu Negative (C68749) | Estrogen Receptor Negative (C15493)",
    "Mismatch Repair Deficiency (C136712) | Microsatellite Instability High (C36493) | ALK Gene Translocation Negative (C134488) | HPV Negative (C131488)",
    "",
    "",
    "",
    "",
    "",
    "TACSTD2 (Pancreatic Carcinoma Marker Protein GA733-1; Membrane Component, Chromosome 1, Surface Marker 1; …) (C17774)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Estrogen Receptor Negative (C15493) | Progesterone Receptor Negative (C15497) | HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD-L1 Positive (C128554) | Activating EGFR Gene Mutation Negative (C134494)",
    "",
    "",
    "",
    "",
    "",
    "Mesothelin Positive (C128841)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "RET Fusion (C131069)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ATM Deficient Tumor (ATM Serine/Threonine Kinase Deficient Tumor; AT Mutated Deficient Tumor; Ataxia Telangiectasia Mutated Deficient Tumor; Serine-Protein Kinase ATM Deficient Tumor; A-T Mutated Deficient Tumor)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428)",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712) | FLT3 Internal Tandem Duplication (C67494) | IDH1/2 Mutation Status by Sequencing (C157186)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MSI-H Negative (C157521) | KRAS NP_004976.2:p.G12D (C98369) | KRAS NP_004976.2:p.G13D (C98403) | KRAS NP_004976.2:p.G12C (C98365) | HLA-C*0802 Positive Cells Present (C163011) | HLA-A*1101 Positive Cells Present (C140184) | KRAS NP_004976.2:p.G12V (C98391)",
    "",
    "",
    "ERBB2 Gene Mutation (C96866) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "EGFR Exon 20 Insertion (C125605) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "DNA Damage Response Deficiency (C123152)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR exon 18 G719X (C107154) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Exon 21 L861Q Mutation (C98497) | EGFR Exon 19 Deletion (C126892) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MET Gene Amplification (C43532) | MET Gene Fusion Positive (C136235) | MET Exon 14 Skipping Mutation (C131179)",
    "",
    "Progesterone Receptor Negative (C15497) | Triple-Negative Breast Cancer Finding (C71428) | HER2/Neu Negative (C68749) | TnMUC1 Positive (C165422) | Estrogen Receptor Negative (C15493)",
    "EGFR wt Allele (C51744) | HER2/Neu Positive (C68748) | ERBB2 Gene Mutation (C96866) | PD-L1 Positive (C128554)",
    "MAGEA4 Positive (Cancer/Testis Antigen 1.4 Positive;…) (C147078) | HLA-A*02 Positive (C69408)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PTK7 Positive (C171069) | EPHA2 Protein Overexpression (C131065)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 19 Deletion (C126892) | EGFR NP_005219.2:p.L858R (C98515) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "Estrogen Receptor Negative (C15493) | HER2/Neu Negative (C68749) | Microsatellite Instability High (C36493) | Triple-Negative Breast Cancer Finding (C71428) | Mismatch Repair Deficiency (C136712) | Progesterone Receptor Negative (C15497)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "ALK Gene Rearrangement (C129574) | ALK Positive (C128831) | ROS1 Gene Rearrangement (C130236) | NTRK2 Gene Rearrangement (C131321) | NTRK3 Gene Rearrangement (C131325) | NTRK1 Gene Rearrangement (C46006)",
    "",
    "",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | MET Positive (C131068) | EGFR wt Allele (C51744) | MET Gene Amplification (C43532) | EGFR Positive (C134501)",
    "Estrogen Receptor Positive (C15492) | Progesterone Receptor Positive (C15496) | CD276 (C93063) | HER2/Neu Negative (C68749)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Progesterone Receptor Negative (C15497) | Estrogen Receptor Negative (C15493) | Mismatch Repair Deficiency (C136712) | HER2/Neu Negative (C68749) | Microsatellite Instability high (C36493) | Triple-Negative Breast Cancer Finding (C71428)",
    "",
    "Castration Levels of Testosterone (C129259) | PSA Level Two or Greater (C137697) | PSA Progression (C123611) | Testosterone Less than 50 ng/dL (157378)",
    "",
    "",
    "",
    "EGFR Exon 19 Deletion (C126892) | EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Gene Mutation (C98357) | MET Overexpression Positive (C148403) | MET Gene Amplification (C43532) | EGFR Positive (C134501)",
    "Castration Levels of Testosterone (C129259) | Testosterone Less than 50 ng/dL (C157378) | EGFR Gene Mutation (C98357) | ALK Gene Mutation (C81945) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "MET Exon 14 Skipping Mutation (C131179) | MET Gene Fusion Positive (C136235) | MET Gene Amplification (C43532) ",
    "",
    "",
    "",
    "",
    "Progesterone Receptor Negative (C15497) | EBV Positive (C129454) | Estrogen Receptor Negative (C15493) | HER2/Neu Negative (C68749) | Triple-Negative Breast Cancer Finding (C71428)",
    "",
    "",
    "",
    "EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "MET Gene Amplification (C43532) | MET Exon 14 Mutation (C127129)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Microsatellite Instability High (C36493) | Mismatch Repair Deficiency (C136712)",
    "",
    "",
    "RET Fusion (C131069) | RET Gene Mutation (C43293) | RET Rearrangement (C46005)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NRG1 Gene Fusion Positive (C164193)",
    "",
    "",
    "",
    "",
    "",
    "NY-ESO-1 (Cancer/Testis Antigen 1; CTAG1B; Cancer/Testis Antigen 1-B; ESO1; CTAG1A; …) (C39286)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR exon 21 L858R mutation (C98516:C98517:C98518:C98515) | EGFR Exon 19 Deletion (C126892) | MET Gene Mutation (C39788) | EGFR Exon 20 Insertion (C125605) | MET Gene Amplification (C43532) | Activating EGFR Gene Mutation (C92172) | MET Exon 14 Skipping Mutation (C131179) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501)",
    "",
    "",
    "",
    "",
    "",
    "BRAF V600E Mutation (Serine/Threonine-Protein Kinase B-raf Val600Glu; …) (C98342)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Activating ERBB2 Mutation (C129700) | Activating ERBB3 Mutation (C141370) | EGFR Gene Amplification (C36649) | Activating EGFR Gene Mutation (C92172) | EGFR Gene Mutation (C98357) | EGFR Positive (C134501) | ERBB2 Gene Mutation (C96866) | ERBB3 Gene Mutation (C138064)",
    "PD-L1 Positive (C128554)",
    "",
    "",
    "",
    "",
    "",
    "",
    "Folate Receptor Alpha Positive (C131327)",
    "",
    "",
    "",
    "NA",
    "KRAS NP_004976.2:p.G12C (C98365)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR Exon 20 Insertion (C125605) | Activating ERBB2 Mutation (C129700) | Activating EGFR Gene Mutation (C92172) | EGFR Gene Mutation (C98357) | ERBB2 Exon 20 Insertion Mutation (C150633) | EGFR Positive (C134501) | ERBB2 Gene Mutation (C96866)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "RET Gene Mutation (C43293) | RET Fusion (C131069)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "hiv_exc_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "HIV Positive (C15175)",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "plt_refined_text": [
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 30,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "NA",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 30,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 80,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 20,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 30,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 80,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "Platelet count >= 20,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 20,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 30,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 20,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 30,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 70,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 70,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 40,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 120,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 20,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 30,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 60,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 30,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 10,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 20,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 20,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 20,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 20,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 30,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 150,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 40,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 40,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 125,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 35,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 80,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 25,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 80,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 80,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "Platelet count >= 75,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 90,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 10,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "Platelet count >= 25,000/uL",
    "Platelet count >= 100,000/uL",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 25,000/ul",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 15,000/uL",
    "",
    "Platelet count >= 50,000/uL",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "Platelet count >= 150,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL\t",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 75,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platelet count >= 100,000/uL",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "wbc_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 4,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) =< 25,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) =< 10,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) =< 25,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 1,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "White blood cell count (WBC) < 15,000/uL",
    "White blood cell count (WBC) >= 3,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 1,500/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) < 20,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) =< 50,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) =< 25,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,500/uL",
    "",
    "",
    "White blood cell count (WBC) =< 25,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,500/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 3,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "White blood cell count (WBC) >= 2,000/uL",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "perf_refined_text": [
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 3",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "Performance Status =< 4",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 4",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1 (adults) OR Performance Status =< 2 (pediatrics)",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3 (adults) OR Performance Status =< 2 (pediatrics)",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 4",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 4",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 3",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 4",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2 (adults) OR Performance Status =< 3 (pediatrics)",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "Performance Status =< 3",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 3",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 3",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 2",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "Performance Status =< 1",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "Performance Status =< 2",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Performance Status =< 1",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "bmets_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Metastatic Malignant Neoplasm in the Central Nervous System (C4015)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "pt_inc_refined_text": [
    "",
    "",
    "Immunotherapeutic agent (C308) | Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Cisplatin Regimen (C160011) | Carboplatin Regimen (C160006) | Oxaliplatin Regimen (C160101)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Oxaliplatin Regimen (C160101)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "EGFR-targeting agent (C163952)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Poly (ADP-Ribose) Polymerase Inhibitor (C62554) ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "Cisplatin (C376) | Carboplatin (C1282)",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "Regimen Used to Treat Non-Small Cell Lung Carcinoma (C63360) | EGFR-targeting agent (C163952) | ALK Inhibitor (C141136) | PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893) | Anti-CTLA-4 Monoclonal Antibody (C128036)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Doublet (C162261) & Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Immune Checkpoint Inhibitor (C143250)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Carboplatin (C1282)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Taxane Compound (C1490)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (C2167)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Pembrolizumab (C106432)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "EGFR-targeting agent (C163952)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "Osimertinib (C116377)",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Immune Checkpoint Inhibitor (C143250)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Doublet (C162261) | Anti-PD1 Monoclonal Antibody (C128037) | Anti-PD-L1 Monoclonal Antibody (C128057)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Osimertinib (C116377) | Osimertinib Regimen (C160100)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Osimertinib (C116377) | Osimertinib Regimen (C160100)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)\n",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946)",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "PD1 Inhibitor (C124946) | PD-1 Ligand Inhibitor (C156893)",
    "",
    "",
    "No Prior Cancer Therapy (C15903)",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Antineoplastic agent (C274)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Osimertinib (C116377)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Doublet (C162261)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno/hormone Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Platinum Compound (C1450)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "pt_exc_refined_text": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Sotorasib (C154287) | KRASG12C Inhibitor JNJ-74699157 (C167157) | KRAS G12C Inhibitor D-1553 (C178562) | KRAS G12C Inhibitor GDC-6036 (C173995) | KRAS G12C Inhibitor JDQ443 (C177916) | KRAS G12C Inhibitor LY3499446 (C166410) | KRAS G12C Inhibitor MRTX849 (C157493)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "C69145 (MEK inhibitor) | C1902 (RAS inhibitor) | C2336 (RAF inhibitor) ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Immune Checkpoint Inhibitor (C143250)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (C2167) | Immune Checkpoint Inhibitor (C143250)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Anti-sCLU Monoclonal Antibody AB-16B5 (C121778) | Docetaxel (C1526) | Docetaxel Regimen (C160024)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "NA",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Chemo/immuno Therapy Regimen (C62634)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "RET Inhibitor (C159438)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Regimen Used to Treat Non-Small Cell Lung Carcinoma (C63360) | Immune Checkpoint Inhibitor (C143250)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor (C2167) | Anti-VEGF Monoclonal Antibody (C2496) | Nintedanib (C62765) | Bevacizumab (C2039) | Bevacizumab Regimen (C159998)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Anti-PD1 Monoclonal Antibody (C128037) | Anti-PD-L1 Monoclonal Antibody (C128057) ",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Condition",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "Poziotinib (C98838)",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "va_matches": [
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false
  ],
  "nih_cc_matches": [
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false
  ],
  "lead_disease_matches": [
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false
  ],
  "disease_matches": [
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false,
    false
  ],
  "age_matches": [
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false
  ],
  "gender_matches": [
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    false,
    false,
    false,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true,
    true,
    true,
    true,
    true,
    false,
    true,
    true
  ],
  "biomarker_exc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "biomarker_inc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "hiv_exc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "plt_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "wbc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "perf_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "bmets_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "pt_inc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ],
  "pt_exc_matches": [
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    "",
    ""
  ]
}
